Clustering O 0 2.832814607245382e-05
of O 0 1.0255045168605648e-07
missense O 0 6.822571594966576e-05
mutations O 0 4.2467316234251484e-05
in O 0 5.82088489409216e-07
the O 0 6.0219623264856637e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
gene O 0 2.652001603564713e-05
in O 0 3.659682334955505e-08
a O 0 1.81899721951595e-08
sporadic B-Disease 0 0.00075522530823946
T I-Disease 1 0.9995201826095581
- I-Disease 0 0.2911367118358612
cell I-Disease 0 0.21856525540351868
leukaemia I-Disease 0 0.29040321707725525
. O 0 8.920764003050863e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.34166911244392395
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.0132087169267834e-08
is O 0 8.264770534616162e-10
a O 0 5.474375619485272e-09
recessive B-Disease 0 0.016843633726239204
multi I-Disease 0 0.005066438112407923
- I-Disease 1 0.9999313354492188
system I-Disease 1 0.9975321292877197
disorder I-Disease 0 0.09471649676561356
caused O 0 2.486996208972414e-07
by O 0 5.858457718943555e-09
mutations O 0 2.944089771972358e-07
in O 0 3.5167291301263504e-09
the O 0 4.866865577213275e-09
ATM O 0 2.3241016151587246e-06
gene O 0 4.237378163907124e-07
at O 0 9.421118818409013e-08
11q22 O 0 1.5067329286466702e-06
- O 0 1.318217982770875e-06
q23 O 0 2.6189873096882366e-06
( O 0 6.084123782557072e-08
ref O 0 2.8457716325647198e-06
. O 0 3.2282463369170955e-09
3 O 0 1.5648318196781474e-08
) O 0 8.55862403170704e-09
. O 0 5.37938973366181e-08

The O 0 8.314780757245899e-07
risk O 0 5.707460672965681e-07
of O 0 1.0205868150592323e-08
cancer B-Disease 0 7.157152595027583e-06
, O 0 4.480506188286881e-09
especially O 0 3.4966120665558265e-08
lymphoid B-Disease 0 7.662847201572731e-05
neoplasias I-Disease 0 0.00011385933612473309
, O 0 6.276845265773545e-09
is O 0 2.299882950751453e-09
substantially O 0 3.209486294508679e-07
elevated O 0 4.198730948701268e-06
in O 0 1.2222241707604553e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 6.847914482932538e-05
and O 0 4.358348704158743e-08
has O 0 3.6215654919402596e-09
long O 0 3.158309613837673e-09
been O 0 1.9589232458372408e-09
associated O 0 2.0912823472940545e-08
with O 0 8.238636439727998e-08
chromosomal O 1 1.0
instability O 1 0.9999984502792358
. O 0 1.3812301631332957e-06

By O 0 1.9109324966848362e-06
analysing O 0 4.800114038516767e-05
tumour B-Disease 1 0.9999991655349731
DNA O 0 3.7636048091371777e-06
from O 0 6.071442015809225e-08
patients O 0 3.724446173691831e-08
with O 0 6.199837976339495e-09
sporadic B-Disease 0 0.003971896134316921
T I-Disease 1 0.999584972858429
- I-Disease 0 0.015918591991066933
cell I-Disease 0 0.050190966576337814
prolymphocytic I-Disease 0 0.3962770402431488
leukaemia I-Disease 1 0.9586755037307739
( O 0 5.545693966269027e-07
T B-Disease 0 0.006362488493323326
- I-Disease 0 1.0369283700129017e-05
PLL I-Disease 0 1.1416060260671657e-05
) O 0 3.483702659679011e-09
, O 0 1.6723269991025802e-10
a O 0 1.2636256485620834e-09
rare O 0 1.7815228403605943e-08
clonal B-Disease 0 8.098477906059998e-07
malignancy I-Disease 0 1.4132219803286716e-06
with O 0 1.0613755430100014e-09
similarities O 0 3.147721017171534e-08
to O 0 4.9094173171226885e-09
a O 0 2.006874844084905e-08
mature B-Disease 0 9.091669994631957e-07
T I-Disease 0 0.011785292997956276
- I-Disease 0 2.518864130252041e-05
cell I-Disease 0 8.233188418671489e-05
leukaemia I-Disease 0 0.0001635142689337954
seen O 0 1.8037064819509396e-07
in O 0 3.8407385716254794e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.999996542930603
T I-Disease 1 1.0
, O 0 3.748768850897477e-09
we O 0 2.833363266230293e-10
demonstrate O 0 4.3523051829197357e-10
a O 0 7.221101494536697e-10
high O 0 6.057836010597839e-09
frequency O 0 5.5706930623955486e-08
of O 0 5.541893055571734e-10
ATM O 0 1.178313686978072e-05
mutations O 0 1.0885257779591484e-06
in O 0 1.4944073711831152e-07
T B-Disease 0 0.029704593122005463
- I-Disease 0 8.960846753325313e-05
PLL I-Disease 0 0.0002277662424603477
. O 0 7.048155339361983e-07

In O 0 9.822529136727098e-07
marked O 0 4.356853082754242e-07
contrast O 0 4.847875345603825e-08
to O 0 2.723853587127678e-09
the O 0 2.838064894206127e-09
ATM O 0 4.5266888264450245e-06
mutation O 0 5.231445356912445e-07
pattern O 0 9.97104848465824e-07
in O 0 1.6773353195276286e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
, O 0 1.6405576896971752e-09
the O 0 2.8224031445311937e-10
most O 0 1.4464836273209158e-10
frequent O 0 4.095498162826061e-09
nucleotide O 0 2.9152777969443378e-08
changes O 0 5.645490297467859e-09
in O 0 4.323654767546259e-09
this O 0 1.504568558630126e-08
leukaemia B-Disease 0 2.9439561330946162e-05
were O 0 3.338330145652435e-08
missense O 0 2.4498251150362194e-05
mutations O 0 1.644403164391406e-05
. O 0 7.151245426939568e-07

These O 0 3.6540541259455495e-07
clustered O 0 1.5691559838160174e-06
in O 0 2.055893233432471e-08
the O 0 2.1852408771394494e-09
region O 0 4.4537009635803315e-09
corresponding O 0 4.190046087870769e-09
to O 0 6.545558539627905e-10
the O 0 2.2082309314441773e-09
kinase O 0 7.628377147739229e-07
domain O 0 2.2527176568587493e-08
, O 0 3.032551154635854e-10
which O 0 9.110307508386484e-10
is O 0 2.57568660844143e-10
highly O 0 9.969862713177235e-10
conserved O 0 6.083912929000235e-09
in O 0 3.895152644872724e-09
ATM O 0 4.079381142219063e-06
- O 0 1.9568597053876147e-07
related O 0 1.460067355907313e-08
proteins O 0 7.753826913869943e-09
in O 0 4.051283308825759e-09
mouse O 0 6.544914867845364e-07
, O 0 2.4081887595173157e-09
yeast O 0 4.024718407436012e-07
and O 0 1.5407065845352008e-08
Drosophila O 0 6.965284455873189e-07
. O 0 8.078762903096504e-08

The O 0 6.182877427818312e-07
resulting O 0 8.996346991807513e-07
amino O 0 8.484987574775005e-07
- O 0 1.4084146187087754e-06
acid O 0 3.649241477887699e-07
substitutions O 0 7.972771953745905e-08
are O 0 9.270062495403408e-10
predicted O 0 3.209265386772131e-08
to O 0 1.2828885731508421e-09
interfere O 0 2.2742344896187205e-08
with O 0 8.90487072968682e-10
ATP O 0 7.703459203867169e-08
binding O 0 6.246225581207909e-08
or O 0 1.5441514733538497e-08
substrate O 0 5.100034741190029e-07
recognition O 0 5.347339637751247e-08
. O 0 7.424003456435457e-08

Two O 0 2.102649716562155e-07
of O 0 1.0916309634012578e-08
seventeen O 0 1.4231611089599028e-07
mutated O 0 7.366976660705404e-06
T B-Disease 0 0.0002214119303971529
- I-Disease 0 4.107284894416807e-06
PLL I-Disease 0 1.0089939678437077e-05
samples O 0 8.561844566656873e-08
had O 0 1.0543664608064773e-08
a O 0 3.8720564532468416e-09
previously O 0 2.4743718185504804e-08
reported O 0 2.485976892785402e-06
A B-Disease 1 0.9999949932098389
- I-Disease 1 0.9999850988388062
T I-Disease 1 1.0
allele O 0 0.00010256670793751255
. O 0 4.900794010609388e-07

In O 0 2.91281111231001e-07
contrast O 0 1.8262808509916795e-07
, O 0 2.8866700141350066e-09
no O 0 2.7746382968985017e-09
mutations O 0 1.0977155540103922e-07
were O 0 4.006919240850948e-09
detected O 0 8.942920715071523e-08
in O 0 2.2391368759144825e-09
the O 0 1.5885037729646e-09
p53 O 0 5.194269903086024e-08
gene O 0 3.654458069490829e-08
, O 0 3.4090685829823997e-10
suggesting O 0 5.640528488726204e-09
that O 0 4.0239195309155207e-10
this O 0 4.832437117130439e-09
tumour B-Disease 1 1.0
suppressor O 0 5.641459210892208e-05
is O 0 2.600656578977123e-09
not O 0 2.908160656733827e-10
frequently O 0 4.823661026165382e-09
altered O 0 1.589841929217073e-07
in O 0 9.542956647123901e-09
this O 0 3.1018529966786446e-08
leukaemia B-Disease 0 0.0001309528452111408
. O 0 1.7332453694507421e-07

Occasional O 0 6.890531221870333e-05
missense O 0 0.0008024013368412852
mutations O 0 0.0001102097230614163
in O 0 3.039323814846284e-07
ATM O 0 0.00010931431461358443
were O 0 9.993423333298779e-08
also O 0 5.8334137520432705e-09
found O 0 3.6459621988171875e-09
in O 0 5.115964540891582e-08
tumour B-Disease 1 0.9999998807907104
DNA O 0 7.873484264564468e-07
from O 0 2.124879827647419e-08
patients O 0 2.0918008658554754e-08
with O 0 3.929972791638647e-09
B B-Disease 0 1.382189338983153e-06
- I-Disease 0 8.050488986555138e-07
cell I-Disease 0 9.659308489062823e-06
non I-Disease 0 2.394948751316406e-06
- I-Disease 0 0.12866802513599396
Hodgkins I-Disease 1 0.9995582699775696
lymphomas I-Disease 1 0.5255340933799744
( O 0 1.6355852494598366e-07
B B-Disease 0 3.40817314281594e-06
- I-Disease 0 1.4796886489421013e-06
NHL I-Disease 0 5.229310886534222e-07
) O 0 1.9896351233228415e-09
and O 0 5.662677549089778e-10
a O 0 8.741004364765104e-09
B B-Disease 0 1.1426976698203362e-06
- I-Disease 0 9.388503485752153e-07
NHL I-Disease 0 1.2769905879395083e-06
cell O 0 3.6727419683302287e-06
line O 0 2.27593718591379e-05
. O 0 1.9812222262771684e-07

The O 0 1.1475209049649493e-07
evidence O 0 6.3326184296386145e-09
of O 0 2.8282015618330547e-10
a O 0 1.4022856209550127e-09
significant O 0 1.4111020130158636e-09
proportion O 0 3.2967057972399516e-09
of O 0 6.627011717164066e-10
loss O 0 2.1122284010743897e-07
- O 0 2.6163309030380333e-07
of O 0 1.721659037556833e-09
- O 0 2.131849441866507e-06
function O 0 6.496323123883485e-08
mutations O 0 1.0496514590840889e-07
and O 0 3.1437935588130017e-10
a O 0 9.777868514859733e-10
complete O 0 2.770238705096517e-09
absence O 0 2.784695807278581e-09
of O 0 6.935725604950704e-11
the O 0 1.0160802199621344e-09
normal O 0 3.494978528806314e-08
copy O 0 2.2165835389387212e-07
of O 0 4.4460093939768797e-10
ATM O 0 4.620055165105441e-07
in O 0 2.777736041181811e-09
the O 0 1.4982589613410369e-09
majority O 0 2.520849751164178e-09
of O 0 1.922767944861903e-09
mutated O 0 0.00019194325432181358
tumours B-Disease 1 0.9999998807907104
establishes O 0 1.341072675131727e-06
somatic O 0 2.341652816539863e-06
inactivation O 0 4.957928013027413e-06
of O 0 8.277644125698203e-10
this O 0 1.228955381904484e-09
gene O 0 4.1671821549016386e-08
in O 0 3.804406123464332e-09
the O 0 6.802906682423782e-09
pathogenesis O 0 1.989207873975829e-07
of O 0 1.1256511278645576e-09
sporadic B-Disease 0 5.937551031820476e-05
T I-Disease 1 0.9695563316345215
- I-Disease 0 0.00012061006418662146
PLL I-Disease 0 6.165301601868123e-05
and O 0 8.909411874924444e-09
suggests O 0 6.643290362262633e-09
that O 0 5.790068424715855e-10
ATM O 0 2.2052945780615119e-07
acts O 0 7.468098139895574e-09
as O 0 4.22176560377352e-09
a O 0 2.4192834757741366e-07
tumour B-Disease 1 0.9999992847442627
suppressor O 0 0.0003610402636695653
. O 0 5.213624945099582e-07

As O 0 3.569360558230983e-07
constitutional O 0 1.231737343232453e-07
DNA O 0 2.1618484424834605e-07
was O 0 1.204538335741745e-07
not O 0 7.810673219310615e-10
available O 0 1.147029693449042e-09
, O 0 1.937053017986301e-10
a O 0 2.6187703117130923e-09
putative O 0 1.5780279909449746e-06
hereditary O 0 0.0007147343130782247
predisposition O 0 1.4345013369165827e-05
to O 0 4.6106757167763135e-07
T B-Disease 1 0.791054904460907
- I-Disease 0 3.714700505952351e-05
PLL I-Disease 0 2.2009709937265143e-05
will O 0 7.72638131252279e-09
require O 0 2.6095756666677516e-09
further O 0 2.434977552923101e-09
investigation O 0 1.380909253612117e-08
. O 0 4.9193156215210365e-09
. O 0 3.5650188578983943e-08

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.01735970564186573
kinase O 0 0.00809870008379221
is O 0 2.2531903454137137e-08
involved O 0 3.743032106484634e-09
in O 0 1.5320260615681036e-09
the O 0 1.9179917654099654e-09
modulation O 0 5.800675495493124e-08
of O 0 1.2586098829814318e-10
the O 0 1.9506571913296966e-09
Ca2 O 0 5.301397436596744e-07
+ O 0 3.5693639688361145e-07
homeostasis O 0 6.260948339331662e-06
in O 0 5.861366147996705e-08
skeletal O 0 0.0007081725634634495
muscle O 0 0.00028659767122007906
cells O 0 4.551076017378364e-06
. O 0 4.322139659507229e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9992651343345642
DM B-Disease 1 1.0
) O 0 2.0874850292784686e-07
, O 0 2.4863964220855905e-09
the O 0 1.7068344515536182e-09
most O 0 2.342548377498588e-09
prevalent O 0 5.0571838073665276e-05
muscular B-Disease 1 0.9993891716003418
disorder I-Disease 1 0.9486317038536072
in O 0 3.3965766306209844e-06
adults O 0 1.542784957564436e-05
, O 0 5.719559936778751e-09
is O 0 2.9296911563392314e-09
caused O 0 7.177072092190429e-08
by O 0 4.59886440040691e-09
( O 0 2.4183997027193982e-08
CTG O 0 1.3544010926125338e-06
) O 0 2.76965228529491e-09
n O 0 7.722938022425296e-08
- O 0 1.05158520113946e-07
repeat O 0 2.0330507766175288e-07
expansion O 0 1.262193105588949e-08
in O 0 6.260712503980415e-10
a O 0 1.1244344344518709e-09
gene O 0 2.077993954685553e-08
encoding O 0 1.8922877487170808e-08
a O 0 6.352845804968865e-09
protein O 0 1.990092215464756e-07
kinase O 0 2.293653778906446e-05
( O 0 4.018601202915306e-07
DM B-Disease 1 0.9999992847442627
protein O 0 6.9711463765997905e-06
kinase O 0 3.2340096367988735e-05
; O 0 5.862719021365592e-08
DMPK O 0 4.971175258106086e-06
) O 0 2.912835972423977e-09
and O 0 6.448148681670318e-10
involves O 0 1.0124896476781942e-09
changes O 0 8.004523266436081e-09
in O 0 8.351661584526937e-09
cytoarchitecture O 0 4.48367245553527e-06
and O 0 3.3674020016860595e-08
ion O 0 3.301175092929043e-05
homeostasis O 0 0.0007183555862866342
. O 0 5.605155024568376e-07

To O 0 1.7905713889376784e-07
obtain O 0 8.827512942843896e-08
clues O 0 1.627007009119552e-07
to O 0 5.786936263518783e-09
the O 0 2.1159043406271394e-09
normal O 0 1.093143708885691e-08
biological O 0 4.524812080575202e-09
role O 0 1.224129131394136e-09
of O 0 3.6809602588228074e-10
DMPK O 0 4.792255481333996e-07
in O 0 8.23706169938987e-09
cellular O 0 1.1805888107119245e-06
ion O 0 2.161660449928604e-05
homeostasis O 0 0.004264326766133308
, O 0 6.108353378664333e-09
we O 0 4.936617226114492e-10
have O 0 2.2651930331463177e-10
compared O 0 2.1139880956866364e-09
the O 0 5.844929873433102e-09
resting O 0 1.0659859128736571e-07
[ O 0 3.161692774256153e-08
Ca2 O 0 3.130376171611715e-07
+ O 0 1.3828207556798588e-07
] O 0 7.460555906391164e-08
i O 0 1.1590026716135071e-08
, O 0 1.9686645369443312e-10
the O 0 9.507523657248385e-10
amplitude O 0 1.469163013467778e-08
and O 0 9.285989199803169e-10
shape O 0 3.03930605127789e-08
of O 0 8.091400882648259e-10
depolarization O 0 1.708858974325267e-07
- O 0 7.105372787918895e-07
induced O 0 2.0531679183477536e-06
Ca2 O 0 8.543376566194638e-07
+ O 0 2.191202526091729e-07
transients O 0 3.9865182088760776e-07
, O 0 3.9518294192575354e-10
and O 0 1.828303342055193e-10
the O 0 5.941910297124764e-10
content O 0 5.240740730272364e-09
of O 0 2.74690242774156e-10
ATP O 0 1.2773520552400441e-07
- O 0 1.764077808275033e-07
driven O 0 1.4875722342821973e-07
ion O 0 3.244625474962959e-07
pumps O 0 3.286844219019258e-07
in O 0 6.959160803177156e-09
cultured O 0 5.554433073484688e-07
skeletal O 0 1.1432512110332027e-05
muscle O 0 1.3424969438347034e-06
cells O 0 2.4484474892005892e-08
of O 0 5.189273455386001e-10
wild O 0 1.797517157342554e-08
- O 0 4.849770903092576e-06
type O 0 1.2520667041826528e-05
and O 0 1.1347204953437995e-08
DMPK O 0 1.7229647710337304e-05
[ O 0 2.1157040919206338e-07
- O 0 5.3396320254250895e-06
/ O 0 9.464475442655385e-05
- O 0 1.5225413335429039e-05
] O 0 7.749496262476896e-07
knockout O 0 9.841396604315378e-06
mice O 0 7.988892321009189e-05
. O 0 2.3786549263604684e-07

In O 0 3.328423190396279e-06
vitro O 0 6.552215927513316e-05
- O 0 2.478482565493323e-05
differentiated O 0 6.171858331072144e-06
DMPK O 0 0.00010190980538027361
[ O 0 1.7524035911264946e-06
- O 0 2.2725733288098127e-05
/ O 0 0.00012493992107920349
- O 0 7.743964488327038e-06
] O 0 4.515589182574331e-07
myotubes O 0 1.2472095249904669e-06
exhibit O 0 6.836391008846476e-08
a O 0 2.2640548991148535e-08
higher O 0 2.1734953747909458e-07
resting O 0 2.495432624982641e-07
[ O 0 9.360220332155222e-08
Ca2 O 0 7.788965490362898e-07
+ O 0 3.4372953905403847e-07
] O 0 1.7505934124528721e-07
i O 0 2.2304000424355763e-08
than O 0 6.506014615936806e-10
do O 0 1.4908501100308058e-09
wild O 0 1.5122184393590032e-08
- O 0 4.318071205489105e-06
type O 0 3.773315256694332e-05
myotubes O 0 5.960514045000309e-06
because O 0 1.5143305498455106e-09
of O 0 1.0136561728879556e-10
an O 0 3.930030745280533e-10
altered O 0 2.6206910774817516e-07
open O 0 8.791114503026165e-09
probability O 0 2.6649003004308724e-09
of O 0 9.066105088884058e-10
voltage O 0 5.221569153945893e-06
- O 0 6.457711378970998e-07
dependent O 0 1.2843047159094567e-07
l O 0 2.1308494524419075e-06
- O 0 3.298494277714781e-07
type O 0 8.743857620174822e-07
Ca2 O 0 8.835241374072211e-07
+ O 0 1.1529771626328511e-07
and O 0 7.817204661364485e-09
Na O 0 6.622581736337452e-07
+ O 0 4.1612062773310754e-07
channels O 0 1.3287723277244368e-06
. O 0 3.8280356307041075e-07

The O 0 1.8799754570864025e-06
mutant O 0 9.455478902964387e-06
myotubes O 0 1.7894097254611552e-05
exhibit O 0 7.078508588165278e-07
smaller O 0 1.7663150231328473e-07
and O 0 1.176690833659677e-08
slower O 0 1.268356299988227e-06
Ca2 O 0 2.903782160501578e-06
+ O 0 3.500276193335594e-07
responses O 0 4.8708983513279236e-08
upon O 0 1.0218101031966853e-08
triggering O 0 3.233042491501692e-07
by O 0 6.754885983895065e-09
acetylcholine O 0 2.9008237106609158e-05
or O 0 2.2737170013442665e-07
high O 0 5.910289928579004e-07
external O 0 9.903242244035937e-07
K O 0 3.4676529594435124e-06
+ O 0 1.3517997103917878e-06
. O 0 1.9961593977768644e-07

In O 0 3.7379825812422496e-07
addition O 0 3.244327828610949e-08
, O 0 2.4065451853516606e-09
we O 0 2.996563552848386e-10
observed O 0 1.1751515316404948e-09
that O 0 2.216352379402764e-10
these O 0 7.600398643781148e-10
Ca2 O 0 1.7838119958923926e-07
+ O 0 1.5608203796091402e-07
transients O 0 1.1040817753382726e-06
partially O 0 2.7148283265887585e-07
result O 0 7.584705308261164e-09
from O 0 9.659069100109718e-10
an O 0 1.3640129303826853e-10
influx O 0 2.1164370256343545e-09
of O 0 4.710013490338838e-10
extracellular O 0 5.4297874640951704e-08
Ca2 O 0 2.1571612762727455e-07
+ O 0 2.3131084603278396e-08
through O 0 1.9751724700256545e-09
the O 0 6.448139355796911e-09
l O 0 1.3000204717172892e-06
- O 0 4.914882083539851e-07
type O 0 1.124760842685646e-06
Ca2 O 0 2.2383794657798717e-06
+ O 0 6.572868187504355e-07
channel O 0 3.969756562582916e-06
. O 0 3.178050747010275e-07

Neither O 0 1.7759880392986815e-06
the O 0 6.667487895128943e-08
content O 0 1.0340840361777737e-07
nor O 0 1.6573597605429313e-08
the O 0 1.022333884215243e-09
activity O 0 1.3009610277947559e-08
of O 0 2.1733195243456294e-09
Na O 0 4.264556423549948e-07
+ O 0 4.465723009161593e-07
/ O 0 7.825336751920986e-07
K O 0 5.075808076071553e-07
+ O 0 2.1616794754208968e-07
ATPase O 0 2.192173496951e-06
and O 0 3.246302426873626e-08
sarcoplasmic O 0 2.333677366550546e-05
reticulum O 0 2.0408908312674612e-05
Ca2 O 0 8.066534974204842e-06
+ O 0 8.821409096526622e-07
- O 0 1.1920335509785218e-06
ATPase O 0 3.5075518098892644e-06
are O 0 3.951559968129459e-09
affected O 0 2.364293294476738e-08
by O 0 1.1926386100924447e-08
DMPK O 0 1.8623079085955396e-05
absence O 0 4.215813191876805e-07
. O 0 1.3038729207437427e-07

In O 0 3.282928275893937e-07
conclusion O 0 7.260441492462633e-08
, O 0 3.19380211166731e-09
our O 0 1.2033958274315637e-09
data O 0 2.016701827756151e-08
suggest O 0 6.045716371971821e-09
that O 0 6.308648048403143e-10
DMPK O 0 9.126714530793834e-07
is O 0 6.638384841828326e-10
involved O 0 3.301159068325177e-10
in O 0 8.442644916506481e-10
modulating O 0 2.00812365847014e-07
the O 0 2.101493645767505e-09
initial O 0 1.0373747194591942e-08
events O 0 2.2869175442252754e-09
of O 0 4.2306386172086263e-10
excitation O 0 8.024044291232713e-07
- O 0 5.7958259276347235e-06
contraction O 0 4.720244760392234e-06
coupling O 0 9.124729558607214e-07
in O 0 5.606476705111163e-08
skeletal O 0 0.00014144224405754358
muscle O 0 3.5505996493157e-05
. O 0 3.9825238218327286e-08
. O 0 1.1099076147047526e-07

Constitutional O 0 9.027247142512351e-05
RB1 O 0 0.014195841737091541
- O 0 7.738571730442345e-05
gene O 0 2.8498801839305088e-05
mutations O 0 2.483784919604659e-05
in O 0 1.0183219956161338e-07
patients O 0 1.0856637544520709e-07
with O 0 7.778178989781281e-09
isolated O 0 6.5794624788395595e-06
unilateral B-Disease 0 0.00010094032768392935
retinoblastoma I-Disease 0 0.0038434562738984823
. O 0 1.0884645007536164e-06

In O 0 6.588356882275548e-07
most O 0 2.3258673209625158e-08
patients O 0 4.715924362130863e-08
with O 0 5.889502663336543e-09
isolated O 0 2.16142484532611e-06
unilateral B-Disease 0 1.6769154171925038e-05
retinoblastoma I-Disease 0 0.0006500447052530944
, O 0 1.3971071410878722e-08
tumor B-Disease 0 6.321735099845682e-07
development O 0 1.4672327797171647e-09
is O 0 5.2898668778667e-10
initiated O 0 4.180737978032312e-09
by O 0 1.0815168760558436e-09
somatic O 0 1.1136291533375697e-07
inactivation O 0 4.2680960632424103e-07
of O 0 2.1352052070877647e-10
both O 0 1.7361686532879617e-09
alleles O 0 4.314109247616216e-08
of O 0 1.2819786343598594e-09
the O 0 7.966585968688378e-08
RB1 O 0 5.564794992096722e-05
gene O 0 4.277531388652278e-06
. O 0 5.020449407311389e-07

However O 0 4.6284341692626185e-07
, O 0 4.774407091900912e-09
some O 0 2.449472569221456e-10
of O 0 1.205890526323472e-10
these O 0 7.383862410392794e-10
patients O 0 4.5352579469692955e-09
can O 0 7.346470098923419e-09
transmit O 0 0.00010708293120842427
retinoblastoma B-Disease 0 0.00014740912592969835
predisposition O 0 4.60404544355697e-06
to O 0 1.296153495644603e-08
their O 0 4.830394217947287e-08
offspring O 0 1.282095013266371e-06
. O 0 1.58498849600619e-07

To O 0 3.207111944902863e-07
determine O 0 3.9305145804746644e-08
the O 0 5.992950136146646e-09
frequency O 0 5.95353776589036e-06
and O 0 3.0806139861283555e-09
nature O 0 2.3909845214831194e-09
of O 0 4.813962006799954e-10
constitutional O 0 5.859778795525017e-08
RB1 O 0 2.8052540073986165e-05
- O 0 9.855991720542079e-07
gene O 0 1.0734397619671654e-06
mutations O 0 9.837378911470296e-07
in O 0 1.2860374098977445e-08
patients O 0 2.493645290257973e-08
with O 0 2.296183687633402e-09
isolated O 0 1.8326016970604542e-06
unilateral B-Disease 0 1.2184097613499034e-05
retinoblastoma I-Disease 0 0.00037939994945190847
, O 0 3.76386477540791e-09
we O 0 6.171236299756799e-10
analyzed O 0 6.7229195543916376e-09
DNA O 0 1.2865844389864378e-08
from O 0 4.0118899313768e-09
peripheral O 0 1.2899701005153474e-06
blood O 0 3.0648067195215845e-07
and O 0 1.0886243906327309e-08
from O 0 1.6868149543824984e-08
tumor B-Disease 0 9.37972163228551e-06
tissue O 0 8.696176337252837e-06
. O 0 2.7733599949897325e-07

The O 0 1.7639885641074216e-07
analysis O 0 1.4440267648296867e-07
of O 0 1.2918516034687855e-08
tumors B-Disease 1 0.9999998807907104
from O 0 4.502026840214057e-08
54 O 0 2.1155952367735154e-07
( O 0 6.974973931761497e-09
71 O 0 3.076963039916336e-08
% O 0 8.632444203904299e-10
) O 0 2.983110980459003e-10
of O 0 4.030094868934242e-10
76 O 0 5.412704240370658e-07
informative O 0 8.379539053748886e-07
patients O 0 4.004133131729759e-07
showed O 0 7.205754809547216e-05
loss O 0 4.1629647284935345e-07
of O 0 4.0015422086980834e-09
constitutional O 0 2.571953814367589e-07
heterozygosity O 0 1.5092357898538467e-05
( O 0 3.8936099144848413e-07
LOH O 0 0.0002879059175029397
) O 0 2.1098644609196526e-08
at O 0 1.3719522939936724e-07
intragenic O 0 1.5995728972484358e-05
loci O 0 2.7175065042683855e-06
. O 0 2.468555351242685e-07

Three O 0 1.41505182682522e-07
of O 0 1.8063534668044667e-08
13 O 0 1.3743461124704481e-07
uninformative O 0 6.840499554527923e-05
patients O 0 1.5082928257470485e-06
had O 0 3.24397575468538e-07
constitutional O 0 8.731825005270366e-07
deletions O 0 1.9037557649426162e-05
. O 0 5.546762622543611e-07

For O 0 6.352823902489035e-07
39 O 0 1.6131880329339765e-06
randomly O 0 6.352533432618657e-07
selected O 0 1.014591362036299e-06
tumors B-Disease 1 0.9999998807907104
, O 0 3.8975993987833135e-08
SSCP O 0 3.411452053114772e-05
, O 0 1.8825176084646955e-08
hetero O 0 3.743180741366814e-06
- O 0 5.703624310626765e-07
duplex O 0 1.0204708814853802e-05
analysis O 0 2.0467300743121086e-08
, O 0 2.1628314417210248e-10
sequencing O 0 4.579004730942415e-09
, O 0 2.1315754716866309e-10
and O 0 1.705431212917219e-10
Southern O 0 1.1381343867356009e-08
blot O 0 3.4714050798356766e-06
analysis O 0 2.608615323751451e-09
were O 0 4.1351905233355524e-10
used O 0 5.626342169939846e-10
to O 0 7.141222058137942e-10
identify O 0 5.810674608142108e-08
mutations O 0 7.916386266515474e-07
. O 0 1.6499295441008144e-07

Mutations O 0 0.00011133243970107287
were O 0 2.799740457248845e-07
detected O 0 1.6834518419273081e-06
in O 0 2.586253522451898e-08
21 O 0 6.593002410681947e-08
( O 0 4.582473511760554e-09
91 O 0 2.2963204671100357e-08
% O 0 5.808075687063763e-10
) O 0 4.1714245946344874e-10
of O 0 7.522376055391078e-10
23 O 0 3.2192179787671193e-05
tumors B-Disease 1 1.0
with O 0 3.735495738510508e-06
LOH O 1 0.997692346572876
. O 0 5.438716357275553e-07

In O 0 1.7352809891235665e-06
6 O 0 3.3719854286573536e-07
( O 0 8.113380189911368e-09
38 O 0 4.139692677540552e-08
% O 0 1.1567449220706294e-09
) O 0 4.6343395787573627e-10
of O 0 8.897265146856626e-10
16 O 0 1.566422542964574e-05
tumors B-Disease 1 1.0
without O 0 1.6158841162905446e-06
LOH O 0 0.013322841376066208
, O 0 1.4243956014681203e-09
one O 0 1.2855683184653799e-09
mutation O 0 5.97821383507835e-08
was O 0 2.122400921678036e-08
detected O 0 1.0933484873021371e-07
, O 0 5.136511771475227e-10
and O 0 3.826213512692078e-10
in O 0 2.8360735981891594e-09
9 O 0 5.720566775835323e-08
( O 0 1.2723297970751446e-09
56 O 0 6.1781650906311825e-09
% O 0 1.4780940360559214e-10
) O 0 1.195240295626121e-10
of O 0 1.4201141651515314e-10
the O 0 5.833728096149571e-07
tumors B-Disease 1 1.0
without O 0 3.494085945021652e-07
LOH O 0 0.0009970094542950392
, O 0 7.836787330184336e-10
both O 0 9.041962734102071e-10
mutations O 0 1.345470082014799e-07
were O 0 9.805027012532719e-09
found O 0 2.3246210290039926e-08
. O 0 7.475369301346291e-08

Thus O 0 2.321931873439098e-07
, O 0 3.036164208936043e-09
a O 0 1.2743625044109308e-09
total O 0 4.1809275486137665e-10
of O 0 1.8720960892615324e-10
45 O 0 7.171486959833828e-09
mutations O 0 5.5745196902989846e-08
were O 0 3.7711944678164855e-09
identified O 0 1.6961388737968264e-08
in O 0 1.1455122717052291e-07
tumors B-Disease 1 1.0
of O 0 1.0452796850302093e-08
36 O 0 7.843768798920792e-07
patients O 0 2.128953298097258e-07
. O 0 1.2604458277110098e-07

Thirty O 0 6.120915713836439e-06
- O 0 1.6441537127320771e-06
nine O 0 1.1004571476291858e-08
of O 0 3.457948927199084e-10
the O 0 1.7544107278055776e-09
mutations O 0 1.0857300480893173e-07
- O 0 4.190192015585126e-08
including O 0 1.4274063042662988e-09
34 O 0 1.2445648067682669e-08
small O 0 3.922184799165507e-09
mutations O 0 2.3985046482266625e-07
, O 0 1.3505392360002588e-09
2 O 0 4.751169235817088e-09
large O 0 3.1007747480771286e-09
structural O 0 3.4013569916169217e-07
alterations O 0 1.1505765087349573e-06
, O 0 1.6618063591877785e-09
and O 0 1.559768314507437e-09
hypermethylation O 0 1.5091954992385581e-05
in O 0 2.1892286383717874e-07
3 O 0 7.690723577979952e-05
tumors O 1 1.0
- O 0 0.0037456678692251444
were O 0 4.144930798588575e-08
not O 0 8.723844979741102e-10
detected O 0 4.603281311688079e-08
in O 0 1.218034006988944e-09
the O 0 1.1138001632104988e-09
corresponding O 0 1.2703734952879131e-08
peripheral O 0 1.0283755500495317e-06
blood O 0 4.435045752870792e-07
DNA O 0 1.7993546634897939e-06
. O 0 3.0252178362388804e-07

In O 0 1.637450168345822e-06
6 O 0 6.8690405896632e-07
( O 0 3.673130066772501e-08
17 O 0 2.8177426614206524e-08
% O 0 7.907658416961283e-10
) O 0 1.3094288153769895e-10
of O 0 3.8074002284282926e-11
the O 0 2.0836408154423225e-09
36 O 0 2.19387015221173e-08
patients O 0 2.4378403740143995e-09
, O 0 2.0125998090314567e-10
a O 0 7.720092121132893e-09
mutation O 0 1.765469761494387e-07
was O 0 9.891682850593497e-08
detected O 0 1.3587425939931563e-07
in O 0 5.715110606985263e-09
constitutional O 0 1.1127772481245302e-08
DNA O 0 3.044980800837038e-08
, O 0 1.2086152079149315e-09
and O 0 4.106329720698909e-10
1 O 0 7.984025662821637e-10
of O 0 8.373777365955348e-11
these O 0 8.75353012297353e-10
mutations O 0 4.170068379494296e-08
is O 0 3.6116923340934193e-10
known O 0 8.378653881813136e-10
to O 0 3.920986035854668e-10
be O 0 3.7961120358254163e-10
associated O 0 3.4941236570773526e-09
with O 0 2.1551567197519717e-09
reduced O 0 6.702423434035154e-07
expressivity O 0 4.4242529838811606e-05
. O 0 2.627593005399831e-07

The O 0 9.200491746241823e-08
presence O 0 1.842205676894082e-08
of O 0 6.284161524483522e-10
a O 0 3.0628732883286602e-09
constitutional O 0 1.6020905491131998e-08
mutation O 0 1.9868340928042016e-07
was O 0 8.525667283265648e-08
not O 0 3.3552688405436015e-10
associated O 0 3.519257107953422e-10
with O 0 1.3838213908101693e-10
an O 0 5.204180975049155e-10
early O 0 5.219336003392527e-07
age O 0 2.988689473681916e-08
at O 0 3.2749039036161776e-08
treatment O 0 8.306785304057485e-08
. O 0 5.562995042396324e-08

In O 0 1.878565058177628e-06
1 O 0 4.017336436845653e-07
patient O 0 3.7398191921056423e-07
, O 0 3.2643070468907354e-09
somatic O 0 9.037864856509259e-07
mosaicism O 0 1.7496782675152645e-05
was O 0 1.258325994513143e-07
demonstrated O 0 5.67466074130607e-09
by O 0 3.7868191915535476e-10
molecular O 0 6.885697345637709e-09
analysis O 0 1.2017535855335382e-09
of O 0 1.7109340333387735e-10
DNA O 0 2.602990534228411e-08
and O 0 2.0255712662731185e-09
RNA O 0 2.746497216321586e-07
from O 0 3.7824193555024976e-08
peripheral O 0 1.4001775525684934e-05
blood O 0 3.2991122225212166e-06
. O 0 3.103830295003718e-07

In O 0 1.7520192159281578e-06
2 O 0 2.8830186238337774e-07
patients O 0 2.5051534180420276e-08
without O 0 1.8731078910150245e-09
a O 0 1.4622522748197753e-08
detectable O 0 3.191903033439303e-06
mutation O 0 4.77296168810426e-07
in O 0 1.4957413085880944e-08
peripheral O 0 1.5340145182562992e-05
blood O 0 1.4357891586769256e-06
, O 0 5.801258584625657e-09
mosaicism O 0 1.5867866522967233e-06
was O 0 1.616927818304248e-07
suggested O 0 9.193839467513953e-09
because O 0 6.093176518895405e-10
1 O 0 6.742152391936429e-10
of O 0 6.43638545239078e-11
the O 0 3.945896054347031e-09
patients O 0 8.871312928704356e-08
showed O 0 0.00026586779858917
multifocal O 1 0.999991774559021
tumors B-Disease 1 1.0
and O 0 9.697011194020888e-08
the O 0 2.666862952693805e-09
other O 0 5.778594824867866e-10
later O 0 1.6141756375986915e-08
developed O 0 7.172296534463385e-08
bilateral B-Disease 0 1.0425125651636336e-07
retinoblastoma I-Disease 0 4.797108340426348e-05
. O 0 4.721009645436425e-07

In O 0 2.878540499295923e-07
conclusion O 0 3.7540011987857724e-08
, O 0 3.813014348708066e-09
our O 0 1.4016358074186996e-09
results O 0 1.1463675342326951e-08
emphasize O 0 1.1080331319135439e-08
that O 0 2.7253904688606667e-10
the O 0 9.186280069961583e-10
manifestation O 0 1.0891726631712118e-08
and O 0 1.223935397476339e-09
transmissibility O 0 1.680572836448846e-07
of O 0 7.043794991723473e-10
retinoblastoma B-Disease 0 2.8012601660520886e-07
depend O 0 3.8462055762522596e-09
on O 0 2.7364672305907334e-08
the O 0 8.477321622457623e-10
nature O 0 1.9713999876991295e-10
of O 0 2.7059497004211508e-11
the O 0 3.593778052923824e-10
first O 0 9.617503460290777e-10
mutation O 0 7.223488474039641e-09
, O 0 8.390292627336038e-11
its O 0 9.38946587147882e-10
time O 0 1.5021848209784139e-09
in O 0 6.684264253209449e-10
development O 0 1.4689710559068203e-10
, O 0 5.618629173032019e-11
and O 0 3.740793785844687e-11
the O 0 1.383037712132662e-10
number O 0 4.3149914197293526e-11
and O 0 3.544638887964524e-11
types O 0 1.9408732954140362e-10
of O 0 3.9019745767809866e-11
cells O 0 1.5522003682377772e-09
that O 0 3.2793573412348564e-10
are O 0 1.3306886148534147e-10
affected O 0 4.123968277980339e-09
. O 0 2.2980062297506265e-09
. O 0 2.9129266110317076e-08

Hereditary B-Disease 1 0.9999992847442627
deficiency I-Disease 1 0.9999592304229736
of I-Disease 0 3.492472799848656e-08
the I-Disease 0 1.7263227292119154e-08
fifth I-Disease 0 5.670995051332284e-08
component I-Disease 0 1.2404601790194647e-08
of I-Disease 0 2.9197266826486157e-10
complement I-Disease 0 1.5086575544387415e-08
in O 0 9.69558389130043e-09
man O 0 2.47731918534555e-07
. O 0 1.0785555559778004e-07

I O 0 0.00033346787677146494
. O 0 3.4409365525789326e-06

Clinical O 0 2.2565362087334506e-05
, O 0 1.2861703169164684e-07
immunochemical O 0 8.231164429162163e-06
, O 0 9.199189854314227e-09
and O 0 3.3588432035713822e-09
family O 0 3.454866970287185e-08
studies O 0 4.93225513764628e-08
. O 0 1.0638673586527148e-07

The O 0 1.6813005743188114e-07
first O 0 2.6641393091608734e-08
recognized O 0 9.61712398606096e-09
human O 0 4.6314343471465236e-09
kindred O 0 1.2920704648422543e-06
with O 0 8.050306377072047e-08
hereditary B-Disease 1 0.9999959468841553
deficiency I-Disease 0 0.014826890081167221
of I-Disease 0 6.945830022253574e-10
the I-Disease 0 4.808357711993949e-09
fifth I-Disease 0 2.559816003611104e-08
component I-Disease 0 1.0444746401105931e-08
of I-Disease 0 2.668362475422015e-10
complement I-Disease 0 4.276342124853727e-08
( O 0 3.1830516888931015e-08
C5 O 0 1.2545971003419254e-05
) O 0 2.2984534275849455e-09
is O 0 1.7253343198575521e-09
described O 0 9.74739364778543e-08
. O 0 1.0267629590998695e-07

The O 0 7.758783908684563e-07
proband O 0 9.16626140679e-06
, O 0 4.649170826098725e-09
a O 0 6.6599099568520614e-09
20 O 0 8.486677138819232e-09
- O 0 1.9194462197447137e-07
year O 0 1.6595361529425645e-08
- O 0 6.969410719648295e-07
old O 0 3.224291731385165e-07
black O 0 3.63509009559948e-08
female O 0 2.1945229633502095e-08
with O 0 2.4970773893073783e-07
systemic B-Disease 1 1.0
lupus I-Disease 1 0.9999992847442627
erythematosus I-Disease 1 1.0
since O 0 0.0010864679934456944
age O 0 3.0950690188547014e-07
11 O 0 1.2860250642177107e-08
, O 0 1.7887675785033252e-09
lacked O 0 4.363256493888912e-07
serum O 0 3.730956223080284e-06
hemolytic O 0 2.0449586372706108e-05
complement O 0 1.3625016492824216e-07
activity O 0 2.2109804831416113e-07
, O 0 1.7608843272398644e-09
even O 0 6.15441875240208e-09
during O 0 1.8158399939238734e-07
remission O 0 2.1725059013988357e-06
. O 0 9.989287974576655e-08

C5 O 0 0.0056862677447497845
was O 0 4.113815066375537e-06
undetectable O 0 5.39467100679758e-06
in O 0 4.789239582692062e-08
her O 0 2.9045546412476142e-08
serum O 0 7.575137317417102e-08
by O 0 1.7495186410698693e-09
both O 0 2.1605648381495257e-09
immunodiffusion O 0 3.3196865842910483e-06
and O 0 7.63896395028496e-08
hemolytic O 0 0.000403679849114269
assays O 0 9.383757424075156e-05
. O 0 1.2692008795056609e-06

Other O 0 3.0339773360310573e-08
complement O 0 6.072993841144125e-08
components O 0 4.089599059398097e-08
were O 0 2.882939442727661e-09
normal O 0 2.0455670934893533e-08
during O 0 3.5285761867953624e-08
remission O 0 3.9706236520942184e-08
of O 0 7.144450586693551e-10
lupus O 0 4.471067313716048e-06
, O 0 3.0116749094588613e-09
but O 0 9.107932186225298e-09
C1 O 0 4.289022399461828e-06
, O 0 6.240531202905686e-09
C4 O 0 1.8139063513444853e-06
, O 0 8.16414136295407e-09
C2 O 0 2.1150192424101988e-06
, O 0 3.3035856272789488e-09
and O 0 1.152279782701271e-08
C3 O 0 2.6109964892384596e-05
levels O 0 1.9271953988209134e-06
fell O 0 0.0008851391612552106
during O 0 1.923886429722188e-06
exacerbations O 0 9.252730524167418e-05
. O 0 5.98925623762625e-07

A O 0 4.350983999756863e-06
younger O 0 1.382832920171495e-06
half O 0 8.439948118166285e-08
- O 0 1.230487396242097e-05
sister O 0 1.5953073670971207e-05
, O 0 1.8641901355920254e-09
who O 0 1.337110977495115e-09
had O 0 7.497512832799202e-09
no O 0 2.9657918343417577e-09
underlying O 0 4.0749924323790765e-07
disease O 0 2.4067587673926027e-06
, O 0 1.4565728623239238e-09
was O 0 1.7055604928373214e-07
also O 0 1.726150666847559e-09
found O 0 1.607703858930165e-09
to O 0 2.9858449046571423e-09
lack O 0 6.306500921482439e-08
immunochemically O 0 6.0173868405399844e-05
detectable O 0 0.00022667543089482933
C5 O 0 0.00012157839955762029
. O 0 4.4408866983758344e-07

By O 0 3.604234279919183e-06
hemolytic O 0 0.011616277508437634
assay O 0 0.0005828567082062364
, O 0 1.2109283886729827e-07
she O 0 2.8166088128500633e-08
exhibited O 0 2.2168288182911056e-07
1 O 0 1.3953254551779537e-08
- O 0 4.546155807361174e-08
2 O 0 2.868426385305156e-09
% O 0 1.672614269310202e-10
of O 0 3.4986080005294795e-11
the O 0 7.89171672455069e-10
normal O 0 3.1161863489614916e-07
serum O 0 1.547438387206057e-06
C5 O 0 1.4011253597345785e-06
level O 0 9.627731500927439e-09
and O 0 1.2540264382465693e-09
normal O 0 1.0986515697197774e-08
concentrations O 0 6.617074443937554e-09
of O 0 1.9875896761778478e-10
other O 0 5.735528718631144e-10
complement O 0 1.9776763338086312e-08
components O 0 1.473106010507763e-07
. O 0 7.372076282763373e-08

C5 O 0 0.0009194862213917077
levels O 0 1.6348350300177117e-06
of O 0 2.1547990058934374e-09
other O 0 4.724923230448042e-10
family O 0 2.643254060075151e-09
members O 0 2.112580388402563e-10
were O 0 8.504740800496791e-10
either O 0 2.3923576453199757e-09
normal O 0 1.3487975536463637e-07
or O 0 7.3048043169876564e-09
approximately O 0 1.8928281164676264e-09
half O 0 1.5260976482522892e-08
- O 0 3.6831909255852224e-07
normal O 0 6.303482109615288e-07
, O 0 1.1109316799817748e-09
consistent O 0 1.0690661689238823e-08
with O 0 1.3266600040751086e-09
autosomal O 0 1.6260952179436572e-05
codominant O 0 3.950201062252745e-06
inheritance O 0 3.289753891522196e-08
of O 0 5.398152480573515e-10
the O 0 1.214712330721568e-08
gene O 0 1.0003755960497074e-05
determining O 0 3.016229129571002e-05
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.0927475386779406e-06

Normal O 0 0.0004590177268255502
hemolytic O 1 0.9444455504417419
titers O 0 0.01928522437810898
were O 0 9.687690862847376e-07
restored O 0 1.8073551473207772e-06
to O 0 9.768310604840735e-09
both O 0 2.7030806037942057e-08
homozygous O 0 0.0033589175436645746
C5 B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
deficient I-Disease 1 1.0
( O 0 7.696357897657435e-06
C5D B-Disease 1 1.0
) O 0 2.477838201286886e-08
sera O 0 3.157185233249038e-07
by O 0 1.2934756599136676e-09
addition O 0 1.2313580155520754e-09
of O 0 4.3145576000824803e-10
highly O 0 2.7444540862120448e-08
purified O 0 3.834996675777802e-07
human O 0 1.0995512411682284e-07
C5 O 0 5.393470200942829e-05
. O 0 2.6436694611220446e-07

In O 0 6.905769964760111e-07
specific O 0 3.5758273497776827e-07
C5 O 0 3.8716963899787515e-05
titrations O 0 1.5304171029129066e-05
, O 0 6.733686941373662e-09
however O 0 3.198398657033863e-09
, O 0 5.30497257233975e-10
it O 0 1.3308315560678352e-09
was O 0 3.95543011677546e-08
noted O 0 6.732604473924653e-10
that O 0 5.066509711770806e-11
when O 0 2.738490545439731e-10
limited O 0 3.701087769591993e-10
amounts O 0 3.120518565769004e-10
of O 0 5.592160068346175e-10
C5 O 0 1.1947101938858395e-06
were O 0 1.998477827669376e-09
assayed O 0 9.866263894764415e-08
in O 0 1.2047761677180802e-09
the O 0 8.643483151438147e-10
presence O 0 3.6289227178798455e-09
of O 0 8.882106716789906e-10
low O 0 6.155913183647499e-07
dilutions O 0 1.886811560325441e-06
of O 0 3.1207345596584446e-09
either O 0 1.71989825048513e-07
C5D B-Disease 1 1.0
serum O 0 4.945367436448578e-06
, O 0 1.191680754075719e-09
curving O 0 8.258869854671502e-08
rather O 0 2.8069699897770306e-09
than O 0 7.736863372187486e-10
linear O 0 1.5749076709425935e-08
dose O 0 4.290394599593128e-07
- O 0 4.314397585858387e-07
response O 0 8.038078647132352e-08
plots O 0 1.0340761491534067e-07
were O 0 3.3254150544337335e-09
consistently O 0 1.6609483566298877e-08
obtained O 0 1.4087166988474564e-09
, O 0 3.16143611289732e-10
suggesting O 0 3.744895504809165e-09
some O 0 1.0826188834300865e-09
inhibitory O 0 2.942927608273749e-07
effect O 0 4.234929917856789e-07
. O 0 8.799909068102352e-08

Further O 0 1.4087464705880848e-06
studies O 0 1.1984515424501296e-07
suggested O 0 6.804129526472025e-08
that O 0 2.966566992057551e-09
low O 0 1.024804987537209e-06
dilutions O 0 2.082012542814482e-05
of O 0 3.4862036812910446e-08
C5D B-Disease 1 1.0
serum O 0 2.6970556064043194e-06
contain O 0 7.690232450840995e-08
a O 0 1.0167127584281843e-08
factor O 0 7.611762775638908e-09
( O 0 1.6814369896422932e-09
or O 0 1.672704308397499e-09
factors O 0 1.4171113171812522e-09
) O 0 6.24048090980267e-10
interfering O 0 1.9182634147796307e-08
at O 0 1.1347637496328389e-08
some O 0 3.801901293787324e-10
step O 0 2.733388182463159e-09
in O 0 1.975677177412649e-09
the O 0 1.1694927692929014e-08
hemolytic O 0 1.466937374061672e-05
assay O 0 9.67489427239343e-07
of O 0 4.029881761624665e-09
C5 O 0 4.270361841918202e-06
, O 0 1.1894938367618124e-09
rather O 0 1.3822313293943012e-09
than O 0 5.476126774262013e-10
a O 0 8.39412628295122e-09
true O 0 4.9754071085317264e-08
C5 O 0 1.4564714547304902e-05
inhibitor O 0 8.527307500116876e-07
or O 0 5.93962745654153e-08
inactivator O 0 8.3406039266265e-06
. O 0 1.9886368818333722e-07

Of O 0 6.23394313947756e-08
clinical O 0 3.20134887488166e-07
interest O 0 9.07935202576482e-08
are O 0 2.2106709796076984e-09
( O 0 3.110180779586358e-09
a O 0 7.99715227373099e-09
) O 0 1.247492220635138e-09
the O 0 1.8110823951644761e-09
documentation O 0 1.930986925913203e-08
of O 0 7.404711066527625e-09
membranous O 1 0.8885947465896606
glomerulonephritis B-Disease 1 1.0
, O 0 5.35759727426921e-06
vasculitis B-Disease 1 1.0
, O 0 1.6037068917285069e-06
and O 0 0.0005622279131785035
arthritis B-Disease 1 1.0
in O 0 4.3517367487311276e-08
an O 0 2.336653537327038e-09
individual O 0 5.41372457973921e-09
lacking O 0 5.790162731500459e-07
C5 O 0 0.000148780585732311
( O 0 5.59587531867578e-09
and O 0 7.386214417870463e-10
its O 0 8.317245558941977e-09
biologic O 0 1.280313313145598e-07
functions O 0 3.159370098870795e-09
) O 0 5.248340095853621e-10
, O 0 2.4127991271605254e-10
and O 0 7.634600729389263e-10
( O 0 2.031033785598879e-09
b O 0 7.9845019484992e-09
) O 0 2.435208701356828e-10
a O 0 7.807425816963587e-10
remarkable O 0 1.0763971936000871e-08
propensity O 0 5.112091798764595e-07
to O 0 3.4838643614421017e-07
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 1.1615989592428377e-07
the O 0 1.2800392745759837e-08
proband O 0 1.826735342547181e-06
, O 0 4.0030592729500825e-10
even O 0 8.4387008492115e-10
during O 0 5.058558016912684e-09
periods O 0 2.7164411164903868e-08
of O 0 8.147260088797736e-10
low O 0 3.4758904803311452e-06
- O 0 7.096217018442985e-07
dose O 0 6.680853630314232e-07
or O 0 6.802413743400848e-09
alternate O 0 2.663062126373461e-08
- O 0 7.387777714029653e-07
day O 0 3.267093404701882e-07
corticosteroid O 0 3.756809746846557e-05
therapy O 0 3.549797384039266e-06
. O 0 1.1364407015435063e-07

Other O 0 2.3419782735345507e-07
observations O 0 3.978060476583778e-07
indicate O 0 1.233044173432063e-07
that O 0 1.3062041448463901e-09
the O 0 9.828938551947886e-09
C5D B-Disease 1 1.0
state O 0 3.0096303227367116e-09
is O 0 4.0194936268278525e-10
compatible O 0 1.4511967627584e-08
with O 0 1.8946261226560068e-10
normal O 0 3.055289710118814e-08
coagulation O 0 3.5180793389599785e-08
function O 0 3.5864804459606603e-09
and O 0 3.682751326117284e-10
the O 0 8.612315305356333e-10
capacity O 0 3.364768019764597e-09
to O 0 1.5092267435790063e-09
mount O 0 2.451616580856353e-07
a O 0 1.63242503958827e-07
neutrophilic O 0 0.00034788684570230544
leukocytosis O 0 0.0003739704261533916
during O 0 4.521576101979008e-06
pyogenic B-Disease 0 0.05876579508185387
infection I-Disease 0 0.13273945450782776
. O 0 1.3393635356351297e-07
. O 0 2.3654213521240308e-07

Susceptibility O 0 0.09352411329746246
to O 0 0.0058291153982281685
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 1 0.9590768814086914
twins O 0 0.022877590730786324
: O 0 1.5425613009156791e-09
the O 0 4.575667345019241e-10
role O 0 9.304995662873239e-10
of O 0 3.3212174677110795e-10
genes O 0 2.5736659026165398e-08
, O 0 3.82354548023045e-09
HLA O 0 5.408463152889453e-07
, O 0 8.744986401687527e-10
and O 0 6.692250087425577e-10
the O 0 7.180314565147228e-09
environment O 0 1.6732164453969744e-07
. O 0 4.929274055598398e-08

OBJECTIVE O 0 9.931038675858872e-07
To O 0 1.598153431814353e-08
determine O 0 7.0030616861060935e-09
the O 0 1.356453616097042e-09
relative O 0 9.178946491772422e-09
effects O 0 2.3829455741974925e-08
of O 0 2.3659280090626567e-10
genetic O 0 9.381737164915194e-09
and O 0 4.5842196705336846e-10
environmental O 0 1.3516859853623941e-09
factors O 0 7.465359441738428e-10
in O 0 8.586862776382986e-09
susceptibility O 0 0.00010139324876945466
to O 0 0.05496968328952789
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.0003827526525128633
AS B-Disease 1 0.9999945163726807
) O 0 5.955395820933518e-08
. O 0 6.279530140318457e-08

METHODS O 0 2.179096009058412e-05
Twins O 0 2.113194204866886e-05
with O 0 2.8570433130425954e-08
AS B-Disease 1 0.9978930354118347
were O 0 5.767179178661763e-09
identified O 0 1.3829460909775548e-09
from O 0 5.58133317341003e-10
the O 0 2.9812978752374875e-09
Royal O 0 1.2342935917786235e-07
National O 0 2.271845644941095e-08
Hospital O 0 4.18042827732279e-06
for O 0 1.4450228036366752e-07
Rheumatic B-Disease 1 0.9998972415924072
Diseases I-Disease 0 0.0019638128578662872
database O 0 5.776887064712355e-06
. O 0 6.785491564187396e-07

Clinical O 0 3.807877146755345e-05
and O 0 6.060011514819053e-07
radiographic O 0 6.0075370129197836e-05
examinations O 0 5.550675268750638e-06
were O 0 1.9494045488954725e-08
performed O 0 4.232249040114766e-08
to O 0 5.281421078251469e-09
establish O 0 8.031366149907626e-08
diagnoses O 0 8.30134013085626e-06
, O 0 2.312348756916549e-09
and O 0 7.306201155188319e-08
disease O 0 8.583555609220639e-05
severity O 0 0.00043753371573984623
was O 0 5.3285216381482314e-06
assessed O 0 2.4520929287064064e-08
using O 0 1.0530319727308779e-08
a O 0 1.124029758159395e-08
combination O 0 2.6495955651739678e-08
of O 0 1.9465911105243094e-09
validated O 0 2.0564665703659557e-07
scoring O 0 1.5592105739870021e-07
systems O 0 9.922490789904259e-06
. O 0 1.503759960996831e-07

HLA O 0 0.001993815880268812
typing O 0 0.0001331335661234334
for O 0 1.8135986579181917e-07
HLA O 0 1.958511711563915e-05
- O 0 2.1401751837402117e-06
B27 O 0 3.939588623325108e-06
, O 0 3.205558130048303e-08
HLA O 0 2.7590904210228473e-06
- O 0 2.512911692065245e-07
B60 O 0 4.333440415393852e-07
, O 0 2.8997375611794496e-09
and O 0 6.9437007255146455e-09
HLA O 0 1.2471674381231423e-05
- O 0 2.4678032787051052e-05
DR1 O 1 0.9896501302719116
was O 0 7.272165589711221e-07
performed O 0 1.818567163525131e-08
by O 0 1.0807168493442987e-09
polymerase O 0 1.586455340429893e-07
chain O 0 5.861086833647278e-07
reaction O 0 1.8489608066829533e-08
with O 0 8.793257233463692e-10
sequence O 0 2.081687355826034e-08
- O 0 8.126858830337369e-08
specific O 0 7.368726961942684e-09
primers O 0 1.1252566309849499e-06
, O 0 1.1470274730029928e-09
and O 0 1.1454424075907355e-09
zygosity O 0 1.4502982139674714e-06
was O 0 5.6258546266008125e-08
assessed O 0 4.297699973676572e-08
using O 0 5.8364442168112873e-08
microsatellite O 0 1.8730406736722216e-05
markers O 0 7.118250778148649e-06
. O 0 3.929885394882149e-07

Genetic O 0 3.3081116271205246e-05
and O 0 1.2614354716333764e-07
environmental O 0 1.6108169020867535e-08
variance O 0 1.8938548507207997e-08
components O 0 1.1615392025987603e-07
were O 0 5.398505642517648e-09
assessed O 0 5.364714450450947e-09
with O 0 7.0328676216036e-10
the O 0 6.69741195835627e-09
program O 0 3.209534682468984e-08
Mx O 0 7.48104525882809e-07
, O 0 2.736234849809449e-10
using O 0 8.309947174822696e-10
data O 0 1.9386591887382565e-08
from O 0 5.159024873968576e-10
this O 0 1.231524188183286e-10
and O 0 2.2850807357421843e-10
previous O 0 5.141434389344113e-09
studies O 0 1.005703187395568e-09
of O 0 2.3645566060714884e-10
twins O 0 2.428476761906495e-07
with O 0 4.284537169496616e-09
AS B-Disease 1 0.9999836683273315
. O 0 1.465134005229629e-07

RESULTS O 0 8.314761544170324e-06
Six O 0 8.844787657835695e-08
of O 0 6.245544525995683e-09
8 O 0 3.508758652515098e-07
monozygotic O 0 1.813268863770645e-05
( O 0 4.148708683260338e-07
MZ O 1 0.9881032109260559
) O 0 7.075634300690581e-08
twin O 0 0.0001800463505787775
pairs O 0 1.4824611582753278e-07
were O 0 5.810630199221123e-08
disease O 0 4.059384366428276e-07
concordant O 0 5.011709163227351e-07
, O 0 2.7389044365833115e-09
compared O 0 1.9897575143090762e-08
with O 0 1.3935188558633627e-09
4 O 0 9.33625265986393e-09
of O 0 4.789142971084459e-10
15 O 0 1.810889749265243e-08
B27 O 0 7.913894819466805e-07
- O 0 3.7420097669382812e-06
positive O 0 4.2899117147499055e-07
dizygotic O 0 1.0304834177077282e-05
( O 0 7.333789397989676e-08
DZ O 0 0.00017091188055928797
) O 0 2.4340966575664424e-08
twin O 0 6.145387487777043e-06
pairs O 0 2.690720002362923e-08
( O 0 1.014794648313e-08
27 O 0 4.370010842080774e-08
% O 0 6.411760566926716e-10
) O 0 2.520795516769425e-10
and O 0 4.6415846166603103e-10
4 O 0 4.34568780960376e-09
of O 0 8.437139875638877e-10
32 O 0 3.985936416484037e-07
DZ O 0 0.023981720209121704
twin O 0 0.00015991542022675276
pairs O 0 1.4126247549484106e-07
overall O 0 4.276905372080364e-07
( O 0 6.760944248895839e-09
12 O 0 6.702434163230464e-09
. O 0 5.46018008584781e-10
5 O 0 1.2685357653197116e-08
% O 0 2.3887509748021785e-09
) O 0 7.3697390412519326e-09
. O 0 4.2966675550815125e-08

Nonsignificant O 0 0.00028853354160673916
increases O 0 2.406338808214059e-06
in O 0 1.6902417243613854e-08
similarity O 0 1.2701942608828176e-08
with O 0 9.9924035712462e-10
regard O 0 1.3517090780013064e-09
to O 0 4.809779241554679e-09
age O 0 4.043619483695693e-08
at O 0 5.365473612073401e-07
disease O 0 7.801069841661956e-06
onset O 0 0.0001050656646839343
and O 0 1.1263925792093232e-08
all O 0 1.6606173380839806e-10
of O 0 7.219858738638507e-11
the O 0 3.047514240961391e-08
disease O 0 5.567284006247064e-06
severity O 0 2.1347773326851893e-06
scores O 0 7.170518045995777e-08
assessed O 0 5.78356242897371e-08
were O 0 4.408401199640366e-09
noted O 0 8.020661468322032e-09
in O 0 6.685672104822515e-08
disease O 0 0.0022433269768953323
- O 0 0.018868129700422287
concordant O 1 0.8785626888275146
MZ O 1 0.9999979734420776
twins O 0 3.567386738723144e-05
compared O 0 1.4659195812782855e-07
with O 0 4.2055170013099996e-08
concordant O 0 0.000712180626578629
DZ O 1 0.9996715784072876
twins O 0 0.00037016987334936857
. O 0 8.857767284098372e-07

HLA O 0 0.004681746941059828
- O 0 1.770577728166245e-05
B27 O 0 8.022047950362321e-06
and O 0 1.8630430531629827e-08
B60 O 0 1.626247012609383e-07
were O 0 1.929384429999459e-09
associated O 0 2.135124743674055e-09
with O 0 3.9529979289909534e-10
the O 0 3.4586648212098225e-08
disease O 0 5.588301519310335e-06
in O 0 7.772854360155179e-09
probands O 0 3.958939487347379e-06
, O 0 7.670916679636264e-10
and O 0 1.674440031074198e-10
the O 0 6.020098863857015e-10
rate O 0 2.810837713695946e-07
of O 0 6.961095033730658e-10
disease O 0 3.833003745512542e-07
concordance O 0 3.431474908666132e-07
was O 0 6.666457608162091e-08
significantly O 0 1.1029077739976856e-07
increased O 0 2.1733042032678895e-08
among O 0 6.307785405113009e-09
DZ O 0 0.0006004562019370496
twin O 0 4.591279139276594e-05
pairs O 0 1.594116660896816e-08
in O 0 2.6897999383379556e-09
which O 0 1.2374772317969018e-09
the O 0 4.838155209796469e-09
co O 0 1.7748388358995726e-07
- O 0 1.4430398778131348e-06
twin O 0 0.0007345564081333578
was O 0 7.666945833761929e-08
positive O 0 1.1806289279547855e-09
for O 0 2.1771354163924173e-10
both O 0 1.7051067224826966e-09
B27 O 0 4.6644865392408974e-07
and O 0 5.3402153810111486e-08
DR1 O 0 0.04418672248721123
. O 0 4.336987728947861e-07

Additive O 0 2.026133006438613e-05
genetic O 0 1.295594529437949e-06
effects O 0 6.247423129934759e-07
were O 0 3.0691187369313866e-09
estimated O 0 1.396893156702106e-09
to O 0 4.821993360160093e-10
contribute O 0 5.844514316954985e-10
97 O 0 1.3379433561055976e-08
% O 0 2.0338859763047168e-10
of O 0 6.286339504502081e-11
the O 0 1.6814658554409334e-09
population O 0 3.952411731233951e-09
variance O 0 6.628711446410307e-08
. O 0 1.1626142537579653e-07

CONCLUSION O 0 4.783702934219036e-06
Susceptibility O 0 2.0360212147352286e-05
to O 0 1.9468896539365232e-07
AS B-Disease 1 0.9896630644798279
is O 0 1.2469973942330626e-09
largely O 0 2.165581713953202e-09
genetically O 0 1.2674885141450432e-08
determined O 0 2.4980867152635255e-08
, O 0 6.112336192742873e-10
and O 0 3.927797531666499e-10
the O 0 8.096217030129083e-10
environmental O 0 1.4170573603422554e-09
trigger O 0 5.131709031047649e-07
for O 0 8.353840397212764e-10
the O 0 4.0365684128573776e-08
disease O 0 1.437843093299307e-05
is O 0 8.302347254129927e-09
probably O 0 8.508204274448872e-08
ubiquitous O 0 8.714579848856374e-07
. O 0 8.32991773336289e-08

HLA O 0 0.0009581479826010764
- O 0 7.818898666300811e-06
B27 O 0 1.990078089875169e-06
accounts O 0 6.445387867870522e-08
for O 0 7.860799788872441e-10
a O 0 1.3928651565464634e-09
minority O 0 1.1651283271518764e-09
of O 0 6.424366594259823e-11
the O 0 5.542421521731455e-10
overall O 0 2.945863997183551e-08
genetic O 0 1.7020506959397608e-07
susceptibility O 0 2.4694617195564206e-07
to O 0 5.1928434885439856e-08
AS B-Disease 1 0.99997878074646
. O 0 2.23329095661029e-07

Cell O 0 0.0003376126114744693
cycle O 0 0.0001711401855573058
- O 0 1.3301161743584089e-05
dependent O 0 5.96186225720885e-07
colocalization O 0 1.6728283753764117e-06
of O 0 3.965989314735907e-09
BARD1 O 0 2.1325226953194942e-06
and O 0 6.406935426639393e-09
BRCA1 O 0 2.726717411860591e-07
proteins O 0 9.19541776056576e-09
in O 0 2.1398540717143533e-09
discrete O 0 5.4728644727219944e-08
nuclear O 0 2.7845439376505965e-07
domains O 0 7.177359293564223e-07
. O 0 1.2743321065045166e-07

Germ O 0 0.02059185318648815
- O 0 0.003881189739331603
line O 0 1.305231035075849e-05
mutations O 0 9.324223242401786e-07
of O 0 2.233229601245057e-09
the O 0 1.7070046709477538e-08
BRCA1 O 0 3.52244160239934e-06
gene O 0 3.346873995724309e-07
predispose O 0 1.937783622452116e-07
women O 0 2.8209405922297037e-09
to O 0 1.9581125609846595e-09
early O 0 3.831022695521824e-06
- O 1 0.5381377339363098
onset O 1 0.9999986886978149
breast B-Disease 1 0.9999998807907104
and I-Disease 1 0.9998425245285034
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 1.3404157783725168e-08
compromising O 0 7.107445867404749e-07
the O 0 5.717804008043004e-09
genes O 0 5.620963605679208e-08
presumptive O 0 1.3483618204190861e-06
function O 0 7.549343372659223e-09
as O 0 1.0393329530344886e-09
a O 0 1.6719013729016297e-08
tumor B-Disease 0 7.870986337366048e-06
suppressor O 0 4.4750409870175645e-05
. O 0 3.8718593486919417e-07

Although O 0 3.530441858856648e-07
the O 0 1.4184642793679814e-08
biochemical O 0 1.0099079617020834e-07
properties O 0 3.204506526799378e-08
of O 0 1.932680682159571e-09
BRCA1 O 0 1.7658447859503212e-06
polypeptides O 0 3.009302247392043e-07
are O 0 9.77941616575606e-10
not O 0 8.27079515985929e-10
understood O 0 1.5168338807214354e-09
, O 0 2.5130136860340713e-10
their O 0 8.85531203920209e-10
expression O 0 1.2579630670472852e-08
pattern O 0 1.9704327769431984e-07
and O 0 2.026908418883977e-09
subcellular O 0 2.3021713957405154e-07
localization O 0 1.2309833152812644e-07
suggest O 0 8.576092724865703e-09
a O 0 9.62038448903968e-10
role O 0 1.306610264428798e-09
in O 0 2.568025569971155e-09
cell O 0 5.359713213692885e-06
- O 0 2.5677789381006733e-05
cycle O 0 7.2253760663443245e-06
regulation O 0 1.8037064819509396e-06
. O 0 1.031200511647512e-07

When O 0 8.024779276638583e-07
resting O 0 1.0560106602497399e-06
cells O 0 1.5154861898736272e-07
are O 0 1.281782902040618e-09
induced O 0 5.984328765862301e-08
to O 0 4.30143742846667e-09
proliferate O 0 2.8132004104008956e-07
, O 0 3.265413772712833e-10
the O 0 7.228487808319528e-10
steady O 0 1.7123632289894886e-07
- O 0 2.361588968824435e-08
state O 0 9.579278481552933e-10
levels O 0 5.011424608625248e-09
of O 0 1.8987718342078352e-10
BRCA1 O 0 6.983829337059433e-08
increase O 0 2.433046430994068e-09
in O 0 2.7521795953333594e-09
late O 0 2.819912424456561e-06
G1 O 0 6.312734512903262e-07
and O 0 7.399850177058909e-10
reach O 0 1.1051893844538085e-09
a O 0 1.8043589955496486e-09
maximum O 0 1.5874990211273143e-08
during O 0 9.780935528169721e-08
S O 0 7.1919935180631e-06
phase O 0 3.400260766284191e-07
. O 0 8.863093370337083e-08

Moreover O 0 1.3969558949611383e-06
, O 0 9.66075042185821e-09
in O 0 5.550062187609228e-09
S O 0 9.158695775113301e-07
phase O 0 6.906206095891321e-08
cells O 0 1.364394961456128e-07
, O 0 7.23972259919492e-09
BRCA1 O 0 1.5281474361472647e-06
polypeptides O 0 2.4869771664270957e-07
are O 0 1.495849000221483e-09
hyperphosphorylated O 0 3.5985493695989135e-07
and O 0 2.661131315306875e-09
accumulate O 0 1.4341426890496223e-07
into O 0 7.158654113936791e-09
discrete O 0 2.764018063317053e-07
subnuclear O 0 8.14881786936894e-06
foci O 0 8.934206562116742e-06
termed O 0 1.8217301658296492e-06
" O 0 9.430539193999721e-08
BRCA1 O 0 7.588203970954055e-06
nuclear O 0 4.076075583725469e-06
dots O 0 4.3792046199087054e-05
. O 0 4.24571084067793e-07

" O 0 4.621307198249269e-06
BRCA1 O 0 6.250243313843384e-05
associates O 0 2.775068878690945e-06
in O 0 3.503507883806378e-08
vivo O 0 5.15574583914713e-07
with O 0 4.088942073821045e-09
a O 0 7.907846111265826e-08
structurally O 0 6.267612479859963e-05
related O 0 2.1463262100951397e-07
protein O 0 1.9701444671227364e-06
termed O 0 1.1516992344695609e-05
BARD1 O 0 0.0003865312901325524
. O 0 7.48769764413737e-07

Here O 0 4.747222703826992e-07
we O 0 7.002661117638809e-09
show O 0 1.0582589915486551e-08
that O 0 1.4423180705325223e-10
the O 0 8.144385721386982e-10
steady O 0 1.8977895877014817e-07
- O 0 3.219958344402585e-08
state O 0 1.3776254581543412e-09
levels O 0 8.787376160057647e-09
of O 0 2.5679999793304376e-10
BARD1 O 0 5.986144060443621e-07
, O 0 3.026859041188601e-10
unlike O 0 9.454809157816157e-10
those O 0 1.2560702478126018e-10
of O 0 1.3655175601368086e-10
BRCA1 O 0 2.2416470812913758e-07
, O 0 3.4432065532108425e-10
remain O 0 9.060832639740113e-10
relatively O 0 2.664442666500122e-09
constant O 0 1.215778588914418e-08
during O 0 3.34698846415904e-08
cell O 0 1.1203780559299048e-05
cycle O 0 1.8254175301990472e-05
progression O 0 8.081326086539775e-06
. O 0 1.9564677700145694e-07

However O 0 6.94939387813065e-07
, O 0 2.450391001218577e-08
immunostaining O 0 3.278002850493067e-06
revealed O 0 2.435504313780257e-07
that O 0 3.760406208641598e-09
BARD1 O 0 2.7627004328678595e-06
resides O 0 1.064910861714452e-07
within O 0 2.1096310476309554e-08
BRCA1 O 0 1.1472247933852486e-06
nuclear O 0 2.0373946085783246e-07
dots O 0 1.1899118135261233e-06
during O 0 1.3608264737285936e-07
S O 0 5.243452960712602e-07
phase O 0 5.750297127349313e-09
of O 0 1.422366807668496e-10
the O 0 7.941212132323017e-10
cell O 0 2.7301339855512197e-07
cycle O 0 1.7719435163598973e-07
, O 0 1.3759440808946977e-10
but O 0 5.724782106697468e-11
not O 0 7.315770211846484e-11
during O 0 1.8245559507690245e-09
the O 0 3.5329115188886817e-09
G1 O 0 1.133033379119297e-06
phase O 0 1.6745924824590475e-07
. O 0 1.4027898487256607e-07

Nevertheless O 0 1.702010558801703e-05
, O 0 1.933880753313133e-07
BARD1 O 0 1.5433295629918575e-05
polypeptides O 0 1.720365503388166e-06
are O 0 1.477170274988282e-09
found O 0 7.786590816571959e-10
exclusively O 0 2.4718278535118543e-09
in O 0 9.547193036141266e-10
the O 0 8.784656890803433e-10
nuclear O 0 1.2184134590143003e-08
fractions O 0 6.0870233298260246e-09
of O 0 2.17125512014249e-10
both O 0 1.3957905942163507e-09
G1 O 0 1.3018269555686857e-06
- O 0 1.6771400623838417e-07
and O 0 6.094156290714636e-09
S O 0 2.9836801331839524e-06
- O 0 3.3085504469454463e-07
phase O 0 1.056619609585141e-07
cells O 0 2.563185432791215e-07
. O 0 8.052932543023417e-08

Therefore O 0 2.8507834031188395e-06
, O 0 6.643938377237646e-08
progression O 0 6.270074663916603e-07
to O 0 1.7068810365117315e-08
S O 0 2.0012307686556596e-06
phase O 0 4.498379269080033e-08
is O 0 9.393513744626603e-10
accompanied O 0 4.1108219051011474e-09
by O 0 4.0972308879005936e-10
the O 0 7.255118728011212e-10
aggregation O 0 2.0707060954805456e-08
of O 0 1.2899501466989705e-09
nuclear O 0 2.3566083484638511e-07
BARD1 O 0 8.092231837508734e-06
polypeptides O 0 7.230768801491649e-07
into O 0 5.8456020468611314e-08
BRCA1 O 0 1.302813325310126e-05
nuclear O 0 1.5752809758851072e-06
dots O 0 2.3011774828773923e-05
. O 0 2.820297595462762e-07

This O 0 5.217161174186913e-07
cell O 0 1.3553878488892224e-05
cycle O 0 2.604878318379633e-05
- O 0 3.124910790575086e-06
dependent O 0 2.9470785989360593e-07
colocalization O 0 1.750392584654037e-06
of O 0 3.4854306107945376e-09
BARD1 O 0 8.22968013380887e-06
and O 0 9.91079041057219e-09
BRCA1 O 0 8.147575840666832e-07
indicates O 0 6.115149719931878e-09
a O 0 2.7676614333671523e-09
role O 0 3.7481973080844e-09
for O 0 8.476981894212088e-10
BARD1 O 0 1.4706748743265052e-06
in O 0 3.891523192578461e-08
BRCA1 O 0 2.79129726550309e-05
- O 0 9.904225407808553e-06
mediated O 0 2.9492139219655655e-05
tumor B-Disease 0 6.314874917734414e-05
suppression O 0 6.32351157037192e-06
. O 0 4.056118427797628e-07

Ethnic O 0 8.838132430355472e-07
differences O 0 3.5880495374840393e-07
in O 0 3.788564129081351e-08
the O 0 6.437402078063315e-08
HFE O 0 0.0003595910675358027
codon O 0 6.132564885774627e-05
282 O 0 8.18632270238595e-06
( O 0 1.7189551044793916e-06
Cys O 1 0.8563589453697205
/ O 0 0.0006221220246516168
Tyr O 0 4.6372577344300225e-05
) O 0 1.8406606727694452e-07
polymorphism O 0 1.9009876268683e-05
. O 0 8.633570018901082e-07

Recent O 0 1.3592535879070056e-06
studies O 0 7.594624662488059e-08
have O 0 5.708552297534197e-09
shown O 0 8.014120567167993e-08
that O 0 3.943054878163821e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.0001155663703684695
HH B-Disease 1 0.9997690320014954
) O 0 6.617490999616393e-09
is O 0 1.1356054985256492e-09
likely O 0 3.930129999218934e-09
to O 0 9.019244240349167e-10
be O 0 5.708908901169707e-10
caused O 0 7.279712832541918e-09
by O 0 8.278638885528267e-10
homozygosity O 0 1.5311862000544352e-07
for O 0 4.4753450945123063e-10
a O 0 4.791941510262632e-09
Cys282Tyr O 0 9.015843716042582e-07
mutation O 0 1.0586288112790498e-07
in O 0 3.86270260221977e-09
the O 0 1.7190840750913594e-08
HFE O 0 1.942905510077253e-05
gene O 0 5.686830490958528e-07
located O 0 3.663496102035424e-07
4 O 0 4.0551128677179804e-07
. O 0 9.67187148148696e-08

5 O 0 2.9444447136484087e-05
Mb O 0 0.0005121089634485543
telomeric O 0 0.0001695493992883712
to O 0 1.2687022490354138e-06
HLA O 0 5.8669709687819704e-05
- O 0 3.6245432966097724e-06
A O 0 5.931537998549175e-07
. O 0 2.6870486635743873e-07

Population O 0 2.7573469196795486e-07
studies O 0 2.2516092101909635e-08
of O 0 2.538589893852361e-10
this O 0 9.107197773694509e-10
polymorphism O 0 1.4393218350505776e-07
are O 0 1.904804369790014e-10
facilitated O 0 1.9076047408361774e-09
by O 0 3.835332329504837e-10
the O 0 1.335301536009581e-09
fact O 0 8.075889956771221e-10
that O 0 2.0118744170627423e-10
the O 0 2.909865237654685e-09
Cys282Tyr O 0 8.658075216771977e-07
mutation O 0 1.6902279753594485e-07
creates O 0 1.589141085389656e-08
a O 0 1.851346276282584e-08
Rsal O 0 3.7375873489509104e-06
restriction O 0 3.1751514484312793e-07
site O 0 5.540820211535902e-07
. O 0 8.887894153986053e-08

We O 0 4.568242673030909e-07
have O 0 9.768943876053982e-09
studied O 0 1.4176771756524431e-08
the O 0 1.4455858732276283e-08
codon O 0 2.4214541554101743e-06
282 O 0 9.529769045002467e-07
( O 0 2.9603688744828105e-07
Cys O 0 0.3007130026817322
/ O 0 0.0001551747409394011
Tyr O 0 6.520470378745813e-06
) O 0 8.283286945243162e-09
polymorphism O 0 1.7028364140969643e-07
in O 0 2.0621051532998536e-09
different O 0 8.103401283321432e-10
ethnic O 0 3.7401131081082895e-09
groups O 0 1.0676438400025745e-08
. O 0 6.595870161163475e-08

In O 0 4.1322545030197944e-07
agreement O 0 2.5249363488910603e-08
with O 0 3.6831042660168123e-09
previous O 0 7.75442146050409e-08
observations O 0 4.006317411153759e-08
the O 0 1.458408505072839e-08
Tyr O 0 1.4796942195971496e-06
allele O 0 3.3725771686476946e-07
appeared O 0 1.338516995019745e-07
to O 0 9.113366727930838e-10
be O 0 2.389656528212214e-10
rare O 0 1.9613908275317726e-09
or O 0 8.297850406790985e-09
absent O 0 4.312998669320223e-08
in O 0 5.099419553289408e-09
Asiatic O 0 1.2167812712959858e-07
( O 0 1.2215425337913643e-09
Indian O 0 4.192122482482574e-10
, O 0 2.1281833240127668e-10
Chinese O 0 6.405673769194209e-10
) O 0 2.7877833375100636e-09
populations O 0 2.0846634640747652e-08
. O 0 2.847528079996664e-08

The O 0 2.766557827271754e-07
highest O 0 3.010200657627138e-07
allele O 0 1.7133805840785499e-06
frequency O 0 2.5078290946112247e-06
( O 0 1.8921975097896393e-08
7 O 0 2.242497565418944e-08
. O 0 6.912604377795617e-10
5 O 0 5.949909009927978e-09
% O 0 4.91081952880279e-10
) O 0 8.791579686473483e-10
was O 0 6.913229810834309e-08
found O 0 4.9274664348786246e-09
in O 0 1.6804150959615072e-08
Swedes O 0 1.688629367890826e-06
. O 0 1.1748365835728691e-07

Saamis O 0 0.0002280970074934885
( O 0 9.202876185554487e-07
2 O 0 1.2579900499076757e-07
% O 0 5.5340794169467245e-09
) O 0 1.0563083741033097e-09
and O 0 1.238107616430284e-09
Mordvinians O 0 2.1711916531330644e-07
( O 0 1.3074079596719912e-09
1 O 0 1.1421417145385249e-09
. O 0 1.3197792858576918e-10
8 O 0 5.6920694824214024e-09
% O 0 2.0039964132578802e-10
) O 0 2.9914981602985335e-10
had O 0 7.226300002827202e-09
significantly O 0 7.172022975510117e-08
lower O 0 2.4544660846004263e-06
frequencies O 0 4.09778266430294e-07
of O 0 7.580897021242095e-10
the O 0 1.701764240635839e-08
Tyr O 0 6.605125690839486e-06
allele O 0 3.34938181367761e-06
. O 0 1.3500303452929074e-07

Comparisons O 0 5.455819973576581e-06
with O 0 7.903579302137587e-08
allele O 0 2.753615035544499e-06
frequencies O 0 1.231384317179618e-06
based O 0 2.085824668540681e-08
on O 0 6.094448679050402e-08
prevalence O 0 5.73657871427713e-07
estimates O 0 7.596348439165013e-08
of O 0 1.0388796489735341e-08
HH B-Disease 1 0.9997542500495911
showed O 0 5.8160685512120835e-06
some O 0 2.771924689781713e-09
disagreements O 0 2.2322215187386973e-08
with O 0 4.1864650635048406e-10
the O 0 2.869356530155187e-09
RFLP O 0 4.4883560690323066e-07
data O 0 4.4316884384443256e-08
, O 0 5.531143321135801e-10
particularly O 0 1.849876918313953e-09
in O 0 5.515532919275756e-09
Finns O 0 1.0823210914168158e-06
. O 0 9.584842075582856e-08

The O 0 2.4430701159872115e-06
newly O 0 2.5543936317262705e-06
described O 0 2.042150072156801e-06
HFE O 0 0.00011924556019948795
marker O 0 1.1068469802921754e-06
provides O 0 1.2275410021800326e-08
a O 0 5.039134443052262e-09
new O 0 8.927561800931016e-09
approach O 0 6.738479108037154e-09
to O 0 1.3415355493151537e-09
the O 0 2.1551977980038828e-09
screening O 0 3.737055820351998e-08
of O 0 1.1460368209981198e-09
HH B-Disease 0 0.13417311012744904
as O 0 5.874118969018127e-10
well O 0 9.698292863236091e-11
as O 0 7.143506619566864e-11
studies O 0 4.894088259654872e-11
of O 0 1.540607225125612e-11
the O 0 4.695885902350483e-10
relationship O 0 2.007386701308178e-09
between O 0 1.510488067957283e-09
the O 0 1.6204717567802618e-08
HFE O 0 2.8989346901653334e-05
Tyr O 0 2.599339495645836e-06
allele O 0 6.44707256469701e-07
and O 0 5.405367264899041e-09
different O 0 2.2448169545441488e-08
disorders O 0 0.0002027971640927717
including O 0 4.7104322220548056e-07
cancer B-Disease 0 0.006595468148589134

Autosomal B-Disease 1 0.9999881982803345
dominant I-Disease 1 0.9999496936798096
neurohypophyseal I-Disease 1 0.999998927116394
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9972801208496094
associated O 0 4.352440100774402e-06
with O 0 3.370454138007517e-08
a O 0 1.909954505663336e-07
missense O 0 0.00012762293044943362
mutation O 0 1.4514879694615956e-05
encoding O 0 6.587297320947982e-06
Gly23 O 0 0.00031278037931770086
- O 0 0.000219089983147569
- O 0 6.64195031276904e-05
> O 0 6.962136922084028e-06
Val O 0 1.9915396478609182e-05
in O 0 1.9996423361590132e-07
neurophysin O 0 3.2492680475115776e-05
II O 0 1.4604744137614034e-05
. O 0 1.7382180317326856e-07

Autosomal B-Disease 1 0.999974250793457
dominant I-Disease 1 0.9999315738677979
neurohypophyseal I-Disease 1 0.999998927116394
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9998559951782227
( O 0 3.2568043479841435e-06
ADNDI B-Disease 0 0.00013446911179926246
) O 0 1.992225762137423e-08
is O 0 3.4913454349805306e-09
an O 0 1.1038842728794407e-07
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 4.455262023839168e-05
by O 0 2.8935576779076655e-07
progressive O 0 0.006619809195399284
degeneration O 0 5.70642550883349e-05
of O 0 1.6865503438268092e-09
the O 0 1.61428648226547e-08
magnocellular O 0 4.894674020761158e-06
neurons O 0 2.8717022360069677e-07
of O 0 8.575286591927522e-10
the O 0 6.44826236850804e-09
hypothalamus O 0 6.308533784249448e-07
leading O 0 1.2465034338049463e-08
to O 0 3.3464504500813064e-09
decreased O 0 4.2684622059141475e-08
ability O 0 5.659505752930727e-09
to O 0 1.3125125430946127e-09
produce O 0 4.74121142346462e-09
the O 0 2.406247823216745e-08
hormone O 0 6.764235536138585e-07
arginine O 0 7.146084612941195e-07
vasopressin O 0 1.3087928891764022e-06
( O 0 4.474376424923321e-08
AVP O 0 1.5610004311383818e-06
) O 0 3.415574312271019e-08
. O 0 6.92232120513836e-08

Affected O 0 6.5939098021772224e-06
individuals O 0 2.025255341209231e-08
are O 0 1.4148158200555372e-09
not O 0 2.5499955480512426e-09
symptomatic O 0 4.7342874154310266e-07
at O 0 1.043238057718554e-06
birth O 0 2.8220722469995962e-06
, O 0 7.281819036641934e-10
but O 0 9.892353602936055e-10
usually O 0 7.041679594976813e-08
develop O 0 5.433819296740694e-06
diabetes B-Disease 0 0.03421768918633461
insipidus I-Disease 0 0.0003169220872223377
at O 0 3.5483351439324906e-06
1 O 0 1.7225211195182055e-06
- O 0 0.000415200978750363
6 O 0 1.330319150838477e-06
yr O 0 9.12899304239545e-06
of O 0 3.8905709764947005e-09
age O 0 7.89172389659143e-08
. O 0 5.225561849897531e-08

The O 0 3.3135015087282227e-07
genetic O 0 1.038976620293397e-06
locus O 0 9.755742667039158e-07
of O 0 2.9859130723508542e-09
the O 0 5.933841507044235e-08
disease O 0 1.3629616660182364e-05
is O 0 5.1708788362248015e-09
the O 0 3.545367732726845e-08
AVP O 0 2.4885363018256612e-05
- O 0 2.4792343538138084e-05
neurophysin O 0 5.9896668972214684e-05
II O 0 1.0153222319786437e-05
( O 0 1.0580894382883343e-08
NPII O 0 4.977481466994504e-07
) O 0 1.3369682028141483e-09
gene O 0 2.3317927144717032e-08
, O 0 4.084715066188238e-10
and O 0 9.826833791137801e-10
mutations O 0 6.296272658801172e-08
that O 0 1.4910633838738363e-09
cause O 0 9.906597853159838e-08
ADNDI B-Disease 0 2.0690044038929045e-05
have O 0 4.061535108235148e-09
been O 0 1.6026306948191404e-09
found O 0 1.2888730083204791e-09
in O 0 5.536252012383613e-10
both O 0 3.2766186985888623e-10
the O 0 1.4002889958675269e-09
signal O 0 1.3894010919557331e-07
peptide O 0 2.670019938477708e-08
of O 0 3.5630914885231846e-10
the O 0 6.732428392552947e-09
prepro O 0 2.5148369786620606e-06
- O 0 1.2911812063975958e-06
AVP O 0 5.663229330821196e-06
- O 0 6.074702696423628e-07
NPII O 0 2.6707132292358438e-06
precursor O 0 2.2982030145612953e-07
and O 0 5.573549177739778e-09
within O 0 2.1364048308214478e-08
NPII O 0 9.41342568694381e-06
itself O 0 5.852696745023422e-07
. O 0 1.326749696772822e-07

An O 0 3.679357121200155e-07
affected O 0 1.1826871286757523e-06
girl O 0 8.365283065359108e-06
who O 0 9.92151427681165e-09
presented O 0 1.443756314500888e-08
at O 0 3.899019773712098e-08
9 O 0 5.6498127065651715e-08
months O 0 4.007515208570567e-09
of O 0 3.1434219116555084e-10
age O 0 7.807845925356105e-09
and O 0 1.0569835007245842e-09
her O 0 6.268326746550201e-09
similarly O 0 2.3223549305839697e-07
affected O 0 5.31429478201062e-08
younger O 0 1.1282659784228599e-07
brother O 0 5.120992341289821e-07
and O 0 7.058041262553161e-09
father O 0 7.638948318344774e-08
were O 0 7.234142729295456e-10
all O 0 3.5079762011891447e-11
found O 0 2.2600056548416347e-10
to O 0 5.629959831665587e-10
have O 0 3.513984936365233e-10
a O 0 5.7059397207126494e-09
novel O 0 9.63624131600227e-08
missense O 0 5.85050383961061e-06
mutation O 0 1.4860381725156913e-06
( O 0 6.819551146008962e-08
G1758 O 0 6.144267899799161e-06
- O 0 3.592459324863739e-05
- O 0 2.1669275156455114e-05
> O 0 1.8154968302042107e-06
T O 0 8.330001037393231e-06
) O 0 3.310252516541823e-09
encoding O 0 4.4420552569590654e-08
the O 0 3.341692256242368e-09
amino O 0 3.749643084915988e-08
acid O 0 5.2434227626463326e-08
substitution O 0 1.1111531250662665e-07
Gly23 O 0 7.80703794589499e-06
- O 0 7.815336175553966e-06
- O 0 1.2694293218373787e-05
> O 0 6.406121428881306e-06
Val O 0 3.484000626485795e-05
within O 0 2.6847894218917645e-07
NPII O 0 3.404026574571617e-05
. O 0 2.6441435352353437e-07

The O 0 1.0376617183283088e-06
mutation O 0 1.0570733138592914e-05
was O 0 1.2068470311987767e-07
confirmed O 0 4.0728007633106245e-08
by O 0 9.784272059221166e-09
restriction O 0 2.996801242716174e-07
endonuclease O 0 2.0341056369943544e-05
analysis O 0 4.2976182612619596e-07
. O 0 2.2663238041786826e-07

A O 0 1.5008106856839731e-05
T1 O 0 0.003365094540640712
- O 0 5.390093974710908e-06
weighted O 0 1.1286140306765446e-06
magnetic O 0 3.666802683710557e-07
resonance O 0 5.095017741041374e-07
imaging O 0 1.0901223959081108e-06
of O 0 2.87815948851744e-09
the O 0 3.9254050676618135e-08
fathers O 0 1.1152503702760441e-06
pituitary O 0 4.0797394831315614e-06
gland O 0 1.222295736624801e-06
demonstrates O 0 8.143818064354491e-08
an O 0 1.1906998054200812e-08
attenuated O 0 5.1214989071013406e-05
posterior O 0 4.246933895046823e-05
pituitary O 0 0.0001246847677975893
bright O 0 6.899828440509737e-05
spot O 0 2.0539220713544637e-05
. O 0 5.291991556077846e-07

This O 0 9.211024689648184e-07
mutation O 0 1.8650378478923813e-05
may O 0 8.80704305927793e-07
be O 0 1.1587987236438835e-09
valuable O 0 6.628920745654909e-10
for O 0 2.50240966837012e-10
developing O 0 2.1040202913269468e-09
models O 0 6.954400078029721e-08
of O 0 4.363736483270486e-09
dominantly B-Disease 0 0.05642827972769737
inherited I-Disease 1 0.9996373653411865
neurodegeneration I-Disease 1 1.0
, O 0 4.4682169075827005e-09
as O 0 4.564092159764499e-10
the O 0 4.978211731732074e-10
early O 0 1.8153481562421803e-07
age O 0 5.136396197258364e-09
of O 0 2.2974484814586305e-10
onset O 0 2.0204092834319454e-06
of O 0 4.562501487725967e-09
symptoms O 0 5.4789015848655254e-05
suggests O 0 1.2985562847234178e-08
that O 0 3.3365954443809187e-10
this O 0 1.439543040326896e-09
mutation O 0 3.1145879120231257e-07
may O 0 1.3028126488734415e-07
be O 0 4.647590645667776e-10
particularly O 0 2.5594582009347278e-09
deleterious O 0 3.2981546382870874e-07
to O 0 3.518050739614864e-09
the O 0 1.6938111357944763e-08
magnocellular O 0 7.189332791313063e-06
neuron O 0 4.181548320048023e-06
. O 0 2.1403041117196153e-08
. O 0 7.197773044254063e-08

Frequent O 0 0.00020990311168134212
inactivation O 0 0.00021685643878299743
of O 0 4.148641323808988e-07
PTEN O 0 0.0010625183349475265
/ O 0 0.000114999151264783
MMAC1 O 0 0.00011264410568401217
in O 0 2.6492725737625733e-06
primary O 1 0.9458296895027161
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.933799234800972e-06

Sporadic B-Disease 1 0.9999967813491821
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 3.525263991832617e-07
the O 0 9.288969593512775e-09
most O 0 2.2723301018601205e-09
common O 0 3.1704608716154326e-08
male B-Disease 0 1.2560839479647257e-07
cancer I-Disease 0 3.308547320557409e-07
in O 0 1.8177062077739947e-09
the O 0 1.7802890273088678e-09
Western O 0 2.8392250328579394e-08
world O 0 1.2577111796474583e-08
, O 0 2.017361555584074e-10
yet O 0 2.2255448872687822e-10
many O 0 1.1070702514437425e-11
of O 0 7.424569639646883e-12
the O 0 1.1596294063886958e-10
major O 0 4.787115703841494e-10
genetic O 0 2.116675279495439e-09
events O 0 4.559359001454766e-10
involved O 0 6.448726552754636e-10
in O 0 2.2225510321050024e-09
the O 0 2.3317738850892056e-09
progression O 0 1.2219230072219034e-08
of O 0 7.194674717103666e-11
this O 0 7.420372094557592e-10
often O 0 4.401749009730338e-08
fatal O 0 0.04572940990328789
cancer B-Disease 0 0.00030524239991791546
remain O 0 4.384538243584757e-08
to O 0 3.9472962676256884e-09
be O 0 5.307211559113512e-09
elucidated O 0 1.5735932947791298e-06
. O 0 4.201780967605373e-08

Numerous O 0 9.090412277146243e-06
cytogenetic O 0 0.0007302298326976597
and O 0 5.604786679214158e-07
allelotype O 0 2.704004327824805e-05
studies O 0 9.407364132130169e-08
have O 0 3.2224267698666154e-09
reported O 0 2.0133624900608993e-07
frequent O 0 4.74820978979551e-07
loss O 0 2.7072917418990983e-07
of O 0 3.777825163808757e-09
heterozygosity O 0 6.620039130211808e-06
on O 0 1.31253784729779e-06
chromosomal O 0 0.0026592870708554983
arm O 0 0.00035220899735577404
10q O 0 7.589564575027907e-06
in O 0 7.0295874365911e-07
sporadic B-Disease 1 0.9999990463256836
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.6811512750791735e-06

Deletion O 0 0.00014289708633441478
mapping O 0 7.288854249054566e-06
studies O 0 2.3497501899782947e-07
have O 0 6.587569600924326e-09
unambiguously O 0 4.279834797671356e-07
identified O 0 1.1786203124586336e-08
a O 0 2.6840192290933373e-09
region O 0 6.5960437112266845e-09
of O 0 8.583435628928271e-10
chromosome O 0 5.479444098455133e-07
10q23 O 0 2.033628732078796e-07
to O 0 2.7908104716090065e-09
be O 0 3.890487376700946e-10
the O 0 6.20526463546156e-10
minimal O 0 1.2209980582156277e-08
area O 0 3.0676439166654745e-09
of O 0 1.3898716622051666e-09
loss O 0 5.859756129211746e-07
. O 0 1.370482465290479e-07

A O 0 5.7696192925504874e-06
new O 0 1.2602586139109917e-06
tumor B-Disease 0 1.615283872524742e-05
suppressor O 0 2.2133941456559114e-05
gene O 0 2.5496331090835156e-06
, O 0 3.252525004882045e-08
PTEN O 0 8.846803393680602e-05
/ O 0 3.0324554245453328e-05
MMAC1 O 0 4.8686717491364107e-05
, O 0 6.066542823646159e-09
was O 0 2.0238806186512193e-08
isolated O 0 3.59546810102529e-08
recently O 0 9.322518934595792e-08
at O 0 9.077374407695515e-09
this O 0 2.325075548759159e-10
region O 0 9.961405034175641e-10
of O 0 2.993010561613829e-10
chromosome O 0 1.3144929766895075e-07
10q23 O 0 5.75415128878376e-08
and O 0 6.692033038824263e-10
found O 0 9.175843973530107e-10
to O 0 6.558530385447625e-10
be O 0 5.268379621448105e-10
inactivated O 0 9.079091967123532e-08
by O 0 4.776863904432105e-10
mutation O 0 2.095930540235713e-08
in O 0 1.1508916486491216e-08
three O 0 6.282348749664379e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 5.8464513131184503e-05
lines O 0 0.0001065254255081527
. O 0 3.049956944778387e-07

We O 0 2.0716129256470595e-06
screened O 0 1.300700387218967e-05
80 O 0 4.109987912670476e-06
prostate B-Disease 1 0.9988620281219482
tumors I-Disease 1 1.0
by O 0 7.544711877471855e-08
microsatellite O 0 5.476286332850577e-06
analysis O 0 2.4887180316568447e-08
and O 0 1.8690642367147348e-09
found O 0 5.220717191889435e-09
chromosome O 0 3.869965610192594e-07
10q23 O 0 1.2943135629939206e-07
to O 0 7.10214553834021e-09
be O 0 1.3256582498399894e-09
deleted O 0 1.228220583016082e-07
in O 0 8.413552521346901e-09
23 O 0 3.9874493040770176e-08
cases O 0 1.7909977501062713e-08
. O 0 5.308591255470674e-08

We O 0 3.1927382337926247e-07
then O 0 3.2426143548036634e-08
proceeded O 0 3.4770195611599775e-08
with O 0 1.3001515419830412e-09
sequence O 0 1.337728949835082e-08
analysis O 0 4.5080565946875595e-09
of O 0 5.295479610367693e-10
the O 0 5.230973876280132e-09
entire O 0 2.1219157986251957e-07
PTEN O 0 2.9179560442571528e-05
/ O 0 4.104806066607125e-06
MMAC1 O 0 7.847271263017319e-06
coding O 0 4.35255196862272e-06
region O 0 1.2008634087123937e-07
and O 0 1.559519269278553e-08
tested O 0 9.830179692471575e-08
for O 0 8.260547246230487e-10
homozygous O 0 1.3161736944766744e-07
deletion O 0 1.1988905157522822e-07
with O 0 9.932075162311094e-10
new O 0 3.863500452894186e-08
intragenic O 0 3.874779849866172e-06
markers O 0 1.0017067353373932e-07
in O 0 3.049152264011923e-09
these O 0 3.57242790904877e-10
23 O 0 2.6774438222076924e-09
cases O 0 2.762328144001458e-10
with O 0 1.1862969495624043e-09
10q23 O 0 9.268086955671606e-07
loss O 0 1.3934536013948673e-07
of O 0 1.192172405239944e-08
heterozygosity O 0 2.099342418659944e-05
. O 0 3.6513441159513604e-07

The O 0 9.607153828028459e-08
identification O 0 3.324427311213185e-08
of O 0 1.64221702902978e-09
the O 0 4.744034054482427e-09
second O 0 2.676280885793858e-08
mutational O 0 3.943222964153392e-06
event O 0 2.03220107408697e-08
in O 0 4.883034865343916e-09
10 O 0 3.4836029616513997e-09
( O 0 3.5187019964411093e-09
43 O 0 1.6252323931098545e-08
% O 0 5.5077959970617485e-09
) O 0 2.4106148543978634e-07
tumors B-Disease 1 1.0
establishes O 0 9.905538900056854e-05
PTEN O 0 0.0012844486627727747
/ O 0 3.416798426769674e-05
MMAC1 O 0 8.63305467646569e-06
as O 0 1.6677354608418682e-08
a O 0 1.0361763891353348e-08
main O 0 5.2332314481873254e-08
inactivation O 0 5.876836439711042e-07
target O 0 3.4439715079770394e-08
of O 0 1.3510751406542454e-09
10q O 0 4.91145215164579e-07
loss O 0 6.246440165114109e-08
in O 0 1.450674318448364e-07
sporadic B-Disease 1 0.9999991655349731
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.025222928774383e-07
. O 0 1.3541591670218622e-07

Risk O 0 5.031506225350313e-05
reversals O 0 1.9530019926605746e-05
in O 0 3.0596169153795927e-07
predictive O 0 1.2415711353241932e-05
testing O 0 2.873064295272343e-05
for O 0 2.815937705236138e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 2.551136276451871e-06

The O 0 1.0820831874980286e-07
first O 0 6.680407693693269e-08
predictive O 0 7.709514306952769e-07
testing O 0 7.087762696755817e-07
for O 0 2.795242153297295e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.3618054595099238e-07
HD B-Disease 0 0.0029125739820301533
) O 0 7.96963650628868e-09
was O 0 4.761323424418151e-08
based O 0 1.9913473092714185e-09
on O 0 7.097122001198386e-09
analysis O 0 1.8891637143525486e-09
of O 0 2.352545658279581e-10
linked O 0 9.438115000648395e-08
polymorphic O 0 5.889286853744125e-07
DNA O 0 1.1852937120693241e-07
markers O 0 1.0841407771522427e-07
to O 0 1.8043245786358852e-09
estimate O 0 4.954749943664183e-09
the O 0 7.507110488802482e-10
likelihood O 0 6.241626770986386e-09
of O 0 2.980898305970925e-10
inheriting O 0 4.3675026262235406e-08
the O 0 3.8311300798454795e-09
mutation O 0 1.82515961455465e-07
for O 0 5.899970734191129e-09
HD B-Disease 0 2.9674978577531874e-05
. O 0 1.6436176508705103e-07

Limits O 0 2.494345835657441e-06
to O 0 6.166088439840678e-08
accuracy O 0 1.0627742597080214e-07
included O 0 5.343045561545523e-09
recombination O 0 3.155475170046884e-08
between O 0 4.351593752005556e-09
the O 0 2.687441158499837e-09
DNA O 0 6.072600200468514e-08
markers O 0 1.4504212231258862e-07
and O 0 1.3016304700741443e-09
the O 0 1.7372616678557051e-09
mutation O 0 8.010987784246026e-08
, O 0 8.975432064239897e-10
pedigree O 0 1.8603554963192437e-07
structure O 0 2.909095364600489e-08
, O 0 1.3882653360219877e-10
and O 0 1.1935703814192067e-10
whether O 0 1.8989457228890672e-10
DNA O 0 1.6074707120949938e-09
samples O 0 2.053783809685683e-09
were O 0 7.090055209602042e-10
available O 0 6.426747467536131e-10
from O 0 1.434072971484568e-09
family O 0 7.805583734921129e-09
members O 0 4.99480146132214e-09
. O 0 2.2806418087384372e-08

With O 0 1.4901749523232866e-07
direct O 0 1.3352770622532262e-07
tests O 0 1.1653849441017883e-07
for O 0 7.498552889728671e-10
the O 0 6.7628658229068606e-09
HD B-Disease 0 0.00010505103273317218
mutation O 0 3.3189033388225653e-07
, O 0 1.1114339448781152e-09
we O 0 4.3096720636626173e-10
have O 0 2.047493424806035e-10
assessed O 0 2.6111042217280556e-09
the O 0 5.452228668545445e-10
accuracy O 0 2.032453139122481e-08
of O 0 1.905189339623803e-10
results O 0 9.675890311200419e-09
obtained O 0 9.159965563831918e-10
by O 0 5.157894111817996e-10
linkage O 0 2.5490097144142965e-08
approaches O 0 3.158870054420504e-09
when O 0 7.531851253794741e-10
requested O 0 1.1478701322786833e-09
to O 0 9.776730536259493e-10
do O 0 9.968799119519645e-10
so O 0 2.601488746645231e-10
by O 0 1.2119895365092503e-10
the O 0 1.296793339378155e-09
test O 0 1.670591132096888e-08
individuals O 0 1.68313429860234e-09
. O 0 2.2485879824785115e-08

For O 0 2.946965338423979e-08
six O 0 5.366617816804364e-09
such O 0 3.3898439610879905e-10
individuals O 0 1.4807294279606253e-10
, O 0 2.84058165878065e-10
there O 0 2.778094698729916e-10
was O 0 5.765958377423885e-09
significant O 0 4.194265768031613e-10
disparity O 0 5.2697890495778665e-09
between O 0 1.7913284189319256e-09
the O 0 4.428612854212588e-08
tests O 0 1.6532370636923588e-06
. O 0 1.6454040974167583e-07

Three O 0 1.7352763848066388e-07
went O 0 6.635567473267656e-08
from O 0 1.6122179147259885e-09
a O 0 1.6470792507661258e-09
decreased O 0 4.707845135953903e-08
risk O 0 2.0663770694540062e-09
to O 0 2.3402518811721507e-10
an O 0 1.3524589781432894e-10
increased O 0 5.202429775863493e-08
risk O 0 1.4038331386245773e-08
, O 0 1.6091264432027685e-10
while O 0 2.0114522547576286e-10
in O 0 5.329068297754702e-10
another O 0 4.5289108574486647e-10
three O 0 2.3009874561275012e-10
the O 0 1.6680210546127228e-09
risk O 0 3.264594639063034e-08
was O 0 1.6299298977173748e-07
decreased O 0 6.105246939114295e-07
. O 0 7.188841522065559e-08

Knowledge O 0 2.3310531105380505e-07
of O 0 4.819384891163736e-09
the O 0 3.5859741842614312e-09
potential O 0 2.1628778767990298e-09
reasons O 0 5.274602976612641e-10
for O 0 1.126393631145639e-10
these O 0 2.2989564418818276e-10
changes O 0 3.4808200766178743e-09
in O 0 8.957068864390294e-09
results O 0 1.166261114349254e-07
and O 0 1.2972534157995597e-09
impact O 0 3.950316518341879e-09
of O 0 1.9460184852437834e-10
these O 0 2.0300190417543718e-09
risk O 0 8.553711516867679e-09
reversals O 0 2.3273850402460994e-08
on O 0 2.958809730557732e-08
both O 0 1.5490978499954622e-09
patients O 0 5.006686176756148e-09
and O 0 9.32914634432791e-10
the O 0 3.3630487283886623e-09
counseling O 0 5.390417889827859e-09
team O 0 8.022815189967503e-10
can O 0 4.516454710223883e-10
assist O 0 3.916001134474101e-10
in O 0 4.525741725824872e-10
the O 0 3.378992363689548e-10
development O 0 1.010715885985114e-10
of O 0 9.885822022104307e-11
strategies O 0 5.088110821560576e-09
for O 0 2.0052734472919553e-10
the O 0 2.157608092190344e-09
prevention O 0 4.3553324502454416e-08
and O 0 8.699684861390722e-10
, O 0 2.7851990158644924e-10
where O 0 5.330806907011265e-10
necessary O 0 9.107233300831297e-10
, O 0 1.8559689896058273e-10
management O 0 6.207265257351935e-10
of O 0 4.462778410707635e-11
a O 0 5.001579594932082e-09
risk O 0 1.53447761164216e-08
reversal O 0 2.1970944175109253e-08
in O 0 2.0638877273881917e-09
any O 0 1.8667911660941172e-09
predictive O 0 2.877848714888387e-07
testing O 0 2.578334488134715e-07
program O 0 3.8306204430682556e-08
. O 0 4.273584153224874e-09
. O 0 3.347173560541705e-08

A O 0 3.3599071684875526e-06
novel O 0 2.684702167243813e-06
common O 0 6.998416779424588e-07
missense O 0 5.1074632210657e-05
mutation O 0 9.151587619271595e-06
G301C O 0 2.9467937565641478e-06
in O 0 4.836220313109152e-08
the O 0 7.414945457639988e-08
N O 0 7.50621029510512e-06
- O 0 5.021185643272474e-06
acetylgalactosamine O 0 5.8463287132326514e-05
- O 0 4.170333795627812e-06
6 O 0 3.1528827548754634e-07
- O 0 2.906932422774844e-06
sulfate O 0 5.692577815352706e-06
sulfatase O 0 1.4796442883380223e-05
gene O 0 9.411363066647027e-07
in O 0 1.1545164824156018e-07
mucopolysaccharidosis B-Disease 0 6.999922334216535e-05
IVA I-Disease 0 0.00011002555402228609
. O 0 1.3128483260516077e-06

Mucopolysaccharidosis B-Disease 0 0.013460174202919006
IVA I-Disease 1 0.739082932472229
( O 0 0.0001585423160577193
MPS B-Disease 1 0.9999995231628418
IVA I-Disease 1 0.9999995231628418
) O 0 1.1424216239674934e-07
is O 0 4.9319512918089e-09
an O 0 2.3079083533161793e-08
autosomal B-Disease 1 0.9952294826507568
recessive I-Disease 1 0.9999991655349731
lysosomal I-Disease 1 0.9999986886978149
storage I-Disease 1 0.9999992847442627
disorder I-Disease 1 0.9997847676277161
caused O 0 2.2024455574864987e-06
by O 0 2.7183224560189956e-08
a O 0 3.5513041893864283e-06
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 4.3944092453784833e-07
N O 0 3.8279311411315575e-05
- O 0 1.0669570656318683e-05
acetylgalactosamine O 0 0.0001669329940341413
- O 0 2.6433759558130987e-05
6 O 0 9.98505583993392e-07
- O 0 1.9761358998948708e-05
sulfate O 0 1.9426441212999634e-05
sulfatase O 0 3.4576994949020445e-05
( O 0 9.29093957324767e-08
GALNS O 0 9.093021617445629e-06
) O 0 8.798951967037283e-08
. O 0 1.4366463574333466e-07

In O 0 4.051293842621817e-07
previous O 0 2.3038934671149036e-07
studies O 0 2.058019710204917e-08
, O 0 1.4667067560480973e-09
we O 0 1.653115005995076e-10
have O 0 8.320664296457281e-11
found O 0 1.2647222158435056e-10
two O 0 1.939984978216458e-10
common O 0 6.653828155123165e-09
mutations O 0 1.2109883584798808e-07
in O 0 8.377683435867311e-09
Caucasians O 0 5.282230119973974e-08
and O 0 2.284415323572375e-09
Japanese O 0 6.772485505734949e-08
, O 0 3.2053728560299533e-09
respectively O 0 9.675562040456498e-08
. O 0 5.352819698600797e-08

To O 0 5.750227956013987e-07
characterize O 0 3.7695822356909048e-06
the O 0 1.2343926414359885e-07
mutational O 0 3.5927230783272535e-05
spectrum O 0 9.363182016386418e-07
in O 0 2.474474181113351e-09
various O 0 3.1747721118691175e-10
ethnic O 0 3.2903968438802167e-10
groups O 0 3.847450968930133e-10
, O 0 4.98948549143563e-10
mutations O 0 2.7437685901077202e-08
in O 0 1.789402404028806e-09
the O 0 5.468354213888915e-09
GALNS O 0 9.828395377553534e-07
gene O 0 4.7614321374567226e-08
in O 0 7.208596386476529e-09
Colombian O 0 2.553738056576549e-07
MPS B-Disease 1 0.9999984502792358
IVA I-Disease 1 0.9999995231628418
patients O 0 9.438508072889817e-07
were O 0 9.999482131206605e-09
investigated O 0 3.992837704913654e-08
, O 0 3.910679002849804e-10
and O 0 4.4149622846489933e-10
genetic O 0 1.369138846740725e-08
backgrounds O 0 2.1601456623443482e-08
were O 0 4.576455214788666e-09
extensively O 0 7.085344577717478e-08
analyzed O 0 3.3253023445922736e-08
to O 0 3.2289300122556597e-09
identify O 0 1.0445542208969982e-08
racial O 0 8.46861514247621e-09
origin O 0 1.0020861918036417e-09
, O 0 1.6465381835750748e-10
based O 0 1.3831360501370682e-09
on O 0 5.22564835847561e-09
mitochondrial O 0 1.8165569315442553e-07
DNA O 0 1.552951118810597e-07
( O 0 1.2759100442849558e-08
mtDNA O 0 2.4504055318175233e-07
) O 0 1.8606778340313213e-08
lineages O 0 5.642790483761928e-07
. O 0 1.3643064278312522e-07

Three O 0 6.348269607769907e-07
novel O 0 1.1617668178587337e-06
missense O 0 6.139867036836222e-05
mutations O 0 2.857696199498605e-05
never O 0 1.4208340815002884e-07
identified O 0 1.3782621266500428e-08
previously O 0 5.618088216863271e-09
in O 0 7.152727299342132e-10
other O 0 1.7451583234073809e-10
populations O 0 2.1743560285614194e-09
and O 0 9.056133065676875e-10
found O 0 2.2821244893833637e-09
in O 0 4.4834553847294956e-09
16 O 0 5.0335917656241236e-09
out O 0 3.3482239203408426e-10
of O 0 1.0399729688526094e-10
19 O 0 1.3458930858689655e-08
Colombian O 0 7.391224698949372e-08
MPS B-Disease 1 0.9998239874839783
IVA I-Disease 1 0.9999114274978638
unrelated O 0 1.0160476904275129e-06
alleles O 0 4.961817126059032e-07
account O 0 3.8429003978990295e-08
for O 0 8.059013900663103e-09
84 O 0 7.868634952501452e-07
. O 0 1.3999805048570124e-07

2 O 0 9.514985777059337e-07
% O 0 6.944786967721939e-09
of O 0 1.7822553155522058e-10
the O 0 1.335301536009581e-09
alleles O 0 2.9145883928549665e-08
in O 0 3.3105054253468325e-09
this O 0 2.4680590904324617e-09
study O 0 2.0271103906566168e-08
. O 0 5.76556544729101e-08

The O 0 7.362464202742558e-07
G301C O 0 6.023933565302286e-06
and O 0 3.383516755661731e-08
S162F O 0 1.920916247399873e-06
mutations O 0 1.156557800641167e-06
account O 0 2.8962896081452527e-08
for O 0 6.321467793668489e-09
68 O 0 9.605098512110999e-07
. O 0 1.5366894956514443e-07

4 O 0 3.855793238471961e-06
% O 0 3.399734538334087e-08
and O 0 8.47483683230621e-09
10 O 0 3.417542160377707e-08
. O 0 8.205014978557301e-08

5 O 0 2.3388449790218147e-06
% O 0 1.5786127960382146e-08
of O 0 1.2498715395992122e-09
mutations O 0 8.414600216610779e-08
, O 0 8.37588942648182e-10
respectively O 0 1.4230548295302015e-08
, O 0 4.3912290470515813e-10
whereas O 0 4.069871106793244e-09
the O 0 2.4580761870396373e-09
remaining O 0 2.6955109255766274e-09
F69V O 0 6.412231527974654e-07
is O 0 5.259664370704797e-10
limited O 0 6.340192815201817e-10
to O 0 4.1032524600304043e-10
a O 0 4.917514395685885e-09
single O 0 5.0191470535310145e-08
allele O 0 2.1106104668433545e-06
. O 0 9.618062080107848e-08

The O 0 2.2617061858909437e-06
skewed O 0 2.2601887394557707e-05
prevalence O 0 3.6579419884219533e-06
of O 0 3.7466172386757535e-09
G301C O 0 2.4534455178581993e-07
in O 0 4.222731941894153e-09
only O 0 6.509701111490074e-10
Colombian O 0 1.7100973082051496e-08
patients O 0 2.3226046863555894e-08
and O 0 2.001628862657867e-09
haplotype O 0 9.70835344560328e-07
analysis O 0 4.8439905420138984e-09
by O 0 8.670711371117079e-10
restriction O 0 1.3646233476549696e-08
fragment O 0 8.933817241540964e-08
length O 0 1.5967062338972937e-08
polymorphisms O 0 2.0393657962358702e-07
in O 0 2.6360542637604567e-09
the O 0 4.618150306612279e-09
GALNS O 0 1.6268284070974914e-06
gene O 0 8.916862270780257e-08
suggest O 0 5.8051665696723376e-09
that O 0 2.9315341820712604e-10
G301C O 0 4.101707418158185e-08
originated O 0 8.304595233710188e-09
from O 0 1.836258478604691e-09
a O 0 2.930272469114925e-09
common O 0 1.4415302729275936e-08
ancestor O 0 3.304596134512394e-07
. O 0 1.9590387978496437e-07

Investigation O 0 1.132819420490705e-06
of O 0 8.182990285376945e-09
the O 0 5.565475635904704e-09
genetic O 0 2.8534707041671936e-08
background O 0 9.681797585869845e-09
by O 0 3.522104274900073e-10
means O 0 4.5312265051222766e-10
of O 0 2.058944265082019e-10
mtDNA O 0 4.9524945922030383e-08
lineages O 0 2.6415872156348996e-08
indicate O 0 3.3936967014369657e-08
that O 0 5.963619043036772e-10
all O 0 3.3409958133390205e-10
our O 0 1.9581274379731894e-09
patients O 0 2.9211428831388275e-09
are O 0 6.359943821587777e-11
probably O 0 8.434307696703058e-10
of O 0 7.910731791849201e-11
native O 0 2.397240628226882e-09
American O 0 1.5725124313803462e-08
descent O 0 2.9172304039093433e-06

Low O 0 0.00010249318438582122
frequency O 0 1.975789200514555e-05
of O 0 9.611955675836725e-08
BRCA1 O 0 3.253888644394465e-05
germline O 0 1.842673373175785e-05
mutations O 0 3.4065419640683103e-06
in O 0 5.587772733406382e-08
45 O 0 7.377322503998585e-07
German O 1 0.9999998807907104
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.683653512278397e-07
. O 0 3.058403592604009e-07

In O 0 4.755160887270904e-07
this O 0 9.131048805954833e-09
study O 0 9.125391109421344e-09
we O 0 1.0082883417084076e-09
investigated O 0 7.39965955176558e-08
45 O 0 1.203835466867531e-07
German O 1 0.9999947547912598
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.911235069153918e-08
for O 0 2.3394897130657455e-09
germline O 0 5.163134119356982e-06
mutations O 0 8.422578616773535e-07
in O 0 1.1704546665214366e-08
the O 0 5.8273453618085114e-08
BRCA1 O 0 2.554643106122967e-05
gene O 0 4.983094186172821e-06
. O 0 4.220640619223559e-07

We O 0 2.91565129373339e-07
identified O 0 9.678108625621462e-08
four O 0 9.125703748225078e-09
germline O 0 2.597500952106202e-06
mutations O 0 6.955174853828794e-07
in O 0 3.769441647705207e-08
three O 0 5.380846346270118e-07
breast B-Disease 1 0.988146960735321
cancer I-Disease 0 1.1815703146567103e-05
families O 0 1.5583500045934784e-09
and O 0 7.296556137070809e-10
in O 0 9.820112722991325e-09
one O 0 9.510389645583928e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 8.966370756979813e-08
. O 0 1.8918384914190511e-10
among O 0 5.911025835469985e-11
these O 0 2.2291857249001623e-10
were O 0 7.130442347680344e-10
one O 0 1.3917815788744292e-09
frameshift O 0 4.4477037590695545e-06
mutation O 0 1.5490610394408577e-07
, O 0 9.197816952521976e-10
one O 0 2.8692581643952053e-09
nonsense O 0 2.1639071690060518e-07
mutation O 0 1.9213324264910625e-07
, O 0 7.484621256104163e-10
one O 0 4.947098841689979e-10
novel O 0 1.0394226812593388e-08
splice O 0 2.642487515913672e-06
site O 0 3.449540884048474e-07
mutation O 0 3.630025560141803e-07
, O 0 1.3636078932677265e-09
and O 0 1.205415101068752e-09
one O 0 8.152285069229492e-09
missense O 0 1.3287292858876754e-05
mutation O 0 8.298110515170265e-06
. O 0 7.072873700053606e-07

The O 0 1.5312198229366913e-06
missense O 0 0.0002395305928075686
mutation O 0 0.0001361396280117333
was O 0 4.977503976988373e-06
also O 0 6.190703949471299e-09
found O 0 3.809249360386957e-09
in O 0 6.431716936816656e-09
2 O 0 2.36552068599849e-07
. O 0 9.846899473586745e-08

8 O 0 4.427998192113591e-06
% O 0 1.360330337263349e-08
of O 0 1.4760485889109276e-10
the O 0 3.8814892966421155e-10
general O 0 6.286223208640251e-10
population O 0 3.1160993230194833e-10
, O 0 1.2616695188594207e-10
suggesting O 0 6.288181086944178e-09
that O 0 4.875652659386276e-10
it O 0 2.365108331403576e-09
is O 0 1.0397335215017733e-09
not O 0 4.869372460802879e-09
disease O 0 4.956492034580151e-07
associated O 0 6.738673619111069e-08
. O 0 1.7204494895395328e-07

The O 0 3.4635306178643077e-07
average O 0 1.1403353710193187e-06
age O 0 4.080801829786651e-08
of O 0 3.0225857372556675e-09
disease O 0 1.5992496628314257e-05
onset O 0 0.00012075150152668357
in O 0 4.769658090708617e-08
those O 0 7.74788411206373e-09
families O 0 1.0385823756564605e-08
harbouring O 0 1.775148234628432e-06
causative O 0 7.074445989019296e-07
mutations O 0 1.6114336176542565e-06
was O 0 1.49195813037295e-07
between O 0 1.9755537650212318e-08
32 O 0 2.509304977138527e-07
. O 0 8.076759883124396e-08

3 O 0 8.624191650596913e-06
and O 0 2.4825601485645166e-07
37 O 0 2.161965085178963e-06
. O 0 2.8690359954453015e-07

4 O 0 3.2708142043702537e-06
years O 0 3.0362873104650134e-08
, O 0 9.134057954440777e-10
whereas O 0 3.4716169938775465e-09
the O 0 3.139822180031615e-09
family O 0 2.692855716190934e-08
harbouring O 0 1.9870843459557364e-07
the O 0 6.417538944702983e-09
missense O 0 2.7043340651289327e-06
mutation O 0 4.27728878094058e-07
had O 0 1.4693619654337908e-08
an O 0 1.0487460899710754e-09
average O 0 7.323166073547327e-08
age O 0 5.666084046396236e-09
of O 0 6.172095612377859e-10
onset O 0 2.723544184846105e-06
of O 0 1.1939473409938728e-08
51 O 0 1.5714621213192004e-06
. O 0 1.5866172020650993e-07

2 O 0 8.437921678705607e-06
years O 0 4.48654560614159e-07
. O 0 2.238293319578588e-07

These O 0 1.9336411583026347e-07
findings O 0 2.3228110990203277e-07
show O 0 1.853360771519874e-07
that O 0 6.3142135964255885e-09
BRCA1 O 0 1.6364791690648417e-06
is O 0 1.982403796674248e-09
implicated O 0 2.1486565415784753e-08
in O 0 9.052972815837279e-10
a O 0 6.618724457396752e-10
small O 0 7.351330100213715e-10
fraction O 0 7.279712832541918e-09
of O 0 2.172513120513031e-07
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.4767991274311498e-08
suggesting O 0 6.117123518833978e-08
the O 0 2.252626085663678e-09
involvement O 0 3.881313936915376e-09
of O 0 2.0341497930509433e-10
another O 0 5.4602247168134e-09
susceptibility O 0 1.2016279242743622e-06
gene O 0 2.359294057896477e-06
( O 0 2.8488108227975317e-07
s O 0 6.717655196553096e-05
) O 0 8.415544812123699e-07

Paternal O 0 0.130567729473114
transmission O 1 0.9997133612632751
of O 0 4.440395059646107e-05
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00018565238860901445

We O 0 5.918716965425119e-07
report O 0 1.5771779260376206e-07
a O 0 9.88371962051815e-09
rare O 0 1.2359612000523157e-08
case O 0 5.3456979287602735e-08
of O 0 6.61189218931213e-08
paternally O 1 0.9999808073043823
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.560387134552002
DM B-Disease 1 1.0
) O 0 1.5124223864404485e-06
. O 0 3.0274802043095406e-07

The O 0 7.37471907541476e-07
proband O 0 1.5191288184723817e-05
is O 0 7.617774855361858e-09
a O 0 6.161618770761379e-09
23 O 0 5.276369208218057e-08
year O 0 5.4222195622344316e-09
old O 0 4.573692422127351e-06
, O 0 2.4881063609427656e-07
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 1.0185449355049059e-06
who O 0 2.739957096764556e-07
suffers O 0 0.22214646637439728
severe O 1 0.9965360164642334
muscular B-Disease 1 0.9999972581863403
weakness I-Disease 1 0.999994158744812
. O 0 4.48310811407282e-06

He O 0 6.655517950093781e-07
presented O 0 8.078131230604413e-08
with O 0 5.966810334712136e-08
respiratory O 0 0.12921078503131866
and O 0 6.145189956896502e-08
feeding O 0 9.547917443342158e-07
difficulties O 0 7.590612938201957e-08
at O 0 2.2728691817519575e-07
birth O 0 6.6859288381238e-06
. O 0 1.566751421933077e-07

His O 0 4.044158686156152e-06
two O 0 7.881176884438901e-07
sibs O 0 0.007867834530770779
suffer O 0 5.430981400422752e-05
from O 0 8.690751656104112e-07
childhood O 0 0.011510318145155907
onset O 1 0.9999966621398926
DM B-Disease 1 1.0
. O 0 2.8669768653344363e-05

Their O 0 4.460964078134566e-07
late O 0 2.644420055730734e-05
father O 0 2.6525489715822914e-07
had O 0 8.396655815090526e-09
the O 0 8.061316059126966e-10
adult O 0 2.898113038440897e-08
type O 0 3.9856666944615426e-07
of O 0 2.635306728393516e-08
DM B-Disease 1 1.0
, O 0 3.658989333743534e-09
with O 0 2.6767594807353134e-09
onset O 0 8.059560059336945e-06
around O 0 1.420368107574177e-07
30 O 0 3.729073583258469e-08
years O 0 1.3042505742077992e-08
. O 0 2.201801230228284e-08

Only O 0 5.074776865399144e-08
six O 0 5.314728213079434e-09
other O 0 1.2851605890595863e-10
cases O 0 3.1828423230351177e-10
of O 0 6.216163139782793e-10
paternal O 0 0.00033949429052881896
transmission O 1 0.9998902082443237
of O 0 2.96565758617362e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 1.3088055084153893e-06
been O 0 9.413933099722271e-08
reported O 0 1.8928203644463792e-06
recently O 0 2.144935933756642e-06
. O 0 2.884831076244154e-07

We O 0 6.646827728218341e-07
review O 0 8.834890508069293e-08
the O 0 4.856368196470839e-09
sex O 0 4.039156209501016e-08
related O 0 1.3263620424197597e-08
effects O 0 1.3514370778011653e-07
on O 0 1.6821326198623865e-06
transmission O 1 0.9964985847473145
of O 0 7.442276910296641e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 4.7413136599061545e-06

Decreased O 0 5.33640049980022e-05
fertility O 0 2.6737561711343005e-06
of O 0 3.5085687688507505e-09
males O 0 5.63172726231187e-08
with O 0 7.412086944214025e-09
adult O 0 9.631024113332387e-06
onset O 1 0.9999934434890747
DM B-Disease 1 1.0
and O 0 2.551203976963734e-07
contraction O 0 8.607952395323082e-07
of O 0 2.2150466183479267e-10
the O 0 2.0538855061147387e-09
repeat O 0 2.4723432190398853e-08
upon O 0 8.865621570208759e-10
male O 0 2.6389519458547284e-09
transmission O 0 9.520394428363943e-07
contribute O 0 6.179740608125428e-10
to O 0 1.947236261123919e-10
the O 0 4.118825003285309e-10
almost O 0 1.6866242846802493e-09
absent O 0 9.008915391461869e-09
occurrence O 0 9.08473563043799e-09
of O 0 9.539639078681716e-10
paternal O 0 3.615444802562706e-05
transmission O 1 0.971149742603302
of O 0 1.0268183814332588e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 7.635882866452448e-06

Also O 0 4.435502773958433e-07
the O 0 2.5599625530503545e-08
fathers O 0 2.4748249671802114e-08
of O 0 4.045922208373298e-10
the O 0 7.522681144678245e-09
reported O 0 1.2306316421017982e-05
congenitally O 0 0.0005337729817256331
affected O 0 2.230379294587692e-07
children O 0 2.177386981827567e-08
showed O 0 2.257623918922036e-07
, O 0 6.305412303397873e-10
on O 0 4.152543198188141e-08
average O 0 8.769046644374612e-08
, O 0 2.761128659045653e-09
shorter O 0 7.46390924177831e-06
CTG O 0 8.847713615978137e-06
repeat O 0 1.5192587170531624e-06
lengths O 0 1.806254203984281e-07
and O 0 2.930764297914834e-09
hence O 0 1.8076804053634987e-08
less O 0 2.9393868672400458e-08
severe O 0 0.0021082505118101835
clinical O 0 4.106848791707307e-05
symptoms O 1 0.7441994547843933
than O 0 1.0560389895886146e-08
the O 0 3.3973815760646175e-08
mothers O 0 1.931952020584049e-08
of O 0 3.0860580757519074e-10
children O 0 6.471697844290247e-09
with O 0 5.946360488451319e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 4.08557161790668e-06

We O 0 1.3908250195981964e-07
conclude O 0 1.0660407667728578e-07
that O 0 2.7460655971367487e-09
paternal O 0 1.2200887795188464e-05
transmission O 1 0.9695206880569458
of O 0 7.860617188271135e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 7.037866112113988e-08
rare O 0 2.7748884079414893e-08
and O 0 5.329060748238135e-09
preferentially O 0 1.7830127774232096e-07
occurs O 0 1.4825340066693116e-08
with O 0 3.7016121279265235e-09
onset O 0 3.679963629110716e-05
of O 0 6.239771721539e-08
DM B-Disease 1 1.0
past O 0 1.0845550377780455e-06
30 O 0 1.2968039087013494e-08
years O 0 3.9520250960656256e-10
in O 0 4.2325998261816267e-10
the O 0 2.093061057806267e-09
father O 0 4.146654575265529e-08
. O 0 2.5208639620188933e-09
. O 0 2.1310002651375726e-08

The O 0 3.416725576244062e-06
RB1 O 0 0.0003771435876842588
gene O 0 1.0026593372458592e-05
mutation O 0 3.62004561793583e-06
in O 0 2.5418339433258552e-08
a O 0 5.6616247690044474e-08
child O 0 9.489755825597967e-07
with O 0 1.953866757276046e-07
ectopic B-Disease 1 0.99998939037323
intracranial I-Disease 1 0.9999743700027466
retinoblastoma I-Disease 1 0.9344890117645264
. O 0 9.979762580769602e-06

The O 0 3.3242486097151414e-06
RB1 O 0 0.0005122391157783568
gene O 0 1.7542999557917938e-05
mutation O 0 8.17606269265525e-06
was O 0 1.5884477022609644e-07
investigated O 0 8.043092947218611e-08
in O 0 1.2368006174767743e-08
a O 0 3.487420485726034e-08
child O 0 3.987160823726299e-07
with O 0 4.464181202479267e-08
ectopic B-Disease 1 0.9974068999290466
intracranial I-Disease 0 0.19941824674606323
retinoblastoma I-Disease 0 2.7966420020675287e-05
using O 0 1.4480563947927294e-07
DNA O 0 1.5814040921213746e-07
obtained O 0 1.68667977362702e-08
from O 0 3.3809799404593832e-09
both O 0 1.3390916153710464e-09
the O 0 8.680610896760754e-09
pineal B-Disease 0 1.4237481082091108e-05
and I-Disease 0 3.4158387052229955e-07
retinal I-Disease 0 0.000437665730714798
tumours I-Disease 1 0.9999998807907104
of O 0 4.990810875682428e-09
the O 0 6.276225406054436e-08
patient O 0 4.0047234506346285e-06
. O 0 2.30654023880561e-07

A O 0 5.501422492670827e-06
nonsense O 0 2.3572660211357288e-05
mutation O 0 1.501833048678236e-05
in O 0 1.709087200651993e-07
exon O 0 1.7024682165356353e-05
17 O 0 5.92088497342047e-07
( O 0 6.048301770533726e-08
codon O 0 3.718772177307983e-06
556 O 0 3.597540398914134e-07
) O 0 2.4418329580555564e-09
of O 0 3.14124032341212e-10
the O 0 3.6707470396635244e-09
RB1 O 0 3.5880743780580815e-06
gene O 0 6.023010001854345e-08
was O 0 2.713670710363658e-08
found O 0 8.471842116719586e-10
to O 0 4.1015155161083783e-10
be O 0 2.7283864056926177e-10
present O 0 5.328133489967968e-10
homozygously O 0 1.3669998111254245e-07
in O 0 1.1723062520729854e-09
both O 0 3.822041294565537e-10
the O 0 2.0690984481319674e-09
retinal B-Disease 0 1.6741262243158417e-07
and I-Disease 0 6.117984785447561e-09
the I-Disease 0 1.4399753922589298e-07
pineal I-Disease 0 0.10297616571187973
tumours I-Disease 1 0.9999996423721313
. O 0 4.555686530238745e-07

The O 0 2.320360295016144e-07
same O 0 1.0310785825140556e-07
mutation O 0 4.383618374959042e-07
was O 0 3.006155324669635e-08
present O 0 3.5528460173850362e-09
heterozygously O 0 2.747815130987874e-07
in O 0 1.997052745394967e-09
the O 0 6.724057421969576e-10
DNA O 0 7.225707143732052e-09
from O 0 8.684316044060836e-10
the O 0 9.130382006006244e-10
constitutional O 0 2.4903499262762807e-09
cells O 0 2.0703458947224362e-09
of O 0 7.1050519634408e-11
the O 0 4.8176387323906056e-09
patient O 0 7.36471150730722e-08
, O 0 7.852497541094294e-10
proving O 0 7.408454294477451e-09
it O 0 6.049796774654226e-10
to O 0 6.472718472316785e-10
be O 0 2.432061774193528e-10
of O 0 2.052341629976695e-10
germline O 0 2.0075933093721687e-07
origin O 0 1.2686155237418006e-08
. O 0 4.6918621876557154e-08

The O 0 4.0773949194772285e-07
initial O 0 5.759969781138352e-07
mutation O 0 2.1093428586027585e-06
was O 0 2.636111844367406e-07
shown O 0 1.181426956264886e-08
to O 0 1.4937192593933446e-09
have O 0 5.999054586425245e-10
occurred O 0 8.949077034969832e-09
in O 0 1.1922877130032816e-09
the O 0 7.477604313521624e-09
paternally O 0 3.0070154934946913e-06
derived O 0 1.8141557234230277e-07
RB1 O 0 2.379613033554051e-05
allele O 0 4.336286565376213e-06
. O 0 2.298034473824373e-07

The O 0 5.139604013493226e-07
mutation O 0 3.900049705407582e-06
is O 0 6.479059067032722e-09
in O 0 1.2215565226014746e-09
an O 0 2.926383302348512e-10
area O 0 2.123683451316083e-09
of O 0 6.875715968801543e-11
the O 0 3.5113184582158397e-10
gene O 0 5.5261266673767295e-09
that O 0 6.47566722467019e-11
encodes O 0 2.2498352070243754e-09
the O 0 5.642268319228094e-10
protein O 0 1.2432717966248674e-08
- O 0 2.7148665537879424e-08
binding O 0 1.680815664428792e-08
region O 0 2.4647333063398946e-09
known O 0 1.7824397513521717e-09
as O 0 4.781567364275929e-10
the O 0 8.71308580840946e-10
pocket O 0 2.9072764391457895e-06
region O 0 1.594457188502929e-08
and O 0 1.2905241320027017e-08
has O 0 9.29956611717131e-10
been O 0 2.551687194873864e-10
detected O 0 1.0079543422136794e-08
in O 0 2.520997577359907e-10
other O 0 6.813716951770132e-11
cases O 0 2.8998464740581653e-10
of O 0 3.601271225672775e-10
retinoblastoma B-Disease 0 6.361335636029253e-07
. O 0 8.660121508796692e-09
. O 0 5.4398011428702375e-08

Low O 0 0.0001339385489700362
levels O 0 1.916393102874281e-06
of O 0 5.177481554596852e-09
beta O 0 1.1313819925362623e-07
hexosaminidase O 0 1.3245718264442985e-06
A O 0 5.221705734470561e-08
in O 0 1.1454473813898858e-08
healthy O 0 2.9478199436994146e-08
individuals O 0 1.9700843734149487e-10
with O 0 2.423468314916022e-09
apparent O 0 3.109198223683052e-05
deficiency O 0 8.478209201712161e-05
of O 0 4.591219626703946e-10
this O 0 5.986860784901182e-09
enzyme O 0 8.454866247120663e-07
. O 0 1.3343453986180975e-07

Appreciable O 0 7.165245187934488e-05
beta O 0 1.1661909411486704e-05
hexosaminidase O 0 3.0077901101321913e-05
A O 0 1.0895580544456607e-06
( O 0 4.486922122737269e-08
hex O 0 3.524406793076196e-07
A O 0 9.583906113164176e-09
) O 0 1.0132005234808616e-09
activity O 0 2.0970221115135246e-08
has O 0 1.0844127817932758e-09
been O 0 7.614473496175833e-10
detected O 0 3.344295507190509e-08
in O 0 3.845809448677073e-09
cultured O 0 1.0493527042854112e-06
skin O 0 0.0023323881905525923
fibroblasts O 0 1.497737571298785e-06
and O 0 1.1359649931819149e-07
melanoma B-Disease 0 3.25269102177117e-05
tissue O 0 1.7414182593711303e-06
from O 0 8.264334105945181e-09
healthy O 0 5.572096029027307e-08
individuals O 0 1.9996779232478445e-10
previously O 0 1.2129968141039171e-08
reported O 0 1.1566637567739235e-06
as O 0 7.784831268509151e-08
having O 0 1.3888225112168584e-06
deficiency B-Disease 0 2.5391843792021973e-06
of I-Disease 0 3.735698139717414e-10
hex I-Disease 0 3.913466741778393e-07
A I-Disease 0 9.11138986481319e-09
activity O 0 2.810164367872403e-08
indistinguishable O 0 8.684403418612874e-09
from O 0 1.6656484524979476e-10
that O 0 2.737982410239148e-11
of O 0 1.4407755544176837e-10
patients O 0 1.8864570350274334e-08
with O 0 2.5691003884276142e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999552965164185
( O 0 5.490470584845752e-07
TSD B-Disease 0 9.388778562424704e-05
) O 0 1.4663318381735735e-07
. O 0 1.487338181505038e-07

Identification O 0 4.933896889269818e-06
and O 0 9.501078324092305e-08
quantitation O 0 8.837298992148135e-06
of O 0 5.620542253836902e-09
hex O 0 1.2258257129360572e-06
A O 0 3.005020232649258e-08
, O 0 1.1804442978657903e-09
amounting O 0 4.101173622927945e-09
to O 0 7.519740385930618e-09
3 O 0 1.2166024987436685e-07
. O 0 8.544030549728632e-08

5 O 0 1.1141449249407742e-05
% O 0 5.185559075471247e-07
- O 0 9.454261999053415e-06
6 O 0 1.4696333892061375e-06
. O 0 3.577491440864833e-07

9 O 0 3.616526100813644e-06
% O 0 9.921608423724138e-09
of O 0 4.1004361017726865e-10
total O 0 7.723976458429149e-10
beta O 0 1.3832052836448838e-08
hexosaminidase O 0 3.398030230528093e-07
activity O 0 8.728330413987351e-08
, O 0 5.899675192821974e-10
has O 0 4.687742416464857e-10
been O 0 3.9223849168656955e-10
obtained O 0 1.9133659101555622e-09
by O 0 2.731225468011189e-09
cellulose O 0 5.276828596834093e-05
acetate O 0 1.3198734450270422e-05
gel O 0 2.8464692150009796e-06
electrophoresis O 0 8.243358138315671e-07
, O 0 7.412977343079774e-09
DEAE O 0 3.1323222628998337e-06
- O 0 1.284936161027872e-06
cellulose O 0 3.849162385449745e-05
ion O 0 4.731845820060698e-06
- O 0 1.510783363301016e-06
exchange O 0 4.066831991167419e-07
chromatography O 0 5.450778530757816e-07
, O 0 1.901563795314587e-09
radial O 0 2.941367540643114e-07
immunodiffusion O 0 1.4123907021712512e-06
, O 0 2.629546358434709e-09
and O 0 5.42317080132193e-09
radioimmunoassay O 0 9.986208169721067e-06
. O 0 1.6696490945378173e-07

Previous O 0 5.8735367929330096e-06
family O 0 3.265336374624894e-07
studies O 0 3.319143715430073e-08
suggested O 0 1.6343154385367598e-08
that O 0 2.9732100115253957e-10
these O 0 1.9714074817045457e-10
individuals O 0 1.6675302805246872e-10
may O 0 5.110226908300319e-09
be O 0 2.9833044368210437e-10
compound O 0 9.247039578497152e-09
heterozygotes O 0 4.92438694266184e-08
for O 0 2.108840324588357e-10
the O 0 1.083962031245278e-09
common O 0 1.3338715909583243e-08
mutant O 0 5.321375056155375e-07
TSD B-Disease 0 6.043624580343021e-06
gene O 0 4.861987576987303e-07
and O 0 4.862504177083338e-09
a O 0 1.1304755354046847e-08
rare O 0 1.0746661871507968e-07
( O 0 5.8688279125362897e-08
allelic O 0 4.977741355105536e-06
) O 0 6.380681583095793e-08
mutant O 0 2.025303501795861e-06
gene O 0 5.597075414698338e-06
. O 0 4.236901247622882e-07

Thus O 0 5.846711133017379e-07
, O 0 4.60487692421907e-09
the O 0 3.0689080166013127e-09
postulated O 0 1.1473326821942464e-07
rate O 0 1.1242917707932065e-07
mutant O 0 6.221328163746875e-08
gene O 0 6.358303039633029e-08
appears O 0 1.7985048117452607e-08
to O 0 1.2839018737054175e-09
code O 0 8.954541108607827e-09
for O 0 1.372282704137362e-10
the O 0 3.463513364998505e-10
expression O 0 1.0662980498565844e-09
of O 0 1.038379382478638e-10
low O 0 4.3983920505752394e-08
amounts O 0 2.7221398468668667e-09
of O 0 2.357164019528568e-09
hex O 0 1.6318380176016944e-06
A O 0 1.7087286607875285e-07
. O 0 1.4811934079261846e-07

Heterozygotes O 0 3.9878512325230986e-05
for O 0 2.018437328388245e-08
the O 0 4.2264547417403264e-09
rare O 0 1.442779140603534e-08
mutant O 0 4.969228371010104e-07
may O 0 1.3993451375426957e-07
be O 0 1.1589091908348337e-09
indistinguishable O 0 1.9307989873595943e-08
from O 0 3.997529418597878e-09
heterozygotes O 0 3.167523914271442e-07
for O 0 9.60897805768468e-10
the O 0 8.57835047440858e-09
common O 0 3.741007219559833e-07
TSD B-Disease 0 0.00011001977691194043
mutant O 0 9.27823748497758e-06
. O 0 5.246344585430052e-07

However O 0 6.577935209861607e-07
, O 0 1.1624807783050528e-08
direct O 0 2.9499798159804413e-08
visualization O 0 2.810521380069986e-07
and O 0 1.0418601092965218e-08
quantitation O 0 3.376523636688944e-06
of O 0 3.4059117748341805e-09
hex O 0 7.333963480959937e-07
A O 0 6.633476878903366e-09
by O 0 3.7371944427988524e-10
the O 0 7.773754417961243e-10
methods O 0 1.3864991821321837e-08
described O 0 6.136709629345205e-08
may O 0 4.6566636768829994e-08
prevent O 0 2.2193242799062318e-08
false O 0 5.8870909924735315e-08
- O 0 5.349941716303874e-07
positive O 0 8.028241893498489e-08
prenatal O 0 1.2187955690023955e-05
diagnosis O 0 3.067253146582516e-06
of O 0 3.815640692295119e-09
TSD B-Disease 0 1.0690074304875452e-05
in O 0 7.103123778051668e-08
fetuses O 0 1.013387418424827e-06
having O 0 6.0909717269908015e-09
the O 0 3.674347492932384e-09
incomplete O 0 3.381523754342197e-07
hex B-Disease 0 4.780752078659134e-06
A I-Disease 0 2.3929535473143915e-06
deficiency I-Disease 0 1.0168067092308775e-05
of O 0 1.6939451230602032e-10
the O 0 7.68713448451308e-09
type O 0 7.435264251398621e-06
described O 0 1.2471626575916162e-07
in O 0 6.782746808653428e-09
the O 0 4.332809666607318e-09
four O 0 7.093413856296138e-09
healthy O 0 2.8260268436497427e-07
individuals O 0 5.0375131621649416e-08

The O 0 2.7586406758928206e-06
tumor B-Disease 0 9.611892164684832e-05
suppressor O 0 0.00021103247127030045
gene O 0 3.666910924948752e-05
Smad4 O 0 0.00045738372136838734
/ O 0 0.00010920242493739352
Dpc4 O 0 9.160022273135837e-06
is O 0 7.453994754769155e-09
required O 0 1.7544976582684058e-09
for O 0 3.6980465911717886e-10
gastrulation O 0 1.25145419360706e-07
and O 0 2.068084370421275e-09
later O 0 1.7549938391425712e-08
for O 0 5.925477331025775e-10
anterior O 0 9.33835764271862e-08
development O 0 9.30666432807925e-10
of O 0 2.2232918284181835e-10
the O 0 3.935418657619039e-09
mouse O 0 6.084807864681352e-06
embryo O 0 1.9602905467763776e-06
. O 0 2.807170176311047e-07

Mutations O 0 0.00011350550630595535
in O 0 4.5423334427141526e-07
the O 0 2.754744627964101e-07
SMAD4 O 0 0.001052442705258727
/ O 0 9.315870556747541e-05
DPC4 O 0 0.00013004893844481558
tumor B-Disease 0 3.612342698033899e-05
suppressor O 0 2.2220570826902986e-05
gene O 0 1.7517219248475158e-06
, O 0 5.762286203747635e-09
a O 0 7.083125197482332e-09
key O 0 2.687073497043002e-08
signal O 0 1.5861891142776585e-06
transducer O 0 7.943868922666297e-07
in O 0 4.9685384695408175e-09
most O 0 2.143497823681173e-09
TGFbeta O 0 2.2015908598405076e-06
- O 0 3.4928001468870207e-07
related O 0 1.7217256953472315e-08
pathways O 0 2.0456411675695563e-08
, O 0 1.74928738161384e-10
are O 0 1.7771218524531562e-11
involved O 0 9.290200553291328e-11
in O 0 4.239119610893738e-10
50 O 0 1.4478976906318053e-09
% O 0 6.700628385480911e-10
of O 0 4.5896637601572365e-09
pancreatic B-Disease 0 0.024908391758799553
cancers I-Disease 0 0.00022413536498788744
. O 0 5.707291848011664e-07

Homozygous O 0 0.0010321337031200528
Smad4 O 0 0.0005363538512028754
mutant O 0 6.706409476464614e-05
mice O 0 0.0008589487988501787
die O 0 3.193049269611947e-05
before O 0 2.2656625731087843e-07
day O 0 1.4575360296475992e-07
7 O 0 2.551724662680499e-07
. O 0 1.3266914322684897e-07

5 O 0 4.120010999031365e-06
of O 0 1.6098563548894163e-07
embryogenesis O 0 5.39868779014796e-05
. O 0 1.53743269493134e-06

Mutant O 0 6.986652351770317e-06
embryos O 0 6.105723855398537e-07
have O 0 3.166748641092454e-09
reduced O 0 1.3542388543896777e-08
size O 0 1.4104999834785303e-08
, O 0 2.4434263501404985e-09
fail O 0 7.580282357366741e-08
to O 0 7.916384880957139e-09
gastrulate O 0 8.205034646380227e-06
or O 0 2.0021186486474107e-08
express O 0 3.308676355118223e-08
a O 0 8.662566663986127e-09
mesodermal O 0 7.066124680932262e-07
marker O 0 3.312080139039608e-07
, O 0 1.1166185753808122e-09
and O 0 1.8449931582509294e-09
show O 0 2.958703646527283e-07
abnormal O 0 3.1409433631779393e-06
visceral O 0 2.0951965780113824e-06
endoderm O 0 1.1246772373851854e-05
development O 0 1.460026197719344e-07
. O 0 1.1742037742124012e-07

Growth B-Disease 1 0.9999998807907104
retardation I-Disease 1 0.9999998807907104
of O 0 2.5466139419449974e-08
the O 0 7.034121551896533e-08
Smad4 O 0 0.0001779370941221714
- O 0 2.958707045763731e-05
deficient O 0 1.695624268904794e-05
embryos O 0 8.513074334359771e-08
results O 0 1.7991363066016675e-08
from O 0 1.6709313932494751e-09
reduced O 0 2.1013262241353914e-08
cell O 0 1.8252153211051336e-07
proliferation O 0 6.511992012292467e-08
rather O 0 1.5642224182599307e-09
than O 0 9.695672043008585e-10
increased O 0 1.515747172220472e-08
apoptosis O 0 5.654264327858982e-07
. O 0 5.230696942248869e-08

Aggregation O 0 2.275544284202624e-05
of O 0 1.2448668940123753e-07
mutant O 0 3.3203198199771577e-06
Smad4 O 0 3.703431866597384e-05
ES O 0 3.430929382375325e-06
cells O 0 1.484311411559247e-07
with O 0 2.652021047211406e-09
wild O 0 1.3903368767387292e-07
- O 0 1.0174139788432512e-05
type O 0 1.1694586646626703e-05
tetraploid O 0 7.940385330584832e-06
morulae O 0 2.4604949430795386e-05
rescues O 0 4.189787432551384e-06
the O 0 1.2845571006891987e-07
gastrulation B-Disease 0 7.156422361731529e-05
defect I-Disease 0 8.004234405234456e-05
. O 0 7.200381446637039e-07

These O 0 2.3501222301547386e-07
results O 0 2.581710134563764e-07
indicate O 0 1.3143099408807757e-07
that O 0 3.1201095040955806e-09
Smad4 O 0 1.0940781294266344e-06
is O 0 1.5645417184018129e-09
initially O 0 5.579856576787279e-09
required O 0 3.2573768682375714e-10
for O 0 2.3990538722262755e-11
the O 0 1.6192834573214299e-10
differentiation O 0 1.8332628748396473e-09
of O 0 8.133095585893813e-11
the O 0 2.6541109310329603e-09
visceral O 0 4.943962395032031e-08
endoderm O 0 3.389712333046191e-07
and O 0 1.7450926259598987e-09
that O 0 2.329900994357814e-10
the O 0 2.9325759598464174e-09
gastrulation B-Disease 0 9.67944401963905e-07
defect I-Disease 0 4.812553697775002e-07
in O 0 5.691743965030582e-09
the O 0 5.201454378322978e-09
epiblast O 0 2.058987547570723e-06
is O 0 3.0335245426726942e-09
secondary O 0 1.711020480854586e-08
and O 0 6.509787708885995e-10
non O 0 1.0206919753841248e-08
- O 0 6.758019139851967e-07
cell O 0 1.7159838989755372e-06
autonomous O 0 1.2613563740160316e-06
. O 0 2.2592415405142674e-07

Rescued O 0 5.466746733873151e-05
embryos O 0 1.1552434443728998e-05
show O 0 1.0294597814208828e-05
severe O 0 0.00038649354246445
anterior O 0 0.00016008905367925763
truncations O 0 0.00010315876716049388
, O 0 1.9674279982950793e-08
indicating O 0 2.503701921341417e-07
a O 0 6.644544470191249e-09
second O 0 6.675985542159424e-09
important O 0 5.160245564184152e-10
role O 0 2.14044182378359e-09
for O 0 7.708787497229252e-10
Smad4 O 0 6.088257009650988e-07
in O 0 1.0522730242712441e-08
anterior O 0 1.9310109564685263e-06
patterning O 0 1.2111783689761069e-05
during O 0 3.526770342432428e-07
embryogenesis O 0 1.6561974916839972e-05
. O 0 5.67423512620735e-07

Prevalence O 0 0.00025143957464024425
of O 0 1.397270068537182e-07
p16 O 0 2.4281591322505847e-05
and O 0 8.483137037273991e-08
CDK4 O 0 4.329545845394023e-05
germline O 0 5.312642315402627e-05
mutations O 0 1.094678373192437e-05
in O 0 1.592403293670941e-07
48 O 0 1.2117421647417359e-05
melanoma B-Disease 1 0.9589536190032959
- O 0 0.2157927006483078
prone O 0 0.0018370336620137095
families O 0 4.996404712187541e-08
in O 0 1.1387341913859927e-07
France O 0 1.0219210707873572e-05
. O 0 2.688437632514251e-07

The O 0 1.4585679082301795e-06
French O 0 2.1762176402262412e-05
Familial B-Disease 0 0.002698727650567889
Melanoma I-Disease 0 0.017699170857667923
Study O 0 6.725833259224601e-07
Group O 0 3.1366695907308895e-07
. O 0 2.987530081099976e-07

Germline O 0 0.003022389952093363
mutations O 0 0.0006187446415424347
in O 0 4.315891430906049e-07
the O 0 3.707202722580405e-08
p16 O 0 1.6647423990434618e-06
and O 0 8.821651853452295e-09
CDK4 O 0 2.385345624134061e-06
genes O 0 3.557411432097979e-08
have O 0 1.1020003798378752e-09
been O 0 1.0434704211803592e-09
reported O 0 1.7859491663330118e-08
in O 0 9.76342451330936e-10
a O 0 1.2962417805795212e-09
subset O 0 4.0267469358923336e-09
of O 0 1.3650833796674533e-09
melanoma B-Disease 0 5.274606337479781e-06
pedigrees O 0 1.227186089636234e-06
, O 0 1.3789477337766698e-09
but O 0 5.613939868531759e-10
their O 0 2.9540434542951743e-09
prevalence O 0 6.844819040452421e-07
is O 0 1.3142434918123058e-09
not O 0 5.664362867641159e-10
well O 0 1.661175641487489e-09
known O 0 1.9295656628059987e-08
. O 0 3.7768185023878686e-08

We O 0 2.0673682854521758e-07
searched O 0 9.253147226218061e-08
for O 0 1.604444355152168e-09
such O 0 9.82048220521392e-10
germline O 0 1.6652203385092434e-06
mutations O 0 6.739419404766522e-07
in O 0 3.040790730324261e-08
48 O 0 7.386882998616784e-07
French O 0 0.00016525661339983344
melanoma B-Disease 1 0.9974232912063599
- O 0 0.2528877556324005
prone O 0 0.0005803870735689998
families O 0 8.027594589066211e-09
selected O 0 4.691152355462691e-09
according O 0 4.3816661410289726e-10
to O 0 5.170955330591198e-10
two O 0 2.5166302375367877e-10
major O 0 1.0062057853588158e-09
criteria O 0 1.947125793932969e-09
families O 0 2.2816271094683316e-10
with O 0 4.2887698947779995e-10
at O 0 5.053604112958965e-08
least O 0 2.489243700054544e-09
three O 0 1.1343650463402355e-09
affected O 0 5.180247342195798e-09
members O 0 5.714322903749292e-10
( O 0 2.8334188328926757e-09
n O 0 1.4713003793076496e-07
= O 0 1.1838748292802848e-07
20 O 0 9.086017271897617e-09
) O 0 1.0694021224111339e-09
or O 0 4.27774349276433e-09
families O 0 3.1308680648045595e-10
with O 0 1.2710532626414306e-10
two O 0 4.1348274804065e-10
affected O 0 2.330849069309693e-09
members O 0 1.5085438453965594e-10
, O 0 1.1033943203564434e-10
one O 0 9.066792455714179e-11
of O 0 2.930940212753086e-11
them O 0 1.385857956170966e-10
affected O 0 6.724544809877386e-10
before O 0 9.46791089972976e-10
the O 0 2.066842252901324e-09
age O 0 1.0717545739780121e-09
of O 0 8.040979687651273e-11
50 O 0 3.819558447304416e-09
( O 0 2.4505206752678532e-09
n O 0 1.0571175579343617e-07
= O 0 9.164832448504967e-08
28 O 0 3.279229332520117e-08
) O 0 3.986091734464736e-10
, O 0 7.56851178951301e-11
and O 0 1.305867219913992e-10
one O 0 1.5942001885260737e-10
additional O 0 8.611477086972741e-10
minor O 0 4.9022521153574417e-08
criterion O 0 2.3153447159529605e-07
. O 0 6.770392957378135e-08

Sixteen O 0 7.996910426300019e-06
different O 0 1.7036211374943377e-07
p16 O 0 2.2013111447449774e-05
germline O 0 4.81441747979261e-05
mutations O 0 1.4021135029906873e-05
were O 0 3.8969449889236785e-08
found O 0 1.932313153929499e-08
in O 0 9.197171912944668e-09
21 O 0 2.4051006519698603e-08
families O 0 3.8042083372324953e-10
, O 0 1.5882455073334967e-10
while O 0 3.5432276557223474e-10
one O 0 8.01776645076302e-10
germline O 0 4.007357290447544e-07
mutation O 0 1.5115732310277963e-07
, O 0 1.7324107703942104e-09
Arg24His O 0 5.327244707586942e-07
, O 0 8.804014184349285e-10
was O 0 7.236920396280766e-09
detected O 0 5.8116388146345344e-08
in O 0 2.157566791893828e-09
the O 0 1.2117920000775939e-08
CDK4 O 0 9.610168490326032e-06
gene O 0 2.684681476239348e-06
. O 0 9.34719608380874e-08

The O 0 3.091131191013119e-07
frequency O 0 1.8222531252831686e-06
of O 0 6.238377370237913e-09
p16 O 0 2.083023673549178e-06
gene O 0 6.477850433839194e-07
mutation O 0 2.1785672288388014e-07
in O 0 5.15968734404737e-09
our O 0 2.2082182749016965e-09
sample O 0 7.509678212613835e-09
( O 0 1.8079071573140482e-09
44 O 0 1.831386153838821e-09
% O 0 2.1951153394983436e-10
) O 0 2.3957311134914505e-10
is O 0 1.7934094487248586e-10
among O 0 7.011795311040459e-11
the O 0 9.332473682732711e-10
highest O 0 2.775057872383968e-08
rates O 0 8.764481208345387e-06
yet O 0 7.110426913925494e-09
reported O 0 3.656159606180154e-07
and O 0 1.6388188583960073e-09
the O 0 2.9003957013884474e-09
CDK4 O 0 7.6118171818961855e-06
mutation O 0 8.22242043341248e-08
is O 0 4.924203822476159e-10
the O 0 9.049174742870036e-10
second O 0 7.646670852068382e-09
mutation O 0 5.686777271307619e-08
detected O 0 6.814935460397464e-08
in O 0 3.218458832776605e-09
this O 0 1.4387085967015878e-09
gene O 0 1.4885840471379197e-07
worldwide O 0 7.797149947919024e-08
. O 0 5.324542229345752e-08

In O 0 3.038106115127448e-06
summary O 0 3.831055892078439e-06
, O 0 1.3596325842968326e-08
our O 0 9.838879932999589e-09
results O 0 5.52192567226939e-08
show O 0 8.747263535724414e-08
frequent O 0 2.4994690761559468e-08
involvement O 0 8.647083049595494e-09
of O 0 3.910455292910342e-10
the O 0 2.265825083114237e-09
p16 O 0 2.896053103995655e-07
gene O 0 1.7363491622290894e-07
in O 0 1.692177242773596e-08
familial B-Disease 0 9.097417932935059e-05
melanoma I-Disease 0 0.004253758583217859
and O 0 1.849465114389659e-08
confirm O 0 2.3797939263658918e-07
the O 0 2.3989190633955104e-09
role O 0 7.852108407924163e-10
of O 0 4.9384607514468826e-11
the O 0 9.153573454767638e-10
CDK4 O 0 4.385316287880414e-07
gene O 0 2.3778286006859162e-08
as O 0 1.7239395466717156e-09
a O 0 3.196997511167865e-08
melanoma B-Disease 0 8.473682100884616e-05
- O 0 3.979831944889156e-06
predisposing O 0 2.6964899006998166e-06
gene O 0 1.0206626939179841e-06
. O 0 2.1951175099843567e-08
. O 0 5.2228415370336734e-08

Progression O 0 9.291509195463732e-05
of O 0 1.4670271752947883e-07
somatic O 0 2.0783663785550743e-05
CTG O 0 0.00011984368757111952
repeat O 0 6.102305633248761e-06
length O 0 1.1579766834302063e-07
heterogeneity O 0 1.767727155765897e-07
in O 0 3.7413685483045356e-09
the O 0 3.0008833196149e-09
blood O 0 1.8026111092694919e-07
cells O 0 3.774132721900969e-07
of O 0 8.447580057691084e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.007859718054533005
. O 0 1.3260935247672023e-06

The O 0 1.6164084115644073e-07
genetic O 0 1.0895539617195027e-06
basis O 0 1.8228007547804737e-07
of O 0 5.309665311870049e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.3272917568683624
DM B-Disease 1 1.0
) O 0 7.838259818981896e-08
is O 0 7.155019354776471e-10
the O 0 2.9337490770053876e-10
expansion O 0 2.0890846830212695e-09
of O 0 2.021263156848363e-10
an O 0 1.744407174264495e-09
unstable O 0 1.815862924559042e-05
CTG O 0 6.744731308572227e-06
repeat O 0 5.055406973042409e-07
in O 0 6.5254428527339314e-09
the O 0 2.6621418403038888e-09
34 O 0 1.9156491504190853e-08
UTR O 0 1.6348056419701607e-07
of O 0 9.534927292165207e-10
the O 0 4.578125256671228e-08
DM B-Disease 1 0.9999986886978149
protein O 0 5.188279601497925e-07
kinase O 0 2.3625543690286577e-06
gene O 0 6.493908131233184e-07
on O 0 1.6503607014328736e-07
chromosome O 0 5.542994585994165e-06
19 O 0 5.890921102036373e-07
. O 0 8.074634649801737e-08

One O 0 1.2526409420843265e-07
of O 0 4.305385381542237e-09
the O 0 5.652688095381109e-09
principal O 0 7.321891537515057e-09
features O 0 3.2615437017824433e-09
of O 0 3.791307268130595e-10
the O 0 3.1765688390805735e-07
DM B-Disease 1 1.0
mutation O 0 2.243656354039558e-06
is O 0 3.169570605976446e-09
an O 0 1.3980232527188718e-09
extraordinarily O 0 2.5371991796419024e-07
high O 0 1.6658000845382048e-07
level O 0 1.5988424806323565e-08
of O 0 6.942915686813933e-10
somatic O 0 4.531836168553127e-07
mosaicism O 0 5.639236405841075e-06
, O 0 2.7548738845695198e-09
due O 0 1.8151986580505763e-08
to O 0 1.5647684259434413e-09
an O 0 8.575467003169024e-10
extremely O 0 8.688218855468222e-08
high O 0 5.150133119968814e-08
degree O 0 1.9814814233853895e-09
of O 0 4.921978380423297e-10
somatic O 0 6.578832199011231e-07
instability O 0 3.172385163452418e-07
both O 0 1.2554002282172405e-09
within O 0 1.688468698191059e-09
and O 0 1.3194955128525976e-09
between O 0 1.9459600597571125e-09
different O 0 7.4565260632653e-09
tissues O 0 1.692140585873858e-06
. O 0 5.526192481397629e-08

This O 0 4.7617228915441956e-07
instability O 0 5.225499990046956e-06
appears O 0 2.595891146484064e-07
to O 0 4.436981004829477e-09
be O 0 1.1592562465523315e-09
biased O 0 1.3580386593048388e-08
towards O 0 1.1517387044079896e-09
further O 0 1.120826431666444e-09
expansion O 0 2.5521849078558034e-09
and O 0 9.591247240869905e-11
continuous O 0 1.8556972625205503e-09
throughout O 0 3.7935441454806096e-09
the O 0 1.0269423089681595e-09
life O 0 1.4192746977670367e-10
of O 0 8.857803379669349e-12
an O 0 2.4277359636504237e-11
individual O 0 1.1396147914233268e-10
, O 0 7.522860112629814e-11
features O 0 1.1438143765474251e-08
that O 0 4.2336170680279395e-10
could O 0 8.243112858963286e-09
be O 0 3.182381025368386e-10
associated O 0 6.62996990641318e-10
with O 0 1.601899446423971e-10
the O 0 4.605852144123901e-09
progressive O 0 7.459716044877496e-08
nature O 0 1.3804661858074496e-09
of O 0 3.545479188016287e-10
the O 0 4.338244963264515e-08
disease O 0 9.77427771431394e-06
. O 0 1.0028595198718904e-07

Although O 0 3.646468655915669e-07
increasing O 0 8.571338128149364e-08
measured O 0 1.9812372897831665e-07
allele O 0 1.0227576012766804e-06
size O 0 1.417450619101146e-07
between O 0 4.513884022117054e-08
patients O 0 1.1576123171153085e-07
clearly O 0 1.3366552309435065e-08
correlates O 0 1.5236139461194398e-08
with O 0 3.2428520979621567e-10
an O 0 7.164278059690332e-10
increased O 0 2.8855925648940683e-08
severity O 0 2.211693981735152e-06
of O 0 6.868408952698246e-09
symptoms O 0 0.0016599961090832949
and O 0 1.4143274329470046e-09
an O 0 3.310554053115311e-10
earlier O 0 2.2979926939115103e-07
age O 0 5.427072125030463e-09
of O 0 1.5823611865251053e-10
onset O 0 9.337802566733444e-07
, O 0 5.283121162769078e-10
this O 0 2.8572802457382807e-10
correlation O 0 1.0141599560142822e-08
is O 0 5.83585957336652e-10
not O 0 1.8249587951935098e-10
precise O 0 2.29684049557477e-09
and O 0 7.412238600679188e-10
measured O 0 6.048105660738656e-08
allele O 0 1.4747337218068424e-07
length O 0 1.3543137278304584e-08
cannot O 0 4.066635472810276e-09
be O 0 2.815161159741564e-10
used O 0 7.405638879909304e-10
as O 0 1.3941349463753028e-10
an O 0 1.09595256481132e-10
accurate O 0 3.1548612611231874e-08
predictor O 0 2.530244955778471e-07
of O 0 3.430352113475976e-10
age O 0 7.550236880149441e-09
of O 0 1.6585923745537912e-09
onset O 0 2.6571100534056313e-05
. O 0 2.2851882874874718e-07

In O 0 4.508876259023964e-07
order O 0 3.5101233919476726e-08
to O 0 3.2365077284879362e-09
further O 0 5.647924350427047e-09
characterize O 0 9.711133941436856e-08
the O 0 8.40001934676593e-09
dynamics O 0 4.298725286844274e-07
of O 0 2.898284634511583e-08
DM B-Disease 1 1.0
CTG O 0 6.300980021478608e-05
repeat O 0 4.251790869602701e-06
somatic O 0 2.1267019292281475e-06
instability O 0 1.6919210565902176e-06
, O 0 3.856460040196907e-09
we O 0 1.1618993545070566e-09
have O 0 4.673690323642177e-10
studied O 0 1.059763832245153e-08
repeat O 0 1.3723186498282303e-07
length O 0 1.736778898475677e-08
changes O 0 1.1723940041008518e-08
over O 0 3.885439525674883e-09
time O 0 5.554743331970258e-09
in O 0 2.6157014332284234e-08
111 O 0 0.0016755035612732172
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 1.20100230560638e-06
with O 0 3.0340800982742167e-09
varying O 0 8.03614668143382e-08
clinical O 0 3.387798983567336e-07
severity O 0 0.00010213219502475113
and O 0 1.1440766201076258e-07
CTG O 0 1.625775985303335e-05
repeat O 0 1.504834472143557e-06
size O 0 7.227929188502458e-08
over O 0 2.6362152460990274e-09
time O 0 2.1747665890359258e-09
intervals O 0 2.377497665406736e-08
of O 0 2.6470367564535024e-10
1 O 0 1.1855895820644946e-08
- O 0 3.470732394816878e-07
7 O 0 6.448117773061313e-08
years O 0 1.7018097153709277e-08
. O 0 4.311797852096788e-08

We O 0 2.8134525109635433e-07
have O 0 3.5635963069324816e-09
found O 0 1.0211939072135578e-09
a O 0 1.0526176597025483e-09
direct O 0 4.645138051984077e-09
progression O 0 7.59629017466068e-08
of O 0 2.3892646194845213e-10
the O 0 1.530752524736556e-09
size O 0 6.980271027856588e-09
heterogeneity O 0 1.4116950275422369e-08
over O 0 2.7403677105297675e-09
time O 0 2.3370547719281376e-09
related O 0 1.702263330294329e-09
to O 0 1.3209914273559775e-09
initial O 0 3.462783482177656e-08
CTG O 0 1.201348254653567e-06
repeat O 0 1.0130970196087219e-07
size O 0 1.3546547883436233e-08
and O 0 7.94039445306538e-10
the O 0 1.9274313256545383e-09
time O 0 6.8142180786878725e-09
interval O 0 3.524096925389131e-08
and O 0 1.4669278014523002e-09
always O 0 1.61274682497492e-09
biased O 0 1.4883932308862313e-08
towards O 0 2.5642223899779992e-09
further O 0 1.1523457743578547e-08
expansion O 0 1.2498583146225428e-07
. O 0 5.985241813277753e-08

Attempts O 0 5.692664217349375e-06
to O 0 1.1525364129738591e-07
mathematically O 0 4.946971330355154e-07
model O 0 8.759802483382373e-08
the O 0 6.048138434522343e-09
dynamics O 0 2.156449454560061e-07
have O 0 1.4524974556451298e-09
proved O 0 6.8959615795449736e-09
only O 0 8.288830177782813e-10
partially O 0 1.3257348108197675e-08
successful O 0 9.49878731226761e-10
suggesting O 0 1.939667981787352e-09
that O 0 3.4717791141947174e-11
individual O 0 3.3295623202977964e-11
specific O 0 3.813929172480357e-10
genetic O 0 9.333831485491828e-09
and O 0 1.0187625854030102e-08
/ O 0 1.1121660463686567e-05
or O 0 1.3817999189313923e-08
environmental O 0 3.715490359823548e-09
factors O 0 1.6490785403888708e-09
also O 0 1.209980671212918e-09
play O 0 1.4738212872345002e-09
a O 0 1.8293577763728308e-09
role O 0 2.2296715584957383e-09
in O 0 3.591854147444451e-09
somatic O 0 5.48286323009961e-07
mosaicism O 0 3.931920218747109e-06
. O 0 1.9804923923061324e-08
. O 0 8.765902492768873e-08

Aspartylglucosaminuria B-Disease 1 0.9998838901519775
among O 0 8.357847036677413e-07
Palestinian O 0 2.8718523026327603e-06
Arabs O 0 2.0970915102225263e-06
. O 0 7.136665658435959e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 0 0.010953955352306366
AGU B-Disease 1 1.0
) O 0 1.3947352783816314e-07
is O 0 2.218053518632246e-09
a O 0 6.0660565459613736e-09
rare O 0 1.2010855243715923e-07
disorder B-Disease 0 6.550966645590961e-05
of I-Disease 0 4.3578145536571355e-09
glycoprotein I-Disease 0 7.792445103405043e-06
metabolism I-Disease 0 0.0010756811825558543
caused O 0 2.6457203716745425e-07
by O 0 5.7291900112943495e-09
the O 0 5.079037919131224e-07
deficiency B-Disease 0 3.9992770325625315e-05
of I-Disease 0 6.870292112992615e-10
the I-Disease 0 3.9060910950183825e-08
lysosomal I-Disease 0 3.768982060137205e-05
enzyme I-Disease 0 1.6051391185101238e-06
aspartylglucosaminidase I-Disease 0 1.2011801118205767e-05
( O 0 2.1997870192080882e-07
AGA O 0 3.759304036066169e-06
) O 0 7.869013529671065e-08
. O 0 1.703265297692269e-07

AGU B-Disease 1 1.0
is O 0 2.634051497807377e-06
inherited O 0 1.8736802303465083e-05
as O 0 2.5802719960665854e-08
an O 0 2.312111568869568e-08
autosomal O 1 0.8657680749893188
recessive O 1 0.999954342842102
trait O 0 8.807543781585991e-05
and O 0 5.227146715469644e-08
occurs O 0 1.4360060696105847e-08
with O 0 1.0506902015094965e-09
a O 0 2.5500307643255837e-08
high O 0 1.4010184941071202e-06
frequency O 0 0.005670840851962566
in O 0 7.657999958610162e-07
Finland O 0 3.853451744362246e-06
because O 0 8.390552141968044e-10
of O 0 1.655702519531843e-10
a O 0 5.251167056741224e-09
founder O 0 2.0703751602013654e-07
effect O 0 1.2408914074057975e-07
. O 0 4.735700898095274e-08

While O 0 2.951905742065719e-07
very O 0 3.987114283177107e-08
few O 0 3.484242583340347e-08
patients O 0 5.416051607198824e-08
with O 0 2.3202451870929508e-07
AGU B-Disease 1 1.0
have O 0 7.741106600178682e-08
been O 0 3.217531796551043e-09
reported O 0 4.897223959687835e-08
from O 0 1.4591978736433475e-09
non O 0 2.082520156321266e-09
- O 0 5.4843589225583855e-08
Finnish O 0 1.3502699403034057e-07
origin O 0 2.7004924962881205e-09
, O 0 1.0346118406445726e-09
we O 0 4.983040202688471e-09
diagnosed O 0 3.861081268041744e-07
the O 0 1.8063778028931665e-08
disorder O 0 1.268770847673295e-05
in O 0 1.2394361093015505e-08
8 O 0 4.381244167461773e-08
patients O 0 4.1613978929433415e-09
originating O 0 1.3504703133548901e-08
from O 0 4.708103240602668e-09
3 O 0 5.27570254149623e-09
unrelated O 0 8.531389816823776e-09
families O 0 9.864222771938103e-10
, O 0 1.464115079174988e-10
all O 0 5.138409489569007e-11
Palestinian O 0 1.2501242263596168e-09
Arabs O 0 7.785565525608718e-10
from O 0 4.5997658459917545e-10
the O 0 7.382791600285543e-10
region O 0 3.2391138660159413e-09
of O 0 1.3657370789843526e-09
Jerusalem O 0 3.834246854239609e-06
. O 0 1.794671078414467e-07

The O 0 9.21204332371417e-07
clinical O 0 1.586041798873339e-05
diagnosis O 0 0.009333910420536995
of O 0 5.750310378971335e-07
AGU B-Disease 1 1.0
is O 0 2.0681925150256575e-07
often O 0 1.47000394079555e-08
difficult O 0 7.126666368151291e-09
, O 0 3.10770076339395e-10
in O 0 3.9101422100173977e-10
particular O 0 4.749916571178403e-10
early O 0 4.34233484725155e-08
in O 0 3.3234242025059757e-09
the O 0 1.5391813379395103e-09
course O 0 2.7395055113288436e-09
of O 0 7.890372383245747e-11
the O 0 2.1508418157623055e-08
disease O 0 1.5581091474814457e-06
, O 0 3.376003643307257e-10
and O 0 1.4620220312178134e-10
most O 0 4.71655631217871e-11
of O 0 4.5588345598535085e-11
the O 0 1.706633412368319e-08
patients O 0 3.4928323344729506e-08
are O 0 3.3758700279662435e-09
diagnosed O 0 5.835642014062614e-07
after O 0 7.708923277505164e-09
the O 0 9.025426628284094e-09
age O 0 2.7527151669204386e-09
of O 0 1.9358119274226482e-10
5 O 0 2.395372433738885e-08
years O 0 8.310315102733057e-09
. O 0 2.8660652517942253e-08

However O 0 1.3323405028131674e-06
, O 0 1.0787958082403293e-08
since O 0 1.4704919060193333e-08
these O 0 1.435041530051251e-09
patients O 0 6.738992919252951e-09
excrete O 0 6.259845974909695e-08
early O 0 8.583882049606473e-09
large O 0 7.862479001197187e-10
amounts O 0 9.604690376363578e-10
of O 0 3.901529932459624e-10
aspartylglucosamine O 0 2.87156240119657e-07
in O 0 8.97692586931953e-09
urine O 0 8.463015888082737e-08
, O 0 9.052609772908227e-10
biochemical O 0 5.8408986092217674e-08
screening O 0 1.6682197667705623e-07
is O 0 1.994494569501626e-09
easy O 0 1.054947862400013e-08
by O 0 9.07164476871003e-09
urine O 0 1.7167204759971355e-06
chromatography O 0 1.2675255902649951e-06
. O 0 1.7141172037327124e-08
. O 0 7.149950675966465e-08

Detection O 0 1.1837470083264634e-05
of O 0 6.09307804211312e-08
heterozygous O 0 2.337114892725367e-06
carriers O 0 1.8364841025686474e-07
of O 0 7.040266591928912e-09
the O 0 7.168519459810341e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 7.088019629009068e-07
ATM O 0 1.689822420303244e-05
) O 0 2.6602700486932918e-08
gene O 0 1.8011694180586346e-07
by O 0 9.213940721508607e-09
G2 O 0 5.156805855222046e-06
phase O 0 2.0753846285970212e-07
chromosomal O 0 1.3004795619053766e-05
radiosensitivity O 0 3.7918284760962706e-06
of O 0 9.011974277939316e-09
peripheral O 0 7.912619184935465e-05
blood O 0 5.5958942539291456e-05
lymphocytes O 0 7.219758117571473e-05
. O 0 9.265877451980487e-07

In O 0 0.0009721052483655512
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.010930433869361877
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.3026051703945996e-07
patients O 0 8.007489071815144e-08
, O 0 1.459754650490197e-09
mutations O 0 4.757900740059995e-08
in O 0 1.364562907113509e-09
a O 0 2.139111332510879e-09
single O 0 2.3933661719155452e-09
gene O 0 1.4319253338612725e-08
, O 0 2.9130847734037957e-10
ATM O 0 1.8416703539969603e-07
, O 0 2.1653576154356813e-10
result O 0 3.874373877277293e-10
in O 0 6.9867716057103735e-09
an O 0 3.7576371596514946e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 9.701303582687615e-08
embraces O 0 3.108011981112213e-08
a O 0 5.607564190768244e-09
variety O 0 2.3690405193121933e-09
of O 0 3.1165689473589e-10
clinical O 0 2.3479397981418515e-08
features O 0 1.180856884275272e-06
and O 0 3.30126290748467e-08
manifests O 0 8.107116968858463e-07
extreme O 0 1.5115530231923913e-06
radiosensitivity O 0 3.99971213482786e-06
and O 0 2.326855597090116e-09
a O 0 3.4626959077854735e-09
strong O 0 6.524623330506074e-08
pre O 0 5.065737059339881e-05
- O 0 1.344780048384564e-05
disposition O 0 7.906004384494736e-07
to O 0 4.893946581319142e-08
malignancy B-Disease 0 6.98292933520861e-06
. O 0 1.448662771963427e-07

Heterozygotes O 0 0.00015831284690648317
for O 0 8.07575872840971e-08
the O 0 2.023374889859042e-08
ATM O 0 4.7593534873158205e-06
gene O 0 4.0862707351152494e-07
have O 0 2.47261078278882e-09
no O 0 1.2111581737528354e-09
clinical O 0 5.8226978794095885e-09
expression O 0 5.935207880725102e-09
of O 0 1.5209186132736363e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 1.9459482700767694e-06
may O 0 6.915190169820562e-05
be O 0 7.569085624936633e-08
cancer B-Disease 0 1.0251842468278483e-06
prone O 0 8.518028238313491e-08
with O 0 4.08512002003647e-10
a O 0 6.34314734071495e-09
moderate O 0 1.8199207829638908e-07
increase O 0 1.2190643161602566e-08
in O 0 3.755761479595776e-09
in O 0 1.7812578079201558e-08
vitro O 0 2.6980769689544104e-06
radiosensitivity O 0 1.5378200259874575e-05
. O 0 1.8926927225493273e-07

We O 0 3.963927213135321e-07
performed O 0 1.1083802320399627e-07
a O 0 1.2357820544650622e-08
blind O 0 1.8852885830256128e-07
chromosomal O 0 3.298423507658299e-06
analysis O 0 5.423080295940963e-08
on O 0 1.6989207551887375e-07
G2 O 0 2.5525780074531212e-05
- O 0 1.3211831628723303e-06
phase O 0 1.0337073774735472e-07
lymphocytes O 0 4.419963772761548e-07
from O 0 4.867867886559907e-09
7 O 0 3.787891955653322e-08
unrelated O 0 3.4555199590613483e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.1938309398829006e-06
, O 0 1.1831874369150341e-09
13 O 0 6.295021393043498e-09
obligate O 0 7.194712026148409e-08
A B-Disease 1 0.9999986886978149
- I-Disease 1 0.9999970197677612
T I-Disease 1 1.0
heterozygotes O 0 6.236657645786181e-05
( O 0 2.2879570238387714e-08
parents O 0 4.847003687302731e-09
of O 0 1.0017931623140797e-10
the O 0 4.059373726050808e-09
patients O 0 6.949676834011598e-09
) O 0 4.915336471178477e-10
, O 0 2.5782520562955824e-10
and O 0 5.214434994904593e-10
14 O 0 8.41050518118891e-09
normal O 0 7.026853410252443e-08
controls O 0 1.7901866158354096e-05
following O 0 8.616940760930447e-08
X O 0 2.9684772016480565e-05
- O 0 3.6456373209148296e-07
irradiation O 0 2.041152100673571e-07
with O 0 3.4305953633406716e-09
1 O 0 1.9835999509609792e-08
Gy O 0 5.911592211305106e-07
in O 0 9.075327156438107e-10
order O 0 4.4369788398945786e-10
to O 0 4.84803697187175e-10
evaluate O 0 5.306321160247762e-09
this O 0 4.1107492410041857e-10
cytogenetic O 0 8.943995055687992e-08
method O 0 1.7419601316959188e-09
as O 0 4.690515198468859e-10
a O 0 1.2913532465574917e-09
tool O 0 1.6806618319265e-08
for O 0 3.247816460216768e-10
detection O 0 1.1600598703864762e-08
of O 0 1.9164816400518703e-09
ATM O 0 1.3314030184119474e-05
carriers O 0 8.549537824364961e-07
. O 0 1.4447127227867895e-07

Both O 0 1.7057083141480689e-06
A B-Disease 1 0.9995545744895935
- I-Disease 1 0.9997078776359558
T I-Disease 1 1.0
homozygotes O 0 4.721009827335365e-05
and O 0 2.044279945323524e-08
heterozygotes O 0 5.351645882001321e-07
showed O 0 9.127500533168131e-08
significantly O 0 1.0152480456326884e-07
increased O 0 1.1835222579748006e-08
levels O 0 1.1682932843370963e-08
of O 0 1.8407891877458837e-09
radiation O 0 0.00015638400509487838
- O 0 0.002382159000262618
induced O 0 4.045483728987165e-05
chromatid O 0 2.428071093163453e-05
damage O 0 3.437704947373277e-07
relative O 0 2.25436824763392e-08
to O 0 1.0405468708896137e-09
that O 0 2.0587322124843155e-10
of O 0 1.7977176691719166e-10
normal O 0 2.2460488935394096e-07
controls O 0 0.00031309842597693205
. O 0 1.6063322050285933e-07

These O 0 2.294532777114e-07
results O 0 2.0637102693399356e-07
show O 0 1.6987232243081962e-07
that O 0 9.055252103706835e-10
the O 0 8.280490959577946e-09
G2 O 0 1.065305059455568e-05
- O 0 1.1782515230152057e-06
phase O 0 2.7599512009146565e-07
chromosomal O 0 1.4677516446681693e-05
radiosensitivity O 0 6.030739314155653e-06
assay O 0 4.943962267134339e-06
can O 0 8.18416090453411e-09
be O 0 3.170542439701052e-10
used O 0 4.6032855305355724e-10
for O 0 1.9275322657441585e-11
the O 0 1.3699107126452503e-10
detection O 0 9.640043430181322e-09
of O 0 1.785236514173505e-09
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999991655349731
T I-Disease 1 1.0
heterozygotes O 0 0.0002514911175239831
. O 0 5.375829914555652e-07

In O 0 3.177150631472614e-07
combination O 0 1.6745909192650288e-07
with O 0 5.74929925889478e-09
molecular O 0 1.8099511578384408e-07
genetic O 0 1.2650352232412843e-07
analyses O 0 2.081696095501684e-07
, O 0 2.868913107079152e-09
this O 0 3.0060505196161103e-09
test O 0 1.0097477343151695e-06
may O 0 3.516906019740418e-07
be O 0 2.380617369901472e-10
of O 0 2.882056746034145e-11
value O 0 8.744965168672181e-11
in O 0 2.418849009977464e-10
studies O 0 3.5574418411066233e-10
of O 0 9.971113518192354e-11
familial B-Disease 0 1.1718835679630502e-07
and I-Disease 0 1.3030122758550533e-08
sporadic I-Disease 0 9.650270658312365e-05
cancers I-Disease 0 0.000664335151668638
aimed O 0 3.9252333294825803e-07
at O 0 3.1381418352793844e-07
determination O 0 5.753050924539593e-09
of O 0 8.48166814559903e-11
the O 0 4.872621750529049e-10
potential O 0 3.3428126933188196e-10
involvement O 0 1.6458073792691152e-09
of O 0 5.197138275292446e-10
ATM O 0 9.261671038984787e-06
mutations O 0 7.607714564983326e-07
in O 0 3.491407341016384e-08
tumor B-Disease 0 8.623633220850024e-06
risk O 0 8.879032264985653e-08
or O 0 1.3341972859848283e-08
development O 0 4.39035208188443e-09
. O 0 4.577100920499788e-09
. O 0 5.1119556587764237e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 1.1045725614167168e-06
identification O 0 1.7139315389158583e-07
and O 0 4.351635052302072e-09
detection O 0 4.623519700430734e-08
of O 0 2.247454888859579e-09
founder O 0 5.413231178863498e-07
- O 0 5.186731186768156e-07
effect O 0 1.5219444549074979e-07
mutations O 0 1.7585901446182106e-07
in O 0 1.896543366797232e-09
the O 0 2.3540818183676038e-09
ATM O 0 4.563574407256965e-07
gene O 0 8.564572340219456e-08
in O 0 3.7611953551675015e-09
ethnic O 0 7.780894151210305e-09
populations O 0 6.817444386797433e-08
. O 0 4.494391347975579e-08

To O 0 1.1094821417145795e-07
facilitate O 0 5.345687981161973e-08
the O 0 6.024064802545581e-09
evaluation O 0 1.1925112453070597e-08
of O 0 9.552074686780543e-10
ATM O 0 2.7897026484424714e-06
heterozygotes O 0 6.077582952457306e-07
for O 0 2.5211188692253472e-09
susceptibility O 0 1.3293130507463502e-07
to O 0 2.755341510507492e-09
other O 0 2.0869099781606337e-09
diseases O 0 3.5070527815150854e-07
, O 0 1.299236135343662e-10
such O 0 4.5825324090920105e-10
as O 0 1.694894308457151e-06
breast B-Disease 1 0.9936267137527466
cancer I-Disease 0 1.8595428628032096e-05
, O 0 3.1775422293378597e-09
we O 0 2.9835151016399664e-10
have O 0 1.4405145132290187e-10
attempted O 0 6.639261584950873e-09
to O 0 9.54275103381974e-10
define O 0 4.31639524123284e-09
the O 0 4.201239633960796e-10
most O 0 1.4114728830172396e-10
common O 0 3.296491968285409e-09
mutations O 0 5.283711246306666e-08
and O 0 7.554295522460563e-10
their O 0 3.6336322839503055e-09
frequencies O 0 3.130031473119743e-05
in O 0 8.246493052865844e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 6.971877610340016e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999978542327881
T I-Disease 1 1.0
) O 0 2.03714147772871e-08
homozygotes O 0 6.644166319347278e-07
from O 0 4.3726098297725e-09
10 O 0 2.3232591406241454e-09
ethnic O 0 3.0614191182110062e-09
populations O 0 4.0688409086442334e-08
. O 0 5.773378575213428e-08

Both O 0 5.441730195343553e-07
genomic O 0 1.1875528798555024e-05
mutations O 0 3.096338332397863e-05
and O 0 3.838966122771126e-08
their O 0 9.150366686583311e-09
effects O 0 5.767528250544274e-07
on O 0 9.480966411956615e-08
cDNA O 0 6.830225061094097e-07
were O 0 3.623536315444653e-08
characterized O 0 9.901702924253186e-07
. O 0 1.5002005682163144e-07

Protein O 0 6.022932939231396e-05
- O 0 9.465095899940934e-06
truncation O 0 1.1376186193956528e-05
testing O 0 4.930608952236071e-07
of O 0 1.5481615989187958e-09
the O 0 6.099156735217548e-09
entire O 0 8.469103107699993e-08
ATM O 0 3.7086640531924786e-06
cDNA O 0 1.734979832690442e-06
detected O 0 2.1270873276080238e-06
92 O 0 5.971604082333215e-07
( O 0 9.356165620033607e-09
66 O 0 2.928815412417407e-08
% O 0 1.7672603380702867e-09
) O 0 1.1656841047980038e-09
truncating O 0 4.1382250515198393e-07
mutations O 0 2.3472014731851232e-07
in O 0 8.528411754582521e-09
140 O 0 2.0051881222116208e-07
mutant O 0 3.2533184821659233e-06
alleles O 0 5.569599579757778e-06
screened O 0 7.259648555191234e-06
. O 0 5.632053898807499e-07

The O 0 6.654400976913166e-07
haplotyping O 0 6.019994998496259e-06
of O 0 9.958427860112806e-09
patients O 0 3.535549097932744e-08
with O 0 2.5528570368749115e-09
identical O 0 1.7124892110587098e-05
mutations O 0 4.435766641108785e-06
indicates O 0 1.4454426100485307e-08
that O 0 2.706978530220283e-10
almost O 0 5.107427814010634e-10
all O 0 2.41912948006906e-11
of O 0 5.963215164717095e-12
these O 0 1.3798066855752467e-11
represent O 0 7.086307235448785e-11
common O 0 8.758240244155502e-10
ancestry O 0 2.8600024570835103e-09
and O 0 9.318831262206118e-10
that O 0 3.4292071959818315e-10
very O 0 3.803441117611328e-09
few O 0 6.735870528018495e-09
spontaneously O 0 7.93714605151763e-08
recurring O 0 4.2283355128347466e-07
ATM O 0 1.480519313190598e-05
mutations O 0 3.4061977203236893e-06
exist O 0 1.1857098769496588e-07
. O 0 1.3056298087121831e-07

Assays O 0 0.00013067532563582063
requiring O 0 1.8079757637678995e-06
minimal O 0 4.5562600803350506e-07
amounts O 0 2.2855537906707468e-08
of O 0 2.8840008159392028e-09
genomic O 0 2.853517742096301e-07
DNA O 0 3.9854123201621405e-07
were O 0 2.3313837971272733e-08
designed O 0 1.1285715117992368e-07
to O 0 9.266685752074011e-10
allow O 0 1.825488871176617e-09
rapid O 0 4.830707212022389e-08
screening O 0 4.9001112500945965e-08
for O 0 9.454196314706564e-10
common O 0 8.23883716805085e-09
ethnic O 0 2.8138060770288575e-08
mutations O 0 4.86567023472162e-06
. O 0 2.7342247221895377e-07

These O 0 6.479172611761896e-07
rapid O 0 5.363153832149692e-06
assays O 0 2.7176982257515192e-05
detected O 0 1.2323863302299287e-05
mutations O 0 2.0528407276287908e-06
in O 0 1.8951702429603756e-08
76 O 0 1.658239483504076e-07
% O 0 1.7836743193555549e-09
of O 0 5.153478754849061e-10
Costa O 0 4.814554799281723e-08
Rican O 0 8.584181188098228e-08
patients O 0 3.856741770391636e-08
( O 0 3.0706002185354464e-09
3 O 0 5.452252427318172e-09
) O 0 2.407907484514027e-10
, O 0 6.259001650299467e-11
50 O 0 3.551942906465655e-10
% O 0 5.6059334258007354e-11
of O 0 4.2811670875053665e-11
Norwegian O 0 1.1945143114644452e-06
patients O 0 4.826627275633655e-08
( O 0 1.4837100437148365e-09
1 O 0 2.8448883249154733e-09
) O 0 3.3366145957280935e-10
, O 0 1.6763157528743022e-10
25 O 0 1.2284679939966736e-09
% O 0 8.66440877378416e-11
of O 0 1.160665036303854e-10
Polish O 0 2.3468361177947372e-05
patients O 0 9.241700382744966e-08
( O 0 2.0766182107223585e-09
4 O 0 6.131126273345444e-09
) O 0 2.528037224003299e-10
, O 0 1.0039490072610846e-10
and O 0 2.0161036728971737e-10
14 O 0 8.151379016219096e-10
% O 0 7.077121527698793e-11
of O 0 6.697405824374059e-11
Italian O 0 7.510740260840976e-07
patients O 0 1.632867281387007e-07
( O 0 5.023674365389752e-09
1 O 0 8.214265712069846e-09
) O 0 3.17129211779843e-10
, O 0 9.017966928759336e-11
as O 0 3.247370705672381e-10
well O 0 1.715188130413381e-10
as O 0 2.344751059979444e-10
in O 0 1.098009905220465e-09
patients O 0 2.3480819510979245e-09
of O 0 6.64906740777127e-10
Amish O 0 0.0003570083936210722
/ O 0 3.469435250735842e-05
Mennonite O 0 5.124591098137898e-06
and O 0 9.586337945677315e-09
Irish O 0 9.103958120704192e-08
English O 0 1.312018156340855e-07
backgrounds O 0 3.814464548668184e-07
. O 0 1.1069963079535228e-07

Additional O 0 1.2403369282765198e-06
mutations O 0 4.1889884414558765e-06
were O 0 1.5620972959595747e-08
observed O 0 2.354913775093337e-08
in O 0 3.831656325559152e-09
Japanese O 0 2.9531660672432736e-08
, O 0 6.375687755522108e-10
Utah O 0 5.760692811662693e-09
Mormon O 0 7.800760926102157e-09
, O 0 1.4307391382750723e-10
and O 0 1.4098530676243115e-10
African O 0 5.214932374819625e-10
American O 0 1.0184322718487238e-08
patients O 0 1.4885726784541475e-07
. O 0 7.2464267475425e-08

These O 0 2.0238523745774728e-07
assays O 0 3.282250418124022e-06
should O 0 9.513714260833694e-09
facilitate O 0 6.643923633475879e-09
screening O 0 7.290387316061242e-08
for O 0 4.420230848012352e-09
A B-Disease 1 0.9999971389770508
- I-Disease 1 0.9999681711196899
T I-Disease 1 1.0
heterozygotes O 0 2.095160425596987e-06
in O 0 2.494942918929155e-09
the O 0 9.707940007430693e-10
populations O 0 4.971202116621498e-09
studied O 0 1.6254245949198776e-08
. O 0 3.7718992373925175e-09
. O 0 4.4134850440968876e-08

The O 0 8.18232638266636e-06
von B-Disease 1 0.9927575588226318
Hippel I-Disease 1 0.9997422099113464
- I-Disease 1 0.9938067197799683
Lindau I-Disease 1 0.9992774128913879
tumor I-Disease 0 0.0028385184705257416
suppressor O 0 0.00015039462596178055
gene O 0 6.64143180983956e-06
is O 0 7.639047616692096e-09
required O 0 2.231760776183478e-09
for O 0 1.0533046657101863e-09
cell O 0 8.541013016838406e-07
cycle O 0 1.3114055263940827e-06
exit O 0 3.016738787664508e-07
upon O 0 1.3101520757174967e-08
serum O 0 1.2344955848675454e-06
withdrawal O 0 7.559446544291859e-07
. O 0 1.8535199330926844e-07

The O 0 6.516017378999095e-07
inactivation O 0 6.035601472831331e-06
of O 0 9.233344755443795e-09
the O 0 1.0493952373735738e-07
von B-Disease 1 0.9942207336425781
Hippel I-Disease 1 0.9998414516448975
- I-Disease 1 0.999402642250061
Lindau I-Disease 1 0.9998039603233337
( I-Disease 0 2.5527401703584474e-06
VHL I-Disease 0 0.00033436587546020746
) I-Disease 0 2.0703789971321385e-07
tumor I-Disease 0 1.0164529157918878e-05
suppressor O 0 3.166340684401803e-05
gene O 0 3.904917321051471e-06
predisposes O 0 2.6509153485676507e-06
affected O 0 6.642937933065696e-08
individuals O 0 6.558855125682328e-10
to O 0 1.319797604537598e-09
the O 0 2.4800320019835453e-08
human O 0 4.089509275218006e-06
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
and O 0 1.855673481543363e-08
is O 0 9.38183974952267e-10
associated O 0 6.490413539950168e-09
with O 0 7.717795291739549e-09
sporadic B-Disease 1 0.9983890056610107
renal I-Disease 1 0.9999996423721313
cell I-Disease 1 0.9999996423721313
carcinomas I-Disease 1 1.0
( O 0 3.9347316487692297e-05
RCC B-Disease 0 0.42575329542160034
) O 0 6.84737884171227e-08
and O 0 4.2652636977891234e-08
brain B-Disease 0 5.755716483690776e-05
hemangioblastomas I-Disease 0 0.000188926569535397
. O 0 7.590958830405725e-07

VHL O 0 0.34831029176712036
- O 0 0.003419998800382018
negative O 0 6.0230020608287305e-05
786 O 0 7.654273213120177e-05
- O 0 6.672486051684245e-05
0 O 0 7.84590099556226e-07
RCC B-Disease 0 1.4013328836881556e-05
cells O 0 9.337324513580825e-08
are O 0 1.537215799096714e-09
tumorigenic O 0 6.769345759494172e-07
in O 0 2.2198323179623003e-08
nude O 0 1.385411451337859e-05
mice O 0 1.622515446797479e-05
which O 0 9.92592408266546e-09
is O 0 6.247209416443411e-10
suppressed O 0 1.2931902659829575e-08
by O 0 2.974395452159939e-10
the O 0 6.897287185836376e-10
reintroduction O 0 1.2238827196142665e-07
of O 0 3.9201508705843935e-09
VHL B-Disease 0 7.85244774306193e-05
. O 0 3.018923280251329e-07

Remarkably O 0 0.0002288053510710597
, O 0 2.992791081624091e-08
this O 0 2.6866313618256754e-09
occurs O 0 7.9163244848246e-09
without O 0 1.2512502145511917e-09
affecting O 0 8.297091014242142e-09
the O 0 3.115352198435062e-09
growth O 0 1.1546541145435185e-07
rate O 0 8.172073648893274e-07
and O 0 1.998397891611603e-09
cell O 0 2.384046382530869e-07
cycle O 0 3.377617758815177e-07
profile O 0 2.3611340438378647e-08
of O 0 2.8855950962025645e-10
these O 0 4.733131664380608e-10
cells O 0 7.83608911092415e-09
in O 0 4.2763730334627326e-09
culture O 0 1.5026976996068697e-07
. O 0 9.497146891135344e-08

The O 0 8.798312478575099e-07
786 O 0 2.384738218097482e-05
- O 0 4.356106728664599e-06
0 O 0 1.5401609232412738e-07
cell O 0 1.562895249662688e-06
line O 0 7.260618076543324e-06
, O 0 7.101897958605718e-10
like O 0 7.534020629584859e-10
many O 0 3.428062556043443e-10
cancer B-Disease 0 7.790103495608491e-08
cells O 0 1.3051513647610591e-08
, O 0 1.154776496647969e-09
fails O 0 3.082807964460699e-08
to O 0 6.737794766564775e-10
exit O 0 1.937103100146942e-08
the O 0 1.3591779923771696e-09
cell O 0 2.441015283238812e-07
cycle O 0 8.34897377899324e-08
upon O 0 4.973260026019943e-09
serum O 0 3.8270502500381554e-07
withdrawal O 0 1.2182535158444807e-07
. O 0 7.76847031147554e-08

Here O 0 9.608423852114356e-07
, O 0 1.0850299325682045e-08
it O 0 1.5355249294302098e-09
is O 0 1.3828609091159905e-10
shown O 0 7.191714446186381e-10
that O 0 5.908770694951215e-11
reintroduction O 0 5.746185749444521e-09
of O 0 8.163651005199668e-11
the O 0 7.235550492090681e-10
wild O 0 4.550006948988994e-08
- O 0 1.1663555596896913e-05
type O 0 4.187506056041457e-05
VHL B-Disease 0 9.89745749393478e-05
gene O 0 2.409969738437212e-06
restores O 0 2.3935742774483515e-06
the O 0 5.955540505198087e-09
ability O 0 2.4723950886595958e-08
of O 0 7.193830864338224e-09
VHL O 0 0.0021461492870002985
- O 0 0.00772938784211874
negative O 0 0.001256659859791398
RCC B-Disease 1 0.6204075217247009
cancer I-Disease 0 1.4277535228757188e-05
cells O 0 1.0413082662807938e-07
to O 0 5.579058548477178e-09
exit O 0 5.173999184648892e-08
the O 0 4.188535740468069e-09
cell O 0 3.055060062706616e-07
cycle O 0 2.6507839834266633e-07
and O 0 2.136611776393238e-09
enter O 0 3.389233071970921e-08
G0 O 0 1.1870310117956251e-05
/ O 0 2.188618054788094e-06
quiescence O 0 3.645999413492973e-06
in O 0 1.2566661666824075e-07
low O 0 5.300153497955762e-05
serum O 0 4.2901552660623565e-05
. O 0 8.383791509913863e-07

Both O 0 4.114489911444252e-06
VHL O 0 0.004269968718290329
- O 0 0.00026482451357878745
positive O 0 1.0559834890955244e-06
and O 0 6.785958817090432e-08
VHL O 0 0.0006004149909131229
- O 0 6.607224349863827e-05
negative O 0 7.704737981839571e-06
RCC B-Disease 0 4.4438984332373366e-05
cells O 0 2.0390778843193402e-07
exit O 0 1.1035579916551796e-07
the O 0 3.5499196915367293e-09
cell O 0 4.458965179310326e-07
cycle O 0 1.5766515559789696e-07
by O 0 3.293902262058168e-09
contact O 0 4.747833770579746e-07
inhibition O 0 2.131111841663369e-06
. O 0 1.7744361002769438e-07

The O 0 3.7264969705574913e-06
cyclin O 0 0.00029717147117480636
- O 0 6.472974291682476e-06
dependent O 0 6.956893230380956e-07
kinase O 0 1.4143156477075536e-05
inhibitor O 0 2.046228473773226e-06
, O 0 8.666829920400687e-09
p27 O 0 7.000032269388612e-07
, O 0 1.4764097722164138e-09
accumulates O 0 3.641002166432372e-08
upon O 0 2.3737400933754316e-09
serum O 0 8.73181136284984e-08
withdrawal O 0 1.3875573579014144e-08
, O 0 3.1393354582576194e-10
only O 0 8.13657127785028e-11
in O 0 4.392778918393958e-10
the O 0 5.485137899441384e-10
presence O 0 1.413839267883077e-09
of O 0 7.722046335700838e-10
VHL B-Disease 0 3.207715963071678e-06
, O 0 5.833322158643739e-10
as O 0 3.8751793440816584e-10
a O 0 8.108163029874049e-10
result O 0 8.024789166505286e-10
of O 0 6.811806674278387e-11
the O 0 6.927479145879545e-10
stabilization O 0 1.520861481196789e-08
of O 0 1.4047422947083277e-10
the O 0 4.136273101806864e-09
protein O 0 2.894678061693412e-07
. O 0 9.629773245478646e-08

We O 0 3.56544120450053e-07
propose O 0 3.094390024216409e-07
that O 0 2.7425586246465627e-09
the O 0 3.0520266314226774e-09
loss O 0 1.3532937437332748e-08
of O 0 6.846719302622262e-10
wild O 0 1.219929970375233e-07
- O 0 0.00016655793297104537
type O 0 0.00036381560494191945
VHL B-Disease 0 0.00010439673496875912
gene O 0 1.122510639106622e-06
results O 0 7.975829419137881e-08
in O 0 2.894532169506192e-09
a O 0 1.8616922448089213e-09
specific O 0 1.2623110556830852e-08
cellular O 0 9.472739179727796e-07
defect O 0 6.870789093227359e-07
in O 0 2.849234093105224e-08
serum O 0 1.6138451428560074e-06
- O 0 4.5237268864184443e-07
dependent O 0 4.205589476669047e-08
growth O 0 3.851316776604108e-08
control O 0 9.270247147696864e-08
, O 0 4.6564638256363367e-10
which O 0 8.531417794443996e-10
may O 0 1.9086138891566407e-08
initiate O 0 1.997008780563192e-07
tumor B-Disease 0 2.1402975107776e-06
formation O 0 3.619679205257853e-07
. O 0 2.2341815508752916e-07

This O 0 7.142426170503313e-07
is O 0 3.481578758623982e-08
corrected O 0 4.294676614335913e-07
by O 0 1.3593544068157826e-09
the O 0 1.174320307661958e-09
reintroduction O 0 4.250766849622778e-08
of O 0 6.479302649964325e-10
wild O 0 1.202321016080532e-07
- O 0 0.0004616311634890735
type O 0 0.02094869501888752
VHL B-Disease 0 0.006318626459687948
, O 0 3.730205122565167e-08
implicating O 0 4.240945600031409e-06
VHL B-Disease 0 2.6631607397575863e-05
as O 0 4.318750690401885e-09
the O 0 1.9112140758892338e-09
first O 0 1.1688862322500881e-08
tumor B-Disease 0 6.467763569162344e-07
suppressor O 0 1.1096446996816667e-06
involved O 0 3.3222962159129565e-09
in O 0 1.5180262602498829e-09
the O 0 7.339603924627625e-10
regulation O 0 3.770987788698221e-08
of O 0 4.953566445919932e-10
cell O 0 4.6550255206057045e-07
cycle O 0 1.2291257007746026e-06
exit O 0 2.519620920793386e-07
, O 0 8.328449041528074e-10
which O 0 1.0723434362702733e-09
is O 0 2.856588021682427e-10
consistent O 0 2.5723787544507104e-09
with O 0 2.1095725166730972e-10
its O 0 1.132690030658523e-08
gatekeeper O 0 8.135481976978554e-08
function O 0 1.7472542301888438e-09
in O 0 7.386171674284014e-10
the O 0 7.518205613621376e-09
kidney O 0 1.4148548643788672e-07
. O 0 5.1685717927796304e-09
. O 0 4.0209005902624995e-08

Piebaldism B-Disease 1 1.0
with O 0 0.02445869706571102
deafness B-Disease 1 1.0
: O 0 1.8812649216215505e-08
molecular O 0 2.3605441157315e-08
evidence O 0 2.3778548019492973e-09
for O 0 8.11264944111656e-10
an O 0 9.880326778954895e-09
expanded O 0 0.0003957184962928295
syndrome O 1 0.9998458623886108
. O 0 4.4208445615367964e-07

In O 0 1.9423609387558827e-07
a O 0 5.572202255166303e-08
South O 0 3.871068443572767e-08
African O 0 1.1757351536800797e-08
girl O 0 1.7450842904054298e-07
of O 0 9.815183110717385e-10
Xhosa O 0 4.364077994978288e-06
stock O 0 1.564708895784861e-06
with O 0 6.332352864291124e-09
severe O 0 6.501725874841213e-05
piebaldism B-Disease 0 0.004514673724770546
and O 0 9.150367645816004e-07
profound O 0 0.00021192332496866584
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 5.213582880969625e-06
identified O 0 1.0744346212732125e-07
a O 0 2.286936329198852e-08
novel O 0 5.027539984325813e-08
missense O 0 1.9656069980555912e-06
substitution O 0 1.0518560600303317e-07
at O 0 3.4707049678672774e-08
a O 0 8.133740792004573e-09
highly O 0 2.186192382680474e-08
conserved O 0 1.046962196937784e-07
residue O 0 1.3801515308387025e-07
in O 0 1.4172817364155321e-09
the O 0 2.9484426011805454e-09
intracellular O 0 2.645069230311492e-07
kinase O 0 6.103942382651439e-07
domain O 0 4.5106567370112316e-08
of O 0 1.5309482570557975e-09
the O 0 2.606920723735584e-08
KIT O 0 9.358306851936504e-05
proto O 0 0.0003810702182818204
- O 0 1.0149195077246986e-05
oncogene O 0 1.383990456815809e-05
, O 0 3.448000640560167e-08
R796G O 0 3.78018080482434e-06
. O 0 1.5633260375125246e-07

Though O 0 3.891385404131142e-06
auditory B-Disease 0 0.00011125168384751305
anomalies I-Disease 0 0.007911684922873974
have O 0 1.527472193174617e-08
been O 0 4.856627988658602e-09
observed O 0 1.794920301279035e-08
in O 0 1.0067092937049438e-08
mice O 0 1.2148905170761282e-06
with O 0 4.810027487422985e-09
dominant O 0 2.2236135919229127e-06
white O 0 4.6592759872510214e-07
spotting O 0 5.475617399497423e-06
( O 0 6.424534859661435e-08
W O 0 0.0034382587764412165
) O 0 1.3047898317353201e-09
due O 0 2.509849927889718e-08
to O 0 4.1636784686716055e-08
KIT O 0 0.2555346190929413
mutations O 0 8.552964573027566e-05
, O 0 1.0639967058523325e-06
deafness B-Disease 1 1.0
is O 0 3.503641821112069e-08
not O 0 1.8578931726409564e-09
typical O 0 2.2645473052307352e-08
in O 0 5.931790170166096e-09
human O 0 1.408537464442361e-08
piebaldism B-Disease 0 1.3651769222633447e-05
. O 0 2.1408781947229727e-07

Thus O 0 5.391818262978632e-07
, O 0 1.0456266963387861e-08
the O 0 4.272459275256324e-09
occurrence O 0 2.5446868789913424e-07
of O 0 7.373496657692158e-08
sensorineural B-Disease 1 0.9999998807907104
deafness I-Disease 1 1.0
in O 0 3.2302057206834434e-06
this O 0 2.354765804568615e-08
patient O 0 3.6253621260584623e-07
extends O 0 6.54439062941492e-08
considerably O 0 1.538053027161368e-07
the O 0 3.730089570552764e-09
phenotypic O 0 7.339848195897503e-08
range O 0 2.4802307763138742e-08
of O 0 8.640136939241927e-10
piebaldism B-Disease 0 6.718717031617416e-07
due O 0 2.42287807594721e-08
to O 0 4.540849474210518e-09
KIT O 0 1.8322905361856101e-06
gene O 0 1.5493091609641851e-07
mutation O 0 9.048492444208023e-08
in O 0 2.2234922791852796e-09
humans O 0 5.196070240742756e-09
and O 0 7.731511431074978e-09
tightens O 0 4.553614053293131e-05
the O 0 2.2470389993145545e-09
clinical O 0 4.903717876203473e-09
similarity O 0 7.999654272339285e-09
between O 0 7.237375587720862e-09
piebaldism B-Disease 0 2.865234591808985e-06
and O 0 5.552219239923772e-10
the O 0 3.561080319514076e-10
various O 0 7.537384605349473e-10
forms O 0 1.1119519527369448e-08
of O 0 6.093321758271486e-08
Waardenburg B-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9998472929000854
. O 0 2.7217518905331417e-08
. O 0 7.644050015187531e-08

Cycloheximide O 0 0.00010449653200339526
facilitates O 0 3.270078195782844e-06
the O 0 1.79821668666591e-08
identification O 0 1.4864640185408007e-08
of O 0 9.432258307739971e-10
aberrant O 0 1.1724587238859385e-06
transcripts O 0 1.0230268117084051e-06
resulting O 0 1.7006844643674413e-07
from O 0 1.0838426156567493e-08
a O 0 2.955160738338236e-08
novel O 0 1.1661987997513279e-07
splice O 0 2.9273154723341577e-05
- O 0 3.5269054023956414e-06
site O 0 2.620058694446925e-07
mutation O 0 2.7158100124324847e-07
in O 0 1.3485450089945061e-08
COL17A1 O 0 2.765542149063549e-06
in O 0 8.125956796334322e-09
a O 0 2.0600579020424448e-08
patient O 0 7.526034551119665e-07
with O 0 1.5762937266572408e-07
generalized O 0 0.0013177343644201756
atrophic B-Disease 1 0.9999605417251587
benign I-Disease 1 0.9999631643295288
epidermolysis I-Disease 1 0.9996218681335449
bullosa I-Disease 1 0.9917450547218323
. O 0 2.2014055502950214e-05

Patients O 0 0.00024580644094385207
with O 0 4.068619091412984e-06
generalized O 0 0.02084011770784855
atrophic B-Disease 1 0.9999967813491821
benign I-Disease 1 0.9999918937683105
epidermolysis I-Disease 1 0.9999220371246338
bullosa I-Disease 1 0.9979840517044067
often O 0 2.1297553757904097e-05
show O 0 2.9452398848661687e-06
decreased O 0 8.463272251901799e-07
expression O 0 2.801050946743544e-08
of O 0 1.680606431797571e-09
type O 0 3.796375676756725e-05
XVII O 0 0.00015844166046008468
collagen O 0 2.380659452683176e-06
, O 0 3.4760299083558266e-09
a O 0 1.9195518063952477e-08
transmembrane O 0 2.933428504547919e-07
hemidesmosomal O 0 1.4707857189932838e-06
protein O 0 1.0910673609032528e-07
encoded O 0 1.2312909802858485e-07
by O 0 4.331787550881927e-08
COL17A1 O 0 2.9137187084415928e-05
. O 0 3.4470974696887424e-07

This O 0 3.0824352847957925e-07
report O 0 1.4644662371665618e-07
documents O 0 1.684075989771827e-08
a O 0 7.260050338686597e-09
novel O 0 2.5603972275689557e-08
splice O 0 1.0505209502298385e-05
- O 0 9.018045261655061e-07
site O 0 1.3049439928636275e-07
mutation O 0 2.4907797069317894e-07
in O 0 9.264975453504576e-09
COL17A1 O 0 3.2868424568732735e-06
in O 0 4.91595741891615e-09
a O 0 1.01490691406525e-08
patient O 0 2.8041736754857993e-07
with O 0 7.082668673774606e-08
generalized O 0 0.00027734501054510474
atrophic B-Disease 1 0.9999353885650635
benign I-Disease 1 0.9999688863754272
epidermolysis I-Disease 1 0.998045802116394
bullosa I-Disease 1 0.6181819438934326
, O 0 1.308097523633478e-07
and O 0 3.563147998875138e-09
applies O 0 7.773373056352284e-09
a O 0 3.182449193062098e-09
new O 0 2.831691325866359e-08
methodology O 0 2.0992432681055107e-08
to O 0 2.1844532849257803e-09
define O 0 1.333561261418481e-08
and O 0 7.26949667129162e-10
characterize O 0 4.725640323499647e-08
the O 0 2.295561740695007e-09
resulting O 0 4.720190105444999e-08
mRNA O 0 3.9628386616641365e-07
splice O 0 2.1280417058733292e-05
variants O 0 6.181919616210507e-06
. O 0 5.511565746019187e-07

Mutational O 0 0.0038479322101920843
analysis O 0 4.543452178040752e-06
of O 0 6.009550190810842e-08
COL17A1 O 0 1.7550530174048617e-05
identified O 0 2.1748306266999862e-07
a O 0 2.0980348836019402e-07
maternally O 0 4.724847531178966e-05
inherited O 0 0.00013077890616841614
G O 0 9.759164095157757e-05
- O 0 1.5579395039821975e-05
to O 0 2.0041136394866044e-07
- O 0 5.240331302047707e-05
T O 0 0.00018231877766083926
transversion O 0 3.027029606528231e-06
at O 0 5.2079400347793126e-08
the O 0 5.8088098775499475e-09
- O 0 1.6804445124307676e-07
1 O 0 6.7874967868419844e-09
position O 0 9.818520219084803e-09
of O 0 5.934197577772693e-10
exon O 0 1.0063331501442008e-06
32 O 0 2.2214889838778618e-07
. O 0 8.474194146401715e-08

This O 0 7.796865588716173e-07
acceptor O 0 4.951038590661483e-06
splice O 0 9.743533883010969e-05
- O 0 7.2144698606280144e-06
site O 0 7.082667821123323e-07
mutation O 0 6.204217015692848e-07
led O 0 1.2638408541931767e-08
to O 0 1.3766482398480662e-09
the O 0 1.319812703570733e-09
formation O 0 5.662896374047932e-09
of O 0 3.92946841731856e-10
aberrant O 0 2.386707933510479e-07
transcripts O 0 2.2410250721804914e-07
present O 0 3.1976561842839146e-08
at O 0 1.6319144435783528e-07
extremely O 0 8.055134799178632e-07
low O 0 8.75468977028504e-05
levels O 0 3.6586850455933018e-06
. O 0 1.776108717876923e-07

Based O 0 4.1731598798833147e-07
on O 0 9.163276359913652e-08
our O 0 2.9122639855216903e-09
recent O 0 5.495287780377112e-09
finding O 0 2.8146258657102408e-09
that O 0 1.985798414594342e-09
cycloheximide O 0 2.247517613795935e-06
stabilized O 0 1.1837425518024247e-05
mutant O 0 5.015702413402323e-07
COL17A1 O 0 5.109070002617955e-07
transcripts O 0 1.3321457004167314e-07
in O 0 7.162013648809307e-09
keratinocytes O 0 3.256048159983038e-07
homozygous O 0 1.3770618068065232e-07
for O 0 8.651730443176575e-10
a O 0 1.3009188393198201e-08
frameshift O 0 8.106907625915483e-05
mutation O 0 6.058872941139271e-07
, O 0 1.411605499157531e-09
the O 0 1.9295314235279193e-09
effects O 0 3.1609570072532733e-08
of O 0 3.7040184808212473e-10
the O 0 2.5833877259628935e-09
splice O 0 1.4150116840028204e-05
- O 0 9.909467735269573e-07
site O 0 1.1527946952583079e-07
mutation O 0 7.659870959741966e-08
on O 0 6.3672689343263755e-09
splicing O 0 6.873208491242622e-08
of O 0 8.556057529141015e-10
COL17A1 O 0 5.168367920305172e-07
transcripts O 0 1.0480230372422739e-07
were O 0 2.5822646243511826e-09
determined O 0 5.821520598914276e-09
using O 0 1.675866734274223e-08
reverse O 0 1.0200612905464368e-06
transcriptase O 0 2.9583354717033217e-06
polymerase O 0 1.4011735629537725e-06
chain O 0 9.440893791179406e-07
reaction O 0 5.476289288708358e-08
of O 0 6.04738537024474e-10
total O 0 5.078073517239545e-10
RNA O 0 7.067473717370376e-08
from O 0 7.2448060883800736e-09
keratinocytes O 0 6.310290814326436e-07
incubated O 0 4.0982831706060097e-07
for O 0 4.05732247799051e-09
2 O 0 5.5966683731867306e-08
. O 0 4.93113567756609e-08

5 O 0 4.9863028834806755e-06
h O 0 4.643307875085156e-06
in O 0 1.1255121279418745e-08
the O 0 2.53735676913891e-09
presence O 0 6.102018890175032e-09
or O 0 3.637911083487211e-09
absence O 0 4.071711412478862e-09
of O 0 2.869026682894571e-10
10 O 0 7.944882973731637e-09
microg O 0 2.635342752910219e-06
cycloheximide O 0 3.96983568862197e-06
per O 0 1.6611866726634616e-07
ml O 0 3.060741801164113e-05
. O 0 3.664726193619572e-07

Using O 0 8.26329539904691e-07
this O 0 7.46087991387867e-09
approach O 0 2.3283352135194946e-08
, O 0 6.81541045821632e-10
an O 0 1.3383306685099683e-09
abnormally O 0 6.138095614005579e-06
spliced O 0 4.208684549666941e-05
transcript O 0 0.0031534158624708652
was O 0 1.0415401447971817e-06
identified O 0 4.193931868456957e-09
that O 0 1.4394543890183797e-10
contains O 0 3.0335056688812756e-10
an O 0 1.1009725076061017e-10
extra O 0 2.605830662361086e-09
264 O 0 1.1494941887235655e-08
bases O 0 3.927320246788213e-09
upstream O 0 1.2808622606996778e-08
from O 0 4.53885817819355e-09
exon O 0 3.492566804652597e-07
32 O 0 1.524898962657062e-08
, O 0 3.3365635254689607e-10
resulting O 0 5.210758935447757e-09
in O 0 8.723650246622583e-09
a O 0 1.3434187451366597e-07
premature O 0 6.137065611255821e-06
termination O 0 1.7600040109755355e-06
codon O 0 6.438509899453493e-06
27 O 0 4.468598717721761e-07
bp O 0 5.339594508768641e-07
downstream O 0 8.2468744722064e-08
from O 0 4.3553800566087375e-09
the O 0 6.740780378322597e-09
cryptic O 0 1.4690378975501517e-06
splice O 0 4.4115717173554e-05
site O 0 6.046051566954702e-06
. O 0 3.967959116835118e-07

Three O 0 1.223075400957896e-07
other O 0 4.373293727155669e-09
splice O 0 2.5296058083768003e-06
variants O 0 3.106356132320798e-07
, O 0 1.1756648987670815e-09
including O 0 2.002147198032489e-10
one O 0 2.0620923024683435e-10
derived O 0 4.50257248152397e-10
from O 0 3.3375630037468795e-10
the O 0 8.330292011748952e-10
skipping O 0 1.7228098059263175e-08
of O 0 4.158388633435095e-10
exon O 0 2.1590031451523828e-07
32 O 0 3.9966931097978886e-08
, O 0 6.973148169997501e-10
were O 0 3.899954581498832e-09
also O 0 3.2026230556425617e-09
identified O 0 4.331274894298076e-08
. O 0 8.96370337954977e-08

These O 0 3.041399736503081e-07
results O 0 2.181099318931956e-07
indicate O 0 7.374326571607526e-08
the O 0 5.062110286502275e-09
usefulness O 0 3.133697390467205e-08
of O 0 9.817242574428064e-10
cycloheximide O 0 1.50268920151575e-06
treatment O 0 1.4368526812802429e-08
in O 0 2.300628798579396e-09
evaluating O 0 9.461524008713695e-09
the O 0 6.136028130043769e-09
abnormal O 0 1.8685274483232206e-07
processing O 0 7.101603749504193e-09
of O 0 2.8791571904385194e-10
mRNA O 0 3.581683216680176e-08
due O 0 1.3803089338182417e-08
to O 0 2.6198143654454498e-09
splice O 0 1.0559710062807426e-05
- O 0 1.6382248304580571e-06
site O 0 2.417048960978718e-07
mutations O 0 4.7161316274468845e-07
, O 0 1.203940058758235e-09
because O 0 2.1407440264908928e-09
( O 0 4.16886525300697e-09
i O 0 8.387436523094038e-09
) O 0 1.0398981675763252e-09
aberrant O 0 6.984802070064688e-08
splicing O 0 1.004967629114617e-07
often O 0 7.691930647979461e-09
generates O 0 2.281925404190588e-08
a O 0 1.7565511711836734e-08
premature O 0 1.2923120493724127e-06
termination O 0 3.5711991586140357e-07
codon O 0 1.0140593076357618e-06
, O 0 4.6027435196549504e-09
( O 0 6.38612140946293e-09
ii O 0 1.9038769494272856e-07
) O 0 1.944854277624586e-09
transcripts O 0 1.0153041785088135e-07
with O 0 9.655058974544772e-09
premature O 0 1.4063571143196896e-06
termination O 0 2.0257563448922156e-07
codons O 0 3.4751968769342056e-07
can O 0 4.511162110532041e-09
occur O 0 8.552929031679923e-09
at O 0 5.09758422140294e-08
low O 0 3.4067236356349895e-06
or O 0 1.3258410369587637e-08
undetectable O 0 3.285327636604052e-07
levels O 0 2.4199591663887077e-08
due O 0 5.409234837827626e-09
to O 0 2.3552764183421004e-09
nonsense O 0 1.8022312531229545e-07
- O 0 7.813376612375578e-08
mediated O 0 1.2292683493342338e-07
mRNA O 0 9.256289246195593e-08
decay O 0 1.0047300236237788e-07
, O 0 6.736162738718576e-10
and O 0 7.035497739948937e-10
( O 0 9.457279404045948e-10
iii O 0 2.5531942782208716e-08
) O 0 2.1643871417342808e-10
the O 0 7.539871504924633e-10
levels O 0 5.429577676352437e-09
of O 0 5.6467015091543615e-11
these O 0 1.6446800865654865e-10
transcripts O 0 1.994062159837995e-08
can O 0 1.1308546321586732e-09
be O 0 2.5422630667293333e-10
increased O 0 2.9972451187632032e-09
by O 0 5.046492557170268e-09
cycloheximide O 0 4.491269010031829e-06
. O 0 6.540547303757194e-08

A O 0 4.14183614338981e-06
deletion O 0 3.274280243203975e-05
mutation O 0 5.254383268038509e-06
in O 0 6.571521282694448e-08
COL17A1 O 0 4.943010026181582e-06
in O 0 1.4145088655936888e-08
five O 0 3.275195892271654e-09
Austrian O 0 3.827477030426962e-06
families O 0 2.3791987047161456e-08
with O 0 1.0086201029935182e-07
generalized O 0 0.0015166085213422775
atrophic B-Disease 1 0.999993085861206
benign I-Disease 1 0.9999860525131226
epidermolysis I-Disease 1 0.999902606010437
bullosa I-Disease 1 0.7521452903747559
represents O 0 9.98290374809585e-07
propagation O 0 5.709965194000688e-07
of O 0 2.1879891232146065e-09
an O 0 3.195155029445118e-09
ancestral O 0 7.280034424184123e-07
allele O 0 1.3776736523141153e-05
. O 0 3.5454561952974473e-07

Patients O 0 0.00017799087800085545
with O 0 5.0843573262682185e-06
generalized O 0 0.06085038557648659
atrophic B-Disease 1 0.9999974966049194
benign I-Disease 1 0.9999986886978149
epidermolysis I-Disease 1 0.9999823570251465
bullosa I-Disease 1 0.9982171654701233
, O 0 3.843831564154243e-07
a O 0 1.2365840973416198e-07
usually O 0 4.872831027569191e-08
nonlethal O 0 4.380726466024498e-07
form O 0 8.14879044241934e-08
of O 0 5.070809550034028e-08
junctional B-Disease 0 0.04594465345144272
epidermolysis I-Disease 1 0.6296911835670471
bullosa I-Disease 0 0.06400985270738602
, O 0 8.496819958736523e-08
have O 0 6.407143260389603e-09
generalized O 0 4.391710888285161e-07
blistering B-Disease 0 0.0002732353750616312
, O 0 4.009987719655328e-07
nail B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999769926071167
, O 0 1.5707924205798918e-07
patchy B-Disease 1 0.9988967180252075
alopecia I-Disease 1 0.9999978542327881
, O 0 1.685180563981703e-07
and O 0 2.1635387383867055e-06
dental B-Disease 1 0.9986566305160522
abnormalities I-Disease 1 0.9999938011169434
. O 0 2.2362073650583625e-06

Skin B-Disease 1 0.9999961853027344
fragility I-Disease 0 0.028964074328541756
in O 0 1.231105528631815e-07
most O 0 1.795963933126643e-09
cases O 0 6.183891176902989e-10
is O 0 1.8763035569691056e-10
due O 0 3.907877577091767e-09
to O 0 2.3019368633470094e-09
mutations O 0 4.440293466245748e-08
in O 0 1.3457948089268257e-09
the O 0 3.72239927770579e-09
gene O 0 3.647181756605278e-07
encoding O 0 9.97974325400719e-07
type O 0 7.86737073212862e-05
XVII O 0 0.0001756949641276151
collagen O 0 2.3546304873889312e-05
( O 0 1.48497690588556e-07
COL17A1 O 0 1.904961754917167e-05
) O 0 8.257089234575687e-08
. O 0 1.0290529672829507e-07

Recently O 0 2.8991726139793172e-05
, O 0 7.986622563294077e-08
we O 0 3.722775421266533e-09
reported O 0 8.983026589248766e-08
five O 0 2.605397897426087e-09
Austrian O 0 1.1983023568973294e-06
families O 0 1.3238649287927728e-08
with O 0 5.515294176916541e-08
generalized O 0 0.00021199647744651884
atrophic B-Disease 1 0.9999041557312012
benign I-Disease 1 0.9999305009841919
epidermolysis I-Disease 1 0.9994232654571533
bullosa I-Disease 1 0.8969380855560303
who O 0 6.558935865541571e-07
share O 0 7.028489079630162e-08
the O 0 1.5976748812818187e-08
same O 0 6.648298978007006e-08
COL17A1 O 0 3.694778570206836e-05
mutation O 0 7.314563390536932e-06
. O 0 2.7248327683082607e-07

Affected O 0 3.4701604363363003e-06
individuals O 0 1.1936649890742501e-08
in O 0 6.405151520283425e-09
three O 0 2.0547514800739464e-09
families O 0 7.599790241563653e-10
are O 0 1.5946319265047748e-10
homozygous O 0 4.375181816840268e-08
for O 0 8.089950376266586e-10
4003delTC O 0 1.9773942483425344e-07
, O 0 7.800191603735129e-10
whereas O 0 3.0513280790955832e-09
those O 0 2.28438781779694e-10
in O 0 5.837952343767938e-10
two O 0 5.392091773082086e-10
others O 0 6.214159742334857e-10
are O 0 4.3515252512449365e-10
compound O 0 1.740673098993284e-07
heterozygotes O 0 6.381694220181089e-06
. O 0 1.4497850031602866e-07

To O 0 4.817898684450483e-07
determine O 0 1.1673560607050604e-07
if O 0 1.19307030921334e-09
the O 0 7.577298233307772e-10
occurrence O 0 9.145567858581671e-09
of O 0 4.3202974531197924e-10
4003delTC O 0 1.2781173097664578e-07
in O 0 2.6631319371972495e-09
these O 0 2.883619731886e-10
unrelated O 0 5.5268647436435e-09
families O 0 9.870622097452042e-10
signifies O 0 2.0749117979335097e-09
propagation O 0 2.355887485094854e-09
of O 0 6.409287683917242e-11
an O 0 2.2559573653602172e-10
ancestral O 0 5.494221255730736e-08
allele O 0 1.7112205341618392e-07
or O 0 3.360060674140186e-09
a O 0 1.2641229396592735e-08
mutational O 0 1.373943541693734e-05
hot O 0 2.4655990273458883e-05
spot O 0 1.410606955687399e-06
, O 0 2.7431288351920102e-09
haplotypes O 0 1.6627875254471292e-07
were O 0 5.543809855623749e-09
determined O 0 1.0647824844056686e-08
for O 0 6.836619048655734e-10
polymorphisms O 0 2.134202077286318e-07
both O 0 1.4699639283577426e-09
within O 0 3.730758368902798e-09
and O 0 1.857968356944184e-08
flanking O 0 6.255956395762041e-05
COL17A1 O 0 0.0007718210690654814
. O 0 7.228507001855178e-07

Five O 0 9.263271181225718e-07
intragenic O 0 1.9330162103869952e-05
polymorphisms O 0 1.6831992979859933e-05
were O 0 4.5832798889478e-08
chosen O 0 8.369952730902241e-09
based O 0 3.84187970325911e-09
on O 0 3.32937695191049e-08
their O 0 2.8517405326056178e-08
informativeness O 0 2.4415223379037343e-05
. O 0 2.1713407249990269e-07

One O 0 8.216964175744579e-08
of O 0 1.1029824831254587e-09
these O 0 4.686223076255658e-10
, O 0 1.288115308861748e-10
not O 0 1.56589616273628e-10
previously O 0 2.9242590571243454e-09
reported O 0 2.0160869951268978e-07
, O 0 8.590462230451124e-10
was O 0 1.242375713417232e-08
2988 O 0 6.389254991745474e-08
A O 0 1.2564572493545256e-08
or O 0 1.0085754453825757e-08
C O 0 5.162358434063208e-07
that O 0 2.055350195595551e-10
introduces O 0 7.162860526932491e-09
a O 0 1.892867862451908e-09
new O 0 4.140061626856095e-09
restriction O 0 1.122341597437071e-08
site O 0 7.966795223524059e-09
for O 0 1.0043995635200531e-09
Eco0109 O 0 3.688906815568771e-07
I O 0 2.9772203902211913e-07
. O 0 4.612131121461971e-08

All O 0 4.654505758594496e-08
the O 0 3.1205811268364414e-08
4003delTC O 0 2.0085865344299236e-06
alleles O 0 4.933835953124799e-07
showed O 0 7.972954563228996e-08
the O 0 3.27353477658221e-09
same O 0 5.88302473403246e-09
haplotype O 0 7.53790800445131e-07
for O 0 1.331860066677848e-09
these O 0 1.1477890859978856e-09
five O 0 8.597744738381152e-09
polymorphic O 0 7.269375601026695e-06
markers O 0 9.619301636121236e-06
. O 0 3.0074920687184203e-07

Fourteen O 0 1.6552357919863425e-05
microsatellite O 0 7.505348912673071e-05
polymorphisms O 0 9.570131078362465e-05
were O 0 1.9923443517200212e-07
selected O 0 3.348239729916713e-08
based O 0 5.388906654246739e-09
on O 0 3.258859138099979e-08
their O 0 7.996511897090386e-09
high O 0 3.3751703654161247e-07
heterozygosity O 0 3.8092079535090306e-07
and O 0 1.9297559106234985e-09
their O 0 9.920317900480313e-10
location O 0 1.4638903422792282e-08
within O 0 8.917113270001664e-09
10q23 O 0 7.689834546908969e-07
- O 0 4.6540270659534144e-07
q25 O 0 2.1115226900292328e-06
near O 0 2.7398548354540253e-06
COL17A1 O 0 8.218927541747689e-05
. O 0 4.334647201176267e-07

Three O 0 3.0883228419043007e-07
families O 0 8.687787556027615e-08
shared O 0 1.418398625219197e-07
microsatellite O 0 1.1499553693283815e-05
polymorphisms O 0 3.178351107635535e-05
covering O 0 2.2911726773600094e-06
at O 0 2.0274822531973768e-07
most O 0 4.467543668340568e-09
19 O 0 3.45700286175088e-08
cM O 0 1.0995533017421621e-07
, O 0 1.0020403395927246e-09
whereas O 0 3.3823472911365116e-09
the O 0 2.552345668149769e-09
others O 0 1.3111839392010438e-09
shared O 0 1.4028153083600614e-09
smaller O 0 9.809927981052624e-09
regions O 0 5.019249904592016e-09
consistent O 0 3.566739792404405e-08
with O 0 1.2787062519947767e-09
cross O 0 1.4809350545874622e-07
- O 0 1.1396048194001196e-06
over O 0 4.718918589219356e-09
events O 0 2.0159010016840284e-09
during O 0 1.1338653349568517e-09
passage O 0 3.6220679233700537e-10
of O 0 5.579691569890244e-11
this O 0 2.020449779704947e-10
mutation O 0 4.628581962151657e-09
through O 0 7.055063200311906e-10
several O 0 2.0194992345068385e-09
generations O 0 3.126765690808497e-08
. O 0 2.3295612550100486e-08

These O 0 3.552049179234018e-07
results O 0 4.2676037992350757e-07
indicate O 0 1.8316356431569147e-07
that O 0 3.2395959248532336e-09
4003delTC O 0 5.729727945436025e-07
occurs O 0 1.150715966957705e-08
on O 0 3.7176171030495198e-09
a O 0 1.630889312487227e-09
single O 0 5.379746426115162e-09
ancestral O 0 6.842965660780465e-08
allele O 0 5.799413997920055e-07
. O 0 5.901973576527553e-09
. O 0 4.8443723699165275e-08

The O 0 1.7278863424508017e-06
haptoglobin O 0 0.00017766903329174966
- O 0 1.2333655831753276e-05
gene O 0 4.698700195149286e-06
deletion O 0 5.362289812183008e-06
responsible O 0 2.5834046368800045e-07
for O 0 3.087391675649087e-08
anhaptoglobinemia B-Disease 0 5.514635267900303e-05
. O 0 7.647781785635743e-07

We O 0 4.058478566548729e-07
have O 0 7.30710336682705e-09
found O 0 3.786380542436518e-09
an O 0 1.761808143818655e-09
allelic O 0 1.742650852065708e-06
deletion O 0 4.912445206173288e-07
of O 0 2.8545525943002303e-09
the O 0 4.247549512115256e-08
haptoglobin O 0 9.814339136937633e-06
( O 0 2.13222826062065e-08
Hp O 0 4.0852575011740555e-07
) O 0 1.9456705135922903e-09
gene O 0 1.905147861691603e-08
from O 0 8.794749373208788e-10
an O 0 2.8085914149933444e-10
individual O 0 8.066253220917474e-10
with O 0 5.318541163035206e-09
anhaptoglobinemia B-Disease 0 2.283171852468513e-05
. O 0 2.897163540183101e-07

The O 0 1.9048227386520011e-06
Hp O 0 1.3748898709309287e-05
gene O 0 2.5890969936881447e-06
cluster O 0 1.9308842524878855e-07
consists O 0 1.779349645403272e-08
of O 0 1.3546386234963848e-09
coding O 0 4.838429958908819e-07
regions O 0 5.672723180083494e-09
of O 0 2.455684822155746e-10
the O 0 1.5730515778855647e-09
alpha O 0 2.3289304706963776e-08
chain O 0 3.171658988776471e-07
and O 0 1.4972019179992913e-09
beta O 0 1.2542185068298295e-08
chain O 0 8.90951810106344e-08
of O 0 4.611950821242772e-10
the O 0 3.845273877089994e-09
haptoglobin O 0 7.176832355071383e-07
gene O 0 8.939630191662218e-08
( O 0 2.1507997605141327e-09
Hp O 0 9.359666819364065e-08
) O 0 4.638902595388572e-10
and O 0 1.568975643850834e-10
of O 0 2.0483399698623117e-11
the O 0 1.1015234280264963e-09
alpha O 0 1.4666991177136879e-08
chain O 0 1.56989983679523e-07
and O 0 7.231659715500882e-10
beta O 0 8.178714594464509e-09
chain O 0 6.402368768476663e-08
of O 0 2.7838126248624917e-10
the O 0 4.7281618620331756e-09
haptoglobin O 0 2.917806341429241e-06
- O 0 3.5436951861811394e-07
related O 0 8.336927237451164e-08
gene O 0 7.67808103319112e-07
( O 0 1.9580088661541595e-08
Hpr O 0 1.6459422340631136e-06
) O 0 3.0346876123132915e-09
, O 0 3.970884454584933e-10
in O 0 1.2503388324702769e-09
tandem O 0 5.872965402886621e-07
from O 0 2.1504962255392e-09
the O 0 9.683478907618337e-09
5 O 0 8.716934019048495e-08
side O 0 4.771637236444803e-07
. O 0 1.193363772244993e-07

Southern O 0 1.015198267850792e-05
blot O 0 0.0005705627845600247
and O 0 1.616360520984017e-07
PCR O 0 1.9372530005057342e-05
analyses O 0 5.784157792732003e-07
have O 0 5.398443470028269e-09
indicated O 0 6.123941176383596e-08
that O 0 2.626016348816762e-10
the O 0 4.3859474385676833e-10
individual O 0 8.140731838635062e-11
with O 0 2.465093962289444e-10
anhaptoglobinemia B-Disease 0 3.257035814385745e-07
was O 0 1.0682978057729997e-08
homozygous O 0 1.2662899173676578e-08
for O 0 5.137253469844616e-11
the O 0 2.5808205572630527e-10
gene O 0 1.8172737981103637e-08
deletion O 0 4.1752176827003495e-08
and O 0 6.822485354440744e-10
that O 0 1.157841461596476e-10
the O 0 6.580658795662941e-10
gene O 0 5.062074137640593e-08
deletion O 0 9.599332173593211e-08
was O 0 2.0579255632924287e-08
included O 0 7.335349549997261e-10
at O 0 5.283516735232752e-09
least O 0 1.3083160110838321e-09
from O 0 1.596212162446875e-09
the O 0 1.9381294347198263e-09
promoter O 0 4.471834103014771e-08
region O 0 3.2089821910830096e-09
of O 0 5.141461145719006e-10
Hp O 0 2.9450333727254474e-07
to O 0 3.5440745893566827e-09
Hpr O 0 1.157277324637107e-06
alpha O 0 1.1361498408746229e-08
but O 0 5.300693772802845e-10
not O 0 4.534027597813406e-10
to O 0 2.535789134228139e-09
Hpr O 0 2.2346853256749455e-06
beta O 0 1.125132627066705e-07
( O 0 2.5299788930510658e-08
Hpdel O 0 1.4825616290181642e-06
) O 0 2.3782778413306005e-08
. O 0 5.09355047029203e-08

In O 0 2.1414479078885051e-07
addition O 0 1.0983351117488382e-08
, O 0 1.2112921776719077e-09
we O 0 5.182053119945351e-10
found O 0 3.724357489076624e-10
seven O 0 3.8781294842138436e-10
individuals O 0 5.932859065138629e-11
with O 0 3.262382031188338e-10
hypohaptoglobinemia B-Disease 0 1.0405692592030391e-06
in O 0 2.8295195075855872e-09
three O 0 9.333933626010094e-10
families O 0 2.4151611266454154e-10
, O 0 1.4129784842165094e-10
and O 0 2.7708765837353155e-10
the O 0 8.124494965677798e-10
genotypes O 0 3.4539379356601785e-08
of O 0 1.7040296951265077e-10
six O 0 5.451480378226847e-10
of O 0 3.3480943711916566e-11
the O 0 7.015357739170724e-10
seven O 0 4.1060710387341715e-10
individuals O 0 2.014050211329721e-11
were O 0 2.3140105109842324e-10
found O 0 1.2606309329754595e-09
to O 0 6.515343820012731e-09
be O 0 2.3619987743472848e-08
Hp2 O 0 3.853907765005715e-05
/ O 0 1.5935343981254846e-05
Hpdel O 0 2.4107554054353386e-05
. O 0 2.2954016287712875e-07

The O 0 7.970672299961734e-07
phenotypes O 0 6.4001801547419745e-06
and O 0 2.672205567932906e-08
genotypes O 0 4.861950628765044e-07
in O 0 4.8096508997730325e-09
one O 0 3.8425224113680656e-10
of O 0 5.170814817989644e-11
these O 0 7.057131962140417e-11
three O 0 1.387997911050931e-10
families O 0 1.2410103500393177e-10
showed O 0 8.602288659176338e-09
the O 0 2.3362345391575445e-09
father O 0 2.5607585385500897e-08
to O 0 1.4090902888952428e-09
be O 0 1.6462752272516923e-09
hypohaptoglobinemic B-Disease 0 2.343966940543396e-07
( O 0 5.874480901724155e-09
Hp2 O 0 3.069887952733552e-07
) O 0 1.331778687330143e-09
and O 0 2.757265749053772e-09
Hp2 O 0 2.275403176099644e-06
/ O 0 1.8411486735203653e-06
Hpdel O 0 5.528532369680761e-07
, O 0 7.161053972026821e-10
the O 0 2.293635947836492e-09
mother O 0 1.94234548445138e-08
to O 0 1.3391605602208756e-09
be O 0 7.718718997296037e-10
Hp2 O 0 3.967732027376769e-07
- O 0 1.4846072815544176e-07
1 O 0 9.827608060675175e-09
and O 0 2.7683213499329895e-09
Hp1 O 0 2.8089962142985314e-06
/ O 0 3.90532704841462e-06
Hp2 O 0 9.199576425089617e-07
, O 0 3.10078518417356e-10
one O 0 6.146717163035831e-11
of O 0 1.1775152033988157e-11
the O 0 2.116525010809056e-10
two O 0 1.7145732056356167e-10
children O 0 2.1666135552322885e-10
to O 0 7.777535837583116e-10
be O 0 1.911822922195938e-09
hypohaptoglobinemic B-Disease 0 6.390888529494987e-07
( O 0 2.6534678898570974e-09
Hp2 O 0 9.950665713631679e-08
) O 0 4.5086565036989157e-10
and O 0 7.960699877074262e-10
Hp2 O 0 1.2198619288028567e-06
/ O 0 1.2279084558031172e-06
Hpdel O 0 4.662405217459309e-07
, O 0 3.065034059890337e-10
and O 0 2.2553378609124763e-10
the O 0 2.2749480077521866e-10
other O 0 1.962414952760838e-10
child O 0 5.018905291365172e-09
to O 0 6.317052436699555e-10
be O 0 1.6142793768381125e-09
Hp1 O 0 3.686290312998608e-07
and O 0 5.32883737136558e-09
Hp1 O 0 2.800693664539722e-06
/ O 0 1.6468890180476592e-06
Hpdel O 0 9.834790262175375e-07
, O 0 9.586662574889715e-10
showing O 0 1.2055997089532866e-08
an O 0 8.292878050930597e-10
anomalous O 0 2.783532124794874e-07
inheritance O 0 5.742321107504722e-08
of O 0 2.203850657522821e-09
Hp O 0 1.3440790098684374e-06
phenotypes O 0 3.889408617396839e-07
in O 0 4.8483999037785e-09
the O 0 1.14132996387184e-08
child O 0 7.044943828304895e-08
with O 0 9.453299476547272e-09
Hp1 O 0 2.6102843548869714e-05
. O 0 2.5580473561603867e-07

The O 0 1.197983579004358e-06
Hp2 O 0 0.00012099897139705718
/ O 0 2.383517312409822e-05
Hpdel O 0 4.354412340035196e-06
individuals O 0 6.630959781261936e-09
had O 0 7.111105038148935e-09
an O 0 1.2703097462818391e-09
extremely O 0 2.2227011697850685e-07
low O 0 2.6924175472231582e-05
level O 0 9.06632067199098e-08
of O 0 1.984912234576086e-09
Hp O 0 3.3133323995571118e-06
( O 0 9.22477294551527e-09
mean O 0 4.8466919366774164e-08
+ O 0 2.5111052082138485e-07
/ O 0 5.193167908146279e-06
- O 0 4.992964932171162e-06
SD O 0 0.008801577612757683
= O 0 1.6405136875619064e-06
0 O 0 8.45285299533316e-08
. O 0 6.446516209734909e-09
049 O 0 1.2733477888104971e-05
+ O 0 6.235881642169261e-07
/ O 0 2.08223718800582e-06
- O 0 1.0036992534878664e-06
0 O 0 5.5880285287912557e-08
. O 0 4.752664928275863e-09
043 O 0 5.613266694126651e-06
mg O 0 0.0008215990965254605
/ O 0 1.5780755347805098e-05
ml O 0 5.4859983720234595e-06
; O 0 1.0465405431148156e-08
n O 0 1.6629223864583764e-07
= O 0 1.0542602524310496e-07
6 O 0 9.800558586903207e-09
) O 0 3.252651759044767e-10
, O 0 1.6762678745063653e-10
compared O 0 1.3226023609647086e-09
with O 0 2.400584175887843e-10
the O 0 2.5662383329461136e-09
level O 0 2.521250053177937e-08
( O 0 9.131670974937833e-10
1 O 0 2.5344788490144765e-09
. O 0 2.471883253640783e-10
64 O 0 2.383622899060356e-08
+ O 0 7.537908430776952e-08
/ O 0 1.407080162607599e-06
- O 0 6.269166306083207e-07
1 O 0 4.797028907432832e-08
. O 0 5.122855029071616e-09
07 O 0 1.0676885722205043e-06
mg O 0 0.0001030566927511245
/ O 0 3.654678266684641e-06
ml O 0 1.6997130387608195e-06
) O 0 1.8545933677671655e-09
obtained O 0 1.898874391059735e-09
from O 0 1.5063537084358813e-09
52 O 0 4.8169610522563744e-08
healthy O 0 4.23160315676796e-08
volunteers O 0 9.610540807614143e-09
having O 0 1.7359873538680404e-08
phenotype O 0 1.5703236613262561e-06
Hp2 O 0 9.284966608902323e-07
, O 0 2.0924464383398345e-09
whereas O 0 6.135712382615566e-09
the O 0 5.697631255685565e-09
serum O 0 2.913072023602581e-07
Hp O 0 2.0426240610049717e-07
level O 0 6.760441539910289e-09
of O 0 1.0045408949110879e-10
an O 0 1.3187324843233483e-10
individual O 0 3.807503756725339e-10
with O 0 2.9351723274118058e-09
Hp1 O 0 3.628079139161855e-05
/ O 0 3.011222361237742e-05
Hpdel O 0 2.5544724849169143e-05
was O 0 1.0304155466656084e-06
0 O 0 3.233609788821923e-07
. O 0 1.2375090818750323e-07

50 O 0 2.522335125831887e-05
mg O 0 0.14964796602725983
/ O 0 0.0005891051841899753
ml O 0 0.00013222065172158182
, O 0 4.899426642168692e-09
which O 0 2.8010707087133824e-09
was O 0 2.8881843583405953e-09
approximately O 0 5.357513321868623e-10
half O 0 1.0094390878734316e-09
the O 0 4.3305767305490406e-10
level O 0 2.3565167595052117e-09
of O 0 1.6984097461758552e-10
Hp O 0 2.893127089009795e-07
in O 0 4.71597605411489e-09
control O 0 6.239617391656793e-07
sera O 0 2.735763757755194e-07
from O 0 1.3233039108939693e-09
the O 0 4.170662926128443e-09
Hp1 O 0 2.2884298687131377e-06
phenotype O 0 1.1279242926320876e-06
( O 0 4.5325596609302465e-09
1 O 0 5.461568086673196e-09
. O 0 1.1750372896912609e-09
26 O 0 2.4655713914967237e-08
+ O 0 1.0645595693858922e-07
/ O 0 1.5794643104527495e-06
- O 0 3.5224780958742485e-07
0 O 0 2.1371468150732653e-08
. O 0 2.2579171865544367e-09
33 O 0 1.4489017985397368e-07
mg O 0 0.0003229249850846827
/ O 0 2.3555536245112307e-05
ml O 0 1.0999809092027135e-05
; O 0 2.271975851897423e-08
n O 0 3.552140697138384e-07
= O 0 1.6747745235079492e-07
9 O 0 6.22864249066879e-08
) O 0 1.297892016083324e-09
, O 0 3.4295535855655146e-10
showing O 0 2.2860902504362457e-08
a O 0 1.3116448371874867e-08
gene O 0 1.2316262427702895e-06
- O 0 2.6837651603273116e-06
dosage O 0 6.8051940615987405e-06
effect O 0 5.263242428554804e-07
. O 0 1.0961380780827312e-07

The O 0 2.513395713776845e-07
other O 0 2.7726080986667512e-08
allele O 0 2.4428650249319617e-06
( O 0 2.218147798771497e-08
Hp2 O 0 7.214746915451542e-07
) O 0 1.4134563519618837e-09
of O 0 2.2929787235614896e-10
individuals O 0 2.3968232953919255e-10
with O 0 1.0249189275057802e-09
Hp2 O 0 2.3462094759452157e-05
/ O 0 1.0663968168955762e-05
Hpdel O 0 6.222435786185088e-06
was O 0 2.3157421935593447e-07
found O 0 1.913730951486059e-09
to O 0 5.214733089786705e-10
have O 0 2.1266859107083036e-10
, O 0 4.243073253862306e-11
in O 0 2.2592644421948194e-10
all O 0 1.2045664465887285e-10
exons O 0 1.437924712632821e-08
, O 0 1.8126435075149772e-10
no O 0 3.0565922015668434e-10
mutation O 0 1.2904576962569081e-08
, O 0 1.4033016415559985e-10
by O 0 5.741997433084123e-10
DNA O 0 5.994426999222924e-08
sequencing O 0 8.420482231485948e-07
. O 0 1.3611067117835773e-07

On O 0 1.081063601304777e-06
the O 0 1.1669014199355843e-08
basis O 0 1.8650543331943936e-09
of O 0 1.440275537722968e-10
the O 0 6.921219153355196e-10
present O 0 6.373305216911263e-10
study O 0 6.266435148560845e-10
, O 0 1.0714350240359494e-10
the O 0 3.584249008703466e-10
mechanism O 0 5.4452686804040695e-09
of O 0 3.601600961911089e-10
anhaptoglobinemia B-Disease 0 4.0241235410576337e-07
and O 0 2.834811829721673e-10
the O 0 5.788887147417654e-10
mechanism O 0 4.2864907179307465e-09
of O 0 3.4056371611690395e-10
anomalous O 0 7.954803038501268e-08
inheritance O 0 2.3818413907861213e-08
of O 0 3.109480894991634e-09
Hp O 0 1.1180532055732328e-05
phenotypes O 0 1.3603130355477333e-06
were O 0 1.7522978623674135e-08
well O 0 2.3898460099758267e-08
explained O 0 5.498068276210688e-07
. O 0 1.820709059074943e-07

However O 0 5.549308070840198e-07
, O 0 5.6216578059320454e-09
the O 0 2.3878536925536764e-09
mechanism O 0 2.700437207181494e-08
of O 0 2.8905706717097246e-09
hypohaptoglobinemia B-Disease 0 3.5948555705545004e-06
remains O 0 2.7910363087357837e-07
unknown O 0 9.981057473851251e-07

ATM O 0 0.0011962680146098137
mutations O 0 0.00032620743149891496
and O 0 3.676870221624995e-07
phenotypes O 0 9.44323546718806e-05
in O 0 6.474502151831985e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 5.489549153026019e-07
in O 0 1.794256299092467e-08
the O 0 7.528781154064745e-09
British O 0 1.9545132090570405e-07
Isles O 0 1.3989597391628195e-06
: O 0 9.356356800438448e-10
expression O 0 1.15435139225184e-09
of O 0 1.2897255485810888e-10
mutant O 0 2.129631049285763e-08
ATM O 0 2.1623371537771163e-07
and O 0 1.1792312681890849e-09
the O 0 1.0370952985283566e-09
risk O 0 1.8784072963740073e-08
of O 0 5.608677078328128e-09
leukemia B-Disease 0 0.2023950219154358
, O 0 5.425560175353894e-06
lymphoma B-Disease 1 1.0
, O 0 1.5509132254010183e-06
and O 0 0.00022315492969937623
breast B-Disease 1 0.9999375343322754
cancer I-Disease 0 0.0008129721973091364
. O 0 3.360229925419844e-07

We O 0 1.0646067494235467e-06
report O 0 1.7922661754710134e-07
the O 0 8.734271972343777e-09
spectrum O 0 1.1059263727020152e-07
of O 0 1.2479967059775277e-09
59 O 0 1.1852643666543372e-07
ATM O 0 1.2758105185639579e-05
mutations O 0 5.211485586187337e-06
observed O 0 1.8819164324668236e-06
in O 0 3.1655465136282146e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.00013924702943768352
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.36898224873039e-08
patients O 0 3.1284358215089014e-08
in O 0 2.2386075215763412e-09
the O 0 5.815328218972127e-09
British O 0 5.859465659341367e-07
Isles O 0 5.123687060404336e-06
. O 0 6.868254587288902e-08

Of O 0 1.3139940335804567e-07
51 O 0 9.419409252586775e-07
ATM O 0 1.1006944987457246e-05
mutations O 0 1.8122445908375084e-06
identified O 0 2.3143353899968133e-08
in O 0 4.651122598176016e-09
families O 0 7.56795293099799e-10
native O 0 9.626771602100348e-10
to O 0 3.694669292730879e-10
the O 0 1.5225671834429022e-09
British O 0 1.6077943598702404e-07
Isles O 0 4.499915462474746e-07
, O 0 8.480863233906177e-10
11 O 0 3.428077155476217e-09
were O 0 1.2730653198289588e-09
founder O 0 2.9323983241624774e-08
mutations O 0 8.146614760562443e-08
, O 0 4.491807203965692e-10
and O 0 8.315908517353421e-10
2 O 0 2.390022402209979e-09
of O 0 4.8685500075862365e-11
these O 0 3.5209421489490467e-10
11 O 0 1.5172968437227041e-09
conferred O 0 3.1255653620831936e-09
a O 0 2.898299600317955e-09
milder O 0 2.6735531719168648e-05
clinical O 0 4.780387143910048e-07
phenotype O 0 1.4847137208562344e-06
with O 0 1.6247913015021709e-09
respect O 0 5.974286620968883e-10
to O 0 1.6448910011845896e-09
both O 0 1.017368411737607e-08
cerebellar B-Disease 0 0.0001242863800143823
degeneration I-Disease 0 7.759276195429265e-05
and O 0 2.4060412329163228e-08
cellular O 0 3.315314188512275e-06
features O 0 5.109048743179301e-06
. O 0 2.2205654204299208e-07

We O 0 3.9170325294435315e-07
report O 0 1.308410730871401e-07
, O 0 7.093423626258755e-10
in O 0 7.678675473243857e-10
two O 0 1.4789632851730516e-09
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
families O 0 5.121565394006211e-09
, O 0 2.564553847062001e-10
an O 0 8.557820008192607e-10
ATM O 0 8.670612260175403e-06
mutation O 0 9.210725693264976e-07
( O 0 2.0065533234969735e-08
7271T O 0 1.58143575390568e-06
- O 0 2.5806120902416296e-06
- O 0 3.863570782414172e-06
> O 0 6.985920322222228e-07
G O 0 5.9571843848971184e-06
) O 0 1.3938830090154397e-09
that O 0 4.645180073925559e-10
may O 0 2.828409506605567e-08
be O 0 7.088415271416793e-11
associated O 0 1.5381124152114012e-10
with O 0 5.1255086980228626e-11
an O 0 2.117865605111291e-10
increased O 0 1.5358976312995765e-08
risk O 0 1.2506352398133913e-08
of O 0 4.611381498875744e-09
breast B-Disease 0 0.027138419449329376
cancer I-Disease 0 7.866339046813664e-07
in O 0 7.734328733022267e-09
both O 0 8.236857418353338e-09
homozygotes O 0 1.8581440599518828e-06
and O 0 9.271233558649783e-09
heterozygotes O 0 3.9275585095310817e-07
( O 0 7.50317852293847e-09
relative O 0 3.647299351428046e-08
risk O 0 6.29887892955594e-08
12 O 0 1.03660537931205e-08
. O 0 1.3496147532876535e-09
7 O 0 7.013611025286082e-08
; O 0 1.5005362286046875e-08
P O 0 0.00018240086501464248
= O 0 6.02798706950125e-07
. O 0 8.912810933736637e-09
0025 O 0 1.4030712918611243e-05
) O 0 3.2266089800003783e-09
, O 0 2.9201829843117366e-10
although O 0 4.411763732115048e-10
there O 0 1.7871025492777193e-10
is O 0 1.4152361227370847e-10
a O 0 8.504967841105326e-10
less O 0 1.7026343002157773e-08
severe O 0 0.016726521775126457
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 0.000174930872162804
in O 0 9.628631225666595e-09
terms O 0 8.550673502583095e-10
of O 0 4.7426538390960005e-11
the O 0 5.106823852685238e-10
degree O 0 4.480531501371843e-09
of O 0 5.54762813465004e-09
cerebellar B-Disease 0 0.0013315717224031687
degeneration I-Disease 0 0.0034978745970875025
. O 0 4.6299970790641964e-07

This O 0 7.487526545446599e-07
mutation O 0 1.1351098692102823e-05
( O 0 1.9148279761793674e-07
7271T O 0 6.450961791415466e-06
- O 0 8.37075731396908e-06
- O 0 5.797196536150295e-06
> O 0 1.3804374248138629e-06
G O 0 6.083913831389509e-06
) O 0 2.4013089294783185e-09
also O 0 8.270227280782194e-10
allows O 0 5.795018354071146e-10
expression O 0 1.4075699494853211e-09
of O 0 7.970663018497248e-11
full O 0 3.4401621551438666e-09
- O 0 2.003895183122495e-08
length O 0 6.055733692278409e-09
ATM O 0 1.5900724292805535e-07
protein O 0 1.2663744719532133e-08
at O 0 5.601172414770872e-09
a O 0 2.6555844190312428e-09
level O 0 3.884261357001151e-09
comparable O 0 1.1452530479516554e-08
with O 0 2.8264005025313566e-10
that O 0 3.1195307448328435e-10
in O 0 4.848011325719881e-09
unaffected O 0 5.55740541585692e-07
individuals O 0 3.871598153182276e-09
. O 0 2.5511885937135048e-08

In O 0 4.222645770823874e-07
addition O 0 2.3418973427169476e-08
, O 0 1.2993160991570107e-09
we O 0 2.678903210373562e-10
have O 0 1.1124726834177423e-10
studied O 0 6.574840671902393e-09
18 O 0 2.7393866730562877e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 8.578359711464145e-07
, O 0 2.6000998576414247e-10
in O 0 8.551701013992385e-10
15 O 0 1.6281572756682294e-09
families O 0 1.5238099670966676e-10
, O 0 1.2120034142970582e-10
who O 0 2.444232816145586e-09
developed O 0 9.246728041034658e-06
leukemia B-Disease 1 0.6003093123435974
, O 0 2.347181862205616e-06
lymphoma B-Disease 1 1.0
, O 0 5.709295791689328e-08
preleukemic O 0 0.00023811019491404295
T O 0 0.002080595353618264
- O 0 1.151563310486381e-06
cell O 0 2.5091617317229975e-06
proliferation O 0 8.285816761599563e-07
, O 0 1.7880111613521876e-08
or O 0 8.275164873339236e-05
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 2.3200190213401584e-08
mostly O 0 9.614373297495149e-09
in O 0 8.807381135511605e-08
childhood O 0 1.5771940525155514e-05
. O 0 2.290376670543992e-07

A O 0 2.0682452941400697e-06
wide O 0 3.244517188250029e-07
variety O 0 3.497993006362776e-08
of O 0 2.3455257736060275e-09
ATM O 0 5.382802919484675e-05
mutation O 0 1.6694975784048438e-06
types O 0 9.17149520773819e-08
, O 0 2.2089385876000733e-09
including O 0 3.1846898451703964e-09
missense O 0 2.2588745196117088e-05
mutations O 0 1.7019327060552314e-05
and O 0 2.8652126005113132e-08
in O 0 1.3315512603639945e-07
- O 0 1.027958842314547e-05
frame O 0 0.000653933675494045
deletions O 0 2.5828381922110566e-07
, O 0 5.461304741771755e-10
were O 0 6.120292050937337e-10
seen O 0 6.950431785668343e-09
in O 0 3.3575429103649412e-09
these O 0 6.707344901712986e-09
patients O 0 1.4329040709526453e-07
. O 0 6.94304134185586e-08

We O 0 1.6568294824992336e-07
also O 0 5.018752080587774e-09
show O 0 5.991075635591869e-09
that O 0 7.410608932056917e-11
25 O 0 6.212654835024978e-10
% O 0 5.463469607280835e-11
of O 0 3.017548017014704e-11
all O 0 1.4192321762251936e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.1798234683956252e-06
carried O 0 6.301390840235399e-07
in O 0 2.904765139533083e-08
- O 0 5.702329985979304e-07
frame O 0 7.071180334605742e-06
deletions O 0 7.973393394422601e-07
or O 0 2.2313530578799146e-08
missense O 0 1.1437465445851558e-06
mutations O 0 2.6322732082917355e-07
, O 0 6.789564466203046e-10
many O 0 5.484978443659472e-11
of O 0 1.2329884335748886e-10
which O 0 5.146045367609986e-09
were O 0 1.5056643709598916e-09
also O 0 4.134811937284155e-10
associated O 0 5.407736480833591e-10
with O 0 9.81143430389686e-11
expression O 0 2.1682187156812915e-09
of O 0 1.7342977054468633e-10
mutant O 0 1.755557121896345e-07
ATM O 0 2.813688297464978e-06
protein O 0 1.3037104054092197e-06
. O 0 1.359472321382782e-07

The O 0 1.4515380826196633e-06
DMPK O 0 6.556590960826725e-05
gene O 0 7.024386377452174e-06
of O 0 1.3527110809263831e-07
severely O 1 0.996371865272522
affected O 1 0.754991888999939
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.5642029047012329
is O 0 3.127031504845945e-07
hypermethylated O 0 3.0266452085925266e-05
proximal O 0 2.203155236202292e-05
to O 0 3.4063941001249987e-08
the O 0 1.342997979492111e-08
largely O 0 7.219303910233066e-08
expanded O 0 7.850241559026472e-07
CTG O 0 2.8230413590790704e-05
repeat O 0 8.719802281120792e-06
. O 0 3.4050566455334774e-07

Using O 0 2.7211035558138974e-06
methylation O 0 4.224721487844363e-05
- O 0 6.631229553022422e-06
sensitive O 0 2.3659770249651046e-06
restriction O 0 2.5103724965447327e-07
enzymes O 0 1.3102949480980897e-07
, O 0 9.63658264296896e-10
we O 0 2.467935578120972e-10
characterized O 0 4.7850914342006945e-09
the O 0 2.1928314719588116e-09
methylation O 0 6.04881051913253e-07
pattern O 0 4.725477992906235e-06
on O 0 1.4936122738617996e-07
the O 0 4.824268540204457e-09
5 O 0 7.001351942648171e-09
side O 0 4.987756430097079e-09
of O 0 1.1178859921079365e-10
the O 0 4.289050448136322e-09
CTG O 0 9.929276529874187e-07
repeat O 0 7.405179758279701e-08
in O 0 1.5477601422730913e-09
the O 0 1.94390858965221e-09
DMPK O 0 3.285434218014416e-07
gene O 0 1.72171255030662e-08
of O 0 1.9485588143020038e-10
normal O 0 1.2924283865345387e-08
individuals O 0 2.1422907892088006e-10
and O 0 1.6126107393876765e-10
of O 0 2.2157775614317643e-10
patients O 0 1.4698890105080409e-08
affected O 0 5.5053934744364597e-08
with O 0 2.8034617116645677e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 3.460050379544555e-08
showing O 0 2.669877972039103e-07
expansions O 0 2.838559964857268e-07
of O 0 8.190153000242617e-10
the O 0 1.8920928823717986e-08
repetitive O 0 1.9047945897909813e-05
sequence O 0 1.8203302261099452e-06
. O 0 4.5756544864161697e-07

The O 0 4.1275674789176264e-07
gene O 0 2.177363512601005e-06
segment O 0 9.945093779606395e-07
analyzed O 0 1.3723213498906262e-07
corresponds O 0 4.0628307829138066e-08
to O 0 2.4495812045444154e-09
the O 0 7.195148477023849e-09
genomic O 0 7.194999511739297e-07
SacI O 0 2.3774042347213253e-05
- O 0 1.4227556448531686e-06
HindIII O 0 2.853342948583304e-06
fragment O 0 1.0347642955821357e-06
carrying O 0 5.306505812541218e-08
exons O 0 1.6033063729992136e-06
11 O 0 2.042764464249558e-07
- O 0 1.1706129043886904e-06
15 O 0 3.4101785217899305e-07
. O 0 9.301099623826303e-08

There O 0 6.19687341441022e-07
is O 0 1.997118559415867e-08
constitutive O 0 3.554817737949634e-07
methylation O 0 1.2539670706246397e-06
in O 0 4.475486292676578e-08
intron O 0 7.534410997322993e-06
12 O 0 1.0087740065500839e-07
at O 0 1.3277972499281532e-08
restriction O 0 1.0317785736901897e-08
sites O 0 1.4036181106291679e-09
of O 0 3.230720968527834e-10
SacII O 0 4.665732262765232e-07
and O 0 2.705452084583726e-09
HhaI O 0 3.510238002490951e-07
, O 0 8.77377281938152e-10
localized O 0 1.2685556782798812e-07
1 O 0 1.4274015747162139e-08
, O 0 5.639987921135514e-10
159 O 0 8.801755058129856e-08
- O 0 3.670245405373862e-07
1 O 0 1.1073844952136369e-08
, O 0 5.583463136282774e-10
232 O 0 3.048292995799784e-08
bp O 0 1.220935672563428e-07
upstream O 0 1.3644619656361101e-08
of O 0 3.0416980045799846e-10
the O 0 7.383598177312933e-09
CTG O 0 1.0395881417935016e-06
repeat O 0 1.3897377471039363e-07
, O 0 5.71000913218711e-10
whereas O 0 1.8232618748115215e-09
most O 0 2.506259644263764e-10
, O 0 1.9632198644536913e-10
if O 0 1.1752698814149198e-10
not O 0 8.467863910066598e-11
all O 0 2.1478418002485178e-11
, O 0 1.4424768671195132e-11
of O 0 7.235267072969176e-12
the O 0 6.276156677698097e-11
other O 0 4.251384660980406e-11
sites O 0 6.286103304553592e-10
of O 0 1.9603313416993728e-10
SacII O 0 3.0305827181109635e-07
, O 0 7.20877135762521e-10
HhaI O 0 1.0915252346421767e-07
, O 0 6.932766583034322e-10
and O 0 4.285728161246283e-10
HpaII O 0 8.989402999759477e-08
in O 0 1.9567685249910483e-09
this O 0 4.0370343179496615e-10
region O 0 1.8993018269242157e-09
are O 0 2.7540159042160894e-10
unmethylated O 0 1.3260742548482085e-07
, O 0 2.5847912699106246e-10
in O 0 7.044319016991096e-10
normal O 0 3.2713643349779886e-08
individuals O 0 1.2077572275615012e-10
and O 0 7.897554832325682e-11
most O 0 1.1908757313605633e-10
of O 0 1.3947333565855757e-10
the O 0 2.090077977356941e-08
patients O 0 1.1030066104922298e-07
. O 0 1.0159725150060694e-07

In O 0 3.741649265975866e-07
a O 0 1.7509380612068526e-08
number O 0 8.476077062447018e-10
of O 0 5.614946285703581e-10
young O 0 7.000764412623539e-09
and O 0 5.281625448105842e-08
severely O 1 0.8680115938186646
affected O 0 1.3305932498042239e-06
patients O 0 1.6685920911641006e-07
, O 0 1.1590108872638893e-09
however O 0 2.4260582431878674e-09
, O 0 1.7730431012275005e-10
complete O 0 6.485991743687691e-10
methylation O 0 1.5722724455713433e-08
of O 0 7.780900229681365e-11
these O 0 2.052227970894549e-10
restriction O 0 2.2303734414919063e-09
sites O 0 1.451885389691654e-09
was O 0 3.786734481536769e-09
found O 0 6.181697931317842e-10
in O 0 6.299257782060863e-10
the O 0 7.778208299669132e-09
mutated O 0 2.3297004645428387e-06
allele O 0 2.5068511604331434e-06
. O 0 6.94011532687e-08

In O 0 3.75212266590097e-07
most O 0 4.450083856966103e-09
of O 0 2.1273352523998312e-10
these O 0 1.0234362246563933e-09
patients O 0 2.904519957880325e-09
, O 0 2.517845099081484e-10
the O 0 2.0313437598673545e-09
onset O 0 2.1495393411896657e-06
of O 0 1.2512120228791446e-09
the O 0 1.2701186733465875e-06
disease O 1 0.6552251577377319
was O 0 0.011325595900416374
congenital O 1 0.9997349381446838
. O 0 4.1932625549634395e-07

Preliminary O 0 9.652900189394131e-06
in O 0 1.38155678541807e-06
vivo O 0 2.1648349502356723e-05
footprinting O 0 4.113077011425048e-05
data O 0 3.086815354436112e-07
gave O 0 1.2455551257062325e-08
evidence O 0 1.6760800525261743e-09
for O 0 8.143329344179051e-10
protein O 0 4.010223975114968e-08
- O 0 1.181676410055843e-07
DNA O 0 5.074292630524724e-08
contact O 0 7.732946016858477e-08
in O 0 5.032027683427032e-09
normal O 0 9.921157584358298e-08
genes O 0 1.5742950054686844e-08
at O 0 1.7249272232788826e-08
an O 0 8.626355185725743e-10
Sp1 O 0 2.864104260424938e-07
consensus O 0 4.615525739382065e-09
binding O 0 7.336359963971972e-09
site O 0 1.9890782354536896e-08
upstream O 0 7.833563131498522e-09
of O 0 2.2087563722461567e-10
the O 0 3.343821886048204e-09
CTG O 0 1.0376201089457027e-06
repeat O 0 6.466789415071617e-08
and O 0 2.5892912813851865e-10
for O 0 2.6461317512160853e-11
a O 0 2.1235001257391417e-10
significant O 0 3.625973410414929e-10
reduction O 0 5.535998326422487e-10
of O 0 2.980470384383871e-11
this O 0 8.017961294903841e-11
interaction O 0 3.447254426358626e-10
in O 0 7.389427403303728e-10
cells O 0 2.306300928012206e-09
with O 0 5.724271612272958e-10
a O 0 1.5770780237289728e-08
hypermethylated O 0 2.974579956571688e-06
DMPK O 0 5.247492481430527e-06
gene O 0 7.351778208430915e-07
. O 0 2.368766338634032e-08
. O 0 7.97053729684194e-08

The O 0 5.5031014198902994e-06
hemochromatosis B-Disease 1 0.9999994039535522
gene O 0 1.1130934581160545e-05
product O 0 1.933760955807884e-07
complexes O 0 8.27364274869069e-08
with O 0 9.213250717898802e-10
the O 0 3.6099931932653817e-09
transferrin O 0 4.3333827193237084e-07
receptor O 0 1.275954275570257e-07
and O 0 6.5904726120891155e-09
lowers O 0 1.2491021834648564e-06
its O 0 4.842716005981629e-09
affinity O 0 1.1486503304070084e-08
for O 0 9.080798335503459e-10
ligand O 0 9.184098104242366e-08
binding O 0 3.3874565019687e-07
. O 0 1.0078739620666965e-07

We O 0 7.244850053211849e-07
recently O 0 4.3127189996994275e-07
reported O 0 1.8639053678271011e-07
the O 0 3.019888783484248e-09
positional O 0 2.8668262075370876e-07
cloning O 0 2.039295132760799e-08
of O 0 3.3627645112943583e-10
a O 0 4.410806830890124e-09
candidate O 0 3.411732762970132e-08
gene O 0 6.584035645573749e-07
for O 0 5.35160552317393e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.01624702289700508
HFE O 0 0.4563103914260864
. O 0 1.993332034544437e-06

The O 0 2.627795936405164e-07
gene O 0 9.75144530457328e-07
product O 0 8.336100165706739e-08
, O 0 9.47618539193229e-10
a O 0 1.5547605425325628e-09
member O 0 8.523724503994856e-10
of O 0 1.180887332363767e-10
the O 0 2.0861699034924186e-09
major O 0 8.052452926676779e-09
histocompatibility O 0 4.6154929123076727e-07
complex O 0 2.3564692241961893e-07
class O 0 5.662747639689769e-07
I O 0 3.405986262805527e-06
- O 0 3.415835294617864e-07
like O 0 7.24241644434187e-09
family O 0 1.081826805915398e-08
, O 0 1.978357339060821e-10
was O 0 3.7069465275152425e-09
found O 0 5.39405631272416e-10
to O 0 2.4594676295564e-10
have O 0 2.633329387879968e-10
a O 0 4.9355555198360435e-09
mutation O 0 2.0645587994749803e-07
, O 0 8.328070677521282e-09
Cys O 0 6.145009683677927e-05
- O 0 1.2966650047019357e-06
282 O 0 2.8127651603426784e-06
- O 0 7.985911906871479e-06
- O 0 7.4587219387467485e-06
> O 0 1.952770844582119e-06
Tyr O 0 3.3334517866023816e-06
( O 0 1.1221617413070817e-08
C282Y O 0 8.357784508916666e-08
) O 0 7.848904304275095e-10
, O 0 1.0881043288613057e-10
in O 0 4.030640543550845e-10
85 O 0 4.711139478530413e-09
% O 0 2.45232889550806e-10
of O 0 3.423018535286815e-10
patient O 0 3.60977509217264e-07
chromosomes O 0 2.143664232789888e-06
. O 0 3.1429581781594607e-07

This O 0 8.247557161666919e-07
mutation O 0 5.377520210458897e-06
eliminates O 0 8.658108185954916e-07
the O 0 1.6996361651422376e-08
ability O 0 4.6953712029562666e-08
of O 0 1.5397922936699615e-09
HFE O 0 1.9651793991215527e-05
to O 0 7.712247729330102e-09
associate O 0 1.4518584556810765e-08
with O 0 2.6677788866891206e-09
beta2 O 0 4.685237581725232e-05
- O 0 2.0487419533310458e-05
microglobulin O 0 3.6266261304263026e-05
( O 0 1.7981001576572453e-08
beta2m O 0 7.524907914557843e-07
) O 0 9.127614220005853e-10
and O 0 4.151256283169147e-10
prevents O 0 1.1372881303373106e-08
cell O 0 6.817111852797098e-07
- O 0 1.6688911728124367e-06
surface O 0 5.556928499572678e-07
expression O 0 6.647842383245006e-07
. O 0 1.0781277381965992e-07

A O 0 1.7010930832839222e-06
second O 0 1.2636509438834764e-07
mutation O 0 5.194646064410335e-07
that O 0 2.406875587723789e-09
has O 0 1.5333211367263289e-09
no O 0 7.158731940570817e-10
effect O 0 1.66274869428662e-08
on O 0 8.531865347549683e-08
beta2m O 0 3.1928955195326125e-06
association O 0 1.2755523748353426e-08
, O 0 6.13176676100835e-10
H63D O 0 6.412146262846363e-07
, O 0 1.1582175218904922e-09
was O 0 1.0872818201335122e-08
found O 0 6.790277229384856e-10
in O 0 7.938668056262088e-10
eight O 0 4.312262491534824e-10
out O 0 3.078456933813811e-10
of O 0 5.3877399069923726e-11
nine O 0 1.5349069792947034e-09
patients O 0 5.232660083009932e-09
heterozygous O 0 4.751416327053448e-08
for O 0 6.885024217417879e-10
the O 0 3.5273499676691245e-09
C282Y O 0 9.570974270900479e-07
mutant O 0 1.4880888556945138e-06
. O 0 1.1847716052670876e-07

In O 0 3.5293209066367126e-07
this O 0 1.4203051179606518e-08
report O 0 4.8346340264515675e-08
, O 0 1.0399496819246679e-09
we O 0 4.125665920007293e-10
demonstrate O 0 3.687483207670539e-09
in O 0 4.9222061981879506e-09
cultured O 0 2.4329091274921666e-07
293 O 0 3.2741081668064e-07
cells O 0 2.7234014510213456e-07
overexpressing O 0 6.084117103455355e-06
wild O 0 1.9165304365742486e-07
- O 0 2.7461042009235825e-06
type O 0 4.01808256356162e-06
or O 0 3.9297649578884375e-08
mutant O 0 4.7307716499744856e-07
HFE O 0 2.468583943482372e-06
proteins O 0 3.041312623963677e-08
that O 0 6.238540795067138e-10
both O 0 5.831786720200682e-10
the O 0 1.9494819092358284e-09
wild O 0 2.6427009913732036e-08
- O 0 4.227978934068233e-06
type O 0 1.2697608326561749e-05
and O 0 3.692552752454503e-08
H63D O 0 2.443679295538459e-05
HFE O 0 2.561239125498105e-05
proteins O 0 1.7170989963233296e-07
form O 0 2.3257653580799342e-08
stable O 0 4.2670296807045816e-07
complexes O 0 3.808328585819254e-08
with O 0 9.132246070464589e-10
the O 0 1.1880636918704113e-08
transferrin O 0 2.488265863576089e-06
receptor O 0 1.0253427262796322e-06
( O 0 7.732695195272754e-08
TfR O 0 8.328984222316649e-06
) O 0 2.2359287754625257e-08
. O 0 5.818226966880502e-08

The O 0 2.1413836748251924e-06
C282Y O 0 4.307964627514593e-05
mutation O 0 7.521832685597474e-06
nearly O 0 1.187969047578008e-07
completely O 0 1.4695055483571196e-07
prevents O 0 1.9474908796723867e-08
the O 0 2.737833737498363e-09
association O 0 1.60599356036073e-09
of O 0 7.846984173554006e-11
the O 0 1.966312668244541e-09
mutant O 0 3.2198087751567073e-07
HFE O 0 4.77097773909918e-06
protein O 0 9.73084297584137e-08
with O 0 7.428320181190884e-09
the O 0 5.555752835562089e-08
TfR O 0 5.550935020437464e-05
. O 0 1.290495248440493e-07

Studies O 0 6.099512575019617e-06
on O 0 2.0670844946835132e-07
cell O 0 2.6188124593318207e-06
- O 0 6.898068818372849e-07
associated O 0 7.005255042713543e-08
transferrin O 0 9.355906627206423e-07
at O 0 5.943650904782771e-08
37 O 0 4.454943791643018e-08
degrees O 0 9.168276449145196e-08
C O 0 5.535883701668354e-06
suggest O 0 2.8274655505811097e-08
that O 0 9.47307676746334e-10
the O 0 6.250764794657471e-09
overexpressed O 0 2.704615326365456e-06
wild O 0 1.0183686072195997e-07
- O 0 1.8243363228975795e-06
type O 0 2.2110066311142873e-06
HFE O 0 1.4754113180970307e-05
protein O 0 1.2089897438727348e-07
decreases O 0 4.693159993962581e-08
the O 0 1.6084185094911163e-09
affinity O 0 9.911244269744657e-09
of O 0 5.34668198604038e-10
the O 0 1.604439070490571e-08
TfR O 0 2.8029219265590655e-06
for O 0 7.441380844852574e-09
transferrin O 0 3.1922440939524677e-06
. O 0 1.6538237446184212e-07

The O 0 1.5246886277964222e-06
overexpressed O 0 0.00010823238699231297
H63D O 0 6.138357275631279e-05
protein O 0 7.878877568145981e-07
does O 0 2.2941973654155845e-08
not O 0 4.308989831613985e-10
have O 0 8.411346619219273e-11
this O 0 1.4164837358610072e-10
effect O 0 4.314164581131763e-09
, O 0 9.627501573739039e-11
providing O 0 7.23840362648609e-11
the O 0 1.3363148088085808e-10
first O 0 1.5406433073739123e-10
direct O 0 2.701109336200602e-10
evidence O 0 1.683939515606525e-10
for O 0 9.598312422642863e-11
a O 0 2.012466415735048e-09
functional O 0 8.657742966988735e-09
consequence O 0 3.1971056912993845e-09
of O 0 3.2884020506607214e-10
the O 0 1.113195491342367e-08
H63D O 0 2.8148208002676256e-05
mutation O 0 2.0177808437438216e-06
. O 0 8.720925137595259e-08

Addition O 0 1.577800730956369e-06
of O 0 9.509835052767812e-08
soluble O 0 5.515932116395561e-06
wild O 0 1.269372774004296e-06
- O 0 0.00012919756409246475
type O 0 0.006270775571465492
HFE O 1 0.7467306852340698
/ O 0 0.00028302372083999217
beta2m O 0 1.2882740520581137e-05
heterodimers O 0 2.2237961729842937e-06
to O 0 1.893092793636697e-08
cultured O 0 1.8938519019684463e-07
cells O 0 1.7683747444152687e-07
also O 0 8.186674449461862e-09
decreased O 0 1.9280683716260683e-08
the O 0 5.924731261153227e-10
apparent O 0 6.1232734438476655e-09
affinity O 0 4.166830436247437e-09
of O 0 1.7074296143615442e-10
the O 0 3.443851870343906e-09
TfR O 0 5.268465201879735e-07
for O 0 2.7058943974367367e-10
its O 0 7.65593477503046e-10
ligand O 0 6.838865918012971e-09
under O 0 2.60137600349708e-09
steady O 0 4.99046166169137e-07
- O 0 9.487822438813964e-08
state O 0 2.929618547753421e-09
conditions O 0 2.810244659201544e-08
, O 0 1.332756266458901e-10
both O 0 1.3316256430861984e-10
in O 0 8.00230548492209e-10
293 O 0 1.8943172364060956e-08
cells O 0 1.2468102106311107e-08
and O 0 9.176053805681761e-10
in O 0 7.84364040384844e-09
HeLa O 0 5.405161118687829e-06
cells O 0 4.768380108544079e-07
. O 0 1.3233756135377917e-07

Furthermore O 0 2.5586114134057425e-06
, O 0 2.7366448662746734e-08
at O 0 5.410950620898802e-08
4 O 0 2.687201572371123e-08
degrees O 0 1.842199139900913e-07
C O 0 2.4582597689004615e-05
, O 0 1.107692382262826e-09
the O 0 5.526442414804933e-09
added O 0 5.7965831246065136e-08
soluble O 0 5.773489064608839e-08
complex O 0 1.9320182786941587e-08
of O 0 7.005506397206318e-09
HFE O 0 0.0006700017838738859
/ O 0 1.2761148354911711e-05
beta2m O 0 6.310570825007744e-06
inhibited O 0 8.118521463984507e-07
binding O 0 7.494599429946902e-08
of O 0 2.169195045809147e-09
transferrin O 0 4.3897765067413275e-07
to O 0 9.625969354942754e-09
HeLa O 0 2.358895926590776e-06
cell O 0 9.568418590788497e-07
TfR O 0 2.4247979126812425e-06
in O 0 5.9665805629549595e-09
a O 0 9.607553863588691e-09
concentration O 0 4.1317855448141927e-07
- O 0 6.814303787905374e-07
dependent O 0 1.0850924070382462e-07
manner O 0 5.553167170546658e-07
. O 0 1.2853143971369718e-07

Scatchard O 0 0.0006233879830688238
plots O 0 1.014329245663248e-05
of O 0 1.0836917141432423e-08
these O 0 2.862523551527829e-09
data O 0 2.9575289772765245e-08
indicate O 0 2.9741602958210933e-08
that O 0 6.329161639229142e-10
the O 0 1.6032819516453856e-09
added O 0 1.0109809878144915e-08
heterodimer O 0 1.2977817220871657e-07
substantially O 0 2.210482819009485e-07
reduced O 0 1.3154354938649249e-08
the O 0 1.954299166939677e-09
affinity O 0 1.3692798894737734e-08
of O 0 2.8271782692712577e-09
TfR O 0 2.6219158826279454e-06
for O 0 1.0107882530974166e-08
transferrin O 0 4.118293873034418e-06
. O 0 1.5710230627519195e-07

These O 0 1.1202140370869529e-07
results O 0 6.646980210689435e-08
establish O 0 2.6751887816089948e-08
a O 0 6.089171389334069e-09
molecular O 0 1.1833217428147691e-07
link O 0 2.1087837467348436e-06
between O 0 7.629557075006232e-08
HFE O 0 0.00013240774569567293
and O 0 2.780916608102757e-09
a O 0 1.9222621272518836e-09
key O 0 4.5894359423925835e-09
protein O 0 7.992364103870386e-09
involved O 0 7.51443129942686e-10
in O 0 4.471729209143405e-09
iron O 0 2.4632645363453776e-06
transport O 0 5.555696791503806e-09
, O 0 2.1683208006884058e-10
the O 0 1.4527551384091453e-09
TfR O 0 4.862571927333192e-07
, O 0 3.224576994309558e-10
and O 0 3.1821259516284783e-10
raise O 0 4.582438428712976e-09
the O 0 6.249462058960376e-10
possibility O 0 8.138469342888754e-10
that O 0 2.340274085632643e-10
alterations O 0 2.4698074696516414e-08
in O 0 1.0274869843840406e-09
this O 0 7.960472281354214e-10
regulatory O 0 3.758379421014979e-07
mechanism O 0 3.315903995826375e-07
may O 0 1.1259785281936274e-07
play O 0 1.8900432330326566e-09
a O 0 9.921301558080131e-10
role O 0 8.8993018509953e-10
in O 0 4.5590373143333807e-10
the O 0 2.702759571704405e-09
pathogenesis O 0 7.184659693848516e-07
of O 0 8.578125232361344e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 4.098369288385584e-07
. O 0 2.837339252437232e-07

Genomic O 0 6.429158383980393e-05
organization O 0 3.179775660555606e-07
of O 0 1.2341849320307574e-08
the O 0 7.930231049613212e-08
UBE3A O 0 0.00018748038564808667
/ O 0 4.224797885399312e-05
E6 O 0 9.066145139513537e-06
- O 0 1.7973197827814147e-05
AP O 0 1.3457359273161273e-05
gene O 0 4.770040504809003e-07
and O 0 4.235460870916086e-09
related O 0 3.307515328287991e-08
pseudogenes O 0 2.118408701790031e-06
. O 0 1.553807322807188e-07

The O 0 2.191924750150065e-06
UBE3A O 0 0.0003083527844864875
gene O 0 9.772627890924923e-06
encodes O 0 2.433067493257113e-06
the O 0 8.742309631770695e-08
E6 O 0 7.628968432982219e-06
- O 0 7.529296453867573e-06
AP O 0 1.7862128515844233e-05
ubiquitin O 0 3.2478747016284615e-06
- O 0 2.247130765908878e-07
protein O 0 4.665304942363946e-08
ligase O 0 6.04529120096231e-08
and O 0 2.4438084889055744e-09
has O 0 1.1726236648357258e-09
recently O 0 8.92245477501774e-09
been O 0 4.148090482214428e-10
shown O 0 1.0566388874977406e-09
to O 0 5.819885684488213e-10
be O 0 1.7614787406472487e-09
mutated O 0 3.974389073846396e-06
in O 0 0.01642454043030739
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 9.461278750677593e-06
who O 0 3.245411051011615e-08
lack O 0 4.485595894720973e-08
15q11 O 0 2.3329064333665883e-06
- O 0 7.536830253229709e-07
q13 O 0 1.952450702447095e-06
deletions O 0 2.4118828605423914e-06
or O 0 8.534112083680157e-08
chromosome O 0 3.867887699016137e-06
15 O 0 3.5936312769990764e-07
paternal O 0 3.765392830246128e-05
uniparental B-Disease 0 0.002191481413319707
disomy I-Disease 0 0.000624254287686199
. O 0 1.141548523264646e-06

Previous O 0 3.067064972128719e-05
UBE3A O 0 0.00042004790157079697
cDNA O 0 1.924334719660692e-05
analysis O 0 6.530400469273445e-07
has O 0 2.2874422356267132e-08
shown O 0 1.0202170663831112e-08
a O 0 1.1485933981703056e-08
coding O 0 5.637099889099773e-07
region O 0 1.9077223356589457e-08
of O 0 1.3767559314814548e-09
approximately O 0 4.073469028753607e-08
2 O 0 1.1988814208052645e-07
. O 0 8.809750084992629e-08

6 O 0 3.146561357425526e-05
kb O 0 0.00018970890960190445
and O 0 3.7938789887448365e-08
a O 0 1.0403056904806363e-07
3 O 0 7.568723958684132e-07
- O 0 1.2307489669183269e-05
untranslated O 0 9.641068572818767e-06
region O 0 5.843427857143979e-07
( O 0 4.0971880110873826e-08
UTR O 0 9.286259228247218e-07
) O 0 4.6226884542477364e-09
of O 0 9.155005642469405e-10
< O 0 7.049231953715207e-08
50 O 0 2.3660344794507182e-08
bp O 0 2.8289770170886186e-07
, O 0 9.775854570293063e-10
whereas O 0 5.463662411386849e-09
Northern O 0 1.8029252757401082e-08
analysis O 0 9.414899970749957e-09
has O 0 2.2991109016601285e-09
indicated O 0 1.277363814722321e-08
mRNA O 0 4.5276458138232556e-08
sizes O 0 1.149086870100291e-07
of O 0 1.7717830536057022e-09
5 O 0 1.0427591945472159e-07
- O 0 3.832561560557224e-06
8 O 0 9.56463168222399e-07
kb O 0 6.720712553942576e-05
. O 0 2.2968029611547536e-07

We O 0 2.4127697884068766e-07
have O 0 9.018663149618078e-09
analyzed O 0 3.293169115181627e-08
additional O 0 2.8592495038282095e-09
cDNA O 0 9.88881510011197e-08
clones O 0 1.0693296559338705e-07
and O 0 4.3386957915281243e-10
provide O 0 2.606142246452947e-10
evidence O 0 1.8137225055170347e-10
for O 0 5.991069446098507e-11
an O 0 2.963935485933433e-10
additional O 0 3.562590666916776e-09
0 O 0 9.541139434077195e-08
. O 0 7.214279662548506e-08

5 O 0 1.6137440979946405e-05
kb O 0 2.8442002076189965e-05
of O 0 2.0809688194844966e-08
5 O 0 2.289629748020161e-07
- O 0 1.430308884664555e-06
UTR O 0 5.144089300301857e-06
and O 0 3.229282441452597e-08
> O 0 2.39646993804854e-07
2 O 0 5.484609744144109e-08
kb O 0 5.00354690302629e-06
of O 0 4.019686805634137e-09
3 O 0 5.217086709308205e-07
- O 0 1.2082758075848687e-05
UTR O 0 3.5947683500126004e-05
. O 0 7.124215244402876e-07

We O 0 2.7372357180865947e-07
have O 0 3.380554280951742e-09
established O 0 1.5729975100242655e-09
the O 0 5.089593191343056e-10
genomic O 0 1.8450363015176663e-08
organization O 0 1.3075974747422947e-09
of O 0 5.101109534777493e-10
UBE3A O 0 1.607786543900147e-06
and O 0 1.6249803724832645e-09
the O 0 8.917449001444311e-10
sequence O 0 1.0387250171106643e-08
of O 0 1.7997394685664858e-09
intron O 0 1.5028559573693201e-05
- O 0 5.557163603953086e-06
exon O 0 7.156538231356535e-06
borders O 0 7.970778028720815e-07
. O 0 2.5631194944253366e-07

We O 0 7.775257699904614e-07
have O 0 8.518154182013404e-09
also O 0 6.29510532590416e-09
mapped O 0 4.21991579457881e-08
two O 0 1.3344714222540688e-09
highly O 0 6.019171827631453e-09
homologous O 0 8.760954983699776e-08
processed O 0 7.081926156615737e-08
pseudogenes O 0 2.4863888370418863e-07
, O 0 2.7169992922182473e-09
UBE3AP1 O 0 1.1988361166004324e-06
and O 0 2.5538113845868793e-09
UBE3AP2 O 0 4.3447249709061e-07
, O 0 3.806465143085802e-10
to O 0 6.759857673621639e-10
chromosomes O 0 1.5623536242515e-08
2 O 0 4.751985471784792e-09
and O 0 6.544185193746443e-10
21 O 0 6.963356113942609e-09
, O 0 2.5712196261018505e-10
respectively O 0 3.7838683297763964e-09
, O 0 2.2059691573428353e-10
and O 0 3.3235239560447383e-10
determined O 0 6.3927143578723644e-09
their O 0 4.824204147269029e-09
genomic O 0 5.538569780583202e-07
organization O 0 5.668205105280322e-08
. O 0 6.702398280822308e-08

These O 0 3.412992555240635e-07
results O 0 2.904131690684153e-07
will O 0 3.156683581195807e-09
form O 0 1.5467714886696626e-09
the O 0 5.077753217896941e-10
basis O 0 6.321391743391302e-10
for O 0 1.5419986121312235e-10
studies O 0 4.3481401812428544e-10
of O 0 2.1319820908693998e-10
mutation O 0 1.1262105203968531e-07
and O 0 1.021295670255995e-08
imprinting O 0 1.971460051208851e-06
of O 0 2.806388010867522e-08
UBE3A O 0 0.0001455048768548295
. O 0 3.586585251014185e-07

Mutation O 0 0.00043635789188556373
spectrum O 0 3.2665491744410247e-05
and O 0 3.494066049825051e-07
genotype O 0 0.00012933931429870427
- O 0 0.00014801915676798671
phenotype O 0 0.00017951239715330303
analyses O 0 3.994127382611623e-06
in O 0 3.793611824676191e-07
Cowden B-Disease 1 0.9773126840591431
disease I-Disease 0 0.03562077879905701
and O 0 3.5316205071467266e-07
Bannayan B-Disease 1 0.9996347427368164
- I-Disease 1 0.9999979734420776
Zonana I-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
, O 0 2.8631585990979147e-08
two O 0 6.156370346843687e-08
hamartoma B-Disease 0 0.11490039527416229
syndromes I-Disease 0 0.0001592213084222749
with O 0 2.547386941387231e-07
germline O 0 0.0022835189010947943
PTEN O 0 0.008572847582399845
mutation O 0 0.00025973364245146513
. O 0 1.1739153933376656e-06

The O 0 2.7181959012523293e-05
tumour B-Disease 1 0.999997615814209
suppressor O 0 0.0019317053956910968
gene O 0 0.0001337950670858845
PTEN O 0 0.0001889845880214125
, O 0 1.382461434218385e-08
which O 0 2.8159412579498166e-09
maps O 0 1.2084871059414581e-07
to O 0 2.3708681240464102e-08
10q23 O 0 5.54026792087825e-06
. O 0 1.8760178477350564e-07

3 O 0 5.285558472678531e-06
and O 0 4.12775591485115e-08
encodes O 0 2.7200425734008604e-07
a O 0 2.6563252930600356e-08
403 O 0 1.4779199375425378e-07
amino O 0 1.0281171824999547e-07
acid O 0 1.7273937658046634e-07
dual O 0 3.251365683354379e-07
specificity O 0 7.953996146170539e-07
phosphatase O 0 0.00025445318897254765
( O 0 6.131585195134903e-08
protein O 0 8.823150778880517e-07
tyrosine O 0 2.108668559230864e-05
phosphatase O 0 0.00032153341453522444
; O 0 4.325223912360343e-08
PTPase O 0 1.3299792271936894e-06
) O 0 2.512636543272606e-09
, O 0 7.111942701421015e-10
was O 0 8.636203752132587e-09
shown O 0 4.0050696092919225e-09
recently O 0 4.8686501941119786e-08
to O 0 8.995964528857314e-10
play O 0 3.507705681471407e-09
a O 0 2.6151862897449973e-09
broad O 0 8.758160419120031e-09
role O 0 4.335041658976024e-09
in O 0 4.84448969828577e-09
human O 0 4.002986742079884e-08
malignancy B-Disease 0 8.359157618542667e-06
. O 0 1.2044992558912782e-07

Somatic O 0 0.0011843547690659761
PTEN O 0 0.002945393556728959
deletions O 0 0.00020261200552340597
and O 0 3.308260261292162e-07
mutations O 0 8.36021081340732e-06
were O 0 1.1639649244443717e-08
observed O 0 2.853013469916732e-08
in O 0 6.6837571033318e-09
sporadic B-Disease 0 0.0035996483638882637
breast I-Disease 0 0.3381132185459137
, I-Disease 0 2.654395636625395e-08
brain I-Disease 0 0.000773870327975601
, I-Disease 0 2.2469380667189398e-07
prostate I-Disease 1 0.646018385887146
and I-Disease 0 1.5714501842012396e-06
kidney I-Disease 0 0.00010728672350523993
cancer I-Disease 0 3.40536716976203e-05
cell O 0 2.3770640837028623e-05
lines O 0 2.9543623895733617e-05
and O 0 3.476215315600939e-09
in O 0 1.073520050631771e-09
several O 0 3.309615026481083e-09
primary O 0 9.815749990593758e-07
tumours B-Disease 1 0.9999977350234985
such O 0 6.98867763659905e-09
as O 0 4.6181621655705385e-06
endometrial B-Disease 1 0.9999526739120483
carcinomas I-Disease 1 1.0
, O 1 0.7186084389686584
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9972091317176819
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 5.308674190018792e-06

In O 0 4.017328762984107e-07
addition O 0 4.005171305720978e-08
, O 0 9.574734782802352e-09
PTEN O 0 5.971472546661971e-06
was O 0 5.969929617322123e-08
identified O 0 5.156598259503653e-09
as O 0 1.0802057026637613e-09
the O 0 1.53134827041157e-09
susceptibility O 0 2.7155405746270844e-07
gene O 0 1.745577122846953e-07
for O 0 8.154088071421484e-09
two O 0 3.826068564194429e-07
hamartoma B-Disease 1 0.9999204874038696
syndromes I-Disease 1 0.9992699027061462
Cowden B-Disease 1 0.999717652797699
disease I-Disease 1 0.9999051094055176
( O 0 9.538280210108496e-07
CD B-Disease 0 0.0005903366836719215
; O 0 2.3921862180031894e-07
MIM O 0 3.48165885952767e-05
158350 O 0 2.597934326331597e-06
) O 0 1.496580281923343e-08
and O 0 1.9852803845310518e-08
Bannayan B-Disease 0 0.0001025755045702681
- I-Disease 0 0.0001936813205247745
Zonana I-Disease 0 0.0008219675510190427
( I-Disease 0 2.943286858680949e-07
BZS I-Disease 0 1.556433562655002e-05
) I-Disease 0 4.03779303326246e-08
or I-Disease 0 4.879062487361807e-08
Ruvalcaba I-Disease 0 2.364227475482039e-05
- I-Disease 0 3.4576733014546335e-05
Riley I-Disease 0 0.0004796955327037722
- I-Disease 1 0.9538305997848511
Smith I-Disease 1 0.610449492931366
syndrome I-Disease 1 0.9999810457229614
( O 0 3.4205396559627843e-07
MIM O 0 6.300414679571986e-05
153480 O 0 1.100610552384751e-05
) O 0 1.349366272052066e-07
. O 0 1.6045132156250475e-07

Constitutive O 0 2.7342995963408612e-05
DNA O 0 1.5394808769997326e-06
from O 0 5.722574769606581e-08
37 O 0 1.2812562033559516e-07
CD B-Disease 0 2.362121676924289e-06
families O 0 8.288754571594836e-09
and O 0 2.7152224912896372e-09
seven O 0 1.0131797623103012e-08
BZS B-Disease 0 1.9175702163920505e-06
families O 0 4.0646348509199015e-09
was O 0 2.170462387596217e-08
screened O 0 1.2734695076233038e-07
for O 0 2.0019276902871752e-08
germline O 0 4.3625484977383167e-05
PTEN O 0 0.00019356278062332422
mutations O 0 3.4959819458890706e-05
. O 0 9.666446203482337e-07

PTEN O 0 0.003075323300436139
mutations O 0 0.0003579298791009933
were O 0 1.2502253809998365e-07
identified O 0 1.4881178955761243e-08
in O 0 3.3646527786146407e-09
30 O 0 5.8161049310001545e-09
of O 0 4.445551426979222e-10
37 O 0 2.8780181793308657e-08
( O 0 2.665001774815323e-09
81 O 0 1.7105767469161037e-08
% O 0 9.673338796645226e-10
) O 0 5.974059025248835e-10
CD B-Disease 0 1.783439188329794e-06
families O 0 2.933213449907157e-09
, O 0 2.3800589277200856e-10
including O 0 5.105518785519791e-10
missense O 0 1.255366896657506e-06
and O 0 1.835499574553978e-08
nonsense O 0 1.2089107030988089e-06
point O 0 8.280573382535295e-08
mutations O 0 2.955849538466282e-07
, O 0 3.793182656863792e-09
deletions O 0 6.792011504330731e-07
, O 0 4.836383737938377e-09
insertions O 0 4.142552825214807e-07
, O 0 3.3724527614964472e-09
a O 0 2.060344961307692e-08
deletion O 0 8.89549028215697e-06
/ O 0 3.635981784100295e-06
insertion O 0 9.508526659374184e-07
and O 0 3.134151427275356e-08
splice O 0 2.770558603515383e-05
site O 0 5.136505478731124e-06
mutations O 0 2.9891005397075787e-05
. O 0 5.13271743329824e-07

These O 0 2.0011533763408806e-07
mutations O 0 2.1233540792309213e-06
were O 0 1.0045572373940104e-08
scattered O 0 2.3350862576876352e-08
over O 0 6.268362717776199e-09
the O 0 5.269728653445327e-09
entire O 0 7.822574588089992e-09
length O 0 8.1375111093962e-09
of O 0 3.7138447872564484e-10
PTEN O 0 6.753168690920575e-07
, O 0 3.016496774588262e-10
with O 0 6.603299851359878e-11
the O 0 4.2726283622229744e-10
exception O 0 8.260830908213279e-10
of O 0 2.308838190079321e-11
the O 0 2.855128355960801e-10
first O 0 2.4486983551952335e-09
, O 0 3.1842145586935544e-10
fourth O 0 2.5550599858092937e-08
and O 0 1.6300372163158272e-09
last O 0 8.536195394981405e-08
exons O 0 3.848706455755746e-06
. O 0 2.39984103700408e-07

A O 0 8.37973493617028e-06
hot O 0 1.3781820598524064e-05
spot O 0 9.544403383188182e-07
for O 0 2.209070260050794e-08
PTEN O 0 1.1455999811005313e-05
mutation O 0 3.519754727676627e-07
in O 0 7.945731184122451e-09
CD B-Disease 0 5.780838819191558e-06
was O 0 3.073291310329296e-08
identified O 0 3.347740085146711e-09
in O 0 2.2114552411522936e-09
exon O 0 2.893518740165746e-07
5 O 0 1.216989709007521e-08
that O 0 2.218424888233983e-10
contains O 0 6.741676661370377e-10
the O 0 3.259441827552223e-09
PTPase O 0 6.811608272982994e-07
core O 0 5.510110412387803e-08
motif O 0 5.918728618325986e-08
, O 0 1.9802638695498587e-10
with O 0 7.161978649028455e-11
13 O 0 7.337672136564777e-10
of O 0 6.388198303675097e-11
30 O 0 2.408694133038125e-09
( O 0 8.273666751712483e-10
43 O 0 4.0011451929444775e-09
% O 0 3.8420316927911813e-10
) O 0 8.825348785101994e-10
CD B-Disease 0 3.42739735970099e-06
mutations O 0 3.2195106314247823e-07
identified O 0 1.1156355839148091e-08
in O 0 2.8844959754081856e-09
this O 0 6.046546818794241e-09
exon O 0 4.6222594392020255e-06
. O 0 1.688831048340944e-07

Seven O 0 3.745880121641676e-07
of O 0 7.532357848560878e-09
30 O 0 1.6796619206616015e-08
( O 0 5.571954897476417e-09
23 O 0 7.975978100205339e-09
% O 0 3.560129691049241e-10
) O 0 2.319202468958892e-10
were O 0 3.4451902442000915e-10
within O 0 3.2526331628091043e-10
the O 0 1.4010130833241874e-09
core O 0 1.2006938732156414e-07
motif O 0 9.912646703469363e-08
, O 0 1.8322027228734328e-10
the O 0 4.765870476042267e-10
majority O 0 9.207435369695816e-10
( O 0 3.3895400375349993e-10
five O 0 1.3274539800711693e-10
of O 0 2.819216561589233e-11
seven O 0 4.4636488949478803e-10
) O 0 1.1003468969317254e-10
of O 0 5.47308552645287e-11
which O 0 1.032427587865925e-09
were O 0 1.6161648686008334e-09
missense O 0 3.8495034004881745e-07
mutations O 0 7.793403256073361e-08
, O 0 7.939728319250605e-10
possibly O 0 7.310714256192341e-09
pointing O 0 6.329614166133979e-08
to O 0 1.564508855800284e-09
the O 0 4.795443597771509e-09
functional O 0 8.79894823668792e-09
significance O 0 1.2406559113387061e-09
of O 0 1.9516051275036972e-10
this O 0 1.5738618186489362e-09
region O 0 2.8893486714309802e-08
. O 0 7.082304165351161e-08

Germline O 0 0.013983586803078651
PTEN O 0 0.011976758018136024
mutations O 0 0.002494733314961195
were O 0 5.628918415823136e-07
identified O 0 4.3174512853738634e-08
in O 0 4.870208236695817e-09
four O 0 9.955117841187189e-10
of O 0 1.9286218455594195e-10
seven O 0 2.5768867040198984e-09
( O 0 4.3575569819154225e-09
57 O 0 3.702531969906886e-08
% O 0 2.722965408707978e-09
) O 0 4.860130520256689e-09
BZS B-Disease 0 2.681756996025797e-06
families O 0 2.6385306384213436e-08
studied O 0 3.9523538930552604e-07
. O 0 1.5437252898209408e-07

Interestingly O 0 2.7402405976317823e-05
, O 0 2.9333603990266965e-08
none O 0 4.91039120475989e-09
of O 0 2.3480495325856054e-10
these O 0 7.746726593538256e-10
mutations O 0 2.3911096036499657e-07
was O 0 1.1485741424621665e-07
observed O 0 1.1245144371230253e-08
in O 0 2.2586235104427033e-09
the O 0 4.127887365257266e-09
PTPase O 0 2.1127696072653634e-06
core O 0 5.224056849328917e-07
motif O 0 1.904815462694387e-06
. O 0 1.0175045872529154e-07

It O 0 7.49585694848065e-07
is O 0 2.1127961602473988e-08
also O 0 3.615030053083501e-09
worthy O 0 2.245047037163772e-09
of O 0 1.9710841292486236e-10
note O 0 4.421708510449207e-08
that O 0 1.5701610844853775e-10
a O 0 1.6045239581430337e-09
single O 0 1.4412827376020232e-08
nonsense O 0 7.19339467991631e-08
point O 0 6.147965692093749e-09
mutation O 0 2.4418296717954036e-08
, O 0 2.1890485257802794e-10
R233X O 0 2.566112300428358e-08
, O 0 4.4603723492464553e-10
was O 0 6.96673030375905e-09
observed O 0 2.1946473527378885e-09
in O 0 6.359922588572431e-10
the O 0 7.03208991037485e-10
germline O 0 1.2376978020256502e-07
DNA O 0 9.646756282677416e-09
from O 0 1.2326033527187974e-09
two O 0 8.464912659711388e-10
unrelated O 0 2.8547555430691318e-08
CD B-Disease 0 8.69005816639401e-06
families O 0 8.399475781573074e-09
and O 0 4.081204707517827e-09
one O 0 1.281886330417592e-08
BZS B-Disease 0 1.4467657820205204e-05
family O 0 5.564209573094558e-07
. O 0 1.6544484537917015e-07

Genotype O 0 0.010011470876634121
- O 0 0.0034211333841085434
phenotype O 0 0.0001678643748164177
studies O 0 2.5104395717789885e-07
were O 0 1.147706463200393e-08
not O 0 7.939697788117428e-10
performed O 0 7.434074689172121e-09
on O 0 2.1073376377245268e-09
this O 0 1.4935647163483168e-10
small O 0 3.9677652829972487e-10
group O 0 1.5835154298926568e-09
of O 0 6.908557059759346e-10
BZS B-Disease 0 2.637138095451519e-06
families O 0 4.356877525424352e-08
. O 0 1.2776737889907963e-07

However O 0 9.973512078431668e-07
, O 0 1.2962355810941517e-07
genotype O 0 1.705094109638594e-05
- O 0 5.054991106590023e-06
phenotype O 0 7.547183031419991e-06
analysis O 0 6.335532276580125e-08
inthe O 0 3.3944361348403618e-06
group O 0 1.1160826041134442e-08
of O 0 1.4210903565015087e-09
CD B-Disease 0 1.1101252312073484e-05
families O 0 4.420610100197564e-09
revealed O 0 2.3768537360524533e-08
two O 0 4.124894870116691e-10
possible O 0 4.368425177148083e-09
associations O 0 3.822116401153153e-09
worthy O 0 1.3339674920231914e-09
of O 0 1.7729483159367732e-10
follow O 0 3.412728233342932e-08
- O 0 1.695041305538325e-06
up O 0 4.2547252832036975e-08
in O 0 5.615634623978849e-09
independent O 0 2.9703958404070363e-08
analyses O 0 1.9735244904950378e-07
. O 0 4.690340560387085e-08

The O 0 2.952671422917774e-07
first O 0 7.898982090637219e-08
was O 0 2.5970296135824356e-08
an O 0 3.086176036948274e-10
association O 0 1.5039365308666675e-09
noted O 0 6.090248860779468e-10
in O 0 4.541081399800362e-10
the O 0 5.399408697925878e-10
group O 0 3.7391054141799884e-10
of O 0 9.045028614984574e-11
CD B-Disease 0 1.1932754659937927e-06
families O 0 2.1121906446097682e-09
with O 0 3.8627415932523945e-08
breast B-Disease 1 0.7945274114608765
disease I-Disease 0 0.00021444994490593672
. O 0 4.3412583750068734e-07

A O 0 5.264344508759677e-06
correlation O 0 3.1048596156324493e-06
was O 0 1.767349715464661e-07
observed O 0 3.050491415024226e-08
between O 0 9.102786857617673e-10
the O 0 1.5916518103509247e-09
presence O 0 2.01044940695283e-08
/ O 0 6.121360343058768e-07
absence O 0 6.816856856772802e-09
of O 0 4.392033126077166e-10
a O 0 1.3184395797338766e-08
PTEN O 0 1.0862124327104539e-05
mutation O 0 2.4618927341180097e-07
and O 0 1.2228176249351463e-09
the O 0 1.4496468470071022e-09
type O 0 2.7943013947151485e-07
of O 0 8.847989896310082e-09
breast O 0 7.047846156638116e-05
involvement O 0 4.950454695062945e-07
( O 0 1.7080638770039513e-07
unaffected O 0 8.99524602573365e-05
versus O 0 6.11672512604855e-05
benign O 1 0.9738177061080933
versus O 0 0.0011046223808079958
malignant O 0 0.05397426709532738
) O 0 2.2772432828332967e-07
. O 0 2.064255539835358e-07

Specifically O 0 6.041050824023841e-07
and O 0 7.577503957634235e-09
more O 0 3.1288863167056036e-10
directly O 0 1.070226463006918e-09
, O 0 3.207279442030142e-10
an O 0 5.754024479109887e-10
association O 0 3.1299578040488996e-08
was O 0 2.401319818545744e-07
also O 0 1.034785479525624e-09
observed O 0 1.8152322978082225e-09
between O 0 2.56248078311927e-10
the O 0 2.5294552563615014e-10
presence O 0 5.784748235981851e-10
of O 0 2.0277812762259373e-10
a O 0 8.836420484215068e-09
PTEN O 0 3.1768147891853005e-05
mutation O 0 3.2995214951370144e-06
and O 0 2.5757683488336625e-06
malignant B-Disease 1 0.9999798536300659
breast I-Disease 1 0.9999842643737793
disease I-Disease 1 0.8749308586120605
. O 0 1.5124223864404485e-06

Secondly O 0 0.00011825813999166712
, O 0 3.750101029709185e-08
there O 0 3.3500908713790523e-09
appeared O 0 1.0146654005893652e-07
to O 0 1.6881145370462036e-09
be O 0 2.430698142763532e-10
an O 0 5.542221126475511e-10
interdependent O 0 3.2436324204354605e-07
association O 0 8.792674144331158e-09
between O 0 1.8750272445799965e-09
mutations O 0 5.015577286826556e-08
upstream O 0 1.8272734436663995e-08
and O 0 6.640740179975069e-10
within O 0 7.527456435951763e-10
the O 0 3.2226479262931207e-09
PTPase O 0 1.0412998108222382e-06
core O 0 1.1255898613171667e-07
motif O 0 7.510669064458853e-08
, O 0 2.3711416163862964e-10
the O 0 6.890225612288248e-10
core O 0 4.038008682982763e-08
motif O 0 2.9553579139474095e-08
containing O 0 2.3342836552586732e-09
the O 0 1.1412946143707359e-09
majority O 0 1.481956446447441e-09
of O 0 7.347195074558499e-10
missense O 0 1.1640925094980048e-06
mutations O 0 5.544848136196379e-07
, O 0 1.2300951368615642e-09
and O 0 6.869375068774275e-10
the O 0 9.76029701504899e-10
involvement O 0 1.6779095890484541e-09
of O 0 1.4829934502635922e-10
all O 0 3.704901940793093e-10
major O 0 2.914531060937975e-09
organ O 0 2.2614607587456703e-05
systems O 0 7.736136467428878e-05
( O 0 1.1403834321299655e-08
central O 0 4.0215994090431195e-07
nervous O 0 0.0013225253205746412
system O 0 0.00010145186388399452
, O 0 5.3854162018751595e-08
thyroid O 0 0.00037174386670812964
, O 0 3.77573066145942e-08
breast O 0 0.0075056059285998344
, O 0 6.773207701371575e-07
skin O 1 0.9999991655349731
and O 0 0.0023802132345736027
gastrointestinal O 1 0.9999371767044067
tract O 1 0.6536734700202942
) O 0 3.083796684677509e-07
. O 0 5.240388532001816e-07

However O 0 2.9548405677815026e-07
, O 0 6.9406027591867314e-09
these O 0 3.7946279451972487e-10
observations O 0 6.467490099026918e-09
would O 0 2.94813307100128e-09
need O 0 7.008817415332658e-10
to O 0 4.806750553143502e-10
be O 0 2.191935383200061e-10
confirmed O 0 1.7552810316345813e-09
by O 0 1.1676662414750183e-10
studying O 0 1.4066915687838133e-10
a O 0 2.9481431185196527e-10
larger O 0 4.259592956135094e-10
number O 0 1.8786884548038785e-10
of O 0 2.71389577477521e-10
CD B-Disease 0 8.220495146815665e-06
families O 0 1.878478883554635e-08
. O 0 4.8072138270072173e-08

Molecular O 0 0.0038872896693646908
defects O 1 0.9951646327972412
leading O 0 2.474013740538794e-07
to O 0 1.2886130384970329e-08
human O 0 2.051639214073475e-08
complement B-Disease 0 3.954694420826854e-06
component I-Disease 1 0.9972807168960571
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 6.105628003183483e-09
an O 0 1.0355989399357668e-09
African O 0 5.3659627852198355e-09
- O 0 1.5931962593640492e-07
American O 0 2.2064551075118288e-08
family O 0 5.427923355227904e-08
. O 0 3.701035211634007e-08

Complement B-Disease 0 0.0006030046497471631
component I-Disease 1 0.9973275661468506
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.011544441098522e-06
C6D B-Disease 0 0.00027755898190662265
) O 0 1.3711439805774717e-07
was O 0 9.771789336809888e-06
diagnosed O 0 6.80624543747399e-06
in O 0 6.687710385477885e-09
a O 0 1.797606508091576e-08
16 O 0 1.8703174475831474e-07
- O 0 3.925768510271155e-07
year O 0 1.2228626111721042e-08
- O 0 1.9613887047853495e-07
old O 0 9.4706457787197e-08
African O 0 1.465048748983122e-09
- O 0 1.3373948171135908e-08
American O 0 1.8741119767184955e-09
male O 0 1.6013634862588333e-08
with O 0 7.677847690956696e-08
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.954216486410587e-06

The O 0 8.790327683527721e-07
patients O 0 8.869466796568304e-07
father O 0 9.170294106297661e-07
and O 0 8.802171436173012e-09
two O 0 3.0267106598813598e-09
brothers O 0 2.1403873233794e-06
also O 0 5.020676319134054e-09
had O 0 7.1434049786489595e-09
C6D B-Disease 0 1.8942830593005056e-06
, O 0 6.36034724887935e-10
but O 0 5.47333900424718e-10
gave O 0 2.6824376053724563e-09
no O 0 5.900113730916701e-10
history O 0 9.995529959283544e-10
of O 0 2.221127282098223e-09
meningitis B-Disease 1 0.9999995231628418
or O 0 4.049562818408958e-08
other O 0 6.419766940268801e-09
neisserial B-Disease 0 0.0004463325603865087
infection I-Disease 0 0.0005203702603466809
. O 0 4.294766711154807e-07

By O 0 3.5721700442081783e-07
using O 0 2.552941680278309e-07
exon O 0 7.96786025603069e-06
- O 0 1.5045245618239278e-06
specific O 0 8.501196901988806e-08
polymerase O 0 5.337437869457062e-06
chain O 0 2.064922227873467e-05
reaction O 0 1.2301389915592154e-06
( O 0 3.645984492095522e-08
PCR O 0 9.920617230818607e-06
) O 0 2.4202591930588824e-08
/ O 0 5.962522209301824e-07
single O 0 8.263202744274167e-08
- O 0 4.674229785450734e-07
strand O 0 1.4436125184147386e-06
conformation O 0 1.7076418998840381e-06
polymorphism O 0 3.953002476464462e-07
as O 0 2.927618591996861e-09
a O 0 3.7138536690406454e-09
screening O 0 5.503377664695108e-08
step O 0 6.423539922195687e-09
and O 0 5.770587341302758e-10
nucleotide O 0 1.6413034487072764e-08
sequencing O 0 4.9409902835861885e-09
of O 0 4.671105724440849e-10
target O 0 4.5171997697934785e-08
exons O 0 1.748446010196858e-07
, O 0 1.7501661231378307e-09
we O 0 2.728677839236582e-10
determined O 0 1.4861514241459872e-09
that O 0 1.118527978571926e-10
the O 0 8.680623442280933e-10
proband O 0 2.2310004510472936e-07
was O 0 5.8234976840765285e-09
a O 0 8.0581796790824e-10
compound O 0 1.0709948483622611e-08
heterozygote O 0 3.9891379088885515e-08
for O 0 9.047172455645125e-10
two O 0 6.004162944606151e-09
C6 O 0 7.505878602387384e-05
gene O 0 6.924526132934261e-06
mutations O 0 3.069551894441247e-05
. O 0 5.662369630954345e-07

The O 0 3.159691459586611e-07
first O 0 2.9569310555643824e-08
, O 0 2.0837480629865013e-09
1195delC O 0 1.2702432172773115e-07
located O 0 2.885581551481664e-08
in O 0 7.466730345129236e-09
exon O 0 7.890923825470963e-07
7 O 0 1.5024326671664312e-07
, O 0 3.802075321246434e-10
is O 0 9.507899328964342e-11
a O 0 1.2569958407482318e-09
novel O 0 9.815524393275155e-09
mutation O 0 3.386583458109271e-08
, O 0 2.6568697242268513e-10
while O 0 2.380381169952983e-10
the O 0 5.486833209999986e-10
second O 0 2.109762808899518e-09
, O 0 1.8051944661312547e-10
1936delG O 0 3.53827473986712e-08
in O 0 4.881870907524899e-09
exon O 0 3.0910101145309454e-07
12 O 0 2.313465685688243e-08
, O 0 3.713284957296281e-10
has O 0 5.932171975864264e-10
been O 0 4.338364945066786e-10
described O 0 2.9843929549855375e-09
before O 0 2.176214763949247e-09
to O 0 7.791270406620754e-10
cause O 0 7.775419419431273e-09
C6D B-Disease 0 6.14973373558314e-07
in O 0 9.522296284814047e-10
an O 0 1.927136367152471e-10
unrelated O 0 6.807241881290338e-09
African O 0 2.1910335767927336e-09
- O 0 4.276187581808699e-08
American O 0 4.815525755930139e-09
individual O 0 3.981109220063672e-09
. O 0 2.654552666569998e-08

Both O 0 1.1813591527243261e-06
mutations O 0 1.7549158656038344e-05
result O 0 1.9439100640283868e-07
in O 0 1.7708555333229015e-07
premature O 0 5.957969551673159e-05
termination O 0 9.290652087656781e-06
codons O 0 2.395154115220066e-05
and O 0 7.413842695314088e-07
C6 O 0 0.0010524963727220893
null O 0 2.0630661310860887e-05
alleles O 0 1.1695880857587326e-05
. O 0 8.261798143394117e-07

Allele O 0 0.00028822285821661353
- O 0 9.803889952308964e-06
specific O 0 2.1492532198408298e-07
PCR O 0 1.4116424608801026e-05
indicated O 0 7.686550134167192e-07
that O 0 2.0046395654560456e-09
the O 0 2.080312810903706e-09
probands O 0 7.336754492826003e-07
two O 0 3.2558442608632276e-09
brothers O 0 4.504294679463783e-07
also O 0 6.004643449131208e-09
inherited O 0 1.0262637317737244e-07
the O 0 4.0209449103656425e-09
1195delC O 0 4.647772868793254e-07
mutation O 0 1.1095287533180453e-07
from O 0 6.649083506005127e-09
their O 0 8.345053537084368e-09
heterozygous O 0 2.9010609523538733e-06
mother O 0 7.852655414808396e-08
and O 0 4.639088557745197e-10
the O 0 1.8385891698002865e-09
1936delG O 0 1.6062863039678632e-07
mutation O 0 2.7860359352871455e-08
from O 0 9.685358071109818e-10
their O 0 2.5578770213030566e-09
homozygous O 0 5.099198574498587e-07
father O 0 9.688525892670441e-08
. O 0 8.581394261852893e-09
. O 0 4.8173102840110005e-08

PAX6 O 0 0.03260483965277672
mutations O 0 0.010367035865783691
reviewed O 0 0.0002792290470097214
. O 0 6.351476713462034e-06

Mutations O 0 0.00044375218567438424
in O 0 7.8997788932611e-07
PAX6 O 0 2.2963851733948104e-05
are O 0 2.4338864257344994e-09
responsible O 0 5.161931770913952e-09
for O 0 6.388444773186563e-10
human O 0 5.634753996730524e-09
aniridia B-Disease 1 1.0
and O 0 1.0039408238071701e-07
have O 0 8.624149727687325e-10
also O 0 7.432979232113723e-10
been O 0 2.4179724888995224e-10
found O 0 6.232962479479909e-10
in O 0 1.565266916081498e-09
patients O 0 5.154011883945486e-09
with O 0 4.6597200764608715e-08
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999998807907104
, O 0 1.3034347823293047e-08
with O 0 1.2423565749486443e-06
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.5150159001350403
, O 0 7.41873451559627e-09
with O 0 3.244396040713582e-08
autosomal B-Disease 1 0.929882824420929
dominant I-Disease 0 0.2120073288679123
keratitis I-Disease 0 0.0920180231332779
, O 0 1.0177410025846712e-08
and O 0 5.673361780367259e-09
with O 0 2.1566588515042895e-08
isolated B-Disease 0 0.14318612217903137
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 1.8328707938053412e-06

No O 0 6.542038022416818e-07
locus O 0 1.5076197996677365e-06
other O 0 4.828401678480532e-09
than O 0 5.5438622581505115e-09
chromosome O 0 9.033753940457245e-07
11p13 O 0 1.2428993159119273e-06
has O 0 1.3407329468861917e-08
been O 0 3.4854970021314102e-09
implicated O 0 9.610158713257988e-08
in O 0 6.973765920292863e-08
aniridia B-Disease 1 1.0
, O 0 7.031369264609566e-09
and O 0 4.468804881696542e-09
PAX6 O 0 2.4368664526264183e-06
is O 0 2.7932602897351444e-09
clearly O 0 1.5393283314679707e-09
the O 0 1.5428665289807242e-10
major O 0 2.3908647284187623e-10
, O 0 1.4638833201185975e-10
if O 0 1.1263635857350351e-10
not O 0 2.252934505619919e-10
only O 0 9.299436914966819e-11
, O 0 1.5337298098216934e-10
gene O 0 2.2957731715678165e-08
responsible O 0 7.222086395586302e-08
. O 0 8.664073902764358e-08

Twenty O 0 7.28845088815433e-06
- O 0 1.6095921182568418e-06
eight O 0 3.2467546873249375e-08
percent O 0 3.5004692477969e-08
of O 0 1.0545309070408848e-09
identified O 0 4.171484491166666e-08
PAX6 O 0 1.505234104115516e-05
mutations O 0 2.6954432996717514e-06
are O 0 1.1004236633027631e-08
C O 0 0.00012563115160446614
- O 0 0.0002885827561840415
T O 0 0.0005787982372567058
changes O 0 2.1501163871562312e-07
at O 0 1.2466394139210024e-07
CpG O 0 1.8054618067253614e-06
dinucleotides O 0 3.3286218581451976e-07
, O 0 6.846589406528381e-10
20 O 0 1.014031858481701e-09
% O 0 2.580682612052243e-10
are O 0 1.663118393002705e-10
splicing O 0 2.4652027263982745e-07
errors O 0 8.762342673662715e-08
, O 0 6.377122718781436e-10
and O 0 3.049086538808865e-10
more O 0 1.1653099318831295e-10
than O 0 2.5163471306655083e-10
30 O 0 1.403425375912093e-09
% O 0 1.4390948155362793e-10
are O 0 1.0675511863400544e-10
deletion O 0 8.297980969018681e-08
or O 0 2.360638617915356e-08
insertion O 0 1.4023055427969666e-07
events O 0 1.517220198365976e-07
. O 0 1.3378290475429822e-07

There O 0 5.142624104337301e-07
is O 0 1.8267227730461855e-08
a O 0 1.3961800604533892e-08
noticeably O 0 1.646154123591259e-05
elevated O 0 5.009849701309577e-06
level O 0 1.9071729084885192e-08
of O 0 5.260537561113665e-10
mutation O 0 1.1919454578901423e-07
in O 0 4.650333007560903e-09
the O 0 4.314987922526825e-09
paired O 0 5.0843102172848376e-08
domain O 0 1.246439218505202e-08
compared O 0 7.116668143680727e-09
with O 0 2.4931148812079584e-10
the O 0 1.9717394383889086e-09
rest O 0 1.7114668571238667e-09
of O 0 1.5558336563525899e-10
the O 0 5.066340680315307e-09
gene O 0 6.061248427613464e-07
. O 0 5.738609587524479e-08

Increased O 0 1.1107669706689194e-05
mutation O 0 7.281608304765541e-06
in O 0 4.191894831251375e-08
the O 0 1.036433339152154e-08
homeodomain O 0 9.128663691626571e-07
is O 0 1.4449483831668886e-09
accounted O 0 1.707368468828463e-09
for O 0 1.435533636406916e-10
by O 0 6.547555830849205e-10
the O 0 2.0193922978251067e-08
hypermutable O 0 2.0409221178852022e-05
CpG O 0 1.7979198673856445e-05
dinucleotide O 0 2.302661869180156e-06
in O 0 2.0897591213042688e-08
codon O 0 3.705570406964398e-06
240 O 0 4.787248713000736e-07
. O 0 1.354828356170401e-07

Very O 0 6.347906378323387e-07
nearly O 0 4.201676517823216e-08
all O 0 2.133276666427264e-09
mutations O 0 3.8900392951290996e-07
appear O 0 1.1875770411506892e-07
to O 0 1.7863580836774418e-08
cause O 0 4.27726433827047e-07
loss O 0 4.068872172524607e-08
of O 0 1.3362536077643483e-10
function O 0 1.6258918655864818e-09
of O 0 9.451144727945504e-11
the O 0 9.189926042374452e-10
mutant O 0 5.179153461654096e-08
allele O 0 3.679160087699529e-08
, O 0 1.1191148702183185e-10
and O 0 6.293310317317946e-11
more O 0 4.27476179454267e-11
than O 0 1.3538552223746336e-10
80 O 0 1.228421031562732e-09
% O 0 1.7988256717504925e-10
of O 0 1.180770203834669e-10
exonic O 0 7.460724873453728e-07
substitutions O 0 3.1688287549513916e-08
result O 0 1.7610496172437706e-08
in O 0 3.4906882717677945e-08
nonsense O 0 2.6036714189103805e-06
codons O 0 7.889879270805977e-06
. O 0 2.709983561999252e-07

In O 0 4.1791696503423736e-07
a O 0 3.896150246873731e-08
gene O 0 1.3905410867209866e-07
with O 0 1.7257851814278524e-09
such O 0 7.972992821514424e-10
extraordinarily O 0 5.959349209661013e-07
high O 0 1.0925521110038972e-07
sequence O 0 1.9625218783403398e-08
conservation O 0 2.3151112138464214e-09
throughout O 0 2.01626626505913e-09
evolution O 0 2.216302918967017e-09
, O 0 2.0913919207554699e-10
there O 0 2.1768779834285823e-10
are O 0 2.0727353167160345e-10
presumed O 0 3.693207872856874e-08
undiscovered O 0 1.2360582957171573e-07
missense O 0 3.3826765957201133e-06
mutations O 0 1.0875596672121901e-06
, O 0 2.263173204397617e-09
these O 0 3.167912876467227e-10
are O 0 1.0833124675091454e-10
hypothesized O 0 5.644134049020977e-09
to O 0 4.869054048839416e-10
exist O 0 8.826073205625562e-10
in O 0 9.023700675570012e-10
as O 0 3.4107092705681907e-09
- O 0 5.792328039433414e-08
yet O 0 4.965544420088008e-09
unidentified O 0 1.0625228696881095e-07
phenotypes O 0 7.505742587454733e-07
. O 0 4.592360713928656e-09
. O 0 3.6563822192192674e-08

Genetic O 0 0.0001309288782067597
heterogeneity O 0 3.50611844623927e-05
and O 0 3.182263128564955e-07
penetrance O 0 2.7565880373003893e-05
analysis O 0 1.1018606471679959e-07
of O 0 2.240627905436554e-09
the O 0 1.5001241138179466e-08
BRCA1 O 0 4.6779855438217055e-06
and O 0 2.823859901468495e-08
BRCA2 O 0 3.5053178635280346e-06
genes O 0 3.0626443958681193e-07
in O 0 2.0095924355700845e-06
breast B-Disease 1 0.9943601489067078
cancer I-Disease 0 8.786723628873006e-05
families O 0 1.1006528666257509e-07
. O 0 2.217357319977964e-07

The O 0 0.0005821066442877054
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.000240044086240232
Consortium O 0 1.3498026419256348e-05
. O 0 5.507036462404358e-07

The O 0 1.8050900507660117e-07
contribution O 0 2.3314903785376373e-08
of O 0 2.7673077163115067e-09
BRCA1 O 0 2.3527557004854316e-06
and O 0 3.4196872888969665e-08
BRCA2 O 0 0.00012012661318294704
to O 0 6.573119026143104e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 1.3333051356312353e-05
assessed O 0 1.6259486201875006e-08
by O 0 2.167011459164314e-09
linkage O 0 3.2993875720421784e-07
and O 0 4.029082401046935e-09
mutation O 0 7.014079272948948e-08
analysis O 0 3.01621039255906e-09
in O 0 3.364646339321098e-09
237 O 0 2.761119333172246e-08
families O 0 1.2690312134466808e-09
, O 0 1.2569856266964052e-10
each O 0 5.0565853587647425e-11
with O 0 3.4124125747325706e-10
at O 0 2.5303938500087497e-08
least O 0 6.026486532029196e-10
four O 0 2.3845481145201575e-10
cases O 0 2.288234046687876e-10
of O 0 3.020096173145248e-09
breast B-Disease 1 0.7222936749458313
cancer I-Disease 0 6.447613145610376e-07
, O 0 1.787375386586021e-10
collected O 0 4.915992612986031e-10
by O 0 2.3828989892393793e-09
the O 0 6.556334847118706e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999995231628418
Linkage O 0 1.219046680489555e-05
Consortium O 0 1.8795381038216874e-06
. O 0 1.6405874703195877e-07

Families O 0 6.406962711480446e-07
were O 0 1.6009604308919734e-08
included O 0 1.7647542316368003e-09
without O 0 3.7009395548182056e-10
regard O 0 5.725560026093035e-10
to O 0 4.3228690072005804e-10
the O 0 1.5060922509135821e-09
occurrence O 0 4.432694566958162e-08
of O 0 1.392605497585464e-08
ovarian B-Disease 0 9.435727406525984e-05
or I-Disease 0 8.341014989809992e-08
other I-Disease 0 2.4004673804256527e-08
cancers I-Disease 0 6.628827395616099e-05
. O 0 3.007905036156444e-07

Overall O 0 3.2695188565412536e-05
, O 0 3.7754790582766873e-07
disease O 0 3.98393276554998e-05
was O 0 3.220905000489438e-07
linked O 0 7.031190421002975e-07
to O 0 6.711721400876058e-09
BRCA1 O 0 3.0465670874946227e-07
in O 0 1.7321928336144765e-09
an O 0 4.194153913061882e-10
estimated O 0 1.2336712762461843e-09
52 O 0 3.300291817609491e-09
% O 0 9.385737326228494e-11
of O 0 2.1612055894904003e-11
families O 0 2.2421532686056622e-10
, O 0 1.4010656523844034e-10
to O 0 1.106467695244362e-09
BRCA2 O 0 1.6385453704970132e-07
in O 0 1.5335375191938283e-09
32 O 0 4.796513852767248e-09
% O 0 1.303796515195188e-10
of O 0 5.4697569390471656e-11
families O 0 2.9609914520278835e-10
, O 0 1.5720490187387526e-10
and O 0 3.1853444881768667e-10
to O 0 4.826907762378596e-10
neither O 0 1.7052724787802731e-09
gene O 0 7.432345405788965e-09
in O 0 1.0960117258207447e-09
16 O 0 2.1572048591878e-09
% O 0 2.94764795905067e-10
( O 0 9.743705842168993e-10
95 O 0 5.586952411817947e-08
% O 0 5.384139800668208e-09
confidence O 0 4.5580071628137375e-07
interval O 0 1.4208302445695153e-06
[ O 0 2.8917864369759627e-07
CI O 0 7.098313290043734e-06
] O 0 1.3460631009820645e-07
6 O 0 1.4495341815745633e-08
% O 0 2.4953568100727352e-09
- O 0 9.954595014960432e-08
28 O 0 4.3553654904826544e-08
% O 0 5.878019182503635e-10
) O 0 3.046337071488381e-10
, O 0 3.062521347629854e-10
suggesting O 0 1.7031020149715914e-08
other O 0 3.440943308063993e-09
predisposition O 0 1.3647713785758242e-06
genes O 0 7.109317152753647e-07
. O 0 2.0461530425563978e-07

The O 0 1.5530000041508174e-07
majority O 0 5.626412402648384e-08
( O 0 1.5675233555612067e-08
81 O 0 3.046195118372452e-08
% O 0 6.813512531955723e-10
) O 0 1.2308877528344198e-10
of O 0 1.757440859506687e-10
the O 0 7.094076863722876e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.3203321103105736e-08
were O 0 1.5866324920565944e-09
due O 0 6.736564195364281e-09
to O 0 6.748742897855209e-09
BRCA1 O 0 7.053628792164091e-07
, O 0 2.9160646120018896e-10
with O 0 1.66543237534178e-10
most O 0 9.164736747280244e-10
others O 0 1.1951292178125072e-09
( O 0 1.0676127759623455e-09
14 O 0 4.972577460904404e-09
% O 0 4.469595527023529e-10
) O 0 5.024419214016973e-10
due O 0 2.8070946456182355e-08
to O 0 7.040122085300027e-08
BRCA2 O 0 3.417352127144113e-05
. O 0 1.4303073214705364e-07

Conversely O 0 1.003495435725199e-05
, O 0 1.362054202758145e-08
the O 0 1.7138449548426138e-09
majority O 0 4.985651891331599e-10
of O 0 6.37186692298286e-11
families O 0 1.3238610208077262e-10
with O 0 3.3578809177647884e-10
male B-Disease 0 1.3855975922183461e-08
and I-Disease 0 1.8648348643068857e-08
female I-Disease 0 5.619622811536829e-07
breast I-Disease 0 0.15120412409305573
cancer I-Disease 0 2.7442404189059744e-06
were O 0 4.64903804342498e-09
due O 0 3.1321615523438595e-08
to O 0 2.4824787558941352e-08
BRCA2 O 0 5.145006525708595e-06
( O 0 2.1581605835763185e-08
76 O 0 1.8040609006675368e-07
% O 0 7.183465822180324e-09
) O 0 1.229026391769139e-08
. O 0 8.61892957004784e-08

The O 0 1.6770633237683796e-07
largest O 0 4.689464105922525e-08
proportion O 0 2.4698923795085648e-08
( O 0 7.362152665280064e-09
67 O 0 4.8674806407689175e-08
% O 0 5.486738841042893e-10
) O 0 1.6195832175380787e-10
of O 0 5.081287474117957e-11
families O 0 2.970115264844253e-10
due O 0 4.576935275224514e-09
to O 0 6.168470734202458e-10
other O 0 2.1281953976881596e-10
genes O 0 6.618134928970676e-09
was O 0 3.465300935090454e-08
found O 0 1.00194275098886e-09
in O 0 8.802267803531549e-10
families O 0 2.6778559925055845e-10
with O 0 1.6524938362127983e-10
four O 0 9.07925734594528e-10
or O 0 1.6846181116747516e-09
five O 0 1.2630130274970952e-10
cases O 0 1.8917843680466007e-10
of O 0 6.989940293244956e-10
female O 0 7.811885325281764e-07
breast B-Disease 0 0.15307597815990448
cancer I-Disease 0 3.2156428915186552e-06
only O 0 1.7856086387268988e-08
. O 0 1.3080502014872764e-07

These O 0 1.8635090270890942e-07
estimates O 0 1.3526671693853132e-07
were O 0 5.819145165730788e-09
not O 0 1.9307280219038603e-09
substantially O 0 1.5988371160347015e-07
affected O 0 5.8656355328423615e-09
either O 0 1.5925658569670986e-09
by O 0 6.317630862895385e-10
changing O 0 2.8047344002857244e-08
the O 0 3.528184189249828e-09
assumed O 0 4.959262511761153e-08
penetrance O 0 5.1341464768484e-07
model O 0 2.4285640165544464e-08
for O 0 7.468492491113921e-10
BRCA1 O 0 1.978405208546974e-07
or O 0 1.3408653076751875e-09
by O 0 2.6330582159062033e-10
including O 0 1.8363627285467032e-10
or O 0 5.097338551252051e-09
excluding O 0 1.3266003406897653e-07
BRCA1 O 0 6.6226598391949665e-06
mutation O 0 8.617414550826652e-07
data O 0 1.12516431727272e-06
. O 0 3.1274637990463816e-07

Among O 0 1.3208413918164297e-07
those O 0 6.148282327700372e-09
families O 0 3.3732243664985617e-09
with O 0 7.531180123976355e-09
disease O 0 4.429007731232559e-06
due O 0 2.1023249985319126e-07
to O 0 5.397612312663114e-08
BRCA1 O 0 7.194161298684776e-06
that O 0 2.7969386806603325e-09
were O 0 1.3411549204533912e-08
tested O 0 2.2826393220043428e-08
by O 0 2.0404954115260665e-10
one O 0 8.67740809762374e-11
of O 0 3.0194190897558926e-11
the O 0 1.2692804585157091e-09
standard O 0 1.5329131031194265e-07
screening O 0 1.0451880250172962e-08
methods O 0 5.333372410376569e-09
, O 0 4.387553931284316e-10
mutations O 0 1.4461402741972051e-08
were O 0 1.3331383774684014e-09
detected O 0 5.470140607144458e-08
in O 0 3.889317312655294e-09
the O 0 6.8093459759666075e-09
coding O 0 3.739537532965187e-07
sequence O 0 1.629220491849992e-08
or O 0 2.402353427299886e-09
splice O 0 1.7564782694989844e-07
sites O 0 6.470735058883292e-09
in O 0 5.734194230555545e-10
an O 0 1.1235998936820479e-10
estimated O 0 9.375453746685025e-10
63 O 0 7.2705681475326855e-09
% O 0 3.890591460109505e-10
( O 0 7.395589141090397e-10
95 O 0 3.957278948973908e-08
% O 0 4.031534661663727e-09
CI O 0 1.1036069054171094e-06
51 O 0 5.5980137858568924e-08
% O 0 2.0848374138182635e-09
- O 0 1.7280315489642817e-07
77 O 0 1.2178608699286997e-07
% O 0 4.532067165996523e-09
) O 0 9.196680750278574e-09
. O 0 6.853062473055616e-08

The O 0 3.47934218325463e-07
estimated O 0 9.839821757395839e-08
sensitivity O 0 2.630983431117784e-07
was O 0 9.843350312621624e-08
identical O 0 3.319871666462859e-08
for O 0 3.1163430169733886e-10
direct O 0 1.920946290923098e-09
sequencing O 0 1.5429032274028032e-08
and O 0 1.5421904864254543e-09
other O 0 5.455734752857211e-10
techniques O 0 9.778007381555653e-08
. O 0 5.2179721876655094e-08

The O 0 7.099391723386361e-07
penetrance O 0 3.289685264462605e-05
of O 0 3.0601889022818796e-08
BRCA2 O 0 5.634430635836907e-06
was O 0 3.7264502594780424e-08
estimated O 0 2.2633761531665186e-09
by O 0 1.0949230411227973e-09
maximizing O 0 1.5401894870592514e-08
the O 0 1.3027886325289728e-08
LOD O 0 2.529248195060063e-05
score O 0 4.854407720245035e-08
in O 0 3.701867967720318e-08
BRCA2 O 0 3.27687339449767e-05
- O 0 2.7099004000774585e-06
mutation O 0 4.3612016042970936e-07
families O 0 4.153444255194927e-09
, O 0 4.296146494109365e-10
over O 0 9.201537309877494e-10
all O 0 4.567348999007237e-10
possible O 0 8.39214031600477e-09
penetrance O 0 2.6065260954055702e-06
functions O 0 1.7351406711441086e-07
. O 0 9.806078793417328e-08

The O 0 1.8728911754806177e-07
estimated O 0 7.846022498370075e-08
cumulative O 0 2.6751817472359107e-07
risk O 0 1.9624289393505023e-07
of O 0 2.3608098587146742e-08
breast B-Disease 1 0.9215951561927795
cancer I-Disease 0 2.15333766391268e-05
reached O 0 9.060426009455114e-08
28 O 0 4.97549201838865e-08
% O 0 1.8009549407338454e-09
( O 0 1.4433838568805868e-09
95 O 0 3.3812781907727185e-08
% O 0 3.970916928608403e-09
CI O 0 1.8421515051159076e-06
9 O 0 8.436085607854693e-08
% O 0 2.0457611160651368e-09
- O 0 6.339013935985349e-08
44 O 0 1.075153743812507e-08
% O 0 2.6290736254708236e-10
) O 0 1.2419337780400497e-10
by O 0 6.940016339385124e-10
age O 0 1.992696230246338e-09
50 O 0 9.419062196869277e-10
years O 0 4.670482334212522e-10
and O 0 2.6850571765990594e-10
84 O 0 4.457899382970254e-09
% O 0 2.5431262651309794e-10
( O 0 6.875103264469828e-10
95 O 0 2.8352905800943518e-08
% O 0 4.481010229540061e-09
CI O 0 7.948931397550041e-07
43 O 0 2.033228518882879e-08
% O 0 1.495606527512905e-09
- O 0 3.8956596171146884e-08
95 O 0 3.829809713806753e-08
% O 0 9.473437589946343e-10
) O 0 3.26829230345993e-10
by O 0 1.326824539127358e-09
age O 0 7.0863954704236676e-09
70 O 0 9.22625087440565e-09
years O 0 1.5679361808906833e-08
. O 0 5.606444730688054e-08

The O 0 1.043849806592334e-05
corresponding O 1 0.9910151362419128
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 3.399579145479947e-05
were O 0 1.5230189376325143e-07
0 O 0 8.244985565397656e-07
. O 0 2.383425794505456e-07

4 O 0 2.101247673635953e-06
% O 0 4.5676845417119694e-08
( O 0 2.4159561462511192e-08
95 O 0 1.1727847493148147e-07
% O 0 1.2927438675092162e-08
CI O 0 2.257235109937028e-06
0 O 0 3.3349316197472945e-08
% O 0 2.3908841573216932e-09
- O 0 7.633094156744846e-08
1 O 0 8.741938728462628e-09
% O 0 2.3833249263027767e-10
) O 0 6.909964267443058e-11
by O 0 2.1729412713611396e-10
age O 0 1.783773018182444e-09
50 O 0 6.245458039622065e-10
years O 0 3.192265896068136e-10
and O 0 3.441413820581829e-10
27 O 0 7.1694215009188156e-09
% O 0 3.1606522954419347e-10
( O 0 3.783216795394395e-10
95 O 0 1.4333108033781627e-08
% O 0 2.8814717278891067e-09
CI O 0 5.377917204896221e-07
0 O 0 1.0062370492391892e-08
% O 0 7.504319388118574e-10
- O 0 3.3409229160952236e-08
47 O 0 3.794913894239471e-08
% O 0 4.3442935360182844e-10
) O 0 9.446007864788442e-11
by O 0 5.077617770687937e-10
age O 0 4.008593013082873e-09
70 O 0 5.20251619562373e-09
years O 0 8.727610634196026e-09
. O 0 2.530529030764228e-08

The O 0 8.422514383710222e-07
lifetime O 0 1.8010713347393903e-06
risk O 0 6.135844046184502e-07
of O 0 4.5003442750157774e-08
breast B-Disease 1 0.9902212619781494
cancer I-Disease 0 7.252964860526845e-05
appears O 0 1.1880981531930956e-07
similar O 0 1.649129721670306e-08
to O 0 2.269674670429822e-09
the O 0 2.2055830495304463e-09
risk O 0 4.277123100138169e-09
in O 0 1.981269814876896e-09
BRCA1 O 0 2.7009065206584637e-07
carriers O 0 6.360460158560954e-09
, O 0 3.141384097293809e-10
but O 0 6.968747245927887e-10
there O 0 8.023059994144432e-10
was O 0 7.216602870840916e-09
some O 0 6.572928312742476e-11
suggestion O 0 6.614837566587539e-10
of O 0 5.48407881606483e-11
a O 0 4.359086425154146e-09
lower O 0 2.2228179659578018e-05
risk O 0 3.5718183966082506e-08
in O 0 1.1686677403588419e-08
BRCA2 O 0 1.3344488252187148e-06
carriers O 0 5.2446733178612703e-08
< O 0 7.022901371556145e-08
50 O 0 3.895241462714694e-09
years O 0 1.1289559287419593e-09
of O 0 7.859045636493533e-10
age O 0 2.9542478685584683e-08
. O 0 4.090277627710748e-08

Eye B-Disease 0 0.39059650897979736
movement I-Disease 0 0.00021774695778731257
abnormalities I-Disease 1 0.7736884355545044
correlate O 0 5.003527803637553e-06
with O 0 6.011028830243959e-08
genotype O 0 0.00013417925219982862
in O 0 1.2719466440103133e-06
autosomal O 1 0.9998672008514404
dominant O 1 0.9994483590126038
cerebellar B-Disease 1 0.9999959468841553
ataxia I-Disease 1 1.0
type I-Disease 1 0.9999998807907104
I I-Disease 1 0.6557773351669312
. O 0 7.199186597972584e-07

We O 0 1.2980902965864516e-06
compared O 0 1.1055780078095268e-06
horizontal O 0 2.5106237444560975e-05
eye O 0 0.0004636902594938874
movements O 0 4.1832834540400654e-05
( O 0 6.324774659560717e-08
visually O 0 3.966771089380927e-07
guided O 0 4.2438082914486586e-07
saccades O 0 9.996460903494153e-06
, O 0 4.000122899583403e-09
antisaccades O 0 4.874095793638844e-07
, O 0 5.461471275225449e-10
and O 0 5.132770319882241e-10
smooth O 0 2.939600030060774e-08
pursuit O 0 2.1975429476128738e-08
) O 0 1.489906309437572e-09
in O 0 2.34369679219526e-09
control O 0 3.2983808750941535e-07
subjects O 0 2.5267045344889993e-08
( O 0 5.120706081385151e-09
n O 0 2.0304253212088952e-07
= O 0 2.1674635775070783e-07
14 O 0 2.535872845044196e-08
) O 0 1.0650906823173045e-09
and O 0 1.883407430014472e-09
patients O 0 2.9472224660764823e-09
with O 0 2.9536251222594956e-10
three O 0 9.354287344720547e-10
forms O 0 6.841579303085155e-09
of O 0 5.673394198879578e-09
autosomal O 0 0.011517276056110859
dominant O 0 0.0015086927451193333
cerebellar B-Disease 0 0.0072156162932515144
ataxias I-Disease 0 0.3923008441925049
type I-Disease 1 0.990908145904541
I I-Disease 0 7.807476504240185e-05
spinocerebellar B-Disease 1 0.7660583257675171
ataxias I-Disease 0 9.8854121461045e-05
1 I-Disease 0 1.16824701024143e-07
and I-Disease 0 6.299345045590599e-09
2 I-Disease 0 1.8771428855757222e-08
( O 0 7.789015654680043e-09
SCA1 B-Disease 0 1.4064723927731393e-06
, O 0 3.376932289356205e-09
n O 0 2.1683153761387075e-07
= O 0 2.966552301586489e-07
11 O 0 2.4027578149343753e-08
; O 0 5.1709085902018614e-09
SCA2 B-Disease 0 2.994349642904126e-06
, O 0 6.555382014994393e-09
n O 0 2.3373284818717366e-07
= O 0 1.410592034289948e-07
10 O 0 9.801455647107105e-09
) O 0 3.4005178672913416e-09
and O 0 3.0606091883100817e-08
SCA3 B-Disease 1 1.0
/ O 0 0.00833800993859768
Machado B-Disease 0 1.510808306193212e-05
- I-Disease 0 0.0004903866210952401
Joseph I-Disease 0 0.00018554036796558648
disease I-Disease 0 0.03978236764669418
( O 0 1.2305748953167495e-07
MJD B-Disease 1 1.0
) O 0 2.377266383746246e-08
( O 0 2.200575366373414e-08
n O 0 5.490481385095336e-07
= O 0 5.351329832592455e-07
16 O 0 1.0278014883624564e-07
) O 0 2.9234406895284337e-08
. O 0 7.254018186131361e-08

In O 0 2.7401135866966797e-06
SCA1 B-Disease 0 4.030792479170486e-05
, O 0 6.940472729866087e-08
saccade O 0 5.457032784761395e-06
amplitude O 0 4.2350106355115713e-07
was O 0 5.589680895923266e-08
significantly O 0 5.6763301614637385e-08
increased O 0 1.8056818262834895e-08
, O 0 1.1321408255327015e-09
resulting O 0 2.8621704117881563e-08
in O 0 4.5659341196824244e-08
hypermetria B-Disease 0 3.491500683594495e-05
. O 0 4.3702110019694373e-07

The O 0 8.174341701305821e-07
smooth O 0 1.233890543517191e-06
pursuit O 0 4.7101357836254465e-07
gain O 0 7.021802161943924e-07
was O 0 6.042537279427052e-07
decreased O 0 1.645050929255376e-06
. O 0 1.6691969051407796e-07

In O 0 3.172849574184511e-06
SCA2 B-Disease 0 5.179643630981445e-05
, O 0 8.269950768635681e-08
saccade O 0 2.1978084987495095e-05
velocity O 0 1.7056822798622306e-06
was O 0 1.1334225291648181e-06
markedly O 0 2.1176967493374832e-05
decreased O 0 8.05160107120173e-06
. O 0 4.03514519575765e-07

The O 0 4.096813768228458e-07
percentage O 0 3.513835338253557e-07
of O 0 2.984859914789695e-09
errors O 0 5.61086288541901e-08
in O 0 1.1543387579138198e-08
antisaccades O 0 2.1579691747319885e-05
was O 0 9.554906910125283e-08
greatly O 0 6.0259033318743604e-09
increased O 0 6.62395693851181e-09
and O 0 1.9257482275492066e-09
was O 0 1.1517744091804616e-08
significantly O 0 4.809158227203625e-08
correlated O 0 8.640013504646049e-08
with O 0 7.011388358790782e-09
age O 0 1.9976869225502014e-07
at O 0 2.0378331555548357e-06
disease O 0 0.00011512071796460077
onset O 0 0.00040133390575647354
. O 0 1.0403350643173326e-06

In O 0 2.7844907890539616e-07
addition O 0 1.6188435481012675e-08
, O 0 9.064825556848177e-10
a O 0 2.306864033130296e-09
correlation O 0 1.7702502574934442e-08
between O 0 2.0960013724646842e-09
smooth O 0 1.3016911282193178e-07
pursuit O 0 3.283353677829837e-08
gain O 0 8.103192783437407e-08
and O 0 8.724710398588797e-10
the O 0 8.886953395403907e-10
number O 0 5.878871833786548e-10
of O 0 1.3287111411131036e-09
trinucleotide O 0 1.4522106539516244e-05
repeats O 0 4.130540764890611e-05
was O 0 2.986610070365714e-07
found O 0 5.778402112355252e-08
. O 0 7.786672284737506e-08

In O 0 1.679059823800344e-05
SCA3 B-Disease 1 0.9999997615814209
, O 0 6.78682511079387e-07
gaze B-Disease 0 0.0001100928129744716
- I-Disease 0 5.710644836653955e-05
evoked I-Disease 0 3.331462721689604e-05
nystagmus I-Disease 0 5.3552372264675796e-05
was O 0 4.122217376334447e-07
often O 0 2.2562596235786714e-09
present O 0 1.875692490216352e-09
as O 0 2.266417054030967e-09
was O 0 2.0796356636765267e-08
saccade O 0 6.945371637812059e-07
hypometria O 0 6.530488008138491e-07
and O 0 1.6810264291677868e-09
smooth O 0 2.5080026944124256e-08
pursuit O 0 4.4627167739008655e-08
gain O 0 1.3703883894322644e-07
was O 0 3.7049130696686916e-07
markedly O 0 6.225320703379111e-06
decreased O 0 3.571655952328001e-06
. O 0 2.237802334548178e-07

Three O 0 2.7692581738847366e-07
major O 0 1.254053927368659e-07
criteria O 0 9.577423298878784e-08
, O 0 7.056250694859045e-09
saccade O 0 3.0762319056520937e-06
amplitude O 0 3.782030830734584e-07
, O 0 9.930658073642462e-09
saccade O 0 8.491196581417171e-07
velocity O 0 1.3838867118920462e-07
, O 0 1.070496025157297e-09
and O 0 3.068877374445833e-10
presence O 0 2.0882280349354687e-09
of O 0 2.431891132914643e-09
gaze B-Disease 0 3.274405389674939e-05
- I-Disease 0 5.803004114568466e-06
evoked I-Disease 0 3.4851116197387455e-06
nystagmus I-Disease 0 3.2754403491708217e-06
, O 0 1.1669432087302312e-09
permitted O 0 1.949734595996233e-09
the O 0 1.88865567629648e-09
correct O 0 1.1484427631103244e-07
assignment O 0 7.176179650514314e-09
of O 0 4.63563666619482e-11
90 O 0 1.0751327605973415e-09
% O 0 1.4122376879033283e-10
of O 0 2.3504408488972395e-11
the O 0 1.3196816972538272e-09
SCA1 B-Disease 0 2.358996624707288e-07
, O 0 1.468999089038192e-10
90 O 0 8.12432510155503e-10
% O 0 1.0796490090836386e-10
of O 0 2.6272126835147347e-11
the O 0 1.0812363226975208e-09
SCA2 B-Disease 0 1.0011467566073406e-06
, O 0 4.494695171608498e-10
and O 0 3.250623936690289e-10
93 O 0 4.405602105350681e-09
% O 0 1.0678159051424885e-10
of O 0 2.0533977296288697e-11
the O 0 2.963756129403805e-09
patients O 0 5.3415574186033155e-09
with O 0 5.7132907294032975e-09
SCA3 B-Disease 1 1.0
to O 0 5.370877964594456e-09
their O 0 1.6052035256564068e-09
genetically O 0 2.1459696242231985e-08
confirmed O 0 7.022338621709423e-08
patient O 0 7.184632977441652e-08
group O 0 1.4788730240411496e-09
and O 0 4.814577070355597e-10
, O 0 1.4565723627235627e-10
therefore O 0 8.268082329898618e-10
, O 0 5.59404800259955e-10
may O 0 2.766042683788328e-08
help O 0 5.434737104792475e-09
orient O 0 2.096535808959743e-06
diagnoses O 0 5.690432658411737e-07
of O 0 8.10321587607632e-10
SCA1 B-Disease 0 2.572371158748865e-06
, O 0 3.0505540316028146e-09
SCA2 B-Disease 0 1.2822576991311507e-06
, O 0 1.6901634536381493e-09
and O 0 4.938455866465574e-09
SCA3 B-Disease 1 0.9999998807907104
at O 0 5.897239319097025e-08
early O 0 4.9158476400634754e-08
clinical O 0 1.2877309885084287e-08
stages O 0 8.44234282482148e-09
of O 0 3.753081179169726e-10
the O 0 5.602478836408409e-08
diseases O 0 3.5253719943284523e-06
. O 0 8.561579889487803e-09
. O 0 4.358257399417198e-08

Genetic O 0 1.2705070730589796e-05
basis O 0 2.2002193134085246e-07
and O 0 2.4314331881214457e-08
molecular O 0 1.0904573173320387e-06
mechanism O 0 2.8395386834745295e-05
for O 0 6.950653187232092e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 8.523832366336137e-05

Ventricular B-Disease 1 0.9999047517776489
fibrillation I-Disease 1 0.9999372959136963
causes O 0 1.6391048120567575e-05
more O 0 1.741562272172814e-08
than O 0 3.2475395705944266e-09
300 O 0 3.510121748817596e-09
, O 0 3.0873945067178e-10
000 O 0 2.774696472584992e-09
sudden O 0 4.2483272011395457e-08
deaths O 0 3.248619151463572e-08
each O 0 1.5347139115107211e-09
year O 0 2.8058833034805275e-09
in O 0 2.0592123561868902e-09
the O 0 9.895339658783087e-09
USA O 0 8.935007826949004e-07
alone O 0 5.869443597816826e-08
. O 0 4.3306638275453224e-08

In O 0 4.802842568096821e-07
approximately O 0 8.385824656897967e-08
5 O 0 5.3171543612506866e-08
- O 0 1.7012716568842734e-07
12 O 0 1.618152012383689e-08
% O 0 2.237675877925227e-10
of O 0 2.240924980301262e-11
these O 0 1.3245506080838965e-10
cases O 0 2.891065720156405e-10
, O 0 3.966463824056632e-10
there O 0 3.8183398110014366e-10
are O 0 2.69401917440959e-10
no O 0 2.732048809406251e-09
demonstrable O 0 4.604366495186696e-06
cardiac O 0 1.6613417756161653e-05
or O 0 9.084392615932302e-08
non O 0 1.813700691855047e-07
- O 0 0.03286192566156387
cardiac O 0 0.01348175760358572
causes O 0 9.924035282438126e-08
to O 0 4.58352245047422e-09
account O 0 2.845593982669925e-09
for O 0 1.6100903943438993e-10
the O 0 5.165780025961908e-10
episode O 0 1.0346439260899842e-08
, O 0 1.9665216677289266e-10
which O 0 3.757005817561776e-10
is O 0 1.7836290777673014e-10
therefore O 0 1.2677586758158554e-09
classified O 0 2.6153573529086316e-08
as O 0 9.935263278748607e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.00023743188648950309
IVF B-Disease 1 1.0
) O 0 6.461327757278923e-07
. O 0 3.754281010515115e-07

A O 0 1.0871666518141865e-06
distinct O 0 1.5412334164466301e-07
group O 0 5.6698706174529434e-08
of O 0 1.1276179101571415e-08
IVF B-Disease 1 1.0
patients O 0 2.1612518139590975e-06
has O 0 8.921825944696593e-09
been O 0 1.1986150960652253e-09
found O 0 7.76527786516823e-10
to O 0 4.860629121417048e-10
present O 0 5.927296986563135e-10
with O 0 5.550948589672089e-10
a O 0 1.2392895598623e-08
characteristic O 0 4.5851425056753214e-07
electrocardiographic O 0 3.746599395526573e-05
pattern O 0 1.3157739886082709e-05
. O 0 1.8672520241125312e-07

Because O 0 2.1757476531547582e-07
of O 0 1.4915128021542046e-09
the O 0 1.1576233305277128e-09
small O 0 1.000750926571925e-09
size O 0 7.971627802305647e-09
of O 0 2.761680051310833e-10
most O 0 6.890199522047169e-10
pedigrees O 0 2.472084474902658e-07
and O 0 9.751253138290394e-10
the O 0 6.206913649720036e-09
high O 0 1.875182078947546e-06
incidence O 0 1.5673402913307655e-06
of O 0 1.0662288829621502e-09
sudden B-Disease 0 1.2300157550271251e-06
death I-Disease 0 2.72165380010847e-07
, O 0 2.4860963288020343e-10
however O 0 2.2966292756443352e-10
, O 0 4.082983950937091e-11
molecular O 0 4.275263254527317e-09
genetic O 0 9.456364580273657e-09
studies O 0 2.5217730126314564e-09
of O 0 2.630168305373104e-09
IVF B-Disease 1 1.0
have O 0 1.3992511149751863e-08
not O 0 1.373747338107023e-09
yet O 0 3.4922913449975113e-09
been O 0 6.6614851412794e-09
done O 0 1.9731173139803104e-08
. O 0 3.430715267427331e-08

Because O 0 8.702352351974696e-05
IVF B-Disease 1 1.0
causes O 0 0.000511622114572674
cardiac O 0 0.2468900978565216
rhythm O 1 0.523984432220459
disturbance O 0 0.0016102984081953764
, O 0 3.5550847599097324e-08
we O 0 1.8996930695180936e-09
investigated O 0 3.3019873058037774e-08
whether O 0 5.746678688467455e-09
malfunction O 0 1.0227176062471699e-05
of O 0 5.458742902142433e-10
ion O 0 2.3146360206283134e-07
channels O 0 4.5546568117060815e-07
could O 0 1.2844149921420467e-07
cause O 0 1.0571981334805969e-07
the O 0 1.9243980631244995e-08
disorder O 0 8.744942192606686e-07
by O 0 6.086764980928194e-10
studying O 0 6.2343685769405965e-09
mutations O 0 1.0949407425187019e-07
in O 0 4.254820495930289e-09
the O 0 2.975419910455912e-08
cardiac O 0 1.460984094592277e-05
sodium O 0 2.5256549633922987e-06
channel O 0 3.1777490221429616e-06
gene O 0 3.4543015772214858e-06
SCN5A O 0 2.906087138399016e-05
. O 0 1.9672782514135179e-07

We O 0 4.468696772619296e-07
have O 0 7.963634196528346e-09
now O 0 3.872174580976662e-09
identified O 0 3.526145819776616e-09
a O 0 6.205871816433728e-09
missense O 0 3.280110149717075e-06
mutation O 0 3.247355948587938e-07
, O 0 1.010460048966877e-09
a O 0 1.0544026096681591e-08
splice O 0 7.839302270440385e-05
- O 0 2.995303702846286e-06
donor O 0 1.3672188003965857e-07
mutation O 0 4.560207287340745e-07
, O 0 1.307348118650964e-09
and O 0 8.95752583218723e-10
a O 0 1.5774871187090866e-08
frameshift O 0 4.287979027139954e-05
mutation O 0 2.6732612923296983e-07
in O 0 4.273869258497598e-09
the O 0 4.245295670557425e-09
coding O 0 3.0810272733106103e-07
region O 0 7.539587620897237e-09
of O 0 1.1391937393412377e-09
SCN5A O 0 3.2165016818908043e-06
in O 0 1.3553448141578883e-08
three O 0 3.2921832371357596e-08
IVF B-Disease 1 0.9999967813491821
families O 0 8.11977827197552e-08
. O 0 1.0475434919499094e-07

We O 0 1.7606777191758738e-07
show O 0 1.756161793764477e-07
that O 0 1.5776547845902655e-09
sodium O 0 2.742575766490063e-08
channels O 0 5.819866810696794e-09
with O 0 3.5137101561666384e-10
the O 0 5.150877058213155e-09
missense O 0 2.1791167910123477e-06
mutation O 0 3.842951912247372e-07
recover O 0 2.19033125858914e-07
from O 0 1.3410731192209369e-08
inactivation O 0 1.6929926687225816e-06
more O 0 1.7096040139108482e-09
rapidly O 0 3.414460181261347e-08
than O 0 8.268665752098059e-10
normal O 0 3.409254034636433e-08
and O 0 8.385001026844918e-10
that O 0 1.8809077906301042e-10
the O 0 4.3742200972474166e-09
frameshift O 0 7.694457963225432e-06
mutation O 0 1.342399258419391e-07
causes O 0 4.806926856559812e-09
the O 0 1.234349067402718e-09
sodium O 0 4.1793052218963567e-07
channel O 0 9.377649234920682e-07
to O 0 2.6102726646826113e-09
be O 0 1.278701255991166e-09
non O 0 1.0541050698975596e-08
- O 0 4.895580332231475e-07
functional O 0 2.597325021724828e-07
. O 0 8.826132358308314e-08

Our O 0 3.6856786778116657e-07
results O 0 2.3478104083096696e-07
indicate O 0 7.493999021335185e-08
that O 0 2.7671387403671588e-09
mutations O 0 1.8778455057599786e-07
in O 0 1.7526689433111642e-08
cardiac O 0 7.717540938756429e-06
ion O 0 4.7284447646234185e-06
- O 0 3.1843808301346144e-06
channel O 0 1.0384496818005573e-06
genes O 0 4.299397460272303e-08
contribute O 0 2.454164205190068e-09
to O 0 3.547819815707953e-10
the O 0 1.0011500517492777e-09
risk O 0 6.724856227435794e-09
of O 0 6.454042300596541e-10
developing O 0 1.3101926299441402e-07
IVF B-Disease 1 0.9999994039535522
. O 0 6.437402078063315e-08
. O 0 9.07910902014919e-08

Molecular O 0 4.4873871956951916e-05
heterogeneity O 0 4.227550016366877e-05
in O 0 6.089058501856925e-07
mucopolysaccharidosis B-Disease 0 5.003590922569856e-05
IVA I-Disease 0 4.8559391871094704e-05
in O 0 3.325896216210822e-07
Australia O 0 4.854870638837383e-08
and O 0 2.356305595085928e-09
Northern O 0 1.071168824751112e-07
Ireland O 0 3.0071216770011233e-06
: O 0 1.0122230831299817e-09
nine O 0 8.654238436989203e-10
novel O 0 7.064627105535237e-09
mutations O 0 3.144768356833083e-08
including O 0 6.68176569629253e-10
T312S O 0 1.245204117594767e-07
, O 0 4.10397271721763e-10
a O 0 1.825213757911115e-09
common O 0 1.1817447465034547e-08
allele O 0 2.2711574843015114e-07
that O 0 1.7262297147269123e-09
confers O 0 7.362703513535962e-08
a O 0 9.493342645328084e-08
mild O 0 0.01898231729865074
phenotype O 0 0.0013517166953533888
. O 0 7.882078989496222e-07

Mucopolysaccharidosis B-Disease 0 0.013019428588449955
IVA I-Disease 1 0.83915776014328
( O 0 0.00030133427935652435
MPS B-Disease 1 0.9999992847442627
IVA I-Disease 1 0.9999988079071045
) O 0 4.430319577863884e-08
is O 0 3.1550764223453598e-09
an O 0 7.730553974738541e-09
autosomal B-Disease 1 0.9592887759208679
recessive I-Disease 1 0.9999995231628418
lysosomal I-Disease 1 0.9999991655349731
storage I-Disease 1 0.9999996423721313
disorder I-Disease 1 0.9995872378349304
caused O 0 1.0627281881170347e-06
by O 0 1.2539601357275387e-08
a O 0 1.5084021924849367e-06
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999998807907104
in O 0 2.127650162719874e-07
N O 0 1.900291499623563e-05
- O 0 4.989737590221921e-06
acetylgalactosamine O 0 0.00013178662629798055
- O 0 3.246803316869773e-05
6 O 0 2.0157576727797277e-06
- O 0 2.5365088731632568e-05
sulfate O 0 1.361762588203419e-05
sulfatase O 0 4.841245026909746e-05
( O 0 1.5224757987652993e-07
GALNS O 0 1.4319071851787157e-05
) O 0 1.2024334239413292e-07
. O 0 8.752487445917723e-08

Previous O 0 2.765233375612297e-06
studies O 0 7.508936050726334e-08
of O 0 1.840245067441515e-09
patients O 0 9.654542942882927e-09
from O 0 6.658128492986748e-10
a O 0 1.3008344623699486e-08
British O 0 2.0074508029210847e-06
- O 0 7.367071361841226e-07
Irish O 0 4.2195861027494175e-08
population O 0 6.59541143921416e-10
showed O 0 6.839739885577956e-09
that O 0 1.1308626257644505e-10
the O 0 9.879324025519054e-10
I113F O 0 1.2119866710236238e-07
mutation O 0 2.6432553923427804e-08
is O 0 2.2834904800372868e-10
the O 0 1.788002662594934e-10
most O 0 2.372806673367478e-10
common O 0 1.8420184266787487e-09
single O 0 3.472592169373456e-08
mutation O 0 3.3300190693807963e-07
among O 0 3.685734384362149e-08
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
patients O 0 1.6532778317923658e-05
and O 0 1.4243527246549093e-08
produces O 0 1.41972876122054e-07
a O 0 9.535081346712104e-08
severe O 0 0.0001669576740823686
clinical O 0 9.391152161697391e-06
phenotype O 0 0.0003002145094797015
. O 0 8.922039569370099e-07

We O 0 9.233416449205833e-07
studied O 0 3.3800441201492504e-07
mutations O 0 6.78192066061456e-07
in O 0 7.712555927241738e-09
the O 0 5.9477076597147516e-09
GALNS O 0 1.4234043419492082e-06
gene O 0 1.3382053509758407e-07
from O 0 6.018976872468329e-09
23 O 0 2.678114086052119e-08
additional O 0 2.615157690399883e-08
MPS B-Disease 1 0.9999984502792358
IVA I-Disease 1 0.9999997615814209
patients O 0 2.621980911499122e-06
( O 0 7.225128495491617e-09
15 O 0 4.416514265415117e-09
from O 0 1.7091703607974296e-09
Australia O 0 4.797154229407852e-09
, O 0 2.425409317829974e-10
8 O 0 3.5064280368146683e-09
from O 0 1.0339351597110635e-09
Northern O 0 9.554361213304219e-08
Ireland O 0 4.822513801627792e-07
) O 0 3.720111718674701e-10
, O 0 5.61078995764408e-11
with O 0 9.596096833819345e-11
various O 0 1.4723519070614088e-09
clinical O 0 1.4212379539912945e-07
phenotypes O 0 3.869068677886389e-06
( O 0 6.47060147684897e-08
severe O 0 6.034753459971398e-05
, O 0 7.448054617498201e-09
16 O 0 2.781183283673272e-08
cases O 0 3.3013496381073537e-09
; O 0 2.1640622627217e-09
intermediate O 0 1.9284177810163783e-08
, O 0 7.51592177383742e-10
4 O 0 1.1913427577781022e-08
cases O 0 9.708630344107405e-09
; O 0 5.846003148235468e-08
mild O 0 0.07391074299812317
, O 0 1.671643090617181e-08
3 O 0 3.046119445571094e-08
cases O 0 5.967752958468964e-09
) O 0 1.2699689300177397e-08
. O 0 6.528046725406966e-08

We O 0 3.040147191768483e-07
found O 0 1.7993146528283432e-08
two O 0 1.1647794950775392e-09
common O 0 3.3019540435219596e-09
mutations O 0 5.2488964286112605e-08
that O 0 4.394354324865901e-10
together O 0 1.0411166373458514e-09
accounted O 0 2.1562380769779566e-09
for O 0 1.1924941589747107e-10
32 O 0 2.3380712921294844e-09
% O 0 8.250418404021076e-11
of O 0 1.569884847119063e-11
the O 0 1.3262880793618592e-09
44 O 0 8.751097624326576e-09
unrelated O 0 1.7521909256856816e-08
alleles O 0 1.1599097859971153e-07
in O 0 1.0320934329399734e-08
these O 0 1.1585782999645744e-08
patients O 0 3.0526049954460177e-07
. O 0 2.0860960603386047e-07

One O 0 4.2162878344242927e-07
is O 0 8.694347464199836e-09
the O 0 3.6742984210746954e-09
T312S O 0 6.672913741567754e-07
mutation O 0 2.6052808266285865e-07
, O 0 1.3255950781498882e-09
a O 0 5.5278448485296394e-09
novel O 0 2.8944782570761163e-08
mutation O 0 9.08558774881385e-08
found O 0 3.5002938325590094e-09
exclusively O 0 1.0861127996975029e-08
in O 0 3.9589096445524774e-08
milder O 0 0.009082144126296043
patients O 0 8.612898454884999e-06
. O 0 4.1895691538229585e-07

The O 0 2.037258468590153e-07
other O 0 2.9966793491098542e-09
is O 0 5.691426219200935e-10
the O 0 1.0119219906457033e-09
previously O 0 8.999022860223249e-09
described O 0 3.232894130178465e-08
I113F O 0 1.669145888172352e-07
that O 0 1.3582087676766719e-09
produces O 0 4.627869287787689e-08
a O 0 5.700155725207878e-08
severe O 0 0.0002427534927846864
phenotype O 0 0.0003082222829107195
. O 0 6.013551683281548e-07

The O 0 9.93139906313445e-07
I113F O 0 5.6516942095186096e-06
and O 0 2.3594322939857193e-08
T312S O 0 7.719961558905197e-07
mutations O 0 4.6809924469926045e-07
accounted O 0 2.986768876667156e-08
for O 0 1.4741755594016581e-09
8 O 0 3.452166197348561e-08
( O 0 3.5947604892783147e-09
18 O 0 6.4633836061034344e-09
% O 0 2.7049087969466257e-10
) O 0 1.6595060048363308e-10
and O 0 9.476057716284458e-10
6 O 0 2.0318173810096596e-08
( O 0 1.4441852158597612e-09
14 O 0 3.6351714971516458e-09
% O 0 2.4580279478492173e-10
) O 0 2.050917352613979e-10
of O 0 2.1780534320559042e-10
44 O 0 9.294002900617215e-09
unrelated O 0 4.0172750459532836e-08
alleles O 0 2.098078653034463e-07
, O 0 9.276274859360001e-09
respectively O 0 1.614684350670359e-07
. O 0 2.3485495148634072e-07

The O 0 8.21826347419119e-07
relatively O 0 6.722389684910013e-07
high O 0 4.776122182192921e-07
residual O 0 5.653299126606726e-07
GALNS O 0 6.4192699937848374e-06
activity O 0 4.0315447336070065e-07
seen O 0 5.093152566360004e-08
when O 0 2.225940765043788e-09
the O 0 1.994734377674945e-09
T312S O 0 1.766726143159758e-07
mutant O 0 9.68586491012502e-08
cDNA O 0 1.2567477369884728e-07
is O 0 5.262045021936501e-09
overexpressed O 0 6.86898772528366e-07
in O 0 4.8430393029264e-09
mutant O 0 8.260066408638522e-08
cells O 0 2.8504407723062286e-08
provides O 0 1.5890765370230042e-09
an O 0 2.7667151902832643e-10
explanation O 0 1.5021274224480408e-09
for O 0 2.2858435977379798e-10
the O 0 8.650612670635383e-09
mild O 0 0.0075683072209358215
phenotype O 0 0.0001049286947818473
in O 0 5.597266294898873e-08
patients O 0 1.9598322964498038e-08
with O 0 2.5420312521617916e-09
this O 0 3.0030378184164874e-08
mutation O 0 3.0025566957192495e-06
. O 0 1.625905809987671e-07

The O 0 1.2311171815326816e-07
distribution O 0 3.2912414127395095e-08
and O 0 1.2658400994070007e-09
relative O 0 5.371881606208717e-09
frequencies O 0 4.505428563561509e-08
of O 0 2.525694930977096e-10
the O 0 1.7159023091295467e-09
I113F O 0 9.002494749665857e-08
and O 0 2.2450599157508577e-09
T312S O 0 1.0720600585045759e-07
mutations O 0 9.601365036360221e-08
in O 0 3.991639907496847e-09
Australia O 0 2.3954214167787313e-09
corresponded O 0 4.040456857978825e-09
to O 0 2.9354005337545175e-10
those O 0 1.1433834434804169e-10
observed O 0 1.2970258200795115e-09
in O 0 1.089026646639013e-09
Northern O 0 4.908782713641813e-08
Ireland O 0 9.930848818839877e-07
and O 0 1.4520571411935634e-09
are O 0 1.8879299165663888e-11
unique O 0 4.461263303223717e-11
to O 0 1.4099901801678527e-10
these O 0 4.22454814186235e-11
two O 0 3.21604375075335e-11
populations O 0 3.7580882850107855e-10
, O 0 5.638726638390601e-11
suggesting O 0 1.7563727139346952e-09
that O 0 8.004805152062033e-11
both O 0 3.691091321478268e-10
mutations O 0 2.5718893681414556e-08
were O 0 1.3417504884927212e-09
probably O 0 5.883686871044347e-09
introduced O 0 2.031964640991646e-08
to O 0 3.683032212542514e-10
Australia O 0 5.948498915664402e-10
by O 0 1.7947610064794617e-10
Irish O 0 3.718765739790797e-09
migrants O 0 4.4257794651336724e-10
during O 0 1.8297625636876091e-09
the O 0 1.7278635189299507e-09
19th O 0 1.413330892319209e-07
century O 0 1.9528904715571116e-07
. O 0 8.887131031087847e-08

Haplotype O 0 0.00045011815382167697
analysis O 0 3.3014380278473254e-06
using O 0 2.9520970201701857e-07
6 O 0 1.5145282361572754e-07
RFLPs O 0 5.801333031740796e-07
provides O 0 2.187421799249023e-09
additional O 0 7.722945061239272e-10
data O 0 1.6017422055369934e-08
that O 0 2.4278948296263536e-10
the O 0 1.6961896331935122e-09
I113F O 0 1.8720251659942733e-07
mutation O 0 3.89373546738625e-08
originated O 0 8.012054131256718e-09
from O 0 9.940015477383213e-10
a O 0 5.731780383655405e-09
common O 0 4.4120543662984346e-08
ancestor O 0 6.718717031617416e-07
. O 0 2.2481340522517712e-07

The O 0 2.9294866976670164e-07
other O 0 1.053825648966722e-08
9 O 0 5.010567249996711e-08
novel O 0 3.5233039596960225e-08
mutations O 0 2.6174237177656323e-07
identified O 0 1.3781885854768916e-08
in O 0 6.634527149884661e-09
these O 0 2.9869955397998638e-09
23 O 0 3.485692161575571e-07
patients O 0 9.223505514910357e-09
were O 0 1.410865202444711e-09
each O 0 2.1981233500056874e-10
limited O 0 3.0295406183711293e-09
to O 0 1.4779707457890368e-09
a O 0 4.0707330839495626e-09
single O 0 5.956520610084226e-08
family O 0 7.99553916408513e-08
. O 0 4.8497895477339625e-08

These O 0 1.4771660516998963e-07
data O 0 1.630755548376328e-07
provide O 0 2.8422904030378504e-09
further O 0 1.1412401024202268e-09
evidence O 0 3.404545811935833e-10
for O 0 3.2148617101768195e-10
extensive O 0 2.3980009089541454e-08
allelic O 0 2.675965333764907e-06
heterogeneity O 0 2.757946276688017e-06
in O 0 4.862024525209563e-06
MPS B-Disease 1 0.9999997615814209
IVA I-Disease 1 0.9999967813491821
in O 0 4.934975095238769e-07
British O 0 2.270552249683533e-05
- O 0 1.5452731531695463e-05
Irish O 0 3.0689628260915924e-07
patients O 0 1.1342530470415113e-08
and O 0 2.2583941661213913e-10
provide O 0 9.250769594792985e-11
evidence O 0 9.214352891806499e-11
for O 0 6.841077010433239e-11
their O 0 3.0975473297445433e-09
transmission O 0 0.0035803671926259995
to O 0 1.6406641600852367e-09
Australia O 0 1.1313464609585822e-09
by O 0 3.901984291232452e-10
British O 0 3.244823076897774e-08
- O 0 1.0047050835737537e-07
Irish O 0 2.560890521863257e-08
migrants O 0 1.878227351426176e-09
. O 0 1.2633750712254255e-09
. O 0 1.8823453018512737e-08

Identification O 0 2.2062083644414088e-06
of O 0 4.318274804404609e-08
constitutional O 0 3.225894147362851e-07
WT1 O 0 0.00012571168190333992
mutations O 0 5.770290954387747e-06
, O 0 2.384940689381665e-09
in O 0 3.9231125015248836e-09
patients O 0 2.115739938801653e-08
with O 0 1.4076431575915649e-08
isolated O 0 0.1269100457429886
diffuse B-Disease 1 0.9999986886978149
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 2.314653180235382e-08
and O 0 1.1303931124473365e-09
analysis O 0 2.8762769943568856e-09
of O 0 1.0709881870241134e-09
genotype O 0 0.00016570505977142602
/ O 0 0.00012319235247559845
phenotype O 0 5.870334007340716e-06
correlations O 0 2.969677268538362e-07
by O 0 2.723848480101765e-09
use O 0 7.672764645860752e-09
of O 0 3.9347633484787536e-10
a O 0 1.876838595649133e-08
computerized O 0 7.00942036928609e-05
mutation O 0 4.774924036610173e-06
database O 0 1.605532702342316e-06
. O 0 4.737011067845742e-07

Constitutional O 0 9.835851415118668e-06
mutations O 0 1.122078174375929e-05
of O 0 1.7502337357200304e-08
the O 0 5.7533611652615946e-08
WT1 O 0 2.4731867597438395e-05
gene O 0 1.0386773965365137e-06
, O 0 3.48666739924397e-09
encoding O 0 1.0389830862322924e-07
a O 0 1.0961087326677443e-07
zinc O 0 0.0002666837244760245
- O 0 1.3672804470843403e-06
finger O 0 5.295028586260742e-06
transcription O 0 3.317175583106291e-07
factor O 0 1.8411553170949446e-08
involved O 0 3.524955660694218e-09
in O 0 1.3595807146771222e-08
renal O 0 5.114899067848455e-06
and O 0 1.121609738419238e-08
gonadal O 0 2.1688067590730498e-06
development O 0 3.992333130753423e-09
, O 0 3.20948850829339e-10
are O 0 8.426617736922992e-11
found O 0 5.705969585712012e-10
in O 0 7.680125424514017e-10
most O 0 5.89335413803127e-10
patients O 0 6.295357124486145e-09
with O 0 2.9460661465918747e-08
Denys B-Disease 1 0.9999922513961792
- I-Disease 1 0.9999986886978149
Drash I-Disease 1 0.9999995231628418
syndrome I-Disease 1 1.0
( O 0 5.625349785987055e-07
DDS B-Disease 1 1.0
) O 0 5.0611664192956596e-08
, O 0 5.012208870169843e-09
or O 0 7.781214321767038e-07
diffuse B-Disease 1 0.9994590878486633
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 6.400564416253474e-06
DMS B-Disease 1 0.6478773951530457
) O 0 1.1630595153633294e-08
associated O 0 4.68801530928431e-08
with O 0 2.3737186438665958e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 3.882592409354402e-06
/ O 0 0.0010178317315876484
or O 0 2.954951924039051e-06
Wilms B-Disease 0 0.007499414030462503
tumor I-Disease 0 0.0015520798042416573
( O 0 1.6908726365727489e-06
WT B-Disease 1 0.9999685287475586
) O 0 1.8552282199379988e-07
. O 0 1.541597924870075e-07

Most O 0 9.519486638964736e-07
mutations O 0 3.440746513660997e-05
in O 0 2.888095423259074e-06
DDS B-Disease 1 1.0
patients O 0 6.015470717102289e-05
lie O 0 1.2932007109611732e-07
in O 0 4.151038623945169e-08
exon O 0 2.936680175480433e-06
8 O 0 2.559304164151399e-07
or O 0 2.9876122908945035e-08
exon O 0 1.6977365930870292e-06
9 O 0 3.66866373724406e-07
, O 0 5.319332530007159e-09
encoding O 0 7.981123530953482e-07
zinc O 0 0.001134165795519948
finger O 0 0.001020279130898416
2 O 0 4.956993393534503e-07
or O 0 2.877634699416376e-07
zinc O 0 3.4532738936832175e-05
finger O 0 3.850645589409396e-05
3 O 0 7.007165692130002e-08
, O 0 5.331365904304164e-10
respectively O 0 4.019610422290043e-09
, O 0 1.2166728735607535e-10
with O 0 2.2333095095472544e-10
a O 0 4.1499145453371966e-08
hot O 0 0.0003223882522433996
spot O 0 6.226282494026236e-06
( O 0 7.861403084064023e-09
R394W O 0 1.2819357664284325e-07
) O 0 2.4442281532088828e-09
in O 0 6.429006660368941e-09
exon O 0 2.713557250899612e-06
9 O 0 8.002234608284198e-07
. O 0 1.0743342215846496e-07

We O 0 3.556245360414323e-07
analyzed O 0 2.7880673769686837e-07
a O 0 1.1834432100954473e-08
series O 0 2.3866117970783307e-08
of O 0 1.8033233795122783e-09
24 O 0 2.3171384100351133e-07
patients O 0 1.0013205375969392e-08
, O 0 1.07289377382358e-09
10 O 0 6.744484082332747e-09
with O 0 1.1867411053856358e-08
isolated B-Disease 0 0.00022069366241339594
DMS I-Disease 1 0.997979462146759
( O 0 1.0816271611702177e-07
IDMS B-Disease 0 2.425944148853887e-05
) O 0 4.5178008001300896e-09
, O 0 6.753877457299495e-10
10 O 0 3.036540574541391e-09
with O 0 9.960174907064356e-09
DDS B-Disease 1 1.0
, O 0 1.838909113871523e-08
and O 0 6.110381089996508e-09
4 O 0 4.996233471388223e-08
with O 0 5.3639187314047376e-08
urogenital B-Disease 1 0.9889742136001587
abnormalities I-Disease 1 0.9999855756759644
and O 0 3.446736627665814e-06
/ O 0 0.11379960179328918
or O 0 7.166502473410219e-05
WT B-Disease 1 0.9999996423721313
. O 0 5.083656446913665e-07

We O 0 1.1831068604806205e-06
report O 0 1.4130898762232391e-06
WT1 O 0 0.00014046404976397753
heterozygous O 0 1.4958054634917062e-05
mutations O 0 7.819056008884218e-06
in O 0 5.1323251426538263e-08
16 O 0 2.9212790764177043e-07
patients O 0 2.9693083547499555e-08
, O 0 1.7475375591047282e-09
4 O 0 9.489719232647076e-09
of O 0 2.7568591853821545e-10
whom O 0 5.4671858151778e-09
presented O 0 1.9504497572597757e-08
with O 0 3.9403325047260296e-08
IDMS B-Disease 0 0.0019585411064326763
. O 0 6.602144253520237e-07

One O 0 2.891372616886656e-07
male O 0 9.812121248842232e-08
and O 0 4.3885020062361946e-09
two O 0 4.7727315433121476e-09
female O 0 2.395711078406748e-07
IDMS B-Disease 0 0.0007789458613842726
patients O 0 1.2426445437085931e-06
with O 0 2.6223185045637365e-07
WT1 O 1 0.5577937960624695
mutations O 0 0.007640987168997526
underwent O 0 0.0026200038846582174
normal O 0 0.0001734766410663724
puberty O 0 0.0007456507883034647
. O 0 1.695038122306869e-06

Two O 0 9.50771948282636e-07
mutations O 0 2.2368118152371608e-05
associated O 0 4.832633067053393e-07
with O 0 5.53005179426691e-08
IDMS B-Disease 0 0.00094476348021999
are O 0 2.3756832057131305e-09
different O 0 9.861006455835764e-10
from O 0 3.94379684465207e-09
those O 0 2.2159394319487546e-09
described O 0 1.458607954418767e-07
in O 0 1.0881614116442506e-06
DDS B-Disease 1 1.0
patients O 0 0.00012246923870407045
. O 0 8.026073032851855e-07

No O 0 3.640950581029756e-06
WT1 O 0 0.0002643283223733306
mutations O 0 2.9098588129272684e-05
were O 0 1.0321509336108647e-07
detected O 0 5.331870056579646e-07
in O 0 4.745644766046553e-09
the O 0 2.1414137130193467e-09
six O 0 3.3490175077588447e-09
other O 0 1.9328576517096963e-09
IDMS B-Disease 0 8.50593569339253e-05
patients O 0 6.25717220259503e-08
, O 0 1.71339709087448e-09
suggesting O 0 1.6891723930712033e-07
genetic O 0 2.0911672038437246e-07
heterogeneity O 0 1.5121297280984436e-07
of O 0 2.174658897402537e-09
this O 0 7.6851002006606e-08
disease O 0 0.00023212908126879483
. O 0 6.451143690355821e-07

We O 0 5.600714985121158e-07
analyzed O 0 3.609696705098031e-06
genotype O 0 6.150244735181332e-05
/ O 0 8.16647443571128e-05
phenotype O 0 9.795656296773814e-06
correlations O 0 6.70962492677063e-07
, O 0 3.445264296075834e-09
on O 0 2.9586347594090512e-08
the O 0 1.640701685623469e-09
basis O 0 7.187463402225092e-10
of O 0 6.282204617624743e-11
the O 0 1.4099343914608653e-09
constitution O 0 2.461773229711639e-09
of O 0 5.648414028169846e-11
a O 0 2.0402588507550945e-09
WT1 O 0 3.1057184060045984e-06
mutation O 0 6.660001616864974e-08
database O 0 1.2300910512408336e-08
of O 0 9.26062448947107e-10
84 O 0 1.8386606370768277e-07
germ O 0 4.5760323700960726e-05
- O 0 0.0012445967877283692
line O 0 0.004747894126921892
mutations O 0 9.835634955379646e-07
, O 0 3.9607483959258616e-10
to O 0 5.509179779039641e-10
compare O 0 6.536978069959787e-09
the O 0 4.298474631792004e-10
distribution O 0 1.9053685296199774e-09
and O 0 3.6238717582293134e-10
type O 0 2.085363348669489e-08
of O 0 1.8703685822352156e-10
mutations O 0 3.8577127270400524e-08
, O 0 1.6292188431688004e-10
according O 0 3.1663843769180744e-10
to O 0 1.096764568053743e-09
the O 0 6.835096932888973e-09
different O 0 1.1016273049335723e-07
symptoms O 0 0.00017029988521244377
. O 0 2.0733784822368762e-07

This O 0 6.3771409486435e-07
demonstrated O 0 5.705191483684757e-07
( O 0 4.381628926353187e-08
1 O 0 1.123804604930001e-08
) O 0 1.238381508450459e-09
the O 0 1.0283398577115577e-09
association O 0 3.0244369231269275e-09
between O 0 2.6347273252014247e-09
mutations O 0 1.2194415432986716e-07
in O 0 5.25325072331384e-09
exons O 0 5.431930958366138e-07
8 O 0 1.501848174711995e-07
and O 0 4.005329401479685e-09
9 O 0 2.093841260375484e-07
and O 0 4.390379260144073e-08
DMS B-Disease 0 0.02772407978773117
; O 0 2.3520186687164824e-08
( O 0 7.061474516234512e-09
2 O 0 1.2734496124267025e-08
) O 0 1.6728765039886184e-09
among O 0 9.143365509167722e-10
patients O 0 8.223310921096072e-09
with O 0 6.7361534128451694e-09
DMS B-Disease 0 0.021087517961859703
, O 0 1.2311630603889512e-09
a O 0 5.551501924827562e-09
higher O 0 6.240534133894471e-08
frequency O 0 7.139354920582264e-07
of O 0 1.5106494943850635e-09
exon O 0 6.798796903240145e-07
8 O 0 4.078421156350487e-08
mutations O 0 1.0837955244369368e-07
among O 0 4.1521272531319653e-10
46 O 0 1.963637785706851e-08
, O 0 4.290621635760772e-09
XY O 0 8.592167432652786e-06
patients O 0 2.1151508988737078e-08
with O 0 3.2965046248278895e-09
female O 0 4.3819298412017815e-08
phenotype O 0 4.0998310169015895e-07
than O 0 1.1226664042851553e-09
among O 0 4.222608929183025e-10
46 O 0 8.85021744778669e-09
, O 0 3.303623596906391e-09
XY O 0 8.619834261480719e-06
patients O 0 1.5127145758242477e-08
with O 0 1.110954994665292e-09
sexual O 0 4.8152344334084773e-08
ambiguity O 0 3.95661494678734e-08
or O 0 2.6716501011492255e-08
male O 0 7.785127564829963e-08
phenotype O 0 2.0036216028529452e-06
; O 0 1.4687259408674436e-08
and O 0 1.2286231587665952e-08
( O 0 5.6992397468036415e-09
3 O 0 8.26294677125361e-09
) O 0 5.715783957249698e-10
statistically O 0 2.2102324415129715e-09
significant O 0 2.723395120529659e-10
evidence O 0 1.1833409807593398e-09
that O 0 7.145881664172293e-10
mutations O 0 6.612964398300392e-08
in O 0 8.884584623558567e-09
exons O 0 3.372506398591213e-07
8 O 0 1.2590317055583e-07
and O 0 3.6290057625620875e-09
9 O 0 8.419464592179793e-08
preferentially O 0 1.2410262684170448e-07
affect O 0 1.7638431160094115e-08
amino O 0 1.7611101910119942e-08
acids O 0 5.384889867343645e-09
with O 0 1.7188397927192511e-10
different O 0 3.597659947729426e-10
functions O 0 3.585892249802214e-09
. O 0 1.6651157119795812e-09
. O 0 1.2604031596197274e-08

The O 0 3.6134849779045908e-06
185delAG O 0 0.00019578629871830344
BRCA1 O 0 0.0001697058032732457
mutation O 0 6.2546232584281825e-06
originated O 0 4.480521056393627e-07
before O 0 8.861162470452655e-09
the O 0 1.6217354126268901e-09
dispersion O 0 1.9765828085382964e-08
of O 0 1.308509967046234e-10
Jews O 0 6.268969232614552e-10
in O 0 3.887282995496122e-10
the O 0 7.002297075509034e-10
diaspora O 0 1.0816613160713473e-09
and O 0 4.1315717513867867e-10
is O 0 1.5032790290359088e-10
not O 0 4.0192252304116494e-10
limited O 0 3.728097830446586e-09
to O 0 1.0351531187779983e-08
Ashkenazim O 0 8.085211447905749e-06
. O 0 1.0755582735555436e-07

The O 0 7.446650442943792e-07
185delAG O 0 1.2414408047334291e-05
mutation O 0 6.108668912929716e-06
in O 0 7.936525747709311e-08
BRCA1 O 0 9.125050382863265e-06
is O 0 6.0519464994968075e-09
detected O 0 1.3013834632147336e-07
in O 0 4.0948187063349906e-09
Ashkenazi O 0 1.977358294880105e-07
Jews O 0 2.273747634617962e-09
both O 0 4.6455964075597933e-10
in O 0 1.3867212267371087e-08
familial B-Disease 0 0.20503900945186615
breast I-Disease 1 0.9999996423721313
and I-Disease 1 0.999998927116394
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.481140543546644e-08
in O 0 2.2395727494739504e-09
the O 0 2.7782021128075485e-09
general O 0 4.685599019893516e-09
population O 0 8.399378970125326e-09
. O 0 3.568897000150173e-08

All O 0 3.595708903958439e-07
tested O 0 4.355325927463127e-06
Ashkenazi O 0 5.664865966537036e-06
mutation O 0 1.3719878779738792e-06
carriers O 0 1.1356389251204746e-07
share O 0 3.2301450403338094e-08
the O 0 3.4354410427539506e-09
same O 0 1.539384797411003e-08
allelic O 0 7.896208558122453e-07
pattern O 0 8.497773933413555e-07
at O 0 5.863669727546039e-08
the O 0 3.932328951350428e-08
BRCA1 O 0 1.8686303519643843e-05
locus O 0 7.347604878304992e-06
. O 0 5.632215334117063e-07

Our O 0 5.953697836957872e-07
previous O 0 1.9049612376420555e-07
study O 0 1.4148272775571513e-08
showed O 0 3.1894696661538546e-08
that O 0 3.426585404309179e-10
this O 0 1.2201126775579496e-09
Ashkenazi O 0 1.1377923101463239e-06
mutation O 0 1.2577932295698702e-07
also O 0 5.022869675741504e-09
occurs O 0 2.8802902285463006e-09
in O 0 9.626698327380723e-10
Iraqi O 0 2.6528303997963576e-09
Jews O 0 4.67686445126958e-10
with O 0 1.3747872285030382e-10
a O 0 2.1785031556476042e-09
similar O 0 5.706998607024616e-08
allelic O 0 7.261795417434769e-06
pattern O 0 1.776800854713656e-05
. O 0 3.6559015370585257e-07

We O 0 3.7319986745387723e-07
extended O 0 1.2875484856067487e-07
our O 0 7.390262179995943e-09
analysis O 0 3.844093487970213e-09
to O 0 4.745542847572892e-10
other O 0 3.185824382079261e-10
non O 0 3.15110715298772e-09
- O 0 1.6478664122132614e-07
Ashkenazi O 0 7.947384688122838e-07
subsets O 0 4.096812844522901e-08
354 O 0 2.2863256177174662e-08
of O 0 3.290045735848679e-10
Moroccan O 0 2.901122009291157e-08
origin O 0 2.546816535442531e-09
, O 0 3.213414812019977e-10
200 O 0 1.8421237868437856e-09
Yemenites O 0 1.487576497538612e-07
and O 0 1.3703373991091894e-09
150 O 0 7.718781169785416e-09
Iranian O 0 3.7333865776645325e-08
Jews O 0 5.316504925190202e-08
. O 0 7.80567575020541e-08

Heteroduplex O 0 0.0005966830067336559
analysis O 0 2.045647079285118e-06
complemented O 0 5.453877633954107e-07
by O 0 2.9245434962632544e-09
direct O 0 8.465159240245157e-09
DNA O 0 4.9045809191738954e-08
sequencing O 0 7.667018309120976e-08
of O 0 1.7216393866092972e-09
abnormally O 0 1.60653894454299e-06
migrating O 0 5.0344009849823124e-08
bands O 0 8.650566485357558e-08
were O 0 8.138705709370697e-09
employed O 0 6.192701818008572e-08
. O 0 4.1678816842249944e-08

Four O 0 1.2122397663461015e-07
of O 0 3.389554636967773e-09
Moroccan O 0 1.1827034995803842e-07
origin O 0 1.1740745264887664e-08
( O 0 3.996965425301369e-09
1 O 0 1.694773321680998e-09
. O 0 1.799553145387378e-10
1 O 0 1.6481414011337847e-09
% O 0 1.9834919817718344e-10
) O 0 1.6176135431145156e-10
and O 0 3.5217145866184296e-10
none O 0 4.861287483670651e-10
of O 0 5.757501767011952e-11
the O 0 2.4977282464533346e-09
Yemenites O 0 2.929648985627864e-07
or O 0 1.6627352827924824e-09
Iranians O 0 1.2612274558065906e-09
was O 0 9.790875887816242e-10
a O 0 4.4691009226660583e-10
carrier O 0 7.676277391510666e-09
of O 0 2.0572955838904505e-10
the O 0 8.841881893317804e-09
185delAG O 0 3.361990593475639e-06
mutation O 0 2.886682750613545e-06
. O 0 1.0675139350269092e-07

BRCA1 O 0 0.005955335218459368
allelic O 0 0.0005145197501406074
patterns O 0 0.0016504491213709116
were O 0 8.87310704911215e-08
determined O 0 2.3249095093547112e-08
for O 0 5.095887600781168e-10
four O 0 2.8256297301965105e-10
of O 0 4.4739087434741975e-11
these O 0 9.847167525833811e-11
individuals O 0 4.182249338513522e-11
and O 0 1.7284591813382377e-10
for O 0 2.041297270105602e-10
12 O 0 2.5434911954391737e-09
additional O 0 1.0901614055924824e-09
non O 0 9.800184663788514e-09
- O 0 1.605044303687464e-06
Ashkenazi O 0 5.893185516470112e-06
185delAG O 0 1.1582466186155216e-06
mutation O 0 3.6984246776228247e-07
carriers O 0 1.451806355134977e-07
who O 0 9.019957758482633e-08
had O 0 0.024185482412576675
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.4540029244235484e-06

Six O 0 8.941877354118333e-07
non O 0 3.9735027712595183e-07
- O 0 2.688796712391195e-06
Ashkenazi O 0 8.167902706190944e-06
individuals O 0 1.7864014711932441e-09
shared O 0 1.561209050926493e-09
the O 0 1.1939603750121819e-09
common O 0 2.9158448100474743e-08
Ashkenazi O 0 6.9341213020379655e-06
haplotype O 0 5.308801064529689e-06
, O 0 2.3206550014975846e-09
four O 0 1.2656373726827042e-09
had O 0 7.377094934923889e-09
a O 0 2.763156814467038e-09
closely O 0 6.802105190217844e-08
related O 0 1.824828466112649e-08
pattern O 0 3.935922904929612e-06
, O 0 7.198988627443725e-10
and O 0 6.112546024894527e-10
the O 0 3.2207494449210117e-09
rest O 0 1.8265033929765195e-08
( O 0 5.69497959901355e-09
n O 0 3.4288970596207946e-07
= O 0 2.2666912968816177e-07
6 O 0 4.1754962154527675e-08
) O 0 1.124524473539168e-09
displayed O 0 3.071656351494312e-08
a O 0 1.76651298033903e-08
distinct O 0 3.5165035683348833e-07
BRCA1 O 0 3.5458393540466204e-05
allelic O 0 2.696153569559101e-05
pattern O 0 7.343984907492995e-05
. O 0 5.875469355487439e-07

We O 0 2.4626487515888584e-07
conclude O 0 1.342614268651232e-07
that O 0 1.660903192757246e-09
the O 0 6.795410900650722e-09
185delAG O 0 5.737947958550649e-06
BRCA1 O 0 9.021417099575046e-06
mutation O 0 2.6121747964680253e-07
occurs O 0 1.211089628583295e-08
in O 0 1.0769676261901395e-09
some O 0 2.595437198493755e-10
non O 0 3.350672184154746e-09
- O 0 2.483476464476553e-07
Ashkenazi O 0 9.80532718131144e-07
populations O 0 1.1245229636358545e-08
at O 0 7.773198262839287e-08
rates O 0 3.693726057463209e-06
comparable O 0 2.0476750961506696e-08
with O 0 5.496437749386018e-10
that O 0 9.599250283542915e-10
of O 0 3.7188225832096578e-09
Ashkenazim O 0 1.4809344975219574e-05
. O 0 1.0591762134026794e-07

The O 0 2.09151821195519e-07
majority O 0 5.3537181798901656e-08
of O 0 1.762816559391922e-09
Jewish O 0 1.0005438610960482e-07
185delAG O 0 2.6932441414828645e-06
mutation O 0 7.552961278634029e-07
carriers O 0 1.1645117581338127e-07
have O 0 2.744201754723008e-09
a O 0 4.9819850467258675e-09
common O 0 2.0937488187655617e-08
allelic O 0 2.138961008313345e-06
pattern O 0 1.07815649244003e-05
, O 0 1.0835671249154188e-09
supporting O 0 1.0149083795596425e-09
the O 0 1.4776493362234078e-09
founder O 0 2.1786746629004483e-08
effect O 0 3.0813074314295363e-09
notion O 0 1.2675651639426633e-09
, O 0 1.1071594335776425e-10
but O 0 1.20486745580628e-10
dating O 0 5.1272541767843904e-09
the O 0 4.2460143734324163e-10
mutations O 0 8.145958574345968e-09
origin O 0 3.6452368901152e-10
to O 0 1.8265047807553003e-10
an O 0 1.2315218289593588e-10
earlier O 0 9.715705573398736e-09
date O 0 1.0798436811398915e-08
than O 0 1.2201104571119004e-09
currently O 0 2.960868883405965e-09
estimated O 0 1.152723783093279e-08
. O 0 4.1919907545207025e-08

However O 0 9.916028602674487e-07
, O 0 1.0487705814909987e-08
the O 0 2.7043633998857786e-09
different O 0 1.7072154800956696e-09
allelic O 0 4.872562158197979e-07
pattern O 0 1.1841204923257465e-06
at O 0 5.7845113587973174e-08
the O 0 2.193393200400351e-08
BRCA1 O 0 3.1508948268310633e-06
locus O 0 2.779972305688716e-07
even O 0 3.5938692022341456e-09
in O 0 6.259327500757195e-10
some O 0 1.4387571689589151e-10
Jewish O 0 1.1129980492796676e-08
mutation O 0 7.454936934436773e-08
carriers O 0 9.00278251947384e-09
, O 0 6.164448396184241e-10
might O 0 1.917311420740475e-09
suggest O 0 1.9991106547934123e-09
that O 0 1.8205224827649857e-10
the O 0 1.504355306991556e-09
mutation O 0 4.435967682070441e-08
arose O 0 9.571757608739517e-09
independently O 0 2.9978014737253034e-08
. O 0 5.084734411298086e-09
. O 0 4.123734242966748e-08

Crystal O 0 7.99625413492322e-05
structure O 0 1.4754456287846551e-06
of O 0 1.6502184507771744e-08
the O 0 3.3148353395517915e-07
hemochromatosis B-Disease 1 1.0
protein O 0 2.317775033588987e-05
HFE O 0 0.000255575287155807
and O 0 2.7553429760018844e-08
characterization O 0 4.828781996479847e-08
of O 0 5.451480378226847e-10
its O 0 3.951514671030054e-09
interaction O 0 5.092576582654829e-09
with O 0 7.500588594666624e-09
transferrin O 0 5.286793566483539e-06
receptor O 0 1.6835289216032834e-06
. O 0 2.9276770874275826e-07

HFE O 0 0.0045987763442099094
is O 0 2.576923350261495e-07
an O 0 2.8701791165985924e-08
MHC O 0 8.292984603031073e-06
- O 0 1.7365258599966182e-06
related O 0 9.55359524823507e-08
protein O 0 8.512311211461565e-08
that O 0 5.244797929293554e-10
is O 0 1.835522289717062e-10
mutated O 0 2.8056279077759427e-08
in O 0 2.6269946218349105e-09
the O 0 3.4124422398917886e-08
iron B-Disease 1 0.9903444647789001
- I-Disease 1 0.9990621209144592
overload I-Disease 1 0.9999563694000244
disease I-Disease 1 0.9999980926513672
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 3.0106712074484676e-05

HFE O 0 0.002254652790725231
binds O 0 1.5679019270464778e-05
to O 0 5.120475066178187e-07
transferrin O 0 2.2000665921950713e-05
receptor O 0 5.530902399186743e-06
( O 0 1.465511445530865e-07
TfR O 0 4.324862857174594e-06
) O 0 3.0405105100328456e-09
and O 0 6.762037041418978e-10
reduces O 0 1.2399989479661144e-08
its O 0 3.305243190254714e-09
affinity O 0 2.342165394964013e-08
for O 0 2.7183937323371765e-09
iron O 0 7.415875188598875e-06
- O 0 3.9383795069625194e-07
loaded O 0 2.1320823861969984e-07
transferrin O 0 1.0968361721097608e-06
, O 0 7.655062361777709e-09
implicating O 0 2.6524933218752267e-06
HFE O 0 6.868108903290704e-05
in O 0 1.1913886055481271e-07
iron O 0 0.00011839727085316554
metabolism O 0 6.017685154802166e-05
. O 0 2.189439527455761e-07

The O 0 5.054697339801351e-06
2 O 0 2.455168669257546e-06
. O 0 5.642257860927202e-07

6 O 0 1.7166505131172016e-05
A O 0 1.1479800150482333e-06
crystal O 0 9.559074896969832e-06
structure O 0 2.4153965227924346e-07
of O 0 8.372747828389038e-09
HFE O 0 5.292850255500525e-05
reveals O 0 3.042966625343979e-07
the O 0 4.149065979675015e-09
locations O 0 5.4025356632791954e-08
of O 0 3.0737485445797574e-08
hemochromatosis B-Disease 1 1.0
mutations O 0 0.00010370448580943048
and O 0 4.696768485246139e-08
a O 0 5.281434027892828e-07
patch O 0 0.12466999888420105
of O 0 2.996421999412746e-09
histidines O 0 8.160632205544971e-06
that O 0 2.1662138749434234e-09
could O 0 2.7646749334309106e-09
be O 0 3.802380077466694e-10
involved O 0 7.863273920882818e-10
in O 0 1.2709938879140736e-08
pH O 0 4.344283752288902e-06
- O 0 6.336034061860119e-07
dependent O 0 1.4580169249711616e-07
interactions O 0 2.751992838057049e-07
. O 0 8.907682769176972e-08

We O 0 6.201578912623518e-07
also O 0 3.4403608850652745e-08
demonstrate O 0 1.8997411643795203e-08
that O 0 3.902439704717153e-09
soluble O 0 5.986132691759849e-07
TfR O 0 3.816796834144043e-06
and O 0 9.141923662525642e-09
HFE O 0 2.131783367076423e-05
bind O 0 5.74163038891129e-07
tightly O 0 2.326731873836252e-06
at O 0 7.286411118911928e-08
the O 0 4.119479424247174e-09
basic O 0 8.47394687752967e-09
pH O 0 3.522544744782863e-08
of O 0 4.862490271539954e-11
the O 0 8.20783996324792e-10
cell O 0 9.451770210944233e-08
surface O 0 5.18342275768191e-08
, O 0 5.35722688432827e-10
but O 0 1.769391022587996e-10
not O 0 2.3179112795812529e-10
at O 0 6.241507755078146e-09
the O 0 1.544829153488081e-08
acidic O 0 1.27007513128774e-06
pH O 0 8.62205070006894e-07
of O 0 3.742889109759062e-09
intracellular O 0 2.162858208976104e-06
vesicles O 0 1.1042901860491838e-05
. O 0 5.650415459967917e-07

TfR O 0 0.035896237939596176
HFE O 0 0.006764568388462067
stoichiometry O 0 0.00015742755203973502
( O 0 1.129320366999309e-06
2 O 0 2.7681915071298135e-07
1 O 0 3.2491641377419e-08
) O 0 6.558158460734376e-09
differs O 0 6.650746797731699e-08
from O 0 3.588959529565727e-08
TfR O 0 8.299091859953478e-06
transferrin O 0 1.1964342547798879e-06
stoichiometry O 0 6.120835678302683e-07
( O 0 1.7115397099587426e-08
2 O 0 1.4777232770768478e-08
2 O 0 1.0012784379398454e-08
) O 0 1.041720487648945e-09
, O 0 3.0621474800263115e-10
implying O 0 7.029719917284183e-09
a O 0 1.004231031664915e-09
different O 0 3.8826150627890854e-10
mode O 0 5.442340800243528e-09
of O 0 9.031547731908063e-11
binding O 0 3.76765685317082e-09
for O 0 5.660787394390354e-10
HFE O 0 1.8104412902175682e-06
and O 0 2.9538067547463243e-09
transferrin O 0 1.8713522820235085e-07
to O 0 1.2964477491550497e-08
TfR O 0 8.366810106963385e-07
, O 0 3.527509673251217e-10
consistent O 0 3.244691404447053e-09
with O 0 4.018979871123207e-10
our O 0 2.572800861244673e-09
demonstration O 0 6.4021592471874555e-09
that O 0 5.335923924931762e-10
HFE O 0 9.544357908453094e-07
, O 0 1.106655433957826e-09
transferrin O 0 1.0217714674354283e-07
, O 0 8.438910126251642e-10
and O 0 2.5392208335972555e-09
TfR O 0 9.121588959715154e-07
form O 0 8.656058980704984e-09
a O 0 3.202050535833223e-08
ternary O 0 7.133032227102376e-07
complex O 0 7.176031431299634e-07
. O 0 2.2729169302238006e-07

Identification O 0 1.7500186686447705e-06
of O 0 8.2110851451489e-09
three O 0 5.0956958652648154e-09
novel O 0 5.30957393607423e-08
mutations O 0 1.5145947429573425e-07
and O 0 1.0224002755521155e-09
a O 0 6.1530220918371015e-09
high O 0 2.841989044100046e-07
frequency O 0 1.531059069748153e-06
of O 0 3.2612806899479097e-10
the O 0 3.957488559080957e-09
Arg778Leu O 0 1.1537398449945613e-06
mutation O 0 7.73610295823346e-08
in O 0 4.136596842840845e-09
Korean O 0 3.2290486728925316e-08
patients O 0 3.7187817270023515e-08
with O 0 1.545418548687394e-08
Wilson B-Disease 0 6.873415259178728e-05
disease I-Disease 0 9.774960926733911e-05
. O 0 2.686156790332461e-07

Four O 0 2.622316287670401e-06
mutations O 0 3.8588757888646796e-05
- O 0 1.2953947589267045e-05
- O 0 2.123435024259379e-06
R778L O 0 3.2132059004652547e-06
, O 0 7.341525609660948e-09
A874V O 0 1.7805793106617784e-07
, O 0 1.4825501937210106e-09
L1083F O 0 4.434766864847006e-08
, O 0 3.8934716561911387e-10
and O 0 8.703004428234351e-10
2304delC O 0 4.956643238074321e-07
- O 0 8.599484431215387e-07
- O 0 3.018313066149858e-07
in O 0 4.504868034160836e-09
the O 0 4.96174834552221e-09
copper O 0 2.578912301487435e-07
- O 0 8.822424568677434e-09
transporting O 0 3.4583595986958926e-09
enzyme O 0 1.525079262876261e-08
, O 0 1.1444292180584625e-09
P O 0 1.4924975175745203e-06
- O 0 2.8522254069685005e-07
type O 0 2.9836514841008466e-06
ATPase O 0 1.2682207852776628e-06
( O 0 1.158967322112403e-08
ATP7B O 0 6.228078177628049e-07
) O 0 6.905448435290396e-10
, O 0 1.1330540672371825e-10
were O 0 1.143643027501362e-10
identified O 0 4.1728967503651404e-10
in O 0 1.0674457984194419e-09
Korean O 0 1.4372036005738664e-08
Patients O 0 3.0761061253770094e-08
with O 0 1.7307998589899398e-08
Wilson B-Disease 0 4.123468534089625e-05
disease I-Disease 0 3.8889775169081986e-05
. O 0 2.068488385020828e-07

Arg778Leu O 0 0.00036468025064095855
, O 0 7.037704818912971e-08
the O 0 6.303070954061241e-09
most O 0 1.5905017303197155e-09
frequently O 0 4.164933287142958e-08
reported O 0 1.3839736823229032e-07
mutation O 0 3.89385448329449e-08
of O 0 1.5305737233184402e-10
this O 0 2.452600067481825e-10
enzyme O 0 8.63332161316066e-09
, O 0 5.014137438585919e-10
was O 0 1.0704108710513083e-08
found O 0 5.381909362611736e-10
in O 0 3.445571328253294e-10
six O 0 2.345730831798676e-10
of O 0 8.156646885693064e-11
eight O 0 3.083059363362395e-09
unrelated O 0 4.471859327281891e-08
patients O 0 1.823756612395755e-08
studied O 0 8.79643202722491e-09
, O 0 1.9556406494203316e-10
an O 0 3.196774511771139e-10
allele O 0 6.200939850486975e-08
frequency O 0 2.1056357013549132e-07
of O 0 1.981133701534077e-09
37 O 0 1.6506534450400068e-07
. O 0 4.152970944915069e-08

5 O 0 3.3071573852794245e-06
% O 0 2.3204039578672564e-08
, O 0 7.817260172515716e-10
which O 0 5.079497378268627e-10
is O 0 1.200811255985812e-10
considerably O 0 2.1244098036277137e-08
higher O 0 1.7960710252395984e-08
than O 0 2.905621299120753e-10
those O 0 1.1238528163648454e-10
in O 0 1.8306448024141275e-10
other O 0 2.444898172804244e-10
Asian O 0 7.3352133256321395e-09
populations O 0 2.9707246440580093e-08
. O 0 2.9712005300552846e-08

The O 0 3.2850141451490344e-07
novel O 0 3.4223373290842574e-07
single O 0 3.592034047983361e-08
nucleotide O 0 4.741033308164333e-07
deletion O 0 5.135370884090662e-07
, O 0 2.54425791545998e-09
2304delC O 0 1.1817136424951968e-07
, O 0 1.565443108475506e-09
was O 0 1.0027117802735575e-08
found O 0 9.171609582914186e-10
in O 0 1.8584496164208986e-09
one O 0 9.076456919387965e-09
patient O 0 4.4435893187255715e-07
. O 0 1.6778007250195515e-07

Since O 0 2.4990383735712385e-06
a O 0 1.9478144963613886e-07
mutation O 0 1.997125991692883e-06
at O 0 2.50621013719865e-07
cDNA O 0 6.045596819603816e-06
nucleotide O 0 1.8486032786313444e-05
2302 O 0 0.00022671888291370124
( O 0 7.076119601379105e-08
2302insC O 0 1.0699524182200548e-06
) O 0 5.139591419123235e-09
had O 0 8.20530843270717e-09
been O 0 6.860131351871246e-10
previously O 0 4.445960932741855e-09
described O 0 3.2989011522488454e-09
, O 0 1.0482435058856154e-10
this O 0 1.712762431882453e-10
region O 0 1.0557544838363242e-09
of O 0 9.635860859225076e-11
the O 0 4.141009757319125e-09
ATP7B O 0 4.156888735451503e-06
gene O 0 4.0680345136934193e-07
may O 0 5.069668773671765e-08
be O 0 1.0716134646315822e-09
susceptible O 0 1.3004057564103277e-07
to O 0 1.2701651286306515e-08
gene O 0 4.592933237290708e-06
rearrangements O 0 7.559883670182899e-05
causing O 0 9.6157229563687e-05
Wilson B-Disease 0 0.00040048506343737245
disease I-Disease 0 0.0010293296072632074
. O 0 7.337986289712717e-07

Disruption O 0 6.246966950129718e-05
of O 0 4.99169914291997e-08
splicing O 0 3.8646617213089485e-06
regulated O 0 4.511775273385865e-07
by O 0 5.331277197484496e-09
a O 0 8.961102082594152e-09
CUG O 0 6.1824152908229735e-06
- O 0 2.6228036631437135e-07
binding O 0 2.9671070933545707e-07
protein O 0 1.2404955214151414e-06
in O 0 2.274504822707968e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 2.958933691843413e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999815225601196
DM B-Disease 1 1.0
) O 0 7.072084713399818e-07
is O 0 5.803372449264543e-09
caused O 0 3.100403844769062e-08
by O 0 4.248762675018725e-09
a O 0 1.872365729127523e-08
CTG O 0 1.1612306707320386e-06
expansion O 0 1.6831576132858572e-08
in O 0 3.6989724616631747e-09
the O 0 4.621075522237561e-09
3 O 0 1.0498212965615039e-08
untranslated O 0 1.7260535400964727e-07
region O 0 7.3638095621220145e-09
of O 0 2.251767217131828e-09
the O 0 3.7847803469048813e-07
DM B-Disease 1 1.0
gene O 0 2.0990300981793553e-05
. O 0 4.311131931444834e-07

One O 0 4.502727222188696e-07
model O 0 7.59203089728544e-07
of O 0 6.07255401519069e-08
DM B-Disease 1 1.0
pathogenesis O 0 2.5722441932884976e-05
suggests O 0 8.650121685604972e-08
that O 0 1.930323012544477e-09
RNAs O 0 4.935360493618646e-07
from O 0 3.6157539184955567e-09
the O 0 2.332877224731078e-09
expanded O 0 1.5637011685498692e-08
allele O 0 5.978749584301113e-08
create O 0 3.109658974764784e-09
a O 0 3.9639624915821514e-09
gain O 0 5.050934603900714e-08
- O 0 6.458038370737995e-08
of O 0 9.581306859018923e-10
- O 0 1.7993529866089375e-07
function O 0 9.273320777936078e-09
mutation O 0 8.398994388869596e-09
by O 0 3.0415006624373575e-10
the O 0 5.850704365428783e-10
inappropriate O 0 1.387594394941516e-08
binding O 0 5.287378090912398e-09
of O 0 1.4980923446206162e-10
proteins O 0 3.282055738296208e-09
to O 0 3.3059115445155385e-09
the O 0 2.9689797287346664e-08
CUG O 0 7.368171645794064e-05
repeats O 0 3.205313259968534e-05
. O 0 2.471881543897325e-07

Data O 0 9.326836334366817e-06
presented O 0 1.711240003032799e-07
here O 0 4.104914630431722e-09
indicate O 0 8.783924698718693e-09
that O 0 3.87415238778388e-10
the O 0 1.5061699665253059e-09
conserved O 0 4.674104658874967e-08
heterogeneous O 0 1.6026537252855633e-07
nuclear O 0 2.9534459144997527e-07
ribonucleoprotein O 0 1.5930094150462537e-06
, O 0 4.906402839566226e-09
CUG O 0 2.1652126633853186e-06
- O 0 2.1021484997163498e-07
binding O 0 1.0336817268807863e-07
protein O 0 1.1354180884382004e-07
( O 0 1.1433890279022307e-08
CUG O 0 9.129194040724542e-06
- O 0 3.1289573598769493e-06
BP O 0 1.2462429594961577e-06
) O 0 2.7427993209983015e-09
, O 0 4.727447322494527e-10
may O 0 6.578152245140245e-09
mediate O 0 5.503472522150332e-08
the O 0 1.3846491064839483e-08
trans O 0 1.887304847514315e-06
- O 0 1.5746726376164588e-06
dominant O 0 1.4614080612318503e-07
effect O 0 2.15436450901052e-08
of O 0 3.2564570484616695e-10
the O 0 3.773561907394196e-09
RNA O 0 7.188744461927854e-07
. O 0 8.529099204679369e-08

CUG O 0 0.004136085044592619
- O 0 0.0012772754998877645
BP O 0 1.8396392988506705e-05
was O 0 4.1498353198221594e-08
found O 0 7.890633146878656e-10
to O 0 6.131813390375385e-10
bind O 0 1.1685228784585888e-08
to O 0 1.1785770137606733e-09
the O 0 4.584466584134361e-09
human O 0 5.6495110811738414e-08
cardiac O 0 0.000501414411701262
troponin O 0 0.012796156108379364
T O 0 0.00023927949951030314
( O 0 3.3109994745927906e-08
cTNT O 0 2.899059552419203e-07
) O 0 3.088691968855528e-09
pre O 0 6.694910439364321e-07
- O 0 9.215013960783836e-07
messenger O 0 4.133302979880682e-07
RNA O 0 2.2464452342774166e-07
and O 0 2.0590160687561365e-09
regulate O 0 5.7989826274251755e-08
its O 0 1.175885344650851e-08
alternative O 0 7.360302589631829e-08
splicing O 0 3.1803137972019613e-06
. O 0 1.633748780704991e-07

Splicing O 0 7.17756847734563e-05
of O 0 3.011832063748443e-07
cTNT O 0 1.818037526390981e-05
was O 0 1.0679176511985133e-06
disrupted O 0 4.132242611376569e-05
in O 0 3.912984539056197e-06
DM B-Disease 1 1.0
striated O 1 0.8544259667396545
muscle O 0 0.011632845737040043
and O 0 1.6885950415712614e-08
in O 0 4.7544510550778796e-09
normal O 0 1.1414415013177859e-07
cells O 0 1.2288603556953603e-07
expressing O 0 2.29741576873721e-08
transcripts O 0 1.609690656323437e-07
that O 0 5.446899375982639e-09
contain O 0 1.8274204194312915e-07
CUG O 0 5.422495087259449e-05
repeats O 0 1.6892681742319837e-05
. O 0 2.94398887490388e-07

Altered O 0 2.8521937565528788e-05
expression O 0 6.209757543729211e-07
of O 0 1.5866302049971637e-08
genes O 0 4.2220256091241026e-07
regulated O 0 7.922344593680464e-07
posttranscriptionally O 0 2.504977601347491e-06
by O 0 1.0681347362151428e-08
CUG O 0 3.4701533877523616e-05
- O 0 5.170328222448006e-06
BP O 0 1.3447148603518144e-06
therefore O 0 8.404716034249304e-09
may O 0 1.252229697712437e-08
contribute O 0 2.6324968871449528e-09
to O 0 5.851011763979841e-08
DM B-Disease 1 1.0
pathogenesis O 0 1.7316080629825592e-05
. O 0 3.4792883241152595e-08
. O 0 7.68672734352549e-08

Identification O 0 2.060299721051706e-06
of O 0 2.5651434754081492e-08
a O 0 5.855511275854042e-08
novel O 0 2.513544359317166e-07
nonsense O 0 1.570461336086737e-06
mutation O 0 5.082565621705726e-07
and O 0 3.968759099137742e-09
a O 0 9.017545821166095e-09
missense O 0 6.452337402151898e-07
substitution O 0 4.510424389536638e-08
in O 0 7.103703403288364e-09
the O 0 8.881196222887411e-09
vasopressin O 0 1.1281566685283906e-06
- O 0 9.116397450270597e-07
neurophysin O 0 1.3365923905439558e-06
II O 0 1.2683136674240814e-07
gene O 0 2.4006551413435773e-08
in O 0 8.213273949841948e-10
two O 0 5.99897409525596e-10
Spanish O 0 5.2646178971826885e-08
kindreds O 0 1.9215171960240696e-06
with O 0 5.833506122598919e-08
familial B-Disease 0 0.0052614458836615086
neurohypophyseal I-Disease 1 0.9996083378791809
diabetes I-Disease 1 0.9999794960021973
insipidus I-Disease 1 0.8584585785865784
. O 0 4.939249720337102e-06

Familial B-Disease 1 0.9998925924301147
neurohypophyseal I-Disease 1 0.9999964237213135
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.999998927116394
( O 0 0.0012538287555798888
FNDI B-Disease 1 1.0
) O 0 8.679025853552957e-08
is O 0 1.9175234733381785e-09
an O 0 5.3671298516633215e-09
autosomal B-Disease 1 0.9205395579338074
dominant I-Disease 1 0.9981222748756409
disease I-Disease 1 0.9804589748382568
caused O 0 1.2315193089307286e-05
by O 0 1.3341799842692126e-07
deficiency O 0 0.0008991521317511797
in O 0 8.06968891708948e-09
the O 0 8.899123571382006e-08
antidiuretic O 0 7.617065421072766e-05
hormone O 0 1.2362942470645066e-05
arginine O 0 9.112145562539808e-06
vasopressin O 0 4.237792381900363e-06
( O 0 7.55693960741155e-08
AVP O 0 9.120466870626842e-07
) O 0 4.054336866232688e-09
encoded O 0 1.1072176064885753e-08
by O 0 2.4877058191208334e-09
the O 0 1.87964364073423e-08
AVP O 0 9.541514373268e-06
- O 0 5.208792117628036e-06
neurophysin O 0 2.9946757422294468e-05
II O 0 1.3635025425173808e-05
( O 0 7.464469575779731e-08
AVP O 0 3.1148958896665135e-06
- O 0 1.0970998118864372e-06
NPII O 0 4.490754690777976e-06
) O 0 8.014345631579545e-09
gene O 0 9.900213626679033e-08
on O 0 5.510099754246767e-08
chromosome O 0 4.233761046634754e-06
20p13 O 0 4.980058292858303e-06
. O 0 2.6376204687039717e-07

In O 0 1.860437066625309e-07
this O 0 5.097601007975072e-09
study O 0 3.1033782210698746e-09
, O 0 4.823373367379702e-10
we O 0 2.897601603102373e-10
analyzed O 0 4.910428508253517e-09
two O 0 2.615244965031849e-10
families O 0 4.428490352204051e-10
with O 0 1.31374233713899e-09
FNDI B-Disease 1 0.9999979734420776
using O 0 6.143947217651657e-08
direct O 0 2.0486165652755517e-08
automated O 0 3.5255604871053947e-06
fluorescent O 0 2.800725496854284e-06
, O 0 6.089238557827059e-10
solid O 0 6.545537001301227e-09
phase O 0 5.469355635057127e-09
, O 0 2.6850521805954486e-10
single O 0 2.7918647393931906e-09
- O 0 3.47062574235224e-08
stranded O 0 7.784322519910347e-09
DNA O 0 1.996532006387497e-08
sequencing O 0 2.2534653254524528e-08
of O 0 1.5692397381528167e-09
PCR O 0 4.901935608359054e-05
- O 0 1.1395612091291696e-05
amplified O 0 3.4733318898361176e-05
AVP O 0 1.2880332178610843e-05
- O 0 2.2463605091616046e-06
NPII O 0 1.7181720977532677e-05
DNA O 0 2.385839252383448e-06
. O 0 3.3107789931818843e-07

In O 0 3.209902672551834e-07
one O 0 2.17872342389569e-09
of O 0 5.668812641523857e-11
the O 0 4.284780030783253e-10
families O 0 7.538045188049125e-10
, O 0 3.046935481698654e-10
affected O 0 3.207941690064331e-09
individuals O 0 1.345473454872348e-10
presented O 0 2.541318711024587e-09
a O 0 9.505280118560222e-09
novel O 0 6.283663367412373e-08
nonsense O 0 2.6788148943523993e-07
mutation O 0 1.329597125732107e-07
in O 0 8.91641516176378e-09
exon O 0 2.294871990216052e-07
3 O 0 7.538049295874316e-09
of O 0 6.872844654504107e-11
the O 0 9.256881372543546e-10
gene O 0 2.165450752045217e-08
, O 0 1.3043910396248748e-10
consisting O 0 2.204379179193694e-10
in O 0 9.204960127462414e-10
a O 0 9.93801041460074e-09
G O 0 5.884446636628127e-06
to O 0 1.3142542165667237e-08
T O 0 6.375325938279275e-06
transition O 0 4.264393282937817e-08
at O 0 2.7575667971291296e-08
nucleotide O 0 1.0587520193894306e-07
2101 O 0 1.4767704215046251e-06
, O 0 5.824838944512578e-10
which O 0 6.047073952686333e-10
produces O 0 3.920876068264079e-09
a O 0 2.998869153003625e-09
stop O 0 3.880005650103158e-08
signal O 0 1.850423132054857e-06
in O 0 4.0639005050024934e-08
codon O 0 2.775386519715539e-06
82 O 0 4.7524591195724497e-07
( O 0 4.750936355435442e-08
Glu O 0 1.8302038370165974e-05
) O 0 1.5194087765735276e-08
of O 0 1.1672598887457752e-08
NPII O 0 5.080376286059618e-05
. O 0 2.8284347308726865e-07

The O 0 7.66351877246052e-06
premature O 0 0.00017811651923693717
termination O 0 2.470345634719706e-06
eliminates O 0 4.6024166522329324e-07
part O 0 5.461140872853321e-09
of O 0 3.815733284895373e-10
the O 0 6.354615056380908e-09
C O 0 2.432713699818123e-05
- O 0 9.091115202863875e-07
terminal O 0 3.8238908928178716e-07
domain O 0 2.9668344225797227e-08
of O 0 1.0997726063166624e-09
NPII O 0 8.258473371824948e-07
, O 0 4.027681799190219e-10
including O 0 1.8835788484494742e-10
a O 0 2.4291328948322644e-09
cysteine O 0 7.350089248348013e-08
residue O 0 1.7776814331682544e-07
in O 0 4.053184898822337e-09
position O 0 2.147357669457506e-08
85 O 0 1.110947156490738e-08
, O 0 2.0095157482469261e-10
which O 0 4.0078415586286553e-10
could O 0 1.5263094121920062e-09
be O 0 1.4653805946451826e-10
involved O 0 1.1580026521018638e-10
in O 0 1.4263530356828369e-09
the O 0 1.6198628216557154e-08
correct O 0 1.95566717593465e-05
folding O 0 2.825115927862498e-07
of O 0 9.874652207031431e-10
the O 0 3.779564039518846e-08
prohormone O 0 7.619666575919837e-05
. O 0 2.419668874154013e-07

In O 0 3.2045988973550266e-07
the O 0 1.1569927238497257e-08
second O 0 2.5725029217937845e-08
family O 0 7.143350355676148e-09
, O 0 1.9006488050088421e-10
a O 0 1.140467720261995e-09
G279A O 0 4.1367407277448365e-08
substitution O 0 1.2365483748055794e-08
at O 0 4.3110986780448e-08
position O 0 1.1242960340496211e-07
- O 0 1.2926876991059544e-07
1 O 0 2.032781720728849e-09
of O 0 5.533166286264546e-11
the O 0 6.570299304620164e-10
signal O 0 2.2743479632936214e-07
peptide O 0 1.9127465833435053e-08
was O 0 4.8465969015865085e-09
observed O 0 9.027333325306586e-10
in O 0 6.294214038859991e-10
all O 0 2.6464511138080127e-10
affected O 0 6.2425553615241824e-09
individuals O 0 1.9617460988996527e-09
. O 0 2.9184210603716565e-08

This O 0 1.1057076108045294e-06
missense O 0 0.0002634165866766125
mutation O 0 4.250827259966172e-05
, O 0 8.448097332802718e-08
which O 0 5.501373223637529e-08
replaces O 0 1.8268909116159193e-05
Ala O 0 7.40105224394938e-06
with O 0 1.690951023647358e-08
Thr O 0 0.0002226444339612499
, O 0 3.665499681559936e-09
is O 0 7.190589790262436e-10
frequent O 0 2.8372166838153134e-08
among O 0 8.948632945759982e-09
FNDI B-Disease 1 1.0
patients O 0 3.622483973231283e-06
and O 0 5.740270481169318e-09
is O 0 7.492563236510819e-10
thought O 0 1.476218258744666e-09
to O 0 1.0961831442557468e-09
reduce O 0 1.3838254098175184e-08
the O 0 1.7838615029575067e-09
efficiency O 0 1.2915535307911341e-08
of O 0 2.468651116860343e-10
cleavage O 0 9.504286424544262e-08
by O 0 5.343188114181885e-09
signal O 0 3.85123257728992e-06
peptidases O 0 4.090913535037544e-06
. O 0 1.2336483834474166e-08
. O 0 6.042686351293014e-08

Genetic O 0 6.120751640992239e-05
heterogeneity O 0 2.5560761059750803e-05
of O 0 2.537981060868333e-07
Saethre B-Disease 1 0.7425650954246521
- I-Disease 1 0.9999538660049438
Chotzen I-Disease 1 0.9999966621398926
syndrome I-Disease 1 1.0
, O 0 4.615050563927525e-09
due O 0 3.250100633067632e-08
to O 0 1.0841445075016054e-08
TWIST O 0 4.130995876039378e-06
and O 0 5.478984732576464e-08
FGFR O 0 5.092954233987257e-05
mutations O 0 4.241042915964499e-06
. O 0 1.2548673566925572e-07

Thirty O 0 2.1035790268797427e-05
- O 0 1.156687631009845e-05
two O 0 1.1670549859843504e-08
unrelated O 0 1.0879481493475396e-07
patients O 0 2.203288573809914e-08
with O 0 1.0186649301857642e-09
features O 0 1.3791647290872788e-07
of O 0 1.103768010324302e-08
Saethre B-Disease 1 0.8853724002838135
- I-Disease 1 0.9989583492279053
Chotzen I-Disease 1 0.9999655485153198
syndrome I-Disease 1 0.9999871253967285
, O 0 8.099013126816601e-10
a O 0 6.0847131777563845e-09
common O 0 2.78129789421655e-07
autosomal B-Disease 0 0.05722964555025101
dominant I-Disease 0 0.030016561970114708
condition I-Disease 0 9.699156362330541e-05
of O 0 2.0011984958046014e-08
craniosynostosis B-Disease 1 0.7904207110404968
and O 0 3.7997306208126247e-06
limb B-Disease 0 0.08622964471578598
anomalies I-Disease 0 4.526411430560984e-05
, O 0 1.7589910639159712e-09
were O 0 1.8017968228534187e-09
screened O 0 5.8400186020435285e-08
for O 0 8.420452668467249e-10
mutations O 0 8.33950366541103e-08
in O 0 4.815415621806096e-09
TWIST O 0 1.6447465895907953e-06
, O 0 5.09716358010337e-09
FGFR2 O 0 1.7662252957961755e-06
, O 0 2.224960216068439e-09
and O 0 7.316796057921238e-09
FGFR3 O 0 1.342966606898699e-05
. O 0 1.7935246887645917e-07

Nine O 0 2.1217063022049842e-06
novel O 0 7.63983621254738e-07
and O 0 1.4743478438106195e-08
three O 0 5.944770009591593e-09
recurrent O 0 2.3401571525027975e-06
TWIST O 0 1.697608058748301e-05
mutations O 0 7.800891580700409e-06
were O 0 1.2467816112859964e-08
found O 0 6.180521872067857e-09
in O 0 9.946012902162238e-09
12 O 0 3.133374448793802e-08
families O 0 2.287869804717957e-08
. O 0 7.951830127694848e-08

Seven O 0 3.208470502613636e-07
families O 0 1.795403115067984e-08
were O 0 2.3776915991646774e-09
found O 0 8.578067700604208e-10
to O 0 7.641710597638962e-10
have O 0 4.3265643845380453e-10
the O 0 1.6380438117025165e-09
FGFR3 O 0 1.3409243138085003e-06
P250R O 0 2.7581356221162423e-07
mutation O 0 1.068773016754676e-07
, O 0 5.572440842094295e-10
and O 0 5.10899655914443e-10
one O 0 2.3042684427210247e-10
individual O 0 1.9888335422990622e-10
was O 0 4.3791306580942546e-08
found O 0 5.645832135137141e-10
to O 0 5.281599602113829e-10
have O 0 2.2543358846327521e-10
an O 0 4.79971451472494e-10
FGFR2 O 0 3.893122539011529e-06
VV269 O 0 8.819314416541602e-07
- O 0 8.043919024203205e-07
270 O 0 1.041159862325003e-06
deletion O 0 1.4485976862488315e-05
. O 0 3.946497031392937e-07

To O 0 2.4196666004172585e-07
date O 0 7.841549631848466e-08
, O 0 8.84530226841207e-10
our O 0 1.1361254159680811e-09
detection O 0 7.42080388249633e-08
rate O 0 7.929850767141033e-07
for O 0 1.4439620610318116e-09
TWIST O 0 6.845360758234165e-07
or O 0 3.931916836563687e-08
FGFR O 0 4.60480987385381e-06
mutations O 0 2.8221970183039957e-07
is O 0 6.985887979205074e-10
68 O 0 1.2670630766820068e-08
% O 0 2.8606828017530006e-10
in O 0 1.2029621743181451e-09
our O 0 2.9541801893628872e-08
Saethre B-Disease 0 0.13888776302337646
- I-Disease 1 0.9983300566673279
Chotzen I-Disease 1 0.999992847442627
syndrome I-Disease 1 0.9999998807907104
patients O 0 2.1780893177947291e-07
, O 0 3.4932889914074394e-10
including O 0 3.445610741170668e-10
our O 0 2.217072303523082e-09
five O 0 2.244635810555451e-09
patients O 0 7.475608576612558e-09
elsewhere O 0 5.7676555087482484e-08
reported O 0 7.776718007335148e-07
with O 0 2.188103032096933e-08
TWIST O 0 0.00010551405284786597
mutations O 0 3.060245580854826e-05
. O 0 3.7860220913898956e-07

More O 0 7.954893987971445e-08
than O 0 1.5055185542678373e-08
35 O 0 1.639494939809083e-08
different O 0 2.2525059595324137e-09
TWIST O 0 6.448870408348739e-06
mutations O 0 9.653346069171675e-07
are O 0 1.2950408523337842e-09
now O 0 2.60552246444945e-09
known O 0 3.0546238871664855e-09
in O 0 1.5113296170099488e-09
the O 0 2.0458625904495875e-09
literature O 0 2.0324220528777914e-08
. O 0 4.0922834898537985e-08

The O 0 3.229794174330891e-07
most O 0 1.309647501557265e-08
common O 0 1.7356795112277723e-08
phenotypic O 0 1.955775701389939e-07
features O 0 2.086939474565952e-07
, O 0 1.3518768327003272e-09
present O 0 1.2661732773366907e-09
in O 0 8.169480647524097e-10
more O 0 2.413047539562285e-10
than O 0 2.504357832222581e-10
a O 0 1.402705507302926e-09
third O 0 5.3140389866257465e-09
of O 0 1.5790960206096827e-10
our O 0 3.000980575151857e-09
patients O 0 2.31903984904136e-09
with O 0 8.5133750049593e-10
TWIST O 0 2.7271410090179415e-06
mutations O 0 3.12460173290674e-07
, O 0 1.1481656736478385e-09
are O 0 1.0695816454742157e-09
coronal B-Disease 0 2.977693384309532e-06
synostosis I-Disease 0 4.564155005937209e-06
, O 0 5.211196363319459e-09
brachycephaly B-Disease 0 1.3021422091696877e-06
, O 0 7.752332997768008e-09
low B-Disease 0 8.956559031503275e-05
frontal I-Disease 1 0.9999853372573853
hairline I-Disease 1 0.9999998807907104
, O 0 1.0535070487094345e-06
facial B-Disease 1 0.9801687002182007
asymmetry I-Disease 0 7.311645458685234e-05
, O 0 1.0971776731594218e-07
ptosis B-Disease 0 0.0008365301764570177
, O 0 4.13074054961271e-08
hypertelorism B-Disease 0 5.877095100004226e-05
, O 0 1.4836881057078699e-08
broad B-Disease 0 8.677864684614178e-07
great I-Disease 0 8.701483693585033e-07
toes I-Disease 0 0.00027151964604854584
, O 0 3.1156075497307256e-09
and O 0 4.753834215165398e-09
clinodactyly B-Disease 0 6.895793376315851e-06
. O 0 8.1878177127237e-08

Significant O 0 3.0253092972998274e-06
intra O 0 6.782087439205498e-05
- O 0 2.076232703984715e-05
and O 0 4.1006593676229386e-08
interfamilial O 0 3.832016773230862e-06
phenotypic O 0 1.202572548208991e-06
variability O 0 4.3622790713016e-07
is O 0 1.7970672727685155e-09
present O 0 1.1506342545430925e-09
for O 0 7.133312274199e-10
either O 0 1.1526402943218272e-08
TWIST O 0 6.1156583797128405e-06
mutations O 0 3.7295333186193602e-06
or O 0 1.6993097062822926e-07
FGFR O 0 0.00015981511387508363
mutations O 0 2.421284807496704e-05
. O 0 6.913545576026081e-07

The O 0 3.5260370623291237e-07
overlap O 0 3.7287898635440797e-07
in O 0 2.970566015392251e-08
clinical O 0 6.315829637060233e-08
features O 0 4.3298547325321124e-07
and O 0 1.789624226589126e-09
the O 0 5.764130284191538e-10
presence O 0 7.757401943031539e-10
, O 0 1.210335442980437e-10
in O 0 3.8560760140526895e-10
the O 0 4.789298957419419e-10
same O 0 6.643653960303197e-10
genes O 0 1.4142573778741507e-09
, O 0 6.068655300506265e-11
of O 0 4.0886884156154935e-11
mutations O 0 8.093241632423087e-09
for O 0 7.573277421846214e-11
more O 0 1.7523330009261429e-10
than O 0 4.0649431043426887e-10
one O 0 1.0690187624007308e-09
craniosynostotic B-Disease 0 1.990078089875169e-06
condition I-Disease 0 1.4225044253635133e-07
- O 0 2.7246189304719337e-08
such O 0 6.17344952935639e-10
as O 0 2.9909974497144276e-09
Saethre B-Disease 0 1.4655129234597553e-06
- I-Disease 0 2.473081792686571e-07
Chotzen I-Disease 0 9.693125093690469e-07
, I-Disease 0 2.101910423490949e-09
Crouzon I-Disease 0 1.8688909619868355e-07
, I-Disease 0 9.324147010048023e-10
and I-Disease 0 4.743825776643007e-09
Pfeiffer I-Disease 0 2.7514741304912604e-05
syndromes I-Disease 0 3.316319634905085e-06
- O 0 1.491818721888194e-07
support O 0 1.901712343155282e-09
the O 0 1.3743867155469047e-09
hypothesis O 0 6.286549947276399e-09
that O 0 2.803426379927032e-10
TWIST O 0 9.502709019670874e-08
and O 0 1.718909348191744e-09
FGFRs O 0 1.9784579308179673e-07
are O 0 1.8673315671513535e-10
components O 0 8.967321329933498e-10
of O 0 2.92087812270303e-11
the O 0 3.12586817541316e-10
same O 0 4.721076862779228e-10
molecular O 0 2.6408655262599723e-09
pathway O 0 1.209343847285993e-09
involved O 0 1.843096369968933e-10
in O 0 4.3090064849593546e-10
the O 0 1.2766785406626013e-09
modulation O 0 1.6331490826360096e-07
of O 0 1.1342028427563378e-09
craniofacial O 0 5.09554138261592e-06
and O 0 7.083192699042229e-09
limb O 0 4.125639350149868e-07
development O 0 2.0881962825569644e-09
in O 0 1.8338259799577372e-09
humans O 0 1.3525428776972603e-08
. O 0 4.001427633681942e-09
. O 0 3.557363825734683e-08

Mutation O 0 0.00018059741705656052
analysis O 0 3.0232731660362333e-06
of O 0 1.3328954651115055e-07
UBE3A O 0 0.2059873640537262
in O 1 0.8284475207328796
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.003637908259406686
. O 0 1.96556015907845e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.18541038036346436
AS B-Disease 1 0.9999997615814209
) O 0 5.711615358450217e-08
is O 0 1.7243670935584987e-09
caused O 0 2.3105817703594766e-08
by O 0 7.76126896084861e-09
chromosome O 0 3.7689710552513134e-06
15q11 O 0 3.0899718694854528e-06
- O 0 1.5519607359237853e-06
q13 O 0 1.497174821452063e-06
deletions O 0 3.71608081195518e-07
of O 0 2.706236346128321e-09
maternal O 0 3.738082909876539e-07
origin O 0 4.274969711559606e-09
, O 0 1.2573507790492044e-09
by O 0 1.0254161075806678e-08
paternal O 0 5.2418356062844396e-05
uniparental B-Disease 0 0.003559612203389406
disomy I-Disease 0 0.011867376044392586
( O 0 1.6551505268580513e-06
UPD B-Disease 1 0.9999998807907104
) O 0 2.1002202643671808e-08
15 O 0 5.575505390709168e-09
, O 0 3.428762274104713e-10
by O 0 5.1182649229986055e-09
imprinting O 1 0.7894169092178345
defects O 1 0.9582604169845581
, O 0 9.000460932107046e-10
and O 0 4.157183208786108e-10
by O 0 1.8852186478568456e-09
mutations O 0 1.3618340233279014e-07
in O 0 6.991330181449484e-09
the O 0 4.629635341757421e-08
UBE3A O 0 6.465987826231867e-05
gene O 0 6.379053502314491e-06
. O 0 4.708060998837027e-07

UBE3A O 0 0.002234549494460225
encodes O 0 2.2313750378089026e-05
a O 0 6.552496643053018e-07
ubiquitin O 0 1.4830007785349153e-05
- O 0 1.6511964986420935e-06
protein O 0 7.113671358638385e-07
ligase O 0 4.1248839011132077e-07
and O 0 1.5218946103345843e-08
shows O 0 5.872248038940597e-07
brain O 0 8.586954209022224e-05
- O 0 7.346455731749302e-06
specific O 0 3.7925627793811145e-07
imprinting O 0 8.37713378132321e-05
. O 0 3.945763182855444e-07

Here O 0 1.603336841071723e-06
we O 0 1.235238187291543e-07
describe O 0 7.384446121250221e-07
UBE3A O 0 7.555927004432306e-05
coding O 0 2.8972213840461336e-05
- O 0 8.04730188974645e-06
region O 0 2.531985501263989e-07
mutations O 0 3.1769975521456217e-06
detected O 0 8.454608177999035e-07
by O 0 1.0557630325536138e-08
SSCP O 0 1.9377405351406196e-06
analysis O 0 1.637507374141478e-08
in O 0 5.01778529837793e-09
13 O 0 2.0314686821620853e-08
AS B-Disease 1 0.9063668251037598
individuals O 0 1.0368500502622169e-09
or O 0 9.459106387055272e-09
families O 0 1.7035048927027674e-08
. O 0 6.831919563410338e-08

Two O 0 4.2205121530969336e-07
identical O 0 4.000154604000272e-06
de O 0 4.29629244536045e-06
novo O 0 1.2389996300044004e-05
5 O 0 3.8307308614093927e-07
- O 0 7.009812748037803e-07
bp O 0 8.956608326116111e-07
duplications O 0 4.1785321513998497e-07
in O 0 1.669880766996812e-08
exon O 0 1.0218275292572798e-06
16 O 0 6.789052520161931e-08
were O 0 3.933437131564688e-09
found O 0 1.2591945264261994e-08
. O 0 7.782722377669415e-08

Among O 0 1.0791234927864934e-07
the O 0 4.9290926895650955e-09
other O 0 5.851217843577672e-10
11 O 0 4.21299750641424e-09
unique O 0 1.1960344936667866e-09
mutations O 0 1.2121276427023986e-07
, O 0 1.0884847467806935e-09
8 O 0 1.897322121635625e-08
were O 0 1.2507873625722254e-09
small O 0 1.2009538918889007e-09
deletions O 0 2.49451403533385e-07
or O 0 2.552595290694626e-08
insertions O 0 6.534892236231826e-07
predicted O 0 1.9018004877580097e-06
to O 0 1.2876793853422441e-08
cause O 0 7.900579390707207e-08
frameshifts O 0 4.310015356168151e-06
, O 0 1.3617366123597208e-09
1 O 0 3.024165806664314e-09
was O 0 4.149564247768467e-09
a O 0 1.2789891368214512e-09
mutation O 0 2.0954908919179616e-08
to O 0 1.1664936794275604e-09
a O 0 3.700941331175045e-09
stop O 0 5.929610225052784e-08
codon O 0 4.987379043086548e-07
, O 0 1.2615594124909535e-09
1 O 0 1.2652945358127e-09
was O 0 2.7134776647841363e-09
a O 0 3.1721529847317242e-09
missense O 0 6.2362738617594e-07
mutation O 0 1.38040164188169e-07
, O 0 1.0633897096212763e-09
and O 0 1.5241828910106392e-09
1 O 0 1.9657624861224576e-08
was O 0 2.0427702906999912e-07
predicted O 0 9.472362449969296e-08
to O 0 1.1588782156124466e-09
cause O 0 3.2961524620844784e-09
insertion O 0 1.5703783162734908e-08
of O 0 3.1038263625937645e-10
an O 0 3.0040330223357614e-09
isoleucine O 0 7.478166025975952e-06
in O 0 3.962806083279702e-09
the O 0 4.946044462883492e-09
hect O 0 3.98910430021715e-07
domain O 0 1.357877987828715e-08
of O 0 2.063252901862711e-10
the O 0 2.9854918537353115e-09
UBE3A O 0 1.487393660681846e-06
protein O 0 3.246029933734462e-08
, O 0 3.8616254638412784e-10
which O 0 3.3258704124072835e-10
functions O 0 2.2761950102534456e-09
in O 0 3.539406545627344e-09
E2 O 0 4.510510223099118e-07
binding O 0 4.0399033451876676e-08
and O 0 5.096774557955541e-09
ubiquitin O 0 4.005561322628637e-07
transfer O 0 1.2727119269584364e-07
. O 0 1.0591680421612182e-07

Eight O 0 1.228525263741176e-07
of O 0 7.784719535663953e-10
the O 0 9.80197478739342e-10
cases O 0 9.030484693361984e-10
were O 0 4.4951518063385265e-09
familial O 0 6.829833978372335e-07
, O 0 1.1017929679724148e-08
and O 0 2.089295847440553e-09
five O 0 2.2093979978876632e-09
were O 0 6.566068577740225e-09
sporadic O 0 3.6477870253293077e-06
. O 0 3.1502980846198625e-07

In O 0 6.080609296077455e-07
two O 0 2.2038937785850976e-08
familial O 0 4.327817350713303e-06
cases O 0 6.36165111700393e-08
and O 0 8.20749956886857e-09
one O 0 2.03899852557754e-09
sporadic O 0 1.6865050156411598e-06
case O 0 2.4501105144736357e-08
, O 0 3.5105569562432493e-09
mosaicism O 0 9.691192417449201e-07
for O 0 6.361260407317104e-09
UBE3A O 0 9.937263712345157e-06
mutations O 0 9.641404403737397e-07
was O 0 5.2344098833145836e-08
detected O 0 9.268408973639453e-08
in O 0 5.811358949614487e-09
the O 0 2.853267844216134e-09
mother O 0 5.478313358509013e-09
of O 0 8.385204336436303e-11
three O 0 1.42256018076381e-09
AS B-Disease 1 0.9999971389770508
sons O 0 2.309723186044721e-07
, O 0 7.793034967340517e-11
in O 0 2.592898951103706e-10
the O 0 2.9137530166423176e-09
maternal O 0 2.2002025445999607e-07
grandfather O 0 4.8392099216698625e-08
of O 0 1.2300475915605347e-10
two O 0 1.1289279511217387e-09
AS B-Disease 1 0.9952507019042969
first O 0 1.0549175755159013e-08
cousins O 0 8.141271479189527e-08
, O 0 2.9583047123082906e-10
and O 0 1.5881423953700846e-10
in O 0 4.152879706786905e-10
the O 0 1.6905890021234882e-09
mother O 0 5.406212810754596e-09
of O 0 8.787736510695865e-11
an O 0 7.482509056799813e-10
AS B-Disease 1 0.9999986886978149
daughter O 0 1.6000549294403754e-05
. O 0 4.5772868162430314e-08

The O 0 2.053589440720316e-07
frequencies O 0 1.5326545508287381e-06
with O 0 3.2714126962929413e-09
which O 0 2.709945157164384e-09
we O 0 5.899607469217472e-10
detected O 0 1.1519220777245209e-07
mutations O 0 1.2180083786006435e-07
were O 0 6.1058371692013225e-09
5 O 0 5.8412301662258415e-09
( O 0 1.8800803136542754e-09
14 O 0 3.7624006132830345e-09
% O 0 2.3369464696720854e-10
) O 0 1.2665496429420386e-10
of O 0 9.041441206836254e-11
35 O 0 6.21643936327132e-09
in O 0 2.4355117922425507e-09
sporadic O 0 9.7832094070327e-07
cases O 0 6.2335128170332155e-09
and O 0 4.36837499506737e-09
8 O 0 1.5981870049586178e-08
( O 0 8.671356410694386e-10
80 O 0 1.8270633894701405e-09
% O 0 2.0469857753280252e-10
) O 0 7.205441104884969e-11
of O 0 6.542759389827069e-11
10 O 0 1.541893501766367e-09
in O 0 2.6705837541385335e-09
familial O 0 4.159067827913532e-07
cases O 0 1.1935648913663499e-08
. O 0 9.59890744667291e-09
. O 0 6.945783326273158e-08

The O 0 2.924720502051059e-05
hemochromatosis B-Disease 1 1.0
845 O 0 0.00146567658521235
G O 0 0.001836684183217585
- O 0 3.517444565659389e-05
- O 0 4.714072474598652e-06
> O 0 3.0580946486225e-07
A O 0 2.5183135576867244e-08
and O 0 2.5895245947538115e-09
187 O 0 6.750625658469289e-08
C O 0 4.645527042157482e-06
- O 0 3.0397002319659805e-06
- O 0 5.7480142459098715e-06
> O 0 1.7074758034141269e-06
G O 0 3.03990254906239e-05
mutations O 0 1.8151488347939448e-06
: O 0 5.575399253388014e-09
prevalence O 0 1.5070190784172155e-07
in O 0 1.1527963472701686e-08
non O 0 5.3929714027844966e-08
- O 0 4.510150120040635e-06
Caucasian O 0 2.3607976800121833e-06
populations O 0 4.6171396661520703e-07
. O 0 1.9381347726721287e-07

Hemochromatosis B-Disease 1 0.9363089203834534
, O 0 4.30453411581766e-07
the O 0 4.679841367760673e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 3.518924884815533e-08
iron I-Disease 1 0.5981723666191101
metabolism I-Disease 0 0.021878262981772423
, O 0 2.281362876388471e-09
leads O 0 5.468041130995971e-09
, O 0 1.2075092037378e-09
if O 0 2.1555266460637768e-09
untreated O 0 1.2141151728428667e-07
, O 0 5.432392313764467e-10
to O 0 6.707843613895648e-09
progressive O 0 0.0001113936014007777
iron B-Disease 1 0.9249195456504822
overload I-Disease 0 0.0004407200904097408
and O 0 3.700654005456272e-08
premature B-Disease 0 5.392576895246748e-06
death I-Disease 0 1.6413650882896036e-06
. O 0 1.6356133869521727e-07

The O 0 1.0023190043284558e-05
hemochromatosis B-Disease 1 0.9999998807907104
gene O 0 5.211919778957963e-05
, O 0 6.234811422700659e-08
HFE O 0 5.291290653985925e-05
, O 0 1.0946228812258596e-08
recently O 0 8.031978637745851e-08
has O 0 2.8722748623977168e-09
been O 0 7.994510053954684e-10
identified O 0 1.0572295261468412e-09
, O 0 1.0533383193456203e-10
and O 0 1.8001881929574637e-10
characterization O 0 2.9214324293036498e-09
of O 0 3.135276760435346e-11
this O 0 2.99740954279315e-10
gene O 0 3.4357903189174976e-08
has O 0 2.0057868699296932e-09
shown O 0 2.5772948220037506e-09
that O 0 6.625339860066859e-11
it O 0 1.5101157824215505e-10
contains O 0 3.1671093525531546e-10
two O 0 1.5689337329316544e-10
mutations O 0 1.240263802770869e-08
that O 0 3.028851613962047e-10
result O 0 3.0879674373096577e-09
in O 0 3.5464953196395754e-09
amino O 0 3.682403715288274e-08
acid O 0 5.938551339568221e-08
substitutions O 0 1.3028288492478168e-07
- O 0 1.9752229718505987e-07
cDNA O 0 7.290678354365809e-07
nucleotides O 0 2.2342666738950356e-07
845 O 0 1.9983604033768643e-06
G O 0 9.97773531707935e-06
- O 0 3.2236414426733973e-06
- O 0 3.1036281598062487e-06
> O 0 2.9128386813681573e-07
A O 0 4.9687781000784526e-08
( O 0 6.4364664709160024e-09
C282Y O 0 1.362473085464444e-07
) O 0 2.0318475790759294e-09
and O 0 1.0920468973552033e-09
187 O 0 5.1009198642759657e-08
C O 0 7.12165228833328e-06
- O 0 1.084254381567007e-05
- O 0 2.3255221094586886e-05
> O 0 4.57070109405322e-06
G O 0 2.343517007830087e-05
( O 0 7.796941758897447e-08
H63D O 0 1.224534662469523e-05
) O 0 7.414663372173891e-08
. O 0 1.40625630251634e-07

Although O 0 4.322866152506322e-05
hemochromatosis B-Disease 1 1.0
is O 0 1.516583552074735e-07
common O 0 4.580465784442822e-08
in O 0 2.993995806832572e-08
Caucasians O 0 2.346722567381221e-07
, O 0 3.8904377497317455e-09
affecting O 0 1.0995156429771669e-07
> O 0 5.741488280364138e-07
= O 0 6.663203180323762e-07
1 O 0 5.984088602417614e-08
/ O 0 4.5041829821457213e-07
300 O 0 2.7923865442147644e-09
individuals O 0 1.2013427752588512e-10
of O 0 7.789854872264357e-11
northern O 0 7.153849068686213e-09
European O 0 1.4571211792713257e-08
origin O 0 1.2340924948617271e-09
, O 0 2.7288654669277435e-10
it O 0 9.120356692093878e-10
has O 0 6.410831865366617e-10
not O 0 8.887186125905444e-11
been O 0 1.0419703988517881e-10
recognized O 0 1.2719238162706148e-10
in O 0 2.442600288699026e-10
other O 0 6.58327004021686e-10
populations O 0 1.1961012624794876e-08
. O 0 5.7921404561511736e-08

The O 0 2.546483415244438e-07
present O 0 6.573088029426799e-08
study O 0 1.8240593036011887e-08
used O 0 2.0419028246010384e-08
PCR O 0 3.3479832381999586e-06
and O 0 5.9944365027320146e-09
restriction O 0 7.21510531320746e-08
- O 0 1.0683673679068306e-07
enzyme O 0 7.786390199271409e-08
digestion O 0 7.002970647818074e-08
to O 0 1.964828078016012e-09
analyze O 0 1.1962974610923993e-08
the O 0 2.604210624923553e-09
frequency O 0 2.619691485961084e-07
of O 0 3.880053500715519e-10
the O 0 6.364659022040087e-09
845 O 0 4.140056830692629e-07
G O 0 3.0917522053641733e-06
- O 0 1.99278451873397e-06
- O 0 1.2994776170671685e-06
> O 0 9.167105474716664e-08
A O 0 1.7454730993904377e-08
and O 0 3.328251674261651e-09
187 O 0 9.611772355810899e-08
C O 0 2.708288320718566e-06
- O 0 1.5229564951368957e-06
- O 0 2.00171575670538e-06
> O 0 8.70814119480201e-07
G O 0 5.057054750068346e-06
mutations O 0 1.0618740589052322e-06
in O 0 5.34941051455462e-08
HLA O 0 4.910037205263507e-06
- O 0 1.7904501703469577e-07
typed O 0 9.86024346616432e-08
samples O 0 8.584832400515552e-09
from O 0 1.7272505647980552e-09
non O 0 2.865539139307316e-09
- O 0 8.060293055223156e-08
Caucasian O 0 7.02310174460763e-08
populations O 0 5.360316190916592e-09
, O 0 2.763803907956941e-10
comprising O 0 3.5459929437209325e-10
Australian O 0 1.9012156293740645e-09
Aboriginal O 0 1.5220300575435886e-09
, O 0 7.629400583519796e-11
Chinese O 0 8.922565464253296e-11
, O 0 1.490363249478932e-10
and O 0 9.477287843395743e-10
Pacific O 0 3.840665385723696e-08
Islanders O 0 1.5632888334948802e-06
. O 0 1.1396924293194388e-07

Results O 0 6.142240636108909e-06
showed O 0 7.128986112547864e-07
that O 0 3.982354890297302e-09
the O 0 8.301934251164766e-09
845 O 0 9.735769026519847e-07
G O 0 6.997669061092893e-06
- O 0 2.6627074021234876e-06
- O 0 9.16371106995939e-07
> O 0 1.1838636027050597e-07
A O 0 1.6941600122777345e-08
mutation O 0 1.5865975910855923e-07
was O 0 1.7392451923115004e-08
present O 0 4.952754317777419e-10
in O 0 3.788958036210488e-10
these O 0 5.144394354950066e-10
populations O 0 2.7337323516007928e-09
( O 0 1.8500252441100429e-09
allele O 0 6.70858852913625e-08
frequency O 0 3.03090672559847e-07
0 O 0 6.412803621458352e-09
. O 0 2.7506774635810416e-10
32 O 0 3.0104629900051805e-09
% O 0 2.5707883044567836e-10
) O 0 1.2318789044396539e-10
, O 0 1.0469228262088848e-10
and O 0 3.70196318044691e-10
, O 0 1.9746779211793353e-10
furthermore O 0 1.6588010964824207e-09
, O 0 7.543093927253608e-10
it O 0 1.087018475232071e-08
was O 0 3.61061836429144e-07
always O 0 1.5463526015224716e-09
seen O 0 1.32111732664697e-09
in O 0 8.576774845892032e-10
conjunction O 0 5.615570231043421e-09
with O 0 2.539133792112125e-09
HLA O 0 6.702078394482669e-07
haplotypes O 0 1.5214337167890335e-07
common O 0 4.7179287143706006e-09
in O 0 6.0990750228029356e-09
Caucasians O 0 3.443617302423263e-08
, O 0 3.5686142929591824e-10
suggesting O 0 1.1516206654960115e-08
that O 0 6.76287525980257e-10
845 O 0 2.4031618295339285e-07
G O 0 3.040644969587447e-06
- O 0 1.0737089723988902e-06
- O 0 1.3093897450744407e-06
> O 0 1.460026197719344e-07
A O 0 8.742743062839509e-08
may O 0 3.3625570949880057e-07
have O 0 3.2053712462065675e-10
been O 0 4.382309792827499e-10
introduced O 0 4.131968101006578e-09
into O 0 3.297817019465299e-10
these O 0 9.342229073672215e-11
populations O 0 1.4289998073735433e-09
by O 0 3.905105572243883e-09
Caucasian O 0 1.124042455558083e-06
admixture O 0 4.2608835428836755e-06
. O 0 6.030436452419963e-07

187 O 0 0.00010827709047589451
C O 0 0.00015262363012880087
- O 0 1.3208279597165529e-05
- O 0 3.9966803342395e-06
> O 0 1.2132001074860455e-06
G O 0 9.940438758349046e-06
was O 0 6.361930360299084e-08
present O 0 9.21087872640669e-10
at O 0 3.4172340512839128e-09
an O 0 5.053781837460747e-10
allele O 0 1.388352046660657e-07
frequency O 0 3.329383844175027e-07
of O 0 2.103305973832903e-09
2 O 0 9.115304777651545e-08
. O 0 6.702487809207014e-08

68 O 0 2.2160849766805768e-05
% O 0 7.046045880088059e-08
in O 0 8.528493466997134e-09
the O 0 1.667966875729121e-09
two O 0 6.092037985183651e-10
populations O 0 4.00060340410846e-09
analyzed O 0 3.3914314911953625e-08
( O 0 4.704566070046212e-09
Australian O 0 1.7522946649251026e-08
Aboriginal O 0 6.952407982652176e-09
and O 0 7.692806947012798e-10
Chinese O 0 1.116995607119975e-09
) O 0 6.849269595932128e-09
. O 0 3.4157242367882645e-08

In O 0 3.6736560105055105e-07
the O 0 2.33629791068779e-08
Australian O 0 1.2912678037935166e-08
Aboriginal O 0 7.566902660016694e-09
samples O 0 1.3377442265039008e-08
, O 0 8.921736127653901e-10
187 O 0 4.456558500010033e-08
C O 0 1.22850110528816e-06
- O 0 1.9018422108274535e-06
- O 0 4.7885005187708884e-06
> O 0 8.996673273031774e-07
G O 0 2.184162258345168e-05
was O 0 7.395581747005053e-08
found O 0 1.1623891849055212e-09
to O 0 4.5013870408894263e-10
be O 0 2.905172213907292e-10
associated O 0 1.8173664795284594e-09
with O 0 2.8749771452396544e-09
HLA O 0 1.3614642284665024e-06
haplotypes O 0 1.6650535883400153e-07
common O 0 9.674653966840197e-09
in O 0 8.819817765015614e-09
Caucasians O 0 3.622776389988758e-08
, O 0 4.2886882933856896e-10
suggesting O 0 9.133243494829912e-09
that O 0 2.2520364739708754e-10
it O 0 9.181971294403013e-10
was O 0 1.0600407662764155e-08
introduced O 0 7.924209732834697e-09
by O 0 7.677181113052711e-10
recent O 0 1.4423608085678552e-08
admixture O 0 1.0406694173070719e-06
. O 0 2.1719704079714575e-07

In O 0 2.4879594207050104e-07
the O 0 6.409734076839868e-09
Chinese O 0 2.443967028753491e-09
samples O 0 1.2322280085186321e-08
analyzed O 0 2.9429322978558048e-08
, O 0 1.1704786029298475e-09
187 O 0 3.87515370903202e-08
C O 0 1.0078111927214195e-06
- O 0 7.536355610682222e-07
- O 0 1.515215899416944e-06
> O 0 6.474984388660232e-07
G O 0 2.0016406779177487e-05
was O 0 1.7120660800173937e-07
present O 0 2.152116929110548e-09
in O 0 6.029513333061232e-09
association O 0 2.6431481447986016e-09
with O 0 9.170555287374427e-11
a O 0 8.403316931193672e-10
wide O 0 2.440883051235687e-09
variety O 0 2.4293227429694753e-09
of O 0 1.8192461981314523e-09
HLA O 0 1.8677451407711487e-06
haplotypes O 0 2.3767275081354455e-07
, O 0 3.774034973424989e-10
showing O 0 9.95595872410604e-09
this O 0 3.6287342575214154e-10
mutation O 0 1.0848395071150208e-08
to O 0 6.430094234843864e-10
be O 0 2.0626352015273852e-10
widespread O 0 2.528959486269855e-09
and O 0 1.1971551527878432e-09
likely O 0 7.247764166606885e-09
to O 0 1.1194185578489169e-09
predate O 0 9.190546990112125e-08
the O 0 5.441496697677906e-10
more O 0 4.673654796505389e-10
genetically O 0 1.6118896439820674e-08
restricted O 0 2.0336512918106564e-08
845 O 0 6.596334856112662e-07
G O 0 7.730077413725667e-06
- O 0 2.192311512771994e-06
- O 0 2.233078930657939e-06
> O 0 4.727916405045107e-07
A O 0 1.685140347262859e-07
mutation O 0 4.122805421502562e-06
. O 0 1.7431732146633294e-07

Genotype O 0 0.0328095369040966
- O 0 0.0066001336090266705
phenotype O 0 0.0020496633369475603
correlations O 0 0.0001893481967272237
in O 0 2.2339598217513412e-05
attenuated B-Disease 1 0.999990701675415
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999996423721313
coli I-Disease 1 1.0
. O 0 9.860002319328487e-05

Germ O 0 0.008743172511458397
- O 0 0.0031689361203461885
line O 0 2.0162720829830505e-05
mutations O 0 1.470258439439931e-06
of O 0 2.632235984734166e-09
the O 0 1.9924197403042854e-08
tumor B-Disease 0 5.280736786517082e-06
suppressor O 0 1.6600495655438863e-05
APC O 0 1.428520249646681e-06
are O 0 6.0966791615157945e-09
implicated O 0 9.383974202137324e-07
in O 0 2.1363739506341517e-06
attenuated B-Disease 1 0.9999922513961792
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.03218431398272514
AAPC B-Disease 1 1.0
) O 0 5.08643474006476e-08
, O 0 1.1547873768336103e-09
a O 0 7.629073373038864e-09
variant O 0 0.00020408714772202075
of O 0 1.2019304449495394e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 0.00020054279593750834
FAP B-Disease 0 0.00023006650735624135
) O 0 8.561923436900543e-07
. O 0 5.406059813140018e-07

AAPC B-Disease 1 0.9999996423721313
is O 0 7.315040306821174e-07
recognized O 0 1.9288444619292022e-08
by O 0 1.9939241369115734e-09
the O 0 2.164396661896717e-09
occurrence O 0 5.600064056920928e-08
of O 0 2.3840627250137914e-09
< O 0 2.0856086280218733e-07
100 O 0 3.763586775562544e-08
colonic B-Disease 0 7.132310201996006e-06
adenomas I-Disease 0 3.2650050343363546e-06
and O 0 2.851700875439178e-09
a O 0 1.4386434266100423e-08
later O 0 7.439339242409915e-07
onset O 0 0.1403474360704422
of O 0 0.008123370818793774
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 4.180453458957345e-07
age O 0 1.089717613922403e-07
> O 0 1.1497643725988382e-07
40 O 0 2.7977085537145285e-08
years O 0 1.2594827403233921e-08
) O 0 1.6522623269565884e-08
. O 0 8.030738030129214e-08

The O 0 1.8469874873972003e-07
aim O 0 8.369669757257725e-08
of O 0 4.753306082072584e-10
this O 0 7.193305395780669e-10
study O 0 2.9837441406499465e-09
was O 0 9.543593471050826e-09
to O 0 2.9906039866745004e-09
assess O 0 4.0372160015067493e-07
genotype O 0 2.4491433578077704e-05
- O 0 1.45262902151444e-05
phenotype O 0 2.973305163322948e-05
correlations O 0 4.969288966094609e-06
in O 0 1.408206458108907e-06
AAPC B-Disease 1 0.9999997615814209
families O 0 9.140869110524363e-07
. O 0 4.460177081000438e-07

By O 0 7.209623049675429e-07
protein O 0 2.421223143755924e-06
- O 0 2.6814475404535187e-06
truncation O 0 1.0187576663156506e-05
test O 0 1.7168301837955369e-06
( O 0 2.2549357936441083e-08
PTT O 0 4.54078275424763e-07
) O 0 2.402811727364451e-09
assay O 0 9.025981029253671e-08
, O 0 2.976904278639836e-10
the O 0 6.355860282525327e-10
entire O 0 1.134701044236408e-08
coding O 0 1.491815879717251e-07
region O 0 4.450491086771535e-09
of O 0 1.6781968870116515e-10
the O 0 3.37103767122926e-09
APC B-Disease 0 1.2154684725373954e-07
gene O 0 9.491984798160047e-08
was O 0 3.597128284127393e-08
screened O 0 3.7514386264092536e-08
in O 0 2.3171344842864983e-09
affected O 0 7.106644606125201e-09
individuals O 0 6.095733917632629e-10
from O 0 9.051785987423955e-09
11 O 0 6.138922685750003e-07
AAPC B-Disease 1 0.9999998807907104
kindreds O 0 3.1795316317584366e-06
, O 0 1.6949737169369428e-09
and O 0 5.436009975490208e-10
their O 0 2.3629123102608673e-09
phenotypic O 0 2.3649296565508848e-07
differences O 0 1.1603611937971436e-07
were O 0 5.3689753087837744e-08
examined O 0 1.422720401933475e-06
. O 0 1.1528562282592247e-07

Five O 0 1.1299969173705904e-06
novel O 0 1.5665990531488205e-06
germ O 0 7.25714344298467e-05
- O 0 0.0001198280297103338
line O 0 4.849386095884256e-05
APC B-Disease 0 2.259410166516318e-06
mutations O 0 5.143486987435608e-07
were O 0 4.4000176835368165e-09
identified O 0 9.567851400049676e-09
in O 0 4.646219409210062e-09
seven O 0 2.1692249774218908e-08
kindreds O 0 2.6420138965477236e-06
. O 0 2.0410740830811847e-07

Mutations O 0 0.0004036487080156803
were O 0 2.3251406844337907e-07
located O 0 9.977481596479265e-08
in O 0 4.7050776608159595e-09
three O 0 3.450043306596484e-10
different O 0 1.278022826456393e-10
regions O 0 4.834020406185857e-10
of O 0 1.0977140724177659e-10
the O 0 3.8852987493953606e-09
APC B-Disease 0 1.4993652541761548e-07
gene O 0 7.109643718195002e-08
( O 0 2.273296662025359e-09
1 O 0 2.782158059488893e-09
) O 0 2.772652940574716e-10
at O 0 5.856479745602883e-09
the O 0 3.6347693743721265e-09
5 O 0 2.1316914455837832e-08
end O 0 3.153850514081569e-08
spanning O 0 2.9379240373827997e-08
exons O 0 2.2575333957775e-07
4 O 0 2.9288990788245428e-08
and O 0 3.106167323352338e-09
5 O 0 7.959382486433242e-09
, O 0 4.2620390550140996e-10
( O 0 5.082695930802572e-10
2 O 0 8.979130217134923e-10
) O 0 2.2443009950467996e-10
within O 0 9.372325138201631e-10
exon O 0 1.0926186888582379e-07
9 O 0 1.0564402685986352e-07
, O 0 5.77434211557204e-10
and O 0 1.0926469729000132e-09
( O 0 1.789088432957442e-09
3 O 0 7.559949111168862e-09
) O 0 5.66440616633912e-10
at O 0 1.8087565223368074e-08
the O 0 3.851520435915745e-09
3 O 0 2.6200055458502902e-08
distal O 0 3.8518095379913575e-07
end O 0 3.790074742937577e-08
of O 0 3.435098872017761e-10
the O 0 6.820160436404876e-09
gene O 0 6.04039371410181e-07
. O 0 5.0022880060396346e-08

Variability O 0 4.5418390072882175e-05
in O 0 8.915007754239923e-08
the O 0 7.79876785372835e-09
number O 0 1.0741781686363083e-08
of O 0 5.203799560149491e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 9.791061529540457e-06
most O 0 1.0749543477572843e-09
apparent O 0 7.2774635206940275e-09
in O 0 1.2763694545725457e-09
individuals O 0 8.247381944048726e-11
with O 0 3.3336758353819107e-10
mutations O 0 6.770935812028256e-08
in O 0 4.974057166151624e-09
region O 0 1.7347460357086675e-08
1 O 0 3.38556311874072e-08
, O 0 7.443918259575355e-10
and O 0 6.320841183793391e-09
upper O 1 0.9525266885757446
- O 1 0.9977778792381287
gastrointestinal O 0 0.30497419834136963
manifestations O 0 1.329127144344966e-06
were O 0 9.222748786896773e-09
more O 0 9.749467899666797e-10
severe O 0 6.821815532020992e-06
in O 0 8.727494282823045e-09
them O 0 7.434103110881551e-09
. O 0 4.132553144131634e-08

In O 0 2.7081929943051364e-07
individuals O 0 6.803205110372801e-09
with O 0 2.2478834349470844e-09
mutations O 0 2.851877241027978e-07
in O 0 1.079400924197671e-08
either O 0 9.588587701614415e-09
region O 0 1.7211149838658457e-08
2 O 0 2.160862777600414e-08
or O 0 4.454041135915077e-09
region O 0 5.622365240043337e-09
3 O 0 1.1734342386660046e-08
, O 0 1.664098719933449e-10
the O 0 6.297203314353794e-10
average O 0 9.782330501195702e-09
number O 0 2.910441332382163e-10
of O 0 4.2572295688714235e-10
adenomas B-Disease 0 2.7662889579005423e-07
tended O 0 3.550342171365628e-07
to O 0 5.9565516963289156e-09
be O 0 1.1471521510486582e-09
lower O 0 1.7469538988734712e-06
than O 0 4.922710572508038e-10
those O 0 5.385767179455492e-11
in O 0 1.47063625166588e-10
individuals O 0 2.7739846877872232e-11
with O 0 1.0232757002848203e-10
mutations O 0 1.6445939721165814e-08
in O 0 2.7705819860557312e-09
region O 0 8.632679460163217e-09
1 O 0 7.405346114097711e-09
, O 0 2.0846574466659717e-10
although O 0 2.403682586304967e-09
age O 0 7.64347785064956e-09
at O 0 1.2285931916267145e-07
diagnosis O 0 2.2200574676389806e-05
was O 0 3.8003253166607465e-07
similar O 0 1.5885204618371063e-07
. O 0 1.9856103961046756e-07

In O 0 9.25097174331313e-06
all O 0 6.799211860197829e-07
AAPC B-Disease 1 0.999997615814209
kindreds O 0 2.3167451217886992e-05
, O 0 1.1647823150440217e-08
a O 0 5.6703974848915095e-09
predominance O 0 4.5145426952331036e-07
of O 0 1.0100385416933477e-08
right O 0 0.00519010704010725
- O 1 0.9999995231628418
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 4.456226452020928e-05
rectal B-Disease 1 0.9995146989822388
polyp I-Disease 0 0.0020500801037997007
sparing O 0 3.1176864467852283e-06
was O 0 7.953070735311485e-07
observed O 0 1.1133173529742635e-06
. O 0 2.001985563993003e-07

No O 0 1.440601954527665e-05
desmoid B-Disease 0 0.2575284540653229
tumors I-Disease 1 1.0
were O 0 9.700489300712434e-08
found O 0 1.8702563053807353e-08
in O 0 1.3780781848993229e-08
these O 0 1.3587329483755184e-08
kindreds O 0 4.768385224451777e-06
. O 0 3.181768590820866e-07

Our O 0 8.101954449557525e-07
data O 0 3.925177054497908e-07
suggest O 0 3.417379446091218e-08
that O 0 8.344158142215008e-10
, O 0 6.578600442175286e-10
in O 0 1.7741680125027415e-08
AAPC B-Disease 1 1.0
families O 0 3.6249863111237346e-09
, O 0 9.240541665178625e-11
the O 0 1.4985097884778753e-10
location O 0 1.6289090076782031e-09
of O 0 9.011054402652263e-11
the O 0 5.92366111717979e-09
APC B-Disease 0 1.8008927327173296e-06
mutation O 0 1.518806811873219e-06
may O 0 2.212041181337554e-07
partially O 0 3.3817752864706563e-07
predict O 0 1.0551092088917358e-07
specific O 0 2.954461919557616e-08
phenotypic O 0 1.367335244140122e-06
expression O 0 8.335479151355685e-07
. O 0 1.9741570156384114e-07

This O 0 2.54429380674992e-07
should O 0 1.6024756632759818e-08
help O 0 4.229002481537236e-09
in O 0 1.1637468766423353e-09
the O 0 1.4713242846298158e-09
design O 0 1.46257574940023e-08
of O 0 5.221322263437855e-10
tailored O 0 5.69954636375769e-07
clinical O 0 5.39051200121321e-07
- O 0 0.00017908103473018855
management O 0 2.799812364173704e-07
protocols O 0 4.174938794676564e-08
in O 0 1.42938694214223e-09
this O 0 3.6790723245694323e-10
subset O 0 6.9442305239419966e-09
of O 0 1.2224422585305206e-09
FAP B-Disease 0 8.29492478260363e-07
patients O 0 6.880238601070232e-08
. O 0 8.18561307625032e-09
. O 0 9.799273215094217e-08

Wilms B-Disease 0 0.05690450966358185
' I-Disease 0 5.259070167085156e-05
tumor I-Disease 0 0.00011516529775690287
1 O 0 4.6588760937993356e-07
and O 0 4.5920124591702915e-08
Dax O 1 0.9998304843902588
- O 0 5.5717882787575945e-06
1 O 0 3.817652327597898e-08
modulate O 0 6.896266881994961e-07
the O 0 9.137808731907171e-09
orphan O 0 3.6263858760321455e-07
nuclear O 0 1.8692867342906538e-07
receptor O 0 1.9817448446701746e-06
SF O 0 0.0001600921095814556
- O 0 8.85567317254754e-07
1 O 0 1.8168510251825865e-08
in O 0 5.487672982695813e-09
sex O 0 3.2818135764500767e-08
- O 0 4.3486831913241986e-08
specific O 0 1.294560014741819e-08
gene O 0 3.432974153838586e-07
expression O 0 2.1354684065499896e-07
. O 0 8.457013223051035e-08

Products O 0 4.044259185320698e-06
of O 0 5.0552426245076276e-08
steroidogenic O 0 2.5592784368200228e-05
factor O 0 4.1332754108225345e-07
1 O 0 1.6737112673581578e-07
( O 0 1.481923987967093e-07
SF O 0 0.02939044125378132
- O 0 1.1941899174416903e-05
1 O 0 5.12743270064675e-08
) O 0 4.717361612449622e-09
and O 0 1.425502471619211e-08
Wilms B-Disease 0 2.5162589736282825e-05
tumor I-Disease 0 4.5714159568888135e-06
1 O 0 5.289004434416711e-08
( O 0 2.0006298839803094e-08
WT1 O 0 3.156901357215247e-06
) O 0 2.469405790961332e-09
genes O 0 8.515863569868998e-09
are O 0 1.1442451847143431e-10
essential O 0 3.37743971678961e-10
for O 0 2.1457381704781398e-10
mammalian O 0 6.380632555647026e-08
gonadogenesis O 0 5.123131927575741e-07
prior O 0 1.364266832837302e-08
to O 0 8.25248847036164e-09
sexual O 0 6.103243066490904e-08
differentiation O 0 5.538675509342283e-07
. O 0 2.648689019224548e-07

In O 0 1.5408262470373302e-06
males O 0 4.401212265747745e-07
, O 0 2.0029551350830843e-08
SF O 0 0.0005999404820613563
- O 0 1.5099450365596567e-06
1 O 0 2.335362481176162e-08
participates O 0 1.4521187807758906e-08
in O 0 1.0312920517563384e-09
sexual O 0 2.071582239082659e-09
development O 0 4.2577005809896207e-10
by O 0 4.2729625393533865e-10
regulating O 0 2.7611825714757288e-08
expression O 0 6.160560950263516e-09
of O 0 4.202538039788095e-10
the O 0 9.815674495428084e-09
polypeptide O 0 2.779751866910374e-06
hormone O 0 1.8894279492087662e-06
Mullerian O 0 6.6094862631871365e-06
inhibiting O 0 1.0660382940841373e-06
substance O 0 8.116214189612947e-07
( O 0 1.1018438073051584e-07
MIS O 0 3.67970387742389e-05
) O 0 1.1195646720807417e-07
. O 0 1.5577273870803765e-07

Here O 0 1.0886597010539845e-06
, O 0 1.948304451104832e-08
we O 0 2.4393564945768276e-09
show O 0 3.260973002738865e-08
that O 0 4.041705192747713e-09
WT1 O 0 2.3608095943927765e-05
- O 0 2.2998833628662396e-06
KTS O 0 3.0027917091501877e-05
isoforms O 0 1.2494381280703237e-06
associate O 0 8.465486445174975e-08
and O 0 5.9039555466711136e-09
synergize O 0 1.0326979236197076e-06
with O 0 3.634161060972474e-08
SF O 0 0.10540970414876938
- O 0 1.1328214895911515e-05
1 O 0 5.174196715529433e-08
to O 0 5.344880094071414e-09
promote O 0 6.040059474798909e-08
MIS O 0 1.7811542420531623e-05
expression O 0 2.265036016524391e-07
. O 0 1.300805223536372e-07

In O 0 2.4017740543058608e-06
contrast O 0 3.4871195566665847e-06
, O 0 9.534699785263001e-08
WT1 O 0 0.00011677738802973181
missense O 0 9.766556468093768e-05
mutations O 0 1.8453360098646954e-05
, O 0 9.90134285672184e-09
associated O 0 1.814098027352884e-08
with O 0 5.093606425532471e-09
male B-Disease 0 3.989907213508559e-07
pseudohermaphroditism I-Disease 1 1.0
in O 0 2.5121689759544097e-06
Denys B-Disease 1 0.9999758005142212
- I-Disease 1 0.9999319314956665
Drash I-Disease 1 0.9999940395355225
syndrome I-Disease 1 0.9999998807907104
, O 0 1.201916965953842e-08
fail O 0 4.596622318331356e-07
to O 0 8.398786555119386e-09
synergize O 0 3.3864919259940507e-06
with O 0 1.350277614164952e-07
SF O 1 0.9681024551391602
- O 0 5.319359843269922e-05
1 O 0 5.411068855210033e-07
. O 0 1.063236538811907e-07

Additionally O 0 5.215900273469742e-06
, O 0 3.025990480409746e-08
the O 0 1.9099614334550097e-08
X O 0 0.00020471448078751564
- O 0 5.992820661049336e-06
linked O 0 3.377750772415311e-06
, O 0 4.389874685983841e-09
candidate O 0 3.0385407967514766e-08
dosage O 0 3.005894541274756e-06
- O 0 2.0338393369456753e-06
sensitive O 0 1.2030625839543063e-05
sex O 0 1.9444144072622294e-07
- O 0 1.2893461587282218e-07
reversal O 0 1.7155997511508758e-07
gene O 0 1.2033602558858547e-07
, O 0 3.127479830666857e-09
Dax O 0 0.2313024252653122
- O 0 3.888733601797867e-07
1 O 0 1.364115931323795e-08
, O 0 2.0436006220592162e-09
antagonizes O 0 4.845023227062484e-07
synergy O 0 1.0911214332054442e-07
between O 0 3.937620363103633e-08
SF O 0 0.0036906113382428885
- O 0 3.929618287656922e-06
1 O 0 2.394614107004145e-08
and O 0 2.8723519118756258e-09
WT1 O 0 8.685034913469281e-07
, O 0 3.2333224986302866e-10
most O 0 2.1394244709149746e-10
likely O 0 1.370049962368114e-09
through O 0 7.597876772180712e-10
a O 0 2.057477077599401e-09
direct O 0 6.813880126799177e-09
interaction O 0 1.091822632304229e-08
with O 0 3.271688697736863e-08
SF O 1 0.540595293045044
- O 0 1.3506049072020687e-05
1 O 0 3.419199003928952e-07
. O 0 1.31619387389037e-07

We O 0 4.0337948803426116e-07
propose O 0 8.12581788522948e-07
that O 0 9.334311990016886e-09
WT1 O 0 7.518504844483687e-06
and O 0 2.2994191439806855e-08
Dax O 1 0.9999090433120728
- O 0 8.671117029734887e-06
1 O 0 3.2707838215628726e-08
functionally O 0 5.306799621962455e-08
oppose O 0 5.188207197193151e-09
each O 0 2.085822764508194e-10
other O 0 5.499287483723414e-11
in O 0 1.586205833348231e-09
testis O 0 1.5430482847023086e-07
development O 0 1.6894705634484808e-09
by O 0 6.628000814856705e-09
modulating O 0 4.330929004936479e-05
SF O 0 0.027824629098176956
- O 0 8.098315447568893e-06
1 O 0 2.097818736501722e-07
- O 0 1.281722234125482e-06
mediated O 0 4.092138624400832e-06
transactivation O 0 2.3526465156464837e-05
. O 0 6.909539251864771e-08
. O 0 9.049579574593736e-08

A O 0 3.183312173860031e-06
mouse O 0 6.064544140826911e-05
model O 0 5.685730229743058e-06
for O 0 9.044055104823201e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9987687468528748
- O 1 0.5689993500709534
centre O 0 0.00011646679195109755
mutations O 0 6.884567119413987e-05
. O 0 1.0783040806927602e-06

Imprinting O 0 0.0003794610674958676
in O 0 4.139492091326247e-07
the O 0 3.710024998326844e-08
15q11 O 0 3.4240977129229577e-06
- O 0 1.1239288824071991e-06
q13 O 0 8.292836355394684e-07
region O 0 2.5774731682304264e-08
involves O 0 1.6191492591133283e-08
an O 0 3.9119791850339425e-09
imprinting O 0 2.1674421077477746e-05
centre O 0 1.5765449461468961e-06
( O 0 1.53687658155377e-08
IC O 0 4.629829390978557e-07
) O 0 1.2208484223563687e-09
, O 0 2.7314064898753543e-10
mapping O 0 1.0231049785147661e-08
in O 0 1.5100386496769147e-09
part O 0 1.1913124930984509e-09
to O 0 3.7793582152723104e-10
the O 0 1.0792501337064664e-09
promoter O 0 4.1202280698371396e-08
and O 0 7.671648316609492e-10
first O 0 4.347230131429569e-09
exon O 0 5.734494834541692e-07
of O 0 7.580337246793079e-09
SNRPN O 0 4.006781819043681e-05
. O 0 2.346348821902211e-07

Deletion O 0 7.15216519893147e-05
of O 0 1.3400916998307366e-07
this O 0 7.38402405886518e-08
IC O 0 2.0033956388942897e-05
abolishes O 0 1.6376643543480895e-05
local O 0 1.6602538721599558e-07
paternally O 0 3.7732472719653742e-06
derived O 0 4.929452401825074e-08
gene O 0 1.2988341779873736e-07
expression O 0 1.2940216898016388e-08
and O 0 2.3811088656344737e-09
results O 0 1.345269993180409e-07
in O 0 4.4137643271824345e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 3.360723712830804e-05
PWS B-Disease 1 1.0
) O 0 5.013416171095741e-07
. O 0 2.3726691722458781e-07

We O 0 4.3044272501902014e-07
have O 0 1.0183312859624039e-08
created O 0 9.739195228064546e-09
two O 0 2.1963391105828123e-09
deletion O 0 6.461795578616147e-07
mutations O 0 2.858526499949221e-07
in O 0 1.6444747785726577e-08
mice O 0 1.960456938832067e-05
to O 0 6.85128540567348e-08
understand O 0 6.610781611016137e-07
PWS B-Disease 1 1.0
and O 0 2.2362016238730575e-08
the O 0 2.7865447727037918e-09
mechanism O 0 1.4498715117383654e-08
of O 0 4.5871231812988356e-10
this O 0 4.474963066769533e-09
IC O 0 8.547869583708234e-06
. O 0 1.0921832682697641e-07

Mice O 0 0.002351366449147463
harbouring O 0 4.332598109613173e-05
an O 0 1.1651404463464132e-07
intragenic O 0 1.1722299859684426e-05
deletion O 0 3.7708116451540263e-06
in O 0 5.121871282653956e-08
Snrpn O 0 8.136867108987644e-06
are O 0 4.635959172105686e-09
phenotypically O 0 9.539699021843262e-07
normal O 0 4.031760454381583e-07
, O 0 1.3114890284882108e-09
suggesting O 0 1.8994331441035683e-08
that O 0 1.0768156366580683e-09
mutations O 0 3.136896609134965e-08
of O 0 6.198332958007313e-10
SNRPN O 0 5.36183961230563e-06
are O 0 4.1216544066635663e-10
not O 0 5.547212689194225e-10
sufficient O 0 6.295513887977222e-09
to O 0 2.130382625864513e-08
induce O 0 1.0552783351158723e-05
PWS B-Disease 1 0.9999998807907104
. O 0 2.162668351957109e-06

Mice O 0 0.00015109249216038734
with O 0 4.257428543041897e-08
a O 0 2.6575213141200038e-08
larger O 0 3.8798280144192177e-08
deletion O 0 3.2972329222502594e-07
involving O 0 1.814444061665199e-08
both O 0 1.276321359711119e-08
Snrpn O 0 4.012078534287866e-06
and O 0 7.368052390432922e-09
the O 0 3.428406003536111e-08
putative O 0 3.202093284926377e-05
PWS O 1 1.0
- O 0 0.0020971449557691813
IC O 0 2.824904913723003e-05
lack O 0 3.241229151740299e-08
expression O 0 7.063333917756154e-09
of O 0 4.86401419141913e-10
the O 0 5.043278683558583e-09
imprinted O 0 1.947360942722298e-06
genes O 0 1.264277784684964e-07
Zfp127 O 0 1.4400017107618623e-06
( O 0 1.7894988602051853e-08
mouse O 0 1.0761220892163692e-06
homologue O 0 1.2101171478207107e-06
of O 0 3.997224773399921e-09
ZNF127 O 0 5.382240033213748e-06
) O 0 9.468168471471472e-09
, O 0 4.3396499727066384e-09
Ndn O 0 6.392506747943116e-06
and O 0 1.2440996677298699e-08
Ipw O 0 4.299333795643179e-06
, O 0 1.5837389177875139e-09
and O 0 1.46793543986945e-09
manifest O 0 2.430538259545756e-08
several O 0 3.111569446545559e-09
phenotypes O 0 7.181549221968453e-07
common O 0 2.41082858565278e-07
to O 0 6.408999524865067e-06
PWS B-Disease 1 1.0
infants O 1 0.6756370663642883
. O 0 6.373346650434542e-07

These O 0 8.027889464301552e-08
data O 0 1.2532409243704024e-07
demonstrate O 0 9.032090630967105e-09
that O 0 4.217835802844405e-10
both O 0 1.7737770974246558e-10
the O 0 3.511164414771173e-10
position O 0 1.8539602075762218e-09
of O 0 3.535941678345367e-11
the O 0 1.1056912052609391e-09
IC O 0 3.632006553289102e-07
and O 0 5.381334267084981e-10
its O 0 3.3516629471819215e-09
role O 0 1.2691280248944281e-09
in O 0 4.225735039664613e-10
the O 0 3.064730136337346e-10
coordinate O 0 2.8600459778260756e-09
expression O 0 7.901250209663147e-10
of O 0 7.187268141750636e-11
genes O 0 4.557448640696293e-09
is O 0 3.5719374680276417e-10
conserved O 0 3.1649731724314734e-09
between O 0 8.247386107385068e-10
mouse O 0 4.2680960632424103e-07
and O 0 1.262209337049569e-09
human O 0 2.78868622638484e-10
, O 0 1.169578600634935e-10
and O 0 2.1950817552518487e-10
indicate O 0 2.230590379070918e-09
that O 0 1.06672469468716e-10
the O 0 8.212287516684569e-10
mouse O 0 3.0354595992321265e-07
is O 0 3.0401495210163887e-10
a O 0 5.64890190180023e-10
suitable O 0 2.5967012984295934e-09
model O 0 3.471956588896319e-08
system O 0 6.689983678143108e-08
in O 0 1.0727790877851362e-09
which O 0 5.045537876391393e-10
to O 0 2.79814865722372e-10
investigate O 0 2.2754007567016288e-09
the O 0 5.040660666644214e-10
molecular O 0 7.675780011595634e-09
mechanisms O 0 6.710774158591448e-09
of O 0 2.4834093115266853e-10
imprinting O 0 3.693940868743084e-07
in O 0 3.835012307717989e-09
this O 0 2.027208956256743e-10
region O 0 6.220919335220287e-10
of O 0 1.1493856560962357e-10
the O 0 2.190803760626636e-09
genome O 0 1.894967738280684e-08
. O 0 3.398857639780317e-09
. O 0 2.5919622004266785e-08

Mutations O 0 3.7594119930872694e-05
of O 0 2.585035474567121e-08
the O 0 2.5312147045042366e-08
ATM O 0 5.8363880270917434e-06
gene O 0 8.864984692991129e-07
detected O 0 2.5807894417084754e-06
in O 0 1.6619409848317446e-07
Japanese O 0 0.07864397019147873
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.6207469701766968
: O 0 1.1628998208834673e-08
possible O 0 9.08828834411679e-09
preponderance O 0 5.715800455163844e-08
of O 0 3.248045721271353e-10
the O 0 1.2157710393978505e-09
two O 0 2.116965935883286e-09
founder O 0 7.950464464556717e-08
mutations O 0 1.7581038491698564e-07
4612del165 O 0 2.0042550374910206e-07
and O 0 1.3717842861638019e-08
7883del5 O 0 4.080591224919772e-06
. O 0 3.737241627277399e-07

The O 0 3.087373670496163e-06
ATM O 0 0.00025088616530410945
( O 0 2.1216658296907553e-06
A O 1 0.9999984502792358
- O 1 0.9999994039535522
T O 1 1.0
, O 0 1.1174564384930363e-08
mutated O 0 3.170485740611184e-07
) O 0 1.5375147821572455e-09
gene O 0 1.855797293615069e-08
on O 0 6.2744391904345775e-09
human O 0 1.7809215435704573e-08
chromosome O 0 1.8049573782263906e-06
11q22 O 0 3.207330792065477e-06
. O 0 2.117908621812603e-07

3 O 0 1.7373495211359113e-05
has O 0 8.10855667054966e-08
recently O 0 1.3056472880634828e-07
been O 0 2.3561885775791325e-09
identified O 0 1.2508540869760054e-09
as O 0 2.6765437088904775e-10
the O 0 3.4419192496137896e-10
gene O 0 9.246297949516702e-09
responsible O 0 1.2607271893116945e-09
for O 0 5.387226081898788e-11
the O 0 2.9839435367051692e-09
human O 0 2.6350085136073176e-07
recessive B-Disease 1 0.9999983310699463
disease I-Disease 1 0.9999998807907104
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0021004583686590195
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 2.0207646400649537e-07
. O 0 8.661909589591232e-08

In O 0 5.524074140339508e-07
order O 0 1.9502488513012395e-08
to O 0 2.1904820179941e-09
define O 0 5.353899545923468e-09
the O 0 1.1490310924955338e-09
types O 0 6.759615978069178e-09
of O 0 2.5790700686201262e-09
disease O 0 1.9267399693490006e-05
- O 0 8.893912308849394e-06
causing O 0 2.636760655150283e-06
ATM O 0 6.164907972561195e-05
mutations O 0 2.7659164061333286e-06
in O 0 1.8232906739967802e-08
Japanese O 0 1.8944890598504571e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.5249360103553045e-06
as O 0 3.246214186347629e-09
well O 0 6.726147971924945e-10
as O 0 3.7620470627608427e-10
to O 0 4.977984136012026e-10
look O 0 4.989288093781852e-09
for O 0 1.0534608602119633e-10
possible O 0 3.1219609120114455e-09
mutational O 0 1.4872900919726817e-06
hotspots O 0 1.224564556423502e-07
, O 0 1.5338066372549974e-09
reverse O 0 5.502852218342014e-07
- O 0 1.3365742290716298e-07
transcribed O 0 8.087025804570658e-08
RNA O 0 5.557586391091718e-08
derived O 0 4.967382505327578e-09
from O 0 5.347080000994708e-10
ten O 0 7.86634923866103e-10
patients O 0 5.505492728374861e-10
belonging O 0 1.0747022161083919e-09
to O 0 7.024448800407868e-10
eight O 0 1.4000032244609883e-09
unrelated O 0 1.989814535363621e-08
Japanese O 0 7.849852181607275e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
families O 0 4.994727831331147e-08
was O 0 2.863344406023316e-08
analyzed O 0 1.7077015357358505e-08
for O 0 6.91501744753964e-10
mutations O 0 3.2130014204767576e-08
by O 0 7.79234010650498e-10
the O 0 4.0509511300967915e-09
restriction O 0 2.126562890225614e-07
endonuclease O 0 1.0827044206962455e-05
fingerprinting O 0 1.6911725424506585e-06
method O 0 1.1625248816926614e-06
. O 0 1.759281360591558e-07

As O 0 1.8230859666346078e-07
has O 0 7.68568320097529e-09
been O 0 1.0164988850647205e-09
reported O 0 9.50036849189928e-09
by O 0 5.746347286894604e-10
others O 0 1.0598399935446423e-09
, O 0 4.5353942823567195e-10
mutations O 0 1.2664831849917846e-08
that O 0 1.5398912700526068e-10
lead O 0 2.5920843249593872e-09
to O 0 4.098710260080907e-09
exon O 0 6.079681611481647e-07
skipping O 0 2.53979948183769e-07
or O 0 4.6775383566455275e-08
premature O 0 2.444230062792485e-07
protein O 0 3.419530969495099e-08
truncation O 0 5.569289669438149e-07
were O 0 6.633717575255105e-09
also O 0 3.116059410501748e-09
predominant O 0 6.994160628437385e-08
in O 0 2.9567377435313347e-09
our O 0 1.2875025490188818e-08
mutants O 0 6.209805292201054e-07
. O 0 8.026342612765802e-08

Six O 0 3.3182988090629806e-07
different O 0 1.3174592972120536e-08
mutations O 0 4.018562833607575e-07
were O 0 9.285001212333555e-09
identified O 0 8.70882033154885e-09
on O 0 8.698382458760534e-08
12 O 0 8.49624903764834e-09
of O 0 7.533858953356898e-11
the O 0 3.4767790868528436e-09
16 O 0 6.587333700736053e-08
alleles O 0 5.693732987310796e-07
examined O 0 2.011607648455538e-06
. O 0 2.84366990399576e-07

Four O 0 2.345290681660117e-07
were O 0 1.0165885910851102e-08
deletions O 0 2.5388305857632076e-07
involving O 0 8.675133500446464e-09
a O 0 2.8505006355317164e-08
loss O 0 1.1048616244124787e-07
of O 0 7.23499815613593e-10
a O 0 1.9994359945485485e-08
single O 0 1.2155726381024579e-07
exon O 0 3.183336275469628e-06
exon O 0 2.0801890059374273e-06
7 O 0 1.918957508451058e-07
, O 0 3.2637403890589667e-09
exon O 0 5.364552748687856e-07
16 O 0 3.77084390379423e-08
, O 0 2.8954045827589425e-09
exon O 0 7.089952873684524e-07
33 O 0 1.4478658272309985e-07
or O 0 5.8904497279854695e-08
exon O 0 5.2389223128557205e-06
35 O 0 8.448691914964002e-07
. O 0 1.743520670061116e-07

The O 0 5.831981866322167e-07
others O 0 1.0665187488712036e-07
were O 0 5.830488092328778e-09
minute O 0 7.168959825776255e-08
deletions O 0 1.007167384159402e-06
, O 0 5.2002544492779634e-09
4649delA O 0 3.625092404035968e-07
in O 0 1.808094296507079e-08
exon O 0 1.0709406979003688e-06
33 O 0 6.8737584513201e-08
and O 0 3.822728800173536e-09
7883del5 O 0 4.940352482663002e-07
in O 0 4.979830947604569e-08
exon O 0 6.156215476949001e-06
55 O 0 1.865583840299223e-06
. O 0 1.8877317131682503e-07

The O 0 6.29012731678813e-07
mutations O 0 1.0018335160566494e-05
4612del165 O 0 1.6341273294528946e-06
and O 0 9.455931149204844e-09
7883del5 O 0 2.5213853405148257e-07
were O 0 4.911065776269652e-09
found O 0 1.6416845660671697e-09
in O 0 8.924782579633472e-10
more O 0 1.6143709979932197e-10
than O 0 1.1558334844785634e-10
two O 0 1.3414426514035682e-10
unrelated O 0 4.8874051472580504e-09
families O 0 7.585423955625004e-10
; O 0 6.366550064917931e-10
44 O 0 3.138433068983204e-09
% O 0 5.061779329018634e-10
( O 0 1.0452811949335228e-09
7 O 0 9.320773486365397e-09
of O 0 1.9190372901878305e-10
16 O 0 5.352735588104451e-09
) O 0 7.837890059203545e-11
of O 0 3.7538954583693496e-11
the O 0 1.2151658568271273e-09
mutant O 0 6.587534073787538e-08
alleles O 0 3.1434851166523003e-08
had O 0 7.920160527419284e-09
one O 0 1.642839614346414e-10
of O 0 7.750625141689227e-11
the O 0 1.2398989612805167e-09
two O 0 4.911721251943391e-09
mutations O 0 1.6447480675196857e-06
. O 0 1.4579642027001682e-07

The O 0 3.567842554730305e-07
4612del165 O 0 6.620285148528637e-06
mutations O 0 1.3496304518412217e-06
in O 0 1.0428741425982935e-08
three O 0 5.179859319248692e-10
different O 0 1.5142950782198739e-10
families O 0 5.339710895668759e-10
were O 0 6.367520954952965e-10
all O 0 1.215958306266529e-10
ascribed O 0 1.2885540634499648e-08
to O 0 7.086202735706593e-10
the O 0 1.2845976504749501e-09
same O 0 2.893611750209857e-08
T O 0 6.001450674375519e-05
- O 0 4.862386617787706e-07
- O 0 1.6024611682041723e-07
> O 0 1.7031638321896025e-08
A O 0 3.029037909385579e-09
substitution O 0 3.973750661856457e-09
at O 0 3.007031068591459e-09
the O 0 2.0343913220699505e-09
splice O 0 1.6093741805889294e-06
donor O 0 4.733027836323345e-08
site O 0 6.118570894386721e-08
in O 0 2.6349196602382108e-08
intron O 0 1.8955528503283858e-05
33 O 0 1.3547899015975418e-06
. O 0 1.1285285239637233e-07

Microsatellite O 0 0.0015134699642658234
genotyping O 0 8.842239913064986e-05
around O 0 1.403487203788245e-06
the O 0 2.6320766011167507e-08
ATM O 0 7.26725420463481e-06
locus O 0 1.6118747225846164e-06
also O 0 8.053912203820346e-09
indicated O 0 3.512755597512296e-08
that O 0 2.2589154158314528e-10
a O 0 2.772834184483486e-09
common O 0 9.886132801284475e-09
haplotype O 0 5.319108367984882e-06
was O 0 3.639356549456352e-08
shared O 0 7.941485247187074e-10
by O 0 1.7862029910720167e-10
the O 0 6.600470170425865e-10
mutant O 0 5.26342276430114e-08
alleles O 0 5.3260965415802275e-08
in O 0 3.688081173791602e-09
both O 0 1.8448321981168192e-08
mutations O 0 4.117107891943306e-06
. O 0 3.1946208878252946e-07

This O 0 1.4203735076989688e-07
suggests O 0 4.1934065109217045e-08
that O 0 1.0707799091846937e-09
these O 0 2.3095704515530002e-10
two O 0 5.833833416346579e-10
founder O 0 6.42601705180823e-08
mutations O 0 7.030466235846689e-07
may O 0 5.4107132996250584e-08
be O 0 7.858221295897749e-10
predominant O 0 2.6750358372851224e-08
among O 0 6.046150802241357e-10
Japanese O 0 3.5859351044109644e-08
ATM O 0 8.744043952901848e-06
mutant O 0 2.9148220619390486e-06
alleles O 0 5.234737272985512e-06
. O 0 4.3280630279696197e-07

W474C O 0 0.0004139069060329348
amino O 0 2.039334322034847e-05
acid O 0 5.222709660301916e-06
substitution O 0 1.0301247357347165e-06
affects O 0 2.8533790441542806e-07
early O 0 7.296799964251477e-08
processing O 0 1.2667803694910162e-08
of O 0 2.0744042594778023e-10
the O 0 1.2170261465271892e-09
alpha O 0 1.865133647527273e-08
- O 0 1.0097361169414398e-08
subunit O 0 8.874271095749009e-09
of O 0 3.809457749248679e-10
beta O 0 3.553091687535925e-08
- O 0 1.4892314936787443e-07
hexosaminidase O 0 5.256480903881311e-07
A O 0 1.4903704936841677e-08
and O 0 7.415363323381996e-10
is O 0 1.579707475940495e-10
associated O 0 5.796237267929882e-09
with O 0 9.490044305948686e-09
subacute O 0 0.00010478990589035675
G B-Disease 0 0.00014073995407670736
( I-Disease 0 1.0947444195608114e-07
M2 I-Disease 0 4.7907531552482396e-05
) I-Disease 0 1.6161833116257185e-07
gangliosidosis I-Disease 0 2.8828428185079247e-05
. O 0 3.7575011901935795e-07

Mutations O 0 0.00024412362836301327
in O 0 4.241283590999956e-07
the O 0 9.150963364845666e-08
HEXA O 0 4.438333780854009e-05
gene O 0 7.620450901413278e-07
, O 0 3.0884388380059136e-09
encoding O 0 3.106222479232201e-08
the O 0 3.0458737754202048e-09
alpha O 0 3.8190869133813976e-08
- O 0 4.108879991804315e-08
subunit O 0 2.190700598703188e-08
of O 0 1.3906061857582586e-09
beta O 0 1.0163194730239411e-07
- O 0 5.714927624467236e-07
hexosaminidase O 0 1.6956670378931449e-06
A O 0 8.191988598582611e-08
( O 0 7.267794810417172e-09
Hex O 0 1.7435772292628826e-07
A O 0 7.465520646121604e-09
) O 0 4.540076647963076e-10
, O 0 1.6294271487637957e-10
that O 0 2.8399207985252417e-10
abolish O 0 1.4685276994441665e-07
Hex O 0 5.565499705539878e-08
A O 0 4.033388290025641e-09
enzyme O 0 1.0377036829822828e-07
activity O 0 7.36763354325376e-07
cause O 0 0.0007251655915752053
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999690055847168
( O 0 3.525933323089703e-07
TSD B-Disease 0 4.643806823878549e-05
) O 0 1.0586405529977583e-08
, O 0 9.510588983019375e-10
the O 0 1.4653624980098812e-08
fatal O 0 0.0012169533874839544
infantile B-Disease 0 0.1009683907032013
form I-Disease 0 1.1874752203766548e-07
of I-Disease 0 1.062011900643256e-08
G I-Disease 0 5.733239959226921e-05
( I-Disease 0 3.3501816432135456e-08
M2 I-Disease 0 4.936923232889967e-06
) I-Disease 0 1.1169876579231186e-08
gangliosidosis I-Disease 0 1.2208115549583454e-06
, I-Disease 0 6.4767116114694545e-09
Type I-Disease 0 1.3403695220404188e-06
1 I-Disease 0 2.715633797834016e-07
. O 0 1.3820863387081772e-07

Less O 0 2.115315328410361e-05
severe O 0 0.11258165538311005
, O 0 7.68162578879128e-07
subacute O 0 0.26620370149612427
( O 0 1.9060183831243194e-06
juvenile O 0 0.33132413029670715
- O 1 0.969414472579956
onset O 1 0.9995259046554565
) O 0 2.2735500238013628e-07
and O 0 4.1502400449644483e-07
chronic O 0 0.0022147633135318756
( O 0 9.601365036360221e-08
adult O 0 9.501867680228315e-06
- O 0 0.006937501020729542
onset O 0 0.3968145549297333
) O 0 6.598874779939479e-09
variants O 0 9.298438641280882e-08
are O 0 4.3415518402589726e-10
characterized O 0 9.229876418714866e-09
by O 0 4.716999013609779e-10
a O 0 4.777030770952706e-09
broad O 0 9.29632903989841e-08
spectrum O 0 1.4192578134952782e-07
of O 0 7.64229346472689e-10
clinical O 0 3.3610493943569963e-08
manifestations O 0 2.6333571767622743e-08
and O 0 1.2678408323196777e-09
are O 0 9.279273877060845e-11
associated O 0 1.8258857759079206e-09
with O 0 1.772303415137344e-09
residual O 0 2.9149532565497793e-07
levels O 0 7.204531016213878e-08
of O 0 1.1288245893581461e-09
Hex O 0 2.1873776745451323e-07
A O 0 1.2999043619288386e-08
enzyme O 0 2.2532124432927958e-07
activity O 0 6.313987341854954e-07
. O 0 1.2639546298487403e-07

We O 0 2.925410740317602e-07
identified O 0 2.1156112950393435e-07
a O 0 9.973980752420175e-08
1422 O 0 8.509214239893481e-05
G O 0 8.905535651138052e-05
- O 0 2.4318740543094464e-05
- O 0 7.4993199632444885e-06
> O 0 1.3640843690154725e-06
C O 0 3.703648644659552e-06
( O 0 1.5327955793509318e-08
amino O 0 3.129474279717215e-08
acid O 0 6.340742686461454e-08
W474C O 0 8.513285365552292e-08
) O 0 1.1534182497996426e-09
substitution O 0 3.4309031171630977e-09
in O 0 6.427850474111096e-10
the O 0 9.227213992879513e-10
first O 0 1.601863641731427e-09
position O 0 4.964105571048094e-09
of O 0 3.1306832126709594e-10
exon O 0 1.2621093503639713e-07
13 O 0 4.818227150593657e-09
of O 0 5.271032499365447e-10
HEXA O 0 9.745216402734513e-07
of O 0 2.419919542528959e-10
a O 0 4.657283003695056e-09
non O 0 1.1725348691982163e-08
- O 0 3.8558374626518344e-07
Jewish O 0 1.3891043693092797e-07
proband O 0 8.778049050306436e-06
who O 0 2.8021357678653658e-08
manifested O 0 2.624007038320997e-07
a O 0 5.1903381148576955e-08
subacute O 0 1.7077809388865717e-05
variant O 0 2.5147164706140757e-05
of O 0 3.474719179052954e-08
G B-Disease 0 0.0001964649563888088
( I-Disease 0 1.0568030717195143e-07
M2 I-Disease 0 2.2055643057683483e-05
) I-Disease 0 1.0948906492558308e-07
gangliosidosis I-Disease 0 3.4642016544239596e-05
. O 0 2.65813014266314e-07

On O 0 1.1017739325325238e-06
the O 0 6.216915693357805e-08
second O 0 1.4200794851149112e-07
maternally O 0 6.7789674176310655e-06
inherited O 0 3.8261628105829e-06
allele O 0 7.80565926561394e-07
, O 0 1.5192515023798592e-09
we O 0 2.1508848868645458e-10
identified O 0 1.6224810384102284e-09
the O 0 3.34485505959492e-09
common O 0 1.654787638472044e-06
infantile O 1 0.9999837875366211
disease O 1 0.9681352376937866
- O 0 0.0008695429423823953
causing O 0 1.8462123989593238e-05
4 O 0 4.975559022568632e-07
- O 0 2.5763999929040438e-06
bp O 0 7.371955916823936e-07
insertion O 0 1.627500552103811e-07
, O 0 2.5908635237215094e-09
+ O 0 8.980919119494502e-08
TATC O 0 1.7979823496716563e-06
1278 O 0 3.997748081019381e-06
, O 0 2.2167130353523135e-09
in O 0 9.623656538337855e-09
exon O 0 2.3021984816296026e-06
11 O 0 2.552620230744651e-07
. O 0 5.739025255024899e-08

Pulse O 0 0.007970858365297318
- O 0 2.0458637663978152e-05
chase O 0 2.6430145680933492e-06
analysis O 0 3.3157267154138026e-08
using O 0 3.8202305319146035e-08
proband O 0 2.5002875645441236e-06
fibroblasts O 0 4.511147153607453e-07
revealed O 0 4.674880571542417e-08
that O 0 6.052220391516983e-10
the O 0 1.1085355966500288e-09
W474C O 0 1.575775172568683e-07
- O 0 2.3856969733060396e-08
containing O 0 9.042519621971223e-09
alpha O 0 1.3061275616621515e-08
- O 0 2.982670466167292e-08
subunit O 0 2.135989340956712e-08
precursor O 0 3.952767713144567e-08
was O 0 9.423163582766847e-09
normally O 0 4.0853556093622956e-09
synthesized O 0 2.0606632844533124e-08
, O 0 2.322877029614645e-10
but O 0 2.0324898708512507e-10
not O 0 1.7719983813613283e-10
phosphorylated O 0 1.6988002116136158e-08
or O 0 1.6507180067293348e-09
secreted O 0 1.3591943570645526e-08
, O 0 3.8520620027071573e-10
and O 0 2.14187417801881e-10
the O 0 1.5217718196680607e-09
mature O 0 3.7953121534428647e-08
lysosomal O 0 6.13193662957201e-07
alpha O 0 4.486400229097853e-08
- O 0 6.892874182540254e-08
subunit O 0 5.3712494008095746e-08
was O 0 5.863166663289121e-08
not O 0 4.07023614812374e-09
detected O 0 8.360843821719754e-07
. O 0 1.2820983386063745e-07

When O 0 8.319341304741101e-07
the O 0 4.943698428405696e-08
W474C O 0 1.459654754398798e-06
- O 0 1.8213724217730487e-07
containing O 0 2.4304593893020865e-08
alpha O 0 6.982777023267772e-08
- O 0 1.2581675434830686e-07
subunit O 0 1.1142410016873328e-07
was O 0 1.0096922409275066e-07
transiently O 0 6.330121209430217e-07
co O 0 7.808534974174108e-08
- O 0 3.637961398794687e-08
expressed O 0 1.2461248699580096e-09
with O 0 1.6782321365926833e-10
the O 0 5.298308458634438e-10
beta O 0 1.0074238332435925e-08
- O 0 8.983246146954116e-09
subunit O 0 6.354081705239878e-09
to O 0 1.823999173922175e-09
produce O 0 8.00603494610641e-09
Hex O 0 1.6867673480192025e-07
A O 0 1.281187245183446e-08
( O 0 4.160611855041907e-09
alphabeta O 0 1.9533506190327898e-07
) O 0 1.0888834278688364e-09
in O 0 4.272378006930921e-09
COS O 0 6.072882570151705e-06
- O 0 1.8818467140135908e-07
7 O 0 1.6942021119348283e-08
cells O 0 8.798630268813667e-09
, O 0 2.834795731487816e-10
the O 0 6.20631823711193e-10
mature O 0 7.09912528762402e-09
alpha O 0 5.85177906131662e-09
- O 0 9.920245958028318e-09
subunit O 0 8.330311551674185e-09
was O 0 7.924165323913712e-09
present O 0 1.7607791613638568e-10
, O 0 3.3453878556244376e-11
but O 0 4.2960052182294817e-11
its O 0 8.196138212568371e-10
level O 0 7.352147335382142e-09
was O 0 2.167773160977049e-08
much O 0 6.47573217271713e-10
lower O 0 4.782302198691468e-07
than O 0 1.99413610624255e-10
that O 0 1.1722250947698853e-10
from O 0 2.3646920532804927e-10
normal O 0 1.0996179966582531e-08
alpha O 0 1.2624844281106107e-08
- O 0 1.960968987191336e-08
subunit O 0 1.2421766726333772e-08
transfections O 0 1.0658395410700905e-07
, O 0 1.5598627944868326e-10
although O 0 1.4095008493697492e-10
higher O 0 1.273891103714675e-09
than O 0 9.308700338328535e-11
in O 0 3.50462742160218e-10
those O 0 4.158436373025154e-10
cells O 0 6.3427481045152945e-09
transfected O 0 6.324726342654685e-08
with O 0 3.5772418360835445e-10
an O 0 3.149663307944195e-10
alpha O 0 2.0284447899143743e-08
- O 0 3.917752877669045e-08
subunit O 0 3.706036011408287e-08
associated O 0 6.445498712537301e-08
with O 0 7.109819932793471e-08
infantile O 0 0.443837970495224
TSD B-Disease 0 0.0008325560484081507
. O 0 1.2716627679765224e-06

Furthermore O 0 3.5109653708786936e-06
, O 0 1.0438074404817144e-08
the O 0 1.7919367101271177e-09
precursor O 0 6.71634765581075e-08
level O 0 1.274620853308761e-08
of O 0 2.6508564787697253e-10
the O 0 3.0728324329487577e-09
W474C O 0 1.414644401620535e-07
alpha O 0 2.201469584406368e-08
- O 0 2.2951601508225394e-08
subunit O 0 1.4454756502857435e-08
was O 0 9.434224068627373e-09
found O 0 7.435134175004521e-10
to O 0 1.1890470830167033e-09
accumulate O 0 6.627801241165798e-08
in O 0 1.9066916934207256e-09
comparison O 0 5.616920262241365e-09
to O 0 7.125221523907044e-10
the O 0 1.178887321096056e-09
normal O 0 2.1620252255161176e-08
alpha O 0 2.117960740122271e-08
- O 0 2.892121742092968e-08
subunit O 0 3.89347576401633e-08
precursor O 0 1.0410004591676625e-07
levels O 0 2.8220193826200557e-07
. O 0 4.336614978228681e-08

We O 0 6.774538405807107e-07
conclude O 0 4.362233028132323e-07
that O 0 4.935941877448613e-09
the O 0 2.0600383621172114e-08
1422 O 0 1.851504021033179e-05
G O 0 1.0069186828332022e-05
- O 0 2.848788653864176e-06
- O 0 2.926478373410646e-06
> O 0 8.589075264353596e-07
C O 0 6.565021067217458e-06
mutation O 0 2.1067886279979575e-07
is O 0 1.089022538813822e-09
the O 0 1.7177688160785465e-09
cause O 0 1.1229239760268683e-08
of O 0 7.070851126833588e-10
Hex B-Disease 0 2.513889739930164e-06
A I-Disease 0 3.986689080193173e-06
enzyme I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999997615814209
in O 0 2.6985732759499115e-08
the O 0 4.282464161065036e-08
proband O 0 2.7515845431480557e-05
. O 0 2.2543601119195955e-07

The O 0 5.537703486879764e-07
resulting O 0 6.570443247255753e-07
W474C O 0 4.993593393010087e-06
substitution O 0 5.089331125418539e-07
clearly O 0 6.935232477189857e-08
interferes O 0 2.3253844005921565e-07
with O 0 1.8362164011520576e-09
alpha O 0 4.466310343786972e-08
- O 0 2.3899417556094704e-08
subunit O 0 1.4847327811651212e-08
processing O 0 2.531850507025979e-09
, O 0 1.04255083732685e-10
but O 0 8.009676949471967e-11
because O 0 8.580305910221853e-11
the O 0 3.352172706083678e-10
base O 0 2.1955266493733916e-09
substitution O 0 4.429134392580636e-09
falls O 0 9.712593964650296e-07
at O 0 4.916998364024039e-09
the O 0 7.926941880675997e-10
first O 0 1.2724097331329176e-09
position O 0 3.5586378288599008e-09
of O 0 1.5534851183218734e-10
exon O 0 1.4412695747978432e-07
13 O 0 5.117825718770064e-09
, O 0 4.4917214392370397e-10
aberrant O 0 1.9822503816158132e-07
splicing O 0 6.854512548670755e-07
may O 0 2.257815481243597e-07
also O 0 1.7483577918753213e-09
contribute O 0 1.062805621288021e-09
to O 0 3.5601042114308257e-09
Hex B-Disease 0 3.3701253414619714e-06
A I-Disease 0 1.0663260354704107e-06
deficiency I-Disease 0 1.0672756616258994e-05
in O 0 2.1307879904952642e-09
this O 0 1.8418885305848676e-09
proband O 0 1.4693810044263955e-06
. O 0 7.76603759078398e-09
. O 0 7.351869868443828e-08

Two O 0 9.822726951824734e-07
frequent O 0 1.2719679034489673e-05
missense O 0 0.0017604152671992779
mutations O 0 0.031237119808793068
in O 0 0.0035840438213199377
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.2268350474187173e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 6.762249995517777e-06
an O 0 5.225829954724759e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.8785589933395386
by O 0 7.65300626426324e-07
early O 1 0.8062047362327576
childhood O 1 0.9999991655349731
deafness B-Disease 1 1.0
and O 1 0.6621332168579102
goiter B-Disease 1 1.0
. O 0 5.820740625495091e-06

A O 0 8.720390951566515e-07
century O 0 1.461767737964692e-07
after O 0 1.3206618909578083e-08
its O 0 1.6531158664179202e-09
recognition O 0 1.4011893867404979e-09
as O 0 2.942481813761333e-09
a O 0 1.2896732926037657e-07
syndrome O 0 0.03610115498304367
by O 0 2.7211637387836163e-09
Vaughan O 0 1.084016162167245e-06
Pendred O 0 9.92378659248061e-07
, O 0 1.5505788875103121e-09
the O 0 1.118657078080787e-08
disease O 0 2.7877106276719132e-06
gene O 0 1.060039721778594e-06
( O 0 3.832864337027786e-08
PDS O 0 3.8098944514786126e-06
) O 0 2.8799165274762117e-09
was O 0 1.8099092002898942e-08
mapped O 0 1.4258674241318658e-07
to O 0 1.0768510527725539e-08
chromosome O 0 2.4981020487757633e-06
7q22 O 0 6.370810297084972e-06
- O 0 7.807224392308854e-06
q31 O 0 1.7775058950064704e-05
. O 0 6.842716970822948e-07

1 O 0 2.2470289877674077e-06
and O 0 1.6856892770533705e-08
, O 0 1.8967023507343583e-09
recently O 0 1.527646986687614e-08
, O 0 1.656586950948835e-10
found O 0 5.131624569720827e-10
to O 0 4.2925754617506584e-10
encode O 0 3.0897659542006295e-08
a O 0 2.3944130234099248e-08
putative O 0 2.5984127205447294e-06
sulfate O 0 4.860958142671734e-06
transporter O 0 2.2865993742016144e-05
. O 0 3.2514773806724406e-07

We O 0 6.624451316383784e-07
performed O 0 2.565543013588467e-07
mutation O 0 2.2567736834844254e-07
analysis O 0 7.269000956711125e-09
of O 0 2.5595839336922666e-10
the O 0 4.681873999601294e-09
PDS B-Disease 0 1.7130898868344957e-06
gene O 0 1.7610906866138976e-07
in O 0 9.394915956306704e-09
patients O 0 2.0530798394702288e-08
from O 0 6.043157085855455e-09
14 O 0 1.9775896475948684e-08
Pendred B-Disease 0 5.459424983200734e-07
families O 0 2.203682569756893e-09
originating O 0 1.1119264620162994e-08
from O 0 7.395236090168567e-10
seven O 0 4.75800510102431e-10
countries O 0 1.8316821670527617e-10
and O 0 7.322334960591093e-10
identified O 0 6.8388397167495896e-09
all O 0 3.9672527485379305e-09
mutations O 0 2.1078869849588955e-06
. O 0 1.9618748581251566e-07

The O 0 8.834938398649683e-07
mutations O 0 5.0061530600942206e-06
include O 0 3.229350298283862e-08
three O 0 4.518352358928723e-09
single O 0 1.3192067882528136e-08
base O 0 4.063288017164268e-08
deletions O 0 4.082079669842642e-07
, O 0 2.09414730001356e-09
one O 0 2.8612954228179888e-09
splice O 0 8.978297955763992e-06
site O 0 7.438835609718808e-07
mutation O 0 5.192506478124415e-07
and O 0 1.7642939553752512e-08
10 O 0 1.4755215715922532e-07
missense O 0 9.998483437811956e-05
mutations O 0 5.286151645123027e-05
. O 0 6.87231590745796e-07

One O 0 1.6588356857027975e-06
missense O 0 0.00028197572100907564
mutation O 0 4.4606229494092986e-05
( O 0 2.497780258181592e-07
L236P O 0 1.5945081486279378e-06
) O 0 1.2405666716119867e-08
was O 0 1.9876029710985677e-08
found O 0 1.05283459728156e-09
in O 0 7.390780765170746e-10
a O 0 2.654591879647228e-09
homozygous O 0 9.255706601152269e-08
state O 0 1.029904272975557e-09
in O 0 1.1370641095354017e-09
two O 0 1.5757092297619124e-09
consanguineous O 0 4.875973900198005e-07
families O 0 1.0487319901386627e-09
and O 0 4.44195763504851e-10
in O 0 7.609363139593484e-10
a O 0 1.0010683837435863e-08
heterozygous O 0 1.8051434835797409e-07
state O 0 4.1805686690210564e-10
in O 0 4.3490855361483227e-10
five O 0 4.41902292536156e-10
additional O 0 8.4527312926852e-10
non O 0 1.0556341578649153e-08
- O 0 2.12811391975265e-06
consanguineous O 0 1.4930861652828753e-05
families O 0 5.826322535540385e-08
. O 0 6.9612745789982e-08

Another O 0 2.1644553271471523e-05
missense O 0 0.0013810424134135246
mutation O 0 0.00011387660197215155
( O 0 6.523043225570291e-07
T416P O 0 2.0096574644412613e-06
) O 0 2.686617328606644e-08
was O 0 1.1921200915310237e-08
found O 0 1.2055393350252075e-09
in O 0 9.37225297370503e-10
a O 0 2.8215809688703075e-09
homozygous O 0 2.3688658146170383e-08
state O 0 3.6615499521275297e-10
in O 0 8.093762327021636e-10
one O 0 4.674564069162557e-10
family O 0 1.4208408893878754e-09
and O 0 1.4294571082373864e-10
in O 0 2.5439508832825197e-10
a O 0 2.0210328965930557e-09
heterozygous O 0 5.787148893432459e-08
state O 0 4.552190013829005e-10
in O 0 1.0812446493702055e-09
four O 0 2.240504004547006e-09
families O 0 1.2937650950561874e-08
. O 0 4.718812718351728e-08

Pendred B-Disease 0 0.0019760553259402514
patients O 0 1.3755457075603772e-05
in O 0 7.59010632123136e-08
three O 0 4.920835738886353e-09
non O 0 2.0383074783580923e-08
- O 0 1.0854582797037438e-06
consanguineous O 0 5.1841134336427785e-06
families O 0 6.2790004307089475e-09
were O 0 2.7324396079109192e-09
shown O 0 2.783670849382247e-09
to O 0 9.10676367649188e-10
be O 0 6.095896565305736e-10
compound O 0 3.0971115450029174e-08
heterozygotes O 0 1.599050705181071e-07
for O 0 1.1310099523598183e-09
L236P O 0 4.217832270114741e-07
and O 0 2.588577885376253e-08
T416P O 0 5.518436864804244e-06
. O 0 2.435063208849897e-07

In O 0 2.232434894722246e-07
total O 0 5.684301473962705e-09
, O 0 8.457747280310457e-10
one O 0 3.49039186442468e-10
or O 0 5.01547692266513e-10
both O 0 1.6558761306573189e-10
of O 0 2.784597379068554e-11
these O 0 1.441198826945822e-10
mutations O 0 1.0858207666331054e-08
were O 0 9.77005698565847e-10
found O 0 8.829120767828158e-10
in O 0 7.907582366684096e-10
nine O 0 1.0311838050114375e-09
of O 0 5.687202445092687e-11
the O 0 1.493756340842367e-09
14 O 0 9.065729500434827e-09
families O 0 2.2136708022202356e-09
analyzed O 0 1.4851185881070705e-07
. O 0 5.098916133761122e-08

The O 0 1.3509551877177728e-07
identification O 0 6.28903507049472e-08
of O 0 1.7872773261373709e-09
two O 0 3.9416834241023935e-09
frequent O 0 5.121392518958601e-07
PDS B-Disease 0 0.0001183696003863588
mutations O 0 2.805291160257184e-06
will O 0 2.510059493587846e-09
facilitate O 0 3.6486336174590406e-09
the O 0 3.938527282087989e-09
molecular O 0 2.06831214200065e-06
diagnosis O 0 0.0009000010322779417
of O 0 3.5458995171211427e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.213659510947764e-06

Insertional O 0 0.00048523888108320534
mutation O 0 1.2138656529714353e-05
by O 0 6.44112319037049e-08
transposable O 0 3.1521303753834218e-06
element O 0 1.0900272684466472e-07
, O 0 1.0797571725618127e-08
L1 O 0 1.2452386727090925e-05
, O 0 3.3447851155443686e-09
in O 0 4.301076383939062e-09
the O 0 4.73735397577002e-08
DMD B-Disease 1 0.9999997615814209
gene O 0 2.8333690806903178e-06
results O 0 3.083819990479242e-07
in O 0 1.7608607549846056e-07
X B-Disease 1 0.9994860887527466
- I-Disease 1 0.9925948977470398
linked I-Disease 1 0.9992000460624695
dilated I-Disease 1 0.9937428832054138
cardiomyopathy I-Disease 1 1.0
. O 0 2.785297965601785e-06

X B-Disease 1 0.9999194145202637
- I-Disease 1 0.9997127652168274
linked I-Disease 1 0.9997242093086243
dilated I-Disease 1 0.9999845027923584
cardiomyopathy I-Disease 1 1.0
( O 0 7.049970008665696e-06
XLDCM B-Disease 0 0.0002964832237921655
) O 0 1.0984755327569928e-08
is O 0 9.284501500950171e-10
a O 0 5.921514834028585e-09
clinical O 0 1.4536310288804088e-07
phenotype O 0 1.6430800542366342e-06
of O 0 3.8496916765495826e-09
dystrophinopathy B-Disease 0 4.266772521077655e-05
which O 0 2.946740629283795e-08
is O 0 1.5117678220377684e-09
characterized O 0 4.144835941133351e-08
by O 0 5.175664341550146e-09
preferential O 0 3.0054965804993117e-07
myocardial B-Disease 0 9.962939657270908e-06
involvement I-Disease 0 1.176536414959628e-07
without O 0 1.4679305770926021e-08
any O 0 3.51212414706481e-09
overt O 0 2.4322872604898294e-07
clinical O 0 7.763002827232413e-07
signs O 0 2.7369340386940166e-05
of O 0 7.827366630408505e-07
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 1.0750209185061976e-05

To O 0 3.230508980323066e-07
date O 0 1.2089390111214016e-07
, O 0 8.401201401220248e-10
several O 0 1.1818703793409213e-09
mutations O 0 9.163416336832597e-08
in O 0 1.798669480024273e-08
the O 0 8.164890914486023e-07
Duchenne B-Disease 1 0.9999938011169434
muscular I-Disease 1 0.9997796416282654
dystrophy I-Disease 1 0.9998130202293396
gene O 0 0.00010175307397730649
, O 0 4.860772833126248e-07
DMD O 1 1.0
, O 0 1.6939143421268454e-08
have O 0 8.829053599335168e-10
been O 0 6.894512183386325e-10
identified O 0 2.2359147866524154e-09
in O 0 2.3684034733406634e-09
patients O 0 5.956869664203168e-09
with O 0 2.492312578539213e-09
XLDCM B-Disease 0 0.00021769525483250618
, O 0 8.231638704003785e-10
but O 0 1.9766939474141765e-10
a O 0 1.043311215198628e-09
pathogenic O 0 5.408484682334347e-08
correlation O 0 1.0811791462117526e-08
of O 0 3.3811328736810253e-10
these O 0 1.8975274684862597e-09
cardiospecific O 0 2.3322390916291624e-06
mutations O 0 3.6291118021836155e-07
in O 0 5.044070405801904e-08
DMD O 1 0.9999998807907104
with O 0 1.7481518455042533e-08
the O 0 2.111474728394569e-08
XLDCM B-Disease 0 9.682690142653883e-05
phenotype O 0 7.273619758052519e-06
has O 0 6.086373183222804e-09
remained O 0 2.2821605938361245e-08
to O 0 1.5945841314035647e-09
be O 0 4.1806500483687614e-09
elucidated O 0 1.6848041468620067e-06
. O 0 9.343043672060958e-08

We O 0 6.377846375471563e-07
report O 0 1.5277686316039762e-07
here O 0 1.8326615780495104e-09
the O 0 4.339117676277482e-10
identification O 0 4.287153299031843e-09
of O 0 1.6482851195043224e-10
a O 0 1.635736657235043e-09
unique O 0 3.339321930084793e-09
de O 0 3.190613711012702e-07
novo O 0 1.992280886042863e-06
L1 O 0 2.9976811219967203e-06
insertion O 0 1.7715886713176587e-07
in O 0 8.83967388176643e-09
the O 0 1.1605975736017626e-08
muscle O 0 2.2930876184545923e-06
exon O 0 1.293272475777485e-06
1 O 0 4.3503838753622404e-08
in O 0 4.452802926380173e-08
DMD O 1 1.0
in O 0 1.0118283455540222e-07
three O 0 8.637011106316095e-09
XLDCM B-Disease 0 3.5804539948003367e-05
patients O 0 2.075858773764594e-08
from O 0 9.474540041409796e-10
two O 0 9.191327698943041e-10
unrelated O 0 4.992432423023274e-08
Japanese O 0 1.7980562461161753e-07
families O 0 3.2978014985474147e-08
. O 0 1.245151821649415e-07

The O 0 5.423400466497696e-07
insertion O 0 2.316832251381129e-06
was O 0 5.031300815971917e-07
a O 0 2.2162362611766184e-08
5 O 0 4.4673669208350475e-08
- O 0 9.736598372001026e-08
truncated O 0 1.0229142333173513e-07
form O 0 3.82209464078187e-09
of O 0 3.350932586965172e-10
human O 0 2.0712425108371235e-09
L1 O 0 2.5151366571662948e-06
inversely O 0 5.4679492222931e-07
integrated O 0 5.833272354038854e-08
in O 0 6.512884009879372e-09
the O 0 6.22899642976904e-09
5 O 0 2.8369134597028278e-08
- O 0 1.6954247428202507e-07
untranslated O 0 4.3269074012641795e-07
region O 0 9.303190218190593e-09
in O 0 4.404198783447555e-09
the O 0 5.683108650345048e-09
muscle O 0 2.2902463570062537e-06
exon O 0 5.215266014602093e-07
1 O 0 1.2861035791900122e-08
, O 0 2.774134255645322e-10
which O 0 6.957749931757462e-10
affected O 0 1.8574005666849303e-09
the O 0 1.0630246682907796e-09
transcription O 0 3.7545312636666495e-08
or O 0 2.794229958524852e-09
the O 0 7.453124228895547e-10
stability O 0 6.711491362665356e-09
of O 0 5.413171647039583e-11
the O 0 1.2505153579311923e-09
muscle O 0 2.0310856996275106e-07
form O 0 2.4798509912216105e-09
of O 0 3.340046572652966e-10
dystrophin O 0 7.81582002673531e-07
transcripts O 0 7.474399410511978e-08
but O 0 1.1720222570232863e-09
not O 0 1.4893004884886096e-10
that O 0 2.351077492412923e-11
of O 0 4.1254354099518054e-11
the O 0 2.4532891274020585e-09
brain O 0 4.6475423687297734e-07
or O 0 7.118270417549866e-09
Purkinje O 0 6.541208108501451e-07
cell O 0 1.7556108389271685e-07
form O 0 1.0930832239353094e-08
, O 0 6.333170099459551e-10
probably O 0 4.938766728912469e-09
due O 0 3.795252112581693e-09
to O 0 6.814786512876481e-10
its O 0 2.5918025503557374e-09
unique O 0 3.480645494047252e-10
site O 0 6.44349240630504e-09
of O 0 7.208056929108864e-10
integration O 0 4.0768732390006335e-08
. O 0 4.87835478679699e-08

We O 0 3.922516498278128e-07
speculate O 0 2.2742482030935207e-07
that O 0 7.183763583995528e-10
this O 0 1.681275674236815e-10
insertion O 0 4.2757037910234885e-09
of O 0 5.60157233098213e-11
an O 0 6.011424691365619e-10
L1 O 0 2.639727199493791e-06
sequence O 0 7.662194434487901e-08
in O 0 3.694529482345388e-07
DMD O 1 1.0
is O 0 9.292974390007203e-09
responsible O 0 4.7647730205824246e-09
for O 0 8.821389452240425e-11
some O 0 2.4529029848952e-11
of O 0 1.7224324397324686e-11
the O 0 2.8401428431301667e-10
population O 0 1.2132246596241458e-10
of O 0 5.950731574166923e-11
Japanese O 0 5.1046967541878985e-08
patients O 0 1.1112777364985504e-08
with O 0 3.478424215330733e-09
XLDCM B-Disease 0 2.9338441891013645e-05
. O 0 1.5627469096557434e-08
. O 0 6.53173302112009e-08

Severe O 0 0.005679084453731775
early O 0 0.0015969526721164584
- O 1 0.9991757273674011
onset O 1 0.9999998807907104
obesity B-Disease 1 1.0
, O 0 0.0014844281831756234
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 2.8243673000361014e-07
red O 0 0.00012439842976164073
hair O 1 0.9997662901878357
pigmentation O 1 0.8128289580345154
caused O 0 5.264615538180806e-06
by O 0 6.301294774857524e-08
POMC O 0 0.0002814764156937599
mutations O 0 4.934917797072558e-06
in O 0 5.237575706473763e-08
humans O 0 4.260783725840156e-07
. O 0 2.2076893912981177e-07

Sequential O 0 6.695278716506436e-05
cleavage O 0 2.4992528778966516e-05
of O 0 8.484573044142962e-09
the O 0 9.946145240746773e-09
precursor O 0 1.7299508670021169e-07
protein O 0 3.78263678157964e-07
pre O 0 2.8844682674389333e-05
- O 0 5.465667709358968e-05
pro O 0 1.1047642146877479e-05
- O 0 1.5028732377686538e-05
opiomelanocortin O 0 2.9640894354088232e-05
( O 0 1.1677769862217247e-07
POMC O 0 1.7167734768008813e-05
) O 0 1.3142692267820166e-08
generates O 0 1.0547611140054869e-07
the O 0 2.4817781607566758e-08
melanocortin O 0 4.983705002814531e-05
peptides O 0 5.583602614933625e-06
adrenocorticotrophin O 0 1.5318073565140367e-05
( O 0 1.9941843731885456e-07
ACTH O 0 1.0729190762504004e-05
) O 0 1.5130435571109047e-08
, O 0 5.486930465536943e-09
melanocyte O 0 1.58821239892859e-05
- O 0 1.3096959264657926e-05
stimulating O 0 1.5836476450203918e-05
hormones O 0 1.3198218766774517e-05
( O 0 4.7130829017305587e-08
MSH O 0 6.955076059966814e-06
) O 0 2.3287205497268815e-09
alpha O 0 5.359253485437421e-09
, O 0 3.14788584088177e-10
beta O 0 2.807907240054419e-09
and O 0 1.6451223716629215e-10
gamma O 0 6.068602953490654e-09
as O 0 6.324298307269771e-10
well O 0 1.6425295845667875e-10
as O 0 1.3133608089965776e-10
the O 0 4.025101363325234e-10
opioid O 0 3.6965058569649045e-08
- O 0 1.0507933012604553e-07
receptor O 0 2.8008432195747446e-07
ligand O 0 2.501386688891216e-07
beta O 0 1.303303974964365e-06
- O 0 1.2549584425869398e-05
endorphin O 0 0.0003115227445960045
. O 0 4.614212514297833e-07

While O 0 2.4919341967688524e-07
a O 0 2.3345162247778717e-08
few O 0 3.440030926782356e-09
cases O 0 3.939037984679317e-09
of O 0 2.6350188697676913e-09
isolated O 0 0.0002631811366882175
ACTH B-Disease 1 0.9992169141769409
deficiency I-Disease 0 0.012065140530467033
have O 0 9.834807634945264e-09
been O 0 1.9212402335710976e-08
reported O 0 1.1346639894327382e-06
( O 0 5.103635558612041e-08
OMIM O 0 1.6393581972806714e-05
201400 O 0 1.0040458846560796e-06
) O 0 5.477853282087608e-09
, O 0 6.686138309675016e-10
an O 0 5.61494939432805e-09
inherited O 0 0.010587602853775024
POMC O 1 0.5331718325614929
defect O 0 0.000245937000727281
has O 0 2.8561334630694546e-08
not O 0 1.9612487189846206e-09
been O 0 5.233368849388853e-09
described O 0 2.9359521036553815e-08
so O 0 5.812134773464095e-09
far O 0 3.5508019635699384e-08
. O 0 6.43877697825701e-08

Recent O 0 3.8039258924982278e-06
studies O 0 1.0301094732767524e-07
in O 0 1.5744721082455726e-08
animal O 0 7.49374180486484e-08
models O 0 1.7528570595004567e-07
elucidated O 0 2.76899953632892e-07
a O 0 6.036429134326227e-09
central O 0 3.006465121302426e-08
role O 0 3.5716669621876918e-09
of O 0 4.187886704087873e-10
alpha O 0 6.54719940484938e-08
- O 0 2.3032173430692637e-06
MSH O 0 3.273658876423724e-05
in O 0 3.306529494651045e-09
the O 0 9.390361821459692e-10
regulation O 0 1.0944538608725907e-08
of O 0 1.3445780600029877e-10
food O 0 2.537768217791836e-09
intake O 0 1.3017304567597421e-08
by O 0 1.8650535282827008e-10
activation O 0 6.076421144030064e-09
of O 0 2.218979167079027e-10
the O 0 9.229383479691933e-09
brain O 0 9.41820144362282e-06
melanocortin O 0 3.449860741966404e-05
- O 0 2.668304887265549e-06
4 O 0 2.551050783949904e-07
- O 0 6.748076089024835e-07
receptor O 0 1.0182359346799785e-06
( O 0 6.624603088312142e-08
MC4 O 0 5.359124406822957e-05
- O 0 5.556867108680308e-06
R O 0 1.0816475878527854e-05
; O 0 2.6686146625820584e-08
refs O 0 1.3246058188087773e-06
3 O 0 8.425279673929253e-08
- O 0 5.617431497739744e-07
5 O 0 1.4551464033729644e-08
) O 0 3.741445486760142e-10
and O 0 1.0323247812138447e-10
the O 0 4.094480865468597e-10
linkage O 0 1.4777571166746384e-08
of O 0 3.1758320973018783e-10
human O 0 3.6138942505203886e-08
obesity B-Disease 1 0.9999990463256836
to O 0 2.591418457598138e-08
chromosome O 0 7.611416208419541e-07
2 O 0 1.2003865457188567e-08
in O 0 2.162506618219595e-09
close O 0 9.880082529889478e-09
proximity O 0 7.768688803366786e-09
to O 0 2.0823018864746246e-09
the O 0 3.0603040102050727e-09
POMC O 0 5.610949756373884e-06
locus O 0 1.3208590132762765e-07
, O 0 4.659617691693541e-10
led O 0 8.906671511432762e-10
to O 0 3.210804955244839e-10
the O 0 5.808884484537202e-10
proposal O 0 2.018594402741769e-09
of O 0 7.563027981660753e-11
an O 0 8.075104473981298e-10
association O 0 3.5863161329530158e-09
of O 0 8.008123053571126e-10
POMC O 0 1.1766338502638973e-05
with O 0 1.8421037140115004e-08
human O 0 8.245355616054439e-07
obesity B-Disease 1 0.9999998807907104
. O 0 5.906960041102138e-07

The O 0 3.210643626516685e-07
dual O 0 3.908662620233372e-07
role O 0 3.3316766234747774e-08
of O 0 3.176439555829802e-09
alpha O 0 3.4476002497285663e-07
- O 0 3.163344445056282e-06
MSH O 0 6.514770211651921e-05
in O 0 3.2883299638797325e-08
regulating O 0 6.89299213263439e-07
food O 0 7.370557852937054e-08
intake O 0 5.078156277704693e-07
and O 0 8.963563224995141e-09
influencing O 0 8.249358529610618e-07
hair O 0 0.3503420352935791
pigmentation O 0 0.002959210891276598
predicts O 0 1.0329540600650944e-06
that O 0 1.0521480353631318e-09
the O 0 3.405794757327385e-09
phenotype O 0 3.3531742360537464e-07
associated O 0 3.5450615776255745e-09
with O 0 1.4642441703571762e-09
a O 0 1.4559881833520194e-07
defect O 0 3.357069545018021e-06
in O 0 2.1488039791961455e-08
POMC O 0 1.300854273722507e-05
function O 0 2.2283758838170797e-08
would O 0 4.113849705333905e-09
include O 0 8.72291749942633e-09
obesity B-Disease 1 0.9999922513961792
, O 0 5.1566768632937965e-09
alteration O 0 3.8816642700112425e-07
in O 0 1.3779342111774895e-07
pigmentation O 1 0.8539339900016785
and O 0 6.311744800768793e-05
ACTH B-Disease 1 0.9920527935028076
deficiency I-Disease 0 0.001881054020486772
. O 0 2.6583634848975635e-07

The O 0 3.55059256662571e-07
observation O 0 7.152527814469067e-07
of O 0 4.736267378291359e-09
these O 0 1.4328652042649992e-08
symptoms O 0 1.3887502973375376e-05
in O 0 7.843684812769425e-09
two O 0 2.3233299728531165e-09
probands O 0 9.133332241617609e-07
prompted O 0 3.034289974834792e-08
us O 0 1.4055524522049723e-09
to O 0 5.488905996386961e-10
search O 0 2.164470824794762e-09
for O 0 3.5903657824576385e-10
mutations O 0 5.04052160010815e-08
within O 0 3.2668481253494974e-09
their O 0 2.161410961321053e-08
POMC O 0 8.823515963740647e-05
genes O 0 1.2460147900128504e-06
. O 0 2.0713784465442586e-07

Patient O 0 0.000892503245268017
1 O 0 1.1052342188122566e-06
was O 0 8.254129824081247e-08
found O 0 1.5824255239493823e-09
to O 0 8.648595728466546e-10
be O 0 4.374393069994653e-10
a O 0 6.330658219866336e-10
compound O 0 1.6307687644712132e-08
heterozygote O 0 5.62766828693384e-08
for O 0 3.825659233847034e-10
two O 0 4.23208329491942e-10
mutations O 0 4.477074000419634e-08
in O 0 4.602427328137537e-09
exon O 0 6.45310024083301e-07
3 O 0 7.140574354025375e-08
( O 0 7.936219681425882e-09
G7013T O 0 1.9964373620950937e-07
, O 0 3.2097411395426434e-09
C7133delta O 0 6.757516644029238e-07
) O 0 1.455828568808215e-09
which O 0 1.6101896482823008e-09
interfere O 0 9.420019431161109e-09
with O 0 4.1065098543846545e-10
appropriate O 0 2.6788742335526194e-09
synthesis O 0 1.0747765344376603e-08
of O 0 1.1053602477772984e-09
ACTH O 0 1.4583523579858593e-06
and O 0 6.385281192677894e-09
alpha O 0 3.730404500856821e-07
- O 0 2.0604529709089547e-05
MSH O 0 0.0006498086731880903
. O 0 2.85026743540584e-07

Patient O 0 0.00032527331495657563
2 O 0 1.043112661136547e-06
was O 0 5.796693614001924e-08
homozygous O 0 1.271377527700679e-07
for O 0 9.950751334031338e-10
a O 0 3.4255542846750586e-09
mutation O 0 9.43415585652474e-08
in O 0 1.7880180891438613e-08
exon O 0 2.6374948447482893e-06
2 O 0 8.281458008241316e-08
( O 0 2.1510551562187175e-08
C3804A O 0 6.402369194802304e-07
) O 0 8.94387230943039e-09
which O 0 4.407293729968842e-08
abolishes O 0 4.52647618658375e-05
POMC O 0 0.00013818041770718992
translation O 0 2.933690666395705e-06
. O 0 5.309928496899374e-07

These O 0 1.481307947415189e-07
findings O 0 7.520316813725003e-08
represent O 0 3.927957070715138e-09
the O 0 1.427512441587453e-09
first O 0 1.1647127706737592e-09
examples O 0 1.5059659075333798e-09
of O 0 1.883388445200751e-10
a O 0 1.2841969976307155e-07
genetic B-Disease 1 0.999998927116394
defect I-Disease 1 0.9999892711639404
within O 0 8.833016096332358e-09
the O 0 1.6255857104852112e-08
POMC O 0 2.4133731130859815e-05
gene O 0 1.7570579302628175e-07
and O 0 1.922841441626133e-09
define O 0 1.564924545505164e-08
a O 0 2.9887523567140306e-08
new O 0 6.788224709453061e-06
monogenic B-Disease 1 0.934532105922699
endocrine I-Disease 1 0.9691221714019775
disorder I-Disease 0 0.00019686359155457467
resulting O 0 8.931380790500043e-08
in O 0 3.013492033687726e-08
early O 0 0.00021506402117665857
- O 1 0.9978442192077637
onset O 1 0.9999998807907104
obesity B-Disease 1 1.0
, O 0 0.00015876560064498335
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 1.6230768551395158e-07
red O 0 2.0403149392222986e-05
hair O 1 0.9091756343841553
pigmentation O 0 0.002069527516141534
. O 0 3.0708068976537106e-08
. O 0 9.418027957508457e-08

A O 0 3.216498498659348e-06
European O 0 1.656789891057997e-06
multicenter O 0 4.566085044643842e-05
study O 0 4.249842788794922e-07
of O 0 2.0603711448075046e-07
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 7.506602628382097e-08
classification O 0 2.9495419084923924e-07
of O 0 2.4472881499093546e-09
105 O 0 5.604198349828948e-07
mutations O 0 1.8578073195385514e-06
and O 0 3.4758043110372228e-09
a O 0 6.7641692247377705e-09
general O 0 4.614522097767804e-09
system O 0 1.3986513636154996e-07
for O 0 1.6587600182305096e-09
genotype O 0 1.1852694115077611e-06
- O 0 4.951682512910338e-07
based O 0 2.8727642487069716e-08
prediction O 0 2.4548404553570435e-07
of O 0 6.0225713305328554e-09
metabolic O 0 0.00028118217596784234
phenotype O 0 3.28602000081446e-05
. O 0 3.8580006389565824e-07

Phenylketonuria B-Disease 1 0.9993701577186584
( O 0 0.00013658784155268222
PKU B-Disease 0 0.08667422086000443
) O 0 7.607113161611778e-07
and O 0 4.769312340613396e-07
mild B-Disease 1 0.999994158744812
hyperphenylalaninemia I-Disease 1 1.0
( O 1 0.520033597946167
MHP B-Disease 1 1.0
) O 0 2.63356383811697e-07
are O 0 2.5177708806722876e-08
allelic B-Disease 0 0.01438246387988329
disorders I-Disease 1 0.9967767596244812
caused O 0 1.4705220792166074e-06
by O 0 2.7402958124866927e-08
mutations O 0 1.1091473197666346e-06
in O 0 1.4877064025142772e-08
the O 0 3.352418787017086e-08
gene O 0 5.338073606253602e-06
encoding O 0 1.3116083209752105e-05
phenylalanine O 0 0.008931875228881836
hydroxylase O 0 0.00899716280400753
( O 0 1.9793346837104764e-06
PAH O 0 0.00011606644693529233
) O 0 1.9534660111730773e-07
. O 0 1.84202164632552e-07

Previous O 0 4.131078185309889e-06
studies O 0 1.6306948680266942e-07
have O 0 3.483463295594902e-09
suggested O 0 1.2749613809148741e-08
that O 0 4.3265810378834146e-10
the O 0 2.868207671369305e-09
highly O 0 6.994400791882072e-08
variable O 0 6.146858595457161e-06
metabolic O 0 0.0008914736099541187
phenotypes O 0 1.7600206774659455e-05
of O 0 4.373721651518281e-07
PAH B-Disease 1 0.9997043013572693
deficiency I-Disease 0 0.48095449805259705
correlate O 0 1.047575642587617e-05
with O 0 7.552255851805967e-07
PAH O 0 0.015709687024354935
genotypes O 0 0.00027573038823902607
. O 0 1.6730868992453907e-06

We O 0 5.397776021709433e-07
identified O 0 5.843684647288683e-08
both O 0 5.922700552218885e-09
causative O 0 6.199804261086683e-07
mutations O 0 1.663445686972409e-06
in O 0 6.986227418792623e-08
686 O 0 2.993384669025545e-06
patients O 0 2.057031451840885e-07
from O 0 7.3267956146594315e-09
seven O 0 1.4027250472281594e-08
European O 0 1.4636368916853826e-07
centers O 0 2.255099929016069e-07
. O 0 1.1090357077137014e-07

On O 0 7.179166914283996e-07
the O 0 9.577364679103084e-09
basis O 0 2.0921031573806204e-09
of O 0 1.0054264365511045e-10
the O 0 6.554528586555364e-10
phenotypic O 0 7.963152626189185e-08
characteristics O 0 2.75444964614735e-08
of O 0 1.6664627455753589e-09
297 O 0 6.080725256651931e-07
functionally O 0 3.149756366838119e-06
hemizygous O 0 3.672061939141713e-05
patients O 0 1.9369041126537923e-07
, O 0 7.127749501734115e-10
105 O 0 5.941290570632418e-09
of O 0 1.021138867907112e-10
the O 0 1.7421130094064097e-09
mutations O 0 3.961523020734603e-08
were O 0 2.271194787795139e-09
assigned O 0 5.960370419444416e-09
to O 0 5.287889570659843e-10
one O 0 2.0509720310979418e-10
of O 0 7.850112920815278e-11
four O 0 9.38937705363685e-10
arbitrary O 0 2.5109224921493478e-08
phenotype O 0 1.3945838190920767e-06
categories O 0 1.4929729275081627e-07
. O 0 1.0394429494908763e-07

We O 0 1.8602064244532812e-07
proposed O 0 1.3459245451485913e-07
and O 0 9.646628384984979e-09
tested O 0 1.4305008733117575e-07
a O 0 1.0851561427216438e-08
simple O 0 1.281857020529742e-08
model O 0 1.0906486380690694e-08
for O 0 3.684985649954342e-10
correlation O 0 1.189133858048308e-08
between O 0 9.07585118170573e-09
genotype O 0 1.4628376447944902e-06
and O 0 1.19750982463529e-08
phenotypic O 0 9.641624956202577e-07
outcome O 0 8.24800565624173e-07
. O 0 4.7788876145205e-07

The O 0 5.506994398274401e-07
observed O 0 9.590498848410789e-07
phenotype O 0 3.156350430799648e-06
matched O 0 2.8937091656189295e-07
the O 0 1.618504086309258e-08
predicted O 0 8.609151223026856e-07
phenotype O 0 1.3257205182526377e-06
in O 0 7.74817898729907e-09
79 O 0 3.4146555805136813e-08
% O 0 1.4898914046934664e-10
of O 0 1.5163811178942055e-11
the O 0 9.004856860173049e-10
cases O 0 8.780703386612743e-10
, O 0 2.4179633295595693e-10
and O 0 7.739430762931931e-10
in O 0 1.1626730689329179e-09
only O 0 3.59613672173964e-10
5 O 0 1.3737420090365049e-09
of O 0 1.2433558349567164e-10
184 O 0 1.4907856282775356e-08
patients O 0 1.0986619614072879e-08
was O 0 2.2767910223819854e-08
the O 0 1.9577950371996167e-09
observed O 0 3.621090627348167e-08
phenotype O 0 8.220883529475032e-08
more O 0 4.1585473953276164e-10
than O 0 2.935053311503566e-10
one O 0 3.780360746663547e-10
category O 0 2.9458735451015627e-09
away O 0 1.4139417414682498e-09
from O 0 5.330074714926525e-10
that O 0 4.0116657218369767e-10
expected O 0 4.978406664690738e-08
. O 0 3.5896370320642745e-08

Among O 0 3.27657261323111e-07
the O 0 2.1071496547619972e-08
seven O 0 5.173108608147459e-09
contributing O 0 8.562069275797057e-09
centers O 0 2.9219509034561497e-09
, O 0 1.5633416783344956e-10
the O 0 4.4737577531428485e-10
proportion O 0 6.592568713159608e-10
of O 0 1.798839271982544e-10
patients O 0 2.0111119436450053e-09
for O 0 2.631491691218457e-10
whom O 0 1.2385232839307037e-09
the O 0 1.6697653260067113e-09
observed O 0 6.988719292166934e-08
phenotype O 0 3.9821219388613827e-07
did O 0 1.277624495088503e-08
not O 0 6.684277020774232e-10
match O 0 3.7185601264866364e-09
the O 0 4.289418598091288e-09
predicted O 0 3.8688622794325056e-07
phenotype O 0 3.6761932165063627e-07
was O 0 2.7996515328254645e-08
4 O 0 1.0875804257182153e-08
% O 0 2.0874675321636005e-09
- O 0 6.123801199464651e-08
23 O 0 3.966286143963771e-08
% O 0 1.3666074938356587e-09
( O 0 8.070088597378344e-09
P O 0 2.5889296011882834e-05
< O 0 2.425301204311836e-07
. O 0 5.280998305323692e-09
0001 O 0 8.064834219112527e-06
) O 0 1.2108140046152016e-09
, O 0 1.2168538399137674e-10
suggesting O 0 1.958665230006318e-09
that O 0 1.9161991438032544e-10
differences O 0 8.181300636955768e-10
in O 0 2.795262632471207e-10
methods O 0 1.5732586344796573e-09
used O 0 9.034119008433095e-10
for O 0 2.1799985427950475e-10
mutation O 0 2.210950178493931e-08
detection O 0 7.20714155022506e-08
or O 0 1.0763339730601729e-07
phenotype O 0 1.9212540792068467e-05
classification O 0 3.3978267310885713e-06
may O 0 3.466941222995956e-07
account O 0 2.7360849141899735e-09
for O 0 1.844499691872059e-10
a O 0 1.1309235770085024e-09
considerable O 0 1.025355023109853e-09
proportion O 0 1.311026287531547e-09
of O 0 1.0816034734517643e-09
genotype O 0 3.477746213320643e-05
- O 0 0.000560127489734441
phenotype O 0 0.00026067334692925215
inconsistencies O 0 8.976688150141854e-06
. O 0 3.0908981329957896e-07

Our O 0 1.008200570140616e-06
data O 0 6.615486540795246e-07
indicate O 0 1.3076099492081994e-07
that O 0 2.2127168985974777e-09
the O 0 2.0439367531821517e-08
PAH O 0 3.728051524376497e-05
- O 0 3.5857685816154117e-06
mutation O 0 2.862448582163779e-06
genotype O 0 1.5215860003081616e-06
is O 0 1.0818221873876155e-09
the O 0 8.8305518453069e-10
main O 0 5.864472463201764e-09
determinant O 0 2.7667125479524657e-08
of O 0 1.3006724586261953e-09
metabolic O 0 2.990643224620726e-05
phenotype O 0 8.818036576485611e-07
in O 0 8.866522627215545e-09
most O 0 1.927674908586141e-08
patients O 0 4.231554555644834e-07
with O 0 2.5764418296603253e-06
PAH B-Disease 1 0.9999337196350098
deficiency I-Disease 1 0.6932768821716309
. O 0 5.756335212936392e-07

In O 0 7.230865435303713e-07
the O 0 2.7944926372924783e-08
present O 0 6.114088346720337e-09
study O 0 3.5521752206335577e-09
, O 0 4.984653800832461e-10
the O 0 2.281906885670537e-09
classification O 0 7.753725839165782e-08
of O 0 1.4281605897892291e-09
105 O 0 2.884291234295233e-06
PAH O 0 0.00010711274080676958
mutations O 0 1.9986789538961602e-06
may O 0 3.740735721180499e-08
allow O 0 1.6382595280362011e-09
the O 0 2.940574006515817e-09
prediction O 0 9.338233297739862e-08
of O 0 1.5271822695339665e-10
the O 0 3.3004112776069405e-09
biochemical O 0 2.996926866671856e-07
phenotype O 0 7.982082479429664e-07
in O 0 1.9560305375421194e-08
> O 0 1.405197309622963e-07
10 O 0 1.1436529945285656e-08
, O 0 9.40387545611543e-10
000 O 0 4.731743441510616e-09
genotypes O 0 1.1236144104032064e-07
, O 0 1.883680322833925e-09
which O 0 2.7807642410948574e-08
may O 0 7.935012291682142e-08
be O 0 3.1523317289838815e-10
useful O 0 2.692282785599076e-10
for O 0 1.3437961854378955e-10
the O 0 1.0817190476686278e-09
management O 0 1.438034402667654e-08
of O 0 1.2167964413833943e-09
hyperphenylalaninemia B-Disease 1 0.9999997615814209
in O 0 2.098355935231666e-06
newborns O 0 2.8897326046717353e-05
. O 0 1.4779101320527843e-07

Somatic O 0 9.70520923146978e-05
instability O 0 1.8415808881400153e-05
of O 0 3.0068434853092185e-08
the O 0 1.1229865748418888e-07
CTG O 0 2.7088617571280338e-05
repeat O 0 1.1356794402672676e-06
in O 0 1.7158050980015105e-08
mice O 0 8.219031428779999e-07
transgenic O 0 1.990646438798649e-07
for O 0 3.4599032527893314e-09
the O 0 3.234898997561686e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 6.758070867363131e-07
is O 0 2.4016673094706675e-08
age O 0 8.465223189091375e-09
dependent O 0 1.8187813477510417e-09
but O 0 2.0963880631441612e-10
not O 0 2.620922645579782e-10
correlated O 0 7.52823581251505e-09
to O 0 6.028831878168717e-10
the O 0 1.6820014270280126e-09
relative O 0 1.3710099722175073e-08
intertissue O 0 3.666886811970471e-07
transcription O 0 3.413106526295451e-07
levels O 0 1.9878423529462452e-07
and O 0 2.2364746499192734e-08
proliferative O 0 5.446624709293246e-05
capacities O 0 3.367420049471548e-06
. O 0 3.051743249216088e-07

A O 0 1.389645694871433e-05
( O 0 1.1737811291823164e-06
CTG O 0 1.8820470359059982e-05
) O 0 4.7223156940390254e-08
nexpansion O 0 1.0600285804684972e-06
in O 0 6.86362922053263e-09
the O 0 7.789907385813422e-09
3 O 0 1.213733185068122e-07
- O 0 7.749474661977729e-07
untranslated O 0 2.154310777768842e-06
region O 0 6.352036052703625e-08
( O 0 1.0550504470074884e-08
UTR O 0 4.0118999322658055e-07
) O 0 1.44250034139759e-09
of O 0 3.7622049919860956e-10
the O 0 6.266918717301451e-08
DM O 1 0.9999998807907104
protein O 0 2.1889291019761004e-06
kinase O 0 1.5906405678833835e-05
gene O 0 1.5716000234533567e-06
( O 0 2.1176536080247388e-08
DMPK O 0 2.8267888865229907e-06
) O 0 2.5623110300188046e-09
is O 0 5.322922103090377e-10
responsible O 0 5.900150590321118e-09
for O 0 1.4209554421995563e-08
causing O 0 0.22213177382946014
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00044255645480006933
DM B-Disease 1 1.0
) O 0 6.794156206524349e-07
. O 0 3.649227267032984e-07

Major O 0 5.369090104068164e-06
instability O 0 1.929152313095983e-05
, O 0 1.5563992761258305e-08
with O 0 1.3753491678869523e-09
very O 0 4.5446530982928834e-09
large O 0 2.3775372781642545e-09
expansions O 0 9.618612750728062e-08
between O 0 2.9928695077785505e-09
generations O 0 2.1332033917076387e-09
and O 0 9.147884116877947e-10
high O 0 1.4754477639655761e-08
levels O 0 6.771681881900804e-09
of O 0 7.152590741910103e-10
somatic O 0 3.148991538637347e-07
mosaicism O 0 1.9420881471887697e-06
, O 0 3.006945137329353e-09
is O 0 6.308311650826681e-10
observed O 0 2.025448431197674e-08
in O 0 3.1992851035056447e-08
patients O 0 2.2824396239684575e-07
. O 0 7.441554572551468e-08

There O 0 4.27941444058888e-07
is O 0 5.206744813079922e-09
a O 0 8.759664105184584e-09
good O 0 3.7399559005280025e-09
correlation O 0 2.6428319088722674e-08
between O 0 5.9870322033361845e-09
repeat O 0 7.309336069738492e-07
size O 0 1.4917789314949914e-07
( O 0 3.924017999423768e-09
at O 0 6.877611369304759e-09
least O 0 1.7383819939098544e-09
in O 0 4.262512565134102e-09
leucocytes O 0 5.591418243966473e-07
) O 0 1.336412425168021e-09
, O 0 3.664253622748248e-10
clinical O 0 1.3735331094721914e-08
severity O 0 2.640379307194962e-06
and O 0 6.717179701354326e-08
age O 0 5.040319805971194e-08
of O 0 5.596345165059802e-09
onset O 0 0.0002139364805771038
. O 0 2.8958874054296757e-07

The O 0 8.963821528595872e-06
trinucleotide O 0 0.0021179616451263428
repeat O 0 7.860142068238929e-05
instability O 0 9.896823030430824e-06
mechanisms O 0 6.551284741362906e-07
involved O 0 3.797680037109785e-08
in O 0 3.954525880089932e-07
DM B-Disease 1 1.0
and O 0 1.1625894025257821e-08
other O 0 6.496441717906976e-10
human O 0 5.4611852817743056e-08
genetic B-Disease 1 0.9999998807907104
diseases I-Disease 1 1.0
are O 0 1.3504703133548901e-08
unknown O 0 8.428848019548241e-08
. O 0 1.3477739457812277e-07

We O 0 3.9442846855308744e-07
studied O 0 5.037513801653404e-07
somatic O 0 2.974818016809877e-06
instability O 0 1.9284675545350183e-06
by O 0 2.2330477023047024e-08
measuring O 0 9.302924013354641e-07
the O 0 3.8638908961274865e-08
CTG O 0 7.247210760397138e-06
repeat O 0 6.539087848977942e-07
length O 0 2.1006009376378643e-08
at O 0 7.014906433511214e-09
several O 0 6.930598317467229e-10
ages O 0 9.052804728071351e-09
in O 0 5.427555627157687e-10
various O 0 5.434786509717071e-10
tissues O 0 2.8834412191258707e-08
of O 0 2.9255797784344395e-10
transgenic O 0 1.0665085170558086e-07
mice O 0 4.3826318574247125e-07
carrying O 0 5.367703170833238e-09
a O 0 1.3528731912515468e-08
( O 0 1.3630470085956858e-08
CTG O 0 1.1291696182524902e-06
) O 0 1.9497421455128006e-09
55expansion O 0 1.5301453970550938e-07
surrounded O 0 7.694469061902964e-09
by O 0 2.490582851066847e-09
45 O 0 7.64448415679908e-09
kb O 0 5.998121537231782e-07
of O 0 2.5507823631087945e-10
the O 0 5.797885282987636e-09
human O 0 4.531654340667046e-08
DM B-Disease 1 1.0
region O 0 2.5545631388013135e-08
, O 0 4.986707713428018e-10
using O 0 2.352843031516727e-09
small O 0 5.975292705073798e-09
- O 0 5.136671916261548e-06
pool O 0 1.0580408797977725e-06
PCR O 0 2.859105370589532e-05
. O 0 2.012018853747577e-07

These O 0 2.82295076203809e-07
mice O 0 3.848471806122689e-06
have O 0 1.8374216592675907e-09
been O 0 8.772433890413822e-10
shown O 0 2.034635793179973e-09
to O 0 1.1177095915471114e-09
reproduce O 0 2.3256750125710823e-07
the O 0 2.2247015341037013e-09
intergenerational O 0 3.3133876087276803e-08
and O 0 1.4751206922625215e-09
somatic O 0 1.791662924688353e-07
instability O 0 1.5151061916185427e-07
of O 0 5.418970272508261e-10
the O 0 7.085976250209569e-09
55 O 0 9.872645279074277e-08
CTG O 0 2.543901246099267e-06
repeat O 0 4.1605989054005477e-07
suggesting O 0 5.8715151851629344e-08
that O 0 5.522941548541382e-10
surrounding O 0 4.166742950673097e-09
sequences O 0 1.8696891146419148e-08
and O 0 1.425123796749972e-09
the O 0 3.2543665540174516e-09
chromatin O 0 1.0328988082619617e-06
environment O 0 3.972327888845939e-08
are O 0 2.10072292894381e-10
involved O 0 1.0626435287264258e-09
in O 0 1.303579022504664e-08
instability O 0 1.547659735479101e-06
mechanisms O 0 1.5871136156420107e-06
. O 0 2.1243191383746307e-07

As O 0 1.4306374396255706e-07
observed O 0 1.1559454549114889e-07
in O 0 1.4515808555159992e-09
some O 0 7.035547144873533e-11
of O 0 3.970458337110294e-11
the O 0 1.6967720561922306e-09
tissues O 0 1.396498987560335e-06
of O 0 3.3153977341271457e-08
DM B-Disease 1 1.0
patients O 0 1.3630595958602498e-06
, O 0 1.0797772675985584e-09
there O 0 4.702105926845945e-10
is O 0 1.6730863916514238e-10
a O 0 1.635527602239506e-09
tendency O 0 1.7067572244400253e-08
for O 0 5.734894226172571e-10
repeat O 0 6.984868150539114e-08
length O 0 1.1839737190655342e-08
and O 0 1.1481546824398947e-09
somatic O 0 5.667199687309221e-08
mosaicism O 0 3.5044848800680484e-07
to O 0 2.1642851955050446e-09
increase O 0 2.103903939953966e-09
with O 0 3.4299527107428673e-10
the O 0 6.089031945322176e-09
age O 0 5.815328218972127e-09
of O 0 1.4041021123567532e-10
the O 0 4.825216226578277e-09
mouse O 0 1.1161792826896999e-05
. O 0 1.3398413045706548e-07

Furthermore O 0 6.980884791119024e-06
, O 0 3.3229504481369077e-08
we O 0 1.9051760169475074e-09
observed O 0 8.941570150966527e-09
no O 0 7.604937235505815e-10
correlation O 0 6.7916015034086286e-09
between O 0 1.1801764010499483e-09
the O 0 1.1660576948457901e-09
somatic O 0 3.291041252850846e-07
mutation O 0 3.556204433152743e-07
rate O 0 7.951971952024905e-07
and O 0 1.2599490339937347e-08
tissue O 0 2.0982638488931116e-06
proliferation O 0 1.257968733625603e-06
capacity O 0 2.2210356576124468e-07
. O 0 1.0451844190129123e-07

The O 0 9.17675095024606e-07
somatic O 0 3.048754297196865e-05
mutation O 0 2.485652112227399e-05
rates O 0 3.9904458390083164e-05
in O 0 1.0171627096156044e-08
different O 0 1.875191779632246e-09
tissues O 0 1.0716854603742831e-06
were O 0 4.47953185656047e-09
also O 0 1.280040962114981e-09
not O 0 2.233241369609118e-10
correlated O 0 9.869873807133445e-09
to O 0 3.866224007609276e-10
the O 0 5.717626927470576e-10
relative O 0 8.355756975220174e-09
inter O 0 6.797461793439652e-08
- O 0 2.8299421046540374e-06
tissue O 0 4.3920002212871623e-07
difference O 0 1.9051760169475074e-09
in O 0 8.394377970510902e-10
transcriptional O 0 8.026802333915839e-08
levels O 0 1.1451635195669496e-08
of O 0 1.34836100618152e-10
the O 0 9.975322790012342e-10
three O 0 1.1448133552249828e-09
genes O 0 3.5703404677178696e-08
( O 0 6.056785295527334e-09
DMAHP O 0 7.493626412724552e-07
, O 0 2.495994744222685e-09
DMPK O 0 1.2713087471638573e-06
and O 0 5.094335175925835e-09
59 O 0 2.0909233455768117e-08
) O 0 5.137481551287237e-10
surrounding O 0 3.727600006442344e-09
the O 0 1.405001004428641e-08
repeat O 0 9.809349421630031e-07
. O 0 8.783638705267549e-09
. O 0 4.9857046491297297e-08

A O 0 3.7067757148179226e-06
novel O 0 6.12971916780225e-06
missense O 0 0.00012114997662138194
mutation O 0 2.013981247728225e-05
in O 0 3.80182257231354e-07
patients O 0 2.2558592149835022e-07
from O 0 2.0938406564141587e-08
a O 0 1.2919605296701775e-07
retinoblastoma B-Disease 0 0.00025140983052551746
pedigree O 0 3.3386699215043336e-05
showing O 0 8.212487045966554e-06
only O 0 1.3667098563985292e-08
mild O 0 1.61163552547805e-05
expression O 0 6.541570485296688e-08
of O 0 1.8296020254382483e-09
the O 0 3.828619199452987e-08
tumor B-Disease 0 1.978749605768826e-05
phenotype O 0 2.928387766587548e-05
. O 0 3.0146941298880847e-07

We O 0 2.8752205594173574e-07
have O 0 3.227261569094253e-09
used O 0 4.487810123521285e-09
single O 0 1.5140857456685808e-08
strand O 0 3.4052970931952586e-07
conformation O 0 1.0097304539158358e-06
polymorphism O 0 3.665166445898649e-07
analysis O 0 1.472731803175975e-08
to O 0 3.447986118843005e-09
study O 0 2.204472826505821e-09
the O 0 4.517542340209957e-09
27 O 0 5.278010206666295e-08
exons O 0 5.166839756043373e-08
of O 0 3.5627109595814943e-10
the O 0 3.884935484421703e-09
RB1 O 0 2.0061188479303382e-06
gene O 0 2.8638249105483737e-08
in O 0 9.253227628569505e-10
individuals O 0 9.813436868677528e-11
from O 0 3.7441152955786094e-10
a O 0 1.4137806481073767e-08
family O 0 1.171779686615082e-07
showing O 0 1.5695361526013585e-06
mild O 0 3.969767567468807e-05
expression O 0 2.5283098281647653e-08
of O 0 1.2901150148181273e-09
the O 0 3.34350431785424e-08
retinoblastoma B-Disease 0 7.277420081663877e-05
phenotype O 0 6.467060302384198e-05
. O 0 4.483684392653231e-07

In O 0 3.6571847772393085e-07
this O 0 9.945026135937951e-09
family O 0 2.0859840077491754e-08
affected O 0 8.464432710297842e-09
individuals O 0 5.370342504029679e-10
developed O 0 1.4109431845099607e-07
unilateral B-Disease 0 0.015316649340093136
tumors I-Disease 1 1.0
and O 0 8.015433081709489e-07
, O 0 9.288468882928669e-10
as O 0 3.4325051134764806e-10
a O 0 8.380907634553125e-10
result O 0 9.903869946370492e-10
of O 0 2.425409317829974e-10
linkage O 0 1.4530087355524302e-07
analysis O 0 1.694922779904573e-08
, O 0 1.0759553248362863e-09
unaffected O 0 3.396915815301327e-07
mutation O 0 2.427675553917652e-07
carriers O 0 2.2716161396374446e-08
were O 0 4.706002254550867e-09
also O 0 2.807398313819931e-09
identified O 0 4.447606283264349e-09
within O 0 3.541304138821033e-09
the O 0 2.8442114441418198e-08
pedigree O 0 3.1033735012897523e-06
. O 0 1.2232806056999834e-07

A O 0 2.811008926073555e-06
single O 0 4.87615977817768e-07
band O 0 4.890363811682619e-07
shift O 0 1.8291011372184585e-07
using O 0 2.3670409632359224e-08
SSCP O 0 2.627783715070109e-06
was O 0 1.529507187569834e-08
identified O 0 3.046524366112635e-09
in O 0 2.8170050736520125e-09
exon O 0 4.7499304400844267e-07
21 O 0 5.736388075661125e-08
which O 0 8.197014178534801e-10
resulted O 0 3.6098759537139813e-09
in O 0 1.938787574928824e-09
a O 0 1.717527275957309e-08
missense O 0 4.6940826905483846e-06
mutation O 0 4.5001598891758476e-07
converting O 0 1.7673345098501159e-07
a O 0 2.4858746883182903e-07
cys O 0 0.06115823611617088
- O 0 1.8000231648329645e-05
- O 0 8.465277460345533e-06
> O 0 2.8890017347293906e-06
arg O 0 1.0761508519863128e-06
at O 0 4.1035466580297e-08
nucleotide O 0 1.9872132384080032e-07
position O 0 6.799536578228071e-08
28 O 0 1.860791343233359e-08
in O 0 2.659893194589813e-09
the O 0 1.8816525226839076e-08
exon O 0 6.9144030021561775e-06
. O 0 2.3100007240373088e-07

The O 0 5.92938363297435e-07
mutation O 0 5.774695182481082e-06
destroyed O 0 8.938690143622807e-07
an O 0 2.8582642030983152e-08
NdeI O 0 4.3782474676845595e-06
restriction O 0 4.2064479544023925e-07
enzyme O 0 4.826525810130988e-07
site O 0 6.23721348347317e-07
. O 0 1.3747393268204178e-07

Analysis O 0 5.63679861897981e-07
of O 0 4.818144105911415e-09
all O 0 1.179082942392995e-09
family O 0 3.5788474406217574e-09
members O 0 2.4947130472519063e-10
demonstrated O 0 2.6510296180504156e-09
that O 0 1.975043323332315e-10
the O 0 3.329356346171153e-09
missense O 0 3.283684236521367e-06
mutation O 0 1.7835819789979723e-06
co O 0 3.621599091729877e-07
- O 0 1.052076299856708e-06
segregated O 0 6.744987786078127e-07
with O 0 5.931258595381905e-09
patients O 0 6.817275277626322e-08
with O 0 1.0648474244590034e-06
tumors B-Disease 1 1.0
or O 0 2.9915017876191996e-05
who O 0 1.2337377341964384e-08
, O 0 7.934788937014048e-11
as O 0 1.2948375704979753e-10
a O 0 5.1248560950512e-10
result O 0 9.250280541550637e-10
of O 0 2.481709560075984e-10
linkage O 0 1.6009640546599258e-07
analysis O 0 1.741977584401866e-08
had O 0 5.048613260782986e-08
been O 0 2.690436096131066e-09
predicted O 0 2.954856448411647e-08
to O 0 1.2958388806438847e-09
carry O 0 1.0306357545175615e-08
the O 0 1.4827404193340499e-08
predisposing O 0 1.5034546549941297e-06
mutation O 0 2.293783154527773e-06
. O 0 1.5211666948289349e-07

These O 0 1.2501766377681633e-07
observations O 0 2.960165375043289e-07
point O 0 7.514807442987603e-09
to O 0 1.0734013677904386e-09
another O 0 3.7646097350574337e-10
region O 0 1.803626026308791e-09
of O 0 3.3979938307560076e-10
the O 0 1.408392336088582e-08
RB1 O 0 3.5105301776638953e-06
gene O 0 5.5331430104388346e-08
where O 0 3.7099738836587903e-09
mutations O 0 6.978649480515742e-08
only O 0 6.200308044768121e-10
modify O 0 7.775541632781824e-08
the O 0 7.738988339056618e-10
function O 0 7.333950113874721e-10
of O 0 5.723144180791451e-11
the O 0 4.549030596656678e-10
gene O 0 1.301224017424829e-08
and O 0 9.90443616011305e-10
raise O 0 6.6887313465713305e-09
important O 0 2.9748153940190036e-10
questions O 0 9.572465042850808e-10
for O 0 1.9851649490920664e-10
genetic O 0 9.016995150545881e-09
counseling O 0 5.203984798640704e-09
in O 0 2.0554296042973874e-09
families O 0 8.730053902006318e-10
with O 0 3.890888167212836e-10
these O 0 2.661273423854027e-09
distinctive O 0 1.0233702596451622e-06
phenotypes O 0 8.354961664736038e-07
. O 0 8.638807003080728e-09
. O 0 7.967815918163978e-08

Maternal B-Disease 0 0.0038283916655927896
disomy I-Disease 0 0.09801839292049408
and O 0 0.0024882082361727953
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 4.645185526896967e-06
with O 0 1.11526547996732e-08
gamete O 0 1.4622336266256752e-06
complementation O 0 1.0108643436979037e-05
in O 0 7.0501160465141766e-09
a O 0 3.2098392832580203e-09
case O 0 2.946716426421858e-09
of O 0 1.2692102924205528e-09
familial O 0 2.5720521534822183e-06
translocation O 0 4.432256901054643e-06
( O 0 3.772081313968556e-08
3 O 0 6.241211991664386e-08
; O 0 1.0497392288755236e-08
15 O 0 1.6011345138622346e-08
) O 0 1.836983676284376e-09
( O 0 5.4151501061028284e-09
p25 O 0 2.490615713668376e-07
; O 0 4.350937832242607e-09
q11 O 0 1.665618896140586e-07
. O 0 2.008275101772483e-09
2 O 0 1.8574368709778355e-08
) O 0 1.1525039589344033e-08
. O 0 3.916004942539075e-08

Maternal B-Disease 0 0.021539177745580673
uniparental I-Disease 1 0.5280985832214355
disomy I-Disease 0 0.48496541380882263
( I-Disease 0 3.2810348784551024e-05
UPD I-Disease 1 0.9999998807907104
) I-Disease 0 8.559901232274569e-08
for I-Disease 0 6.414198061577281e-09
chromosome I-Disease 0 1.1109385695817764e-06
15 I-Disease 0 3.750522736822859e-08
is O 0 8.464783873840531e-10
responsible O 0 1.6950124637205022e-09
for O 0 8.867815509683297e-11
an O 0 9.603329242935388e-11
estimated O 0 4.691284583024924e-10
30 O 0 1.1633651819664692e-09
% O 0 1.1029020058339611e-10
of O 0 6.235123528597342e-11
cases O 0 4.9076196440012154e-09
of O 0 4.469966938813741e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.8302549253567122e-05
PWS B-Disease 1 1.0
) O 0 3.5690749200512073e-07
. O 0 1.8887581632043293e-07

We O 0 1.0259765303999302e-06
report O 0 9.234053521822716e-08
on O 0 6.386779549671928e-09
an O 0 3.938915860146608e-10
unusual O 0 7.2467964962186215e-09
case O 0 3.462742315107903e-09
of O 0 8.748105573275211e-10
maternal B-Disease 0 7.466697411473433e-07
disomy I-Disease 0 3.6290537082095398e-06
15 I-Disease 0 5.651203238699054e-08
in O 0 1.2798200543784333e-07
PWS B-Disease 1 1.0
that O 0 1.1610382877336178e-08
is O 0 2.963285450352515e-10
most O 0 1.0565154306974023e-10
consistent O 0 3.6573286621433e-09
with O 0 4.903574768455599e-10
adjacent O 0 1.6682707837389898e-07
- O 0 3.121830786767532e-06
1 O 0 1.6477336828302214e-08
segregation O 0 1.9642632409500038e-08
of O 0 7.363128162740651e-11
a O 0 8.732439660263935e-09
paternal O 0 4.8467377382621635e-06
t O 0 1.623612843104638e-05
( O 0 1.7552952868982175e-08
3 O 0 1.960714790527618e-08
; O 0 2.0791188770630242e-09
15 O 0 4.168483780375709e-09
) O 0 9.377350007611085e-10
( O 0 1.884726152923122e-09
p25 O 0 2.857891558960546e-07
; O 0 3.1932052557692714e-09
q11 O 0 7.726075779146413e-08
. O 0 8.144370178264637e-10
2 O 0 1.888075917833021e-09
) O 0 2.7289381865358564e-10
with O 0 4.0674946744090335e-10
simultaneous O 0 9.22218958976373e-08
maternal O 0 4.115204319532495e-06
meiotic O 0 8.350059033546131e-06
nondisjunction O 0 9.454838618694339e-06
for O 0 2.578333457847748e-08
chromosome O 0 3.901492618751945e-06
15 O 0 1.2550169969927083e-07
. O 0 7.693034120848097e-08

The O 0 1.8656301108421758e-06
patient O 0 1.076069111149991e-05
( O 0 1.834079341733741e-07
J O 0 0.0001436173915863037
. O 0 9.141817969293697e-09
B O 0 5.952750115056915e-08
. O 0 2.999147874493957e-10
) O 0 1.8881471386400506e-10
, O 0 9.708638754046817e-11
a O 0 1.867425103441178e-09
17 O 0 5.758850463166709e-08
- O 0 2.1379298686952097e-07
year O 0 1.8722870365195377e-08
- O 0 2.55734761367421e-07
old O 0 2.2944385591472383e-07
white O 0 1.5798539365619035e-08
male O 0 3.049623220618969e-09
with O 0 2.696086909281803e-09
PWS B-Disease 1 1.0
, O 0 5.065905916978863e-09
was O 0 2.554212308325532e-08
found O 0 5.255492707689768e-10
to O 0 3.834213224696015e-10
have O 0 2.67142308274515e-10
47 O 0 9.500802811146514e-09
chromosomes O 0 1.0357772417535216e-08
with O 0 4.096277483878197e-10
a O 0 8.057907230352157e-09
supernumerary O 0 4.69572057681944e-07
, O 0 2.4469055670550688e-09
paternal O 0 4.14341639043414e-06
der O 0 0.04395643621683121
( O 0 2.9598426820598434e-08
15 O 0 9.330840988752698e-09
) O 0 2.1634916080870426e-10
consisting O 0 3.2569294483586475e-10
of O 0 8.949990054629708e-11
the O 0 1.2665218207530415e-08
short O 0 5.239161964709638e-06
arm O 0 0.0066422829404473305
and O 0 1.8107368937592128e-09
the O 0 3.7036671507451047e-09
proximal O 0 1.170206701317511e-06
long O 0 2.1729461252562032e-07
arm O 0 8.29706641525263e-06
of O 0 1.3795449227416157e-09
chromosome O 0 3.994742314716859e-07
15 O 0 8.554560615436912e-09
, O 0 6.936337615393029e-10
and O 0 6.2045577564617815e-09
distal O 0 0.00015112836263142526
chromosome O 0 0.006954038515686989
arm O 1 0.7679985761642456
3p O 0 0.0025841451715677977
. O 0 9.353631753583613e-07

The O 0 2.175005874960334e-06
t O 0 5.5099888413678855e-05
( O 0 3.138374893296714e-08
3 O 0 1.4211669174812869e-08
; O 0 1.971637964004458e-09
15 O 0 1.8238566212858132e-09
) O 0 3.566416606481937e-10
was O 0 1.41801788089424e-08
present O 0 6.98185176339905e-10
in O 0 7.879759622575477e-10
the O 0 9.595260141992412e-10
balanced O 0 8.635216097729881e-09
state O 0 3.046058127953444e-10
in O 0 1.4054183372635976e-09
the O 0 5.841909622716912e-09
patients O 0 1.2375605429326697e-08
father O 0 2.581620783814742e-08
and O 0 1.2332360688205313e-09
a O 0 2.313302438494702e-08
sister O 0 8.74702072906075e-06
. O 0 6.045176803581853e-08

Fluorescent O 0 7.310711225727573e-05
in O 0 4.1613213852542685e-07
situ O 0 1.0809450259330333e-06
hybridization O 0 3.9319996858466766e-07
analysis O 0 3.3311046365724906e-08
demonstrated O 0 1.7321870160458275e-08
that O 0 2.778191676711117e-09
the O 0 5.208804410017365e-08
PWS B-Disease 1 0.9999998807907104
critical O 0 6.64010002537907e-08
region O 0 1.5022401100850402e-08
resided O 0 7.758341524777279e-08
on O 0 5.14170928056501e-09
the O 0 1.231945323532102e-09
derivative O 0 5.0016964792121144e-08
chromosome O 0 2.5860742880468024e-07
3 O 0 6.89153045740909e-09
and O 0 5.138569014739858e-10
that O 0 1.071104108185672e-10
there O 0 2.455001202328333e-10
was O 0 7.338738949869139e-09
no O 0 1.8195470130599745e-10
deletion O 0 9.541699874660026e-09
of O 0 3.1600974614853783e-10
the O 0 4.0552048830022613e-08
PWS B-Disease 1 1.0
region O 0 5.450456797007064e-08
on O 0 8.22707946213086e-08
the O 0 2.6382676043823494e-09
normal O 0 2.3232736623413075e-08
pair O 0 6.85163437097458e-09
of O 0 4.4416442745998097e-10
15s O 0 9.226219077618225e-08
present O 0 6.377016692482584e-09
in O 0 4.472584791415102e-08
J O 0 0.001591844018548727
. O 0 3.004519157912e-07

B O 0 0.0008987044566310942
. O 0 1.5091033674252685e-05

Methylation O 0 7.914973684819415e-05
analysis O 0 2.481315277691465e-06
at O 0 4.600814804689435e-07
exon O 0 3.439545480432571e-06
alpha O 0 8.240758120336977e-08
of O 0 9.182671845131551e-10
the O 0 1.5437268130469306e-09
small O 0 4.5203778498148495e-09
nuclear O 0 2.635664202443877e-07
ribonucleoprotein O 0 4.082588475284865e-06
- O 0 1.494763750997663e-06
associated O 0 3.9748974245412683e-07
polypeptide O 0 2.2155445549287833e-06
N O 0 1.329540396000084e-06
( O 0 2.2148503475705184e-08
SNRPN O 0 1.3130286333762342e-06
) O 0 4.217370896952843e-09
gene O 0 1.0720191312429961e-07
showed O 0 7.785424571693511e-08
a O 0 7.974867877180714e-09
pattern O 0 5.821179343001859e-07
characteristic O 0 1.3344110705304502e-08
of O 0 1.5343208648044282e-10
only O 0 3.127943737357697e-10
the O 0 1.8267706236585468e-09
maternal O 0 5.114398504701967e-07
chromosome O 0 4.612052180164028e-07
15 O 0 3.016137029021593e-08
in O 0 7.01278182191345e-08
J O 0 0.008923676796257496
. O 0 4.524382575255004e-07

B O 0 0.0013438896276056767
. O 0 1.4091969205765054e-05

Maternal B-Disease 0 0.0036306350957602262
disomy I-Disease 0 0.0008818089845590293
was O 0 6.427623588933784e-07
confirmed O 0 1.1556367951470747e-07
by O 0 1.2890752465466448e-08
polymerase O 0 2.5301487767137587e-06
chain O 0 3.973604634666117e-06
reaction O 0 3.5032050504923973e-07
analysis O 0 5.157977867042973e-08
of O 0 3.7162557475767244e-09
microsatellite O 0 4.519666163105285e-06
repeats O 0 4.846118372370256e-06
at O 0 7.069752427923959e-08
the O 0 7.300193782810993e-09
gamma O 0 5.790626573798363e-07
- O 0 1.4325612482934957e-06
aminobutyric O 0 5.934933142270893e-06
acid O 0 5.664141440320236e-07
receptor O 0 4.86711428493436e-07
beta3 O 0 2.5366502995893825e-06
subunit O 0 9.831273928284645e-07
( O 0 1.304833148196849e-07
GABRB3 O 0 9.582751772541087e-06
) O 0 1.2322331599534664e-07
locus O 0 8.489880201523192e-06
. O 0 4.24846120949951e-07

A O 0 1.2171740308986045e-05
niece O 0 0.0002120472490787506
( O 0 2.131356637846693e-07
B O 0 2.1562809138231387e-07
. O 0 1.2321755837874093e-09
B O 0 1.6242436728930443e-08
. O 0 8.6310736335804e-11
) O 0 9.62316892838544e-11
with O 0 1.0361299318528694e-10
45 O 0 3.4585048158675136e-09
chromosomes O 0 1.2502488822008218e-08
and O 0 4.956042798376359e-10
the O 0 1.429419582699154e-09
derivative O 0 3.889156019454276e-08
3 O 0 3.7069818326074255e-09
but O 0 3.4911773472146024e-10
without O 0 3.977691787060422e-10
the O 0 2.894239514716901e-09
der O 0 3.9283797377720475e-05
( O 0 3.15559400831944e-09
15 O 0 2.284380240524797e-09
) O 0 3.038450879788712e-10
demonstrated O 0 2.3188984066280227e-09
a O 0 6.946720976230836e-09
phenotype O 0 6.905480063323921e-07
consistent O 0 2.4262538644848064e-08
with O 0 4.67620442368144e-10
that O 0 7.043526317751514e-10
reported O 0 1.7352134307202505e-07
for O 0 1.298382179548696e-09
haploinsufficiency O 0 1.0097170388689847e-06
of O 0 4.207608927941919e-09
distal O 0 3.543969796737656e-05
3 O 0 2.8506638045655563e-06
p O 0 0.0002298787876497954
. O 0 3.900474041529378e-07

Uniparental B-Disease 1 0.9999994039535522
disomy I-Disease 1 0.9999994039535522
associated O 0 4.1779057937674224e-05
with O 0 9.250324239928887e-08
unbalanced O 0 0.00029957949300296605
segregation O 0 9.63985939961276e-07
of O 0 1.5360551719467708e-09
non O 0 1.6990107098990848e-08
- O 0 1.5265976571754436e-06
Robertsonian O 0 6.965484317333903e-06
translocations O 0 1.0339294931327458e-05
has O 0 2.795121822884994e-08
been O 0 3.4058726949837137e-09
reported O 0 5.620148968432659e-08
previously O 0 1.1520358000893793e-08
but O 0 4.447137380569899e-10
has O 0 5.734915875521551e-10
not O 0 1.408761718391105e-10
, O 0 5.139978026535985e-11
to O 0 1.9450312194191355e-10
our O 0 2.1119600512875536e-10
knowledge O 0 1.4845216722569887e-10
, O 0 7.553051933895105e-11
been O 0 9.444314774675888e-11
observed O 0 7.147762937087521e-10
in O 0 3.3093167095543663e-10
a O 0 2.2341755112620376e-09
case O 0 1.4244451840284e-08
of O 0 2.3749008093432167e-08
PWS B-Disease 1 0.9999998807907104
. O 0 4.292113544579479e-07

Furthermore O 0 1.973581902348087e-06
, O 0 3.0702913988989167e-08
our O 0 1.2374802516035288e-08
findings O 0 3.843538110004374e-08
are O 0 3.6027689165329946e-10
best O 0 1.7367051130534605e-09
interpreted O 0 1.2744263422348467e-08
as O 0 2.069516780167646e-09
true O 0 5.373849365497563e-09
gamete O 0 2.734803672410635e-07
complementation O 0 7.827486570022302e-07
resulting O 0 5.902944977265179e-08
in O 0 1.4915596580067358e-07
maternal B-Disease 0 0.01943170092999935
UPD I-Disease 1 1.0
15 I-Disease 0 1.3756846783508081e-05
and O 0 5.364908702176763e-06
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9869851469993591
- I-Disease 1 0.9993021488189697
Jampel I-Disease 1 0.9996125102043152
syndrome I-Disease 1 0.9999994039535522
type I-Disease 0 0.0001108368014683947
2 I-Disease 0 2.6749728476715973e-07
and O 0 1.0164958297309568e-07
Stuve B-Disease 1 0.9947412014007568
- I-Disease 1 0.9999998807907104
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 4.377433082680682e-09
a O 0 6.693491538811713e-09
case O 0 7.309458815996095e-09
for O 0 9.95098003997441e-10
" O 0 3.3357190343252796e-09
lumping O 0 1.3296630640979856e-07
" O 0 1.5662383390235846e-08
. O 0 2.598337545123286e-08

Recent O 0 2.075013753710664e-06
studies O 0 1.0833036157009701e-07
demonstrated O 0 1.8605252449788168e-08
the O 0 1.5650490903240666e-09
existence O 0 2.3218105216216145e-09
of O 0 1.2582809794103866e-10
a O 0 1.775037006268576e-09
genetically O 0 1.1451088077762961e-08
distinct O 0 4.587913160492008e-09
, O 0 8.358845282607774e-10
usually O 0 1.417754802446325e-09
lethal O 0 1.4966659023230022e-08
form O 0 1.7658754458693693e-09
of O 0 3.4373728863279496e-10
the O 0 3.9515086314168e-08
Schwartz B-Disease 0 0.09838525950908661
- I-Disease 1 0.9070864915847778
Jampel I-Disease 1 0.9999113082885742
syndrome I-Disease 1 0.9999991655349731
( O 0 5.228263262324617e-07
SJS B-Disease 1 0.7719202637672424
) O 0 8.443679533343129e-09
of O 0 7.573270011107525e-09
myotonia B-Disease 1 0.6779031753540039
and O 0 1.4731144801771734e-06
skeletal B-Disease 1 0.9997753500938416
dysplasia I-Disease 1 0.9999910593032837
, O 0 4.158813027288488e-08
which O 0 4.1760856106520805e-08
we O 0 9.856686133957737e-09
called O 0 1.0555404514889233e-06
SJS B-Disease 1 0.9879348278045654
type I-Disease 0 2.8900465622427873e-05
2 I-Disease 0 4.927835561829852e-07
. O 0 2.100969993534818e-07

This O 0 6.537256922456436e-06
disorder O 1 0.5350881814956665
is O 0 1.996596843412135e-08
reminiscent O 0 5.196192205403349e-07
of O 0 2.6642280048783107e-10
another O 0 1.3443043345162664e-09
rare O 0 1.3129563214420159e-08
condition O 0 8.665774089422484e-07
, O 0 1.772256119636495e-09
the O 0 4.2695937452208454e-08
Stuve B-Disease 1 0.9184495210647583
- I-Disease 1 0.9999964237213135
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 3.1124321253628295e-07
SWS B-Disease 1 0.9841466546058655
) O 0 2.2803677168781178e-08
, O 0 9.101935871669298e-10
which O 0 1.7029453402983563e-09
comprises O 0 3.5157299294041877e-09
campomelia B-Disease 0 3.1299643410420686e-07
at O 0 4.927412433630707e-08
birth O 0 7.869145406402822e-07
with O 0 2.484984840123161e-08
skeletal B-Disease 1 0.9990960359573364
dysplasia I-Disease 1 0.9998376369476318
, O 0 2.5939604242353198e-08
contractures B-Disease 0 4.801968680112623e-05
, O 0 8.902905079821721e-09
and O 0 9.662463718029812e-09
early B-Disease 0 1.964658849828993e-06
death I-Disease 0 4.916278612654423e-06
. O 0 1.9426758512963715e-07

To O 0 7.89072089446563e-07
test O 0 4.1807325601439516e-07
for O 0 2.764036999280961e-09
possible O 0 9.433485992360602e-09
nosologic O 0 1.5344153325713705e-06
identity O 0 3.365090606166632e-08
between O 0 7.251082845272094e-09
these O 0 5.125516366888405e-08
disorders O 0 0.0002988326596096158
, O 0 2.8359221637686005e-09
we O 0 8.582911603660648e-10
reviewed O 0 6.642872030226954e-09
the O 0 1.2518445169362735e-09
literature O 0 5.978311179433149e-10
and O 0 1.974448243791116e-10
obtained O 0 6.035481558974709e-10
a O 0 1.2204828259143596e-09
follow O 0 3.9568863741124005e-08
- O 0 6.454109779951978e-07
up O 0 1.105615865526488e-08
of O 0 3.756918387498587e-11
the O 0 1.5200478375998472e-10
only O 0 3.6244365148041524e-11
two O 0 8.485746133546357e-11
surviving O 0 6.309481825894636e-09
patients O 0 1.3546178623258243e-09
, O 0 9.56486764791542e-11
one O 0 4.6391060437578346e-10
with O 0 4.991953517219372e-09
SJS B-Disease 1 0.845008909702301
type I-Disease 0 3.986008323408896e-06
2 I-Disease 0 2.0366712760733208e-08
at O 0 1.5031808686671866e-07
age O 0 4.293633892871185e-09
10 O 0 8.804736384426803e-10
years O 0 1.7683789155231722e-10
and O 0 1.2507722635390905e-10
another O 0 5.650389045541715e-10
with O 0 2.831398449032463e-09
SWS B-Disease 1 0.8769265413284302
at O 0 1.8552366327639902e-06
age O 0 3.618881194711321e-08
7 O 0 3.4806621584948516e-08
years O 0 1.0082311874271e-08
. O 0 3.650264090993005e-08

Patients O 0 3.175285382894799e-05
reported O 0 5.889645763090812e-06
as O 0 8.030508524825564e-08
having O 0 8.19874088620054e-08
either O 0 9.732938224260579e-07
neonatal O 1 0.9999997615814209
SJS B-Disease 1 1.0
or O 0 0.00013063369260635227
SWS B-Disease 1 0.9995911717414856
presented O 0 5.161638938488977e-08
a O 0 8.733338496824672e-09
combination O 0 1.625858558895743e-08
of O 0 3.38435890423483e-10
a O 0 1.5719127333113647e-08
severe O 0 1.1510666809044778e-05
, O 0 4.3754905476589556e-08
prenatal O 0 0.2778693735599518
- O 1 0.9924059510231018
onset O 1 0.9999997615814209
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 0.9999992847442627
( O 0 2.987410425703274e-07
with O 0 4.42584365600851e-07
congenital B-Disease 1 0.9999998807907104
joint I-Disease 0 8.886119030648842e-05
contractures I-Disease 1 0.9995982050895691
, O 0 2.7370576844987227e-06
respiratory O 1 0.9999274015426636
and O 0 2.3857316477915447e-07
feeding O 0 1.4370178860190208e-06
difficulties O 0 2.2902494123400174e-08
, O 0 8.820233432516034e-10
tendency O 0 1.0458504817734138e-07
to O 0 3.97607990976212e-08
hyperthermia B-Disease 0 0.0012862037401646376
, O 0 1.5248661222599935e-09
and O 0 4.935628572511064e-10
frequent O 0 5.206192099649343e-08
death O 0 2.5877270672935992e-06
in O 0 1.3869413351130788e-07
infancy O 0 4.9261907406616956e-05
) O 0 4.4424236511630966e-10
with O 0 2.450996350322754e-10
a O 0 4.603524672575077e-09
distinct O 0 6.423995557724993e-08
campomelic B-Disease 0 0.0023575793020427227
- I-Disease 0 0.07685548812150955
metaphyseal I-Disease 0 0.24772760272026062
skeletal I-Disease 1 0.9968343377113342
dysplasia I-Disease 1 0.9998466968536377
. O 0 1.4247638091546833e-06

The O 0 2.0857500260262896e-07
similarity O 0 1.30513697627066e-07
of O 0 2.196330672887825e-09
the O 0 7.680700520040773e-09
clinical O 0 9.396353561896831e-08
and O 0 1.8688727010385264e-08
radiographic O 0 3.872829984175041e-05
findings O 0 6.016511520101631e-07
is O 0 1.8443457872052704e-09
so O 0 6.348433445602097e-10
extensive O 0 3.045327767736694e-09
that O 0 1.4333756404028009e-09
these O 0 2.6470848624171595e-08
disorders O 0 9.023675374919549e-05
appear O 0 2.928184983375104e-07
to O 0 5.425861093755202e-09
be O 0 1.006190464281076e-09
a O 0 2.3738850885024476e-09
single O 0 1.2389445025462464e-08
entity O 0 1.3413294652764307e-07
. O 0 3.652646185514641e-08

The O 0 6.46013234018028e-07
follow O 0 7.392675911432889e-07
- O 0 1.5775796100570005e-06
up O 0 3.0405931994437196e-08
observation O 0 3.512674950911787e-08
of O 0 1.8256689215956357e-10
an O 0 5.774914990652746e-10
identical O 0 2.542014101436507e-07
and O 0 1.943571303897329e-09
unique O 0 3.847379304033893e-09
pattern O 0 5.848216915183002e-06
of O 0 1.4690201055600483e-08
progressive O 0 0.09612203389406204
bone B-Disease 1 0.9991474151611328
dysplasia I-Disease 1 0.9999674558639526
in O 0 1.7784986994229257e-07
the O 0 2.795553477596968e-08
two O 0 1.0256254512341911e-08
patients O 0 4.500962447195889e-08
( O 0 2.0051826865596922e-09
one O 0 1.0776292080905137e-09
with O 0 1.5841477463141018e-08
SJS B-Disease 1 0.999516487121582
type I-Disease 0 7.117262430256233e-05
2 I-Disease 0 2.6311832712622163e-08
, O 0 2.8952593100761703e-10
one O 0 3.9877720570125064e-10
with O 0 3.4730740505750646e-09
SWS B-Disease 0 0.42974281311035156
) O 0 2.200687632125664e-09
surviving O 0 1.8239305177303322e-08
beyond O 0 2.1715720777137903e-08
infancy O 0 1.8594239463709528e-06
adds O 0 1.5874718428676715e-08
to O 0 4.778759610246652e-10
the O 0 2.8976071542174964e-10
evidence O 0 4.0795142264293816e-10
in O 0 4.3272577188169237e-10
favor O 0 2.6917912343549233e-09
of O 0 4.848259016476675e-10
identity O 0 1.0230078828499245e-07
. O 0 5.6009188398320475e-08

The O 0 4.1053323229789385e-07
hypothesis O 0 1.219557134390925e-06
that O 0 2.469157500684105e-08
SWS B-Disease 0 0.32503464818000793
and O 0 2.6564526933725574e-07
SJS B-Disease 1 0.9875708818435669
type I-Disease 0 2.5250064936699346e-05
2 I-Disease 0 1.9948000584690817e-08
are O 0 1.5981244105844894e-10
the O 0 1.1669253341395347e-09
same O 0 2.81652887679229e-07
disorder O 0 1.1071352673752699e-05
should O 0 8.378286397991985e-10
be O 0 2.4789040264927564e-10
testable O 0 6.40353903236246e-09
by O 0 4.2424200263901923e-10
molecular O 0 1.2787118031098998e-08
methods O 0 3.348584698414925e-08
. O 0 5.138081959898955e-09
. O 0 6.830759957665578e-08

A O 0 5.674171006830875e-06
mouse O 0 4.601733235176653e-05
model O 0 1.6736677252993104e-06
of O 0 5.956804471907162e-08
severe O 1 0.9961263537406921
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.31837886571884155
defects O 1 0.9999991655349731
in O 0 5.238632638793206e-06
hemostasis O 1 0.940527081489563
and O 0 4.188405000604689e-06
thrombosis B-Disease 0 0.004963311832398176
. O 0 1.145836108662479e-06

von B-Disease 1 0.9470376968383789
Willebrand I-Disease 1 0.8429240584373474
factor I-Disease 0 0.00032129959436133504
( I-Disease 0 2.6673644242691807e-05
vWf I-Disease 0 0.0014002089155837893
) I-Disease 0 9.125742508331314e-05
deficiency I-Disease 1 0.9989262223243713
causes O 0 0.0002231953403679654
severe O 1 0.9999984502792358
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 2.7798640076071024e-05
humans O 0 4.293482561479323e-06
. O 0 1.212506049341755e-06

We O 0 1.2158903928138898e-07
generated O 0 3.51413582677651e-08
a O 0 1.3793061803824003e-08
mouse O 0 2.0605159534170525e-06
model O 0 8.866221179459899e-08
for O 0 5.67506874826762e-10
this O 0 1.3153368394469567e-09
disease O 0 7.3741432515817e-08
by O 0 4.1590234034494244e-10
using O 0 2.0421715873908397e-08
gene O 0 3.376310075964284e-07
targeting O 0 5.40493601874914e-07
. O 0 1.6158179505509906e-07

vWf B-Disease 0 0.010463441722095013
- I-Disease 1 0.9417783617973328
deficient I-Disease 0 0.27898451685905457
mice O 0 0.0002435110800433904
appeared O 0 9.862628758128267e-07
normal O 0 3.7554269738393486e-07
at O 0 2.5796427394197963e-07
birth O 0 5.01501347116573e-07
; O 0 1.3543647314762097e-09
they O 0 3.8845260341702215e-10
were O 0 1.034469843119723e-09
viable O 0 1.3449256819342281e-08
and O 0 1.966196538916165e-09
fertile O 0 9.14722875222651e-08
. O 0 1.0127936889148259e-07

Neither O 0 8.078739483607933e-05
vWf O 0 0.0007223398424685001
nor O 0 3.6166929930914193e-05
vWf O 0 0.0003052217361982912
propolypeptide O 0 0.00019715720554813743
( O 0 1.7064502344510402e-06
von B-Disease 0 0.0018457815749570727
Willebrand I-Disease 0 0.005811059381812811
antigen O 0 5.2689490985358134e-05
II O 0 6.978081364650279e-05
) O 0 1.4700880512918957e-08
were O 0 2.7802429247714144e-09
detectable O 0 2.2444622516104573e-07
in O 0 4.5495101019810136e-09
plasma O 0 1.5196732761069143e-07
, O 0 2.29244201399581e-09
platelets O 0 1.6297370564188896e-07
, O 0 1.0068028633014592e-09
or O 0 1.6040710981712891e-09
endothelial O 0 1.7261449158922915e-08
cells O 0 6.601077906509545e-09
of O 0 2.6293645039032754e-10
the O 0 9.537751921584459e-09
homozygous O 0 1.7973068224819144e-06
mutant O 0 1.9543563212209847e-06
mice O 0 1.0909223419730552e-05
. O 0 1.9376541615656606e-07

The O 0 2.3578095351695083e-06
mutant O 0 4.85717537230812e-05
mice O 0 0.001610400271601975
exhibited O 0 0.007896787486970425
defects O 1 0.8506723642349243
in O 0 9.424605451613388e-08
hemostasis O 0 4.044704110128805e-05
with O 0 6.687123743631673e-09
a O 0 1.0044598042213693e-07
highly O 0 2.0770410174009157e-06
prolonged O 1 0.5308147072792053
bleeding O 1 0.9800140857696533
time O 0 2.7124914936393907e-07
and O 0 9.377478349392732e-09
spontaneous O 0 9.123148458911601e-08
bleeding O 0 3.692282007250469e-06
events O 0 5.387108092946846e-09
in O 0 1.5088008620267601e-09
approximately O 0 2.299444412656726e-09
10 O 0 2.4490161010248812e-09
% O 0 5.473359543373135e-10
of O 0 2.3726085540687336e-09
neonates O 0 6.029198175383499e-06
. O 0 2.3633310775039718e-07

As O 0 7.714046290629994e-08
in O 0 6.7019354510478024e-09
the O 0 2.3644315394477644e-09
human O 0 7.639338939213758e-09
disease O 0 2.5263918246309913e-07
, O 0 2.4929816544450034e-10
the O 0 2.3590711606402692e-09
factor O 0 7.956893810501242e-09
VIII O 0 3.8711579009031993e-07
level O 0 7.4131891736328726e-09
in O 0 2.6286888221704885e-09
these O 0 1.2767176205130681e-09
mice O 0 2.9679831641260535e-06
was O 0 1.272828455967101e-07
reduced O 0 9.14844644483992e-09
strongly O 0 1.0654102489127126e-08
as O 0 4.0070086138044303e-10
a O 0 5.002159242373239e-10
result O 0 3.2839392316574845e-10
of O 0 7.431955051373507e-11
the O 0 1.0301184349970072e-09
lack O 0 1.285171080667169e-09
of O 0 1.8922065303517144e-10
protection O 0 4.669736153317672e-09
provided O 0 8.263734585511884e-09
by O 0 2.1738431499329636e-08
vWf O 0 1.0739080607891083e-05
. O 0 1.7814490149703488e-07

Defective O 1 0.759681224822998
thrombosis B-Disease 0 0.38252130150794983
in O 0 6.847429858680698e-07
mutant O 0 1.0184546226810198e-05
mice O 0 0.004961503203958273
was O 0 1.6003367591110873e-06
also O 0 3.1720923665545797e-09
evident O 0 2.678511412668172e-09
in O 0 4.928300545437025e-10
an O 0 3.186255981280084e-10
in O 0 2.0619006502187176e-09
vivo O 0 1.3274990351419547e-07
model O 0 6.614641989699521e-08
of O 0 7.72682451355422e-09
vascular B-Disease 0 0.010341339744627476
injury I-Disease 0 6.723712431266904e-05
. O 0 3.2516697956452845e-07

In O 0 2.686525704120868e-07
this O 0 9.624372410144133e-09
model O 0 5.0309648003121765e-08
, O 0 7.084323683237415e-10
the O 0 4.827941602059127e-09
exteriorized O 0 5.419820354291005e-06
mesentery O 0 1.7991478671319783e-05
was O 0 1.493645243044739e-07
superfused O 0 7.499525054299738e-07
with O 0 4.03306499308087e-09
ferric O 0 3.458794481048244e-06
chloride O 0 2.161592789207134e-07
and O 0 2.8999920242966937e-09
the O 0 3.4992724273763542e-09
accumulation O 0 8.113956084798701e-08
of O 0 4.726394831067182e-09
fluorescently O 0 1.727903145365417e-05
labeled O 0 4.500444447330665e-06
platelets O 0 2.6390323455416365e-06
was O 0 5.6861697572685443e-08
observed O 0 2.6292365618019176e-08
by O 0 7.724053396884756e-09
intravital O 0 6.7455030148266815e-06
microscopy O 0 7.885530976636801e-06
. O 0 2.8287826125961146e-07

We O 0 2.1053324417152908e-07
conclude O 0 2.2775256525164878e-07
that O 0 3.818188876181239e-09
these O 0 1.5617093174213892e-09
mice O 0 6.244582095860096e-07
very O 0 1.4187510721797025e-08
closely O 0 6.241956498342915e-07
mimic O 0 0.0001338115253020078
severe O 0 0.0005216430290602148
human O 0 4.525635631580371e-06
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 0.0009809513576328754
will O 0 1.2264298732134193e-07
be O 0 1.6973094041361492e-09
very O 0 7.518933253791715e-10
useful O 0 7.317671468776155e-10
for O 0 9.591357569282977e-11
investigating O 0 1.4087946365037851e-09
the O 0 4.4453310477088337e-10
role O 0 7.33963168020324e-10
of O 0 2.6742577596827743e-10
vWf O 0 7.393860812499042e-08
in O 0 2.0437838088582794e-09
normal O 0 1.8290836578671588e-07
physiology O 0 5.1865971073539185e-08
and O 0 3.428855421816479e-09
in O 0 2.3196474074893558e-08
disease O 0 3.825327439699322e-06
models O 0 3.173716436322138e-07
. O 0 9.884662865999871e-09
. O 0 7.919922495602805e-08

Oral O 0 9.574000432621688e-05
contraceptives O 0 0.0014635586412623525
and O 0 1.10742881531678e-08
the O 0 6.793868578824913e-09
risk O 0 9.44202227515234e-08
of O 0 1.615448184111301e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.494758392567746e-06

Hereditary B-Disease 1 0.9999998807907104
Ovarian I-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.7647116780281067
Clinical O 0 1.8905233446275815e-05
Study O 0 6.163984380691545e-07
Group O 0 9.002415026770905e-07
. O 0 5.817272494823555e-07

BACKGROUND O 0 4.879204061580822e-05
Women O 0 8.933783135489648e-08
with O 0 5.0154982389472025e-09
mutations O 0 3.7156061694076925e-07
in O 0 6.408585218053986e-09
either O 0 8.455831590481466e-09
the O 0 1.3968672440967111e-08
BRCA1 O 0 1.9000547126779566e-06
or O 0 6.127303553427055e-09
the O 0 7.675926561034885e-09
BRCA2 O 0 1.0637105560817872e-06
gene O 0 5.780375644803826e-08
have O 0 6.211813285972312e-10
a O 0 2.8607989310813764e-09
high O 0 9.473012596572516e-08
lifetime O 0 6.964010168530876e-08
risk O 0 5.24625932030176e-07
of O 0 1.638022149563767e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.7463443100496079e-06

Oral O 0 0.00031015416607260704
contraceptives O 0 0.008955640718340874
protect O 0 4.310878284741193e-05
against O 1 0.9963589310646057
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.2938964744080295e-07
general O 0 1.0482065881944891e-08
, O 0 1.7427975729233935e-09
but O 0 7.666002277417761e-10
it O 0 1.3067473769723392e-09
is O 0 1.6717881246020028e-10
not O 0 2.998345668969726e-11
known O 0 3.300491546731621e-10
whether O 0 3.5466696246544416e-10
they O 0 3.3115898911972863e-10
also O 0 6.320861611897044e-10
protect O 0 1.6406579428362988e-09
against O 0 5.467123198599211e-09
hereditary B-Disease 0 3.7116574276296888e-06
forms I-Disease 0 1.2489205403198866e-07
of I-Disease 0 3.338319584145211e-05
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.474369224131806e-07

METHODS O 0 1.2602617971424479e-05
We O 0 6.470059332741585e-08
enrolled O 0 6.489648285423755e-08
207 O 0 3.1280066536965023e-07
women O 0 2.0336123895958735e-08
with O 0 1.0327285053790547e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 5.919033441159627e-08
161 O 0 2.716259750457084e-08
of O 0 3.6995634333791827e-10
their O 0 6.264169627456795e-08
sisters O 0 3.0687164809251044e-08
as O 0 8.729754696901182e-10
controls O 0 1.301629595218401e-06
in O 0 1.458410392451981e-09
a O 0 3.345142163269088e-09
case O 0 9.012008916897685e-09
- O 0 7.259422432071005e-07
control O 0 1.1036754585802555e-06
study O 0 6.688427589551793e-08
. O 0 6.155912046779122e-08

All O 0 1.4160859507228452e-07
the O 0 1.6108446132534482e-08
patients O 0 2.855806613411005e-08
carried O 0 1.6434116290042766e-08
a O 0 5.568363992125569e-09
pathogenic O 0 1.0427327197248815e-06
mutation O 0 4.0420857772005547e-07
in O 0 6.681870612368357e-09
either O 0 3.6505916511941905e-08
BRCA1 O 0 3.7915499433438526e-06
( O 0 2.001347354507743e-08
179 O 0 8.157125819252542e-08
women O 0 4.382445961681469e-09
) O 0 3.8516083655792954e-09
or O 0 4.9156785308923645e-08
BRCA2 O 0 4.462974175112322e-06
( O 0 1.783712555436523e-08
28 O 0 7.22835622468665e-08
women O 0 5.985022255572403e-09
) O 0 7.912309030189135e-09
. O 0 4.572191159013528e-08

The O 0 3.7617283510371635e-07
control O 0 1.9058602447330486e-06
women O 0 1.266816518352698e-08
were O 0 1.0860791155309357e-09
enrolled O 0 1.8365526877062166e-09
regardless O 0 4.699282074582811e-10
of O 0 6.122192336421861e-11
whether O 0 1.0008540662909127e-09
or O 0 4.302438849634882e-09
not O 0 5.142334336127874e-10
they O 0 3.3031241630787633e-10
had O 0 5.534818381391915e-09
either O 0 1.0648962600612322e-08
mutation O 0 6.59462443763914e-07
. O 0 1.041733383999599e-07

Lifetime O 0 1.701184555713553e-05
histories O 0 6.372906682372559e-06
of O 0 1.8921289424156384e-08
oral O 0 1.4308722029454657e-06
- O 0 3.2221446417679545e-06
contraceptive O 0 2.9309667297638953e-06
use O 0 1.534468729857963e-08
were O 0 2.1748205458749226e-09
obtained O 0 1.074267785838856e-09
by O 0 7.114072664293758e-10
interview O 0 1.5041558754091966e-07
or O 0 3.2361004986825037e-09
by O 0 7.55664475438067e-10
written O 0 1.915863911960969e-09
questionnaire O 0 6.352675718801493e-09
and O 0 2.840462587361259e-10
were O 0 3.11948911146942e-10
compared O 0 2.7976163607945637e-09
between O 0 3.7734393387722776e-09
patients O 0 7.597606099807308e-09
and O 0 4.234531836289079e-09
control O 0 2.7314617909723893e-06
women O 0 1.1928700249796975e-09
, O 0 1.1313760345244006e-10
after O 0 1.5670442721216205e-09
adjustment O 0 4.921802521096197e-09
for O 0 1.733659465985582e-10
year O 0 2.79260364832723e-10
of O 0 2.000360849185867e-10
birth O 0 2.6214632953269756e-07
and O 0 7.0231664928144255e-09
parity O 0 1.0714524023569538e-06
. O 0 7.948644764610435e-08

RESULTS O 0 1.2093133591406513e-05
The O 0 2.3125797099510237e-07
adjusted O 0 4.486069155973382e-05
odds O 0 6.9724360400869045e-06
ratio O 0 3.406647374504246e-05
for O 0 0.00027650195988826454
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.0422262874953958e-07
with O 0 1.533373761297696e-09
any O 0 1.1131332522396065e-09
past O 0 3.767060885451201e-09
use O 0 1.9026158426527218e-09
of O 0 4.291617616836163e-10
oral O 0 2.5936370207091386e-07
contraceptives O 0 8.559916750527918e-05
was O 0 6.965404395486985e-07
0 O 0 2.0279811963064276e-07
. O 0 1.4358887767684791e-07

5 O 0 5.4644015108351596e-06
( O 0 9.60658539383985e-08
95 O 0 1.8277026470059354e-07
percent O 0 1.2270686511328677e-07
confidence O 0 1.4567577011348476e-07
interval O 0 8.570079046421597e-08
, O 0 6.56759313599764e-10
0 O 0 1.666933258093195e-09
. O 0 1.469638022388864e-10
3 O 0 1.9703974007967417e-09
to O 0 1.6398506996750939e-09
0 O 0 1.0586667542611394e-08
. O 0 9.269089384922324e-10
8 O 0 4.6590269420221375e-08
) O 0 1.1515020048591396e-08
. O 0 3.935495485052343e-08

The O 0 3.4471403864699823e-07
risk O 0 6.996575052653498e-07
decreased O 0 1.6047214046466252e-07
with O 0 1.0976831665843179e-09
increasing O 0 5.318784523922204e-09
duration O 0 1.7049677225600135e-08
of O 0 8.67668381587805e-10
use O 0 5.656163537537395e-08
( O 0 1.2787801040303748e-08
P O 0 3.1460574518860085e-06
for O 0 2.555906819523557e-09
trend O 0 9.7770744389436e-08
, O 0 1.8689787495418386e-09
< O 0 3.979767626560715e-08
0 O 0 9.917106247314678e-09
. O 0 1.2089748091526076e-09
001 O 0 5.4885443745433804e-08
) O 0 4.6018805432979093e-10
; O 0 2.4428706280055223e-10
use O 0 7.186243822232541e-10
for O 0 1.3422411793140299e-10
six O 0 4.1972270103940446e-10
or O 0 8.952299457298807e-10
more O 0 2.6298410671365957e-10
years O 0 1.3547367672117616e-09
was O 0 3.737895326594298e-09
associated O 0 6.075606684419199e-10
with O 0 1.187206166708421e-10
a O 0 3.516742452802646e-09
60 O 0 1.0924558146996333e-08
percent O 0 3.225060041245342e-08
reduction O 0 8.221256564411306e-09
in O 0 1.30763062600181e-08
risk O 0 2.845786184479948e-07
. O 0 9.505718168156818e-08

Oral O 0 9.728020086186007e-05
- O 0 3.914610715582967e-05
contraceptive O 0 1.0798438779602293e-05
use O 0 2.1136872874194523e-07
protected O 0 2.4720566216274165e-06
against O 1 0.9814971685409546
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 3.69282537882043e-09
for O 0 3.0206936951771013e-10
carriers O 0 3.010399707292777e-09
of O 0 2.303929963476392e-10
the O 0 2.2292304890925152e-08
BRCA1 O 0 1.515642725280486e-05
mutation O 0 5.457030169964128e-07
( O 0 1.4553574345654852e-08
odds O 0 3.49688633605183e-07
ratio O 0 1.45670767892625e-07
, O 0 7.398043289086331e-10
0 O 0 4.111222029479222e-09
. O 0 3.4449931796132205e-10
5 O 0 2.3950741390166286e-09
; O 0 1.0331525635010053e-09
95 O 0 8.394962236479842e-08
percent O 0 6.002710506436415e-07
confidence O 0 3.98010968183371e-07
interval O 0 4.3261561444296603e-08
, O 0 2.2782699338197432e-10
0 O 0 9.532163947056915e-10
. O 0 8.378857330182399e-11
3 O 0 8.677975005255689e-10
to O 0 6.418270359631606e-10
0 O 0 2.8150715092323253e-09
. O 0 2.4728499803394755e-10
9 O 0 1.2185203956960322e-08
) O 0 1.7030939158946268e-10
and O 0 1.214711248254119e-10
for O 0 9.399638706275582e-11
carriers O 0 1.2209647737293494e-09
of O 0 2.0532892053282126e-10
the O 0 3.039253826386812e-08
BRCA2 O 0 1.2302725735935383e-05
mutation O 0 7.017598022684979e-07
( O 0 2.1019275209255284e-08
odds O 0 3.2062496302387444e-07
ratio O 0 8.31859736649676e-08
, O 0 9.521951005453388e-10
0 O 0 4.977492640279024e-09
. O 0 3.539668280705399e-10
4 O 0 5.285059057058561e-09
; O 0 1.2956139494590957e-09
95 O 0 8.069199708415908e-08
percent O 0 3.0076753887442464e-07
confidence O 0 7.628581499830034e-08
interval O 0 2.678037525072341e-08
, O 0 4.3765796542416524e-10
0 O 0 1.3708472135220973e-09
. O 0 1.0502027719683227e-10
2 O 0 1.635028556989937e-09
to O 0 1.5409674647415272e-09
1 O 0 3.138115767242766e-09
. O 0 5.769894007023879e-10
1 O 0 1.2554917105944696e-08
) O 0 6.53018616958434e-09
. O 0 2.2725695103531507e-08

CONCLUSIONS O 0 1.612760934222024e-05
Oral O 0 1.2040416550007649e-05
- O 0 1.9542314475984313e-05
contraceptive O 0 1.1801254004240036e-05
use O 0 1.44314839189974e-07
may O 0 1.3584289604295918e-07
reduce O 0 3.4277977789543e-08
the O 0 6.979818056862541e-09
risk O 0 4.0495555708730535e-07
of O 0 3.523509803926572e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 6.949864683747364e-08
women O 0 3.3490366035948682e-09
with O 0 1.9815646901122363e-09
pathogenic O 0 1.4012576912136865e-06
mutations O 0 4.920547667097708e-07
in O 0 5.23316945333363e-09
the O 0 4.2746137296489906e-08
BRCA1 O 0 2.455099456710741e-05
or O 0 1.0782979416035232e-06
BRCA2 O 0 0.00021757677313871682
gene O 0 0.00014439900405704975

A O 0 1.6771477930888068e-06
Japanese O 0 1.7029126411216566e-06
family O 0 3.756964019885345e-07
with O 0 4.197959668772455e-08
adrenoleukodystrophy B-Disease 1 1.0
with O 0 4.37534062314171e-08
a O 0 1.9080248137015587e-07
codon O 0 8.956070814747363e-06
291 O 0 1.047195269165968e-06
deletion O 0 2.196986997660133e-06
: O 0 3.1587432669510918e-09
a O 0 2.676361354758683e-09
clinical O 0 2.5367773659468185e-08
, O 0 1.1478612504944863e-09
biochemical O 0 3.392298708604358e-08
, O 0 4.823520471930465e-10
pathological O 0 1.729374332626321e-08
, O 0 7.93636656393204e-10
and O 0 4.7153019266943375e-09
genetic O 0 3.6401900160853984e-07
report O 0 8.109328177852149e-07
. O 0 1.9702298459378653e-07

We O 0 3.654820943665982e-07
report O 0 8.313711674645674e-08
a O 0 8.34584934494842e-09
Japanese O 0 4.74561083763092e-08
family O 0 1.1599606608569957e-07
with O 0 1.9048212607231108e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.0002102448052028194
ALD B-Disease 1 1.0
) O 0 7.727634532272987e-09
with O 0 5.325440644021739e-10
a O 0 3.5877802950778914e-09
three O 0 2.0154202751143657e-09
base O 0 2.956028843925651e-08
pair O 0 6.352775727691551e-08
deletion O 0 4.9025697990146e-07
( O 0 1.805964267020954e-08
delGAG O 0 5.896469019717188e-07
291 O 0 1.4302035822311154e-07
) O 0 2.8845785760012177e-09
in O 0 8.987582233999092e-09
the O 0 3.4779554880515207e-07
ALD B-Disease 1 0.9999998807907104
gene O 0 1.414372309227474e-05
. O 0 2.0409261480835994e-07

A O 0 9.055974032889935e-07
variety O 0 5.878899855815689e-08
of O 0 2.910431229352639e-09
phenotypes O 0 3.2626564916427014e-07
were O 0 7.254624012631439e-09
observed O 0 1.6619496889802576e-08
within O 0 4.170980894002696e-09
this O 0 5.276668435527654e-09
family O 0 1.4713903340179968e-07
. O 0 9.620282526157098e-08

While O 0 3.319922825539834e-07
the O 0 9.13990376716356e-08
proband O 0 3.31975425069686e-05
( O 0 1.1896901241925661e-07
patient O 0 6.441823643399402e-07
1 O 0 6.775056249352929e-08
) O 0 1.9235750770008053e-09
was O 0 3.694990269309528e-08
classified O 0 6.577073552449519e-09
as O 0 9.69961222452298e-10
having O 0 3.6524819280181475e-10
a O 0 4.688305854649855e-10
rare O 0 2.2414914369051075e-09
intermediate O 0 1.9868600986683305e-08
type O 0 1.6546819381346722e-07
of O 0 1.218628864485538e-09
adult O 0 2.3096336008165963e-06
cerebral O 0 6.228181882761419e-05
and O 0 1.0940368611045415e-07
cerebello O 0 0.09873781353235245
- O 0 0.02192808873951435
brain O 0 0.0002961642749141902
stem O 0 3.608815006828081e-07
forms O 0 2.1830839358472076e-08
, O 0 1.0679181983164199e-09
his O 0 1.4093168410056478e-08
younger O 0 1.7488129344656045e-07
brother O 0 3.0750859991712787e-07
( O 0 8.62550386671046e-09
patient O 0 1.2120675307869533e-07
2 O 0 3.8694739856737215e-08
) O 0 3.540101989329969e-09
and O 0 1.60398005988327e-08
nephew O 0 2.5992505470640026e-05
( O 0 1.7680164887678984e-08
patient O 0 1.8948635727156216e-07
3 O 0 4.085513793938844e-08
) O 0 1.8720112127112998e-09
had O 0 1.9958276809006747e-08
a O 0 2.3068569987572118e-07
childhood O 0 0.009786593727767467
ALD B-Disease 1 1.0
type O 0 0.06907453387975693
. O 0 5.621396894639474e-07

Another O 0 7.864592589612585e-06
nephew O 0 0.00025187485152855515
( O 0 7.351364388341608e-07
patient O 0 2.275259930684115e-06
4 O 0 6.550297371177294e-08
) O 0 8.732068956796013e-10
of O 0 3.0750707535887045e-10
patient O 0 2.908264491452428e-07
1 O 0 1.3368087081744306e-07
was O 0 1.291159890115523e-07
classified O 0 5.780691925139081e-09
as O 0 1.5246421902759266e-09
having O 0 1.4965253480880847e-09
an O 0 2.1169257458097945e-09
adolescent O 0 1.3406788639258593e-06
form O 0 2.7106554512101866e-07
. O 0 3.372866501649696e-07

The O 0 5.603632189377095e-07
tau O 0 7.152726198000892e-07
level O 0 4.9021959824813166e-08
in O 0 1.1906930552640915e-08
the O 0 5.863311969278584e-08
cerebrospinal O 0 0.0010579252848401666
fluid O 0 1.0515735084482003e-05
( O 0 4.3943589389527915e-07
CSF O 0 0.07136987894773483
) O 0 4.089378613514327e-09
in O 0 1.0246048454121137e-08
patient O 0 5.73070622067462e-07
1 O 0 1.2715642583316367e-07
was O 0 1.0192561603616923e-06
as O 0 1.7009229580366991e-09
high O 0 1.3580541136093416e-08
as O 0 2.4780816287872653e-10
that O 0 4.881959073110842e-11
of O 0 2.033847118498855e-10
patients O 0 2.3277046068415075e-08
with O 0 2.841300670297642e-07
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.508640706539154
( O 0 6.232290417074182e-08
AD B-Disease 0 1.7070955436793156e-05
) O 0 6.65559483081779e-08
. O 0 8.88267450704916e-08

His O 0 2.819643214024836e-06
brain O 0 0.00010657846723916009
magnetic O 0 6.136128831712995e-06
resonance O 0 3.253938484704122e-05
image O 0 0.00028966693207621574
( O 0 1.169524495026053e-07
MRI O 0 0.00018899573478847742
) O 0 1.6661712010090923e-08
showed O 0 1.5868845366640016e-05
abnormalities B-Disease 0 0.010349365882575512
in I-Disease 0 3.6653038382183922e-09
the I-Disease 0 6.680303421546796e-09
bilateral I-Disease 0 4.6303064493713464e-08
cerebellar I-Disease 0 8.012214675545692e-05
hemispheres I-Disease 0 1.2383049579511862e-05
and O 0 6.753548831284206e-08
brain O 0 2.724702062550932e-05
stem O 0 6.73194278988376e-07
, O 0 1.2314754771480807e-09
but O 0 4.288099320071126e-10
not O 0 1.7595236379008838e-10
in O 0 1.2837892970907205e-09
the O 0 1.201440191778147e-08
cerebral O 0 9.536837751511484e-06
white O 0 9.821239643770241e-08
matter O 0 1.7428308796141323e-09
, O 0 2.520564590380303e-10
where O 0 1.8324788908508083e-10
marked O 0 3.2869738042506924e-09
reductions O 0 3.1672195976995e-09
of O 0 1.0793155258426168e-10
the O 0 5.602839081575439e-09
cerebral O 0 1.0559271004240145e-06
blood O 0 5.0042345378642494e-08
flow O 0 3.018991634462509e-08
and O 0 7.356215192544369e-09
oxygen O 0 2.482735226294608e-07
metabolism O 0 9.663746141086449e-07
were O 0 4.12363831969742e-09
clearly O 0 6.751318171183129e-09
demonstrated O 0 4.883025539470509e-09
by O 0 4.143292819946964e-09
positron O 0 3.025949808943551e-06
emission O 0 1.3584808584710117e-05
tomography O 0 0.00031320261768996716
( O 0 1.100688535871086e-07
PET O 0 5.783920641988516e-06
) O 0 5.997023322379391e-08
. O 0 1.3414739896688843e-07

In O 0 1.3076926279609324e-06
patients O 0 7.619201483066718e-07
2 O 0 5.129271940518265e-08
and O 0 3.826332140022259e-09
3 O 0 9.512607590522748e-09
, O 0 2.651230623929024e-10
the O 0 2.8392994622095102e-09
autopsy O 0 0.00014382926747202873
findings O 0 2.018441875861754e-07
showed O 0 2.0187299014651217e-06
massive O 0 1.4584273912987555e-06
demyelination B-Disease 1 1.0
of I-Disease 0 6.698459564802306e-09
the I-Disease 0 1.585375599688632e-07
cerebral I-Disease 0 0.0001767967187333852
white I-Disease 0 3.9555817465952714e-07
matter I-Disease 0 1.2496664814065639e-09
with O 0 1.81943252131056e-10
sparing O 0 2.6189002078069734e-09
of O 0 1.6240778166753955e-10
the O 0 8.987376176605721e-09
U O 0 5.734139563173812e-07
- O 0 2.1594903500954388e-06
fibers O 0 2.050514467555331e-06
, O 0 7.303643800860016e-10
compatible O 0 1.1219221107694466e-08
with O 0 3.270425041890235e-10
the O 0 1.9312362820045337e-09
findings O 0 3.783025448456101e-08
of O 0 6.596244883638747e-09
childhood O 0 0.00025376511621288955
ALD B-Disease 1 0.9999998807907104
. O 0 2.2992760477791307e-06

Oleic O 0 0.11815690994262695
and O 0 3.8068651520006824e-06
erucic O 0 0.0002486652520019561
acids O 0 2.508974830561783e-06
( O 0 6.057884149868187e-08
Lorenzos O 0 1.4808772448304808e-06
Oil O 0 8.788821759253551e-08
) O 0 9.207997697657788e-10
were O 0 2.8902055748680766e-10
administered O 0 2.055241532517016e-09
to O 0 1.944705951828496e-09
patients O 0 6.730707546864778e-09
1 O 0 3.7074909808865186e-09
and O 0 8.410420693216736e-10
4 O 0 3.1713665027410798e-09
, O 0 7.605122781528806e-11
but O 0 1.3762380124404672e-10
sufficient O 0 1.3436020074308885e-09
effectiveness O 0 1.699694607282254e-08
was O 0 3.7441761691070496e-08
not O 0 1.0243385029085061e-09
obtained O 0 1.5816841170135376e-08
. O 0 1.9223399760903703e-08

The O 0 4.125324437609379e-07
findings O 0 2.536023657739861e-07
in O 0 7.916686861619837e-09
this O 0 1.2167941099150426e-09
family O 0 7.995383022318947e-09
suggest O 0 5.491495258524992e-09
that O 0 2.684555355791929e-10
delGAG291 O 0 6.654515516402171e-08
is O 0 1.0980282655337348e-10
part O 0 1.6589869755723186e-10
of O 0 3.872436052376749e-11
the O 0 1.1842712366316732e-09
cause O 0 1.0348649048808056e-08
of O 0 1.5100531935985373e-09
Japanese O 0 5.170352778804954e-06
ALD B-Disease 1 0.9999997615814209
with O 0 2.93971211817734e-08
phenotypic O 0 1.4067406937101623e-06
variations O 0 2.9944467314635403e-06
. O 0 3.5023731470573694e-07

Moreover O 0 6.866400781291304e-06
, O 0 1.7597939105939986e-08
although O 0 3.552073746249107e-09
the O 0 7.47469253159494e-10
scale O 0 3.4916718405497704e-09
of O 0 1.2462715581751382e-10
the O 0 1.6096122212871933e-09
study O 0 8.694310271728511e-10
is O 0 3.3462382864613005e-10
limited O 0 2.4245039309533922e-09
, O 0 1.9432662423657376e-10
there O 0 1.1922485221305124e-10
is O 0 7.629894632765755e-11
a O 0 5.883156184438576e-10
possibility O 0 2.0612636042471877e-09
that O 0 1.6431006555350791e-09
PET O 0 4.3788384118670365e-07
can O 0 4.4764743023506526e-09
detect O 0 5.876343607269519e-07
an O 0 9.348120499907964e-09
insidious B-Disease 0 1.6653008060529828e-05
lesion I-Disease 0 0.013618644326925278
which O 0 1.1747645523030315e-08
is O 0 1.4118989311029395e-09
undetectable O 0 1.2336346344454796e-07
by O 0 3.0136284578929917e-09
computed O 0 4.407016547247622e-07
tomogram O 0 2.820423333105282e-06
( O 0 2.6095820615523735e-08
CT O 0 0.052865806967020035
) O 0 5.435203842552028e-09
or O 0 1.3147957389492149e-08
MRI O 0 5.671282451658044e-06
analysis O 0 1.377100655730601e-08
, O 0 4.5960649175391666e-10
and O 0 1.431577079102908e-10
that O 0 5.910563011246595e-11
the O 0 1.0404238581784853e-09
higher O 0 4.0583234550695124e-08
level O 0 3.836856166117286e-09
of O 0 3.496715417217189e-10
tau O 0 1.2986454578367557e-08
reflects O 0 2.346264293962008e-09
the O 0 2.413208521900856e-10
process O 0 3.272128679121522e-10
of O 0 4.767452543852357e-10
neuronal B-Disease 0 1.5718968597866478e-06
degeneration I-Disease 0 6.417483382392675e-05
in O 0 8.941894407143991e-07
ALD B-Disease 1 1.0
. O 0 1.22556161841203e-06

Lorenzos O 0 0.0001187647576443851
Oil O 0 1.5670772199882776e-06
should O 0 9.104111242663748e-09
be O 0 1.776079006088338e-10
given O 0 3.6149090665293926e-11
in O 0 1.1091336182822431e-10
the O 0 4.575021472774665e-10
early O 0 6.038884237113962e-08
stage O 0 8.048571942254057e-08
. O 0 4.196909042519792e-09
. O 0 3.3460946013974535e-08

Nonsense O 0 0.00010771839879453182
mutation O 0 3.494328848319128e-05
in O 0 1.8802144552410027e-07
exon O 0 4.859539785684319e-06
4 O 0 5.981600992299718e-08
of O 0 1.3514281915760762e-09
human O 0 4.3994550225079365e-09
complement O 0 6.830108389976886e-08
C9 O 0 5.480826075654477e-06
gene O 0 8.021933126656222e-07
is O 0 2.2783188668995535e-09
the O 0 9.107302134658823e-10
major O 0 2.2002217825445314e-09
cause O 0 9.388968713608392e-09
of O 0 1.874312260952138e-09
Japanese O 0 1.2048833468725206e-06
complement B-Disease 0 7.207222552096937e-06
C9 I-Disease 0 0.07026953995227814
deficiency I-Disease 0 0.0033507575280964375
. O 0 1.891685741384208e-07

Deficiency B-Disease 1 0.9987505674362183
of I-Disease 0 3.885952537530102e-08
the I-Disease 0 1.6011618697575614e-08
ninth I-Disease 0 1.0859993437861704e-07
component I-Disease 0 1.4123979319435875e-08
of I-Disease 0 3.042005536357806e-10
human I-Disease 0 2.286865363743118e-09
complement I-Disease 0 6.259440255007576e-08
( O 0 1.1294733148758951e-08
C9 O 0 1.4103003422860638e-06
) O 0 1.7828409859532712e-09
is O 0 1.3540928101019034e-10
the O 0 2.9975752435795755e-10
most O 0 7.144941305270436e-10
common O 0 1.1608061356582766e-07
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 4.005965692499558e-08
Japan O 0 3.9721541611470457e-07
but O 0 2.284140876440688e-09
is O 0 1.3680227783918752e-10
rare O 0 2.4257101882696475e-10
in O 0 6.028073040731385e-10
other O 0 3.2104008340638757e-10
countries O 0 1.762271883976041e-09
. O 0 1.9754633484581063e-08

We O 0 3.259894754137349e-07
studied O 0 5.979183015369927e-08
the O 0 1.8448489402800305e-09
molecular O 0 1.904486701675978e-08
basis O 0 4.2324406201998954e-09
of O 0 6.3651928172703265e-09
C9 B-Disease 0 0.2624739706516266
deficiency I-Disease 0 0.0027269984129816294
in O 0 1.0306987263675182e-08
four O 0 6.02625993550987e-09
Japanese O 0 1.3003403864786378e-06
C9 B-Disease 0 0.10560280829668045
- I-Disease 1 0.9349489808082581
deficient I-Disease 1 0.7665483951568604
patients O 0 1.203288434226124e-06
who O 0 6.355635662202985e-08
had O 0 1.4016011391504435e-06
suffered O 0 0.026138370856642723
from O 0 8.296243322547525e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 2.8403626401996007e-06

Direct O 0 1.3728687235925463e-06
sequencing O 0 2.2661106413579546e-06
of O 0 2.3987327679719783e-08
amplified O 0 5.413569851953071e-06
C9 O 0 6.494003173429519e-06
cDNA O 0 1.0308215223631123e-06
and O 0 9.976678150280804e-09
DNA O 0 1.671238862854807e-07
revealed O 0 1.7905902893744496e-07
a O 0 2.8100034299427534e-08
nonsense O 0 4.920369178762485e-07
substitution O 0 2.3423177708536969e-07
( O 0 9.170165071736847e-08
CGA O 0 2.3549897377961315e-05
- O 0 3.001772529387381e-05
- O 0 1.2222828445374034e-05
> O 0 2.0212880826875335e-06
TGA O 0 7.834887583157979e-06
) O 0 4.873088599310904e-09
at O 0 2.1682609485651483e-08
codon O 0 3.1548862011732126e-07
95 O 0 2.616549821254921e-08
in O 0 3.061559228356714e-09
exon O 0 4.266118480700243e-07
4 O 0 3.200987919171894e-08
in O 0 4.392563202060273e-09
the O 0 5.841018335672743e-09
four O 0 3.752941779566754e-08
C9 B-Disease 0 0.00022197590442374349
- I-Disease 0 0.0011223054025322199
deficient I-Disease 0 0.0001241603313246742
individuals O 0 1.363411072929921e-08
. O 0 7.462320184004057e-08

An O 0 6.652256274719548e-07
allele O 0 1.6296595276799053e-05
- O 0 7.291707788681379e-07
specific O 0 3.1249648202447133e-08
polymerase O 0 1.9715125745278783e-06
chain O 0 6.397354354703566e-06
reaction O 0 4.995604854229896e-07
system O 0 1.8555036831457983e-06
designed O 0 3.2639277378621046e-06
to O 0 4.903867534267192e-09
detect O 0 9.673639169704984e-07
exclusively O 0 6.24398399651227e-09
only O 0 1.9689726238336647e-10
one O 0 2.445857925914563e-11
of O 0 1.0989997974164556e-11
the O 0 1.4178730411984475e-10
normal O 0 8.965631792534623e-09
and O 0 7.224256193261169e-10
mutant O 0 2.4356987537998975e-08
alleles O 0 1.0970496511220063e-08
indicated O 0 2.172583002391093e-08
that O 0 2.4199381387646213e-10
all O 0 4.769314457253593e-11
the O 0 4.668291309073425e-10
four O 0 6.840623623105557e-10
patients O 0 7.999726436835886e-10
were O 0 2.714749813836903e-10
homozygous O 0 1.072247801658932e-08
for O 0 1.1182506309825868e-10
the O 0 5.696335070304315e-10
mutation O 0 1.2002262295141009e-08
in O 0 3.038006068933896e-09
exon O 0 2.688858273813821e-07
4 O 0 3.954954763685237e-08
and O 0 9.657281641040072e-10
that O 0 1.4512063772897932e-10
the O 0 9.347919105451297e-10
parents O 0 3.6290264127103455e-09
of O 0 9.256258953760366e-11
patient O 0 1.7325900714126874e-08
2 O 0 1.17508278663081e-08
were O 0 9.225089137032683e-09
heterozygous O 0 1.4591480521630729e-06
. O 0 5.222084098477353e-08

The O 0 4.6728391112083045e-07
common O 0 4.601332648235257e-07
mutation O 0 1.3533914398067282e-06
at O 0 1.9398174799789558e-07
codon O 0 2.4924624995037448e-06
95 O 0 1.8211257213351928e-07
in O 0 3.827808470191485e-08
exon O 0 2.53955249718274e-06
4 O 0 2.8259461259949603e-07
might O 0 1.6800880686673736e-08
be O 0 4.51648884958189e-10
responsible O 0 1.8070038798612131e-09
for O 0 2.420450506690486e-10
most O 0 1.8705550441922014e-09
Japanese O 0 1.3219444099377142e-06
C9 B-Disease 0 0.23346592485904694
deficiency I-Disease 0 0.0002420162782073021
. O 0 2.164509105284651e-08
. O 0 1.0758557777990063e-07

BRCA1 O 0 0.00023078822414390743
required O 0 1.6427260618456785e-07
for O 0 7.731969731139543e-09
transcription O 0 3.368675834281021e-06
- O 0 0.0003660475485958159
coupled O 0 0.00014007644494995475
repair O 0 0.00019326733308844268
of O 0 3.793291014630995e-09
oxidative O 0 2.0467944068514043e-06
DNA O 0 3.6755557175638387e-06
damage O 0 3.640993236331269e-05
. O 0 5.51773496226815e-07

The O 0 1.0524965546210296e-05
breast B-Disease 1 0.9999887943267822
and I-Disease 1 0.9978571534156799
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.0004998413496650755
gene O 0 7.096544868545607e-05
BRCA1 O 0 7.000703772064298e-05
encodes O 0 3.185987907272647e-06
a O 0 2.1852895315532805e-06
zinc O 0 0.0005294030415825546
finger O 0 6.797202786401613e-06
protein O 0 6.412537345568126e-08
of O 0 6.559931486904702e-10
unknown O 0 2.488912542730759e-08
function O 0 1.522716814861269e-07
. O 0 8.609153212546516e-08

Association O 0 1.6896893839657423e-06
of O 0 4.799900032992355e-09
the O 0 7.90577736609066e-09
BRCA1 O 0 5.358122052712133e-07
protein O 0 1.0202092504130178e-08
with O 0 4.4967787826699634e-10
the O 0 5.221722609860535e-09
DNA O 0 5.074941782368114e-07
repair O 0 6.033740646671504e-05
protein O 0 6.302701081040141e-07
Rad51 O 0 1.2910487384942826e-05
and O 0 2.9845639293313297e-09
changes O 0 5.643832068358279e-09
in O 0 4.915364226754093e-10
the O 0 4.049651169957258e-10
phosphorylation O 0 3.9210721780591484e-08
and O 0 7.682660063679236e-10
cellular O 0 2.8115527683780783e-08
localization O 0 3.2322652998573176e-08
of O 0 8.226596487359572e-11
the O 0 3.667484094194151e-10
protein O 0 4.180315649193744e-09
after O 0 3.2881524170136345e-09
exposure O 0 4.1362753222529136e-08
to O 0 2.154157963119019e-09
DNA O 0 1.4626685640450887e-07
- O 0 1.052876314133755e-06
damaging O 0 1.3792543995805318e-06
agents O 0 4.705179179609331e-08
are O 0 4.515524343329247e-10
consistent O 0 4.0966701142508555e-09
with O 0 1.8179097116544085e-10
a O 0 9.340096474019788e-10
role O 0 1.2226309964447069e-09
for O 0 4.657441099453763e-10
BRCA1 O 0 1.6664101565311285e-07
in O 0 8.080393243403705e-09
DNA O 0 2.313904133188771e-06
repair O 0 0.0016528056003153324
. O 0 4.086870717401325e-07

Here O 0 1.1467216154414928e-06
, O 0 1.7268233065692584e-08
it O 0 2.4672119902646727e-09
is O 0 4.674011178096293e-10
shown O 0 1.010726058403577e-09
that O 0 2.338489402120558e-10
mouse O 0 5.744336135649064e-07
embryonic O 0 3.1149917845141317e-07
stem O 0 3.947193363273982e-07
cells O 0 3.3862355053315696e-07
deficient B-Disease 0 5.530491307581542e-06
in I-Disease 0 1.7747838754189615e-08
BRCA1 I-Disease 0 1.175347051685094e-06
are O 0 1.0726215471379419e-09
defective O 0 1.421575689164456e-06
in O 0 3.75897935001035e-09
the O 0 1.3133163445644414e-09
ability O 0 4.842956258244158e-09
to O 0 1.2083363198911456e-09
carry O 0 1.4595938679917708e-08
out O 0 4.1260452832148076e-09
transcription O 0 2.125974845057499e-07
- O 0 3.781089162657736e-06
coupled O 0 2.7195521852263482e-06
repair O 0 8.424152611041791e-07
of O 0 2.7544994063433137e-10
oxidative O 0 6.650531503282764e-08
DNA O 0 3.076746395436203e-07
damage O 0 3.3118885767180473e-06
, O 0 7.857446249204258e-09
and O 0 5.653312928899368e-09
are O 0 2.187146463938916e-09
hypersensitive O 0 2.341390609217342e-05
to O 0 2.3297477724781857e-08
ionizing O 0 3.7597089885821333e-06
radiation O 0 4.776095011038706e-06
and O 0 1.2831314677441696e-08
hydrogen O 0 4.181210897513665e-07
peroxide O 0 1.1520177395141218e-05
. O 0 2.656419724189618e-07

These O 0 1.9010211360637186e-07
results O 0 1.4380458424056997e-07
suggest O 0 9.027719727328076e-08
that O 0 6.0802349821642565e-09
BRCA1 O 0 1.468316554564808e-06
participates O 0 5.69541782624583e-08
, O 0 6.209018299507818e-10
directly O 0 3.84809872855385e-09
or O 0 5.252559276414104e-09
indirectly O 0 1.5761097316158157e-08
, O 0 3.5060046532642275e-10
in O 0 1.3661357600724955e-09
transcription O 0 7.457125548171462e-07
- O 0 2.344697350054048e-05
coupled O 0 2.8007310902466998e-05
repair O 0 8.342083674506284e-06
of O 0 1.0079923562500426e-09
oxidative O 0 2.9198696438470506e-07
DNA O 0 5.784709173894953e-07
damage O 0 2.3987317945284303e-06
. O 0 2.5267478775958807e-08
. O 0 1.1628126372897896e-07

Truncation O 0 0.000815206381957978
mutations O 0 0.0003534319985192269
in O 0 4.667899986543489e-07
the O 0 1.001869165406788e-07
transactivation O 0 1.9816048734355718e-05
region O 0 1.279771169038213e-07
of O 0 1.212067068934175e-08
PAX6 O 0 1.7498485249234363e-05
result O 0 5.9360825588328225e-08
in O 0 2.731383119680686e-08
dominant O 0 2.0733617930090986e-05
- O 0 2.7843156203744e-05
negative O 0 2.868121782739763e-06
mutants O 0 2.9884213290642947e-06
. O 0 1.0589600663024612e-07

PAX6 O 0 0.002029500203207135
is O 0 3.3543511790412595e-07
a O 0 5.932268365427262e-08
transcription O 0 4.924162340103067e-07
factor O 0 1.6375262035239757e-08
with O 0 3.5807778964169756e-10
two O 0 5.706034533758952e-10
DNA O 0 5.960759352774403e-08
- O 0 7.096596164046787e-07
binding O 0 4.974467628926504e-07
domains O 0 1.195433441125715e-07
( O 0 5.161616467574959e-09
paired O 0 6.675924169030623e-08
box O 0 3.9618711866751255e-07
and O 0 3.134574599883422e-09
homeobox O 0 1.4888225052800408e-07
) O 0 1.3196717052466056e-09
and O 0 3.9106640148389715e-10
a O 0 9.269429668279372e-09
proline O 0 2.8420718081179075e-05
- O 0 1.5295208868337795e-06
serine O 0 1.2146346307417843e-05
- O 0 1.165450521511957e-05
threonine O 0 8.604724280303344e-05
( O 0 6.643304573117348e-08
PST O 0 1.7115389709942974e-05
) O 0 1.5593110802569754e-08
- O 0 4.08231329629416e-07
rich O 0 7.78480142571425e-08
transactivation O 0 7.850429938116577e-06
domain O 0 1.202314479087363e-06
. O 0 2.383609967182565e-07

PAX6 O 0 0.010567243210971355
regulates O 0 0.0012912957463413477
eye O 0 0.0001685058232396841
development O 0 6.202927238518896e-08
in O 0 7.365102305811888e-09
animals O 0 7.697272152995538e-09
ranging O 0 1.1420944190376758e-08
from O 0 3.449682983713842e-09
jellyfish O 0 4.724982360926333e-08
to O 0 2.07615480363188e-09
Drosophila O 0 3.356270639187642e-08
to O 0 5.395355273662972e-09
humans O 0 8.184288446955179e-08
. O 0 9.291489533325148e-08

Heterozygous O 0 0.000719510717317462
mutations O 0 0.00011040273966500536
in O 0 1.5567084687972965e-07
the O 0 2.9837742943072953e-08
human O 0 3.1487537910379615e-08
PAX6 O 0 9.651730579207651e-06
gene O 0 4.780287099492853e-07
result O 0 1.1565161273097146e-08
in O 0 1.7548591468852237e-09
various O 0 9.98543026042853e-10
phenotypes O 0 1.401150484525715e-07
, O 0 9.892749952555846e-10
including O 0 8.310109045339686e-09
aniridia B-Disease 1 1.0
, O 0 4.076993263879558e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999998807907104
, O 0 6.414164488433016e-08
autosomal B-Disease 0 0.0020228452049195766
dominant I-Disease 0 0.0012777242809534073
keratitis I-Disease 0 0.09090802818536758
, O 0 6.746853387085139e-08
and O 0 9.177619375577706e-08
familial B-Disease 0 0.4284597337245941
foveal I-Disease 1 0.9999336004257202
dysplasia I-Disease 1 0.9999994039535522
. O 0 8.003356924746186e-06

It O 0 6.19332865881006e-07
is O 0 4.993391478080866e-09
believed O 0 3.811094995143094e-09
that O 0 4.1535694328409534e-10
the O 0 1.6862222729230325e-09
mutated O 0 2.6778084816214687e-07
allele O 0 1.4381254231921048e-07
of O 0 8.539687845754429e-10
PAX6 O 0 1.8039008864434436e-06
produces O 0 5.505404132577496e-08
an O 0 2.9199840323457238e-09
inactive O 0 1.892544645443195e-07
protein O 0 1.8432149317959556e-07
and O 0 5.9028096188740165e-08
aniridia B-Disease 1 1.0
is O 0 1.3091405293153002e-08
caused O 0 3.622976763040242e-08
due O 0 2.335883664272842e-08
to O 0 1.59412270051007e-08
genetic O 0 9.652038670537877e-07
haploinsufficiency O 0 3.711287718033418e-05
. O 0 2.5384724722243845e-07

However O 0 7.398473371722503e-07
, O 0 5.300979655231686e-09
several O 0 3.963320338584708e-09
truncation O 0 1.8396444829704706e-06
mutations O 0 2.2661690763925435e-06
have O 0 3.757280264693463e-09
been O 0 1.3701988432757162e-09
found O 0 2.81587153594387e-09
to O 0 6.02963678986157e-10
occur O 0 1.0776620706920426e-09
in O 0 7.74987463092458e-10
the O 0 1.7001486440904046e-08
C O 0 2.5052377168321982e-05
- O 0 7.893784186308039e-07
terminal O 0 2.9997923434166296e-07
half O 0 3.913538826338936e-09
of O 0 3.114905000600743e-10
PAX6 O 0 8.321198379235284e-07
in O 0 8.408419738259454e-09
patients O 0 5.793717505753193e-09
with O 0 2.6868054447959366e-09
Aniridia B-Disease 1 0.9999997615814209
resulting O 0 2.490878792116291e-08
in O 0 2.1952921702705908e-09
mutant O 0 2.513883856636312e-08
proteins O 0 1.3607603932541679e-09
that O 0 1.1513493630710414e-10
retain O 0 1.8969159576442962e-09
the O 0 4.92100193927314e-10
DNA O 0 1.6898484389571422e-08
- O 0 6.34668424481788e-08
binding O 0 2.7748884079414893e-08
domains O 0 1.744251676427666e-08
but O 0 1.1968218638358508e-09
have O 0 6.643945393847162e-10
lost O 0 8.555572250656951e-09
most O 0 1.312319142243723e-10
of O 0 8.23311072095656e-11
the O 0 4.01680511075142e-09
transactivation O 0 4.046940830448875e-06
domain O 0 5.34330297341512e-07
. O 0 1.527598243455941e-07

It O 0 2.195025814444307e-07
is O 0 4.780430273854108e-09
not O 0 3.650852120617998e-10
clear O 0 6.595838875078641e-10
whether O 0 5.41584943558604e-10
such O 0 4.905941763944099e-10
mutants O 0 2.5075061671486765e-07
really O 0 5.324644192228334e-08
behave O 0 4.45404353399681e-08
as O 0 2.6687354548471376e-09
loss O 0 1.7335485935632278e-08
- O 0 3.3232797846949325e-08
of O 0 6.955043208023426e-10
- O 0 2.9624106900882907e-07
function O 0 2.407106336477227e-08
mutants O 0 2.851582614482595e-08
as O 0 1.0375286185748678e-09
predicted O 0 5.304178429810236e-08
by O 0 8.420986574719791e-09
haploinsufficiency O 0 1.1744175026251469e-05
. O 0 2.516643178296363e-07

Contrary O 0 1.7389952517987695e-06
to O 0 9.748561957678703e-09
this O 0 1.177550057462895e-09
theory O 0 1.0164330488393603e-09
, O 0 2.473090621180063e-10
our O 0 6.402668395466549e-10
data O 0 3.673641657542248e-08
showed O 0 3.604380438559929e-08
that O 0 1.3602796666845052e-10
these O 0 1.648719216706951e-10
mutants O 0 1.2985661435038764e-08
are O 0 2.1970336661070178e-10
dominant O 0 2.238525951270276e-07
- O 0 4.0337295104109216e-07
negative O 0 2.0679381407262554e-07
in O 0 1.2427218365473891e-08
transient O 0 1.641373046368244e-07
transfection O 0 2.3202551346912514e-06
assays O 0 7.89033720138832e-07
when O 0 1.1337837335645418e-08
they O 0 6.873359659209655e-10
are O 0 2.8334984358835413e-10
coexpressed O 0 6.000329477728883e-08
with O 0 1.8193502260288597e-09
wild O 0 1.4767211098387634e-07
- O 0 2.168159517168533e-05
type O 0 9.635733294999227e-05
PAX6 O 0 0.00019300178973935544
. O 0 5.474377644532069e-07

We O 0 1.1644839759128445e-07
found O 0 4.374678841401192e-09
that O 0 3.5469877035509967e-10
the O 0 6.587616008246755e-10
dominant O 0 5.527920734493819e-07
- O 0 1.058630346051359e-06
negative O 0 1.9759576730393746e-07
effects O 0 6.507794836352332e-08
result O 0 2.6218738291561294e-09
from O 0 6.221346771084768e-10
the O 0 5.442908901365229e-10
enhanced O 0 1.735547172643237e-08
DNA O 0 1.6740647978963352e-08
binding O 0 1.4348507271222388e-08
ability O 0 4.282592502846683e-09
of O 0 1.9956200580928396e-10
these O 0 2.086118167099471e-09
mutants O 0 3.803051527029311e-07
. O 0 3.616142052464966e-08

Kinetic O 0 1.0218479474133346e-05
studies O 0 3.5661960851030017e-07
of O 0 3.1036742065282397e-09
binding O 0 1.4513939561311417e-07
and O 0 1.514464109675373e-08
dissociation O 0 2.018930871372504e-07
revealed O 0 6.903716354145217e-08
that O 0 5.629455235300895e-10
various O 0 2.105883245562268e-09
truncation O 0 3.108952171260171e-07
mutants O 0 1.916234566579078e-07
have O 0 2.1286106210993694e-09
3 O 0 2.8591202294592222e-08
- O 0 2.7908660626962956e-07
5 O 0 5.132521252448896e-08
- O 0 1.321983091884249e-07
fold O 0 7.596261042408514e-08
higher O 0 8.057999600907806e-09
affinity O 0 2.502921647717926e-09
to O 0 3.5591044000859995e-10
various O 0 1.8035321847076347e-10
DNA O 0 8.987496080692381e-09
- O 0 2.381341701607198e-08
binding O 0 8.811410268094733e-09
sites O 0 3.7537848385227335e-09
when O 0 6.00083926993733e-10
compared O 0 1.4313840113189258e-09
with O 0 9.388063937354474e-11
the O 0 1.1379124309485178e-09
wild O 0 6.343451985912907e-08
- O 0 1.3535059224523138e-05
type O 0 5.53556892555207e-05
PAX6 O 0 0.0001248458429472521
. O 0 5.771154292233405e-07

These O 0 2.757341519554757e-07
results O 0 1.57382132215389e-07
provide O 0 3.886261978891525e-09
a O 0 6.067503388607065e-09
new O 0 2.6413504272682076e-08
insight O 0 1.421877371399205e-08
into O 0 1.9295463005164493e-09
the O 0 1.3790451003359294e-09
role O 0 1.945588801177678e-09
of O 0 8.319526179079162e-10
mutant O 0 2.769268689917226e-07
PAX6 O 0 3.634463837443036e-06
in O 0 4.124427022134114e-08
causing O 0 3.1461836442758795e-06
aniridia B-Disease 1 0.9999994039535522
. O 0 1.0302490238700557e-07
. O 0 1.5958316623709834e-07

Reversal O 0 0.00019424277707003057
of O 0 1.3395823543760343e-06
severe O 1 0.9962809681892395
hypertrophic B-Disease 1 0.9999997615814209
cardiomyopathy I-Disease 1 1.0
and O 0 1.8398428437649272e-05
excellent O 0 5.786039309896296e-06
neuropsychologic O 0 0.00034058644087053835
outcome O 0 2.398472531695006e-07
in O 0 7.680997526904321e-08
very B-Disease 0 2.3155809003583272e-07
- I-Disease 0 2.51740166277159e-05
long I-Disease 0 1.4946054989195545e-06
- I-Disease 0 3.804992502409732e-06
chain I-Disease 0 8.468895430269185e-06
acyl I-Disease 0 2.6897610041487496e-06
- I-Disease 0 8.427801390098466e-07
coenzyme I-Disease 0 1.4283785958468798e-06
A I-Disease 0 8.789355661065201e-07
dehydrogenase I-Disease 0 0.0017947184387594461
deficiency I-Disease 0 0.002327327150851488
. O 0 3.7497508742490027e-07

Very B-Disease 0 1.9511755454004742e-05
- I-Disease 0 0.00012587661331053823
long I-Disease 0 2.419476004433818e-06
- I-Disease 0 2.9685720619454514e-06
chain I-Disease 0 9.775694707059301e-06
acyl I-Disease 0 4.136964889767114e-06
- I-Disease 0 7.277535019056813e-07
coenzyme I-Disease 0 6.282225513132289e-07
A I-Disease 0 7.590279693658886e-08
dehydrogenase I-Disease 0 5.997268544888357e-06
( I-Disease 0 1.0239858738714247e-07
VLCAD I-Disease 0 7.229032053146511e-05
) I-Disease 0 3.0141507068037754e-07
deficiency I-Disease 0 3.05036246572854e-05
is O 0 1.4152071736717176e-09
a O 0 3.520791480582375e-08
disorder O 0 1.721135777188465e-05
of O 0 2.0438657433174967e-09
fatty O 0 1.0224435982308933e-06
acid O 0 1.1513652253825057e-07
beta O 0 3.650486846140666e-08
oxidation O 0 6.593543133703861e-08
that O 0 2.0449419935175683e-09
reportedly O 0 3.8902463472823e-08
has O 0 4.318124524615996e-09
high O 0 1.3225960060481157e-07
rates O 0 1.4333936633192934e-05
of O 0 6.495143978213491e-09
morbidity O 0 0.010224620811641216
and O 0 2.0952055024281435e-07
mortality O 0 1.1157163498864975e-05
. O 0 2.4978254486995866e-07

We O 0 3.9643128957322915e-07
describe O 0 8.233374160226958e-08
the O 0 3.4388896175130412e-09
outcome O 0 5.091945531887632e-09
of O 0 1.6175578931854062e-10
a O 0 4.264985253854547e-09
5 O 0 2.9518595567878947e-08
- O 0 2.873466371511313e-07
year O 0 2.8246464722769815e-08
- O 0 1.6717854123271536e-06
old O 0 5.5212371989910025e-06
girl O 0 1.4396927326743025e-05
with O 0 3.791636800087872e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 1.4505408429954514e-08
was O 0 1.44391059109239e-08
first O 0 3.044561047715888e-09
seen O 0 1.9331240608266853e-08
at O 0 2.524031117445702e-08
5 O 0 5.446982864754091e-09
months O 0 1.9731916101051183e-09
of O 0 2.1365739732992495e-10
age O 0 8.253590699780489e-09
with O 0 1.8254688427532528e-08
severe O 1 0.832622766494751
hypertrophic B-Disease 1 0.9999982118606567
cardiomyopathy I-Disease 1 1.0
, O 0 0.0004349459195509553
hepatomegaly B-Disease 1 1.0
, O 0 1.8887754777097143e-05
encephalopathy B-Disease 1 0.9990134239196777
, O 0 5.5172616697518606e-08
and O 0 1.393045749864541e-07
hypotonia B-Disease 1 0.9673822522163391
. O 0 6.759985353710363e-07

Biochemical O 0 0.00026119453832507133
studies O 0 3.636204928625375e-05
indicated O 1 0.9944829344749451
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 8.091181371128187e-06
by O 0 1.2397860515989123e-08
a O 0 5.8099651312204514e-08
stable O 0 1.3045117157162167e-05
yet O 0 7.678418967316247e-08
inactive O 0 9.300724173044728e-07
enzyme O 0 8.753469273869996e-07
. O 0 9.26278858059959e-08

Molecular O 0 1.472021631343523e-05
genetic O 0 3.2380585253122263e-06
analysis O 0 3.017489689227659e-07
of O 0 4.3345287359386475e-09
her O 0 7.23773752042689e-08
VLCAD O 0 3.758192906389013e-05
gene O 0 2.052130412266706e-06
revealed O 0 3.581212126846367e-07
a O 0 6.887722747705993e-08
T1372C O 0 2.719770009207423e-06
( O 0 5.314173279202805e-08
F458L O 0 2.1691707843274344e-06
) O 0 4.457910307564816e-08
missense O 0 1.7313503121840768e-05
mutation O 0 2.7887265332537936e-06
and O 0 3.834560757809413e-08
a O 0 5.227136625762796e-07
1668 O 0 0.007578646298497915
ACAG O 0 0.0002734889858402312
1669 O 0 5.868845619261265e-05
splice O 0 0.00010363163892179728
site O 0 6.859221230115509e-06
mutation O 0 2.88595947495196e-05
. O 0 5.445000965664804e-07

After O 0 2.3143279577197973e-06
initial O 0 4.516105889251776e-07
treatment O 0 9.917374654833111e-08
with O 0 9.35621891073879e-09
intravenous O 0 1.081723553397751e-06
glucose O 0 6.852381193311885e-05
and O 0 2.942949173245779e-08
carnitine O 0 1.086809106709552e-06
, O 0 9.189785599161837e-10
the O 0 2.9383653288306277e-09
patient O 0 1.0523958593466887e-07
has O 0 4.07121403256383e-09
thrived O 0 4.194494351850153e-08
on O 0 7.13294889820304e-09
a O 0 1.0781108450430565e-08
low O 0 6.288212171057239e-05
- O 0 1.4957840903662145e-05
fat O 0 1.6922254872042686e-05
diet O 0 2.0180915782930242e-07
supplemented O 0 3.047978935910578e-08
with O 0 1.146861161593904e-09
medium O 0 1.4817459259575116e-07
- O 0 1.8474914043054014e-07
chain O 0 7.409092859234079e-07
triglyceride O 0 5.856124971614918e-07
oil O 0 2.945689558941922e-08
and O 0 2.291781875385368e-09
carnitine O 0 6.312349114523386e-07
and O 0 5.20606979748095e-09
avoidance O 0 2.0335509987035039e-07
of O 0 1.093961277121025e-08
fasting O 0 2.1748943254351616e-05
. O 0 1.975759857941739e-07

Her O 0 3.135896986350417e-05
ventricular O 0 0.06485256552696228
hypertrophy O 0 0.0007223315769806504
resolved O 0 7.196276214926911e-07
significantly O 0 4.993213451598422e-07
over O 0 9.887830110244522e-09
1 O 0 1.0976942910190246e-08
year O 0 2.0336154982203425e-09
, O 0 4.505879835914328e-10
and O 0 3.332895293084448e-09
cognitively O 0 1.3772151760349516e-05
, O 0 2.328458315048465e-09
she O 0 3.1959352941868246e-09
is O 0 9.790310923074586e-11
in O 0 4.714372781045029e-10
the O 0 1.167784757782897e-09
superior O 0 2.89568760081238e-08
range O 0 8.086964697895382e-08
for O 0 5.6894213784630665e-09
age O 0 6.620194881179486e-08
. O 0 4.2862392746201294e-08

Clinical O 0 2.150688123947475e-05
recognition O 0 8.147553103299288e-07
of O 0 1.087665509658109e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.4138938908558885e-08
important O 0 3.918817770287575e-10
because O 0 1.1694119006477877e-09
it O 0 2.3951609584571543e-09
is O 0 2.818013600247582e-10
one O 0 4.135054451626097e-11
of O 0 1.2012595779209434e-11
the O 0 5.386993073841495e-10
few O 0 4.615640314398206e-09
directly O 0 7.39429850682427e-08
treatable O 0 2.579323108875542e-06
causes O 0 7.191583506482857e-08
of O 0 5.984771789258048e-09
cardiomyopathy B-Disease 1 1.0
in O 0 2.9130970347068796e-07
children O 0 3.165898831980485e-08
. O 0 4.176322843107982e-09
. O 0 5.8734194396947714e-08

Cloning O 0 3.46978322340874e-06
of O 0 1.519892833812264e-08
a O 0 1.806835925322048e-08
novel O 0 2.42239295289437e-08
member O 0 4.55316495617808e-09
of O 0 3.549660565482782e-10
the O 0 6.0595466422341815e-09
low O 0 1.2763728591380641e-05
- O 0 4.914140845357906e-06
density O 0 5.450289677355613e-07
lipoprotein O 0 8.82100939634256e-05
receptor O 0 3.362779580129427e-06
family O 0 1.0453912864250015e-06
. O 0 2.382080594998115e-07

A O 0 8.323992233272293e-07
gene O 0 1.773104258973035e-06
encoding O 0 5.840252583766414e-07
a O 0 2.323805503579024e-08
novel O 0 6.531534069154077e-08
transmembrane O 0 3.449152643497655e-07
protein O 0 1.1411214728695995e-07
was O 0 2.2600080029633318e-08
identified O 0 4.365626526947608e-09
by O 0 6.216412384851822e-10
DNA O 0 9.495368047396369e-09
sequence O 0 6.9629582100105836e-09
analysis O 0 1.913588620894302e-09
within O 0 4.69887850851336e-10
the O 0 1.2108955615985906e-08
insulin B-Disease 1 0.6196818947792053
- I-Disease 1 0.9965315461158752
dependent I-Disease 1 0.9876735806465149
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 6.044295446372416e-07
IDDM B-Disease 0 4.8051198973553255e-05
) O 0 3.989275043636553e-08
locus O 0 1.7951946347238845e-06
IDDM4 O 0 3.865015514747938e-06
on O 0 2.597939214865619e-07
chromosome O 0 9.36294691200601e-06
11q13 O 0 1.3700940144190099e-05
. O 0 3.2820770456964965e-07

Based O 0 9.30580767999345e-07
on O 0 1.388905559451814e-07
its O 0 5.624953303140501e-08
chromosomal O 0 4.4346019421936944e-05
position O 0 1.6504772304415383e-07
, O 0 4.739428294264769e-10
this O 0 1.9748849777734279e-10
gene O 0 1.7783792216619076e-08
is O 0 2.7579480366135556e-10
a O 0 9.853767801715207e-10
candidate O 0 2.66058330922192e-09
for O 0 2.714320157526373e-10
conferring O 0 7.583637540165e-08
susceptibility O 0 1.1405147688492434e-06
to O 0 3.168946989262622e-07
diabetes B-Disease 0 0.0031335039529949427
. O 0 3.9017206177049957e-07

The O 0 7.025459467513429e-07
gene O 0 4.8894862629822455e-06
, O 0 2.8118208206251438e-08
termed O 0 1.1872164122905815e-06
low O 0 8.887695003068075e-05
- O 0 1.361653357889736e-05
density O 0 3.715167053996993e-07
lipoprotein O 0 1.9669869288918562e-05
receptor O 0 6.004886472510407e-07
related O 0 1.9081740276760684e-07
protein O 0 7.364753287220083e-07
5 O 0 9.435774472876801e-08
( O 0 1.2611462985034905e-08
LRP5 O 0 3.850513166980818e-06
) O 0 1.8266834711511137e-09
, O 0 1.851143127673538e-10
encodes O 0 4.7703565542178694e-09
a O 0 2.0493813313038345e-09
protein O 0 1.2693853079781547e-08
of O 0 8.308441712401304e-10
1615 O 0 1.1660997188300826e-05
amino O 0 2.134099830186642e-08
acids O 0 8.203149270968879e-09
that O 0 1.8109226618268082e-10
contains O 0 1.102162361377168e-09
conserved O 0 1.2075973110370342e-08
modules O 0 1.8171386173548854e-08
which O 0 1.203673605232325e-09
are O 0 6.343709585410195e-11
characteristic O 0 2.3390747116991406e-09
of O 0 2.0951808343827594e-10
the O 0 1.4303531692405613e-08
low O 0 0.00023268171935342252
- O 0 1.8873854060075246e-05
density O 0 8.55960479384521e-07
lipoprotein O 0 0.00012676397454924881
( O 0 1.4680291826607572e-07
LDL O 0 2.807790951919742e-05
) O 0 1.6811940284355842e-08
receptor O 0 2.917370238719741e-07
family O 0 1.3174673085813993e-07
. O 0 7.566501381006674e-08

These O 0 6.539723926834995e-07
modules O 0 7.629759579685924e-07
include O 0 1.2930891024609537e-08
a O 0 9.727703087492046e-09
putative O 0 1.9927280447973317e-07
signal O 0 5.782966354672681e-07
peptide O 0 1.655144359347105e-07
for O 0 5.392358781719508e-10
protein O 0 5.3573319114263995e-09
export O 0 4.020591859443812e-09
, O 0 3.906221179850178e-10
four O 0 7.168132754031831e-10
epidermal O 0 1.4161373940169142e-07
growth O 0 8.387663541498114e-08
factor O 0 2.3358969869491375e-08
( O 0 1.9006002105470543e-08
EGF O 0 8.414036187787133e-07
) O 0 4.911477446967183e-09
repeats O 0 2.13152944184003e-07
with O 0 2.896984430122984e-09
associated O 0 8.13647460518041e-08
spacer O 0 2.2727399482391775e-06
domains O 0 1.0736950883938334e-07
, O 0 4.044928836322015e-09
three O 0 8.672320639391273e-09
LDL O 0 6.179210322443396e-05
- O 0 7.291127985808998e-06
receptor O 0 1.7218591210621526e-06
( O 0 4.869114889061166e-08
LDLR O 0 5.539000085263979e-06
) O 0 5.880758990883805e-09
repeats O 0 1.8966426296174177e-07
, O 0 2.8026192477881295e-10
a O 0 1.891283796240373e-09
single O 0 1.2965640117101884e-08
transmembrane O 0 4.9812182822961404e-08
spanning O 0 3.7187106727287755e-08
domain O 0 4.8162171140120336e-08
, O 0 1.7031338561679377e-09
and O 0 1.34355337966241e-09
a O 0 1.0128879068815877e-08
cytoplasmic O 0 6.134334853413748e-07
domain O 0 6.684231266262941e-07
. O 0 2.158463843215941e-07

The O 0 1.5355527693827753e-07
encoded O 0 4.3029129415117495e-07
protein O 0 3.197315265879297e-07
has O 0 4.320917401656743e-09
a O 0 1.7224474069266194e-09
unique O 0 1.1292896617831616e-09
organization O 0 7.011036751158883e-10
of O 0 1.0934392280503857e-09
EGF O 0 7.520889653278573e-07
and O 0 8.393037376208667e-09
LDLR O 0 1.10599130493938e-05
repeats O 0 4.9391082939109765e-06
; O 0 6.0828915238175796e-09
therefore O 0 2.3355262168678337e-09
, O 0 5.885592013754604e-10
LRP5 O 0 1.3355131613934645e-06
likely O 0 1.8679212843153437e-08
represents O 0 9.42423805661008e-10
a O 0 1.525340298513811e-09
new O 0 8.334109402596823e-09
category O 0 7.021545567198473e-09
of O 0 3.964656103416786e-10
the O 0 1.5931256314161146e-08
LDLR O 0 3.093419218203053e-05
family O 0 1.395802371462196e-07
. O 0 8.778903293205076e-08

Both O 0 2.155265121928096e-07
human O 0 4.1546506679424056e-08
and O 0 1.8388284672710142e-08
mouse O 0 1.2848777259932831e-05
LRP5 O 0 4.272228397894651e-05
cDNAs O 0 2.556816298238118e-06
have O 0 8.406511042835518e-09
been O 0 1.8801842305293803e-09
isolated O 0 1.1557157009178809e-08
and O 0 6.597637991490046e-10
the O 0 1.2498666546179038e-09
encoded O 0 2.7291802595641457e-08
mature O 0 4.806633757681311e-09
proteins O 0 3.449472707472978e-09
are O 0 1.1618522810508125e-10
95 O 0 1.0355440949183503e-08
% O 0 8.789601824155113e-10
identical O 0 3.85953811132822e-08
, O 0 4.713266998912502e-10
indicating O 0 2.211785421479817e-08
a O 0 1.0142295892023867e-08
high O 0 6.012083275663826e-08
degree O 0 1.986764308625766e-09
of O 0 2.2609629446446178e-10
evolutionary O 0 8.996758005253014e-09
conservation O 0 4.108878126629634e-09
. O 0 4.16300149908011e-09
. O 0 3.60708334312676e-08

The O 0 1.142257474384678e-06
APC B-Disease 0 7.39443476049928e-06
variants O 0 1.3722443554797792e-06
I1307K O 0 1.1860485074066673e-06
and O 0 5.6486784139053725e-09
E1317Q O 0 9.994890604048123e-08
are O 0 6.961572984742759e-10
associated O 0 1.716103810167624e-07
with O 1 0.9991722106933594
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 5.1985120080644265e-05
but O 0 3.1053573934514134e-08
not O 0 1.439147689907827e-09
always O 0 2.9226907005686087e-10
with O 0 5.751827139577337e-11
a O 0 4.516310436741833e-09
family O 0 2.9130877265970412e-08
history O 0 2.161043965998033e-08
. O 0 4.452047264180692e-08

Classical O 0 0.015188684687018394
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 1.0
( O 0 0.07459258288145065
FAP B-Disease 0 0.0004347075882833451
) O 0 7.290775982937703e-08
is O 0 1.8853554273334794e-09
a O 0 1.510266933735238e-08
high O 0 2.0557132302201353e-05
- O 1 0.8617691993713379
penetrance O 1 0.9996252059936523
autosomal B-Disease 1 0.9999940395355225
dominant I-Disease 1 0.9987096786499023
disease I-Disease 1 0.802708089351654
that O 0 3.2287266193975483e-09
predisposes O 0 1.9407315221542376e-07
to O 0 1.2540886107359484e-09
hundreds O 0 1.0318724763536125e-09
or O 0 2.0620423146766598e-09
thousands O 0 1.5415670961971273e-09
of O 0 7.910664976407134e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.703961193561554
carcinoma I-Disease 1 1.0
and O 0 1.0832685148898236e-07
that O 0 1.9578585419566252e-09
results O 0 2.5084714749823434e-08
from O 0 5.303498085140745e-09
truncating O 0 1.3003106005271547e-06
mutations O 0 3.1669497957409476e-07
in O 0 5.7452429480520095e-09
the O 0 2.6603309777328832e-08
APC B-Disease 0 1.5989226085366681e-06
gene O 0 1.9221531601942843e-06
. O 0 1.6238882949437539e-07

A O 0 2.317044163646642e-06
variant O 0 5.133068043505773e-05
of O 0 6.920459583170668e-08
FAP B-Disease 0 4.0095495933201164e-05
is O 0 5.33368563537806e-07
attenuated B-Disease 1 0.8963910937309265
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.999998927116394
coli I-Disease 1 1.0
, O 0 1.0790365649882006e-06
which O 0 1.2692472850517333e-08
results O 0 1.2200574772691652e-08
from O 0 5.518521639658047e-09
germ O 0 3.087507502641529e-05
- O 0 6.08426307735499e-05
line O 0 1.3249962648842484e-05
mutations O 0 2.0850777104897134e-07
in O 0 1.5841982170528013e-09
the O 0 2.9249227484484663e-09
5 O 0 8.719723609829089e-09
and O 0 9.193238947879934e-10
3 O 0 2.9954165814416456e-09
regions O 0 1.1980985092918672e-09
of O 0 2.1725972410013838e-10
the O 0 9.8308508000855e-09
APC B-Disease 0 1.032242039400444e-06
gene O 0 1.1518137625898817e-06
. O 0 1.2884119371392444e-07

Attenuated B-Disease 1 0.9999867677688599
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 1 0.998018741607666
have O 0 3.0080195756454486e-07
" O 0 4.7485627874266356e-08
multiple O 0 5.858913027623203e-06
" O 1 0.5428615808486938
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 2.3445304009328538e-07
typically O 0 4.810570786162316e-08
fewer O 0 7.650566402617187e-09
than O 0 9.358266384040803e-10
100 O 0 7.2010246654485854e-09
) O 0 6.266985264069547e-10
without O 0 6.392125717624708e-10
the O 0 7.734595186548177e-09
florid O 0 3.639729766291566e-05
phenotype O 0 2.15634372580098e-06
of O 0 6.801868845940362e-09
classical O 0 7.55693861265172e-07
FAP B-Disease 0 1.4375716091308277e-05
. O 0 3.3503548024782503e-07

Another O 0 8.058600542426575e-07
group O 0 5.3086722573425504e-08
of O 0 1.4465919573325436e-09
patients O 0 1.8239791899077318e-08
with O 0 3.2925204784817197e-09
multiple O 0 7.474205858670757e-07
adenomas B-Disease 0 1.3556244084611535e-05
has O 0 2.6262545915756164e-08
no O 0 2.1860162568998476e-09
mutations O 0 9.325755456757179e-08
in O 0 2.5555169091973085e-09
the O 0 7.088991171855241e-09
APC B-Disease 0 1.4168911377510085e-07
gene O 0 3.489330069328389e-08
, O 0 3.652084745731088e-10
and O 0 1.5417662979633207e-10
their O 0 3.515059354697314e-09
phenotype O 0 8.269649356407172e-07
probably O 0 1.809622673931699e-08
results O 0 5.047840812011373e-09
from O 0 7.534969315159401e-10
variation O 0 9.712982418363936e-09
at O 0 3.124631220430274e-08
a O 0 1.0633049996044974e-08
locus O 0 9.200070394399518e-08
, O 0 8.711308341347035e-10
or O 0 3.0703719566815835e-09
loci O 0 9.341899698256384e-09
, O 0 3.8054998041658905e-10
elsewhere O 0 7.640446497703124e-09
in O 0 3.058594044702545e-09
the O 0 1.0785345061492535e-08
genome O 0 4.102854518350796e-07
. O 0 1.5537140996002563e-07

Recently O 0 2.3843787857913412e-05
, O 0 2.147709921018759e-08
however O 0 6.291516196910152e-09
, O 0 5.730411145599135e-10
a O 0 5.008471859468955e-09
missense O 0 2.1955734155199025e-06
variant O 0 5.924719062022632e-06
of O 0 1.1046778602974427e-08
APC B-Disease 0 1.897563038255612e-06
( O 0 2.5007993897929737e-08
I1307K O 0 5.101552460473613e-07
) O 0 2.5378650292395832e-09
was O 0 6.183753065158726e-09
described O 0 2.1149118012431245e-09
that O 0 1.243825598074011e-10
confers O 0 2.2446489111871415e-09
an O 0 4.667614628139916e-10
increased O 0 4.3856587694790505e-08
risk O 0 1.1650976148303016e-06
of O 0 0.0024247884284704924
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 6.53663150274042e-08
including O 0 4.218787097443055e-09
multiple O 0 3.911325165972812e-07
adenomas B-Disease 0 1.4286034456745256e-05
, O 0 1.3377442265039008e-08
in O 0 6.997202461889174e-08
Ashkenazim O 0 0.00019977979536633939
. O 0 3.8935166912779096e-07

We O 0 2.540928392136266e-07
have O 0 5.006284720110443e-09
studied O 0 7.76426034576616e-09
a O 0 2.80109224704006e-09
set O 0 1.976080410415193e-09
of O 0 2.018393091551829e-10
164 O 0 5.847385864399257e-08
patients O 0 1.2226760048861252e-08
with O 0 3.2097794644414535e-08
multiple O 1 0.9999648332595825
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.002869564574211836
/ I-Disease 1 0.9995299577713013
or I-Disease 1 0.5677666068077087
carcinoma I-Disease 1 1.0
and O 0 3.163937378758419e-07
analyzed O 0 2.6577145035844296e-06
codons O 0 2.2415120838559233e-05
1263 O 0 0.0001309986982960254
- O 0 2.7197205781703815e-05
1377 O 0 0.00014849995204713196
( O 0 2.1412765249806398e-07
exon O 0 3.8037517242628383e-06
15G O 0 3.3833025554486085e-06
) O 0 1.9905803672060074e-09
of O 0 2.4289462108306736e-10
the O 0 1.4871496256674277e-09
APC B-Disease 0 1.0022475294135802e-07
gene O 0 5.733292596232786e-08
for O 0 4.802482411747633e-09
germ O 0 9.648960258346051e-06
- O 0 3.3956486731767654e-05
line O 0 1.5587598682031967e-05
variants O 0 3.781872010222287e-06
. O 0 1.643644509385922e-07

Three O 0 4.1940822370634123e-07
patients O 0 1.5004795272943738e-07
with O 0 4.4158574574737486e-09
the O 0 1.7154974329969264e-08
I1307K O 0 1.4806682884227484e-06
allele O 0 1.2439642205208656e-06
were O 0 9.076612350611413e-09
detected O 0 5.5727337411326516e-08
, O 0 2.6700985866767724e-10
each O 0 1.7576654021134175e-10
of O 0 8.429434927847979e-10
Ashkenazi O 0 1.5922408920232556e-06
descent O 0 4.539423059668479e-07
. O 0 1.6640471756090847e-07

Four O 0 1.4076639445192995e-06
patients O 0 5.498099540091061e-07
had O 0 5.0429065368007286e-08
a O 0 5.101990652178756e-08
germ O 0 0.00010139218647964299
- O 0 3.2074480259325355e-05
line O 0 9.585282896296121e-06
E1317Q O 0 2.396383706582128e-06
missense O 0 3.1361332730739377e-06
variant O 0 9.146458523900947e-07
of O 0 1.9966110986757712e-09
APC O 0 2.3285200256850658e-07
that O 0 1.2460534826175262e-09
was O 0 1.249836323324871e-08
not O 0 8.837051229670934e-11
present O 0 3.89962534486088e-10
in O 0 2.5885615873022516e-09
controls O 0 0.0011039884993806481
; O 0 9.833246439328036e-10
one O 0 1.2911137436955045e-10
of O 0 2.932259990373609e-11
these O 0 7.781821020902413e-11
individuals O 0 1.9290511896197238e-11
had O 0 6.013649023195455e-10
an O 0 9.786538940348422e-11
unusually O 0 7.793997269800457e-08
large O 0 1.2486111033993552e-09
number O 0 3.5565597689135586e-10
of O 0 6.044629241586108e-10
metaplastic B-Disease 0 1.906424768094439e-05
polyps I-Disease 0 5.647248144668993e-07
of I-Disease 0 9.066934980594965e-10
the I-Disease 0 2.8286574860203473e-08
colorectum I-Disease 0 6.953364845685428e-06
. O 0 1.7353359282878955e-07

There O 0 1.7239838712157507e-07
is O 0 2.973092438907088e-09
increasing O 0 1.3039961332950156e-09
evidence O 0 4.720041024697252e-10
that O 0 2.281409505755505e-10
there O 0 4.280230336828339e-10
exist O 0 3.1637963360253707e-09
germ O 0 1.5763720284667215e-06
- O 0 1.908448439280619e-06
line O 0 6.52889980301552e-07
variants O 0 3.8526980716824255e-08
of O 0 2.602938142803879e-10
the O 0 1.3993678438239954e-09
APC B-Disease 0 6.910435246254565e-08
gene O 0 1.8092777054334874e-08
that O 0 1.8895160436294134e-10
predispose O 0 7.077655794773818e-09
to O 0 2.2883474282142657e-10
the O 0 2.1573928754570204e-10
development O 0 6.486164938479533e-10
of O 0 1.8244863397853806e-09
multiple O 1 0.9988572597503662
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9554578065872192
carcinoma I-Disease 1 1.0
, O 0 2.0967462432963657e-08
but O 0 2.4059942926868416e-09
without O 0 8.080867086590615e-10
the O 0 4.113009932638079e-09
florid O 0 1.9904080545529723e-05
phenotype O 0 9.015826663016924e-07
of O 0 5.534457336864307e-10
classical O 0 2.17714184458373e-08
FAP B-Disease 0 1.6682133718859404e-07
, O 0 3.219420841027443e-10
and O 0 2.783197006195337e-10
possibly O 0 2.100483786904306e-09
with O 0 8.770342785346941e-10
importance O 0 3.81278368877247e-08
for O 0 0.44865360856056213
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 9.712631481306744e-07
in O 0 2.3044934849281162e-09
the O 0 1.6474375197361724e-09
general O 0 1.2301185625673838e-09
population O 0 2.075133398449225e-09
. O 0 2.2218347162095142e-09
. O 0 4.3000945026960835e-08

Genomic O 0 3.7852052628295496e-05
structure O 0 6.915379344718531e-07
of O 0 5.482944320789329e-09
the O 0 6.77630964673881e-08
human O 0 4.675418313127011e-05
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 3.344785000081174e-05
CLD B-Disease 1 0.6467130184173584
) O 0 4.08674623031402e-07
gene O 0 9.355253496323712e-06
. O 0 2.785165236218745e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.025087444111704826
CLD B-Disease 1 0.9988967180252075
) O 0 2.1983861131502636e-07
is O 0 4.677670251140853e-09
caused O 0 2.8995343015481012e-08
by O 0 3.434222684006727e-09
mutations O 0 2.526765570110001e-07
in O 0 2.593592896005248e-09
a O 0 4.547436649460224e-09
gene O 0 9.22606062658815e-08
which O 0 3.586152041989976e-09
encodes O 0 9.774166187526134e-08
an O 0 2.2954315781475998e-08
intestinal O 0 0.00021461355208884925
anion O 0 1.988601616176311e-05
transporter O 0 0.00016041513299569488
. O 0 1.1316662948956946e-06

We O 0 8.93476055807696e-07
report O 0 1.722621334465657e-07
here O 0 1.8801016299363482e-09
the O 0 7.505965848864093e-10
complete O 0 2.439654256392032e-09
genomic O 0 2.617058925125093e-08
organization O 0 1.4708388951234497e-09
of O 0 1.2672793370249735e-10
the O 0 1.5816863374595869e-09
human O 0 9.98918814332228e-09
CLD B-Disease 0 2.2034533685655333e-05
gene O 0 3.7660285556739836e-07
which O 0 1.0968738806127476e-08
spans O 0 3.421899208433388e-08
approximately O 0 1.4690733962652303e-08
39kb O 0 1.8068416238747886e-06
, O 0 3.8501837273940964e-09
and O 0 3.491312350334397e-09
comprises O 0 7.2632913017400824e-09
21 O 0 7.285076719654171e-08
exons O 0 2.4167641186068067e-06
. O 0 2.8144697239440575e-07

All O 0 1.0626044968375936e-06
exon O 0 0.00010664494766388088
/ O 0 6.217428017407656e-05
intron O 0 7.734256359981373e-05
boundaries O 0 1.4783571486987057e-06
conform O 0 2.4595369723101612e-06
to O 0 7.512171329437933e-09
the O 0 1.3844827506659385e-08
GT O 0 2.0486089852056466e-05
/ O 0 0.00019652525952551514
AG O 0 0.1501191407442093
rule O 0 8.657084435981233e-07
. O 0 1.1520725706759549e-07

An O 0 1.3716643820771424e-07
analysis O 0 3.045701291171099e-08
of O 0 6.75829781027204e-10
the O 0 2.9863231887361508e-09
putative O 0 2.3801253234978503e-07
promoter O 0 3.764283746932051e-07
region O 0 1.0588284027335249e-08
sequence O 0 6.428309973216528e-08
shows O 0 5.887563148121444e-08
a O 0 2.2222724993525844e-08
putative O 0 1.5700824178566108e-06
TATA O 0 2.49376057581685e-06
box O 0 9.125625979322649e-07
and O 0 9.941935275037395e-09
predicts O 0 1.2743029742523504e-07
multiple O 0 1.8043701643932764e-08
transcription O 0 2.3934481419018994e-07
factor O 0 2.6184769907899863e-08
binding O 0 9.025532676787407e-08
sites O 0 1.5557408516997384e-07
. O 0 1.428554128324322e-07

The O 0 6.154714924377913e-07
genomic O 0 2.5402018763998058e-06
structure O 0 8.216163109864283e-07
was O 0 6.918413930634415e-08
determined O 0 5.326642682490501e-09
using O 0 2.8316629041569286e-09
DNA O 0 6.148775266723305e-09
from O 0 3.8596226215048546e-10
several O 0 1.4933879133316452e-10
sources O 0 8.606271806321786e-10
including O 0 1.4675791137896965e-10
multiple O 0 3.7132374952619784e-09
large O 0 1.3128261144856879e-08
- O 0 0.00013641122495755553
insert O 0 0.00041199804400093853
libaries O 0 2.733374685703893e-06
and O 0 2.5905519951407996e-09
genomic O 0 1.0451306309278152e-07
DNA O 0 2.2071252203659242e-07
from O 0 7.15300672027297e-08
Finnish O 0 0.00019024836365133524
CLD B-Disease 0 0.3713991045951843
patients O 0 1.4091132243265747e-06
and O 0 2.4739234660842158e-08
controls O 0 0.0010424277279525995
. O 0 3.143563560570328e-07

Exon O 0 0.0003406010800972581
- O 0 2.1896365069551393e-05
specific O 0 2.1793776738832094e-07
primers O 0 2.5402319806744345e-05
developed O 0 3.561003438790067e-07
in O 0 4.0474295026626805e-09
this O 0 3.9025496723077424e-10
study O 0 3.1269056788296723e-10
will O 0 6.588873335822143e-10
facilitate O 0 6.768892557573736e-09
mutation O 0 5.4053078457627635e-08
screening O 0 5.5985051261586705e-08
studies O 0 2.8335052082439915e-09
of O 0 3.2546562667157275e-10
patients O 0 9.580579884982399e-09
with O 0 1.708883368145564e-09
the O 0 1.131571366386197e-06
disease O 0 0.0004354914417490363
. O 0 2.3747381305838644e-07

Genomic O 0 6.232233863556758e-05
sequencing O 0 2.483976686562528e-06
of O 0 4.692846644616111e-08
a O 0 1.973554617507034e-07
BAC O 0 0.001798416138626635
clone O 0 9.435251558898017e-05
H O 1 0.9999997615814209
_ O 0 4.02962996304268e-08
RG364P16 O 0 2.3232763624037034e-07
revealed O 0 1.4229625477923946e-08
the O 0 6.22951579209996e-10
presence O 0 8.557689001875701e-10
of O 0 8.046119326365897e-11
another O 0 4.830720823356671e-10
, O 0 2.0031480640891886e-10
highly O 0 3.236680701235173e-09
homologous O 0 2.8288409836818573e-08
gene O 0 8.39600318158773e-08
3 O 0 9.113962029516642e-09
of O 0 2.7619542763979155e-10
the O 0 1.6577772044001904e-08
CLD B-Disease 0 4.6915680286474526e-05
gene O 0 2.1700697061532992e-07
, O 0 7.386636857731332e-10
with O 0 2.515046781947916e-10
a O 0 2.7315798512006495e-09
similar O 0 7.742978702651726e-09
genomic O 0 1.4070693055145966e-07
structure O 0 2.2392839582607849e-07
, O 0 1.1476949390853974e-09
recently O 0 1.7423928966309177e-08
identified O 0 7.702927184993769e-09
as O 0 7.2130941219938904e-09
the O 0 3.275159315307974e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.3998051144881174e-05
( O 0 6.639023553134393e-08
PDS B-Disease 0 2.0967356704204576e-06
) O 0 4.1852938892361635e-09
. O 0 2.5760218402837154e-09
. O 0 2.2072507377401962e-08

The O 0 1.5221636431306251e-06
APCI1307K O 0 0.00013611574831884354
allele O 0 0.000115189679490868
and O 0 6.283232210080314e-07
cancer B-Disease 0 2.8078606192138977e-05
risk O 0 1.0055160259980767e-07
in O 0 7.817935632203898e-09
a O 0 2.6440723388532206e-08
community O 0 1.663859094946929e-08
- O 0 1.5041932499570976e-07
based O 0 7.270623658683917e-09
study O 0 1.0810053963083988e-09
of O 0 8.10949307705755e-10
Ashkenazi O 0 1.5171550558079616e-06
Jews O 0 1.2514375669070432e-07
. O 0 1.1605427374661303e-07

Mutations O 0 0.0007557130302302539
in O 0 1.497310449849465e-06
APC O 0 1.1011879905709065e-05
are O 0 2.4563806988453507e-08
classically O 0 7.999755325727165e-06
associated O 0 1.195920845020737e-06
with O 0 1.388970031257486e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.00020058640802744776
FAP B-Disease 0 6.755718641215935e-05
) O 0 5.103450462229375e-08
, O 0 2.2483723771671293e-09
a O 0 2.102986051966127e-08
highly O 0 1.0750024557637516e-05
penetrant O 1 0.9999936819076538
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.0009506923379376531
by O 0 2.2851251912925363e-07
multiple O 0 0.00024224691151175648
intestinal O 1 0.9999672174453735
polyps B-Disease 0 0.04592126980423927
and O 0 3.31094263117393e-08
, O 0 1.5001146991266978e-09
without O 0 1.954847173024632e-09
surgical O 0 1.9726212485693395e-07
intervention O 0 4.9985590777623656e-08
, O 0 4.4222103756652587e-10
the O 0 8.445399379830576e-10
development O 0 8.200083279064074e-09
of O 0 3.4595232136780396e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.0548934596954496e-06
CRC B-Disease 0 8.572365914005786e-05
) O 0 8.922016547785461e-08
. O 0 1.0637435821081453e-07

APC B-Disease 0 0.00010941568325506523
is O 0 1.7306159350027883e-07
a O 0 6.608512421735213e-07
tumour O 1 1.0
- O 0 2.9352882847888395e-05
suppressor O 0 3.821132122538984e-05
gene O 0 9.209110203300952e-07
, O 0 2.7809483604812613e-09
and O 0 1.9614954105406923e-09
somatic O 0 4.732477236757404e-07
loss O 0 6.999090942372277e-07
occurs O 0 3.0467154488178494e-07
in O 0 3.7531715406657895e-06
tumours B-Disease 1 1.0
. O 0 7.598035267619707e-07

The O 0 2.5294443730672356e-06
germline O 0 0.0003263461694587022
T O 0 0.02578597702085972
- O 0 1.2284764125070069e-05
to O 0 3.455743424751745e-08
- O 0 4.2294084323657444e-07
A O 0 4.307301892936266e-08
transversion O 0 1.0256909490635735e-06
responsible O 0 5.9679576835947046e-09
for O 0 2.28244104172326e-10
the O 0 1.5407793929611557e-09
APC O 0 1.3162465961613634e-07
I1307K O 0 2.0253449406482105e-07
allele O 0 1.5686636345435545e-07
converts O 0 1.555547335385654e-08
the O 0 2.069864057929749e-09
wild O 0 7.619620490117995e-09
- O 0 2.0765446606674232e-07
type O 0 1.476701214642162e-07
sequence O 0 1.4462726127817405e-08
to O 0 3.4561766781848746e-09
a O 0 3.241667911879631e-08
homopolymer O 0 0.0008145293104462326
tract O 0 0.0002980161225423217
( O 0 3.637364898168016e-08
A8 O 0 3.8076701457612216e-05
) O 0 1.7193095835921213e-09
that O 0 6.619217396419685e-10
is O 0 1.2850926989216305e-09
genetically O 0 1.6180817397071223e-07
unstable O 0 0.00017618550918996334
and O 0 6.237416272369956e-08
prone O 0 1.907136720546987e-06
to O 0 5.6370684120565784e-08
somatic O 0 1.185486871690955e-05
mutation O 0 1.9380919184186496e-05
. O 0 8.194627412194677e-07

The O 0 3.744547996120673e-07
I1307K O 0 8.7512016762048e-06
allele O 0 4.122042810195126e-06
was O 0 9.302678449785162e-08
found O 0 1.3035864832033894e-08
in O 0 1.705712548982774e-08
6 O 0 2.7363063281882205e-07
. O 0 9.196105565933976e-08

1 O 0 2.106327656292706e-06
% O 0 3.2623788115415664e-08
of O 0 4.8609560820978e-09
unselected O 0 5.640225936076604e-06
Ashkenazi O 0 3.56013106284081e-06
Jews O 0 5.0461299139215043e-08
and O 0 5.38602984434533e-09
higher O 0 3.5383081353757007e-08
proportions O 0 2.0435548364616807e-08
of O 0 4.660213326346252e-10
Ashkenazim O 0 8.279403118649498e-07
with O 0 1.1182362813499935e-09
family O 0 2.3395310577711825e-08
or O 0 6.706526445299232e-09
personal O 0 2.1154413332169497e-08
histories O 0 4.3134181737514155e-07
of O 0 1.4224604605317381e-08
CRC B-Disease 0 0.00018912932137027383
( O 0 6.830681797964644e-08
ref O 0 4.134503342356766e-06
. O 0 5.5747184646293135e-09
2 O 0 3.462328024284034e-08
) O 0 1.0631894475920944e-08
. O 0 6.405288388577901e-08

To O 0 6.530101472890237e-07
evaluate O 0 3.181662293627596e-07
the O 0 3.41684303073464e-09
role O 0 2.3263453385879984e-09
of O 0 3.868975695375809e-10
I1307K O 0 9.778641185675951e-08
in O 0 2.949056998602373e-08
cancer B-Disease 0 9.521339734419598e-07
, O 0 1.1284478906858908e-09
we O 0 1.5120878993357678e-09
genotyped O 0 5.535486025110004e-07
5 O 0 3.235522072486674e-08
, O 0 7.0393531004242504e-09
081 O 0 5.223416792432545e-06
Ashkenazi O 0 1.7755613725967123e-06
volunteers O 0 1.513773995043266e-08
in O 0 3.650972635327321e-09
a O 0 1.6538356462092452e-08
community O 0 2.4681639843038283e-08
survey O 0 6.122405693531618e-07
. O 0 9.033816894543634e-08

Risk O 0 2.51328747253865e-05
of O 0 1.3803251874833222e-07
developing O 0 2.759031303867232e-05
colorectal B-Disease 1 1.0
, I-Disease 0 6.55316171105369e-06
breast I-Disease 0 0.004393644165247679
and I-Disease 0 2.2969643964643183e-08
other I-Disease 0 5.732294194871201e-09
cancers I-Disease 0 4.822039954888169e-06
were O 0 7.0518102468497545e-09
compared O 0 1.3458956615863826e-08
between O 0 9.291822422596852e-09
genotyped O 0 4.033162440464366e-06
I1307K O 0 4.400582440666767e-07
carriers O 0 3.038784512909842e-08
and O 0 1.250997305746182e-09
non O 0 5.949125636561803e-09
- O 0 2.606742270927498e-07
carriers O 0 2.061304016365284e-08
and O 0 4.2798711796798727e-10
their O 0 4.2491496432539577e-10
first O 0 3.976836193686495e-09
- O 0 7.005001378956877e-08
degree O 0 1.4072700338374489e-08
relatives O 0 4.89765383804297e-08
. O 0 5.814089121258803e-08

Sperm O 0 1.3981107258587144e-05
DNA O 0 4.464677203941392e-06
analysis O 0 3.6556366467266344e-07
in O 0 8.05638933343289e-08
a O 0 5.401648195402231e-07
Friedreich B-Disease 1 0.9999052286148071
ataxia I-Disease 1 0.9999969005584717
premutation O 0 0.02348673716187477
carrier O 0 9.095762834476773e-06
suggests O 0 6.4566833657409e-08
both O 0 4.01070376909729e-09
meiotic O 0 1.9708602394530317e-06
and O 0 7.56354001651971e-09
mitotic O 0 6.16441923284583e-07
expansion O 0 4.557250932180068e-08
in O 0 6.52044063187418e-09
the O 0 1.4396892566992392e-08
FRDA B-Disease 0 1.1053101843572222e-05
gene O 0 2.9026441552559845e-06
. O 0 1.4173586748711386e-07

Friedreich B-Disease 1 0.9999991655349731
ataxia I-Disease 1 1.0
is O 0 4.0651444578543305e-05
usually O 0 4.794389951712219e-07
caused O 0 1.0479331535862002e-07
by O 0 2.2527293364049683e-09
an O 0 1.0223124569108677e-09
expansion O 0 1.9114994032065624e-08
of O 0 1.0554805918161492e-09
a O 0 1.2734307119899313e-07
GAA O 0 0.00011509370960993692
trinucleotide O 0 1.7230617231689394e-05
repeat O 0 1.740803782013245e-06
in O 0 4.24810018273547e-08
intron O 0 7.302184712898452e-06
1 O 0 1.1194083882060113e-08
of O 0 3.66510627403116e-10
the O 0 9.694066882559582e-09
FRDA B-Disease 0 7.86096370575251e-06
gene O 0 2.1144567199371522e-06
. O 0 1.1890185902529993e-07

Occasionally O 0 9.28349527384853e-06
, O 0 2.0720454685374534e-08
a O 0 1.0548291129452991e-08
fully O 0 1.3449590774428088e-08
expanded O 0 2.4323840719375767e-08
allele O 0 1.4010517190854443e-07
has O 0 7.266280355189281e-10
been O 0 2.355095563011389e-10
found O 0 3.2534153149299527e-10
to O 0 5.789991264215644e-10
arise O 0 8.341962676183812e-10
from O 0 4.75296191293495e-10
a O 0 2.388331976632685e-09
premutation O 0 1.5835500732919172e-07
of O 0 2.5234123124384666e-10
100 O 0 4.4909609364651715e-09
or O 0 1.0370166947382131e-08
less O 0 7.811067348484357e-08
triplet O 0 0.000285253714537248
repeats O 0 4.457038448890671e-05
. O 0 3.082367356910254e-07

We O 0 4.446493164778076e-07
have O 0 8.615769431230547e-09
examined O 0 1.716724895572952e-08
the O 0 1.028559570848131e-09
sperm O 0 1.6394825053112072e-08
DNA O 0 2.303747592691252e-08
of O 0 1.313406494674041e-09
a O 0 9.413377455302907e-08
premutation O 0 2.7056472390540875e-05
carrier O 0 7.42788688512519e-06
. O 0 4.665251935875858e-07

This O 0 5.088496664029662e-07
mans O 0 5.932736712566111e-06
leucocyte O 0 5.9910489653702825e-06
DNA O 0 3.244117863232532e-07
showed O 0 2.121157081091951e-07
one O 0 2.8784394867642504e-09
normal O 0 6.216761505584145e-08
allele O 0 1.6915583955778857e-07
and O 0 7.819676017817301e-10
one O 0 4.1209155532406783e-10
allele O 0 2.9062393380741014e-08
of O 0 1.9870931289300842e-10
approximately O 0 3.922155045188447e-09
100 O 0 1.9456491529012965e-08
repeats O 0 5.487735506903846e-06
. O 0 1.1439260561019182e-07

His O 0 5.968324785499135e-07
sperm O 0 6.013127631376847e-07
showed O 0 2.393130671407562e-07
an O 0 3.4192226827656214e-09
expanded O 0 6.709048960829023e-08
allele O 0 5.351860750124615e-07
in O 0 1.0384259674367513e-08
a O 0 2.1372526859408936e-08
tight O 0 4.071631337865256e-06
range O 0 7.027698245565261e-08
centering O 0 1.4854357743843138e-07
on O 0 6.06302847927509e-08
a O 0 5.228978583460275e-09
size O 0 7.423575087983636e-09
of O 0 5.97085825226884e-10
approximately O 0 2.5527706171146747e-08
320 O 0 8.636386041871447e-07
trinucleotide O 0 0.00013588102592620999
repeats O 0 7.08820516592823e-05
. O 0 6.640555625381239e-07

His O 0 5.091296316095395e-06
affected O 0 9.199609849019907e-06
son O 0 2.1956797354505397e-05
has O 0 7.362029208479726e-08
repeat O 0 1.5631874248356326e-06
sizes O 0 1.1258898666710593e-06
of O 0 3.626528632949544e-09
1040 O 0 7.702482434979174e-06
and O 0 2.4391995978589875e-08
540 O 0 1.882250330709212e-06
. O 0 1.4661095804058277e-07

These O 0 1.5640955552953528e-07
data O 0 2.2152670453579049e-07
suggest O 0 4.8115616380073334e-08
that O 0 5.046278395148818e-10
expansion O 0 1.162349949623831e-08
occurs O 0 3.240720580777179e-09
in O 0 9.254339516928667e-10
two O 0 2.452576752798308e-10
stages O 0 2.5880877441153416e-09
, O 0 8.688139097046133e-11
the O 0 2.6897781224555217e-10
first O 0 5.821650939097367e-10
during O 0 7.3841750491965286e-09
meiosis O 0 1.2868494714268763e-08
followed O 0 3.800939119003033e-09
by O 0 7.203631025021195e-10
a O 0 1.4592841379723609e-09
second O 0 1.5492139127104565e-08
mitotic O 0 3.865096459776396e-06
expansion O 0 9.939603842212819e-07
. O 0 2.0754754359586514e-07

We O 0 2.9360987241489056e-07
also O 0 1.0271367756331529e-08
show O 0 1.8431158821385907e-08
that O 0 2.03500355455688e-10
in O 0 6.061832147352675e-10
all O 0 1.3275198995632564e-10
informative O 0 1.9675704621135992e-08
carrier O 0 7.09843774870933e-08
father O 0 1.0721190157880756e-08
to O 0 1.291666107405831e-09
affected O 0 8.403977957982534e-09
child O 0 5.4521727577139245e-08
transmissions O 0 3.87321415473707e-05
, O 0 2.566095114175937e-10
with O 0 1.1313350950503676e-10
the O 0 6.18790241269096e-10
notable O 0 3.429468653504131e-10
exception O 0 3.7290417975732737e-10
of O 0 6.676564856533673e-11
the O 0 2.9595366157764147e-09
premutation O 0 1.065802393895865e-06
carrier O 0 5.260522328853767e-08
, O 0 1.0455418475441292e-10
the O 0 2.490420092371437e-10
expansion O 0 6.160655097176004e-09
size O 0 2.1647734271823538e-08
decreases O 0 7.46532435869085e-08
. O 0 6.073384906102319e-09
. O 0 3.5013304255926414e-08

The O 0 1.0039002518169582e-06
R496H O 0 8.915277248888742e-06
mutation O 0 1.2301495644351235e-06
of O 0 3.929703229488268e-09
arylsulfatase O 0 1.9800540940195788e-06
A O 0 1.4911218215729605e-07
does O 0 4.1202280698371396e-08
not O 0 2.9916609634028646e-08
cause O 0 5.22196251040441e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999998807907104
. O 0 2.494421778465039e-06

Deficiency B-Disease 1 0.9964878559112549
of I-Disease 0 3.926641056750668e-07
arylsulfatase I-Disease 0 0.00011068364256061614
A I-Disease 0 3.4695319754973752e-06
( O 0 5.23863491252996e-07
ARSA O 0 0.00025758857373148203
) O 0 8.018569985779322e-08
enzyme O 0 2.0450579540920444e-06
activity O 0 1.3947014849691186e-05
causes O 0 0.00021598277089651674
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.00010733032104326412
MLD B-Disease 1 0.9999995231628418
) O 0 1.3386768387135817e-06
. O 0 5.809549747937126e-07

A O 0 9.66714765127108e-07
number O 0 2.8393008832949818e-08
of O 0 1.1097441188212542e-08
ARSA O 0 0.0005466744187287986
gene O 0 5.1630013331305236e-06
mutations O 0 3.762621645364561e-06
responsible O 0 2.5557187655067537e-07
for O 0 6.733406365810879e-08
MLD B-Disease 1 1.0
have O 0 2.1663264959670414e-08
been O 0 1.3041958624171457e-08
identified O 0 8.120102990005762e-08
. O 0 7.366439547240589e-08

Recently O 0 1.2369948308332823e-05
, O 0 3.218423572093343e-08
the O 0 1.2800930093703755e-08
R496H O 0 1.7684736803857959e-06
mutation O 0 3.795034047016088e-07
of O 0 5.701457528317633e-09
ARSA O 0 0.0003174191515427083
was O 0 3.478439793980215e-07
proposed O 0 3.4383647040669985e-09
to O 0 4.843702106072101e-10
be O 0 2.4640645079898604e-10
a O 0 2.654191755269153e-09
cause O 0 2.928368481036614e-08
of O 0 9.633794206820312e-09
MLD B-Disease 1 0.9999997615814209
( O 0 4.1062396149982305e-08
Draghia O 0 2.7935018351854524e-06
et O 0 5.093842219139333e-07
al O 0 1.0689584684087095e-07
. O 0 9.999611139122067e-10
, O 0 6.52985887583668e-10
1997 O 0 1.5926941543398243e-08
) O 0 1.11935287705478e-08
. O 0 4.692058652722153e-08

We O 0 3.741124885436875e-07
have O 0 8.340422574804052e-09
investigated O 0 4.12519014503232e-08
the O 0 5.5012234767559676e-09
R496H O 0 4.344066155681503e-07
mutation O 0 1.555042246081939e-07
and O 0 1.117364312186453e-09
found O 0 1.7574283139865088e-09
this O 0 6.222675708045244e-10
mutation O 0 4.483500504193216e-08
at O 0 1.2963389472986364e-08
a O 0 4.597522362814743e-09
relatively O 0 2.7631529064819915e-08
high O 0 3.7471986047421524e-07
frequency O 0 3.0174662697390886e-06
in O 0 1.2220877643187578e-09
an O 0 1.3667840470521497e-10
African O 0 2.4363513984049234e-10
American O 0 6.233509264319537e-10
population O 0 4.153442312304634e-10
( O 0 2.1450927700783495e-09
f O 0 3.860878621253505e-07
= O 0 1.63907046157874e-07
0 O 0 3.156902295131658e-08
. O 0 5.838935113189336e-09
09 O 0 2.820819418047904e-07
, O 0 4.218175586601092e-09
n O 0 4.6417306975854444e-07
= O 0 5.535670766221301e-07
61 O 0 2.2265835752932617e-07
subjects O 0 1.0714406073475402e-07
) O 0 2.554324396442098e-08
. O 0 8.408134277715362e-08

The O 0 3.251435600759578e-06
ARSA O 0 0.0005486538866534829
enzyme O 0 2.7260125534667168e-06
activity O 0 4.7348652287837467e-07
in O 0 1.548608352663905e-08
subjects O 0 9.723715166387592e-09
with O 0 7.243172173154733e-10
and O 0 1.4369314627060703e-09
without O 0 3.2637884062047817e-10
the O 0 1.4105879797554621e-09
R496H O 0 2.21605517936041e-07
mutation O 0 9.482322838039181e-08
was O 0 7.630720944007408e-08
determined O 0 1.4331959619084955e-08
and O 0 8.726524503011035e-10
found O 0 1.862267562380282e-09
to O 0 2.0044024218179857e-09
be O 0 2.6744018111202195e-09
normal O 0 2.5129691039182944e-07
. O 0 8.465953982295105e-08

It O 0 5.987788540551264e-07
is O 0 1.089592416292362e-08
therefore O 0 2.732606363409218e-09
concluded O 0 6.263331187028598e-09
that O 0 2.61091370745703e-10
the O 0 2.0566610636763016e-09
R496H O 0 1.5606656234012917e-07
mutation O 0 9.418549495876505e-08
of O 0 4.381342399994992e-09
ARSA O 0 8.411883027292788e-05
does O 0 2.9280110780405266e-08
not O 0 1.055571297037261e-09
negatively O 0 6.907572736025713e-09
influence O 0 2.5617832299928978e-09
the O 0 9.451743832045167e-10
activity O 0 1.763530477205677e-08
of O 0 1.4133700876328703e-09
ARSA O 0 0.00011394002649467438
and O 0 8.578219024002465e-09
is O 0 4.4490122697027346e-10
not O 0 3.8120018253096077e-10
a O 0 7.458859307973853e-09
cause O 0 1.7253425710350712e-07
of O 0 3.042461571567401e-07
MLD B-Disease 1 0.9999998807907104

Down O 0 0.0003424210590310395
- O 0 1.1115936104033608e-05
regulation O 0 4.457980139704887e-06
of O 0 3.793669378637787e-08
transmembrane O 0 2.32514571507636e-06
carbonic O 0 7.736653060419485e-05
anhydrases O 0 0.00012134652934037149
in O 0 4.372914645500714e-06
renal B-Disease 1 0.9997027516365051
cell I-Disease 1 0.9999927282333374
carcinoma I-Disease 1 1.0
cell O 0 0.20854943990707397
lines O 0 2.896287514886353e-05
by O 0 1.77384649191481e-08
wild O 0 3.7529065366470604e-07
- O 0 7.546615961473435e-05
type O 0 0.01258643064647913
von B-Disease 1 0.9999172687530518
Hippel I-Disease 1 0.9993358254432678
- I-Disease 1 0.7961738109588623
Lindau I-Disease 1 0.7487686276435852
transgenes O 0 0.001040580216795206
. O 0 4.468280621949816e-06

To O 0 1.2838630709666177e-06
discover O 0 3.488084075797815e-06
genes O 0 5.203273758525029e-07
involved O 0 7.582220717949895e-08
in O 0 1.5545204234967969e-07
von B-Disease 1 0.9990656971931458
Hippel I-Disease 1 0.9999697208404541
- I-Disease 1 0.9997938275337219
Lindau I-Disease 1 0.9997472167015076
( O 0 1.5561399777652696e-06
VHL B-Disease 0 0.00020549734472297132
) O 0 1.1569379410047986e-07
- O 0 1.060332920133078e-06
mediated O 0 2.11005931305408e-06
carcinogenesis O 0 2.04994958039606e-05
, O 0 3.5682350407739705e-09
we O 0 1.4787291391371582e-09
used O 0 2.2624841733431822e-07
renal B-Disease 0 0.020850758999586105
cell I-Disease 1 0.9963468909263611
carcinoma I-Disease 1 1.0
cell O 0 0.13835838437080383
lines O 0 0.0006631588912568986
stably O 0 8.804604294709861e-05
transfected O 0 7.084572189341998e-06
with O 0 1.1566331004075892e-08
wild O 0 2.2217389528123022e-07
- O 0 9.832510841079056e-05
type O 0 0.0017940745456144214
VHL O 0 0.06091217324137688
- O 0 6.895744445500895e-05
expressing O 0 1.4258607734518591e-06
transgenes O 0 6.637119076913223e-05
. O 0 7.672064725738892e-07

Large O 0 2.2589708805753617e-06
- O 0 1.6503117876709439e-06
scale O 0 4.835657705370977e-07
RNA O 0 8.658553838358785e-07
differential O 0 4.203412231618131e-07
display O 0 6.394997740244435e-07
technology O 0 7.41064809517411e-08
applied O 0 9.006440926384585e-09
to O 0 1.6462123886284985e-09
these O 0 4.052664870357603e-10
cell O 0 7.867181750498276e-08
lines O 0 1.720032685170736e-07
identified O 0 7.672706026085052e-09
several O 0 1.404684146777413e-09
differentially O 0 1.2441856256373285e-07
expressed O 0 4.199983916208794e-09
genes O 0 8.401686457659707e-09
, O 0 2.0176886550427042e-10
including O 0 1.5296688915533707e-10
an O 0 8.884037949741241e-10
alpha O 0 3.1818990464671515e-07
carbonic O 0 4.647835339710582e-06
anhydrase O 0 1.2657483239308931e-05
gene O 0 2.1526493583223782e-06
, O 0 4.205974235560461e-08
termed O 0 3.354192585902638e-06
CA12 O 0 0.00022515664750244468
. O 0 7.095032970028115e-07

The O 0 4.761051002333261e-07
deduced O 0 1.1877145880134776e-06
protein O 0 1.902279791465844e-07
sequence O 0 4.366112094089658e-08
was O 0 2.2619055073391792e-08
classified O 0 8.832814479831086e-09
as O 0 1.3315526459223292e-09
a O 0 3.7100094107955783e-09
one O 0 3.46242523541207e-09
- O 0 1.9775648070208263e-06
pass O 0 5.611910864899983e-07
transmembrane O 0 6.533751957249478e-07
CA O 0 2.2508199037929444e-07
possessing O 0 7.518277556073372e-09
an O 0 1.4822560956417874e-09
apparently O 0 9.066735628948663e-08
intact O 0 1.9171812937202048e-07
catalytic O 0 3.6255210034141783e-07
domain O 0 3.6650540380378516e-08
in O 0 7.069533403125661e-09
the O 0 8.901174020081726e-09
extracellular O 0 6.287284008976712e-07
CA O 0 1.054546100931475e-05
module O 0 2.430298536637565e-06
. O 0 2.3045700459078944e-07

Reintroduced O 0 0.00027560105081647635
wild O 0 1.5856183381401934e-05
- O 0 0.00016003257769625634
type O 0 0.00011676936992444098
VHL B-Disease 0 0.0008542413706891239
strongly O 0 2.4098180801956914e-06
inhibited O 0 9.190877676701348e-07
the O 0 8.665639761318289e-09
overexpression O 0 1.6577635619796638e-07
of O 0 4.74805084138552e-10
the O 0 2.3768480517105672e-09
CA12 O 0 9.365297728436417e-07
gene O 0 6.790373419107709e-08
in O 0 2.3007693528143136e-09
the O 0 1.1571406055566058e-08
parental O 0 0.000909231835976243
renal B-Disease 1 0.9720423817634583
cell I-Disease 1 0.9999778270721436
carcinoma I-Disease 1 1.0
cell O 1 0.8880465030670166
lines O 0 0.010990962386131287
. O 0 8.475444133182464e-07

Similar O 0 2.0838006093981676e-06
results O 0 5.302782710714382e-07
were O 0 9.498555719744672e-09
obtained O 0 8.361352499264285e-09
with O 0 2.675371257865322e-09
CA9 O 0 2.751300962700043e-05
, O 0 3.307980334099625e-09
encoding O 0 2.0449357407414936e-07
another O 0 7.860506912038545e-08
transmembrane O 0 8.386925856029848e-07
CA O 0 7.018180099294113e-07
with O 0 1.0228839997239447e-09
an O 0 3.3256308817897207e-09
intact O 0 9.106543643611076e-07
catalytic O 0 3.0028143100935267e-06
domain O 0 6.720421765749052e-07
. O 0 1.9681603191656905e-07

Although O 0 7.690010761507438e-07
both O 0 2.5948855508772795e-08
domains O 0 4.4103039442688896e-08
of O 0 3.7831301979984744e-10
the O 0 3.768231948697576e-09
VHL B-Disease 0 3.733255425686366e-06
protein O 0 4.009520182535198e-08
contribute O 0 3.0376643422869165e-09
to O 0 1.5735196479127467e-09
regulation O 0 1.936239186761668e-07
of O 0 1.595326426517829e-09
CA12 O 0 4.799665020982502e-06
expression O 0 2.7779597289168123e-08
, O 0 6.6570488010953e-10
the O 0 1.137910321524771e-09
elongin O 0 3.803690162840212e-07
binding O 0 5.1775728593383974e-08
domain O 0 5.3862688531580716e-08
alone O 0 1.3587018621308289e-08
could O 0 1.4007118132042251e-08
effectively O 0 2.0014969948078942e-07
regulate O 0 3.3256628739763983e-06
CA9 O 0 0.00020274787675589323
expression O 0 2.713044750635163e-06
. O 0 3.732173183834675e-07

We O 0 3.03616548080754e-06
mapped O 0 3.684071998577565e-05
CA12 O 0 0.00011511873890412971
and O 0 4.0399737599727814e-07
CA9 O 0 0.0002904957509599626
loci O 0 3.017241851921426e-06
to O 0 9.178197046821879e-08
chromosome O 0 5.164798494661227e-06
bands O 0 1.1951558462897083e-06
15q22 O 0 2.9940954391349806e-06
and O 0 5.470422337339187e-08
17q21 O 0 8.26869290904142e-06
. O 0 2.3597434051225719e-07

2 O 0 3.0457904358627275e-06
respectively O 0 2.1846049946816493e-07
, O 0 5.729168250923067e-09
regions O 0 3.6626641275461225e-08
prone O 0 2.3771451651555253e-06
to O 0 1.0890106594274584e-08
amplification O 0 1.6378188547605532e-06
in O 0 3.768727996344978e-09
some O 0 2.8337754365281853e-09
human O 0 5.3196394844690076e-08
cancers B-Disease 0 4.81341194245033e-05
. O 0 1.9499110237575223e-07

Additional O 0 3.086438482569065e-07
experiments O 0 4.1266466155320813e-07
are O 0 3.0736237999207106e-09
needed O 0 2.3623760725399734e-09
to O 0 1.6003732783431701e-09
define O 0 1.0553200979757094e-08
the O 0 1.5028325250909802e-09
role O 0 2.6579964895745434e-09
of O 0 1.5820784682318845e-09
CA O 0 2.4417795430053957e-06
IX O 0 1.771187726262724e-06
and O 0 2.3637204193960315e-08
CA O 0 8.896541885405895e-07
XII O 0 3.7886115933361e-07
enzymes O 0 2.6523661489363803e-08
in O 0 1.9997821176787056e-09
the O 0 1.5281008680645414e-09
regulation O 0 9.046732429851545e-08
of O 0 1.3683916222362313e-09
pH O 0 3.7114415363248554e-07
in O 0 1.4758101407608137e-09
the O 0 1.4275723936307827e-09
extracellular O 0 2.844477364760678e-08
microenvironment O 0 5.79904849473678e-07
and O 0 6.513911632310965e-10
its O 0 7.563061288351491e-10
potential O 0 7.974772509022898e-10
impact O 0 8.4351166051988e-09
on O 0 3.769151248889102e-07
cancer B-Disease 0 1.6821149984025396e-06
cell O 0 7.77705224663805e-07
growth O 0 8.517051242051821e-07
. O 0 9.411456147745412e-08

A O 0 2.4000246412470005e-06
gene O 0 4.166096005064901e-06
encoding O 0 1.6229388393185218e-06
a O 0 7.740161578340121e-08
transmembrane O 0 5.005027219340263e-07
protein O 0 1.92149371969208e-07
is O 0 2.221894224163634e-09
mutated O 0 3.4169400464634236e-07
in O 0 4.948377707592044e-08
patients O 0 6.67906988383038e-07
with O 0 0.0015324411215260625
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.19241605699062347
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999998807907104
( O 0 0.06066408008337021
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 6.756027914889273e-07
. O 0 3.628931892762921e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00040333098149858415
WFS B-Disease 0 0.13946619629859924
; O 0 6.625704372709151e-06
OMIM O 0 0.002275340259075165
222300 O 0 2.030609357461799e-05
) O 0 2.7973243277301663e-08
is O 0 3.1135998224129935e-09
an O 0 2.2105369978930867e-08
autosomal B-Disease 1 0.9999994039535522
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999995231628418
defined O 0 2.560439952503657e-06
by O 0 5.360135091336815e-08
young O 0 6.083543269141956e-08
- O 0 5.092752871860284e-06
onset O 0 0.0014533651992678642
non O 0 1.0095109246321954e-06
- O 0 0.0007851057453081012
immune O 0 0.2184349000453949
insulin B-Disease 1 0.999580442905426
- I-Disease 1 0.9998140931129456
dependent I-Disease 1 0.9929306507110596
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 1.461672582081519e-05
progressive O 0 0.09090276062488556
optic B-Disease 1 0.9999935626983643
atrophy I-Disease 1 0.891995370388031
. O 0 1.71622775724245e-06

Linkage O 0 0.00010192050103796646
to O 0 2.6865924951380293e-07
markers O 0 1.4986704854891286e-06
on O 0 1.847787416409119e-07
chromosome O 0 2.4839699108269997e-05
4p O 0 0.0002535655803512782
was O 0 2.2697153667650127e-07
confirmed O 0 3.377114410341164e-08
in O 0 7.360229314912203e-09
five O 0 8.204134260836327e-09
families O 0 1.782335345978936e-08
. O 0 6.328346557893383e-08

On O 0 2.925874014181318e-07
the O 0 4.776538276018982e-09
basis O 0 3.1388460719483646e-09
of O 0 1.1767239405102714e-09
meiotic O 0 1.1004635780409444e-05
recombinants O 0 0.0003250416775699705
and O 0 7.458669415427721e-07
disease O 0 7.229776383610442e-05
- O 0 6.4984069467755035e-06
associated O 0 2.2525463805322943e-07
haplotypes O 0 1.2424418400769355e-06
, O 0 3.223028954835172e-09
the O 0 1.4146815274784785e-08
WFS B-Disease 0 1.5700416042818688e-05
gene O 0 3.6710574136122887e-07
was O 0 3.300343820455964e-08
localized O 0 2.8245665362192085e-07
to O 0 1.3429518830321285e-08
a O 0 1.203250121761812e-07
BAC O 0 0.004188140854239464
/ O 0 1.3506164577847812e-05
P1 O 0 5.954605512670241e-06
contig O 0 7.19797128567734e-07
of O 0 1.2278915662022882e-09
less O 0 5.7117981455689915e-09
than O 0 5.043298223483816e-09
250 O 0 5.047226991905518e-08
kb O 0 4.05705432058312e-05
. O 0 1.5066022740484186e-07

Mutations O 0 0.0002686974185053259
in O 0 5.830824534314161e-07
a O 0 1.0006220207969818e-07
novel O 0 2.726655168316938e-07
gene O 0 9.287162470172916e-07
( O 0 3.56727021255665e-08
WFS1 O 0 2.5195733996952185e-06
) O 0 3.3798062126777495e-09
encoding O 0 3.724431962837116e-08
a O 0 7.45155048775814e-09
putative O 0 1.9818797625248408e-07
transmembrane O 0 1.0044272613640715e-07
protein O 0 1.1182308412571729e-07
were O 0 4.8652504247570505e-09
found O 0 3.4511176139062627e-09
in O 0 1.7896549797669081e-09
all O 0 3.0072305756689843e-10
affected O 0 2.606138638228117e-09
individuals O 0 1.4734692632689672e-10
in O 0 1.1546509304238839e-09
six O 0 1.191654064314207e-08
WFS B-Disease 0 4.358616934041493e-06
families O 0 2.9090772013518063e-09
, O 0 3.916307000917385e-10
and O 0 8.868259460115269e-10
these O 0 1.2041651009653265e-09
mutations O 0 6.068513158652422e-08
were O 0 1.7489247827739973e-09
associated O 0 1.6882722997380029e-09
with O 0 1.617395217756723e-09
the O 0 2.38783258055264e-07
disease O 0 0.00025429722154513
phenotype O 0 4.273507511243224e-05
. O 0 4.5228642875372316e-07

WFS1 O 0 0.0005564393359236419
appears O 0 2.546214318499551e-06
to O 0 1.720799858162536e-08
function O 0 1.5353410987017924e-08
in O 0 3.4139895355167482e-09
survival O 0 1.8203021312501733e-08
of O 0 3.679395121913842e-10
islet O 0 2.249197734727204e-07
beta O 0 1.371243314451931e-07
- O 0 6.744074312337034e-07
cells O 0 1.1294351054402796e-07
and O 0 4.972946943126999e-09
neurons O 0 2.4190572389670706e-07
. O 0 7.381049549337604e-09
. O 0 3.416304039660645e-08

Stable O 0 1.6409818272222765e-05
interaction O 0 5.9190785606233476e-08
between O 0 1.0316663967557815e-08
the O 0 2.5760809041486255e-09
products O 0 8.585110400360918e-09
of O 0 2.6543220399410927e-10
the O 0 5.824674964571841e-09
BRCA1 O 0 1.0366052265453618e-06
and O 0 2.6850701217995265e-08
BRCA2 O 0 8.187260391423479e-06
tumor B-Disease 0 1.436457523595891e-06
suppressor O 0 3.3920255191333126e-06
genes O 0 2.433512520383374e-07
in O 0 2.2812029598640038e-08
mitotic O 0 8.290707228297833e-06
and O 0 6.072993841144125e-08
meiotic O 0 4.758353315992281e-05
cells O 0 8.438437362201512e-06
. O 0 6.687795917059702e-07

BRCA1 O 0 0.0016964321257546544
and O 0 4.7548164161526074e-07
BRCA2 O 0 2.526687785575632e-05
account O 0 1.7723280620884907e-08
for O 0 6.083723524952234e-10
most O 0 3.089061784145031e-10
cases O 0 2.4377833085509337e-10
of O 0 2.6187091384244354e-10
familial O 0 8.067659109656233e-07
, O 0 2.834413370678135e-09
early O 0 1.2831665117118973e-06
onset O 1 0.9461225271224976
breast B-Disease 1 0.5755462050437927
and I-Disease 0 9.285585292673204e-06
/ I-Disease 1 0.9999978542327881
or I-Disease 1 0.9999985694885254
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 6.210323810762475e-09
encode O 0 9.935360623103406e-08
products O 0 1.4993865704582277e-07
that O 0 3.8767763999025817e-10
each O 0 2.570758883546631e-10
interact O 0 4.258197794371199e-09
with O 0 7.791497225184685e-09
hRAD51 O 0 5.0147205001849215e-06
. O 0 1.9413904794873815e-07

Results O 0 3.823872248176485e-06
presented O 0 3.9319283473560063e-07
here O 0 2.4072807747188563e-08
show O 0 6.86386769643832e-08
that O 0 2.8488034153895114e-09
BRCA1 O 0 1.4994224102338194e-06
and O 0 8.532984985265557e-09
BRCA2 O 0 1.2316520496824523e-06
coexist O 0 5.3917780462597875e-08
in O 0 4.683079701806037e-09
a O 0 6.0782059385644516e-09
biochemical O 0 2.0755072682732134e-07
complex O 0 4.962631194871392e-08
and O 0 8.436853882187734e-09
colocalize O 0 1.8149792140320642e-06
in O 0 2.132346210714786e-08
subnuclear O 0 2.086908580167801e-06
foci O 0 6.358303039633029e-07
in O 0 5.519290358080298e-09
somatic O 0 3.3118777764684637e-07
cells O 0 1.38990472464684e-07
and O 0 4.294616662292583e-09
on O 0 1.5093426952716982e-08
the O 0 2.8090856307727563e-09
axial O 0 2.9004910473418022e-08
elements O 0 5.8465463581569566e-09
of O 0 1.886920175664386e-09
developing O 0 6.280775721734244e-08
synaptonemal O 0 1.3541682164941449e-05
complexes O 0 3.36529478772718e-06
. O 0 2.627658375331521e-07

Like O 0 9.807425158214755e-06
BRCA1 O 0 0.00014934458886273205
and O 0 3.2387453074989025e-07
RAD51 O 0 0.0002492368221282959
, O 0 1.4299062911504734e-07
BRCA2 O 0 2.0422849047463387e-05
relocates O 0 6.073971690057078e-06
to O 0 5.074747733146978e-08
PCNA O 0 2.0031127860420384e-05
+ O 0 3.306812459413777e-07
replication O 0 4.738294308026525e-07
sites O 0 2.663951370607265e-08
following O 0 1.2798097692723331e-08
exposure O 0 1.7136669328010612e-07
of O 0 1.4272564241579744e-09
S O 0 1.3347136018637684e-06
phase O 0 9.285872692998964e-08
cells O 0 1.2744098398798087e-07
to O 0 3.147072646925153e-08
hydroxyurea O 0 1.4536433809553273e-05
or O 0 1.8394902667751012e-07
UV O 0 7.910898420959711e-05
irradiation O 0 1.707447154331021e-05
. O 0 3.122492842067004e-07

Thus O 0 3.160434744131635e-06
, O 0 1.7423106157821167e-07
BRCA1 O 0 8.844043804856483e-06
and O 0 3.150814364971666e-08
BRCA2 O 0 1.6191235090445844e-06
participate O 0 3.957020489053775e-09
, O 0 1.0830857322119414e-09
together O 0 1.3987755398403579e-09
, O 0 1.0475779965712917e-10
in O 0 2.602208171165188e-10
a O 0 1.6230228272462455e-09
pathway O 0 1.1343850303546787e-08
( O 0 4.203557946169667e-09
s O 0 5.254791517472768e-07
) O 0 1.7814473229904593e-09
associated O 0 2.704930723851362e-09
with O 0 2.6092758509399516e-10
the O 0 1.0862074573125824e-09
activation O 0 1.1827504309280812e-08
of O 0 3.433631434734963e-10
double O 0 3.0204201806327546e-08
- O 0 1.1118946758870152e-06
strand O 0 3.4817760479199933e-06
break O 0 6.664703960268525e-06
repair O 0 0.0019262413261458278
and O 0 2.8220132008982546e-08
/ O 0 1.6239916931226617e-06
or O 0 2.6419046506021004e-08
homologous O 0 6.113484687375603e-07
recombination O 0 2.7325822884449735e-06
. O 0 2.8274934038563515e-07

Dysfunction O 0 0.0002672544214874506
of O 0 3.208078069860676e-08
this O 0 7.479473040916673e-09
pathway O 0 7.953224923085145e-08
may O 0 7.955850378493778e-08
be O 0 2.978778335105403e-10
a O 0 5.843834860463915e-10
general O 0 5.494111277037916e-10
phenomenon O 0 3.785968871738987e-09
in O 0 1.0496906677204265e-09
the O 0 3.76006004110252e-10
majority O 0 1.775174868212659e-10
of O 0 1.663434667786845e-11
cases O 0 1.418636041972121e-10
of O 0 9.658036592696817e-10
hereditary B-Disease 1 0.601102352142334
breast I-Disease 0 0.02954690344631672
and I-Disease 0 4.012731369584799e-05
/ I-Disease 1 0.9999998807907104
or I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.63454287064269e-08
. O 0 1.4524546543270844e-07

A O 0 4.02554633183172e-06
novel O 0 1.1493032161524752e-06
Arg362Ser O 0 9.725823474582285e-06
mutation O 0 2.2214476302906405e-06
in O 0 2.4254486419295063e-08
the O 0 2.3666888893103533e-08
sterol O 0 2.144233076251112e-05
27 O 0 2.284138872710173e-06
- O 0 3.6319622722658096e-06
hydroxylase O 0 7.351706153713167e-05
gene O 0 4.103338142158464e-06
( O 0 6.726551760039001e-08
CYP27 O 0 4.7825806177570485e-06
) O 0 1.0389152649281641e-08
: O 0 1.0570198050174895e-09
its O 0 6.671454055862114e-09
effects O 0 7.460996442887335e-08
on O 0 5.523010315755528e-08
pre O 0 7.7065737968951e-07
- O 0 1.4740672327206994e-07
mRNA O 0 1.8965376114010724e-07
splicing O 0 2.3263073956059088e-07
and O 0 2.295369005977932e-09
enzyme O 0 8.078377788933722e-08
activity O 0 2.438449087094341e-07
. O 0 5.423432369866532e-08

A O 0 1.8129932186639053e-06
novel O 0 1.0476288707650383e-06
C O 0 2.201500819865032e-06
to O 0 1.797828552696501e-09
A O 0 9.49495149171753e-09
mutation O 0 7.79487479007912e-08
in O 0 2.9239857202156827e-09
the O 0 9.628906560976702e-09
sterol O 0 1.7470056263846345e-05
27 O 0 2.1784539967484307e-06
- O 0 3.6579419884219533e-06
hydroxylase O 0 5.960845737718046e-05
gene O 0 3.1847512218519114e-06
( O 0 3.32176526285366e-08
CYP27 O 0 3.836737505480414e-06
) O 0 5.875488984230515e-09
was O 0 8.27982749029843e-09
identified O 0 2.259649134472852e-09
by O 0 1.1394848398182944e-09
sequencing O 0 7.350440256459478e-08
amplified O 0 1.1776021437981399e-06
CYP27 O 0 1.9292842807772104e-06
gene O 0 1.9402909856580663e-07
products O 0 2.222060579981644e-08
from O 0 1.4928789315860058e-09
a O 0 1.5980987200236996e-08
patient O 0 3.3240092989217374e-07
with O 0 1.042355464164757e-07
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 0.9999998807907104
( O 0 1.0089796660395223e-06
CTX B-Disease 0 0.00027854437939822674
) O 0 1.2534297866295674e-07
. O 0 1.3339789006749925e-07

The O 0 1.5860574649195769e-06
mutation O 0 1.1776081919379067e-05
changed O 0 6.920379860275716e-07
the O 0 1.8980930605039248e-08
adrenodoxin O 0 6.775289875804447e-06
cofactor O 0 7.469624279110576e-07
binding O 0 1.8836315973658202e-07
residue O 0 7.182885042311682e-07
362Arg O 0 8.384542979911203e-07
to O 0 1.985591069342263e-08
362Ser O 0 2.058897280221572e-06
( O 0 5.79783225873598e-08
CGT O 0 7.475678103219252e-06
362Arg O 0 3.3834185160230845e-06
to O 0 4.4757936024097944e-08
AGT O 0 1.0553236279520206e-05
362Ser O 0 1.3324205383469234e-06
) O 0 6.758984483212771e-09
, O 0 3.1225905194887105e-10
and O 0 4.3191766829764333e-10
was O 0 6.678914754587595e-09
responsible O 0 1.0996368260407507e-08
for O 0 1.0940906847167753e-08
deficiency O 0 2.120994167853496e-06
in O 0 3.201291676191431e-09
the O 0 1.1270825162057463e-08
sterol O 0 8.885637726052664e-06
27 O 0 6.481465675278741e-07
- O 0 2.591779946214956e-07
hydroxylase O 0 1.7589200069778599e-06
activity O 0 1.0614918721785216e-07
, O 0 4.416613186286611e-10
as O 0 3.0752467239381076e-10
confirmed O 0 1.59957391776544e-09
by O 0 1.9920490257341328e-10
expression O 0 1.1494738494377543e-09
of O 0 1.9785195704002945e-10
mutant O 0 3.916467861131423e-08
cDNA O 0 9.177321658171422e-08
into O 0 2.9027047432350628e-08
COS O 0 8.166672159859445e-06
- O 0 8.391118058170832e-07
1 O 0 6.129643992380807e-08
cells O 0 2.941218895102793e-07
. O 0 9.512048393389705e-08

Quantitative O 0 1.4722319974680431e-05
analysis O 0 1.050303922056628e-06
showed O 0 7.378012014669366e-07
that O 0 1.3405124787979616e-09
the O 0 1.2945394756158635e-09
expression O 0 4.306083933869331e-09
of O 0 4.371290274196582e-10
CYP27 O 0 6.418973725885735e-07
gene O 0 4.9711953664655084e-08
mRNA O 0 3.920018087910648e-08
in O 0 2.6305695399742035e-09
the O 0 2.9709044113701566e-09
patient O 0 5.6001280057671465e-08
represented O 0 2.4937452991480313e-08
52 O 0 2.262238183448062e-07
. O 0 7.822398373491524e-08

5 O 0 1.4076103980187327e-06
% O 0 1.840502150685097e-08
of O 0 7.272922264434101e-10
the O 0 1.014225770035182e-08
normal O 0 4.1939824768633116e-07
level O 0 7.682797331654001e-07
. O 0 1.885543952084845e-07

As O 0 2.0364194597277674e-07
the O 0 2.2717459913224047e-08
mutation O 0 3.434021778048191e-07
occurred O 0 1.6455547324767394e-07
at O 0 2.1833754360045532e-08
the O 0 2.6118713858380715e-09
penultimate O 0 2.079989371850388e-07
nucleotide O 0 8.661777428642381e-08
of O 0 1.229000012870074e-09
exon O 0 1.2957229955645744e-06
6 O 0 3.915370712093136e-07
( O 0 1.9671427153866716e-08
- O 0 1.1793824796768604e-06
2 O 0 2.3878820698541858e-08
position O 0 1.160732665539399e-08
of O 0 1.2279268712944713e-09
exon O 0 1.3728634939980111e-06
6 O 0 2.557844993589242e-07
- O 0 1.202774342345947e-06
intron O 0 1.0569331607257482e-05
6 O 0 2.039017772403895e-07
splice O 0 3.627759497248917e-06
site O 0 1.6222877263771807e-07
) O 0 6.998451262951733e-10
of O 0 5.1648216953248394e-11
the O 0 3.0589716870643713e-10
gene O 0 1.31316930662706e-08
, O 0 1.4644865875546031e-10
we O 0 4.6199599701424177e-11
hypothesized O 0 1.2939668225797618e-09
that O 0 1.0129835859018499e-10
the O 0 2.8897768622471176e-09
mutation O 0 3.2779229286461486e-07
may O 0 6.772265237486863e-08
partially O 0 6.708281574674402e-08
affect O 0 9.834039360612223e-09
the O 0 2.302613211213611e-09
normal O 0 4.4932857434787365e-08
splicing O 0 1.8064058338040923e-07
efficiency O 0 4.881882986751407e-08
in O 0 5.36834798836594e-09
exon O 0 3.231248513202445e-07
6 O 0 2.1551947781972558e-08
and O 0 1.3204723980919653e-09
cause O 0 1.1377090380904065e-08
alternative O 0 9.548927870639545e-09
splicing O 0 1.2559401341150078e-07
elsewhere O 0 1.9642294901700552e-08
, O 0 2.1224150215104487e-10
which O 0 2.2507741503918766e-10
resulted O 0 2.4158626210635248e-09
in O 0 1.6457039064832202e-09
decreased O 0 5.969143757056372e-08
transcript O 0 4.585977819715481e-07
in O 0 7.2309180865204326e-09
the O 0 2.5268972692060743e-08
patient O 0 1.3933833997725742e-06
. O 0 1.1193490934147121e-07

Transfection O 0 0.0002892681222874671
of O 0 2.9693487135773466e-07
constructed O 0 3.790056780417217e-06
minigenes O 0 1.6754127500462346e-05
, O 0 6.184555090271715e-09
with O 0 1.5506320671931917e-09
or O 0 3.344159615892295e-09
without O 0 4.4484863015448184e-10
the O 0 9.048795046595615e-10
mutation O 0 2.412870614421081e-08
, O 0 3.0592867128476087e-10
into O 0 3.3621569972552834e-09
COS O 0 1.098016946343705e-05
- O 0 1.23282077879594e-07
1 O 0 4.74047023857338e-09
cells O 0 7.428051063129715e-09
confirmed O 0 8.472960999483803e-09
that O 0 2.0847885917607556e-10
the O 0 6.431505328308162e-10
mutant O 0 3.164323203463937e-08
minigene O 0 3.109246051735681e-07
was O 0 1.1556958057212796e-08
responsible O 0 2.467706039510631e-09
for O 0 1.3475331961387838e-10
a O 0 7.27049531690227e-10
mRNA O 0 2.4606197968068955e-08
species O 0 1.0301458575057154e-09
alternatively O 0 4.307654677404571e-08
spliced O 0 1.1560064194782171e-06
at O 0 1.0790205351440818e-07
an O 0 4.960054589275842e-09
activated O 0 5.465303729579318e-06
cryptic O 0 1.1332797384966398e-06
5 O 0 3.014865868067318e-08
splice O 0 2.2509666450787336e-06
site O 0 1.5671324149479915e-07
88 O 0 1.0459183386046789e-07
bp O 0 9.133491118973325e-08
upstream O 0 1.0494249025327917e-08
from O 0 9.168705794593279e-10
the O 0 1.3091447925717148e-09
3 O 0 4.785456475531191e-09
end O 0 4.814791232377047e-09
of O 0 7.411913305332973e-10
exon O 0 9.182730309476028e-07
6 O 0 2.530148606183502e-07
. O 0 7.338154972558186e-08

Our O 0 5.638024731524638e-07
data O 0 1.7777627192572254e-07
suggest O 0 2.432472001601127e-08
that O 0 4.839241785070669e-10
the O 0 1.2773703206292453e-09
C O 0 1.193237437746575e-07
to O 0 6.193688339983794e-10
A O 0 8.03171396057678e-09
mutation O 0 6.712031819233744e-08
at O 0 1.1104089203683998e-08
the O 0 4.784726836959408e-09
penultimate O 0 4.330292711074435e-07
nucleotide O 0 8.115426908261725e-08
of O 0 9.944907120029711e-10
exon O 0 3.337318617013807e-07
6 O 0 1.1029661628469967e-08
of O 0 2.303538887415968e-10
the O 0 4.08993239275901e-09
CYP27 O 0 1.776359113137005e-06
gene O 0 9.856877625225025e-08
not O 0 1.3626355599427598e-09
only O 0 3.0723271149390996e-10
causes O 0 8.70265992602981e-09
the O 0 6.609761271647585e-08
deficiency B-Disease 0 4.261403319105739e-06
in I-Disease 0 2.0562138658419826e-09
the I-Disease 0 8.373706172903894e-09
sterol I-Disease 0 5.063395747129107e-06
27 I-Disease 0 3.8549478631466627e-07
- I-Disease 0 1.1963778945300874e-07
hydroxylase I-Disease 0 1.6226155139520415e-06
activity I-Disease 0 1.5781257900471246e-07
, O 0 1.2216589961866475e-09
but O 0 8.657622951879773e-10
also O 0 2.875744975483485e-09
partially O 0 4.88553411059911e-08
leads O 0 3.1471427686113884e-09
to O 0 7.784451971915018e-10
alternative O 0 1.1043091774354252e-08
pre O 0 2.0369516562368517e-07
- O 0 4.24322514902542e-08
mRNA O 0 4.887929705432725e-08
splicing O 0 5.296151783795722e-08
of O 0 4.570233635980969e-10
the O 0 6.279934794406472e-09
gene O 0 7.415016511913564e-07
. O 0 7.064899421038717e-08

To O 0 2.1254437854167918e-07
our O 0 8.989965216699147e-09
knowledge O 0 2.147659827755888e-09
, O 0 2.3129824444634295e-10
this O 0 1.0517241938456934e-10
is O 0 1.004301364293525e-10
the O 0 2.960223455250599e-10
first O 0 1.9953545482565005e-09
report O 0 1.4577021367756515e-08
regarding O 0 2.188698999816552e-09
effects O 0 3.438537277133946e-08
on O 0 5.9251444639585316e-08
pre O 0 4.2270696098967164e-07
- O 0 3.673620696531543e-08
mRNA O 0 3.1718585091766727e-08
splicing O 0 4.472669701272025e-08
of O 0 2.844572077886909e-10
a O 0 1.6269185998396551e-09
mutation O 0 2.0126018185351313e-08
at O 0 1.216797063108288e-08
the O 0 7.476178787158005e-09
- O 0 7.208516308310209e-07
2 O 0 1.2016854178398262e-08
position O 0 5.52656898022974e-09
of O 0 1.1101686236969499e-10
a O 0 3.070524057235957e-09
5 O 0 2.7406041880340126e-08
splice O 0 7.190456926764455e-06
site O 0 1.4747492969036102e-06
. O 0 2.2477567540590826e-07

ATM O 0 0.0020871914457529783
germline O 0 0.0034239336382597685
mutations O 0 0.0020675095729529858
in O 0 5.696879270544741e-06
classical O 1 0.6688195466995239
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.46667659282684326
in O 0 5.608787034816487e-08
the O 0 1.1397158772297189e-08
Dutch O 0 1.3308166444403469e-06
population O 0 1.9865380451733472e-08
. O 0 5.20913197021855e-08

Germline O 0 0.0014581818832084537
mutations O 0 0.000207560631679371
in O 0 2.6800003638527414e-07
the O 0 3.2379730896536785e-08
ATM O 0 4.713479029305745e-06
gene O 0 1.563589933084586e-07
are O 0 3.86476434188765e-10
responsible O 0 2.8728504020136825e-09
for O 0 1.8461548956238971e-09
the O 0 0.001046117045916617
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.028299745172262192
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.415173412373406e-07
. O 0 1.6570128025250597e-07

In O 0 6.435615773625614e-07
our O 0 2.546866362251876e-08
study O 0 6.0479421470915895e-09
, O 0 7.728456763445024e-10
we O 0 2.128869441841985e-10
have O 0 1.0120160959248281e-10
determined O 0 7.795997736259608e-10
the O 0 2.3936401749580227e-09
ATM O 0 2.204015345341759e-06
mutation O 0 1.6863427276803122e-07
spectrum O 0 9.696031355588275e-08
in O 0 4.146731846788043e-09
19 O 0 2.0244597109808637e-08
classical O 0 3.619309296709616e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 4.3201947619309067e-07
, O 0 1.2733000764875158e-10
including O 0 2.3560918840925815e-11
some O 0 3.371915247019075e-11
immigrant O 0 1.168883434488066e-09
populations O 0 9.007468104726968e-10
, O 0 8.900128550815012e-11
as O 0 3.8873126939620306e-10
well O 0 5.835135707954464e-10
as O 0 5.582855844288304e-10
12 O 0 1.0608370848430582e-09
of O 0 9.705602294074467e-11
Dutch O 0 4.490929228495588e-08
ethnic O 0 2.2436386082347326e-09
origin O 0 1.2980585495370178e-08
. O 0 4.268795805728587e-08

Both O 0 1.7128859042259137e-07
the O 0 6.823806586453429e-08
protein O 0 5.040195105721068e-07
truncation O 0 4.403879756864626e-06
test O 0 1.1251954674662556e-06
( O 0 4.8397545526768226e-08
PTT O 0 7.553811656180187e-07
) O 0 1.3003152998791734e-09
and O 0 3.251926228298174e-10
the O 0 1.0514338288913905e-09
restriction O 0 4.5251852043293184e-08
endonuclease O 0 1.4559982446371578e-06
fingerprinting O 0 2.2442716840487265e-07
( O 0 1.0803793415448126e-08
REF O 0 5.99678287471761e-07
) O 0 2.939787580036324e-10
method O 0 1.0576167719378304e-09
were O 0 2.994432479752618e-10
used O 0 1.2985010844346334e-09
and O 0 3.892587918663537e-10
compared O 0 1.9420445251938645e-09
for O 0 1.205267274873023e-10
their O 0 7.221005460245067e-10
detection O 0 3.693975614282863e-08
efficiency O 0 1.9414306606790888e-08
, O 0 2.397422260713711e-10
identifying O 0 2.5510511481030562e-09
76 O 0 7.929048528865223e-09
% O 0 1.5644871509401526e-10
and O 0 9.403511996852743e-11
60 O 0 7.872292817623361e-10
% O 0 1.0042343345784133e-10
of O 0 3.832332368114422e-11
the O 0 4.018798183125227e-09
mutations O 0 2.20500027126036e-07
, O 0 3.4040672503010683e-09
respectively O 0 1.102617446235854e-07
. O 0 7.12052710127864e-08

Most O 0 4.622201572601625e-07
patients O 0 2.893794714964315e-07
were O 0 8.487859304295853e-09
found O 0 3.87682996816352e-09
to O 0 1.4422693039861656e-09
be O 0 1.2933153437089118e-09
compound O 0 1.1442686798091017e-07
heterozygote O 0 2.9950151656521484e-06
. O 0 1.3809955135002383e-07

Seventeen O 0 9.364428478875197e-06
mutations O 0 1.0522837328608148e-05
were O 0 1.3591995084993869e-08
distinct O 0 3.3378957375873597e-09
, O 0 3.9670086660059667e-10
of O 0 1.4950238269584304e-10
which O 0 2.9213209629119774e-09
10 O 0 3.0724571775664344e-09
were O 0 1.1276646283420177e-09
not O 0 4.781376405915694e-10
reported O 0 1.5815534482044313e-07
previously O 0 1.1170050839837131e-07
. O 0 6.260120954948434e-08

Mutations O 0 0.00047845073277130723
are O 0 6.073804570405628e-08
small O 0 2.8934737272834354e-08
deletions O 0 4.0049640119832475e-06
or O 0 2.284312472511374e-07
point O 0 2.12548428635273e-07
mutations O 0 5.874534053873504e-06
frequently O 0 1.118300588132115e-06
affecting O 0 5.403091449807107e-07
splice O 0 5.703042188542895e-05
sites O 0 3.945232037949609e-06
. O 0 6.411448794096941e-07

Moreover O 0 3.0203393635019893e-06
, O 0 3.007967919188559e-08
a O 0 5.317843587704374e-08
16 O 0 4.92877575197781e-07
. O 0 1.1430994817374085e-07

7 O 0 8.626290218671784e-05
- O 0 1.3599002159025986e-05
kb O 0 4.8073201469378546e-05
genomic O 0 4.006908511655638e-06
deletion O 0 2.0173288248770405e-06
of O 0 3.403671344770487e-09
the O 0 7.65204077879389e-09
3 O 0 2.111877428490061e-08
end O 0 4.9527844048213865e-09
of O 0 3.841311643770773e-11
the O 0 3.5831965172761215e-10
gene O 0 7.599301632410516e-09
, O 0 1.3589622482879093e-10
most O 0 1.6371747013632643e-10
likely O 0 2.932710074787792e-09
a O 0 8.398797768371935e-10
result O 0 1.206786226504164e-09
of O 0 9.304138709476106e-11
recombination O 0 5.7825007004908e-09
between O 0 1.7230619153707494e-09
two O 0 2.7316267026122887e-09
LINE O 0 1.2252145097590983e-05
elements O 0 5.2174122799897305e-09
, O 0 7.44198702662402e-10
was O 0 2.3262002102342194e-08
identified O 0 1.5992359436722836e-08
. O 0 2.9984530414139954e-08

The O 0 1.5732031499737786e-07
most O 0 5.683564285874354e-09
frequently O 0 1.718785824778024e-08
found O 0 5.448364870375144e-09
mutation O 0 5.375287415176899e-08
, O 0 4.644311879520302e-10
identified O 0 2.8395592543972725e-09
in O 0 1.835586127540978e-09
three O 0 5.750896980849518e-10
unrelated O 0 1.7083204184586975e-08
Turkish O 0 5.6284520155713835e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999929666519165
T I-Disease 1 1.0
individuals O 0 2.5003592529770913e-09
, O 0 5.311461825918684e-10
was O 0 2.1457527310531077e-08
previously O 0 4.68478633663949e-09
described O 0 3.9246468297449155e-09
to O 0 5.345631715059085e-10
be O 0 2.4851057323083126e-10
a O 0 2.423930611783476e-09
Turkish O 0 5.617823362058516e-08
A B-Disease 1 0.9999982118606567
- I-Disease 1 0.9999954700469971
T I-Disease 1 1.0
founder O 0 3.2949083106359467e-06
mutation O 0 3.997004569100682e-06
. O 0 2.1733171706728172e-07

The O 0 1.1285865753052349e-07
presence O 0 2.9152777969443378e-08
of O 0 6.725212053915186e-10
a O 0 5.951861226094479e-09
founder O 0 8.996383371595584e-08
mutation O 0 4.057131519630275e-08
among O 0 3.2397917681947774e-10
relatively O 0 1.8670547330401632e-09
small O 0 4.5244386015497184e-10
ethnic O 0 1.7696610843387361e-10
population O 0 9.486379043410764e-11
groups O 0 3.154140490457813e-11
in O 0 1.7848475475368275e-10
Western O 0 2.518960817710081e-09
Europe O 0 2.577566426964495e-08
could O 0 1.9120671712613557e-09
indicate O 0 2.751434191594626e-09
a O 0 1.5477422676823949e-09
high O 0 3.842394491471168e-08
carrier O 0 3.726862729536151e-08
frequency O 0 1.0727411847710755e-07
in O 0 1.7647542316368003e-09
such O 0 1.6822195858523514e-09
communities O 0 3.131205872364262e-08
. O 0 6.652231832049438e-08

In O 0 2.2999952307145577e-06
patients O 0 2.205277809252948e-07
of O 0 1.1116587650406018e-09
Dutch O 0 1.7721362155498355e-07
ethnic O 0 5.939451708236732e-10
origin O 0 7.144463909369847e-10
, O 0 2.780241592503785e-10
however O 0 5.505209621503582e-10
, O 0 5.543561096277294e-11
no O 0 1.3709902657588202e-10
significant O 0 5.25691656871885e-10
founder O 0 1.500404600562888e-08
effect O 0 7.815743607864079e-09
could O 0 4.154006916223807e-09
be O 0 1.2463101661808196e-09
identified O 0 3.4027188178242795e-08
. O 0 2.9760045094917587e-08

The O 0 5.370111466618255e-07
observed O 0 5.25080906754738e-07
genetic O 0 2.1393739757513686e-07
heterogeneity O 0 4.26199505909608e-07
including O 0 6.569952137880364e-09
the O 0 8.22553847257268e-09
relative O 0 2.2220906714665034e-07
high O 0 9.300173928750155e-07
percentage O 0 8.192254341565786e-08
of O 0 1.422999718059259e-09
splice O 0 0.00027314500766806304
- O 0 0.00015734563930891454
site O 0 3.5363188999326667e-06
mutations O 0 3.1428398870048113e-06
had O 0 5.8125149138277266e-08
no O 0 2.5577260309717076e-09
reflection O 0 1.696087004177116e-08
on O 0 8.815242757975739e-09
the O 0 1.7896763182534414e-08
phenotype O 0 7.322520559682744e-06
. O 0 1.1871853189404646e-07

All O 0 5.500501742972119e-07
patients O 0 6.814050834691443e-07
manifested O 0 8.0843716432355e-07
classical O 0 5.732979957429052e-07
A B-Disease 1 0.9999995231628418
- I-Disease 1 0.9998890161514282
T I-Disease 1 1.0
and O 0 1.4344211152206299e-08
increased O 0 2.0451302873425448e-08
cellular O 0 1.960750779517184e-07
radioresistant O 0 8.051179634094296e-07
DNA O 0 2.790301891764102e-07
synthesis O 0 1.36985170229309e-06
. O 0 1.4981031881688978e-07

Determination O 0 9.853397386905272e-07
of O 0 6.3107337133772035e-09
the O 0 2.962766920688864e-09
genomic O 0 8.329282508157121e-08
structure O 0 1.5829938249112274e-08
of O 0 2.0822611690451964e-10
the O 0 3.0046747312439948e-09
COL4A4 O 0 1.5084971209944342e-06
gene O 0 6.678051533981488e-08
and O 0 6.503073635144574e-10
of O 0 3.6636665923239775e-10
novel O 0 4.307622134547273e-07
mutations O 0 6.048402428859845e-05
causing O 0 0.00031546971877105534
autosomal B-Disease 1 0.9999995231628418
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.327667607460171e-05

Autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 5.2829127525910735e-06
a O 0 4.448348136065761e-06
progressive O 0 0.2179824411869049
hematuric B-Disease 1 0.9997996687889099
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.00025772539083845913
by O 0 6.315805762824311e-07
glomerular B-Disease 1 0.9881000518798828
basement I-Disease 1 0.9999935626983643
membrane I-Disease 0 0.3838432729244232
abnormalities I-Disease 1 0.9999470710754395
and O 0 3.20231912098734e-08
associated O 0 4.098985684208856e-08
with O 0 1.0076333545327998e-08
mutations O 0 4.682734470407013e-06
in O 0 4.338286530014557e-08
either O 0 2.2611247985082628e-08
the O 0 2.52315999205166e-08
COL4A3 O 0 6.320732154563302e-06
or O 0 5.205821995701854e-09
the O 0 2.919583019789229e-09
COL4A4 O 0 9.369040867568401e-07
gene O 0 7.616354480433074e-08
, O 0 4.524473018463482e-10
which O 0 2.6971655464613775e-10
encode O 0 7.554241676643869e-09
the O 0 1.1802236965507973e-09
alpha3 O 0 2.80495754623189e-07
and O 0 4.066177616834921e-09
alpha4 O 0 3.1205208870233037e-06
type O 0 4.164162965025753e-05
IV O 0 0.00021872618526685983
collagen O 0 7.981420822034124e-06
chains O 0 1.5324645573855378e-05
, O 0 8.21537771145131e-09
respectively O 0 1.0977365150210971e-07
. O 0 1.1214710582407861e-07

To O 0 2.9462302109095617e-07
date O 0 8.15322138691954e-08
, O 0 1.4295504779937573e-09
mutation O 0 3.55283447106558e-08
screening O 0 2.3567515938793804e-08
in O 0 2.2366526408745813e-09
the O 0 7.059101081452468e-10
two O 0 4.235232442528769e-10
genes O 0 1.793311987796642e-08
has O 0 3.5450209434628732e-09
been O 0 1.8680486046918077e-09
hampered O 0 4.6589470059643645e-08
by O 0 4.546931442472868e-10
the O 0 7.778737654007273e-10
lack O 0 1.9610801871294825e-09
of O 0 4.0162362324736023e-10
genomic O 0 1.8738970197773597e-07
structure O 0 2.869468289645738e-07
information O 0 6.58816219356595e-08
. O 0 8.638266990601551e-08

We O 0 4.343838213571871e-07
report O 0 1.4457299357673037e-07
here O 0 1.6657255574870078e-09
the O 0 9.683325252751729e-10
complete O 0 3.7011744780102163e-09
characterization O 0 1.3780624641412942e-08
of O 0 2.7515850709036727e-10
the O 0 3.9558054609756255e-09
48 O 0 2.058765780077465e-08
exons O 0 3.260214143097073e-08
of O 0 3.0772182024740857e-10
the O 0 2.3091224488069884e-09
COL4A4 O 0 1.5727545132904197e-06
gene O 0 5.5550639643797695e-08
, O 0 3.3854241632269577e-10
a O 0 5.993929796943576e-10
comprehensive O 0 7.497026999203626e-09
gene O 0 1.052958040759222e-07
screen O 0 1.0913665846601361e-06
, O 0 7.360548281987178e-10
and O 0 1.385170728118723e-10
the O 0 1.2585882336324516e-10
subsequent O 0 1.5977473788453267e-09
detection O 0 9.21905574102766e-09
of O 0 2.3694687878439424e-10
10 O 0 3.2282463369170955e-09
novel O 0 1.2240386482176291e-08
mutations O 0 6.556209797281554e-08
in O 0 4.798417219120665e-09
eight O 0 3.9945284413533955e-08
patients O 0 2.938826128229266e-06
diagnosed O 0 0.0002618201251607388
with O 0 2.3744444206386106e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.555920061946381e-05

Furthermore O 0 5.137857442605309e-06
, O 0 2.939813015245818e-08
we O 0 1.368623880892983e-09
identified O 0 5.6035549533817175e-09
a O 0 3.7252687601352363e-09
glycine O 0 1.8336995708523318e-06
to O 0 6.2652310006683365e-09
alanine O 0 6.009894377712044e-07
substitution O 0 2.6199106883950662e-08
in O 0 5.217640985932803e-09
the O 0 7.795228462725845e-09
collagenous O 0 1.6051238844738691e-06
domain O 0 4.6279044596531094e-08
that O 0 1.292624784987595e-09
is O 0 3.977881357641877e-10
apparently O 0 6.23773521724047e-09
silent O 0 2.4333260739695106e-08
in O 0 6.612113079285109e-10
the O 0 1.90744842143431e-09
heterozygous O 0 1.5959305699198012e-07
carriers O 0 1.512651159885081e-08
, O 0 9.080781127046578e-10
in O 0 7.504595167517891e-09
11 O 0 1.234199515920409e-07
. O 0 6.415558573280578e-08

5 O 0 1.919800979521824e-06
% O 0 1.368916890953642e-08
of O 0 5.231389765825156e-10
all O 0 2.6515442619334806e-10
control O 0 3.263262726704852e-08
individuals O 0 1.146399156159994e-10
, O 0 1.3001137666446283e-10
and O 0 2.467827331376071e-10
in O 0 6.821730957895511e-10
one O 0 2.8692073716918287e-10
control O 0 3.110075752488228e-08
individual O 0 5.230931243715986e-10
homozygous O 0 2.6263847985319444e-08
for O 0 2.666281639918111e-10
this O 0 9.88891968312089e-10
glycine O 0 1.4402846773009514e-06
substitution O 0 3.4361445955255476e-07
. O 0 1.4310467122413684e-07

There O 0 7.231334393509314e-07
has O 0 1.896081336383304e-08
been O 0 1.4325529651415536e-09
no O 0 2.4668247999848347e-10
previous O 0 2.5131394743027613e-09
finding O 0 2.0023954716563708e-10
of O 0 5.040908315767645e-11
a O 0 1.4659544689266113e-09
glycine O 0 3.4346115285188716e-07
substitution O 0 5.575845563043913e-09
that O 0 2.5255889046782443e-10
is O 0 1.4564666139804672e-10
not O 0 1.1691549117731626e-10
associated O 0 4.3485381961971825e-10
with O 0 1.5618872861722366e-10
any O 0 8.044282462371655e-10
obvious O 0 1.2249963710075917e-08
phenotype O 0 3.4463579368093633e-07
in O 0 1.0397815941587396e-08
homozygous O 0 6.289707243922749e-07
individuals O 0 1.3055796443950385e-08
. O 0 6.703983501665789e-08

Founder O 0 9.101130854105577e-05
BRCA1 O 0 0.00021693423332180828
and O 0 3.384937485861883e-07
BRCA2 O 0 1.9006503862328827e-05
mutations O 0 1.0068745268654311e-06
in O 0 2.229906570505591e-08
French O 0 1.249819433724042e-06
Canadian O 0 0.0019120067590847611
breast B-Disease 1 0.9999949932098389
and I-Disease 1 0.999923825263977
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.355633199613294e-07
. O 0 3.0716802257302334e-07

We O 0 2.7194744234293466e-07
have O 0 8.793848316202002e-09
identified O 0 7.045451777543121e-09
four O 0 2.3075021893248504e-09
mutations O 0 9.35349220299031e-08
in O 0 1.6774648337047893e-09
each O 0 3.677697313353434e-10
of O 0 6.076754099915149e-10
the O 0 4.730843841116439e-07
breast B-Disease 1 0.7095376253128052
cancer I-Disease 0 1.1207135685253888e-05
- O 0 2.410781235084869e-06
susceptibility O 0 2.855169213944464e-06
genes O 0 2.4842464085850224e-07
, O 0 6.522343998227598e-09
BRCA1 O 0 1.584929464115703e-06
and O 0 6.6886545191380264e-09
BRCA2 O 0 4.146244521052722e-07
, O 0 3.6105973766353827e-10
in O 0 1.238806834891193e-09
French O 0 1.9131303474750894e-07
Canadian O 0 4.497128611546941e-05
breast B-Disease 1 0.9173663258552551
cancer I-Disease 0 0.003654717467725277
and O 0 0.044454798102378845
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.3935651566043816e-07
from O 0 1.1285133894034516e-07
Quebec O 0 4.932226147502661e-05
. O 0 2.7646194666886004e-07

To O 0 5.249026457931905e-07
identify O 0 3.3339782135044516e-07
founder O 0 3.272232049766899e-07
effects O 0 5.147476827005448e-07
, O 0 2.9491680209048354e-09
we O 0 9.386958987889216e-10
examined O 0 4.2417525492055574e-08
independently O 0 2.1318053100571888e-08
ascertained O 0 2.5241948975462947e-08
French O 0 2.077688954216228e-08
Canadian O 0 2.8417613862075086e-07
cancer B-Disease 0 3.9886515423859237e-07
families O 0 5.665140578869909e-10
for O 0 6.50450943107117e-11
the O 0 2.1448053055816985e-10
distribution O 0 1.1808474198460317e-09
of O 0 1.417451295226968e-10
these O 0 5.394961699600742e-10
eight O 0 1.0069916456245664e-08
mutations O 0 7.546726692453376e-07
. O 0 1.099358257761196e-07

Mutations O 0 0.00037394819082692266
were O 0 3.678122197925404e-07
found O 0 2.0359722796570168e-08
in O 0 7.512858779534781e-09
41 O 0 2.216684436007199e-08
of O 0 9.428894331975357e-10
97 O 0 2.1004331074436777e-07
families O 0 2.6289459498229917e-08
. O 0 1.6180679551780486e-07

Six O 0 3.1484361784350767e-07
of O 0 2.625236694697719e-09
eight O 0 6.005697272826183e-09
mutations O 0 1.7799052898226364e-07
were O 0 4.424060229268889e-09
observed O 0 4.926980068375997e-08
at O 0 8.731094425229458e-08
least O 0 2.193777959291765e-08
twice O 0 2.559782501521113e-07
. O 0 7.195878026777791e-08

The O 0 1.459938630432589e-06
BRCA1 O 0 5.481661355588585e-05
C4446T O 0 1.2202983270981349e-05
mutation O 0 5.5167474783957005e-06
was O 0 5.5118238861950886e-08
the O 0 1.8221771869164627e-09
most O 0 6.711756705968241e-10
common O 0 4.8970161259376255e-09
mutation O 0 9.014814850161201e-08
found O 0 5.504886768648021e-09
, O 0 3.5686073540652785e-10
followed O 0 4.994382241108042e-09
by O 0 1.8603718565657346e-09
the O 0 4.3569027496914714e-08
BRCA2 O 0 3.5182431020075455e-05
8765delAG O 0 1.2904578397865407e-05
mutation O 0 1.690641511231661e-05
. O 0 7.84473343173886e-07

Together O 0 3.4595760212141613e-07
, O 0 7.565430948375251e-09
these O 0 1.2620118283734882e-09
mutations O 0 5.6256290292822086e-08
were O 0 1.4598995345949106e-09
found O 0 1.43549594433523e-09
in O 0 2.2828776646832694e-09
28 O 0 5.896662713666956e-09
of O 0 7.868896506613154e-11
41 O 0 4.802968245343209e-09
families O 0 1.826630235957083e-10
identified O 0 9.98668814311543e-10
to O 0 8.059686251726816e-10
have O 0 6.618573467065403e-10
a O 0 2.221225692267126e-08
mutation O 0 1.3482873555403785e-06
. O 0 7.628494813616271e-08

The O 0 4.1011762164089305e-07
odds O 0 1.248984290214139e-06
of O 0 9.573725145983758e-10
detection O 0 2.6796111995963656e-08
of O 0 3.1563027191872095e-10
any O 0 2.5298990680155953e-10
of O 0 9.609376488972643e-11
the O 0 2.132568788226763e-09
four O 0 9.973215142622394e-09
BRCA1 O 0 6.7523837969929446e-06
mutations O 0 1.3641389386975789e-06
was O 0 4.426653958944371e-07
18 O 0 1.6194093177546165e-07
. O 0 9.092678254774e-08

7x O 0 0.000934162933845073
greater O 0 5.286539135340718e-07
if O 0 1.7408117614081675e-08
one O 0 1.5994090496462832e-09
or O 0 7.004193336435094e-10
more O 0 1.2793496817486982e-10
cases O 0 3.3314462299927072e-09
of O 0 2.4025048332987353e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 6.709151278982972e-08
also O 0 1.4961457628359653e-09
present O 0 5.765604105256728e-10
in O 0 1.4809617976396794e-09
the O 0 6.200985058768538e-09
family O 0 8.772241955057325e-08
. O 0 5.0218570635252036e-08

The O 0 1.1158185770909768e-06
odds O 0 1.37962672397407e-06
of O 0 2.3185668940328696e-09
detection O 0 5.677250314306548e-08
of O 0 4.360364846967002e-10
any O 0 2.7242993971832163e-10
of O 0 6.787217315951111e-11
the O 0 1.4836306627685758e-09
four O 0 1.1921360787425783e-08
BRCA2 O 0 5.880351636733394e-06
mutations O 0 7.778847361805674e-07
was O 0 2.880781266867416e-07
5 O 0 1.6283638615277596e-07
. O 0 1.1611338379680092e-07

3x O 0 0.00017498026136308908
greater O 0 3.0807629514129076e-07
if O 0 1.1689040846363241e-08
there O 0 8.816448682225086e-10
were O 0 5.655488855005331e-10
at O 0 1.3465600856576998e-09
least O 0 2.2541338240422704e-10
five O 0 7.545651603546588e-11
cases O 0 2.8998131673674266e-10
of O 0 3.662836922657675e-09
breast B-Disease 1 0.5538920164108276
cancer I-Disease 0 2.082435685224482e-06
in O 0 8.207218016309525e-09
the O 0 3.273049387075844e-08
family O 0 2.2854301562347246e-07
. O 0 6.617834458211291e-08

Interestingly O 0 9.859753845375963e-06
, O 0 1.0783164583472171e-08
the O 0 7.763116260939285e-10
presence O 0 1.4534508041563754e-09
of O 0 2.7720237216755095e-10
a O 0 1.8817499380929803e-07
breast B-Disease 0 0.19536525011062622
cancer I-Disease 0 1.5975003861967707e-06
case O 0 3.73970827638459e-08
< O 0 7.275287572383604e-08
36 O 0 7.507615862323291e-09
years O 0 6.564813137543979e-10
of O 0 2.422357869846792e-10
age O 0 1.2927882764302012e-08
was O 0 1.145041128580715e-08
strongly O 0 1.0392403382297744e-08
predictive O 0 3.1550179357964225e-08
of O 0 1.482314687661912e-10
the O 0 3.559430250543727e-10
presence O 0 5.205580966283208e-10
of O 0 6.170386424031449e-11
any O 0 1.1309272962556349e-10
of O 0 4.5991408598178296e-11
the O 0 1.0322642740590027e-09
eight O 0 4.400050990227555e-09
mutations O 0 4.1471460576758545e-07
screened O 0 1.0387824431745685e-06
. O 0 1.1887555473322209e-07

Carriers O 0 2.4400430902460357e-06
of O 0 4.351593752005556e-09
the O 0 3.7119840534671766e-09
same O 0 4.134648179388023e-09
mutation O 0 2.6139359121657435e-08
, O 0 1.990324988154768e-10
from O 0 1.0169987768593458e-10
different O 0 1.9032063425239443e-10
families O 0 2.1930143812021186e-10
, O 0 8.361408093682243e-11
shared O 0 6.099792893010658e-10
similar O 0 5.641701328329418e-09
haplotypes O 0 1.915277181296915e-07
, O 0 3.8032285654132636e-10
indicating O 0 5.063790275983138e-09
that O 0 1.4035907158760352e-10
the O 0 3.3946251365435387e-10
mutant O 0 1.661880055792153e-08
alleles O 0 5.770117272874131e-09
were O 0 5.630088617536444e-10
likely O 0 1.314835240684431e-09
to O 0 4.217546312190734e-10
be O 0 2.482831440442368e-10
identical O 0 9.652683097272075e-09
by O 0 3.2052613341271297e-10
descent O 0 3.2814237993505913e-09
for O 0 2.1042600995002658e-10
a O 0 4.313514878617752e-09
mutation O 0 6.907733762773205e-08
in O 0 2.566106216406183e-09
the O 0 4.5443151464041875e-09
founder O 0 9.925151545076005e-08
population O 0 1.1164870805657756e-08
. O 0 3.7838916000509926e-08

The O 0 1.7488596881776175e-07
identification O 0 3.7708296929395146e-08
of O 0 1.3159114908845027e-09
common O 0 4.43769394564697e-08
BRCA1 O 0 6.439049684558995e-06
and O 0 5.9254379181084005e-08
BRCA2 O 0 9.672914529801346e-06
mutations O 0 3.6261019431549357e-07
will O 0 2.8456046408109614e-09
facilitate O 0 9.816254475936148e-09
carrier O 0 6.621331749556703e-08
detection O 0 3.3726085035823417e-08
in O 0 5.174114914296979e-09
French O 0 2.964312386666279e-07
Canadian O 0 1.1623214959399775e-05
breast B-Disease 1 0.8257230520248413
cancer I-Disease 0 0.0009394102380611002
and O 0 0.005080255679786205
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.894898660902982e-07
. O 0 3.7592073454106867e-07

Are O 0 6.325968797682435e-07
Dp71 O 0 2.0498324374784715e-05
and O 0 5.6668106651613925e-08
Dp140 O 0 1.1841727427963633e-05
brain O 0 3.653298699646257e-05
dystrophin O 0 5.3465824748855084e-05
isoforms O 0 1.11217036646849e-06
related O 0 1.125102642163256e-07
to O 0 6.516091843877803e-08
cognitive B-Disease 0 8.336413884535432e-06
impairment I-Disease 0 5.347469777916558e-05
in O 0 7.222293061204255e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 0 0.0005036071524955332

Molecular O 0 1.6367213902412914e-05
study O 0 5.474983026942937e-07
and O 0 6.225970139439596e-08
neuropsychological O 0 2.803713186949608e-06
analysis O 0 2.254054365380398e-08
were O 0 9.364145014956193e-09
performed O 0 2.3228970746913546e-08
concurrently O 0 1.3277086097218671e-08
on O 0 2.564267909122009e-08
49 O 0 1.3857778924375452e-07
patients O 0 4.122743746393098e-08
with O 0 5.184234055377601e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.8322296455153264e-05
DMD B-Disease 1 1.0
) O 0 3.9188815748048e-08
in O 0 8.804824425112656e-09
order O 0 1.5769148209443529e-09
to O 0 4.236864470374968e-10
find O 0 2.752860717158967e-10
a O 0 3.5426400701865646e-10
molecular O 0 3.6670801950577925e-09
explanation O 0 1.3412003729840194e-09
for O 0 2.2486458528536701e-10
the O 0 7.245400723832063e-09
cognitive B-Disease 0 4.2314053416703246e-07
impairment I-Disease 0 1.3347603555757814e-07
observed O 0 7.049379746604245e-08
in O 0 3.176659291170836e-08
most O 0 5.131640250510827e-07
DMD B-Disease 1 1.0
patients O 0 2.335320459678769e-05
. O 0 3.809229554008198e-07

Complete O 0 1.099033966056595e-06
analysis O 0 7.641426691407105e-08
of O 0 1.279137906706751e-09
the O 0 5.615731435426596e-09
dystrophin O 0 9.402138857694808e-06
gene O 0 6.331297868200636e-07
was O 0 6.605992552977114e-08
performed O 0 2.3302188623119946e-08
to O 0 9.40446831521058e-10
define O 0 6.423478193795518e-09
the O 0 1.27658605908465e-09
localization O 0 3.8971162297229966e-08
of O 0 2.715417890541971e-10
deletions O 0 1.2175102881428757e-07
and O 0 1.8575635474249452e-09
duplications O 0 1.7463730728195515e-07
in O 0 3.4842342344632016e-09
relation O 0 3.631720035812691e-09
to O 0 1.955365647177132e-09
the O 0 1.2950464700622888e-08
different O 0 8.229245196389456e-08
DMD B-Disease 1 0.9999996423721313
promoters O 0 1.4399618521565571e-05
. O 0 3.271782702540804e-07

Qualitative O 0 5.2839704949292354e-06
analysis O 0 2.623664272505266e-07
of O 0 2.0496120356483516e-09
the O 0 1.1557311552223837e-08
Dp71 O 0 2.6204263576801168e-06
transcript O 0 6.6517382038000505e-06
and O 0 2.9157709580118762e-09
testing O 0 4.697088495930757e-09
for O 0 7.884716490824673e-11
the O 0 1.6874568409264157e-10
specific O 0 4.1013983875792803e-10
first O 0 1.8675390123235047e-09
exon O 0 7.206014629446145e-08
of O 0 6.86133483362994e-10
Dp140 O 0 9.776515241810557e-08
were O 0 4.606880210644704e-09
also O 0 2.114706187938964e-09
carried O 0 3.295883743703598e-08
out O 0 3.0529477612617484e-08
. O 0 4.387968033370271e-08

Neuropsychological O 0 0.0006442213198170066
analysis O 0 2.7687485726346495e-06
assessed O 0 1.377276134917338e-06
verbal O 0 2.4649000351928407e-06
and O 0 1.5608054582116893e-07
visuospatial O 0 2.1875513994018547e-05
intelligence O 0 9.905093065754045e-07
, O 0 1.1502859109668861e-08
verbal O 0 3.9253006889339304e-07
memory O 0 0.005445441231131554
, O 0 1.1600243432496882e-08
and O 0 7.3725794358381336e-09
reading O 0 8.209020165850234e-07
skills O 0 2.2985166481248598e-07
. O 0 8.382578187138279e-08

Comparison O 0 2.0820862118853256e-06
of O 0 1.4132144343648179e-08
molecular O 0 2.8315736244621803e-07
and O 0 1.3252899222493397e-08
psychometric O 0 2.771723075056798e-06
findings O 0 1.3367017004384252e-07
demonstrated O 0 2.7812255609660497e-08
that O 0 8.134155016215061e-10
deletions O 0 1.9480300750274182e-07
and O 0 4.1181520415989326e-09
duplications O 0 1.369740232348704e-07
that O 0 4.5051490316083687e-10
were O 0 1.3465754067354396e-09
localized O 0 1.0487129031844233e-07
in O 0 1.1086144446892376e-08
the O 0 6.740780378322597e-09
distal O 0 9.584821327734971e-07
part O 0 2.1709332109765e-09
of O 0 7.877636043485126e-11
the O 0 8.094843129136109e-10
gene O 0 2.712273428073786e-08
seemed O 0 5.896955368456247e-09
to O 0 6.322598000707558e-10
be O 0 3.216978072817511e-10
preferentially O 0 1.0975141684355094e-08
associated O 0 6.919532946625395e-09
with O 0 3.756334354676483e-09
cognitive B-Disease 0 2.2856293071527034e-06
impairment I-Disease 0 2.9118655220372602e-06
. O 0 2.3446555985628947e-07

Two O 0 4.825835731026018e-07
altered O 0 7.466657280019717e-06
Dp71 O 0 1.719155625323765e-05
transcripts O 0 1.7774791558622383e-06
and O 0 6.847519440356109e-09
two O 0 2.596334924831467e-09
deleted O 0 1.9473074530651502e-07
Dp140 O 0 2.1383213777426135e-07
DNA O 0 5.1605269391075126e-08
sequences O 0 4.560980926271441e-08
were O 0 4.555128274574827e-09
found O 0 2.091337103493629e-09
in O 0 2.015831723767292e-09
four O 0 4.602401126874156e-09
patients O 0 3.000547366127648e-08
with O 0 8.753088565072176e-08
severe O 1 0.9999433755874634
cerebral B-Disease 1 0.9999947547912598
dysfunction I-Disease 1 0.8956764936447144
. O 0 2.2911333417141577e-06

These O 0 2.1317855214419978e-07
findings O 0 1.4441920370700245e-07
suggest O 0 3.2747852429793056e-08
that O 0 6.537223540270531e-10
some O 0 4.074164061673713e-10
sequences O 0 1.2962944495598094e-08
located O 0 4.15834513489699e-08
in O 0 2.529948472940191e-09
the O 0 2.2977784119859734e-09
distal O 0 1.83444313961445e-07
part O 0 1.7260222140436099e-09
of O 0 6.537295010877742e-11
the O 0 6.225548965232974e-10
gene O 0 1.0465205591003723e-08
and O 0 2.5453922303242393e-10
, O 0 4.370737799463953e-11
in O 0 1.733444637830317e-10
particular O 0 8.803896500708674e-10
, O 0 2.2818881506569966e-10
some O 0 7.815053604254274e-10
DMD B-Disease 1 0.9999836683273315
isoforms O 0 6.152214382382226e-08
expressed O 0 1.1279119860319042e-09
in O 0 1.4525389779862508e-09
the O 0 9.01063312852557e-09
brain O 0 4.678798723034561e-05
may O 0 1.3118054198457685e-07
be O 0 2.2000359867213604e-10
related O 0 2.985604263816555e-10
to O 0 4.422134325388072e-10
the O 0 7.721976835739497e-09
cognitive B-Disease 0 6.695383945043432e-07
impairment I-Disease 0 4.53136948408428e-07
associated O 0 1.3786598174192477e-07
with O 0 2.3214538202864787e-07
DMD B-Disease 1 1.0
. O 0 1.1268228661265312e-07
. O 0 1.0664800953463782e-07

I1307K O 0 0.000435100169852376
APC O 0 7.136686326703057e-05
and O 0 1.489203071969314e-07
hMLH1 O 0 3.989841388829518e-06
mutations O 0 2.994209580720053e-06
in O 0 9.614629092880023e-09
a O 0 7.2441430631897674e-09
non O 0 1.7729806955912863e-08
- O 0 2.0940349543252523e-07
Jewish O 0 3.053041197631501e-08
family O 0 1.2720512643227266e-08
with O 0 2.7545690173269577e-09
hereditary B-Disease 0 0.01271103322505951
non I-Disease 0 0.0003332968626637012
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 9.663860510045197e-06

We O 0 3.584236196729762e-07
describe O 0 1.4319984131816454e-07
a O 0 2.3123233106048247e-08
French O 0 1.587420968007791e-07
Canadian O 0 6.548561373165285e-07
hereditary B-Disease 0 0.03581563010811806
non I-Disease 0 0.0006646353867836297
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 7.823933265171945e-05
HNPCC B-Disease 1 0.8022298812866211
) O 0 9.038366499680706e-08
kindred O 0 1.796234187168011e-06
which O 0 6.219118997563555e-09
carries O 0 1.6036558747600793e-08
a O 0 7.740247554011148e-09
novel O 0 5.376640999088522e-08
truncating O 0 2.5327608454972506e-06
mutation O 0 2.2660760805592872e-06
in O 0 8.375067039878559e-08
hMLH1 O 0 1.5261495718732476e-05
. O 0 3.9706011989437684e-07

Interestingly O 0 4.141912722843699e-05
, O 0 8.912832072383026e-08
the O 0 2.8997996892599076e-08
I1307K O 0 2.3966692879184848e-06
APC O 0 9.432164347344951e-07
polymorphism O 0 1.0000951533584157e-06
, O 0 2.2046577896617237e-09
associated O 0 2.0356178964675564e-09
with O 0 2.76202255511393e-10
an O 0 7.642425026155308e-10
increased O 0 1.4928491509635933e-07
risk O 0 1.6844925312398118e-06
of O 0 0.0007542517851106822
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 3.196393905113837e-08
is O 0 1.7614889546990753e-09
also O 0 8.503102111312444e-10
present O 0 4.900956862563532e-10
in O 0 9.985201554485457e-10
this O 0 1.4870418230117366e-09
family O 0 5.36523891980778e-08
. O 0 2.3749731070665803e-08

The O 0 4.682622147811344e-07
I1307K O 0 5.438096195575781e-06
polymorphism O 0 6.937283160368679e-06
has O 0 2.3202623822271562e-08
previously O 0 4.727161329043383e-09
only O 0 4.191386682173004e-10
been O 0 8.140176865900628e-10
identified O 0 1.1386593889994856e-09
in O 0 4.8898735061087e-10
individuals O 0 5.336164843328106e-11
of O 0 2.152920619558074e-10
self O 0 1.356778369654421e-07
- O 0 8.392355994146783e-06
reported O 0 2.089170720864786e-06
Ashkenazi O 0 1.4544549458150868e-06
Jewish O 0 8.987602484467061e-08
origins O 0 6.525214644170774e-07
. O 0 2.247100923113976e-07

In O 0 1.1629268925616998e-07
addition O 0 8.319942956802606e-09
, O 0 5.835848471136273e-10
in O 0 1.053549691931721e-09
this O 0 6.457908652279798e-10
family O 0 1.208311584122157e-08
, O 0 2.468194537641466e-10
there O 0 2.318769065645654e-10
appears O 0 1.1324804205514738e-08
to O 0 1.063815702195825e-09
be O 0 2.7593896612110314e-10
no O 0 1.8472176566142195e-10
relationship O 0 3.636917156324415e-10
between O 0 3.0976640696955826e-10
the O 0 7.412422342589764e-10
I1307K O 0 4.753718840788679e-08
polymorphism O 0 2.582394031946933e-08
and O 0 3.64926477924854e-10
the O 0 2.493766304567657e-10
presence O 0 1.2364013146637376e-09
or O 0 2.7227264887130787e-09
absence O 0 2.0086352581216715e-09
of O 0 1.4330284736630006e-09
cancer B-Disease 0 4.6523669539055845e-07
. O 0 5.353715248901381e-09
. O 0 4.755342075668523e-08

Identification O 0 8.346615345544706e-07
of O 0 5.655427237627464e-09
a O 0 1.2679116423441883e-08
novel O 0 2.6864276136961962e-08
mutation O 0 9.882780460657159e-08
of O 0 8.788176297791495e-10
the O 0 6.649451211870883e-09
CPO O 0 1.20657591651252e-06
gene O 0 3.077315113841905e-08
in O 0 1.1756156048647881e-09
a O 0 4.400369846280228e-09
Japanese O 0 3.0153321972647973e-07
hereditary B-Disease 0 0.0002717345778364688
coproporphyria I-Disease 0 2.3813270672690123e-05
family O 0 4.5448723540175706e-07
. O 0 1.0227073943269716e-07

Hereditary B-Disease 1 0.999322772026062
coproporphyria I-Disease 1 0.6816675662994385
( O 0 1.558432813908439e-05
HCP B-Disease 0 0.024830179288983345
) O 0 2.2028640245252973e-08
is O 0 1.025171170176975e-09
an O 0 4.167696854295855e-09
autosomal B-Disease 1 0.9807503819465637
dominant I-Disease 1 0.9989226460456848
disease I-Disease 1 0.8149735927581787
characterized O 0 1.5632157328582252e-06
by O 0 1.2038487540166898e-08
a O 0 1.858090854511829e-06
deficiency B-Disease 0 0.0001790801907191053
of I-Disease 0 3.2754583489946754e-09
coproporphyrinogen I-Disease 0 5.5633521697018296e-05
oxidase I-Disease 0 1.1631986126303673e-05
( O 0 8.49119814461119e-08
CPO O 0 3.803584831985063e-06
) O 0 1.4426078109863738e-09
caused O 0 6.255988616032937e-09
by O 0 7.461203321845744e-10
a O 0 5.8955942350280566e-09
mutation O 0 1.453740594570263e-07
in O 0 1.0940969907835552e-08
the O 0 2.4752543126282944e-08
CPO O 0 9.078881703317165e-06
gene O 0 1.6069741377577884e-06
. O 0 1.0810186523713128e-07

Only O 0 4.91719788442424e-07
11 O 0 1.236558091477491e-07
mutations O 0 1.5373403527974006e-07
of O 0 4.96424512608229e-10
the O 0 2.1421244777997117e-09
gene O 0 7.935783941093177e-08
have O 0 1.385588976887675e-09
been O 0 3.0993556610070527e-09
reported O 0 5.322380047800834e-07
in O 0 4.3916276126765297e-07
HCP B-Disease 1 0.6225601434707642
patients O 0 2.0058605514350347e-06
. O 0 2.1518066262160573e-07

We O 0 7.555237857559405e-07
report O 0 1.3429345813165128e-07
another O 0 1.7362356885541885e-08
mutation O 0 1.978220325327129e-07
in O 0 6.638869454178575e-09
a O 0 1.1383255227315203e-08
Japanese O 0 2.3242914437560103e-07
family O 0 1.605681347882637e-07
. O 0 6.998110535505475e-08

Polymerase O 0 0.0005309853004291654
chain O 0 0.00027611208497546613
reaction O 0 9.506200512987562e-06
- O 0 8.461758625344373e-06
single O 0 1.6210658770887676e-07
strand O 0 1.3574529020843329e-06
conformational O 0 4.377886568818212e-07
polymorphism O 0 5.506107072505984e-07
and O 0 2.2969632862412936e-09
direct O 0 5.77023850922842e-09
sequence O 0 2.7972175686841183e-08
analyses O 0 4.2009794753994356e-08
demonstrated O 0 1.6824579063268175e-08
a O 0 1.664874993423382e-08
C O 0 1.6958174455794506e-06
to O 0 6.480480152504242e-09
T O 0 4.525677468336653e-07
substitution O 0 1.582097297614382e-08
in O 0 7.115813271951765e-09
exon O 0 2.41452852378643e-07
1 O 0 5.021308702168881e-09
of O 0 1.9883403257203724e-10
the O 0 2.7106481503835766e-09
CPO O 0 3.152414080886956e-07
gene O 0 2.4790768549109998e-08
at O 0 6.764091509126047e-09
nucleotide O 0 1.821597628293148e-08
position O 0 2.2979767422270925e-08
85 O 0 1.2402023408242258e-08
, O 0 4.955267307593658e-10
which O 0 3.920604674245709e-10
lies O 0 1.4686215576986683e-09
in O 0 9.07387331938736e-10
the O 0 2.9698616899054286e-09
putative O 0 7.105359145498369e-08
presequence O 0 1.0781914738799969e-07
for O 0 6.377621208919493e-10
targeting O 0 3.693503813906318e-08
to O 0 1.0971521469116396e-08
mitochondria O 0 2.6846612399822334e-06
. O 0 1.571749947970602e-07

This O 0 2.0325776972640597e-07
mutation O 0 1.8367695702181663e-06
changes O 0 7.067190921361544e-08
the O 0 1.2118520409387656e-08
codon O 0 6.283399898165953e-07
for O 0 1.1267036192919022e-09
glutamine O 0 1.2575330288200348e-07
to O 0 1.6771768418522015e-09
a O 0 8.237815762868195e-09
termination O 0 4.365703887287964e-07
codon O 0 2.37763492805243e-06
at O 0 7.807582136365454e-08
amino O 0 1.625964642926192e-07
acid O 0 5.251189918453747e-07
position O 0 7.913132549219881e-07
29 O 0 1.6838212104630657e-06
. O 0 1.3541088605961704e-07

MaeI O 0 0.00014145438035484403
restriction O 0 2.03473177862179e-06
analysis O 0 1.576699588667907e-07
showed O 0 9.332250527904762e-08
two O 0 4.141852694150572e-10
other O 0 2.453278691305627e-10
carriers O 0 4.398700070851191e-09
in O 0 1.5061957236994772e-09
the O 0 7.607930285757902e-09
family O 0 7.233445842302899e-08
. O 0 4.1988087673416885e-08

The O 0 3.4473678169888444e-06
C O 0 0.01615157537162304
- O 0 0.001332040294073522
T O 0 0.00042029403266496956
mutation O 0 1.4326104746942292e-06
is O 0 2.095841500349138e-09
located O 0 6.2688414459444175e-09
within O 0 8.432040066175261e-10
a O 0 4.1104457615404044e-09
recently O 0 4.328475355919181e-08
proposed O 0 1.4482574250962443e-08
putative O 0 1.3854025837645167e-07
alternative O 0 2.749819927316821e-08
translation O 0 1.1583533421344328e-07
initiation O 0 1.0873133504674115e-07
codon O 0 2.893082182708895e-06
( O 0 3.398768555484821e-08
TIC O 0 4.793489551957464e-06
- O 0 1.783588686521398e-06
1 O 0 2.4948249688350188e-08
) O 0 7.741365326552341e-10
, O 0 1.1904034702414634e-10
supporting O 0 7.290755776878655e-10
that O 0 8.066776691073585e-10
TIC O 0 2.531094878577278e-06
- O 0 1.0359906355006387e-06
1 O 0 1.5432094713219158e-08
is O 0 3.88524462602291e-10
the O 0 1.1437265579061773e-09
real O 0 2.097826090619037e-08
TIC O 0 7.865349402891297e-07
rather O 0 1.558811568713736e-08
than O 0 7.3797830069111114e-09
TIC O 0 3.971641945099691e-06
- O 0 7.849492931200075e-07
2 O 0 2.5980602558206556e-08
. O 0 4.055945801439975e-09
. O 0 3.9203843726909327e-08

Human B-Disease 0 4.335947778599802e-06
complement I-Disease 0 4.986436124454485e-06
factor I-Disease 0 1.6465750377392396e-05
H I-Disease 1 1.0
deficiency I-Disease 1 0.996921718120575
associated O 0 5.609852905763546e-06
with O 0 4.0167895349441096e-05
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.38976972468663e-05

This O 0 1.4744863108262507e-07
study O 0 1.8532965384565614e-08
reports O 0 3.7348467429865195e-08
on O 0 3.140272752943929e-08
six O 0 3.3902465279567195e-09
cases O 0 2.77921974323192e-09
of O 0 4.007943310568862e-09
deficiency B-Disease 0 1.2511081877164543e-05
in I-Disease 0 1.91793336767887e-09
the I-Disease 0 1.4304888384941705e-09
human I-Disease 0 2.7835487248495383e-09
complement I-Disease 0 2.7859083928660766e-08
regulatory I-Disease 0 3.4178034979959193e-07
protein I-Disease 0 5.401983003139321e-07
Factor I-Disease 0 3.7631062355103495e-07
H I-Disease 1 0.9999998807907104
( O 0 3.94904219547243e-07
FH O 0 6.728267180733383e-05
) O 0 9.195221251090402e-10
in O 0 5.477140407883496e-10
the O 0 3.400678072473795e-10
context O 0 1.1461396276502e-09
of O 0 3.4010802507644655e-10
an O 0 6.121324958030527e-08
acute B-Disease 1 0.9998427629470825
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.0022472451964859e-05

Five O 0 2.2809274469182128e-07
of O 0 3.1125546584576114e-09
the O 0 2.6149817866638614e-09
cases O 0 1.2377723290768472e-09
were O 0 1.2581807817824142e-09
observed O 0 7.48152828577986e-09
in O 0 7.0497399029534336e-09
children O 0 5.427040594696564e-09
presenting O 0 1.1396163301924389e-07
with O 0 3.921389634342631e-06
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00022690073819831014
HUS B-Disease 1 0.9999922513961792
) O 0 1.323104697803501e-06
. O 0 7.210097123788728e-07

Two O 0 7.069429130979188e-08
of O 0 1.39286771005942e-09
the O 0 3.649245794434819e-09
children O 0 2.054210801460954e-09
exhibited O 0 6.236702176920517e-08
a O 0 7.37723837573867e-08
homozygous O 0 0.03648173063993454
deficiency O 0 0.0004220163682475686
characterized O 0 5.249176737720518e-08
by O 0 2.5061126507353038e-09
the O 0 7.286116598947956e-09
absence O 0 4.798636599190331e-09
of O 0 1.465562393665465e-10
the O 0 2.308844893050832e-09
150 O 0 1.1169471569871803e-08
- O 0 1.2798639659195032e-07
kD O 0 2.2485392037197016e-07
form O 0 1.7803942764516023e-09
of O 0 5.602921460123866e-10
Factor O 0 2.1833546526295322e-08
H O 1 0.999963641166687
and O 0 1.2296259566113577e-09
the O 0 4.793813679349057e-10
presence O 0 8.098379744581052e-10
, O 0 1.4300570450043182e-10
upon O 0 6.51183662547794e-10
immunoblotting O 0 7.460413087301276e-08
, O 0 1.369032942566406e-10
of O 0 5.484016019075e-11
the O 0 2.81422862791203e-09
42 O 0 6.976227240329536e-08
- O 0 4.2759671714520664e-07
kD O 0 3.0543189950549277e-06
Factor O 0 1.803875022687862e-07
H O 1 0.9998059868812561
- O 0 4.796754637936829e-07
like O 0 1.580293940151023e-08
protein O 0 6.606937574815674e-08
1 O 0 3.774809087531139e-08
( O 0 1.813022265650943e-08
FHL O 0 7.125280717446003e-06
- O 0 4.37884722259696e-07
1 O 0 1.2611703681386643e-08
) O 0 5.418856474648237e-10
and O 0 3.5056371694430766e-10
other O 0 1.3209534577285353e-09
FH O 0 1.887284633994568e-05
- O 0 3.111129558419634e-07
related O 0 5.158174687380779e-08
protein O 0 1.1043327674542525e-07
( O 0 9.589501637208286e-09
FHR O 0 1.995327011172776e-06
) O 0 6.5110956626313055e-09
bands O 0 2.5677141479718557e-07
. O 0 9.922236898773917e-08

Southern O 0 9.065713129530195e-06
blot O 0 0.00047676966642029583
and O 0 7.302940474573916e-08
PCR O 0 4.0488939703209326e-06
analysis O 0 1.8818390401520446e-08
of O 0 2.4620538940922643e-10
DNA O 0 6.761898596607807e-09
of O 0 3.199678300092046e-10
one O 0 9.900280595331878e-10
patient O 0 7.840322524543808e-08
with O 0 4.7640032363460705e-08
homozygous O 0 0.433456152677536
deficiency O 0 0.01739426702260971
ruled O 0 6.774914140805777e-08
out O 0 1.2422708417503259e-09
the O 0 3.0139718498745083e-10
presence O 0 4.35046276781037e-10
of O 0 1.801372419285574e-11
a O 0 1.5990055113324075e-10
large O 0 2.258988690551078e-10
deletion O 0 1.2181089914520271e-08
of O 0 1.2954033679069e-10
the O 0 6.633983584691805e-09
FH O 0 5.715784482163144e-06
gene O 0 2.4601316539474283e-08
as O 0 4.4003681254345395e-10
the O 0 1.5343626369457297e-09
underlying O 0 1.5869940739321464e-07
defect O 0 3.1215699891617987e-07
for O 0 2.8328026591140087e-09
the O 0 6.18012961695058e-07
deficiency O 0 0.00033987738424912095
. O 0 2.4562456246712827e-07

The O 0 1.0725489119067788e-07
other O 0 1.4902531431104649e-09
four O 0 1.5259048469218328e-09
children O 0 1.1263039390030372e-09
presented O 0 7.491852471730454e-09
with O 0 4.0093521391781906e-08
heterozygous O 1 0.6791418790817261
deficiency O 0 0.00703829200938344
and O 0 8.253810968028574e-09
exhibited O 0 5.676421892530925e-07
a O 0 1.655527270827406e-08
normal O 0 1.341410438726598e-06
immunoblotting O 0 5.566939307755092e-06
pattern O 0 3.046921790428314e-07
of O 0 2.030281359699515e-10
proteins O 0 2.949533728369147e-09
of O 0 3.7618533288430456e-10
the O 0 4.181665147484637e-08
FH O 0 0.00039019822725094855
family O 0 1.9829536768156686e-07
. O 0 1.1118632414763852e-07

Factor B-Disease 0 0.006295600440353155
H I-Disease 1 1.0
deficiency I-Disease 1 0.9996432065963745
is O 0 1.2972591001414457e-08
the O 0 7.664733736589824e-09
only O 0 4.6873001480207677e-08
complement B-Disease 1 0.9999997615814209
deficiency I-Disease 1 1.0
associated O 0 1.9766362413520255e-07
with O 0 9.2146464680809e-08
HUS B-Disease 1 0.9999595880508423
. O 0 1.7276952348765917e-06

These O 0 1.8407151003430045e-07
observations O 0 6.600085953323287e-07
suggest O 0 6.42388542360095e-08
a O 0 5.4163584728428305e-09
role O 0 1.1457030879569174e-08
for O 0 4.705301925866934e-09
FH O 0 0.00012842229625675827
and O 0 3.7596908697423714e-08
/ O 0 2.4593946363893338e-05
or O 0 2.7717604211829894e-07
FH O 0 8.872562466422096e-05
receptors O 0 2.4193226977331506e-07
in O 0 1.4522240299186251e-08
the O 0 1.6376947797880348e-08
pathogenesis O 0 3.357107971169171e-06
of O 0 3.27466054272918e-08
idiopathic O 0 0.010715354233980179
HUS B-Disease 1 0.9995786547660828
. O 0 3.2155034546121897e-07
. O 0 5.926997346250573e-07

Further O 0 3.0028320452402113e-07
evidence O 0 1.8351808961369898e-08
for O 0 7.526738676766342e-10
a O 0 8.830383646518669e-10
major O 0 1.8367208864944473e-09
ancient O 0 2.9509475751865466e-08
mutation O 0 2.748945917119272e-05
underlying O 0 0.001112390193156898
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 3.687925413942139e-07
linkage O 0 1.3262024367577396e-05
disequilibrium O 0 1.1206964700249955e-05
studies O 0 3.0723416699629524e-08
in O 0 2.8904936222318156e-09
the O 0 2.339565430276025e-09
Japanese O 0 4.029991274023814e-08
population O 0 1.0095974722901246e-08
. O 0 3.7065522207058166e-08

The O 0 0.0004094214818906039
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.7592291831970215
DM B-Disease 1 1.0
) O 0 5.253423864814977e-07
mutation O 0 3.5151865631632973e-06
is O 0 1.1071964678421864e-08
an O 0 7.579989969030976e-09
unstable O 0 0.00011998350964859128
( O 0 7.16088308649887e-08
CTG O 0 3.144749598504859e-06
) O 0 8.560893327569374e-09
n O 0 9.716173821061602e-08
repeat O 0 1.4882745347222226e-07
, O 0 7.61633311974208e-10
present O 0 1.5679113563038527e-09
at O 0 1.065782218034883e-08
a O 0 2.708126389805443e-09
copy O 0 1.398008606656731e-07
number O 0 2.988213287924424e-10
of O 0 2.2593980852914086e-10
5 O 0 1.965248763724503e-08
- O 0 4.984079282621678e-07
37 O 0 1.0563395136387044e-07
repeats O 0 3.931444609861501e-07
on O 0 1.5687138699149727e-08
normal O 0 8.442814447562341e-08
chromosomes O 0 3.0936874395592895e-08
but O 0 1.3351155736529563e-09
amplified O 0 1.3880952565159532e-07
to O 0 1.5634379346707306e-09
50 O 0 4.62774352172346e-09
- O 0 2.1507352343519415e-08
3000 O 0 3.199742693027474e-08
copies O 0 7.2960872898875095e-09
on O 0 7.931333243504923e-07
DM B-Disease 1 0.9999998807907104
chromosomes O 0 2.6722341317508835e-06
. O 0 1.4699905648285494e-07

Previous O 0 1.2810786756745074e-05
findings O 0 2.0844822756771464e-06
in O 0 1.2170876573236455e-07
Caucasian O 0 1.5980109537849785e-06
populations O 0 1.1602947580513501e-07
of O 0 7.021264458728638e-09
a O 0 1.3218057119956939e-06
DM B-Disease 1 1.0
founder O 0 2.9943610115878982e-06
chromosome O 0 1.8967559753946261e-06
raise O 0 5.638928612938798e-08
a O 0 3.6801619529569507e-09
question O 0 1.1476796180076576e-09
about O 0 1.9182504196191275e-10
the O 0 2.2606783112166795e-10
molecular O 0 3.361118494638049e-09
events O 0 1.0786698201314948e-09
involved O 0 6.439704325345019e-10
in O 0 8.558831976479553e-10
the O 0 3.090306677222543e-09
expansion O 0 1.2739822352614283e-07
mutation O 0 1.730537860566983e-06
. O 0 1.636970949903116e-07

To O 0 3.03739994933494e-07
investigate O 0 1.5443775680523686e-07
whether O 0 8.342460056098844e-09
a O 0 9.160284974996102e-09
founder O 0 5.685909343355888e-08
chromosome O 0 1.590336466961162e-07
for O 0 9.465924710738705e-10
the O 0 1.3938603160568164e-07
DM B-Disease 1 1.0
mutation O 0 7.912030923762359e-07
exists O 0 6.151438025625566e-09
in O 0 9.994081118236409e-10
the O 0 4.2446457459988096e-10
Japanese O 0 3.606820175861003e-09
population O 0 4.201985148721832e-10
, O 0 1.828310280949097e-10
we O 0 4.0358641428817066e-10
genotyped O 0 9.424712743566488e-08
families O 0 1.175978980860748e-09
using O 0 1.1259544407948852e-08
polymorphic O 0 1.729940436234756e-06
markers O 0 3.1095959229787695e-07
near O 0 5.275212515698513e-07
the O 0 5.107832379280808e-08
( O 0 2.320514624898351e-08
CTG O 0 1.6090413055280806e-06
) O 0 1.0156273155814688e-08
n O 0 2.127812734897816e-07
repeat O 0 3.3360646511937375e-07
region O 0 4.8021277621046465e-08
and O 0 1.5622969584683233e-08
constructed O 0 1.3485624776876648e-06
haplotypes O 0 1.7600694263819605e-05
. O 0 3.3778624697333726e-07

Six O 0 2.253272555208241e-07
different O 0 2.2782026931622568e-08
haplotypes O 0 1.0091009698953712e-06
were O 0 1.2233617674439756e-08
found O 0 1.866261634120292e-08
and O 0 1.8796012568600418e-07
DM B-Disease 1 1.0
alleles O 0 3.2903615192481084e-06
were O 0 2.1128080618382228e-08
always O 0 2.6730925029028185e-08
haplotype O 0 3.217845460312674e-06
A O 0 2.3735269394364877e-07
. O 0 2.623466741624725e-07

To O 0 2.058729080545163e-07
find O 0 1.565718577012376e-08
an O 0 6.021649290310904e-10
origin O 0 7.793916068088436e-10
of O 0 1.9784365812292037e-10
the O 0 5.71162406259873e-09
( O 0 1.1432931046329031e-08
CTG O 0 7.490925781894475e-07
) O 0 3.153500127694997e-09
n O 0 1.1892896623066918e-07
repeat O 0 4.303433911445609e-07
mutation O 0 2.1935233007752686e-07
and O 0 4.0123793176860545e-09
to O 0 1.4903583922531993e-09
investigate O 0 5.496944233129852e-09
the O 0 1.1485730144755735e-09
mechanism O 0 3.4198683884767433e-09
of O 0 6.138293345836487e-11
the O 0 3.8969485971485085e-10
expansion O 0 4.22439949687714e-09
mutation O 0 1.302512764311814e-08
in O 0 9.679318457855857e-10
the O 0 9.680648505039358e-10
Japanese O 0 9.713612136863503e-09
population O 0 9.410963119904636e-10
we O 0 2.4805785203696473e-10
have O 0 1.3285027244958059e-10
studied O 0 2.4292161615591112e-09
90 O 0 7.2170300846607915e-09
Japanese O 0 7.795281362632522e-07
DM B-Disease 1 1.0
families O 0 2.0194578453924805e-08
comprising O 0 3.9127105999625655e-09
190 O 0 3.599358677774944e-08
affected O 0 2.1345639922287774e-08
and O 0 4.300773071008734e-09
130 O 0 6.762855520037192e-08
unaffected O 0 1.7886153500512592e-06
members O 0 2.3002394655691205e-08
. O 0 6.849781897244611e-08

The O 0 3.257942751133669e-07
results O 0 1.8170767646097374e-07
suggest O 0 1.9172830434399657e-08
that O 0 2.985308111824736e-10
a O 0 7.378737620911124e-10
few O 0 1.4828160921354083e-09
common O 0 2.483495853411455e-09
ancestral O 0 4.1220200586167266e-08
mutations O 0 9.743676798734668e-08
in O 0 1.6537340385980315e-09
both O 0 1.9283763474930993e-09
Caucasian O 0 4.277941556551923e-08
and O 0 1.2052634446035881e-09
Japanese O 0 8.94238816329107e-09
populations O 0 3.566323014680961e-09
have O 0 1.5093007399435976e-10
originated O 0 1.2763425871753498e-09
by O 0 1.402739591149782e-10
expansion O 0 9.308208648306504e-10
of O 0 4.267022846171642e-11
an O 0 2.446073621431566e-10
ancestral O 0 3.619184951730858e-08
n O 0 1.7976172728140227e-07
= O 0 1.0590731847059942e-07
5 O 0 1.589908116272909e-08
repeat O 0 1.9279843854747014e-07
to O 0 1.5126627062045372e-08
n O 0 6.017062332830392e-07
= O 0 6.091962632126524e-07
19 O 0 1.6305331485000352e-07
- O 0 2.8564826948240807e-07
37 O 0 1.0062662170184922e-07
copies O 0 5.4089593248818346e-08
. O 0 7.236634047558255e-08

These O 0 1.5056096458465618e-07
data O 0 1.1473436245523772e-07
support O 0 8.246823668400793e-09
multistep O 0 7.447304142260691e-07
models O 0 1.189442784266248e-07
of O 0 3.5381038099302486e-09
triplet O 0 2.4470211428706534e-05
repeat O 0 7.289573318303155e-07
expansion O 0 4.115437235441277e-08
that O 0 5.701683014613934e-10
have O 0 1.5687691423682537e-10
been O 0 1.1816690681509812e-10
proposed O 0 6.262277363333624e-10
for O 0 6.559681131612649e-10
both O 0 4.997291114250402e-08
DM B-Disease 1 1.0
and O 0 5.155844178261759e-07
Friedreichs B-Disease 0 0.0005660609458573163
ataxia I-Disease 1 0.7740331888198853
. O 0 5.990392537569278e-08
. O 0 1.2085227751867933e-07

The O 0 2.9452860417222837e-07
molecular O 0 5.160782734492386e-07
basis O 0 1.5746441306419e-07
of O 0 6.386611062225711e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.90658369092489e-08
the O 0 5.8005729108856485e-09
western O 0 4.648588358691086e-08
Cape O 0 8.19856722955592e-07
, O 0 1.2684648886818195e-09
South O 0 1.0421383755954139e-08
Africa O 0 5.427996185858319e-08
. O 0 5.94436500023221e-08

Deficiency B-Disease 1 0.9981671571731567
of I-Disease 0 4.2249737930433184e-08
the I-Disease 0 9.520103816385017e-09
sixth I-Disease 0 4.7532928704185906e-08
component I-Disease 0 8.96865959276738e-09
of I-Disease 0 2.8855950962025645e-10
human I-Disease 0 1.472012067793571e-09
complement I-Disease 0 4.516570939472331e-08
( O 0 2.9416302282925244e-08
C6 O 0 2.568582203821279e-05
) O 0 1.5163131861228862e-09
has O 0 2.4001365339643144e-09
been O 0 1.202031030267392e-09
reported O 0 3.0649903948187784e-08
in O 0 6.235245098018538e-10
a O 0 2.841123447616667e-10
number O 0 6.322040113637684e-11
of O 0 1.9385194838239528e-11
families O 0 9.088643032617583e-11
from O 0 1.9508905602094728e-10
the O 0 5.246258982793961e-10
western O 0 6.0946323543475955e-09
Cape O 0 2.389609505826229e-07
, O 0 6.29128527052103e-10
South O 0 7.01435753924784e-09
Africa O 0 2.1468579802785825e-08
. O 0 3.5978416690340964e-08

Meningococcal B-Disease 1 0.999362051486969
disease I-Disease 1 0.9995718598365784
is O 0 1.4449911134306603e-07
endemic O 0 1.2208390387513646e-07
in O 0 7.88934251261253e-09
the O 0 2.3950390115601294e-08
Cape O 0 3.995666702394374e-06
and O 0 1.517288183983112e-09
almost O 0 9.828671210243556e-10
all O 0 1.2162111595603875e-10
pedigrees O 0 5.774942835046204e-08
of O 0 1.528380644266747e-09
total O 0 1.7609407905183616e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.8017448155660531e-07
C6Q0 O 0 8.813963358988985e-05
) O 0 6.8758541083013824e-09
have O 0 8.573013410284602e-10
been O 0 1.1049913206662154e-09
ascertained O 0 1.7666748064470994e-08
because O 0 7.206242269575114e-10
of O 0 2.4878765714220208e-09
recurrent O 0 0.0003523443592712283
disease O 0 0.004562766291201115
. O 0 6.669967547168199e-07

We O 0 3.193280520008557e-07
have O 0 8.001424411929747e-09
sequenced O 0 9.571780168471378e-08
the O 0 2.6798605556876964e-09
expressed O 0 4.929271213427455e-09
exons O 0 3.3692654000105904e-08
of O 0 4.956439703107662e-10
the O 0 5.063964358953399e-09
C6 O 0 2.4298674361489248e-06
gene O 0 5.724474050339268e-08
from O 0 1.6952388381952233e-09
selected O 0 1.9624311065058464e-09
cases O 0 3.863334652187689e-10
and O 0 3.949252036505868e-10
have O 0 1.3226747475059142e-10
found O 0 9.032258274643823e-10
three O 0 7.353924691422264e-10
molecular O 0 8.931276624934981e-07
defects O 0 0.0005318889743648469
leading O 0 1.5965845534537948e-08
to O 0 1.4799488745609324e-08
total O 0 5.5785189800872104e-08
deficiency O 0 3.686680065584369e-05
879delG O 0 3.7148052456359437e-07
, O 0 1.0621936663568476e-09
which O 0 8.113376637197689e-10
is O 0 1.5453109625251926e-10
the O 0 8.042211341319216e-10
common O 0 8.174456667120467e-09
defect O 0 9.355865415727749e-08
in O 0 2.3661459458423906e-09
the O 0 8.863563216721104e-09
Cape O 0 1.8039335714092886e-07
and O 0 6.958321141503632e-10
hitherto O 0 6.794892648542827e-09
unreported O 0 2.5761939248525323e-09
, O 0 1.499558949236146e-10
and O 0 3.231867273800759e-10
1195delC O 0 1.0742768807858738e-07
and O 0 1.6371568545281434e-09
1936delG O 0 9.008609680449808e-08
, O 0 4.5240072799046516e-10
which O 0 6.536076679886094e-10
have O 0 2.881931915332814e-10
been O 0 4.4117465236581666e-10
previously O 0 2.1632080571265533e-09
reported O 0 2.114868458136243e-08
in O 0 2.5564137473566007e-09
African O 0 4.2910550668295855e-09
- O 0 3.456080435171316e-07
Americans O 0 2.381605312962165e-08
. O 0 4.79195314539993e-08

We O 0 2.7667397262121085e-07
also O 0 1.1600952198875802e-08
show O 0 1.4492576916325106e-08
that O 0 1.9451983079843416e-10
the O 0 1.01789965345489e-09
879delG O 0 2.191637236137467e-07
and O 0 1.3823692412984201e-08
1195delC O 0 2.9802969947922975e-05
defects O 0 0.01206132210791111
are O 0 5.181173268198336e-10
associated O 0 6.471031266386262e-09
with O 0 1.1276566347362404e-08
characteristic O 0 0.0005113573279231787
C6 O 1 0.9990335702896118
/ O 0 0.007229107432067394
C7 O 0 5.472615157486871e-05
region O 0 1.497376160841668e-07
DNA O 0 9.106265679292846e-07
marker O 0 9.066681059266557e-07
haplotypes O 0 1.0829509164977935e-06
, O 0 2.346300043143401e-09
although O 0 1.2798627713195287e-09
small O 0 1.6670158586862271e-09
variations O 0 5.7017540910919706e-08
were O 0 2.1390798465859007e-08
observed O 0 2.1466456701091374e-07
. O 0 8.027507192309713e-08

The O 0 1.87650766747538e-06
1936delG O 0 8.582999726058915e-05
defect O 0 6.854904495412484e-05
was O 0 1.4113254565017996e-07
observed O 0 1.3472440940631714e-08
only O 0 2.6614752068887526e-10
once O 0 1.6199392938176516e-09
in O 0 7.56571583160337e-10
the O 0 1.8631061138307814e-09
Cape O 0 1.2006218241822353e-07
, O 0 9.891630570191268e-11
but O 0 1.3524692477062672e-10
its O 0 2.1911674696895034e-09
associated O 0 1.6897903520884938e-08
haplotype O 0 1.947221790032927e-06
could O 0 1.2674836291637348e-08
be O 0 6.574765620825929e-09
deduced O 0 2.2843778424430639e-07
. O 0 3.800324677172284e-08

The O 0 1.7762917536856548e-07
data O 0 1.541756802225791e-07
from O 0 6.21513507326199e-09
the O 0 2.451895131372339e-09
haplotypes O 0 4.154818213919498e-07
indicate O 0 4.9473584340375965e-08
that O 0 4.021801780496048e-10
these O 0 2.1122018023511657e-10
three O 0 7.828854231561877e-10
molecular O 0 5.532778573069663e-07
defects O 0 0.002289415802806616
account O 0 4.7013188897437885e-09
for O 0 1.1322703885596752e-09
the O 0 5.512769689630659e-07
defects O 0 0.21672499179840088
in O 0 1.6439782868360453e-09
all O 0 2.705976831496315e-10
the O 0 2.3079731459318964e-09
38 O 0 2.183921132825617e-08
unrelated O 0 2.489653283532789e-08
C6Q0 O 0 1.3882066696169204e-06
individuals O 0 1.2485705802589564e-09
we O 0 4.947108278585688e-10
have O 0 1.8543908075763227e-10
studied O 0 2.8808890828457834e-09
from O 0 1.1954004452974232e-09
the O 0 9.187703930990665e-09
Cape O 0 1.5163190028033569e-06
. O 0 6.660648921297252e-08

We O 0 2.570874926277611e-07
have O 0 7.050775074901594e-09
also O 0 2.158917267180982e-09
observed O 0 1.3636554996310224e-08
the O 0 6.579181199839468e-09
879delG O 0 1.682126253399474e-06
defect O 0 4.2719483417386073e-07
in O 0 6.358713111609404e-09
two O 0 2.8713399657931404e-08
Dutch O 1 0.9967597126960754
C6 B-Disease 1 1.0
- I-Disease 1 0.9999943971633911
deficient I-Disease 1 1.0
kindreds O 0 5.0459939302527346e-06
, O 0 2.106445462501938e-09
but O 0 6.690055176505894e-10
the O 0 2.232995566231466e-09
879delG O 0 9.625216534914216e-07
defect O 0 1.655682808632264e-07
in O 0 2.0673232015155918e-09
the O 0 4.553052157518778e-09
Cape O 0 2.6455109036760405e-07
probably O 0 1.722468034870417e-08
did O 0 1.3591237024712655e-09
not O 0 1.0397131766648471e-10
come O 0 1.7079897218774676e-10
from O 0 1.7877775648766914e-10
The O 0 9.416600832423683e-10
Netherlands O 0 7.01219349252824e-08
. O 0 2.928942421931424e-09
. O 0 1.3134272336401409e-08

Complement B-Disease 1 0.9994602799415588
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.5986054791028437e-07
seven O 0 1.9084392732793276e-08
further O 0 2.5909885792430032e-08
molecular O 0 1.7294660210609436e-05
defects O 1 0.9806416630744934
and O 0 2.0268320355398828e-08
their O 0 3.3045516545371356e-08
associated O 0 4.937516564496036e-07
marker O 0 6.1332098084676545e-06
haplotypes O 0 1.551877721794881e-05
. O 0 3.194672615336458e-07

Seven O 0 5.830852387589402e-07
further O 0 9.103906251084481e-08
molecular O 0 6.951322006898408e-07
bases O 0 1.1174754490639316e-06
of O 0 1.9269307358626975e-06
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 5.8576446804181614e-08
described O 0 9.227844088854908e-07
. O 0 4.770477062265854e-07

All O 0 6.55247163194872e-08
these O 0 5.2771316205735275e-09
new O 0 3.126932668351401e-08
molecular O 0 3.0243083983805263e-06
defects O 0 0.00019546416297089309
involve O 0 1.9422010666403366e-08
single O 0 1.5373433370768907e-07
- O 0 3.847976302040479e-07
nucleotide O 0 2.538656360684399e-07
events O 0 9.505370712759031e-09
, O 0 9.143714674308967e-10
deletions O 0 9.973409476060624e-08
and O 0 1.3796764841700337e-09
substitutions O 0 1.5397754182799872e-08
, O 0 4.1056327781952007e-10
some O 0 9.074992840529816e-11
of O 0 1.3957153488508567e-10
which O 0 2.699380052817446e-09
alter O 0 8.959701176536328e-07
splice O 0 2.512216951799928e-06
sites O 0 8.813263008278227e-08
, O 0 2.287685374469106e-09
and O 0 1.0636006519959551e-09
others O 0 4.548434517914757e-09
codons O 0 1.0673974202290992e-06
. O 0 9.720269389390523e-08

They O 0 7.786731259784574e-08
are O 0 9.159755731680264e-10
distributed O 0 9.937778377988593e-10
along O 0 1.0308612852227839e-09
the O 0 3.654846425504843e-09
C7 O 0 3.155282229272416e-06
gene O 0 8.45751344513701e-08
, O 0 5.263738889205172e-10
but O 0 1.6508747147092606e-10
predominantly O 0 5.479575126976499e-10
towards O 0 4.904903150304563e-10
the O 0 2.495452067208248e-09
3 O 0 1.9786799754228923e-08
end O 0 1.1500648611217912e-07
. O 0 4.912622841857228e-08

All O 0 9.816820067953813e-08
were O 0 4.96968555196986e-09
found O 0 2.9220232899973553e-09
in O 0 3.6973641925897027e-09
compound O 0 1.5211942638870823e-07
heterozygous O 0 2.5571089281584136e-06
individuals O 0 1.9769144543602124e-08
. O 0 1.0457927146489965e-07

The O 0 4.556615749606863e-05
C6 O 1 0.9647031426429749
/ O 0 0.12290675193071365
C7 O 0 0.0007061215001158416
marker O 0 6.952927378733875e-06
haplotypes O 0 1.0463614671607502e-05
associated O 0 2.6841800604415766e-07
with O 0 1.107437341829609e-08
most O 0 9.238578400072583e-07
C7 B-Disease 1 0.9999992847442627
defects I-Disease 1 0.9999971389770508
are O 0 1.8697461356964595e-08
tabulated O 0 2.5562994778738357e-06
. O 0 1.1741753347394024e-08
. O 0 4.872347858508874e-08

A O 0 4.6919521992094815e-06
genome O 0 5.874545422557276e-06
- O 0 1.5292248463083524e-06
wide O 0 5.3419778822672015e-08
search O 0 3.18995638792785e-08
for O 0 3.730587394557006e-09
chromosomal O 0 1.139067899202928e-05
loci O 0 6.588036285393173e-07
linked O 0 8.88062368176179e-06
to O 0 2.088440851366613e-07
mental O 0 1.4849083527224138e-05
health O 0 2.819052440372616e-07
wellness O 0 4.2330441374360817e-07
in O 0 9.242700826916916e-09
relatives O 0 1.0165148722762751e-08
at O 0 8.160191100614611e-08
high O 0 1.8145603917218978e-06
risk O 0 4.213208910641697e-07
for O 0 1.3112850183460978e-07
bipolar B-Disease 1 0.9999583959579468
affective I-Disease 0 0.13951393961906433
disorder I-Disease 0 0.08914744853973389
among O 0 6.995411805377216e-09
the O 0 1.1650134190688277e-08
Old O 0 1.6259784842986846e-06
Order O 0 7.509237320846296e-08
Amish O 0 4.660120794142131e-06
. O 0 1.1997850890566042e-07

Bipolar B-Disease 1 0.9999990463256836
affective I-Disease 1 0.9999814033508301
disorder I-Disease 1 0.999998927116394
( O 0 0.00026989183970727026
BPAD B-Disease 1 1.0
; O 0 0.0250527523458004
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 0.999983549118042
) O 0 3.949158156046906e-08
is O 0 1.7569825594421218e-09
characterized O 0 3.423198435825725e-08
by O 0 1.969724827688424e-09
episodes O 0 9.901837216830245e-08
of O 0 5.596068053392855e-09
mania B-Disease 0 0.00011163220915477723
and O 0 7.358786291433717e-08
/ O 0 5.79488551011309e-05
or O 0 3.3134827503999986e-07
hypomania B-Disease 0 0.00019616581266745925
interspersed O 0 1.1137559567941935e-06
with O 0 7.697463111355773e-09
periods O 0 3.121218696833239e-07
of O 0 1.2124369952459801e-08
depression B-Disease 0 8.057183003984392e-05
. O 0 3.281225815499056e-07

Compelling O 0 1.2062756695740973e-06
evidence O 0 5.7437233635937446e-08
supports O 0 4.420477495159503e-08
a O 0 4.639479911361377e-09
significant O 0 2.1471191491428954e-09
genetic O 0 1.4797032932278853e-08
component O 0 1.0085351220823213e-08
in O 0 1.1500922436624705e-09
the O 0 3.870122000648735e-09
susceptibility O 0 3.446604353030125e-07
to O 0 4.198271952304822e-08
develop O 0 4.049890321766725e-06
BPAD B-Disease 1 1.0
. O 0 1.018191255752754e-06

To O 0 2.3631712053884257e-07
date O 0 1.1656516818447926e-07
, O 0 1.8312149574484238e-09
however O 0 1.353876566412282e-09
, O 0 4.5929715586368047e-10
linkage O 0 2.8953508035556297e-08
studies O 0 1.133688032339819e-09
have O 0 2.579029489968576e-10
attempted O 0 7.414009406403466e-09
only O 0 2.199742332731347e-10
to O 0 6.805732644110662e-10
identify O 0 2.1595853993972014e-08
chromosomal O 0 1.916652763611637e-06
loci O 0 6.10800654499144e-08
that O 0 1.5689045618216824e-09
cause O 0 1.5218741822309312e-08
or O 0 5.7409601517122155e-09
increase O 0 4.318363444610895e-09
the O 0 6.571719168846357e-09
risk O 0 4.190935598558099e-08
of O 0 2.784929620247567e-09
developing O 0 1.535571641397837e-06
BPAD B-Disease 1 1.0
. O 0 1.6025145441744826e-06

To O 0 1.4638365541941312e-07
determine O 0 1.9415860919025363e-08
whether O 0 5.017507742621774e-09
there O 0 4.767661265780987e-10
could O 0 1.2083892775294203e-09
be O 0 3.112422541917681e-10
protective O 0 1.226497214901201e-08
alleles O 0 7.140408264660891e-09
that O 0 1.4064822917436715e-10
prevent O 0 4.930635011390905e-09
or O 0 3.2589009268946256e-09
reduce O 0 1.846198038890634e-08
the O 0 3.3136513533094103e-09
risk O 0 8.467614165397208e-09
of O 0 2.8290325637669866e-10
developing O 0 6.535260155260403e-08
BPAD B-Disease 1 1.0
, O 0 1.718538977790729e-09
similar O 0 4.609578496683753e-09
to O 0 1.5435442923816822e-09
what O 0 2.506723162376545e-10
is O 0 8.812611751451982e-11
observed O 0 1.2116642134074596e-09
in O 0 1.396709303769228e-09
other O 0 1.289424389483429e-08
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 7.00843338918844e-09
we O 0 2.9910889320916567e-09
used O 0 5.790494128632417e-07
mental O 0 5.806225999549497e-06
health O 0 9.499326552031562e-07
wellness O 0 1.5711100331827765e-06
( O 0 2.9949822621944122e-09
absence O 0 1.8483710118033514e-09
of O 0 2.9370467169442804e-10
any O 0 5.8052023632626515e-08
psychiatric B-Disease 0 0.09781677275896072
disorder I-Disease 0 0.0003943564370274544
) O 0 2.4211213034419643e-09
as O 0 2.31224284164e-09
the O 0 3.749291099808261e-09
phenotype O 0 7.957775096656405e-07
in O 0 5.5460094294801365e-09
our O 0 3.784741409162962e-09
genome O 0 5.3322871451655374e-08
- O 0 7.981853968885844e-07
wide O 0 1.2203116739328834e-07
linkage O 0 1.7385939372616122e-06
scan O 0 8.879031156538986e-06
of O 0 4.4044151659150543e-10
several O 0 5.930700930356636e-10
large O 0 2.4584605462507625e-09
multigeneration O 0 1.7953470887732692e-06
Old O 0 1.066783283931727e-07
Order O 0 5.11765962940558e-09
Amish O 0 3.271626667356031e-07
pedigrees O 0 3.6306420270193485e-07
exhibiting O 0 4.915434814733999e-08
an O 0 1.6798533675199678e-09
extremely O 0 5.99649695232074e-07
high O 0 4.6569155529141426e-05
incidence O 0 0.00017907253641169518
of O 0 8.577061549885912e-08
BPAD B-Disease 1 1.0
. O 0 1.9015611769646057e-06

We O 0 1.8071190766022482e-07
have O 0 3.0384872395927687e-09
found O 0 1.5531126384971117e-09
strong O 0 4.286940136211115e-09
evidence O 0 7.942090873847008e-10
for O 0 2.4749544080826524e-10
a O 0 3.5979772494698636e-09
locus O 0 1.4181686935899052e-07
on O 0 7.352445408059793e-08
chromosome O 0 6.180133368616225e-06
4p O 0 1.4510671462630853e-05
at O 0 8.303490517391765e-08
D4S2949 O 0 6.228987103895633e-07
( O 0 1.6016995729728478e-08
maximum O 0 6.966733678837045e-08
GENEHUNTER O 0 2.8037400625180453e-05
- O 0 2.411482455499936e-06
PLUS O 0 4.515149782946537e-07
nonparametric O 0 3.911312887794338e-06
linkage O 0 1.7831464447226608e-06
score O 0 5.417321062850533e-07
= O 0 4.7055740992618666e-07
4 O 0 4.896813265986566e-08
. O 0 2.8032087762142055e-09
05 O 0 7.027576884865994e-07
, O 0 3.5875409309937822e-09
P O 0 3.4040770060528303e-06
= O 0 1.0375849512911373e-07
5 O 0 1.1979620850866013e-08
. O 0 1.0448726328604607e-09
22 O 0 2.0671192757504286e-08
x O 0 1.3353730992093915e-06
10 O 0 2.5995470664952336e-08
( O 0 1.7413364972185263e-08
- O 0 1.7104354128605337e-06
4 O 0 5.7463861224960056e-08
) O 0 2.505190277446445e-09
; O 0 2.0321575533444047e-09
SIBPAL O 0 8.065035217441618e-07
Pempirical O 0 3.0974399578553857e-07
value O 0 5.807248015798905e-09
< O 0 3.0592026689646445e-08
3 O 0 6.58829790722848e-09
x O 0 9.397210760653252e-07
10 O 0 4.143429066516546e-08
( O 0 2.024683709578312e-08
- O 0 1.1414767868700437e-06
5 O 0 1.7800998008965507e-08
) O 0 5.682151971164728e-10
) O 0 2.47152964760744e-10
and O 0 3.653638780409807e-10
suggestive O 0 5.012230275269758e-08
evidence O 0 7.933052548203534e-10
for O 0 2.0272863943127106e-10
a O 0 3.789884850391445e-09
locus O 0 3.270909303410008e-07
on O 0 3.193012503288628e-07
chromosome O 0 3.695592749863863e-05
4q O 0 0.0006825926247984171
at O 0 3.089607503170555e-07
D4S397 O 0 7.709190867899451e-07
( O 0 2.1090155399861032e-08
maximum O 0 1.0476593104158383e-07
GENEHUNTER O 0 2.6576524760457687e-05
- O 0 1.586402504472062e-06
PLUS O 0 1.3421305311567266e-07
nonparametric O 0 1.910575292640715e-06
linkage O 0 4.140905787153315e-07
score O 0 7.748300845378253e-08
= O 0 1.5804542385922105e-07
3 O 0 1.2158875684065151e-08
. O 0 8.48066949998838e-10
29 O 0 7.599840756711274e-08
, O 0 2.202388271754785e-09
P O 0 1.336202331003733e-05
= O 0 1.4370205292379978e-07
2 O 0 1.0887697854400358e-08
. O 0 1.3707713852895154e-09
57 O 0 4.075349480103796e-08
x O 0 2.0950487851223443e-06
10 O 0 6.381009853839714e-08
( O 0 1.3373335328026315e-08
- O 0 9.575684316587285e-07
3 O 0 3.546679749888426e-08
) O 0 2.740205617968172e-09
; O 0 3.023277628244614e-09
SIBPAL O 0 8.892724281395203e-07
Pempirical O 0 5.250508365861606e-07
value O 0 1.0379843651264764e-08
< O 0 4.925345464812381e-08
1 O 0 6.626243997942538e-09
x O 0 3.7640251093762345e-07
10 O 0 1.387644754657913e-08
( O 0 8.204260382171924e-09
- O 0 1.1407660167606082e-06
3 O 0 1.6663427970797784e-08
) O 0 2.809464605402212e-10
) O 0 9.55531348489913e-11
that O 0 7.620717945577837e-11
are O 0 6.280766878807853e-11
linked O 0 8.1271217311496e-08
to O 0 2.4815177468440197e-08
mental O 0 4.946272838424193e-06
health O 0 1.7872683883979334e-06
wellness O 0 1.1358387382642832e-05
. O 0 2.848463225291198e-07

These O 0 1.6614116304936033e-07
findings O 0 1.605630757239851e-07
are O 0 1.054052289894969e-09
consistent O 0 1.1101845664995835e-08
with O 0 4.160253253004953e-10
the O 0 2.0994743721303166e-09
hypothesis O 0 7.56646922894788e-09
that O 0 7.990221678744192e-11
certain O 0 6.092735205243116e-10
alleles O 0 2.8062862256206245e-08
could O 0 3.751680299757254e-09
prevent O 0 5.224156751637565e-08
or O 0 1.8098850418368784e-08
modify O 0 3.979714904289722e-07
the O 0 7.561391512922455e-09
clinical O 0 8.340824564356808e-08
manifestations O 0 9.284492108463382e-08
of O 0 4.760367211531502e-09
BPAD B-Disease 1 1.0
and O 0 7.482255703905594e-09
perhaps O 0 3.308030960269548e-09
other O 0 1.8575919691343756e-09
related O 0 6.484043524324079e-07
affective B-Disease 0 0.0013831673422828317
disorders I-Disease 1 0.8224377632141113
. O 0 1.3353476333577419e-06

Segregation O 0 0.00232292921282351
distortion O 0 0.061277080327272415
in O 0 0.00021357044170144945
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 3.195132376276888e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9998987913131714
DM B-Disease 1 1.0
) O 0 4.559424553463032e-07
is O 0 4.1108219051011474e-09
an O 0 4.812110265817182e-09
autosomal B-Disease 0 0.4879656136035919
dominant I-Disease 1 0.990403413772583
disease I-Disease 1 0.8300026059150696
which O 0 5.8363106347769644e-08
, O 0 5.16739595557425e-10
in O 0 1.942777938523932e-09
the O 0 3.2089821910830096e-09
typical O 0 1.1709239799984061e-07
pedigree O 0 7.166893851717759e-07
, O 0 6.644882977191457e-10
shows O 0 9.142620882585106e-09
a O 0 3.995669572987026e-09
three O 0 2.4271087362137678e-09
generation O 0 6.761062820714869e-08
anticipation O 0 4.16205182318663e-07
cascade O 0 4.3705213101929985e-06
. O 0 1.8177388483309187e-07

This O 0 1.3098451745463535e-07
results O 0 5.360186037250969e-07
in O 0 3.492996540899185e-07
infertility B-Disease 0 0.06400464475154877
and O 0 0.0018443871522322297
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.1005139640474226e-05
CDM B-Disease 0 2.704579492274206e-05
) O 0 3.2614566602973127e-09
with O 0 5.104175415659995e-10
the O 0 2.020389411327983e-09
disappearance O 0 9.840328374366436e-08
of O 0 9.303331438559326e-09
DM B-Disease 1 1.0
in O 0 5.7058120006558966e-08
that O 0 8.282607488752092e-09
pedigree O 0 4.37361541116843e-06
. O 0 1.3121056952059007e-07

The O 0 1.1877016703465415e-07
concept O 0 5.586067786111926e-08
of O 0 3.1025673141726884e-09
segregation O 0 5.486754162120633e-07
distortion O 0 3.9612214663975465e-07
, O 0 6.20146711760583e-10
where O 0 3.023806482982394e-10
there O 0 2.7446608874548417e-10
is O 0 3.936962977846292e-10
preferential O 0 1.3607454718567169e-08
transmission O 0 7.496316811739234e-06
of O 0 1.7961103437880155e-10
the O 0 6.885483294638561e-10
larger O 0 4.734126868299882e-09
allele O 0 1.2615701905360766e-07
at O 0 2.9693593361912463e-08
the O 0 1.0252307447444764e-07
DM B-Disease 1 1.0
locus O 0 1.0574094631010666e-06
, O 0 1.381272096701025e-09
has O 0 7.62098273376921e-10
been O 0 5.54185142220831e-10
put O 0 3.451842145452133e-09
forward O 0 2.533695919737511e-09
to O 0 1.7814881791977655e-09
explain O 0 1.0766189717514862e-08
partially O 0 1.901318036345856e-08
the O 0 2.2525101783799073e-09
maintenance O 0 4.2990937032527654e-08
of O 0 1.2162093554479725e-09
DM B-Disease 1 1.0
in O 0 4.642401130183771e-09
the O 0 2.708446578125745e-09
population O 0 2.677269961282036e-09
. O 0 1.691673645609626e-08

In O 0 4.150477366238192e-07
a O 0 1.1856533177478923e-07
survey O 0 3.321404733469535e-07
of O 0 1.124542325925404e-08
DM B-Disease 1 1.0
in O 0 4.262474462279897e-08
Northern O 0 1.2648108338453312e-07
Ireland O 0 2.989596623592661e-07
, O 0 1.3137774201865682e-09
59 O 0 1.3638947748972896e-08
pedigrees O 0 4.606891366165655e-07
were O 0 2.2409027522485303e-08
ascertained O 0 9.414451938027923e-07
. O 0 1.5586144286316994e-07

Sibships O 0 0.0001295600231969729
where O 0 1.4045488683223084e-07
the O 0 6.9037131567029064e-09
status O 0 2.1928314719588116e-09
of O 0 9.614436330407372e-11
all O 0 4.1636482456253177e-11
the O 0 1.5947870801724662e-10
members O 0 9.690803715045604e-11
had O 0 1.7205494806660226e-09
been O 0 4.5287293359841385e-10
identified O 0 1.1712892877824288e-09
were O 0 1.0561532759467696e-09
examined O 0 1.1029114510563431e-08
to O 0 5.407984060568083e-10
determine O 0 9.008257473297476e-10
the O 0 2.8163065213249183e-09
transmission O 0 8.541945135220885e-06
of O 0 3.426630923453189e-10
the O 0 2.2582671732607196e-08
DM B-Disease 1 0.9999998807907104
expansion O 0 5.470474562230265e-08
from O 0 7.431168569382862e-09
affected O 0 1.3592461378664211e-08
parents O 0 4.829230348946112e-09
to O 0 9.645297893712268e-10
their O 0 5.643520317732964e-09
offspring O 0 1.5282830645446666e-07
. O 0 2.9796510148116795e-08

Where O 0 3.7767395610899257e-07
the O 0 8.932062911526373e-08
transmitting O 0 3.358750473125838e-05
parent O 0 3.3987021197390277e-06
was O 0 1.141617786970528e-07
male O 0 1.2588174946870367e-08
, O 0 5.176178152765942e-09
58 O 0 5.028739451518049e-07
. O 0 1.426797666681523e-07

3 O 0 5.546218062590924e-07
% O 0 6.642986161153885e-09
of O 0 3.932130177020099e-10
the O 0 2.7670119528977466e-09
offspring O 0 1.7966740983865748e-08
were O 0 2.3915820435149726e-09
affected O 0 9.86654224988115e-09
, O 0 5.912494382975808e-10
and O 0 7.211631847248157e-10
in O 0 1.7837797905428943e-09
the O 0 9.2254009986803e-10
case O 0 6.694088616754357e-10
of O 0 5.900234467670629e-11
a O 0 1.9216461755178216e-09
female O 0 9.540134904284514e-09
transmitting O 0 2.884280320358812e-06
parent O 0 3.394907821530069e-07
, O 0 5.546728854000094e-09
68 O 0 4.474398167531035e-07
. O 0 1.1140901534645309e-07

7 O 0 9.835804121394176e-06
% O 0 1.3935333242898196e-07
were O 0 2.5839655748427504e-08
affected O 0 3.623592306212231e-07
. O 0 2.9082255537105084e-07

Studies O 0 2.32708475778054e-06
on O 0 2.344445420021657e-07
meiotic O 0 1.7240974557353184e-05
drive O 0 8.83170469023753e-06
in O 0 4.079394102518563e-07
DM B-Disease 1 1.0
have O 0 8.030933251745864e-09
shown O 0 1.2292091788879134e-08
increased O 0 1.81696524492736e-08
transmission O 0 4.1168846109940205e-06
of O 0 1.0170142505927515e-10
the O 0 4.575571310727611e-10
larger O 0 3.774331958084076e-09
allele O 0 2.5125856950580783e-07
at O 0 3.812841953276802e-08
the O 0 9.47494598335652e-08
DM B-Disease 1 0.9999998807907104
locus O 0 1.5923623095659423e-06
in O 0 4.4161627243965995e-08
non O 0 3.1679948619967035e-07
- O 0 0.008595231920480728
DM O 1 1.0
heterozygotes O 0 1.479905222367961e-05
for O 0 4.733118075250786e-08
CTGn O 0 2.3451961169485003e-05
. O 0 2.03628360395669e-07

This O 0 8.938947360093152e-08
study O 0 5.76019854037213e-09
provides O 0 1.0159290075861804e-09
further O 0 6.07465633351012e-10
evidence O 0 2.412476884927628e-10
that O 0 3.7670516706000967e-10
the O 0 2.773417406842782e-08
DM B-Disease 1 1.0
expansion O 0 1.6369695288176445e-07
tends O 0 4.143722378557868e-07
to O 0 4.380172669016247e-09
be O 0 5.8658371493436334e-09
transmitted O 0 6.911278433108237e-06
preferentially O 0 1.316976522502955e-06
. O 0 1.4758565214378905e-07

Diagnosis O 1 0.9433070421218872
of O 0 1.3390431377047207e-05
hemochromatosis B-Disease 1 1.0
. O 0 2.656218384800013e-05

If O 0 4.610548785421997e-06
untreated O 0 0.00018184083455707878
, O 0 1.1934894246223848e-06
hemochromatosis B-Disease 1 1.0
can O 0 1.3002068044443149e-05
cause O 0 1.3534103345591575e-05
serious O 0 1.2507932297012303e-05
illness O 0 0.02900613471865654
and O 0 4.613978887846315e-08
early B-Disease 0 9.289791705668904e-06
death I-Disease 0 3.4834699818020454e-06
, O 0 3.8603734098252573e-10
but O 0 4.583922130763085e-10
the O 0 8.158179909401042e-09
disease O 0 6.48223817734106e-07
is O 0 4.629329974914498e-10
still O 0 4.953020660281027e-09
substantially O 0 5.783198275821633e-07
under O 0 6.654439062003803e-07
- O 1 0.9249352812767029
diagnosed O 0 0.0043237581849098206
. O 0 1.3933073716998479e-07

The O 0 2.684482183212822e-07
cornerstone O 0 4.36566665484861e-07
of O 0 2.6374826767039394e-09
screening O 0 1.3788135788672662e-07
and O 0 1.8975636617568625e-09
case O 0 1.6490155907433746e-09
detection O 0 3.3135769683667604e-08
is O 0 8.24579737823683e-10
the O 0 6.5217309330734e-10
measurement O 0 1.5416590670724872e-08
of O 0 4.801261610509755e-10
serum O 0 3.888652315708896e-07
transferrin O 0 5.360334398574196e-07
saturation O 0 3.2456776466460724e-07
and O 0 4.833165423434593e-09
the O 0 2.888703853898278e-08
serum O 0 2.8482779725891305e-06
ferritin O 0 1.453421646147035e-05
level O 0 7.79925983351859e-07
. O 0 2.2476838523743936e-07

Once O 0 3.503125526549411e-06
the O 0 1.4434952788633382e-07
diagnosis O 0 6.462291821662802e-06
is O 0 2.700837331559569e-09
suspected O 0 1.0619656620747264e-07
, O 0 3.750521226919545e-09
physicians O 0 1.1884785600102532e-08
must O 0 5.068351072168298e-09
use O 0 4.907247941332571e-08
serum O 0 3.0217856874514837e-06
ferritin O 0 8.231259016611148e-06
levels O 0 4.2534676936156757e-07
and O 0 1.616060885112347e-08
hepatic O 0 3.2228952477453277e-05
iron O 0 3.736088183359243e-05
stores O 0 1.2262266864127014e-05
on O 0 9.949201285053277e-07
liver O 0 2.486865923856385e-05
biopsy O 0 2.397855496383272e-05
specimens O 0 1.0393433669264596e-08
to O 0 3.836936546264269e-09
assess O 0 1.2922119196900894e-07
patients O 0 3.164661066534791e-08
for O 0 4.658524677125797e-10
the O 0 1.5795939001250758e-09
presence O 0 9.342897122621707e-09
of O 0 2.500101903279983e-09
iron B-Disease 0 0.0010653948411345482
overload I-Disease 0 1.4065518371353392e-05
. O 0 1.5722223167813354e-07

Liver O 1 0.9995028972625732
biopsy O 1 0.9997127652168274
is O 0 8.771355197723096e-08
also O 0 1.274189975752904e-09
used O 0 8.729054701284156e-10
to O 0 2.4057955627654337e-10
establish O 0 6.334318070067013e-10
the O 0 3.5553729405002343e-10
presence O 0 1.3190225578441073e-09
or O 0 9.558945857079948e-10
absence O 0 2.517491104470082e-09
of O 0 5.721532136959695e-10
cirrhosis B-Disease 0 1.1411774494263227e-06
, O 0 7.212897501496229e-10
which O 0 4.183338564445194e-09
can O 0 8.814637908471923e-09
affect O 0 1.997621978944153e-07
prognosis O 0 7.955188266350888e-06
and O 0 2.356423500771143e-08
management O 0 4.343664272710157e-07
. O 0 1.1225090190691844e-07

A O 0 1.5508539945585653e-06
DNA O 0 2.979485770993051e-06
- O 0 2.131160499629914e-06
based O 0 4.081284998846968e-08
test O 0 2.510587293613753e-08
for O 0 4.389956453909605e-10
the O 0 2.490582851066847e-09
HFE O 0 1.4469356983681791e-06
gene O 0 4.1363382052850284e-08
is O 0 6.800775498305711e-10
commercially O 0 7.424226566854486e-09
available O 0 1.2012677519379622e-09
, O 0 1.1342757288979044e-10
but O 0 7.852973132882468e-11
its O 0 9.34267996299809e-10
place O 0 1.0212211076776612e-09
in O 0 5.270530123446804e-10
the O 0 1.9982149268571447e-09
diagnosis O 0 1.4758651332158479e-06
of O 0 9.229366604301958e-09
hemochromatosis B-Disease 1 1.0
is O 0 4.579802137527622e-08
still O 0 5.881880760227887e-09
being O 0 4.878780490713552e-09
evaluated O 0 1.1022621038137004e-07
. O 0 2.0715514637004162e-08

Currently O 0 3.489756750241213e-07
, O 0 2.200649884542827e-09
the O 0 4.04951239207918e-10
most O 0 3.089085098828548e-10
useful O 0 2.994226810937306e-10
role O 0 6.034768240681387e-10
for O 0 1.0910304604205834e-10
this O 0 2.7388458168076113e-10
test O 0 1.5226174099325362e-08
is O 0 1.48080853135113e-10
in O 0 3.547048210705839e-10
the O 0 3.469166065528384e-10
detection O 0 2.7105977906671797e-08
of O 0 5.1060471406572105e-09
hemochromatosis B-Disease 1 1.0
in O 0 1.4713278595479551e-08
the O 0 3.598986442199248e-09
family O 0 1.3764434037000228e-09
members O 0 5.1854916194304934e-11
of O 0 2.4737545345487888e-11
patients O 0 5.125432855912493e-10
with O 0 9.546204798871472e-11
a O 0 1.4601257092294873e-08
proven O 0 1.1319816195509702e-08
case O 0 9.96933091634844e-10
of O 0 1.910258062842729e-10
the O 0 4.836958211740239e-08
disease O 0 9.511405551165808e-06
. O 0 1.200452288685483e-07

It O 0 3.410197848552343e-07
is O 0 1.2358762901953924e-08
crucial O 0 6.652447126498373e-08
to O 0 2.770235596472048e-07
diagnose O 1 0.9999884366989136
hemochromatosis B-Disease 1 1.0
before O 0 0.0029338665772229433
hepatic B-Disease 1 0.9999756813049316
cirrhosis I-Disease 1 0.9957048296928406
develops O 0 0.00021955651754979044
because O 0 6.859953600724111e-07
phlebotomy O 0 0.023956356570124626
therapy O 0 0.0003891070664394647
can O 0 9.375619924867351e-07
avert O 0 0.04070340469479561
serious O 1 0.8283041715621948
chronic O 1 1.0
disease O 1 0.9999997615814209
and O 0 1.4135939636616968e-06
can O 0 2.633301932064569e-08
even O 0 6.660189288965057e-09
lead O 0 1.0445662113056642e-08
to O 0 3.2247693404485744e-09
normal O 0 1.5280191689726053e-07
life O 0 1.589774534238586e-08
expectancy O 0 4.422771127110536e-08
. O 0 3.209153387473407e-09
. O 0 5.660448110234029e-08

Prevalence O 0 8.937191887525842e-05
of O 0 4.485476168269997e-08
the O 0 3.048653596238182e-08
I1307K O 0 1.5623021454302943e-06
APC B-Disease 0 8.08424090337212e-07
gene O 0 2.673904191397014e-07
variant O 0 6.471428832810489e-07
in O 0 4.361257133211893e-09
Israeli O 0 1.495250678829052e-08
Jews O 0 1.356577739031195e-09
of O 0 8.284890828935687e-11
differing O 0 2.355227124439807e-09
ethnic O 0 3.3103897401076665e-10
origin O 0 1.1244880582239603e-09
and O 0 4.811853138164679e-09
risk O 0 4.0736483697401127e-07
for O 0 0.00041118194349110126
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.053567186521832e-06

BACKGROUND O 0 0.00018737674690783024
& O 0 2.0800738639081828e-05
AIMS O 0 2.9436068871291354e-07
Israeli O 0 6.010799324940308e-08
Jews O 0 9.636807796198354e-09
of O 0 4.6464648795208063e-10
European O 0 3.709374141180888e-08
birth O 0 2.6941663691104623e-06
, O 0 2.04983874318998e-09
i O 0 3.980372920153741e-09
. O 0 3.100193712857191e-10
e O 0 7.514005417874614e-09
. O 0 2.784816544032509e-10
, O 0 2.799958320753859e-10
Ashkenazim O 0 1.6549439862956206e-07
, O 0 3.231941103631897e-10
have O 0 4.205817638602838e-10
the O 0 2.911299112895449e-08
highest O 1 0.997634768486023
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.00011459675442893058
of O 0 4.4825895773037416e-10
any O 0 1.3073331306401315e-09
Israeli O 0 6.314264311413353e-08
ethnic O 0 7.571681059914681e-09
group O 0 4.735438707825779e-08
. O 0 5.8741925101912784e-08

The O 0 9.815150860958965e-07
I1307K O 0 2.1286019546096213e-05
APC B-Disease 0 5.937106379860779e-06
gene O 0 1.9892509044439066e-06
variant O 0 2.511356615286786e-05
was O 0 1.2348581321930396e-06
found O 0 1.1405552946541775e-08
in O 0 1.650586689549982e-08
6 O 0 2.2653989617538173e-07
. O 0 8.550812680141462e-08

1 O 0 6.21950164259033e-07
% O 0 4.6142409892979686e-09
of O 0 1.720555087292297e-10
American O 0 4.723436086706556e-10
Jews O 0 1.175198605096739e-09
, O 0 2.741354365731752e-10
28 O 0 2.114661779017979e-09
% O 0 1.698688273377158e-10
of O 0 1.8796203482551732e-10
their O 0 5.655976929119788e-05
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 1.3775428442386328e-06
, O 0 5.299554128868067e-09
but O 0 1.3868739490163762e-09
not O 0 7.216902075946052e-10
in O 0 2.571020063513174e-09
non O 0 1.5130435571109047e-08
- O 0 3.035349607216631e-07
Jews O 0 4.887575144607581e-08
. O 0 7.821682146413877e-08

We O 0 5.255894279798667e-07
assessed O 0 3.2409175787506683e-07
the O 0 2.3705968743570338e-08
I1307K O 0 1.4852192862235825e-06
prevalence O 0 4.7357099219880183e-07
in O 0 4.118371865757808e-09
Israeli O 0 1.925018544568502e-08
Jews O 0 2.240504004547006e-09
of O 0 7.282204700365114e-11
differing O 0 1.2588577957828306e-09
ethnic O 0 6.08980754712718e-10
origin O 0 6.4118094167398e-10
and O 0 4.231762495976454e-09
risk O 0 3.9338749502348946e-07
for O 0 0.0015660683857277036
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.604432100066333e-06

METHODS O 0 4.22012362832902e-06
DNA O 0 7.420817382808309e-07
samples O 0 1.0993310439744164e-07
from O 0 4.098249295481082e-09
500 O 0 6.045947298360943e-09
unrelated O 0 7.532946710853139e-09
Jews O 0 1.7449395262048029e-09
of O 0 2.8368674076517664e-10
European O 0 2.326009251873984e-08
or O 0 8.428538755822501e-09
non O 0 3.4141329763315298e-09
- O 0 1.569216578900523e-08
European O 0 2.827102774105583e-09
origin O 0 6.116347983642356e-10
, O 0 6.627778881274082e-11
with O 0 1.7656960615841655e-10
or O 0 9.257729027822847e-10
without O 0 2.5400917480489227e-10
a O 0 1.3718803870688134e-09
personal O 0 1.8528016454411045e-08
and O 0 8.666533268808507e-09
/ O 0 7.184836249507498e-06
or O 0 1.7087474546428894e-08
family O 0 7.002607382844417e-09
history O 0 9.656526689383327e-10
of O 0 7.52485851407414e-10
neoplasia B-Disease 0 9.613689144316595e-06
, O 0 2.0039592207865553e-09
were O 0 2.8360791493042825e-09
examined O 0 2.151239897330015e-08
for O 0 3.100743828365893e-10
the O 0 9.815519508293846e-10
I1307K O 0 7.20578086088608e-08
variant O 0 2.3500125223563373e-07
by O 0 8.044865329459583e-10
the O 0 1.8997401429743377e-09
allele O 0 3.81954635031434e-07
- O 0 9.076961760001723e-08
specific O 0 1.6246991307866665e-08
oligonucleotide O 0 7.737379746686202e-06
( O 0 1.1610507755221988e-07
ASO O 0 0.00010909231787081808
) O 0 2.989174063827704e-08
method O 0 3.238899921598204e-07
. O 0 1.0407800488110297e-07

RESULTS O 0 6.76426225254545e-06
In O 0 3.1116304199940714e-08
persons O 0 7.681814295779077e-09
at O 0 2.9348210972557354e-08
average O 0 5.307225023898354e-07
risk O 0 2.241026095362031e-06
for O 0 0.027110902592539787
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.080905225909646e-08
I1307K O 0 6.178886451380095e-07
was O 0 1.261957578435613e-07
found O 0 6.130506768897703e-09
in O 0 1.5510648765371116e-08
5 O 0 2.2971272528593545e-07
. O 0 1.2879353050720965e-07

0 O 0 4.952568815497216e-06
% O 0 3.6545134918242184e-08
of O 0 1.233925406296521e-09
120 O 0 2.0506687903321108e-08
European O 0 2.7065526708724974e-08
and O 0 1.8742273510952145e-08
1 O 0 1.2247093650330498e-07
. O 0 7.900052167997274e-08

6 O 0 5.984230938338442e-06
% O 0 5.131082048137614e-08
of O 0 2.6426592025785567e-09
188 O 0 1.1276333822252127e-07
non O 0 2.447354852108674e-08
- O 0 2.5824783733696677e-07
European O 0 7.84831257760743e-08
Jews O 0 1.794810877697728e-08
( O 0 7.326152573483569e-09
P O 0 2.3443924419552786e-06
= O 0 1.348347353768986e-07
0 O 0 4.020747113031575e-08
. O 0 7.740040608439358e-09
08 O 0 4.3403724703239277e-07
) O 0 2.2097317753377865e-08
. O 0 6.68423183469713e-08

It O 0 4.914779196951713e-07
occurred O 0 1.6934353652686696e-06
in O 0 1.2821264760987106e-07
15 O 0 1.7506852145743323e-07
. O 0 1.0386462889755421e-07

4 O 0 2.6792390599439386e-06
% O 0 1.954799877523783e-08
of O 0 2.046237401742701e-09
52 O 0 1.1019657364386148e-07
Ashkenazi O 0 1.3028826515437686e-06
Israelis O 0 8.492526859527061e-08
with O 0 1.133068607828136e-07
familial O 1 0.8223335146903992
cancer B-Disease 0 0.0532655194401741
( O 0 2.5008381498992094e-07
P O 0 0.0001579258096171543
= O 0 5.088579086987011e-07
0 O 0 6.869250768204438e-08
. O 0 6.030468124862409e-09
02 O 0 4.6293129685182066e-07
) O 0 9.999877592647977e-10
and O 0 6.949553710278167e-10
was O 0 2.0379303578010877e-08
not O 0 5.20064880049631e-10
detected O 0 2.1402389194236093e-08
in O 0 3.1274738354625242e-09
51 O 0 1.630544765873765e-08
non O 0 2.7149791304026394e-09
- O 0 2.145846877965596e-08
European O 0 1.0069109990240577e-08
Jews O 0 3.499045497790121e-09
at O 0 3.354312383407887e-08
increased O 0 2.2882849748384615e-07
cancer B-Disease 0 4.271616035111947e-06
risk O 0 7.833251629563165e-07
. O 0 1.5073698023115867e-07

Colorectal B-Disease 1 0.9999716281890869
neoplasia I-Disease 1 0.9905056357383728
occurred O 0 0.0007010126719251275
personally O 0 6.264878265938023e-06
or O 0 6.747316660948854e-08
in O 0 4.0867274009315224e-09
the O 0 1.640845681549763e-09
families O 0 2.4685897770382326e-10
of O 0 1.0611118234082895e-10
13 O 0 2.5617536980604427e-09
of O 0 2.0444182458057014e-10
20 O 0 5.3821787027175105e-09
Ashkenazi O 0 1.6781272904609068e-07
I1307K O 0 8.066952972285435e-08
carriers O 0 5.755432574972019e-09
, O 0 4.013479548703458e-10
8 O 0 2.945446775370897e-09
of O 0 8.982654897682352e-11
whom O 0 1.5581300694123001e-09
also O 0 3.1573701431142354e-09
had O 0 2.8985209787890653e-09
a O 0 1.7895935844336464e-09
personal O 0 1.341940514265616e-08
or O 0 5.6546611837404726e-09
family O 0 4.1788168481105e-09
history O 0 9.307001280767224e-10
of O 0 1.966031337730101e-09
noncolonic O 0 0.00011393665772629902
neoplasia B-Disease 0 0.0005980064161121845
. O 0 6.176647389111167e-07

CONCLUSIONS O 0 1.8649878256837837e-05
The O 0 2.5772524736566993e-07
I1307K O 0 7.672396350244526e-06
APC O 0 3.11537110064819e-06
variant O 0 1.070658163371263e-05
may O 0 9.575815340667759e-08
represent O 0 4.366850436809955e-09
a O 0 6.45205178173569e-09
susceptibility O 0 3.958721492836048e-07
gene O 0 6.860607868475199e-07
for O 0 1.069301092115893e-07
colorectal B-Disease 1 1.0
, I-Disease 0 7.2003105699991465e-09
or I-Disease 0 4.121900154530067e-09
other I-Disease 0 3.203299570042617e-10
, I-Disease 0 1.7920801509418993e-09
cancers I-Disease 0 3.0453179533651564e-07
in O 0 9.138541479103424e-09
Ashkenazi O 0 9.868857659967034e-07
Jews O 0 9.261672317961711e-09
, O 0 1.671651705947852e-09
and O 0 1.808383109924705e-09
partially O 0 1.3162390644083644e-07
explains O 0 5.325575536119231e-09
the O 0 5.976988348699308e-10
higher O 0 3.2911165703808365e-07
incidence O 0 0.0001971226156456396
of O 0 3.412258956814185e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.2305514474064694e-07
European O 0 5.093599497740797e-07
Israelis O 0 1.1871620699821506e-06
. O 0 2.247336539085154e-07

Systematic O 0 8.171205990947783e-06
analysis O 0 4.4346779759507626e-07
of O 0 2.0733422090302156e-08
coproporphyrinogen O 0 4.648308458854444e-05
oxidase O 0 0.00012327062722761184
gene O 0 0.0007088184356689453
defects O 1 0.5348668098449707
in O 0 9.888324825624295e-08
hereditary B-Disease 0 0.1439625322818756
coproporphyria I-Disease 0 0.0008038594969548285
and O 0 3.4947595395351527e-07
mutation O 0 2.7472531655803323e-05
update O 0 0.00014192453818395734
. O 0 1.067625362338731e-06

Hereditary B-Disease 1 0.999127209186554
coproporphyria I-Disease 1 0.6144234538078308
( O 0 9.89985255728243e-06
HC B-Disease 0 0.0005531710339710116
) O 0 1.1184207693304415e-07
is O 0 1.0193729416130282e-08
an O 0 1.9946021723171725e-08
acute O 0 0.012894518673419952
hepatic B-Disease 1 0.9999771118164062
porphyria I-Disease 1 0.9999986886978149
with O 0 8.070189323916566e-06
autosomal O 1 0.9999964237213135
dominant O 1 0.9729422926902771
inheritance O 0 6.514397682622075e-05
caused O 0 1.0394791161161265e-06
by O 0 2.027535828119653e-08
deficient B-Disease 0 7.340621777984779e-06
activity I-Disease 0 9.716858784258875e-08
of I-Disease 0 5.8228311061725435e-09
coproporphyrinogen I-Disease 0 2.4481112632201985e-05
III I-Disease 0 1.112732570618391e-05
oxidase I-Disease 0 7.036904662527377e-06
( O 0 1.2334076870956778e-07
CPO O 0 4.408741460792953e-06
) O 0 3.8833444904184944e-08
. O 0 5.232313782244091e-08

Clinical O 0 3.211742659914307e-05
manifestations O 0 3.925587861886015e-06
of O 0 1.2658602166482069e-08
the O 0 2.4340045001736144e-07
disease O 0 0.0002257163723697886
are O 0 1.1557174106613388e-09
characterized O 0 1.4763294586828124e-07
by O 0 1.5119098861759994e-08
acute O 0 6.039165327820228e-06
attacks O 0 4.2290987039450556e-05
of O 0 5.332531145540997e-07
neurological B-Disease 1 0.9999990463256836
dysfunction I-Disease 0 0.20223017036914825
often O 0 3.6420408378035063e-07
precipitated O 0 7.686637673032237e-07
by O 0 3.974857332167403e-09
drugs O 0 2.9567056358814625e-08
, O 0 3.6215517251747542e-09
fasting O 0 9.73493456513097e-07
, O 0 8.168207443759457e-09
cyclical O 0 1.3905763807997573e-05
hormonal O 0 2.007098009926267e-05
changes O 0 1.290732711822784e-07
, O 0 9.83120784781022e-09
or O 0 1.3215422995926929e-06
infectious B-Disease 0 0.010344160720705986
diseases I-Disease 0 0.006298575084656477
. O 0 6.275746500250534e-07

Skin O 1 0.9999998807907104
photosensitivity O 1 0.9999929666519165
may O 0 0.10680896788835526
also O 0 5.714394646361143e-08
be O 0 2.9678741686467447e-09
present O 0 1.989533515711628e-08
. O 0 1.0150389329055542e-07

The O 0 1.6664675683841779e-07
seven O 0 2.7243123312814532e-08
exons O 0 6.495728825939295e-07
, O 0 3.1533919919723985e-09
the O 0 1.2510168900803365e-08
exon O 0 7.252341220009839e-06
/ O 0 1.0586370081000496e-05
intron O 0 1.4967784409236629e-05
boundaries O 0 1.6585684647907328e-07
and O 0 4.345969806252015e-09
part O 0 2.702321477698888e-09
of O 0 5.230652022625293e-10
3 O 0 1.1028189916828524e-08
noncoding O 0 5.019204607492611e-08
sequence O 0 4.500067429802357e-09
of O 0 2.1402610239640296e-10
the O 0 3.7500349492347596e-09
CPO O 0 8.920789014155162e-07
gene O 0 2.908690355241106e-08
were O 0 7.816082780998101e-10
systematically O 0 7.529283863050296e-09
analyzed O 0 5.352796872415411e-09
by O 0 2.460992798436479e-10
an O 0 3.4332317544460977e-10
exon O 0 4.0421164726467396e-07
- O 0 1.6979684858142718e-07
by O 0 3.922770375197615e-08
- O 0 4.571355020743795e-06
exon O 0 2.0056169887539e-05
denaturing O 0 0.00014123656728770584
gradient O 0 1.53523069457151e-05
gel O 0 3.332104461151175e-05
electrophoresis O 0 3.0476819574687397e-06
( O 0 3.995016228941495e-08
DGGE O 0 1.6754628404669347e-06
) O 0 2.476872928980356e-09
strategy O 0 1.0609145562057165e-08
followed O 0 2.6816040499255678e-09
by O 0 1.868172283536751e-10
direct O 0 9.085562857613638e-10
sequencing O 0 6.22186036025596e-09
in O 0 1.4386014601797115e-09
seven O 0 5.541684444665407e-09
unrelated O 0 1.802109181880951e-07
heterozygous O 0 4.866561539529357e-06
HC B-Disease 0 2.967506407003384e-05
patients O 0 2.765125657333556e-07
from O 0 2.0666579558792364e-08
France O 0 2.9079474188620225e-06
, O 0 5.733300501020722e-09
Holland O 0 2.3321636035689153e-06
, O 0 1.6333361330111984e-09
and O 0 2.829697809403342e-09
Czech O 0 1.8734070863501984e-06
Republic O 0 5.192511594032112e-07
. O 0 1.0457448240686062e-07

Seven O 0 2.0596100966940867e-06
novel O 0 1.1366481658114935e-06
mutations O 0 5.118739409226691e-06
and O 0 1.0001446781870982e-08
two O 0 2.604717330711992e-09
new O 0 1.2833473306272936e-07
polymorphisms O 0 6.1130112953833304e-06
were O 0 8.408326834796753e-08
detected O 0 5.791736839455552e-06
. O 0 2.1356069623834628e-07

Among O 0 1.7495503357167763e-07
these O 0 9.401835754374588e-09
mutations O 0 2.210548188941175e-07
two O 0 4.9725010775603096e-09
are O 0 3.291553474227271e-09
missense O 0 3.005831331392983e-06
( O 0 3.9447844102369345e-08
G197W O 0 4.61372366089563e-07
, O 0 3.1523936794286556e-09
W427R O 0 2.2079377970385394e-07
) O 0 2.4807687015737656e-09
, O 0 4.99352281746468e-10
two O 0 6.224551429845349e-10
are O 0 5.041141393213877e-10
nonsense O 0 3.8635299404177204e-08
( O 0 3.473253018526634e-09
Q306X O 0 9.595707695098099e-08
, O 0 1.1235918861984828e-09
Q385X O 0 6.543691455362932e-08
) O 0 6.371724814435709e-10
, O 0 1.230852642031266e-10
two O 0 1.0640201220102341e-10
are O 0 8.262055622987319e-11
small O 0 1.0415576179312325e-09
deletions O 0 3.8403581470447534e-07
( O 0 1.233676627521163e-08
662de14bp O 0 3.24005526408655e-07
; O 0 5.201266084498002e-09
1168del3bp O 0 4.87856937070319e-07
removing O 0 3.917685731380516e-08
a O 0 1.6203324904040528e-08
glycine O 0 2.678339569683885e-06
at O 0 2.731988217874459e-07
position O 0 9.324048022563147e-08
390 O 0 4.896495653383681e-08
) O 0 1.7993481149503054e-09
, O 0 2.687983169380459e-10
and O 0 3.2597197163752867e-10
one O 0 2.0502366471220057e-10
is O 0 2.158940803909104e-10
a O 0 2.5233461986573502e-09
splicing O 0 1.4246510318116634e-06
mutation O 0 5.030628926760983e-07
( O 0 4.539743514442307e-08
IVS1 O 0 7.049297437333735e-06
- O 0 2.5528786409267923e-06
15c O 0 2.676859003258869e-05
- O 0 3.967769316659542e-06
- O 0 2.042372216237709e-06
> O 0 6.02309057740058e-07
g O 0 1.25054555155657e-06
) O 0 2.28160224047258e-09
which O 0 1.0125186244991369e-09
creates O 0 3.3838376545247684e-09
a O 0 2.0064145900278163e-09
new O 0 2.504627616417565e-08
acceptor O 0 3.4968530826517963e-07
splice O 0 1.3403476259554736e-05
site O 0 2.931025619545835e-06
. O 0 2.8838601906500116e-07

The O 0 3.0424820351981907e-07
pathological O 0 7.100881589394703e-07
significance O 0 9.575684245533012e-09
of O 0 9.223641850297781e-10
the O 0 3.867177689187429e-09
point O 0 2.1798259197680636e-08
mutations O 0 1.9369595349871815e-07
G197W O 0 3.518040045946691e-07
, O 0 1.3879218885293199e-09
W427R O 0 5.697829408291e-08
, O 0 4.432089972805642e-10
and O 0 1.2927597881073893e-10
the O 0 6.855213063872156e-10
in O 0 7.656683287393662e-09
- O 0 7.974868481142039e-07
frame O 0 1.2968039300176315e-05
deletion O 0 5.228831696513225e-07
390delGly O 0 2.700020615975518e-07
were O 0 8.509299931347414e-10
assessed O 0 3.1961970847760313e-09
by O 0 4.033893774568753e-10
their O 0 1.014428430146097e-09
respective O 0 5.609725572952584e-09
expression O 0 2.692654099689662e-09
in O 0 9.589661287279228e-10
a O 0 1.739098420827645e-09
prokaryotic O 0 1.322383536006555e-08
system O 0 4.346046722503161e-08
using O 0 2.456989989241265e-08
site O 0 1.4417726390547614e-07
- O 0 1.8976864168962493e-07
directed O 0 3.396396763832854e-08
mutagenesis O 0 1.9355427411937853e-06
. O 0 7.668583634767856e-08

These O 0 4.3142165395693155e-07
mutations O 0 5.162405614100862e-06
resulted O 0 2.4105756324388494e-07
in O 0 1.9761078107194407e-08
the O 0 8.173256738075452e-09
absence O 0 1.9146774832279334e-08
or O 0 3.829859096526889e-09
a O 0 3.987409069594605e-09
dramatic O 0 6.749865377742026e-08
decrease O 0 1.651116292578081e-07
of O 0 5.262677404971328e-09
CPO O 0 1.5389496184070595e-05
activity O 0 6.947756787667458e-07
. O 0 1.4499467226869456e-07

The O 0 3.3059453130590555e-07
two O 0 2.2604089267019845e-08
polymorphisms O 0 1.975885197680327e-06
were O 0 1.026241847057463e-08
localized O 0 4.351114739620243e-07
in O 0 3.800803227704819e-08
noncoding O 0 6.787847723899176e-07
part O 0 6.465775470587687e-09
of O 0 3.5753591753895364e-10
the O 0 2.2496078333489322e-09
gene O 0 4.4340730198655365e-08
1 O 0 5.331632912941586e-09
) O 0 9.983582849315553e-10
a O 0 7.956862724256553e-09
C O 0 1.4569881386705674e-05
/ O 0 3.717474328368553e-06
G O 0 2.103469341818709e-06
polymorphism O 0 4.962219577464566e-07
in O 0 7.846348459850105e-09
the O 0 2.005891275302929e-08
promotor O 0 2.59588136941602e-06
region O 0 2.5224766275755428e-08
, O 0 3.2283080653172647e-09
142 O 0 3.247212632118135e-08
bp O 0 2.2273482613854867e-07
upstream O 0 3.843846130280326e-08
from O 0 8.66157090495534e-10
the O 0 1.3325663905661145e-09
transcriptional O 0 2.810936905461858e-07
initiation O 0 2.8921162353867658e-08
site O 0 1.306516708154959e-07
( O 0 1.52985730750288e-08
- O 0 4.100503474546713e-07
142C O 0 3.520137852319749e-06
/ O 0 9.20236561796628e-06
G O 0 2.1228884179436136e-06
) O 0 2.084217021192103e-09
, O 0 3.758984234991658e-10
and O 0 2.1456850185508358e-10
2 O 0 2.780359720233605e-09
) O 0 3.9698319631575885e-10
a O 0 3.0229201364306846e-09
6 O 0 3.1217183504850254e-08
bp O 0 1.9447482202394895e-07
deletion O 0 1.5779031059537374e-07
polymorphism O 0 1.5934546127027716e-07
in O 0 4.741808279362658e-09
the O 0 4.121805563528369e-09
3 O 0 6.389240692072917e-09
noncoding O 0 5.7124438512801134e-08
part O 0 1.5432999322939622e-09
of O 0 2.303270907333399e-10
the O 0 2.8674034258102665e-09
CPO O 0 5.738849608860619e-07
gene O 0 4.578919998721176e-08
, O 0 9.1828994408516e-10
574 O 0 3.842226092842793e-08
bp O 0 5.033969330270338e-08
downstream O 0 6.007576214273058e-09
of O 0 8.331400153105406e-11
the O 0 6.589300216575111e-10
last O 0 3.904822687417209e-09
base O 0 1.3385681452149356e-09
of O 0 5.657795065783233e-11
the O 0 1.2877867661131859e-09
normal O 0 2.365367208767566e-07
termination O 0 3.715712466600962e-07
codon O 0 2.272731080665835e-06
( O 0 4.088250094014256e-08
+ O 0 3.913519037723745e-07
574 O 0 9.78766934167652e-07
delATTCTT O 0 2.7115654575027293e-06
) O 0 8.226326286830954e-08
. O 0 1.1442621428159327e-07

Five O 0 1.9102985788777005e-06
intragenic O 0 6.526734796352684e-05
dimorphisms O 0 4.642987551051192e-05
are O 0 8.369266168983813e-09
now O 0 3.864154773935979e-09
well O 0 2.4828659128672825e-09
characterized O 0 7.57174234422564e-08
and O 0 3.775368906389076e-09
the O 0 2.7721362982902065e-09
high O 0 3.269754600410124e-08
degree O 0 1.6046034501115969e-09
of O 0 8.074472757080287e-10
allelic O 0 1.5050297861307627e-06
heterogeneity O 0 1.0689540204111836e-06
in O 0 2.436889019463706e-07
HC B-Disease 0 0.002367465989664197
is O 0 1.665707216602641e-08
demonstrated O 0 3.961694972076657e-09
with O 0 2.862631243161218e-10
seven O 0 5.366144195662059e-10
new O 0 2.6197144453732335e-09
different O 0 1.0665504035500817e-09
mutations O 0 1.775125824110546e-08
making O 0 7.657526834847772e-10
a O 0 1.1191623183748334e-09
total O 0 3.684507421386485e-10
of O 0 2.7381977241169864e-10
nineteen O 0 1.1510150699223232e-07
CPO O 0 9.560499165672809e-05
gene B-Disease 0 3.7124416849110276e-05
defects I-Disease 0 0.0736401304602623
reported O 0 1.192185777654231e-06
so O 0 8.73458816386119e-09
far O 0 2.1804122951607496e-08
. O 0 9.066783768219011e-09
. O 0 4.8221824755501075e-08

Coincidence O 0 5.14304429088952e-06
of O 0 1.4259456726506414e-08
two O 0 6.155381537809035e-09
novel O 0 2.2666130305992738e-08
arylsulfatase O 0 5.493005232892756e-07
A O 0 7.442618965569636e-08
alleles O 0 2.9266161050145456e-07
and O 0 1.6105467182114808e-08
mutation O 0 1.160405986411206e-06
459 O 0 1.2616678759513889e-06
+ O 0 8.94746506219235e-07
1G O 0 8.608163625467569e-05
> O 0 4.234800883295975e-07
A O 0 1.5672005915234877e-08
within O 0 4.209198323223973e-09
a O 0 2.6134673092315097e-08
family O 0 9.251488108930062e-08
with O 0 4.787586505017316e-08
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999996423721313
: O 0 1.0532891003833811e-08
molecular O 0 5.619195064809901e-08
basis O 0 8.34984614783707e-09
of O 0 3.5906830841980764e-09
phenotypic O 0 2.5135852865787456e-06
heterogeneity O 0 1.7329528418486007e-05
. O 0 7.504654604417738e-07

In O 0 3.243889068471617e-07
a O 0 6.502460081492245e-08
family O 0 2.8279778518935927e-08
with O 0 1.911305114177253e-09
three O 0 7.3006813927634084e-09
siblings O 0 8.593863043415695e-08
, O 0 2.62657756655571e-10
one O 0 6.006954378356966e-10
developed O 0 3.657686420410755e-08
classical O 0 5.738127129006898e-07
late O 1 0.6741122603416443
infantile O 1 0.9999995231628418
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 4.4474913920566905e-06
MLD B-Disease 1 0.9999994039535522
) O 0 1.7556065046164804e-08
, O 0 2.1056019150478278e-09
fatal O 0 3.359503580213641e-06
at O 0 9.609912012820132e-06
age O 0 1.143884702514697e-07
5 O 0 1.3207853477581466e-08
years O 0 2.8971611776285044e-09
, O 0 5.449546924829463e-10
with O 0 4.95387109111789e-09
deficient O 0 7.049411942716688e-05
arylsulfatase O 0 3.881718384945998e-06
A O 0 3.0407272788579576e-07
( O 0 3.720406382967667e-08
ARSA O 0 9.084727935260162e-06
) O 0 4.047715052024614e-09
activity O 0 4.47610943865584e-08
and O 0 3.783196866891103e-09
increased O 0 9.8893998767835e-08
galactosylsulfatide O 0 4.676332537201233e-05
( O 0 6.536668593071226e-07
GS O 1 0.9999988079071045
) O 0 1.3630916839701968e-07
excretion O 0 3.118486120001762e-06
. O 0 1.5803036035322293e-07

The O 0 5.229210842117027e-08
two O 0 6.8470620284699635e-09
other O 0 8.615354540886244e-10
siblings O 0 4.103796769072687e-08
, O 0 9.942687784203486e-10
apparently O 0 2.5926247815277748e-08
healthy O 0 3.421272509740447e-08
at O 0 4.7023618776620424e-08
12 O 0 1.973023344703506e-08
( O 0 4.975651002325776e-09
1 O 0 4.091096883485079e-08
/ O 0 2.2703136437485227e-06
2 O 0 1.229035717642546e-08
) O 0 5.33980248906829e-10
and O 0 2.2671640953486616e-10
15 O 0 7.865958995267874e-10
years O 0 2.4013444011039553e-10
, O 0 7.988332217934158e-11
respectively O 0 1.1579943670625426e-09
, O 0 8.689050173815716e-11
and O 0 1.5480426662772828e-10
their O 0 1.772087143692147e-09
father O 0 4.510570406068837e-08
, O 0 1.846499064761531e-10
apparently O 0 7.745017072124938e-09
healthy O 0 9.116118526719674e-09
as O 0 4.986555612873644e-10
well O 0 9.609582019010077e-10
, O 0 3.8443037642110767e-10
presented O 0 1.2373741142823746e-08
ARSA O 0 7.318997086258605e-05
and O 0 6.197901569748865e-08
GS O 1 0.9999878406524658
values O 0 8.118504091214618e-09
within O 0 8.880818858081341e-10
the O 0 1.8625126996241193e-09
range O 0 5.3165152280598704e-08
of O 0 1.8893054232194118e-08
MLD B-Disease 1 1.0
patients O 0 2.400308630967629e-06
. O 0 2.196064485815441e-07

Mutation O 0 8.803134551271796e-05
screening O 0 7.035301223368151e-06
and O 0 3.998332331889287e-08
sequence O 0 5.78857317634629e-08
analysis O 0 2.790966391330585e-08
disclosed O 0 6.592599532950771e-08
the O 0 5.532064140112425e-09
involvement O 0 1.136433791515401e-08
of O 0 2.559144562930271e-10
three O 0 1.0598542043993575e-09
different O 0 3.7079292969366406e-09
ARSA O 0 0.00097176170675084
mutations O 0 7.078602379806398e-07
being O 0 1.365195401170638e-09
the O 0 3.1176569659230324e-10
molecular O 0 7.27671434219701e-09
basis O 0 2.5718636109672843e-09
of O 0 1.3216440164498522e-09
intrafamilial O 0 7.4783156378543936e-06
phenotypic O 0 5.1390138651186135e-06
heterogeneity O 0 9.867721018963493e-06
. O 0 4.993775633010955e-07

The O 0 4.283035934804502e-07
late O 0 6.514776760013774e-05
infantile O 1 0.9970672726631165
patient O 0 0.0005351904546841979
inherited O 0 0.0024966371711343527
from O 0 4.1809634865330736e-08
his O 0 1.776877951442657e-07
mother O 0 1.2857299225288443e-07
the O 0 3.4015426031430707e-09
frequent O 0 1.8711273241933668e-07
0 O 0 1.7661197659890604e-07
- O 0 7.71110251207574e-07
type O 0 7.826403816579841e-06
mutation O 0 2.262752786919009e-06
459 O 0 9.907899993777392e-07
+ O 0 4.0837656456460536e-07
1G O 0 9.48189972405089e-06
> O 0 1.7438965471683332e-07
A O 0 2.4967482303850375e-08
, O 0 8.429917319752178e-10
and O 0 5.930474444859613e-10
from O 0 9.562920455508106e-10
his O 0 1.4490365352060053e-08
father O 0 2.36550210530595e-08
a O 0 2.0861579130837526e-09
novel O 0 3.826813976814947e-09
, O 0 3.8515773903569084e-10
single O 0 7.288076364631024e-09
basepair O 0 3.072011054428003e-07
microdeletion O 0 1.7430518539640616e-07
of O 0 1.4195785658088766e-09
guanine O 0 8.353800495797259e-08
at O 0 1.5863367508472948e-08
nucleotide O 0 1.1057829141236653e-07
7 O 0 2.8086798664617163e-08
in O 0 7.783446775988523e-09
exon O 0 1.1265128705417737e-06
1 O 0 7.804246848763796e-08
( O 0 3.4723075970077844e-08
7delG O 0 2.1374255538830766e-06
) O 0 4.295987210412022e-08
. O 0 9.058957317620298e-08

The O 0 4.3625701096061675e-07
two O 0 8.535983653246149e-08
clinically O 0 3.919565187970875e-06
unaffected O 0 1.2907877135148738e-05
siblings O 0 7.97454958956223e-07
carried O 0 9.409104961832782e-08
the O 0 2.2407574462590674e-08
maternal O 0 2.9742282094957773e-06
mutation O 0 1.9885526398866205e-06
459 O 0 1.3217994592196192e-06
+ O 0 7.826068326721725e-07
1G O 0 3.309531166451052e-05
> O 0 5.958724500487733e-07
A O 0 9.035074555185929e-08
and O 0 3.661377201424898e-09
, O 0 2.9716734628593144e-10
on O 0 5.631445088027931e-09
their O 0 3.259566172530981e-09
paternal O 0 3.3015976441674866e-07
allele O 0 1.0631127622673375e-07
, O 0 2.59992111173446e-10
a O 0 1.2086704970215578e-09
novel O 0 9.976830028790573e-09
cytosine O 0 1.0412585993435641e-07
to O 0 4.54771464930559e-09
thymidine O 0 7.635291012775269e-07
transition O 0 8.210353286131067e-08
at O 0 3.2935460581029474e-08
nucleotide O 0 3.2978275044115435e-07
2435 O 0 4.872068984695943e-06
in O 0 2.6356334004162818e-08
exon O 0 1.004586010822095e-06
8 O 0 9.390477373472095e-08
, O 0 7.573714433384282e-10
resulting O 0 3.977321583192861e-09
in O 0 2.0868902161907954e-09
substitution O 0 1.2961412387824112e-08
of O 0 1.3679819499401447e-09
alanine O 0 2.1575408482021885e-06
464 O 0 2.513621097932628e-07
by O 0 2.1025369889571266e-08
valine O 0 4.104856270714663e-05
( O 0 5.44665326174254e-08
A464V O 0 1.4972833923820872e-06
) O 0 4.297175593137581e-08
. O 0 6.798161678034376e-08

The O 0 1.826900756896066e-06
fathers O 0 6.697492153762141e-06
genotype O 0 1.3374108675634488e-05
thus O 0 3.2610233802188304e-07
was O 0 6.437954880311736e-07
7delG O 0 2.1314783225534484e-05
/ O 0 2.7592655897024088e-05
A464V O 0 2.682621925487183e-05
. O 0 6.291374461397936e-07

Mutation O 0 0.0001429843105142936
A464V O 0 3.401430512894876e-05
was O 0 9.603074886399554e-07
not O 0 1.637269320120538e-09
found O 0 1.8064146845020446e-09
in O 0 3.4036906626511154e-09
18 O 0 7.380545952173634e-08
unrelated O 0 2.5334734345960896e-06
MLD B-Disease 1 1.0
patients O 0 8.95003381629067e-07
and O 0 1.4961637262445038e-08
50 O 0 1.3006489041345048e-07
controls O 0 0.0008968461188487709
. O 0 2.755348873506591e-07

A464V O 0 8.364720997633412e-05
, O 0 1.3717455260575662e-07
although O 0 7.08516836311901e-08
clearly O 0 2.560647089921986e-07
modifying O 0 5.725517439714167e-06
ARSA O 0 0.0039725829847157
and O 0 1.311679397986154e-06
GS O 1 0.9999998807907104
levels O 0 3.850248504022602e-06
, O 0 2.4974711188008314e-09
apparently O 0 2.5142579573866897e-08
bears O 0 3.1398119659797885e-08
little O 0 5.143464765211547e-09
significance O 0 3.194764897074265e-09
for O 0 6.856690770717933e-10
clinical O 0 3.2595799837054074e-08
manifestation O 0 9.943531864564648e-08
of O 0 1.6907833355617186e-08
MLD B-Disease 1 0.9999997615814209
, O 0 9.402373990496926e-09
mimicking O 0 1.1190923032700084e-06
the O 0 3.448145591278262e-08
frequent O 0 2.783141781037557e-06
ARSA O 0 0.005148967728018761
pseudodeficiency O 0 9.74116483121179e-05
allele O 0 4.491976505960338e-05
. O 0 6.553215712301608e-07

Our O 0 5.148070840732544e-07
results O 0 1.2382338354655076e-07
demonstrate O 0 1.8096262266453778e-08
that O 0 3.125736891540498e-10
in O 0 7.600181595179833e-10
certain O 0 1.7913488470355787e-09
genetic O 0 1.4935496039925056e-07
conditions O 0 1.2562661140691489e-05
MLD B-Disease 1 1.0
- O 0 6.581228080904111e-05
like O 0 1.3752297434166394e-07
ARSA O 0 0.0031561285723000765
and O 0 7.638087708983221e-07
GS O 1 1.0
values O 0 5.863323337962356e-08
need O 0 1.1881990946704946e-09
not O 0 1.6399437363645575e-10
be O 0 1.3823836519932797e-10
paralleled O 0 1.3367316142876007e-08
by O 0 1.4551123639350294e-09
clinical O 0 1.2391694781399565e-07
disease O 0 2.928077947217389e-06
, O 0 2.8403271401522545e-10
a O 0 8.291407560534481e-10
finding O 0 4.716836921048184e-10
with O 0 9.759292263211705e-10
serious O 0 8.588718003466056e-08
diagnostic O 0 7.304859536816366e-06
and O 0 5.147629167367995e-08
prognostic O 0 6.642254447797313e-06
implications O 0 7.049795840430306e-07
. O 0 3.340674652463349e-07

Moreover O 0 1.2924408110848162e-05
, O 0 1.565077383247626e-07
further O 0 1.988301221444999e-07
ARSA O 0 0.0004244637966621667
alleles O 0 4.8192127906077076e-06
functionally O 0 8.484283284815319e-07
similar O 0 3.464752396098447e-08
to O 0 7.0504388993697376e-09
A464V O 0 6.524088576043141e-07
might O 0 9.660952926537902e-09
exist O 0 1.217281497822853e-09
which O 0 7.203740937100633e-10
, O 0 6.059424489945897e-11
together O 0 1.6171322614333405e-10
with O 0 3.257885905494362e-10
0 O 0 3.0480954649192427e-08
- O 0 1.7691367020233884e-06
type O 0 0.00014450933667831123
mutations O 0 1.1595353726079338e-06
, O 0 3.4422953376633814e-09
may O 0 6.873523261674563e-08
cause O 0 6.892309301065325e-08
pathological O 0 5.739549919780984e-07
ARSA O 0 0.030081868171691895
and O 0 2.9324207844183547e-06
GS O 1 1.0
levels O 0 8.021550570447289e-07
, O 0 4.783665685792471e-10
but O 0 3.4612943067280355e-10
not O 0 3.4131156234629145e-10
clinical O 0 5.438770767085543e-09
outbreak O 0 8.721956845647583e-08
of O 0 6.681714626033397e-10
the O 0 8.894186009911209e-08
disease O 0 9.262314961233642e-06
. O 0 4.1769121494894534e-09
. O 0 4.96527263749158e-08

Human O 0 0.00029278211877681315
MLH1 O 1 0.999824583530426
deficiency O 1 0.999440610408783
predisposes O 0 0.0004521057417150587
to O 0 2.676996473383042e-06
hematological B-Disease 1 0.9522563219070435
malignancy I-Disease 1 0.8063616156578064
and O 0 1.529197470517829e-05
neurofibromatosis B-Disease 1 0.999993085861206
type I-Disease 1 0.9094036817550659
1 I-Disease 0 8.505902769684326e-06
. O 0 4.7370966171911277e-07

Heterozygous O 0 0.0010293694213032722
germ O 0 0.003644660348072648
- O 0 0.0009156259475275874
line O 0 2.631100323924329e-05
mutations O 0 1.3643224292536615e-06
in O 0 5.51581713637006e-09
the O 0 4.3887360412497856e-09
DNA O 0 5.504710429704573e-07
mismatch O 0 8.551122846256476e-06
repair O 0 1.2208710359118413e-05
genes O 0 1.7453324119287572e-07
lead O 0 6.467627855499813e-08
to O 0 3.3784391462177155e-07
hereditary B-Disease 1 0.9999998807907104
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.6338781228550943e-06

The O 0 1.174246790469624e-06
disease O 0 0.0002458181115798652
susceptibility O 0 3.5011585168831516e-06
of O 0 6.553431575184732e-09
individuals O 0 5.305329509042167e-09
who O 0 2.0141648349181196e-08
constitutionally O 0 1.63327979407768e-06
lack O 0 1.8789805267260817e-08
both O 0 5.757661014627047e-09
wild O 0 2.80770592553381e-07
- O 0 0.001660478999838233
type O 0 0.0017035381169989705
alleles O 0 7.889117910053756e-07
is O 0 1.1618223716425291e-08
unknown O 0 5.2856766075137784e-08
. O 0 3.884944632659426e-08

We O 0 2.2490132778330008e-07
have O 0 3.0868014810891964e-09
identified O 0 4.340270365332799e-09
three O 0 2.399339060765726e-10
offspring O 0 4.015280996583215e-09
in O 0 2.613132155104836e-09
a O 0 1.791299126807644e-07
hereditary B-Disease 1 0.9999995231628418
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.7933836716110818e-05
who O 0 7.427246373481466e-08
developed O 0 1.7414614603694645e-06
hematological B-Disease 0 0.002101298188790679
malignancy I-Disease 0 0.00014270619431044906
at O 0 3.7407215813800576e-07
a O 0 2.0734134409394755e-08
very O 0 1.63542228648339e-08
early O 0 5.116674856253667e-06
age O 0 2.8085512582265437e-08
, O 0 1.4544955517781233e-10
and O 0 3.712746776685094e-10
at O 0 1.2344957056598105e-08
least O 0 3.1340169348581526e-10
two O 0 1.5946380327314102e-10
of O 0 6.695438647952301e-11
them O 0 2.7381144573901395e-10
displayed O 0 7.782440292203319e-08
signs O 0 9.844833925853891e-08
of O 0 1.3004666232774298e-09
neurofibromatosis B-Disease 0 0.19551262259483337
type I-Disease 0 4.118497599847615e-05
1 I-Disease 0 3.824277428066125e-07
( O 0 1.1652316800336848e-07
NF1 B-Disease 0 3.246654523536563e-05
) O 0 6.916527439670972e-08
. O 0 1.0946943262979403e-07

DNA O 0 4.024655481771333e-06
sequence O 0 8.931966135605762e-07
analysis O 0 6.49885123493732e-08
and O 0 6.252684148222443e-09
allele O 0 4.851140715800284e-07
- O 0 1.1608725714040702e-07
specific O 0 9.626520025562968e-09
amplification O 0 8.373275477424613e-07
in O 0 5.4289044371103046e-09
two O 0 2.8836102394791396e-09
siblings O 0 9.775359188779476e-08
revealed O 0 6.928515716708716e-08
a O 0 6.986507372630513e-08
homozygous O 0 1.4319726687972434e-05
MLH1 O 0 0.0003401957219466567
mutation O 0 9.494078767602332e-06
( O 0 2.2377595598754851e-07
C676T O 0 7.558851848443737e-06
- O 0 4.200225157546811e-05
- O 0 1.34261317725759e-05
> O 0 2.3741863515169825e-06
Arg226Stop O 0 1.1949167856073473e-05
) O 0 8.207816648564403e-08
. O 0 1.3014850708259473e-07

Thus O 0 1.1063099236707785e-06
, O 0 1.8969675608104808e-08
a O 0 2.422748579533618e-08
homozygous O 0 5.64273250347469e-06
germ O 0 0.00021170401305425912
- O 0 0.00025625209673307836
line O 0 0.00026535699726082385
MLH1 O 0 0.0013080573407933116
mutation O 0 9.54481765802484e-06
and O 0 9.495697383954393e-08
consequent O 0 2.6382993382867426e-05
mismatch O 1 0.95859694480896
repair O 1 0.9999998807907104
deficiency O 1 0.9995062351226807
results O 0 5.08679875110829e-07
in O 0 3.0826843300246765e-08
a O 0 1.5898480398846004e-07
mutator O 0 0.0021407969761639833
phenotype O 0 2.047612906608265e-05
characterized O 0 3.6228738053978304e-07
by O 0 2.7192196938585766e-08
leukemia B-Disease 1 0.6644822955131531
and O 0 2.4313719677593326e-06
/ O 1 0.9999189376831055
or O 1 0.9848417043685913
lymphoma B-Disease 1 1.0
associated O 0 2.2557574993697926e-05
with O 0 5.520403192349477e-07
neurofibromatosis B-Disease 1 0.9999979734420776
type I-Disease 0 0.08929982781410217
1 I-Disease 0 6.147687372504151e-07
. O 0 2.8669838059158792e-08
. O 0 1.1933762777971424e-07

Missense O 0 0.010172500275075436
mutations O 0 0.0013408457161858678
in O 0 3.200017886229034e-07
the O 0 6.254998297094971e-09
most O 0 6.154873277708361e-10
ancient O 0 1.5244850937179422e-09
residues O 0 5.574264605456847e-08
of O 0 4.959541666238465e-10
the O 0 8.799888817634383e-09
PAX6 O 0 1.2477372365538031e-05
paired O 0 3.2729934673625394e-07
domain O 0 1.7058076196008187e-07
underlie O 0 5.271943450679828e-07
a O 0 1.7856528700122e-08
spectrum O 0 4.205433015158633e-07
of O 0 6.8955414711524554e-09
human O 0 1.8510233985580271e-06
congenital B-Disease 1 1.0
eye I-Disease 1 0.9998605251312256
malformations I-Disease 1 0.9996665716171265
. O 0 2.0982299702154705e-06

Mutations O 0 6.82183017488569e-05
of O 0 2.0725158478285266e-08
the O 0 2.7224476895071348e-08
human O 0 1.0691828578046625e-07
PAX6 O 0 0.00045970187056809664
gene O 0 0.0005251421243883669
underlie O 1 0.8720622062683105
aniridia B-Disease 1 1.0
( O 0 0.02425091154873371
congenital B-Disease 1 0.9999997615814209
absence I-Disease 0 3.2672772931618965e-07
of I-Disease 0 1.6160631721717778e-09
the I-Disease 0 2.6172585876338417e-08
iris I-Disease 0 2.979362034238875e-05
) O 0 2.246066443944983e-09
, O 0 3.921075686363906e-10
a O 0 5.275631931311864e-09
rare O 0 2.1922873827406875e-07
dominant O 1 0.8348384499549866
malformation B-Disease 1 0.5692120790481567
of I-Disease 0 4.1754071311572716e-09
the I-Disease 0 8.34752427181229e-08
eye I-Disease 0 0.0001360788883175701
. O 0 3.9858150557847694e-07

The O 0 1.2949781194038223e-06
spectrum O 0 3.4312367915845243e-06
of O 0 2.691951905831047e-08
PAX6 O 0 0.00020251622481737286
mutations O 0 7.350079249590635e-05
in O 0 3.16066052619135e-06
aniridia B-Disease 1 1.0
patients O 0 1.4026913049747236e-05
is O 0 3.768246159552291e-09
highly O 0 1.1140875777471138e-08
biased O 0 2.41306452153367e-07
, O 0 4.979949785877125e-10
with O 0 6.243195405097879e-10
92 O 0 3.1324663751775006e-08
% O 0 2.205603061300465e-10
of O 0 2.5263536054809244e-11
all O 0 2.8791571904385194e-10
reported O 0 4.2026945834550133e-07
mutations O 0 2.7652046696857724e-07
leading O 0 3.063540887637828e-08
to O 0 2.6312987344567773e-08
premature O 0 1.7924319308804115e-06
truncation O 0 3.251440148233087e-07
of O 0 1.7893204695695886e-09
the O 0 1.4802678194314467e-08
protein O 0 1.0661322846772237e-07
( O 0 9.034279102593246e-09
nonsense O 0 6.106841254904793e-08
, O 0 6.31592056432595e-10
splicing O 0 9.401964717881128e-08
, O 0 1.121972847961672e-09
insertions O 0 6.441258193490285e-08
and O 0 1.0167102715286092e-09
deletions O 0 5.6699679618077425e-08
) O 0 1.0315654996873036e-09
and O 0 1.1021454859871938e-09
just O 0 4.249151697166553e-09
2 O 0 7.323581296958537e-09
% O 0 3.3459382486888956e-10
leading O 0 6.242968919600855e-10
to O 0 2.0919026233467974e-10
substitution O 0 1.2729657328236499e-09
of O 0 8.039032634021837e-11
one O 0 2.0747921436470307e-10
amino O 0 2.6987416745782866e-09
acid O 0 4.9588058104177435e-09
by O 0 5.858544205317173e-10
another O 0 6.3133223093814195e-09
( O 0 1.2851546493664046e-08
missense O 0 1.6249631471509929e-06
) O 0 2.538970278465058e-08
. O 0 9.662135624921575e-08

The O 0 2.196282196109678e-07
extraordinary O 0 1.2108705504942918e-07
conservation O 0 2.1627428736792353e-08
of O 0 8.463524325819094e-10
the O 0 8.319958055835741e-09
PAX6 O 0 2.9169909794291016e-06
protein O 0 9.500407571749747e-08
at O 0 1.7064870405647525e-08
the O 0 3.1265492417276164e-09
amino O 0 2.5638277278972055e-08
acid O 0 5.683686410407063e-08
level O 0 2.0288432267534517e-08
amongst O 0 7.874804808238878e-09
vertebrates O 0 7.962149339846292e-08
predicts O 0 3.7587949464068515e-07
that O 0 2.131357090817687e-09
pathological O 0 6.015398525960336e-07
missense O 0 1.594270179339219e-05
mutations O 0 1.3201731235312764e-05
should O 0 1.754532164000011e-08
in O 0 3.917385082985447e-09
fact O 0 2.0953379031851682e-09
be O 0 6.068854307983429e-10
common O 0 2.2285873146898894e-09
even O 0 2.777211571824978e-09
though O 0 2.154737499537873e-09
they O 0 4.581579837736882e-10
are O 0 1.2637214885646841e-10
hardly O 0 4.943422560188537e-09
ever O 0 2.6941695541182753e-09
seen O 0 3.3882507466387324e-08
in O 0 7.883645736228573e-08
aniridia B-Disease 1 1.0
patients O 0 1.5708075125075993e-06
. O 0 1.684921642208792e-07

This O 0 1.9265139883373195e-07
indicates O 0 7.550701042191577e-08
that O 0 7.303017079962615e-10
there O 0 3.5627381600455976e-10
is O 0 2.538575460953041e-10
a O 0 3.3251552622459712e-09
heavy O 0 1.6488063920405693e-05
ascertainment O 0 6.582352216355503e-05
bias O 0 3.1792526442586677e-06
in O 0 4.460425362395881e-09
the O 0 4.3031833651951956e-10
selection O 0 9.413494428400782e-10
of O 0 2.753711425551586e-10
patients O 0 8.132095885571289e-09
for O 0 2.3092412426706233e-09
PAX6 O 0 9.51230413193116e-06
mutation O 0 4.0071276430353464e-07
analysis O 0 1.6454471563065454e-08
and O 0 1.4198087150418814e-09
that O 0 4.751448123840873e-10
the O 0 5.631992650023676e-09
missing O 0 1.9838049070131092e-07
PAX6 O 0 5.193363904254511e-05
missense O 0 7.223064312711358e-05
mutations O 0 4.373153205960989e-05
frequently O 0 6.834011855971767e-06
may O 0 3.985529019701062e-06
underlie O 0 2.0737532395287417e-05
phenotypes O 0 5.4394445214711595e-06
distinct O 0 2.6411697717776406e-07
from O 0 3.352937483214191e-07
textbook O 0 0.0010313395177945495
aniridia B-Disease 1 1.0
. O 0 2.068789626719081e-06

Here O 0 2.9954292131151306e-06
we O 0 1.8278450752973185e-08
present O 0 1.066599697452375e-08
four O 0 3.906088785754491e-09
novel O 0 7.017384717755704e-08
PAX6 O 0 1.760922350513283e-05
missense O 0 2.1055097022326663e-05
mutations O 0 5.7735883274290245e-06
, O 0 4.406627507336225e-09
two O 0 1.5400682951138833e-09
in O 0 1.1900641361251019e-08
association O 0 3.53055575885719e-08
with O 0 8.002278839569499e-09
atypical O 0 4.3081294279545546e-05
phenotypes O 0 0.00010673183714970946
ectopia B-Disease 0 0.0004576748760882765
pupillae I-Disease 0 0.00015746448480058461
( O 0 4.855176527485128e-08
displaced B-Disease 0 2.287267797385084e-08
pupils I-Disease 0 3.1448525561472707e-08
) O 0 2.5190004748765205e-08
and O 0 9.098062037082855e-07
congenital B-Disease 1 0.9999895095825195
nystagmus I-Disease 0 0.00010712693620007485
( O 0 3.4604330068077616e-08
searching B-Disease 0 1.1076383543695556e-07
gaze I-Disease 0 5.41507779416861e-06
) O 0 2.1674908534663473e-09
, O 0 3.796568059932781e-10
and O 0 2.404717813764279e-10
two O 0 3.3674693589169635e-10
in O 0 2.5803492675890993e-09
association O 0 1.7832831877839794e-09
with O 0 3.4690866845821233e-10
more O 0 6.696351473323148e-09
recognizable O 0 6.105593638494611e-05
aniridia B-Disease 1 1.0
phenotypes O 0 6.328306335490197e-05
. O 0 5.825044695484394e-07

Strikingly O 0 0.00047072634333744645
, O 0 7.981871164020049e-08
all O 0 1.6678491920885108e-09
four O 0 1.7764458792868254e-09
mutations O 0 1.0896032165419456e-07
are O 0 3.773768519899079e-10
located O 0 7.923922851205134e-09
within O 0 3.12806425206702e-09
the O 0 1.1738640282032975e-08
PAX6 O 0 2.885333969970816e-06
paired O 0 1.8093332698754239e-07
domain O 0 5.4320146603004105e-08
and O 0 3.5096998640682386e-09
affect O 0 1.1119836607065281e-08
amino O 0 2.611653648898482e-08
acids O 0 8.972697251863337e-09
which O 0 1.2583944997146546e-09
are O 0 8.909419729752344e-11
highly O 0 2.313601310532931e-09
conserved O 0 1.0844071418603107e-08
in O 0 2.3541986138297943e-09
all O 0 2.2971462232401763e-10
known O 0 3.2717120124203802e-09
paired O 0 3.5271632725653035e-08
domain O 0 6.179675438033883e-08
proteins O 0 1.129590216919496e-07
. O 0 5.1894371466687517e-08

Our O 0 9.517997909824771e-07
results O 0 2.167000587860457e-07
support O 0 5.582017514882409e-09
the O 0 1.5075178882995033e-09
hypothesis O 0 4.310685586261798e-09
that O 0 1.0762401386754661e-10
the O 0 4.193801972363076e-10
under O 0 3.739492271392919e-09
- O 0 1.6974883720877187e-08
representation O 0 3.435513207250551e-09
of O 0 7.744097585415943e-10
missense O 0 3.925846158381319e-06
mutations O 0 1.0016270834967145e-06
is O 0 4.841275380584875e-09
caused O 0 5.9590547607513145e-08
by O 0 1.1259565724230924e-08
ascertainment O 0 1.8753071344690397e-05
bias O 0 5.916058398724999e-06
and O 0 6.070536517910341e-09
suggest O 0 7.550971403702533e-09
that O 0 2.508507290777118e-10
a O 0 2.805679910622416e-09
substantial O 0 4.078325677170369e-09
burden O 0 5.764686150655507e-08
of O 0 2.9029694204041334e-09
PAX6 B-Disease 0 0.0007466534152626991
- I-Disease 0 0.031631868332624435
related I-Disease 0 6.080422281229403e-06
disease I-Disease 0 0.0017542785499244928
remains O 0 7.473587260165004e-08
to O 0 2.1564479091296107e-09
be O 0 8.380875438085411e-10
uncovered O 0 1.2519913639152946e-07
. O 0 2.9638409504428864e-09
. O 0 3.0419798235925555e-08

The O 0 1.2429396747393184e-06
chromosomal O 0 3.583552461350337e-05
order O 0 3.3662139742318686e-08
of O 0 2.234231022413269e-09
genes O 0 1.3844872626123106e-07
controlling O 0 1.0346063845645403e-06
the O 0 1.630591484058641e-08
major O 0 3.182966779036178e-08
histocompatibility O 0 1.6565750229347032e-06
complex O 0 8.94728842126824e-08
, O 0 5.188167673253474e-09
properdin O 0 1.691764509814675e-06
factor O 0 5.78929046923804e-08
B O 0 1.3512024565898173e-07
, O 0 1.9042785126544004e-09
and O 0 9.515822796402063e-08
deficiency B-Disease 0 1.413982204212516e-06
of I-Disease 0 9.147268359432914e-11
the I-Disease 0 1.0705266673127767e-09
second I-Disease 0 3.8560923343311515e-09
component I-Disease 0 7.549171066045801e-09
of I-Disease 0 5.852925921701058e-10
complement I-Disease 0 1.4268793790961354e-07
. O 0 9.366167574853534e-08

The O 0 1.2220749567859457e-07
relationship O 0 5.148139337052271e-08
of O 0 8.779263427349804e-10
the O 0 2.960947931285318e-09
genes O 0 4.672001452377117e-08
coding O 0 4.315376997965359e-07
for O 0 4.5949803961775615e-09
HLA O 0 3.8109010347398e-07
to O 0 1.5286167887040847e-09
those O 0 2.964449796749591e-10
coding O 0 8.616217428425443e-08
for O 0 1.088856449449338e-09
properdin O 0 7.917759603515151e-07
Factor O 0 4.1201573708349315e-08
B O 0 8.777145410476805e-08
allotypes O 0 5.969429253127601e-07
and O 0 7.154081327342965e-09
for O 0 5.747117448606787e-09
deficiency B-Disease 0 5.981926847198338e-07
of I-Disease 0 6.718964273844108e-11
the I-Disease 0 9.98516380690262e-10
second I-Disease 0 2.947537325326266e-09
component I-Disease 0 4.7204848918624975e-09
of I-Disease 0 2.4780910656829747e-10
complement I-Disease 0 2.6756071136446735e-08
( O 0 1.7710810595872317e-08
C2 O 0 4.42585314885946e-06
) O 0 1.1351268813797333e-09
was O 0 4.3163459473305466e-09
studied O 0 8.634453152467358e-10
in O 0 4.427746780333308e-10
families O 0 4.1271294715095053e-10
of O 0 3.9443739940914213e-10
patients O 0 1.8881237906498427e-08
with O 0 9.825624402992617e-08
connective O 1 0.9998397827148438
tissue O 1 0.9999843835830688
disorders O 1 0.9961180686950684
. O 0 1.667117430770304e-06

Patients O 0 5.655647692037746e-05
were O 0 8.096456127759666e-08
selected O 0 8.559179143219353e-09
because O 0 1.077323008580322e-09
they O 0 2.9700358838979923e-10
were O 0 1.3119193509325555e-09
heterozygous O 0 1.2516368030901504e-07
or O 0 1.5232739514203786e-08
homozygous O 0 3.9384276533382945e-06
for O 0 2.7344540285412222e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 7.521191491832724e-07

12 O 0 2.0776590190507704e-06
families O 0 2.8007679730990276e-08
with O 0 9.0961966847658e-09
15 O 0 2.0478234219467595e-08
matings O 0 1.3917034493715619e-06
informative O 0 3.644668140623253e-06
for O 0 0.0010949079878628254
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 4.251602092608664e-08
found O 0 7.438843852014543e-08
. O 0 1.9897997560747172e-07

Of O 0 1.376515683659818e-07
57 O 0 9.472992132941727e-07
informative O 0 5.564756406783999e-07
meioses O 0 3.1415574994753115e-06
, O 0 1.1101394248314023e-09
two O 0 6.012594311322061e-10
crossovers O 0 4.326287950107144e-08
were O 0 5.71371283619726e-10
noted O 0 1.685939166051753e-09
between O 0 8.206185064807414e-09
the O 0 0.002122208708897233
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.999998927116394
gene O 0 1.878859308135361e-07
and O 0 1.906240942872728e-09
the O 0 1.4768273715048963e-08
HLA O 0 7.645472578587942e-06
- O 0 1.5027839026515721e-06
B O 0 2.635086389091157e-07
gene O 0 5.782018419608903e-08
, O 0 1.9627743874650605e-10
with O 0 1.4763303080034262e-10
a O 0 2.375610819171925e-09
recombinant O 0 3.987966579188651e-08
fraction O 0 7.683309100059432e-09
of O 0 1.9687631525044935e-09
0 O 0 8.40718783479133e-08
. O 0 3.314727692327324e-08

035 O 0 0.031136682257056236
. O 0 5.705826697521843e-05

A O 0 1.3613665032607969e-05
lod O 0 0.001191247021779418
score O 0 8.1140160546056e-07
of O 0 2.067307436348642e-09
13 O 0 2.0054017113579903e-08
was O 0 7.566815618531564e-09
calculated O 0 8.71510152933297e-09
for O 0 1.2620648970340653e-09
linkage O 0 2.3710319965175586e-06
between O 0 4.009878102806397e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 8.865832512583438e-08
HLA O 0 6.635290901613189e-06
- O 0 1.9861342934746062e-06
B O 0 3.2047026365944475e-07
at O 0 7.334625351518298e-09
a O 0 1.880492650485621e-09
maximum O 0 4.149722787616383e-09
likelihood O 0 4.261049291187646e-09
value O 0 3.3860120263184967e-10
of O 0 3.117816074760249e-11
the O 0 4.2611775219469905e-10
recombinant O 0 1.1012676992550041e-08
fraction O 0 2.925056641345236e-09
of O 0 5.850961382058983e-10
0 O 0 5.536763936220268e-08
. O 0 3.963246442140189e-08

04 O 0 0.00493290601298213
. O 0 1.8463180822436698e-05

18 O 0 2.378975295869168e-06
families O 0 2.466864934547175e-08
with O 0 8.67579519336914e-09
21 O 0 1.257071318150338e-07
informative O 0 1.569539165302558e-07
matings O 0 7.570571369797108e-07
for O 0 7.916717059686107e-09
both O 0 1.861842413575232e-08
properdin O 0 1.003225588647183e-05
Factor O 0 3.4473967502890446e-07
B O 0 4.246460036938515e-07
allotype O 0 2.4170728920580586e-06
and O 0 5.978954931151748e-08
HLA O 0 8.802779120742343e-06
- O 0 4.580318545777118e-06
B O 0 5.292385480970552e-07
were O 0 5.039528794270609e-09
found O 0 3.362049483257579e-08
. O 0 8.592142108909684e-08

Of O 0 3.4863506925830734e-07
72 O 0 3.834030849247938e-06
informative O 0 1.6088632719402085e-06
meioses O 0 9.748137927090283e-06
, O 0 5.248703249804976e-09
three O 0 2.0581600868041505e-09
recombinants O 0 5.659654220835364e-07
were O 0 3.781241986189343e-09
found O 0 9.578237092355835e-10
, O 0 6.756476628178021e-11
giving O 0 2.363835238661238e-10
a O 0 8.650311023039592e-10
recombinant O 0 1.5046172308075256e-08
fraction O 0 7.328919693350144e-09
of O 0 2.425970313524317e-09
0 O 0 1.1280378231504073e-07
. O 0 5.070538833251703e-08

042 O 0 0.004702115431427956
. O 0 4.80622002214659e-05

A O 0 1.7558466424816288e-05
lod O 0 0.0008457046351395547
score O 0 2.2263883181494748e-07
of O 0 1.3190551984010312e-09
16 O 0 1.4174418971890645e-08
between O 0 1.0678658846074995e-08
HLA O 0 4.130129127588589e-06
- O 0 2.3924765173433116e-06
B O 0 2.6797499685926596e-07
and O 0 1.9238317605640987e-09
Factor O 0 5.005273084890405e-09
B O 0 3.8577862682132036e-08
allotypes O 0 2.7771525878961256e-07
was O 0 3.326698205796674e-08
calculated O 0 2.1371263869696122e-08
at O 0 4.1935961370143104e-09
a O 0 1.459660059488499e-09
maximum O 0 2.658092634888476e-09
likelihood O 0 2.17016316028662e-09
value O 0 2.1013521478430164e-10
of O 0 3.535773063223502e-11
the O 0 3.19192478004382e-10
recombinant O 0 6.623527504245885e-09
fraction O 0 4.931311803346716e-09
of O 0 1.2267680205013676e-09
0 O 0 1.2845693220242538e-07
. O 0 4.6207865977976326e-08

04 O 0 0.0060936822555959225
. O 0 2.8038524760631844e-05

A O 0 1.4295014807430562e-06
crossover O 0 3.8563891280318785e-07
was O 0 1.947324221873714e-07
shown O 0 1.2622026979158818e-08
to O 0 1.7975027022387735e-09
have O 0 2.9370411658291573e-10
occurred O 0 3.4625509126584575e-09
between O 0 1.08613296134763e-09
genes O 0 1.03774286941416e-08
for O 0 8.65470084487896e-10
Factor O 0 7.129493884150406e-09
B O 0 6.079460490582278e-08
and O 0 9.666316636014471e-09
HLA O 0 2.749406121438369e-06
- O 0 3.608746510508354e-06
D O 0 6.8516314968292136e-06
, O 0 7.492291231869785e-10
in O 0 2.5330242348076126e-09
which O 0 1.4767991274311498e-08
HLA O 0 4.137110408919398e-06
- O 0 2.728140088947839e-06
D O 0 9.500817213847768e-06
segregared O 0 2.0646623397624353e-06
with O 0 1.7572849841940297e-08
HLA O 0 5.657303063344443e-06
- O 0 4.863137519350857e-07
A O 0 1.2349836708835937e-07
and O 0 2.677281685237176e-08
B O 0 6.723690830767737e-07
. O 0 7.835284776547269e-08

These O 0 9.410863555103788e-08
studies O 0 3.2860853593774664e-08
suggest O 0 2.0147757240351893e-08
that O 0 1.8545111279966164e-10
the O 0 5.432371219526999e-10
genes O 0 4.940283737653317e-09
for O 0 6.577685063291483e-10
Factor O 0 1.4575463502808361e-08
B O 0 3.135669658149709e-06
and O 0 0.0012464877218008041
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.0711781461836267e-09
located O 0 5.6236095780093365e-09
outside O 0 5.784089207594434e-09
those O 0 6.8517885809527e-10
for O 0 8.12714562314909e-10
HLA O 0 1.5248151896685158e-07
, O 0 1.3229296824679437e-10
that O 0 7.249526673414053e-11
the O 0 3.027638417751888e-10
order O 0 6.421625453612023e-10
of O 0 2.6204427516773876e-10
genese O 0 8.194658676075051e-07
is O 0 5.164068728191751e-09
HLA O 0 4.237867301526421e-07
- O 0 7.019526293561285e-08
A O 0 2.651233188544211e-08
, O 0 1.984938879928677e-09
- O 0 6.591606904748915e-08
B O 0 6.006444408512834e-08
, O 0 6.019628684406086e-10
- O 0 1.0661201343964422e-07
D O 0 4.981783945368079e-07
, O 0 6.588106171712127e-10
Factor O 0 4.723015756269433e-09
B O 0 1.0616214041192507e-07
allotype O 0 1.2228983905515634e-05
, O 0 1.404368504154263e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 6.360578175268472e-10
that O 0 1.0139733497283032e-10
the O 0 1.063136134682452e-09
genes O 0 1.1959808432493446e-07
coding O 0 1.698093728919048e-05
for O 0 1.115448321797885e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.0243748011239404e-08
Factor O 0 3.803399550861286e-08
B O 0 1.6856353113325895e-07
allotypes O 0 4.275351557225804e-07
are O 0 8.309947174822696e-10
approximately O 0 6.350446835057255e-09
3 O 0 3.727971531475305e-08
- O 0 9.869290806818753e-07
- O 0 1.0713247320381925e-06
5 O 0 2.4480506510826672e-08
centimorgans O 0 1.5995081525943533e-07
from O 0 1.6810712821779816e-09
the O 0 5.502513999999792e-09
HLA O 0 3.698562238696468e-07
- O 0 4.583664647839214e-08
A O 0 2.915110819401434e-08
and O 0 1.0800722982651223e-08
HLA O 0 8.162928679666948e-07
- O 0 3.237568932945578e-07
B O 0 1.1933239818517904e-07
loci O 0 1.2663818438340968e-08
, O 0 2.0216409102324917e-10
and O 0 9.634721492846055e-11
that O 0 5.064480779193303e-11
the O 0 2.2823060108478899e-10
apparent O 0 9.217262508798285e-09
lack O 0 1.543729810649097e-09
of O 0 1.6021255155873604e-10
recombinants O 0 1.0440626851959678e-07
between O 0 7.621186459694229e-10
the O 0 2.1332360322645627e-09
Factor O 0 9.524498523205693e-09
B O 0 8.982357968534416e-08
gene O 0 8.214564672925917e-07
and O 0 0.0002848091535270214
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 5.362794013308303e-07
suggests O 0 1.3025228007279566e-08
that O 0 2.4186738722953294e-10
these O 0 8.57309154222996e-11
two O 0 2.0786382337600884e-10
genes O 0 1.085280310064718e-08
lie O 0 3.0190940858432214e-09
in O 0 1.2957350747910823e-09
close O 0 2.0347998841430126e-08
proximity O 0 8.620897773425895e-09
to O 0 2.125705611533135e-09
one O 0 8.92859619572306e-10
another O 0 8.83881323687774e-09
. O 0 5.4914139013817476e-08

Distribution O 0 1.378763840875763e-06
of O 0 1.977321772983487e-08
emerin O 0 4.4939811232325155e-06
and O 0 1.4223166644455887e-08
lamins O 0 4.967696895619156e-06
in O 0 2.605886706419369e-08
the O 0 3.648350244134235e-08
heart O 0 1.6066032912931405e-06
and O 0 5.5440634305625736e-09
implications O 0 1.825942419486637e-08
for O 0 5.936521496607838e-09
Emery B-Disease 1 0.9608625769615173
- I-Disease 1 0.9836512207984924
Dreifuss I-Disease 1 0.9999499320983887
muscular I-Disease 1 0.9999686479568481
dystrophy I-Disease 1 0.9999256134033203
. O 0 2.4830860638758168e-06

Emerin O 0 0.0002336808538530022
is O 0 9.979555670724949e-08
a O 0 1.3006335564114124e-08
nuclear O 0 6.793405304961198e-08
membrane O 0 7.958384884432235e-08
protein O 0 6.323930534790634e-08
which O 0 3.6914946655031144e-09
is O 0 7.15332681977543e-10
missing O 0 4.106966322581229e-09
or O 0 9.27438215114762e-09
defective O 0 3.3218591397599084e-06
in O 0 1.6893078225166391e-07
Emery B-Disease 1 0.9984513521194458
- I-Disease 1 0.9915680289268494
Dreifuss I-Disease 1 0.9999954700469971
muscular I-Disease 1 0.9999977350234985
dystrophy I-Disease 1 0.9999985694885254
( O 0 3.409544888199889e-06
EDMD B-Disease 1 1.0
) O 0 4.5959470185152895e-07
. O 0 3.7155564314161893e-07

It O 0 4.872134127253958e-07
is O 0 5.491369137189395e-09
one O 0 5.15325282446355e-10
member O 0 3.0961636032778017e-10
of O 0 7.360376197418361e-11
a O 0 3.3219853534660615e-09
family O 0 1.2515181779804152e-08
of O 0 1.3910942397998838e-09
lamina O 0 3.897599071933655e-06
- O 0 9.431561807105027e-07
associated O 0 6.854461531702327e-08
proteins O 0 1.760539269923811e-08
which O 0 3.8698115822910495e-09
includes O 0 4.500547934327415e-09
LAP1 O 0 1.2974912806384964e-06
, O 0 6.212184100462537e-09
LAP2 O 0 3.299876880191732e-06
and O 0 2.7620517428772473e-08
lamin O 0 1.7786387616069987e-05
B O 0 2.2544943476532353e-06
receptor O 0 2.901099833252374e-06
( O 0 2.1916663683896331e-07
LBR O 0 2.0937161025358364e-05
) O 0 1.0483010015605032e-07
. O 0 1.665034545794697e-07

A O 0 3.4429519928380614e-06
panel O 0 1.0514463610888924e-06
of O 0 8.248145277889307e-09
16 O 0 9.1864990281465e-08
monoclonal O 0 6.383748996086069e-07
antibodies O 0 1.305591695199837e-06
( O 0 7.37255447802454e-08
mAbs O 0 1.3307633253134554e-06
) O 0 5.09917663649162e-09
has O 0 2.1178787612541328e-09
been O 0 1.992213505275231e-09
mapped O 0 2.1894349444551153e-08
to O 0 5.47860312671844e-10
six O 0 6.496305160474947e-10
specific O 0 5.655424462069902e-10
sites O 0 6.485364245634173e-09
throughout O 0 4.369674844184601e-09
the O 0 2.498280915474993e-09
emerin O 0 2.2642154817731353e-07
molecule O 0 2.4533933995485313e-08
using O 0 2.5032999673157974e-08
phage O 0 3.6074831655241724e-07
- O 0 8.154123776193956e-08
displayed O 0 4.583874613217631e-08
peptide O 0 3.332845821546471e-08
libraries O 0 5.924903678788951e-09
and O 0 5.297782768032278e-10
has O 0 2.4648214025368986e-10
been O 0 1.6999361640568367e-10
used O 0 1.2473994059902793e-09
to O 0 1.7048693568000317e-09
localize O 0 1.6961796518444316e-06
emerin O 0 1.8054067822959041e-06
in O 0 8.94162077713645e-09
human O 0 9.444792503643384e-09
and O 0 1.513182112944378e-08
rabbit O 0 4.980022640665993e-05
heart O 0 1.503366365795955e-05
. O 0 2.494045361345343e-07

Several O 0 9.519051218376262e-07
mAbs O 0 2.0744355424540117e-05
against O 0 2.1470346212026925e-07
different O 0 5.337323827347973e-08
emerin O 0 1.541996607556939e-05
epitopes O 0 4.804959189641522e-06
did O 0 1.134266511826354e-07
not O 0 4.9545705316234034e-09
recognize O 0 1.1564301516386877e-08
intercalated O 0 3.3590475823075394e-07
discs O 0 1.9218728084524628e-06
in O 0 3.6788145862942656e-09
the O 0 6.591742263140077e-09
heart O 0 2.47858110924426e-07
, O 0 2.5751656362871245e-10
though O 0 1.1218359574627357e-09
they O 0 3.4548372496168156e-10
recognized O 0 8.696997566559617e-10
cardiomyocyte O 0 1.0715346121514813e-07
nuclei O 0 4.743837322962463e-08
strongly O 0 2.8910244864732704e-08
, O 0 3.3446367897482787e-10
both O 0 5.710444339612764e-10
at O 0 1.2827032769280322e-08
the O 0 2.4072199789060278e-09
rim O 0 4.9871502483256336e-08
and O 0 1.121626236333384e-09
in O 0 3.280109739378645e-09
intranuclear O 0 1.0388458804300171e-06
spots O 0 1.8205336971277575e-07
or O 0 2.3864252796101937e-08
channels O 0 2.537325087814679e-07
. O 0 7.060710061068676e-08

A O 0 2.71870412689168e-05
polyclonal O 0 0.0009173628641292453
rabbit O 0 0.0003105240175500512
antiserum O 0 0.00013598238001577556
against O 0 2.1767821181128966e-06
emerin O 0 3.723191548488103e-05
did O 0 1.642762157416655e-07
recognize O 0 2.0270176648296e-08
both O 0 1.7589877332468973e-09
nuclear O 0 4.558954813660421e-08
membrane O 0 1.1519934872694648e-07
and O 0 3.029061224069096e-09
intercalated O 0 9.290266689276905e-08
discs O 0 5.406389504969411e-07
but O 0 3.484066368741878e-10
, O 0 6.833877908007935e-11
after O 0 6.704297672577297e-10
affinity O 0 2.128428100434121e-09
purification O 0 1.9417925045672746e-09
against O 0 5.140666781144887e-10
a O 0 2.598479875715043e-09
pure O 0 1.2797658932584e-08
- O 0 7.030278084130259e-07
emerin O 0 1.0115579698322108e-06
band O 0 2.977463786635326e-08
on O 0 4.8652504247570505e-09
a O 0 2.2256818610344453e-09
western O 0 4.30809059537296e-08
blot O 0 4.056686884723604e-05
, O 0 1.9241255255764145e-09
it O 0 2.8979791899530483e-09
stained O 0 4.465094207262155e-06
only O 0 3.801161885252924e-10
the O 0 1.8033989857002553e-09
nuclear O 0 1.0486728996284e-07
membrane O 0 4.6156338839864475e-07
. O 0 7.526128342760785e-08

These O 0 2.5289568839070853e-07
results O 0 1.8054825545732456e-07
would O 0 1.394886339767254e-08
not O 0 8.608373458507401e-10
be O 0 4.3487285994459057e-10
expected O 0 3.5105569562432493e-09
if O 0 9.681165868968833e-10
immunostaining O 0 3.5675839171744883e-07
at O 0 1.7448339661996215e-08
intercalated O 0 3.727402742015329e-08
discs O 0 9.005978540699289e-07
were O 0 1.186998499491665e-09
due O 0 1.3351155736529563e-09
to O 0 1.8774919119390887e-10
a O 0 9.217099306013665e-10
product O 0 1.8919368294234573e-09
of O 0 6.435980914876183e-11
the O 0 1.409810712615922e-09
emerin O 0 2.6287463583685167e-07
gene O 0 4.34680096361717e-08
and O 0 7.54476259245962e-10
, O 0 1.1458833187871775e-10
therefore O 0 5.508339895321512e-10
, O 0 8.598687040173303e-11
cast O 0 7.484021735670865e-10
some O 0 1.2338212396212356e-10
doubt O 0 3.714156482370612e-10
upon O 0 7.15427925235268e-11
the O 0 4.567340394778796e-10
hypothesis O 0 8.291917374947388e-09
that O 0 2.7960054271858326e-09
cardiac B-Disease 0 0.001237297896295786
defects I-Disease 0 0.4117077589035034
in O 0 7.311343779292656e-07
EDMD B-Disease 1 1.0
are O 0 4.3248671310891496e-09
caused O 0 1.738038157839128e-08
by O 0 1.1744994976581324e-09
absence O 0 9.681133228411909e-09
of O 0 1.384112491287226e-09
emerin O 0 7.870836270740256e-06
from O 0 3.56553577773866e-08
intercalated O 0 3.874513822665904e-06
discs O 0 2.4969423975562677e-05
. O 0 4.231393404552364e-07

Although O 0 4.0566242205386516e-06
emerin O 0 2.4414966901531443e-05
was O 0 1.421907711574022e-07
abundant O 0 1.1436616098592367e-08
in O 0 2.0919195264923474e-09
the O 0 2.05260874963642e-09
membranes O 0 9.13011177772205e-08
of O 0 1.0537225536566552e-09
cardiomyocyte O 0 3.3184107905981364e-06
nuclei O 0 7.230231062749226e-07
, O 0 2.1638226765929858e-09
it O 0 2.094298956478724e-09
was O 0 4.803630204719411e-08
absent O 0 9.068012118973456e-09
from O 0 2.5818888693684983e-10
many O 0 1.4028733730242493e-10
non O 0 6.066438462681845e-09
- O 0 4.045548678277555e-07
myocyte O 0 3.9901683521748055e-06
cells O 0 3.7513530060095945e-08
in O 0 2.4737993875589837e-09
the O 0 1.2997010578885693e-08
heart O 0 1.8495870790502522e-06
. O 0 1.036892527395139e-07

This O 0 6.662428120307595e-08
distribution O 0 2.7038748129371015e-08
of O 0 1.8249736166708885e-09
emerin O 0 3.0853605039737886e-06
was O 0 6.840029698196304e-08
similar O 0 2.0691337532241505e-09
to O 0 3.8922018386067236e-10
that O 0 1.0942857731066624e-10
of O 0 1.3185942615567825e-10
lamin O 0 2.978245561280346e-07
A O 0 1.1023142398869368e-08
, O 0 3.375868196098253e-10
a O 0 1.2076704081209755e-09
candidate O 0 2.415779576381283e-09
gene O 0 1.0600993860521157e-08
for O 0 1.5899245808803641e-10
an O 0 7.189986384048552e-10
autosomal O 0 3.6597914004232734e-05
form O 0 1.5030789768388786e-07
of O 0 5.9421658704650326e-08
EDMD B-Disease 1 1.0
. O 0 1.2939349289808888e-06

In O 0 1.2901361969852587e-06
contrast O 0 1.3002535297346185e-06
, O 0 5.997595309281678e-08
lamin O 0 0.00013768010830972344
B1 O 0 0.004787805024534464
was O 0 6.846476594546402e-07
absent O 0 1.6601603647359298e-07
from O 0 1.2248233538514341e-08
cardiomyocyte O 0 8.552872827749525e-07
nuclei O 0 2.8805808938159316e-07
, O 0 1.932647597513437e-09
showing O 0 1.1089765195038126e-07
that O 0 1.3714179125656756e-08
lamin O 0 2.1428164473036304e-05
B1 O 0 9.372990461997688e-05
is O 0 2.0560491087451283e-09
not O 0 2.3025505113682954e-10
essential O 0 2.5042620754867073e-10
for O 0 1.8143488100808014e-10
localization O 0 1.4872326481452092e-08
of O 0 4.391480512566659e-10
emerin O 0 3.9204073232212977e-07
to O 0 3.833432682398552e-09
the O 0 1.593435783320274e-08
nuclear O 0 1.3489187722370843e-06
lamina O 0 1.1749429177143611e-05
. O 0 1.6559164350837818e-07

Lamin O 1 0.8031291961669922
B1 O 1 0.9987186193466187
is O 0 3.306676887859794e-07
also O 0 2.0174674375539325e-08
almost O 0 7.455274619871943e-09
completely O 0 2.2357502871273027e-07
absent O 0 1.7870165436306706e-07
from O 0 2.1395775817723006e-08
skeletal O 0 0.0007045318488962948
muscle O 0 0.00018778971571009606
nuclei O 0 1.309772051172331e-05
. O 0 2.8532454621199577e-07

In O 0 1.0665350600902457e-05
EDMD B-Disease 1 0.9999998807907104
, O 0 2.1126510318936198e-08
the O 0 2.2566168933479958e-09
additional O 0 2.6244706408107277e-09
absence O 0 6.843106081788619e-09
of O 0 3.943879889334312e-09
lamin O 0 0.00014502699195872992
B1 O 0 0.0024065100587904453
from O 0 4.8976353639318404e-08
heart O 0 7.5280900091456715e-06
and O 0 4.554713584070669e-08
skeletal O 0 0.013477376662194729
muscle O 0 0.0004946647677570581
nuclei O 0 2.153762352463673e-06
which O 0 2.0763460284456414e-08
already O 0 1.174733199604816e-08
lack O 0 9.624133490149234e-09
emerin O 0 9.587412932887673e-06
may O 0 4.6412882426238866e-08
offer O 0 7.152509140517793e-10
an O 0 1.686784323329249e-10
alternative O 0 3.033478135350265e-09
explanation O 0 1.4118020086328897e-09
of O 0 1.984926251141772e-10
why O 0 2.7530615565041217e-09
these O 0 8.547118568458245e-10
tissues O 0 1.1392229737339221e-07
are O 0 4.0906406040264187e-10
particularly O 0 6.712733036096097e-09
affected O 0 2.2520216802490722e-08
. O 0 9.332104866643931e-09
. O 0 7.015792391484865e-08

Genetic O 0 2.0649755242629908e-05
mapping O 0 3.015087258972926e-06
of O 0 2.6755920146115386e-08
the O 0 1.9826964603453234e-07
copper B-Disease 0 7.945290417410433e-05
toxicosis I-Disease 0 0.00014470099995378405
locus O 0 2.2003923731972463e-06
in O 0 6.743341884885012e-08
Bedlington O 0 4.758489376399666e-05
terriers O 0 4.954628457198851e-05
to O 0 5.027290939096929e-08
dog O 0 3.095727151958272e-05
chromosome O 0 2.8182480491523165e-06
10 O 0 1.4304130324660491e-08
, O 0 2.69392674834279e-10
in O 0 6.741200930804325e-10
a O 0 6.646699635126652e-09
region O 0 3.244117507961164e-08
syntenic O 0 2.2090548554842826e-06
to O 0 4.21850554488401e-09
human O 0 7.823603098700005e-09
chromosome O 0 5.784532959296484e-07
region O 0 8.954049235398998e-08
2p13 O 0 6.566711817868054e-06
- O 0 4.890852778771659e-06
p16 O 0 1.4055114661459811e-05
. O 0 2.5274812287534587e-07

Abnormal O 1 0.9978455305099487
hepatic B-Disease 1 0.9998739957809448
copper I-Disease 0 0.3752893805503845
accumulation I-Disease 0 6.768146704416722e-06
is O 0 6.1558744768319684e-09
recognized O 0 3.917205670944668e-09
as O 0 2.9179685334668193e-09
an O 0 2.171899780023523e-07
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 2.3086265343863488e-07
man O 0 1.8465470930095762e-07
, O 0 2.64766919499948e-09
mouse O 0 1.6313774722220842e-06
, O 0 7.0621886116839505e-09
rat O 0 7.560228368674871e-06
and O 0 4.81536304164365e-08
dog O 0 6.488632061518729e-05
. O 0 4.074448725077673e-07

The O 0 3.5730116110244126e-07
major O 0 1.4031563466687658e-07
cause O 0 2.3564420814636833e-07
of O 0 8.501241488545475e-09
hepatic B-Disease 0 0.06564635783433914
copper I-Disease 0 0.05311238765716553
accumulation I-Disease 0 1.9890496787411394e-06
in O 0 3.346809407389628e-08
man O 0 8.775204207722709e-08
is O 0 1.8616852504038661e-09
a O 0 3.0834723219186344e-08
dysfunctional O 0 1.4200651094142813e-05
ATP7B O 0 1.2652136319957208e-05
gene O 0 1.6915531659833505e-06
, O 0 1.4980511053863665e-08
causing O 0 3.81753943656804e-06
Wilson B-Disease 0 0.0001939917856361717
disease I-Disease 0 0.017465006560087204
( O 0 4.2426106006132613e-07
WD B-Disease 0 0.00131357298232615
) O 0 4.7458013341383776e-07
. O 0 5.286029818307725e-07

Mutations O 0 0.00012857714318670332
in O 0 2.0576828774210298e-07
the O 0 2.898201678647183e-08
ATP7B O 0 4.121016445424175e-06
genes O 0 1.770247592958185e-07
have O 0 4.5998733710916895e-09
also O 0 2.1624282364740566e-09
been O 0 1.0110249304418062e-09
demonstrated O 0 4.487108462569722e-09
in O 0 5.99293858982719e-09
mouse O 0 8.883095688361209e-06
and O 0 7.492112530371742e-08
rat O 0 3.3753251045709476e-05
. O 0 1.349021374608128e-07

The O 0 1.6735306189730181e-06
ATP7B O 0 2.6667106794775464e-05
gene O 0 2.5081615149247227e-06
has O 0 2.4281749944066178e-08
been O 0 1.7630317206140944e-09
excluded O 0 3.0265432382492463e-09
in O 0 6.074286074131408e-10
the O 0 1.154192963426226e-09
much O 0 5.739602570997704e-09
rarer O 0 1.5074961368100048e-07
human O 0 6.668238228257906e-08
copper B-Disease 0 0.10424167662858963
overload I-Disease 0 0.00019425815844442695
disease O 0 3.459543449935154e-06
non B-Disease 0 3.7291449928034126e-08
- I-Disease 0 1.5691589396737982e-06
Indian I-Disease 0 4.028208522299792e-08
childhood I-Disease 0 3.327582817291841e-05
cirrhosis I-Disease 0 2.8284688596613705e-05
, O 0 5.477624132055325e-09
indicating O 0 4.458829039322154e-07
genetic O 0 2.372045400989009e-06
heterogeneity O 0 9.148167919192929e-06
. O 0 4.529200623437646e-07

By O 0 1.8984520977483044e-07
investigating O 0 5.44838769656053e-07
the O 0 4.757855265324906e-08
common O 0 1.5112891560420394e-06
autosomal O 1 0.9968517422676086
recessive O 1 0.9999973773956299
copper B-Disease 1 0.9990147352218628
toxicosis I-Disease 1 0.7589128017425537
( O 0 5.316910574038047e-07
CT B-Disease 0 0.38645806908607483
) O 0 2.1380028414341723e-08
in O 0 1.470845312212532e-08
Bedlington O 0 0.00010934079909930006
terriers O 0 0.0005429876036942005
, O 0 7.248178501839675e-09
we O 0 3.149915883682297e-10
have O 0 1.250789055662338e-10
identified O 0 4.642204121108051e-10
a O 0 8.936177908758225e-10
new O 0 8.625108627313693e-09
locus O 0 7.794265854954574e-08
involved O 0 7.821350678227645e-09
in O 0 5.860354121978162e-07
progressive O 1 0.9997958540916443
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 2.71283283836965e-06

We O 0 3.8156653658916184e-07
examined O 0 6.20740138401743e-07
whether O 0 1.9557843344841785e-08
the O 0 3.620186106445544e-08
WD B-Disease 0 6.190699787111953e-05
gene O 0 1.7096689362006146e-06
ATP7B O 0 2.7636711820377968e-05
was O 0 1.059127683333827e-07
also O 0 2.6956550325252238e-09
causative O 0 3.6054945695696006e-08
for O 0 2.234976648196607e-09
CT B-Disease 0 0.0015025015454739332
by O 0 9.966446334885859e-09
investigating O 0 4.881203352624652e-08
the O 0 2.2997262760782178e-08
chromosomal O 0 0.0001043390147970058
co O 0 8.526324108970584e-07
- O 0 1.8005476931648445e-07
localization O 0 1.7073929825528467e-07
of O 0 1.2581760078234083e-09
ATP7B O 0 1.8673424619919388e-06
and O 0 1.0206369083221034e-09
C04107 O 0 3.491700084623517e-08
, O 0 3.637513623644395e-10
using O 0 4.432413547306169e-09
fluorescence O 0 9.038867432309416e-08
in O 0 4.469657088890244e-09
situ O 0 6.038042954514822e-08
hybridization O 0 4.3057571730287236e-08
( O 0 5.562058369434908e-09
FISH O 0 2.4442107005029357e-08
) O 0 1.635191537729952e-08
. O 0 3.7535716757020055e-08

C04107 O 0 0.00012340376270003617
is O 0 1.171198675820051e-07
an O 0 5.9284648301627385e-09
anonymous O 0 3.058724473703478e-07
microsatellite O 0 2.6788638933794573e-05
marker O 0 3.3395772334188223e-06
closely O 0 1.2011352055196767e-06
linked O 0 8.579075256420765e-06
to O 0 1.9556432562239934e-07
CT B-Disease 1 0.9910933375358582
. O 0 7.34574427951884e-07

However O 0 8.740806265450374e-07
, O 0 7.53726183688741e-08
BAC O 0 2.414466143818572e-05
clones O 0 2.0407405827427283e-06
containing O 0 1.742240840485465e-07
ATP7B O 0 4.071095190738561e-06
and O 0 9.099146325297625e-09
C04107 O 0 4.23060271259601e-07
mapped O 0 2.3436271590071556e-07
to O 0 2.397679610410819e-09
the O 0 7.046808914168423e-09
canine O 0 4.085540240339469e-06
chromosome O 0 2.7030448563891696e-06
regions O 0 2.46025905425995e-07
CFA22q11 O 0 1.3708324331673793e-05
and O 0 1.3868111103931824e-08
CFA10q26 O 0 5.207954814068216e-07
, O 0 1.1267229371725307e-09
respectively O 0 4.667670250313449e-09
, O 0 2.081093769534803e-10
demonstrating O 0 4.226373917504134e-09
that O 0 5.4264819304705725e-09
WD B-Disease 0 3.991968333139084e-05
cannot O 0 2.3940385673881792e-08
be O 0 2.244969987685863e-09
homologous O 0 9.693276581401733e-08
to O 0 5.2147289153481324e-08
CT B-Disease 1 0.8964060544967651
. O 0 3.8260574797277513e-07

The O 0 6.319372687357827e-07
copper O 0 4.1630619307397865e-06
transport O 0 1.6803949165478116e-07
genes O 0 2.1353339718643838e-07
CTR1 O 0 4.937271569360746e-06
and O 0 1.3422733147194776e-08
CTR2 O 0 1.0219181604043115e-05
were O 0 1.203913058134276e-08
also O 0 1.740598443156216e-09
excluded O 0 2.9021167691212213e-09
as O 0 2.865849224598094e-10
candidate O 0 1.4696387440338299e-09
genes O 0 9.357735919479637e-09
for O 0 3.0191920075139933e-09
CT B-Disease 1 0.9829511046409607
since O 0 2.1070860611871467e-07
they O 0 5.878602604703076e-10
both O 0 8.469984158487875e-10
mapped O 0 9.924091415314251e-08
to O 0 7.3237629294453654e-09
canine O 0 4.964343588653719e-06
chromosome O 0 4.3465256567287724e-06
region O 0 5.384141559261479e-07
CFA11q22 O 0 0.00013026141095906496
. O 0 4.981911843060516e-07

2 O 0 3.3548192732268944e-05
- O 0 6.91257810103707e-05
22 O 0 5.1488550525391474e-06
. O 0 3.587139474348078e-07

5 O 0 0.0001530866720713675
. O 0 7.638272109034006e-06

A O 0 3.4203508221253287e-06
transcribed O 0 8.169366992660798e-06
sequence O 0 4.0810286350279057e-07
identified O 0 7.16748260742861e-08
from O 0 2.959784639600116e-09
the O 0 2.878049576438002e-09
C04107 O 0 4.5145210947339365e-07
- O 0 1.5788182849973964e-07
containing O 0 6.176328781748452e-08
BAC O 0 5.3062121878610924e-05
was O 0 4.058555447272738e-08
found O 0 4.905838513202809e-10
to O 0 3.434024176129924e-10
be O 0 1.3561372858017506e-10
homologous O 0 2.3429729267832045e-09
to O 0 2.272723259588716e-10
a O 0 6.03520566855309e-10
gene O 0 1.249922210178056e-08
expressed O 0 5.242337675070985e-10
from O 0 5.78374459436759e-10
human O 0 3.0129445605098226e-09
chromosome O 0 4.5849239427298016e-07
2p13 O 0 6.190104500092275e-07
- O 0 2.973514767745655e-07
p16 O 0 3.578535654469306e-07
, O 0 1.6251322509930333e-09
a O 0 3.448729080091084e-09
region O 0 1.047978770429836e-08
devoid O 0 2.4510828922075234e-08
of O 0 3.310711982340564e-10
any O 0 2.6383983886546503e-09
positional O 0 1.340502535640553e-06
candidate O 0 1.3626004147226922e-07
genes O 0 4.889179194833559e-07
. O 0 1.6309250838730804e-07

Molecular O 0 8.05750005383743e-06
analysis O 0 2.768719298273936e-07
of O 0 2.8938917928655883e-09
the O 0 9.951325985468884e-09
APC B-Disease 0 2.468315187797998e-07
gene O 0 1.1239207964308662e-07
in O 0 6.4246545861124105e-09
205 O 0 4.180070334314223e-08
families O 0 4.807981568433206e-09
: O 0 2.1270440964116233e-09
extended O 0 9.947704882051767e-08
genotype O 0 2.1819198082084768e-05
- O 0 1.3199943168729078e-05
phenotype O 0 1.84056243597297e-05
correlations O 0 9.697516816231655e-07
in O 0 4.415101528820742e-08
FAP B-Disease 0 2.350552676944062e-07
and O 0 5.291219129510694e-10
evidence O 0 4.094160843681749e-10
for O 0 1.3742051940823785e-10
the O 0 2.0078454177063776e-10
role O 0 5.123712565335836e-10
of O 0 1.6635529065389676e-10
APC B-Disease 0 5.048960005638037e-08
amino O 0 2.4060092584932136e-08
acid O 0 9.670285550100743e-08
changes O 0 7.324974831135478e-07
in O 1 0.6216796040534973
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.006750617641955614
. O 0 1.1471886409708532e-06

BACKGROUND O 0 0.00019747835176531225
/ O 0 3.5035111068282276e-05
AIMS O 0 4.7510269496342517e-07
The O 0 1.136555205505374e-08
development O 0 1.1243041164732404e-08
of O 0 9.616665010980796e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.788433484113284e-08
a O 0 1.778630220883315e-08
variable O 0 2.697946115404193e-07
range O 0 6.660076934394965e-08
of O 0 5.2401709638161265e-09
extracolonic O 0 2.89285908365855e-05
manifestations O 0 1.5019155625850544e-06
in O 0 5.184884685149882e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999996423721313
polyposis I-Disease 1 1.0
( O 0 0.00011453535262262449
FAP B-Disease 0 1.727654307615012e-05
) O 0 1.1535596478040588e-08
is O 0 5.110214473802444e-10
the O 0 2.5304058848263367e-10
result O 0 1.0319000098846232e-09
of O 0 9.477445217509484e-11
the O 0 4.196660796651486e-09
dominant O 0 2.0354536900413223e-06
inheritance O 0 9.078690936803469e-07
of O 0 1.3720830338570522e-07
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999954700469971
coli I-Disease 1 1.0
( O 0 6.090462193242274e-06
APC B-Disease 0 1.1637223906291183e-05
) O 0 1.3295172607286077e-07
gene O 0 8.2321066656732e-06
mutations O 0 2.5691011614981107e-05
. O 0 6.032529995536606e-07

In O 0 2.870524724585266e-07
this O 0 7.93089327544294e-09
study O 0 2.568828927351774e-09
, O 0 3.117151536891072e-10
direct O 0 4.054089508542802e-09
mutation O 0 7.063700024900754e-08
analysis O 0 3.749791588347762e-09
of O 0 9.915242238367483e-11
the O 0 2.0074479856191374e-09
APC B-Disease 0 7.403188106991365e-08
gene O 0 4.4617038952310395e-08
was O 0 1.2737872978618725e-08
performed O 0 4.972103173628284e-09
to O 0 1.6704884142626497e-09
determine O 0 2.439115753816168e-08
genotype O 0 3.2878017464099685e-06
- O 0 2.696811179703218e-06
phenotype O 0 3.1427050544152735e-06
correlations O 0 1.355898575639003e-07
for O 0 1.1231804375455567e-09
nine O 0 9.925829935752972e-09
extracolonic O 0 1.3075303968435037e-06
manifestations O 0 5.0421757435969994e-08
and O 0 8.864471379155248e-10
to O 0 1.2471852439688291e-09
investigate O 0 1.7906323535044066e-08
the O 0 7.332177975882814e-09
incidence O 0 3.1608911399416684e-07
of O 0 2.2657127285441447e-09
APC B-Disease 0 7.355992579505255e-07
mutations O 0 9.621610388421686e-07
in O 0 1.3382680208451347e-07
non O 0 2.538917033234611e-05
- O 1 0.9999998807907104
FAP O 1 0.9999997615814209
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.5693778954737354e-06

METHODS O 0 4.982300652045524e-06
The O 0 1.1186681803110332e-07
APC B-Disease 0 2.635016016938607e-06
gene O 0 7.197484137577703e-07
was O 0 1.2755297973399138e-07
analysed O 0 1.0727595878279317e-07
in O 0 7.859305206636691e-09
190 O 0 7.437694193868083e-08
unrelated O 0 2.3778792979101127e-07
FAP B-Disease 0 1.1959505172853824e-06
and O 0 1.3019092470756277e-08
15 O 0 7.244643995818478e-08
non O 0 1.9921783405152382e-06
- O 1 0.9999998807907104
FAP O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 5.639139999402687e-06
using O 0 6.638111358370224e-07
denaturing O 0 0.0003017336130142212
gradient O 0 9.15013879421167e-06
gel O 0 8.034979146032128e-06
electrophoresis O 0 1.1445855534475413e-06
, O 0 1.9108385984623055e-09
the O 0 1.707036290099495e-09
protein O 0 5.4817441252907884e-08
truncation O 0 4.5869879272686376e-07
test O 0 2.496322792922001e-07
, O 0 1.0317308118956703e-09
and O 0 7.176312877277269e-10
direct O 0 1.6747769393532508e-08
sequencing O 0 7.10164670181257e-07
. O 0 1.5127557162486482e-07

RESULTS O 0 2.113649679813534e-05
Chain O 0 1.562823490530718e-05
terminating O 0 3.450821623118827e-06
signals O 0 2.1123787519172765e-06
were O 0 2.149241451476769e-09
only O 0 1.4804753256658643e-10
identified O 0 1.2653235126336426e-09
in O 0 1.3521243014125162e-09
patients O 0 3.516051894081329e-09
belonging O 0 7.872957397125901e-09
to O 0 2.181800740075346e-09
the O 0 7.0580008504350644e-09
FAP B-Disease 0 1.697942479950143e-07
group O 0 5.853274753775395e-09
( O 0 7.518061728717385e-09
105 O 0 2.9702496817662905e-07
patients O 0 1.9411369578392623e-07
) O 0 3.2138164129946745e-08
. O 0 9.193738037538424e-08

Amino O 0 1.7319745893473737e-05
acid O 0 4.473251010495005e-06
changes O 0 1.4148170635053248e-07
were O 0 3.223606936941792e-09
identified O 0 3.024696493270085e-09
in O 0 1.990682729768878e-09
four O 0 2.57674925840945e-09
patients O 0 3.2066815869313814e-09
, O 0 1.421292805670049e-10
three O 0 1.0026304786414642e-10
of O 0 1.365184354451543e-10
whom O 0 2.5087909527599095e-09
belonged O 0 1.367752933134625e-08
to O 0 1.1304858160698927e-09
the O 0 2.18680851205022e-09
non O 0 1.3074635596410644e-08
- O 0 5.299112899592728e-07
FAP O 0 5.486032250701101e-07
group O 0 4.493859506737863e-08
of O 0 1.918733914862969e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 3.485894558252767e-05
. O 0 3.8531760537807713e-07

Genotype O 0 0.020593328401446342
- O 0 0.002367995446547866
phenotype O 0 0.00015971931861713529
correlations O 0 3.9951869439391885e-06
identified O 0 8.378150795351758e-08
significant O 0 3.235483214680812e-09
differences O 0 1.9394580164089348e-08
in O 0 1.0636560077159629e-08
the O 0 1.904267632468759e-09
nature O 0 1.308598007732087e-09
of O 0 2.569572332689063e-10
certain O 0 2.4361577199982776e-09
extracolonic O 0 1.387117663398385e-06
manifestations O 0 9.72536966514781e-08
in O 0 2.3458984088620127e-08
FAP B-Disease 0 7.955043201945955e-07
patients O 0 1.4464712982942274e-08
belonging O 0 1.0551953089077415e-08
to O 0 2.8260298545745854e-09
three O 0 4.9247979028166355e-09
mutation O 0 1.3033113646088168e-06
subgroups O 0 4.651714675674157e-07
. O 0 1.054131644195877e-07

CONCLUSIONS O 0 1.4617534361605067e-05
Extended O 0 3.6882981930830283e-06
genotype O 0 6.295310595305637e-05
- O 0 1.3762305570708122e-05
phenotype O 0 8.443636943411548e-06
correlations O 0 5.197183554628282e-07
made O 0 5.756068954809734e-09
in O 0 3.044421603703995e-09
this O 0 6.188162204878722e-10
study O 0 1.7090464599078814e-09
may O 0 4.593992386503487e-08
have O 0 1.7633335069877631e-10
the O 0 1.3924474073778725e-10
potential O 0 1.2716304398363576e-10
to O 0 1.4192665098722301e-10
determine O 0 5.659827051474053e-10
the O 0 3.1076591300305267e-10
most O 0 1.5621405557997292e-10
appropriate O 0 1.273116279065789e-09
surveillance O 0 6.702359911514577e-08
and O 0 4.120760177528382e-09
prophylactic O 0 1.4552649929555628e-07
treatment O 0 3.999621256411956e-08
regimens O 0 2.603175062176888e-07
for O 0 8.340435009301927e-10
those O 0 1.669797189407518e-09
patients O 0 5.5474695948021235e-09
with O 0 1.297545404455036e-09
mutations O 0 5.292960736369423e-07
associated O 0 2.225937656419319e-08
with O 0 3.3764557816340357e-09
life O 0 5.022202032023415e-08
threatening O 0 9.606504136172589e-06
conditions O 0 2.8456877316784812e-06
. O 0 2.3149362959884456e-07

This O 0 9.732364958381368e-08
study O 0 1.5216100379689124e-08
also O 0 1.5326077074107047e-09
provided O 0 5.705175221137893e-10
evidence O 0 2.744524885134325e-10
for O 0 1.2270856553087128e-10
the O 0 8.568109000073321e-10
pathological O 0 2.249111297203399e-08
nature O 0 2.121056441595215e-09
of O 0 3.506472889824863e-10
amino O 0 7.680495350825822e-09
acid O 0 2.3169588914129235e-08
changes O 0 9.120153521280372e-09
in O 0 5.906771516350773e-09
APC O 0 1.2946802030455729e-07
associated O 0 9.284063295922351e-09
with O 0 9.119243693511692e-10
both O 0 6.818911657546778e-09
FAP B-Disease 0 2.5648458290561393e-07
and O 0 9.45979206079528e-09
non O 0 1.7588496348253102e-06
- O 1 0.9999998807907104
FAP O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.00013898119505029172
. O 0 5.345575715409723e-08
. O 0 1.3609589188945392e-07

Inherited B-Disease 1 0.9999986886978149
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999990463256836
and O 0 0.11633113026618958
cancer B-Disease 1 0.8597635626792908
risk O 0 7.469139404747693e-07
of O 0 3.177130114551119e-09
the O 0 1.360651253889955e-07
APC O 0 9.770987162482925e-06
I1307K O 0 1.1132633517263457e-05
polymorphism O 0 2.2147643903736025e-05
. O 0 8.825355735098128e-07

Germ O 0 0.009519675746560097
- O 0 0.05593495815992355
line O 0 8.789589628577232e-05
and O 0 3.735259923587364e-08
somatic O 0 1.31752665311069e-06
truncating O 0 5.697221240552608e-06
mutations O 0 1.031629835779313e-06
of O 0 1.6976202665830442e-09
the O 0 6.5444130115110966e-09
APC B-Disease 0 2.1681995576727786e-07
gene O 0 3.8604436980449464e-08
are O 0 2.2330028104367017e-10
thought O 0 1.7090073800574146e-09
to O 0 7.879132013499657e-09
initiate O 0 8.725385850993916e-05
colorectal B-Disease 1 1.0
tumor I-Disease 0 9.706892888061702e-05
formation O 0 2.737151817200356e-06
in O 0 8.637616701889783e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 4.1262221202487126e-05
sporadic O 1 0.9999915361404419
colorectal O 1 1.0
carcinogenesis O 1 0.9691172242164612
, O 0 2.733651172093232e-07
respectively O 0 1.3353642316360492e-06
. O 0 3.12901221377615e-07

Recently O 0 1.0283510164299514e-05
, O 0 4.421033850121603e-08
an O 0 1.66328160133844e-08
isoleucine O 0 0.0003779569815378636
- O 0 2.0811468857573345e-05
- O 0 9.756685358297545e-06
> O 0 2.2825058749731397e-06
lysine O 0 2.6651852749637328e-05
polymorphism O 0 5.827005679748254e-06
at O 0 3.914444732799893e-07
codon O 0 1.67627731570974e-05
1307 O 0 1.6906269593164325e-05
( O 0 2.823558453712849e-08
I1307K O 0 1.0729007726695272e-07
) O 0 8.326177525219691e-10
of O 0 1.567695417925563e-10
the O 0 1.9300727682747265e-09
APC B-Disease 0 9.88332828910643e-08
gene O 0 6.902333637981428e-08
has O 0 1.6103677280554507e-09
been O 0 5.233366517920501e-10
identified O 0 1.2192195031346387e-09
in O 0 1.0693818053297832e-09
6 O 0 7.720474926031784e-09
% O 0 7.163239446050795e-10
- O 0 4.697843536405344e-08
7 O 0 2.0466833561272324e-08
% O 0 2.2974966373823236e-10
of O 0 6.355263537649591e-11
the O 0 2.490112560593616e-09
Ashkenazi O 0 6.492198849628039e-07
Jewish O 0 8.457674738338028e-08
population O 0 3.96187047613239e-08
. O 0 1.667853979370193e-07

To O 0 4.872534304922738e-07
assess O 0 1.3373689853324322e-06
the O 0 3.275560089832652e-08
risk O 0 2.2690741730002628e-08
of O 0 3.088183597732552e-10
this O 0 6.731680213256652e-10
common O 0 2.007828214800611e-08
APC B-Disease 0 7.36629829134472e-07
allelic O 0 5.981714821245987e-06
variant O 0 0.0029388025868684053
in O 0 0.0007824251661077142
colorectal O 1 1.0
carcinogenesis O 0 0.4793558418750763
, O 0 1.0945461070832607e-07
we O 0 4.386920160470709e-09
have O 0 6.290061249636381e-10
analyzed O 0 1.3977201618331492e-08
a O 0 1.795309789720534e-09
large O 0 2.916816788101073e-09
cohort O 0 4.7783359491404553e-08
of O 0 6.714035993837797e-10
unselected O 0 1.527229642306338e-06
Ashkenazi O 0 1.183345943900349e-06
Jewish O 0 7.262795520546206e-08
subjects O 0 1.0982915199519994e-07
with O 0 2.2569881963363514e-08
adenomatous B-Disease 0 0.0004035036836285144
polyps I-Disease 0 0.00012935091217514127
and O 0 2.4057936087729104e-08
. O 0 9.385659893723641e-08
or O 1 0.999948263168335
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 5.117025470013914e-09
for O 0 9.932548117319584e-10
the O 0 1.4498190203937611e-08
APC O 0 1.6375844325011712e-06
I1307K O 0 3.6543435726343887e-06
polymorphism O 0 6.31592956779059e-06
. O 0 2.7899133669961884e-07

The O 0 2.0047723410243634e-06
APC O 0 1.6984404282993637e-05
I1307K O 0 7.635811016371008e-06
allele O 0 6.197846687427955e-06
was O 0 7.610429975102306e-08
identified O 0 5.402749359006975e-09
in O 0 2.740027982284232e-09
48 O 0 1.7121534412467554e-08
( O 0 1.6372755373694758e-09
10 O 0 1.119679016170494e-09
. O 0 9.926633126600137e-11
1 O 0 1.0866820776556096e-09
% O 0 1.621041911814558e-10
) O 0 1.6890089327148416e-10
of O 0 4.616025339743146e-10
476 O 0 7.964524115777749e-07
patients O 0 3.9253606587408285e-07
. O 0 1.3672109844264924e-07

Compared O 0 2.9740297122771153e-06
with O 0 1.0851415765955608e-08
the O 0 7.63530394465306e-09
frequency O 0 9.784048415895086e-07
in O 0 2.37946085057672e-09
two O 0 1.404811961203123e-10
separate O 0 7.069638208179185e-10
population O 0 3.3154956557979176e-10
control O 0 7.444020955205133e-09
groups O 0 2.3248493408178916e-10
, O 0 1.4935902514778832e-10
the O 0 1.9446058097116747e-09
APC O 0 1.8858928285681031e-07
I1307K O 0 2.7991612228106533e-07
allele O 0 3.058532058730634e-07
is O 0 9.585218174734678e-10
associated O 0 1.5022449950663486e-09
with O 0 8.823846514571798e-11
an O 0 2.740423998837116e-10
estimated O 0 1.6194852126005799e-09
relative O 0 1.2098313462161059e-08
risk O 0 2.1922177850797198e-08
of O 0 2.0258261734795724e-09
1 O 0 1.91810116234592e-07
. O 0 1.8581532401640288e-07

5 O 0 4.926547990180552e-05
- O 0 4.080432336195372e-05
1 O 0 1.925968035720871e-06
. O 0 4.279447125554725e-07

7 O 0 8.614806574769318e-05
for O 0 5.145644536241889e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9903960227966309
( O 0 3.6218716559233144e-07
both O 0 1.2199207333196682e-07
P O 0 0.049473270773887634
= O 0 2.2475433070212603e-06
. O 0 3.712297313995805e-08
01 O 0 1.216041619045427e-05
) O 0 7.823129521966621e-08
. O 0 2.0351380669580976e-07

Furthermore O 0 1.7952579582924955e-06
, O 0 1.3501458617781736e-08
compared O 0 2.22980869324374e-08
with O 0 1.7863843737586649e-09
noncarriers O 0 1.8260629985888954e-06
, O 0 2.3735953202930204e-09
APC O 0 1.1370759978035494e-07
I1307K O 0 1.035908141489017e-07
carriers O 0 1.7094906823444944e-08
had O 0 4.320579893857257e-09
increased O 0 2.2193993309826965e-09
numbers O 0 2.680949240385644e-09
of O 0 2.716683100700834e-09
adenomas B-Disease 0 5.824581239721738e-05
and O 0 0.003844177583232522
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9373400807380676
per O 0 7.694969781368854e-07
patient O 0 2.625088018248789e-05
( O 0 2.0401982681050868e-07
P O 0 0.001872371998615563
= O 0 8.52246273552737e-07
. O 0 9.2197067758093e-09
03 O 0 5.653337211697362e-07
) O 0 1.5311175660670528e-09
, O 0 1.76490141945429e-10
as O 0 3.0476154933012367e-10
well O 0 3.0260569050533093e-10
as O 0 3.915104629381716e-10
a O 0 3.828157346674743e-09
younger O 0 7.085465369982558e-08
age O 0 3.3443974700730905e-08
at O 0 1.6405907388161722e-07
diagnosis O 0 1.8765773347695358e-05
. O 0 1.5543349718427635e-07

We O 0 3.167203601606161e-07
conclude O 0 1.0476214384880222e-07
that O 0 1.674571814547221e-09
the O 0 4.8419583897896246e-09
APC O 0 3.3454443837399594e-07
I1307K O 0 2.267141070433354e-07
variant O 0 4.6128658937050204e-07
leads O 0 3.569101281186704e-08
to O 0 8.280949259642512e-09
increased O 0 3.955438501179742e-07
adenoma B-Disease 1 0.9999992847442627
formation O 0 1.1662454824090673e-07
and O 0 4.39500169591156e-09
directly O 0 4.659824526243028e-09
contributes O 0 7.3417352197679975e-09
to O 0 1.0374218151198988e-09
3 O 0 5.875556485790412e-09
% O 0 9.731039307681044e-10
- O 0 1.5566842037628703e-08
4 O 0 4.822189758613149e-09
% O 0 1.0028274738393961e-10
of O 0 4.2785386344945664e-11
all O 0 2.5136477344034347e-09
Ashkenazi O 0 0.0008317750762216747
Jewish O 1 0.9975423812866211
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.2923311462363927e-06

The O 0 2.518679309559957e-07
estimated O 0 3.5180793389599785e-08
relative O 0 4.772060435698222e-08
risk O 0 1.7738667423827792e-08
for O 0 1.2800458470962894e-09
carriers O 0 4.233193351410591e-08
may O 0 6.358012427654103e-08
justify O 0 2.6645560424753967e-08
specific O 0 2.6710524902995303e-09
clinical O 0 2.3904659585127774e-08
screening O 0 7.660440815016045e-08
for O 0 3.862811459587334e-10
the O 0 1.7453423151181369e-09
360 O 0 1.9376054538611243e-08
, O 0 1.983019026763344e-10
000 O 0 4.868980219008279e-10
Americans O 0 8.459889039302837e-11
expected O 0 2.5341888587604444e-09
to O 0 6.60686838571678e-10
harbor O 0 1.512397318492731e-08
this O 0 2.3555313255485544e-10
allele O 0 2.2956330170131878e-08
, O 0 1.1712684988562927e-10
and O 0 2.819529887343464e-10
genetic O 0 4.65570204610799e-09
testing O 0 1.3775946605676381e-08
in O 0 2.2356718698546274e-09
the O 0 1.3126902898008552e-09
setting O 0 7.658713663261096e-09
of O 0 3.8718031558637733e-10
long O 0 2.9094227471659906e-08
- O 0 5.042368229624117e-07
term O 0 9.029854908249035e-08
- O 0 4.97404073485086e-08
outcome O 0 5.6383773205936905e-09
studies O 0 2.9021278713514675e-09
may O 0 4.360591887575538e-09
impact O 0 1.1129491994665841e-08
significantly O 0 4.1421026253374293e-05
on O 1 0.9999997615814209
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 1.3600808870251058e-06
in O 0 9.028593872528745e-09
this O 0 2.5903148515027397e-09
population O 0 1.0158674790261557e-08
. O 0 5.48378338294242e-08

Localization O 0 2.0862937162746675e-05
of O 0 2.3837367635337614e-08
human O 0 2.8612479496814558e-08
BRCA1 O 0 3.5881973872164963e-06
and O 0 5.434519501079649e-09
its O 0 3.1914897391516206e-08
loss O 0 3.441818421379139e-07
in O 0 2.1846751963039424e-08
high O 0 4.990574780094903e-06
- O 0 3.720084350788966e-06
grade O 0 2.547838846567174e-07
, O 0 1.7939953966816802e-09
non B-Disease 0 7.784444733260898e-08
- I-Disease 1 0.9684776663780212
inherited I-Disease 1 0.9999939203262329
breast I-Disease 1 0.9999945163726807
carcinomas I-Disease 1 1.0
. O 0 4.548967353912303e-06

Although O 0 5.069504709354078e-07
the O 0 1.5382196849600405e-08
link O 0 1.8162832304824406e-07
between O 0 1.0864877886263002e-08
the O 0 5.8706081773607366e-08
BRCA1 O 0 0.0027085065376013517
tumour B-Disease 1 0.9999998807907104
- O 0 5.044838871981483e-06
suppressor O 0 2.651652721397113e-05
gene O 0 2.9553154945460847e-06
and O 0 1.1455844628471823e-07
hereditary B-Disease 1 0.9999822378158569
breast I-Disease 1 0.9999998807907104
and I-Disease 1 0.9999991655349731
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 1.3981493296455483e-08
established O 0 3.2793463500269127e-09
, O 0 9.74572644807381e-11
the O 0 4.389420216188711e-10
role O 0 1.6818314518829425e-09
, O 0 2.222507594629164e-10
if O 0 7.836768733948674e-11
any O 0 1.0740582034873825e-10
, O 0 4.095010094906648e-11
of O 0 9.027483621748544e-11
BRCA1 O 0 2.2949727451759827e-07
in O 0 6.160326471160715e-09
non B-Disease 0 1.2706986751709337e-07
- I-Disease 0 0.018285444006323814
familial I-Disease 0 0.12977267801761627
cancers I-Disease 0 0.09180205315351486
is O 0 2.0906920639163218e-08
unclear O 0 1.888153065010556e-07
. O 0 9.145554002998324e-08

BRCA1 O 0 0.05757793411612511
mutations O 0 0.00012226501712575555
are O 0 7.539443735993245e-09
rare O 0 2.3405219096162e-08
in O 0 5.079347786818289e-08
sporadic B-Disease 1 0.8095555305480957
cancers I-Disease 1 0.9966722726821899
, O 0 8.024196418432439e-09
but O 0 8.574849275078122e-09
loss O 0 3.3165360235898333e-08
of O 0 1.439935726210706e-09
BRCA1 O 0 1.1236191994612454e-06
resulting O 0 2.8065430868196017e-08
from O 0 7.987608796611312e-09
reduced O 0 1.215910145901944e-07
expression O 0 5.0336332435563236e-08
or O 0 1.571876673267525e-08
incorrect O 0 2.7693928927874367e-07
subcellular O 0 1.4322525885290815e-06
localization O 0 6.152461651254271e-07
is O 0 4.59190507839935e-09
postulated O 0 3.834963280269221e-08
to O 0 8.190496614268739e-10
be O 0 1.483850681216481e-10
important O 0 1.190065129774709e-10
in O 0 9.37951383228608e-10
non B-Disease 0 3.092684508487764e-08
- I-Disease 0 0.0007088038837537169
familial I-Disease 1 0.9910070300102234
breast I-Disease 1 0.9999998807907104
and I-Disease 1 0.9999611377716064
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 2.3297136522160145e-06

Epigenetic O 0 0.0003591439744923264
loss O 0 6.295929051702842e-05
, O 0 2.1869807298458e-08
however O 0 8.146735730463206e-09
, O 0 7.661222767296749e-10
has O 0 8.025937692224261e-10
not O 0 1.604186505854699e-10
received O 0 2.632098983212927e-10
general O 0 2.9945809720821615e-10
acceptance O 0 7.26146254237392e-09
due O 0 1.653842041093867e-08
to O 0 3.5162128764198997e-09
controversy O 0 1.4158747063675037e-08
regarding O 0 5.875040898217776e-09
the O 0 4.340866777141628e-09
subcellular O 0 3.4681912097767054e-07
localization O 0 9.165619019313453e-08
of O 0 7.189602246882032e-10
BRCA1 O 0 3.963503729664808e-07
proteins O 0 7.769993537465325e-09
, O 0 2.8948066166378794e-10
reports O 0 3.824712102584726e-09
of O 0 2.1461639410080835e-10
which O 0 1.072973487836748e-09
have O 0 3.645584667477664e-10
ranged O 0 6.305957089836056e-09
from O 0 4.012346843662584e-10
exclusively O 0 1.296125540228843e-09
nuclear O 0 8.514418503580146e-09
, O 0 1.844151359398083e-10
to O 0 5.109562217775476e-10
conditionally O 0 5.3749488415633095e-08
nuclear O 0 1.3795562026075459e-08
, O 0 2.3145624306053492e-10
to O 0 6.227923732282648e-10
the O 0 7.85575249295789e-09
ER O 0 6.596173989237286e-06
/ O 0 1.3196670352044748e-06
golgi O 0 2.1196071884332923e-06
, O 0 1.5578833778562284e-09
to O 0 2.2895494389274518e-09
cytoplasmic O 0 1.5091244165432727e-07
invaginations O 0 6.007006163599726e-07
into O 0 6.7240866208351235e-09
the O 0 1.6891716470013307e-08
nucleus O 0 4.898167844658019e-07
. O 0 9.866921857337729e-08

In O 0 1.6136407055000745e-07
an O 0 4.082941096328341e-09
attempt O 0 5.89485544821855e-08
to O 0 7.962358772317657e-09
resolve O 0 3.700985828913872e-08
this O 0 1.5942860365214528e-09
issue O 0 3.882024479651136e-09
, O 0 3.5369890349912225e-10
we O 0 2.961855760652554e-10
have O 0 6.368930383082727e-10
comprehensively O 0 1.2478501787427376e-07
characterized O 0 1.0169283370942139e-07
19 O 0 4.410690834788511e-08
anti O 0 3.5027981084567728e-06
- O 0 0.00010536866466281936
BRCA1 O 0 5.4377604101318866e-05
antibodies O 0 4.546512172964867e-06
. O 0 3.3273016697421554e-07

These O 0 1.594838067831006e-06
reagents O 0 8.24133530841209e-06
detect O 0 9.110990504268557e-06
a O 0 8.144874641402566e-08
220 O 0 3.917828337307583e-07
- O 0 2.2433246158470865e-06
kD O 0 3.1078664051165106e-06
protein O 0 1.4887146448927524e-07
localized O 0 4.489438936161605e-07
in O 0 1.043204367334738e-08
discrete O 0 2.50335734364171e-08
nuclear O 0 4.7182012963276065e-08
foci O 0 3.1742129635858873e-07
in O 0 2.1208539369155233e-09
all O 0 4.884597171184168e-10
epithelial O 0 5.031943572930686e-08
cell O 0 8.446097581327194e-07
lines O 0 8.359839398508484e-07
, O 0 4.1848524645615726e-10
including O 0 2.9661070821696e-10
those O 0 2.548632693777364e-10
derived O 0 9.601873962594709e-09
from O 0 4.797650632326622e-08
breast B-Disease 0 0.00015832115605007857
malignancies I-Disease 0 3.6355562770040706e-05
. O 0 8.456381692667492e-07

Immunohistochemical O 0 0.0020741436164826155
staining O 0 0.000181387978955172
of O 0 5.282078419099889e-08
human O 0 5.5512934693524585e-08
breast O 0 1.4029884368937928e-05
specimens O 0 5.696199778526534e-08
also O 0 3.23828786008562e-08
revealed O 0 5.749334377469495e-07
BRCA1 O 0 4.157855983066838e-06
nuclear O 0 3.387288245448872e-07
foci O 0 6.85200393490959e-06
in O 0 1.9614745383478294e-07
benign O 1 0.9968973398208618
breast O 0 0.48298734426498413
, O 0 1.6251586032467458e-07
invasive B-Disease 0 0.0007593593909405172
lobular I-Disease 1 0.9982228875160217
cancers I-Disease 1 0.9643275141716003
and O 0 5.265512186269916e-07
low B-Disease 1 0.9979514479637146
- I-Disease 1 0.9988409876823425
grade I-Disease 0 0.15771599113941193
ductal I-Disease 1 0.9985173344612122
carcinomas I-Disease 1 1.0
. O 0 1.4083411770116072e-05

Conversely O 0 2.461982876411639e-05
, O 0 1.4593356922887324e-07
BRCA1 O 0 5.696553216694156e-06
expression O 0 1.366535684610426e-07
was O 0 9.352778107540871e-08
reduced O 0 6.593517554165373e-08
or O 0 8.577204724247167e-09
undetectable O 0 2.0708688452941715e-07
in O 0 1.281763473137687e-09
the O 0 4.074723614078124e-10
majority O 0 2.896640427518804e-10
of O 0 2.2339102789814547e-10
high O 0 1.525129391666269e-06
- O 0 1.5083955076988786e-05
grade O 0 3.5632626804726897e-06
, O 0 3.362511336035823e-08
ductal B-Disease 0 0.0025892227422446012
carcinomas I-Disease 1 1.0
, O 0 9.099268005741123e-09
suggesting O 0 1.9837738562955565e-08
that O 0 2.773097307340322e-10
absence O 0 1.7631091031589108e-09
of O 0 6.081960490789129e-10
BRCA1 O 0 2.4497799131495412e-06
may O 0 3.3393682485893805e-08
contribute O 0 7.664043288890809e-10
to O 0 3.968779471730244e-10
the O 0 1.5589624036138616e-09
pathogenesis O 0 2.2024986279234327e-08
of O 0 5.649857665046554e-11
a O 0 3.99418914609484e-10
significant O 0 6.707085442592131e-10
percentage O 0 1.9259255523706997e-08
of O 0 3.3209908156806023e-09
sporadic B-Disease 1 0.9221966862678528
breast I-Disease 1 0.9999496936798096
cancers I-Disease 0 0.011252488940954208
. O 0 9.69817719465027e-08
. O 0 3.872834497542499e-07

